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PREFACE
The World Health Organization declares chronic respiratory diseases as one of the 4 major health 
problems of mankind. Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) affect more than 30% of 
the population worldwide. The socio-economic impact of chronic upper airway diseases is estimat-
ed in Europe with more than 150 billion Euro per year. Unmet needs in the field of AR and CRS can 
be identified in several domains: education, research, development and clinical care. In addition, 
the huge socioeconomic burden of AR and CRS to health care systems is expected to substantially 
increase in the future, warranting  new policies in healthcare at the global and national level.
To tackle the huge global health problem of chronic upper airways inflammation, the EAACI de-
cided to develop the “Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis” as a follow up 
of the “Global Atlas of Allergy” and “Global Atlas of Asthma” which were launched in 2013 and 
2014, had a huge success worldwide, and are currently translated into several languages. With 
this Atlas, EAACI and the authors of the Atlas aim to increase awareness on the global epidemic 
and the burden of chronic inflammatory upper airways diseases and to bring to the global attention 
the need to be recognized as a main concern in national health strategies; to reinforce the role of 
early diagnosis and treatment, education and prevention in a structured management strategy; to 
reveal their priority for research; to provide guidance on how to overcome barriers; to expand the 
existing programs and tools and explore innovative solutions for a comprehensive global manage-
ment approach.
The EAACI Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis contains 154 chapters writ-
ten by 218 authors with 269 illustrations and 92 tables. It is developed as a desktop reference for 
multisectoral usage covering all aspects of AR and CRS from epidemiology, risk factors and molec-
ular and cellular mechanisms to their management, clinical features and co-morbidities, diagnosis, 
treatment, prevention and control. In addition, the Atlas will offer an educational tool and a desk-
top reference for medical students, allied health workers, primary care physicians, pharmacists, 
medical industry, policy makers, patient organizations and specialists dealing with AR and CRS. We 
would like to thank all of the authors for their contributions.
Cezmi A. Akdis
Peter W. Hellings
Ioana Agache
Editors
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What is allergic rhinitis 
• Allergic rhinitis (AR) is a symptomatic IgE-driven inflammation 
of the nasal mucosa
• Nasal congestion/obstruction, rhinorrhoea, itchy nose and/or 
eyes, and/or sneezing are the symptoms of AR
• Allergen-specific IgE and eosinophilic inflammation are key 
features of allergic rhinitis 
• AR is often associated with conjunctivitis and asthma
• AR is a risk factor for asthma
• A significant percentage of AR patients remains uncontrolled 
despite adequate treatment
Allergic rhinitis represents an in-
flammatory disorder of the nasal 
mucosa initiated by an allergic 
immune response to inhaled al-
lergens in sensitized individuals. 
The allergic immune cascade in 
the nasal mucosa may give rise to 
the following symptoms in a var-
iable degree of severity and du-
ration: nasal congestion/obstruc-
tion, rhinorrhoea, itchy nose and/
or eyes, and/or sneezing. General 
symptoms like fatigue, impaired 
concentration and reduced pro-
ductivity are all associated with 
allergic rhinitis.
The following criteria are utilized 
to define rhinitis: the presence of 2 
or more nasal symptoms for more 
than 1 h per day. The discrimina-
tion between mucosal and ana-
tomic problems giving rise to nasal 
symptoms is a clinical judgement 
based on a proper clinical exami-
nation of the nose and endonasal 
cavity (Figure 1). A history with 2 
nasal symptoms suggestive of AR, 
with confirmation of nasal inflam-
mation by clinical examination and 
diagnostic tests showing sensiti-
zation to inhalant allergens, is the 
cornerstone of the diagnosis.
The new nomenclature on clas-
sification of hypersensitivity / 
allergic diseases for ICD-11 by 
Peter W. Hellings  
University Hospital Leuven 
Belgium
WHAT IS ALLERGIC 
RHINITIS 1
KE Y MESSAGES
crowd-sourcing the allergists 
community, is currently proposing 
specific definitions for subtypes of 
rhinitis. Based on history and clin-
ical examination supplemented by 
diagnostic tests, rhinitis patients 
are classically divided into differ-
ent phenotypes: 1/ allergic, 2/ 
infectious, 3/ non-allergic, non-in-
fectious, and 4/ mixed rhinitis 
(Figure 1). In a recent TF of the 
ENT section of EAACI, different 
rhinitis subtypes are being distin-
guished (Figure 1).
The allergic immune response in-
volves a nasal as well as systemic 
immune response. The systemic 
nature of the allergic immune re-
sponse with increased levels of 
IgE, IL-5 and blood eosinophilia 
has been recognized for several 
decades. In addition to nasal symp-
toms, inhalation of airborne aller-
gens may give rise to conjunctival 
symptoms like itchy eyes, tearing, 
congestion of the conjunctival 
vessels, chemosis and periorbital 
oedema. Allergic rhinitis may be 
a predisposing factor to develop 
disease in adjacent organs like the 
paranasal sinus cavities, middle 
ear, nasopharynx and larynx. In 
view of the consideration of aller-
gic rhinitis and asthma being part 
of the airway allergy syndrome, 
we have nowadays good insight 
into the epidemiologic association 
between AR and AA, diagnostic 
requirements for considering the 
problem of upper or lower airways 
as one entity, and therapeutic im-
plications for optimal treatment of 
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AR and AA. Of note, AR is a major 
risk factor for asthma.
Treatment of AR can be divided 
into medical treatment aiming at 
reducing inflammation with im-
provement of the quality of life, 
and immunotherapy aiming at in-
ducing tolerance (Figure 2). Suc-
cessful immunotherapy for Th2 
mediated allergic conditions is 
associated with the induction of 
IL-10 and TGF-β producing regu-
latory T (Tr)-1 cells.
The majority of AR patients 
are well controlled with guide-
line-based treatment, but up to 
20% of AR patients may experi-
ence bothersome symptoms de-
spite adequate first-line and sec-
ond-line treatment (Figure 3). The 
challenge of AR care in the future 
will be to optimize care pathways 
leading to a higher level of symp-
tom control and prevent the pro-
gression towards asthma.
Figure 1  Mucosal and anatomic factors contributing to nasal symptom severity.
Figure 2  Aims and cornerstones of medical treatment for AR.
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Consider surgery
Figure 3  Treatment algorithm of AR including the new concept of AR control.
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• Better understanding of the underlying immune mechanisms in 
allergic rhinitis (AR) is central to developing improved and more 
targeted therapies
• Development of the Th2 cell response and of the B cell and 
allergen-specific IgE response represent the sensitisation phase
• A type 2 immune response including T cells, innate lymphoid 
cells, local eosinophils and IgE are important players
• An IgE-mediated mast cell degranulation upon exposure to 
allergens represents the early response
• A late-phase response is characterized by recruitment of T cells, 
eosinophils and basophils
• Local IgE production without circulating specific IgE can take 
place
• Epithelial involvement in the type 2 immune response takes 
place, with the secretion of IL-25, IL-33 and TSLP
Mechanistic studies in allergic rhi-
nitis (AR) have been performed in 
biopsies, nasal fluid, nasal scrap-
ings and cultures of cells isolated 
from humans. The data so far is at 
the level of co-expressions, asso-
ciations and correlations. Direct 
evidence for human in vivo rele-
vance has not been demonstrat-
ed for many of the below listed 
findings. Animal models still need 
to be improved and may not fully 
represent the human in vivo situ-
ation. The most decisive data on 
mechanisms of AR reflecting hu-
man in vivo situation are obtained 
from therapeutic response to al-
lergen immunotherapy, anti-his-
tamines, corticosteroids as well 
as response to biologicals, such as 
anti-IgE and anti-IL-5 monoclonal 
antibodies.
IgE SENSITIZATION
After allergen exposure through 
mucosa and skin, allergens are 
taken up by antigen-presenting 
cells, processed to T cell epitope 
peptides and presented to helper 
T lymphocytes by MHC-class-II 
molecules (Figure 1). IL-4 re-
leased from innate lymphoid cells 
(ILC), mast cells or basophils and 
notch, jagged interaction in the 
dendritic cell and T cell interac-
tion may be important in the ini-
Cezmi Akdis  
Swiss Institute of Allergy and Asthma Research 
Davos, Switzerland
THE UNDERLYING 
MECHANISMS IN ALLERGIC 
RHINITIS
2
KE Y MESSAGES
tiation and clonal expansion of a 
Th2 response. This leads to T cell 
sensitization and memory devel-
opment. Activated CD4+ T helper 
2 lymphocytes release cytokines, 
mainly IL-4 and IL-13 and interact 
with B lymphocytes to induce the 
class-switch and synthesis of aller-
gen-specific IgE (IgE sensitization) 
and development of IgE B cell 
memory and IgE-secreting plasma 
cells. Allergen-specific IgE binds 
to the high affinity receptor for 
IgE (FcεRI) on the surface of mast 
cells. The presence of circulating 
IgE towards a specific allergen is 
not fully linked to a clinically sig-
nificant AR, and levels of total IgE 
rarely provide information about 
IgE to specific allergens.
EARLY PHASE (IMMEDIATE) 
RESPONSE
The early or immediate phase re-
sponse occurs in IgE-sensitized 
individuals within minutes of ex-
posure to the allergen and lasts 
for about 2-4 hours. Mast cell de-
granulation is a cardinal compo-
nent of the early phase response. 
Mast cells are abundant in the ep-
ithelial compartment of the nasal 
The underlying mechanisms in allergic rhinitis
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mucosa and can be easily activat-
ed upon re-exposure to the aller-
gens. Upon allergen cross-linking 
of specific IgE bound to the sur-
face high affinity receptors (FcεRI) 
of mast cells degranulate and 
release a variety of pre-formed 
and newly synthesized mediators 
leading to the early phase re-
sponse. Mast cell secretory gran-
ules contain preformed mediators 
that are rapidly (within seconds to 
minutes) released into the extra-
cellular environment. These me-
diators include histamine, leukot-
rienes, prostaglandins, proteases, 
proteoglycans, cytokines and 
chemokines. They are responsi-
ble for mast cell-mediated allergic 
reactions, including edema, in-
creased vascular permeability and 
nasal discharge in AR. Histamine, 
the major mediator of AR, stimu-
lates the sensory nerve endings of 
the trigeminal nerve and induces 
sneezing and pruritus. Histamine 
also stimulates the secretion of 
mucous and nasal discharge, and 
histamine, leukotrienes and pros-
taglandins act on the blood ves-
sels causing nasal congestion.
LATE PHASE RESPONSE
4-6 hours after allergen stimula-
tion, the early phase response is 
usually followed by the late phase 
response. The late phase response 
lasts for about 18-24 hours and is 
characterized by influx of T lym-
phocytes, basophils and eosino-
phils in the nasal submucosa. Sev-
eral mediators released by these 
cells include leukotrienes, kinins, 
histamine, chemokines and cy-
tokines, which result in the con-
tinuation of the symptoms. The 
production and release of a vari-
ety of cytokines such as IL-4, IL-5, 
IL-9 and IL-13 from mast cells, ILC, 
basophils and Th2 cells play a role 
in the orchestration and continu-
ation of the late phase response. 
IL-4 and IL-13 can upregulate the 
expression of vascular cell adhe-
sion molecule 1 on endothelial 
cells facilitating the infiltration of 
the nasal mucosa with eosinophils, 
Th2 lymphocytes and basophils. 
In addition, chemokines, such 
as RANTES, eotaxin, monocyte 
Figure 1  Sensitization and type I hypersensitivity reaction. A) T cell sensitisation, clonal expansion and memory Th2 
cell development after allergen presentation to T cells, B) IgE sensitization after Th2 cell naïve B cell interaction, C) Type I 
hypersensitivity reaction after cross-linking of the FcεRI bound IgE molecules by allergens on mast cells.
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chemoatractant protein (MCP)-4, 
and thymus-and activation regu-
lated chemokine (TARC) released 
from epithelial cells serve as che-
moattractants for eosinophils, 
basophils and T lymphocytes. 
Other cytokines like granulocyte 
macrophage colony-stimulating 
factor (GM-CSF), released largely 
by epithelial cells, and IL-5 from 
type 2 ILC and Th2 lymphocytes 
prolong the survival in the nasal 
mucosa of the infiltrating eosin-
ophils. Other mediators released 
from the eosinophils such as the 
eosinophil cationic protein, plate-
let-activating factor, major basic 
protein have additional roles in 
the late phase response. The late 
phase response is characterized 
by a prolongation of symptoms 
- sneezing, rhinorrhea, but most 
predominant by a sustained nasal 
congestion. AR also triggers a sys-
temic inflammation besides local 
inflammation, which can in turn 
augment inflammation in both the 
upper and lower airways and ex-
plains the link to asthma.
STRUCTURAL TISSUE CELLS IN 
ALLERGIC RHINITIS
Epithelial cells in AR have a wide 
range of immunomodulatory ac-
tivities through the release of 
eicosanoids, endopeptidases, cy-
tokines and chemokines (IL-6, IL-8, 
IL-25, IL31, IL-33, TSLP, GM-CSF, 
TNF-α, RANTES, TARC, eotaxin, 
stem cell factor (SCF)) and thus 
contributing to the enhancement 
of allergic inflammation. Further-
more, nasal epithelial cells in AR 
release matrix metalloproteinase 
(MMP)-2, MMP-9 and MMP-13, 
Figure 1  Type 2 inflammation and cytokine network in the AR nose.  AR inflammation develops as a combination 
of innate and adaptive immune response and involvement of resident tissue cells. Epithelial activation and cytokine 
release (TSLP, IL-25, IL-31, IL-33) leads to type 2 innate lymphoid cells (ILC2) activation. IL-4 from mast cells and ILC2s 
augments the Th2 response. TSLP-induced OX-40-ligand from DC induces a Th2 response. IL-4 and IL-13 lead to B cell 
activation and local IgE production. IL-5 from Th2 cells and ILC2 promotes tissue eosinophilia. IL-4 and IL-13 activate the 
endothelium for tissue migration of eosinophils, basophils and Th2 cells. Multiple Th2 (IL-9, IL-13) and pro-inflammatory 
cytokines (TNF-α, IL-6) released from ILC2, Th2 and mast cells activate the epithelium.
The underlying mechanisms in allergic rhinitis
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which can cleave almost all secret-
ed and cell surface molecules as 
well as extracellular matrix. Nasal 
epithelial cells express HLA-DR and 
CD86 and can present antigen to T 
cells. Epithelial cell-derived thymic 
stromal lymphopoietin (TSLP), IL-
25 and IL-33 are essential factors 
in AR. Increased IL-25 can amplify 
the ongoing allergic inflammation, 
particularly by augmenting the Th2 
type inflammation. IL-33 can am-
plify Th2 and particularly the IL-5, 
IL-9 and IL-13 secreting type 2 ILC 
activation. All three cytokines can 
directly and indirectly enhance in-
nate lymphoid cell-contribution to 
effector functions such as tissue 
eosinophilia and increased Th2 re-
sponse (Figure 2).
Epithelial barrier and tight junc-
tion integrity is essential in AR as 
it is in asthma, chronic rhinosinus-
itis (CRS) and atopic dermatitis. 
In all these diseases the epithelial 
barrier is prone to be impaired by 
allergens and pollutants. With its 
cysteine protease activity Der p 1 
is able to alter the epithelial tight 
junctions, thereby increasing epi-
thelial permeability. Due to their 
enzymatic proteolytic activity 
many allergens can directly acti-
vate epithelial cells and can induce 
cytokine and chemokine release 
and thus airway inflammation in-
dependent of IgE. Furthermore, in 
AR individuals epithelial cells are 
more sensitive to air pollutants 
like diesel exhaust particles.
Endothelial cells play a role in the 
pathogenesis of AR by partici-
pating in the recruitment of leu-
kocytes to the site of the allergic 
response. Endothelial cell VCAM-
1 is over expressed during the 
pollen season. Endothelial cells in 
AR are also an important source of 
several cytokines and chemokines 
like RANTES and eotaxin. Moreo-
ver, similar to epithelial cells, en-
dothelial cells also express the H1 
receptor and stimulation with his-
tamine induces activation of these 
cells.
Tissue macrophages and den-
dritic cells also contribute to AR 
inflammation by releasing mac-
rophage-derived chemokine that 
attracts Th2 cells.
Tissue fibroblasts are also in-
volved in AR. IL-4 promotes the 
proliferation of allergic fibroblasts, 
and the production of GM-CSF 
and SCF increases by histamine 
stimulation.
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mast cells (MCs) have been identi-
fied as important regulators in the 
upper airways. MCs express TLR1, 
TLR2, TLR4, and TLR6, comple-
ment receptors for C3a and C5a.
Upon stimulation (microbial, an-
tigen, allergen, or cellular stress) 
more cells belonging to the innate 
immune system are recruited. 
From these cells, innate lymphoid 
cells will be discussed in detail 
chapter A6. Neutrophils represent 
the prototypic circulating phago-
cyte, which belong to the first 
line defense mechanism. Another 
important cell type is the NK-cells 
exhibiting unique features. They 
are lymphoid cells, which do not 
express the classical antigen-spe-
cific receptors. NK-cells express a 
variety of anti-microbial receptors 
including TLR2, TLR3, TLR4, TLR5, 
TLR7, and TLR8. NK-cells play a 
critical role in anti-microbial ac-
tivities, regulation of apoptosis in 
target cells, they are producing in-
terferon-γ, TNF-α, but also a vari-
ety of TH2-cytokines including IL-
5, IL-10, and IL-13. Furthermore, 
they produce type-I interferon, 
IL-12, and IL-18.
The cellular network of the innate 
immune response is important in 
regulating immune homeostasis in 
the local tissue. From a functional 
point of view, microbial encounter 
may either amplify the inflamma-
• Microbial pattern recognition represents an important task of 
the innate immune system in the upper airways
• Resident cells (macrophages, dendritic cells, epithelial cells, and 
mast cells) contribute to microbe and allergen recognition
• The tissue infiltrating celllular response of the innate immune 
system mainly consists of neutrophils and NK-cells
• Microbes either amplify the inflammatory response or may 
prevent the development of allergic rhinitis in the context of 
the “hygiene hypothesis”
• The underlying mechanisms of pro- and anti-allergic immune 
responses are still not fully elucidated
An important function of the in-
nate immune system in the upper 
respiratory tract is the recogni-
tion of microbial patterns. Several 
strategies have evolved in order 
to fulfill this task such as secret-
ed molecules (e.g. anti-microbial 
peptides, collectins, surfactant 
proteins, pentraxins), membrane 
bound receptors (e.g. toll-like re-
ceptors, C-type lectin receptors), 
cytosolic receptors (e.g. NOD-
like receptors, RIG-I, MDA5) as 
well as receptors, which are both 
secreted or membrane-bound 
(prototypic examples, CD14 and 
LPS-binding proteins) (Table 1). 
These molecules are produced by 
a variety of resident and non-resi-
dent, infiltrative cells in the upper 
respiratory tract including epi-
thelial cells, dendritic cells (DCs), 
macrophages, and mast cells. DCs 
can be subdivided into classic 
myeloid (mDC) and plasmocytoid 
(pDC) types which are thought to 
originate from a common DC-pre-
cursor in the bone marrow. mDCs 
form of subepithelial web, they are 
rich in pattern-recognition recep-
tors and, therefore, sensitive to 
microbes, inflammation, and cel-
lular stress. pDCs are particularly 
relevant for the anti-viral respons-
es, they are expressing TLR7 and 
TLR9 and release large amounts 
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The innate immune response in allergic rhinitis
TABLE 1
Innate Pattern Recognition Receptors in Humans
Pattern Recognition Receptors PAMP Structures Recognized
Membrane Bound
Toll-like receptors Microbial PAMP’s
C-type lectin receptors
Mannose receptor (CD206) Microbial mannan
DECTIN-1 β-1,3-Glucan
DECTIN-2 Fungal mannose
DC-SIGN Microbial mannose, fucose
Siglecs Sialic acid-containing glycans
Cytosolic
NOD-like receptors Peptidoglycans from gram-negative bacteria
Bacterial muramyl dipeptides
Anthrax lethal toxin
Microbial RNA
Bacterial flagellin
RIG-I and MDA5 Viral double-stranded RNA
Secreted
Antimicrobial peptides Microbial membranes (negatively charged)
α-and β-defensins
Cathelicidin (LL-37)
Dermcidin
RegIIIγ
Collectins
Mannose-binding lectins Microbial mannan
Surfactant proteins A and D Bacterial cell wall lipids; viral coat proteins
Pentraxins
C-reactive protein Bacterial phospholipids (phosphorylcholine)
Secreted and Membrane Bound
CD14 Endotoxin
LPS-binding protein Endotoxin
MD-2 Endotoxin
tory response (e.g. Staphylococcus aureus) or may prevent the develop-
ment of allergic inflammation in the context of the “hygiene hypothesis”. 
However, the detailed molecular signals and pathways leading either to 
augmentation and enhancement or to the prevention of the respons-
es have not been fully elucidated 
yet. Certainly, further research is 
needed in this field.
In addition to microbes, many al-
lergens may directly interact with 
cells of the innate immune system. 
One prominent example is the 
structural and functional homol-
ogy of defined allergenic compo-
nents with the pattern recognition 
system (e.g. Der p 2 is a homolog 
for MD-2; Der p 7, Fel d 1, Mus m 
1, and Equ c 1 are homologs for 
lipid-binding proteins). Further-
more, many allergens exhibit pro-
tease activity that is associated 
with their allergenicity. Examples 
are Der p 1, Der p 3, and Der p 9.
In conclusion, the innate immune 
system plays a critical role in the 
first line interaction between the 
environment and the host. This in-
cludes the interactions with path-
ogens, immune-regulatory mi-
crobes, allergens, and toxins. This 
first line defense mechanism plays 
also an important role in orches-
trating the subsequent adaptive 
immune response leading either 
to tolerance or (chronic) inflam-
mation.
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ence 2010;327:656-661.
3. Blander JM, Medzhitov R. Toll-de-
pendent selection of microbial an-
tigens for presentation by dendritic 
cells. Nature 2006;440:808-812.
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the allergic nasal epithelium, Nils-
son et al. have suggested stem cell 
factor (SCF), Salib et al. suggested 
TGF-β I and more recently Ozu et 
al. have shown that RANTES is 
the key molecule regulating the 
intraepithelial migration of MCs.
Activated MCs release a varie-
ty of cytokines such as IL-4, IL-5, 
IL-6, IL-8, IL-10, IL-13 and TNF-α, 
express high levels of very-late 
activation antigen (VLA) 4 and 
5 and via interactions with the 
extra cellular matrix can upreg-
ulate cytokine secretion. Such a 
mechanism may contribute to the 
enhancement of MCs activation 
especially when the levels of an-
tigen in the microenvironment are 
rather low and contribute to nasal 
hyperresponsivess.
The local production of IgE in the 
nasal mucosa of AR patients is 
well established. Cytokines like 
IL-4, and IL-13 released from T 
cells help drive B cells toward IgE 
synthesis and can contribute to 
the local IgE synthesis and MCs 
can orchestrate ongoing allergic 
inflammation (Figure 2). Further-
more, IgE and IL-4 can upregu-
late the FcεRI expression in MCs. 
The augmented FcεRI can bind 
increased number of IgE-Ag com-
plexes, which in turn can enhance 
the sensitivity of MCs to allergen 
• Mast cells are critical cells in the early phase allergic reaction 
and are major producers of histamine, leukotrienes and 
prostaglandins
• Mast cells also produce a variety of inflammatory cytokines and 
chemokines in allergic rhinitis (AR) that regulate the late phase 
reaction
• IgE-activated mast cells express high levels of the high affinity 
IgE receptor (FcεRI), the CD40L, produce IL-4 and IL-13 and 
induce local IgE synthesis in B cells in the nasal mucosa of the 
AR patient
• Mast cells can autoactivate themselves via upregulating the 
FcεRI by IgE or IL-4 and thus amplify the ongoing inflammation 
via the IgE-FcεRI cascade
Mast cells (MCs) have been con-
ventionally known to play a crucial 
role in the immediate phase aller-
gic reaction (Figure 1). However, 
over the last 20 years studies fo-
cused on nasal and bronchial MCs 
have clearly shown their wider 
involvement in ongoing inflam-
mation in AR and asthma. More 
recent human studies implicate 
an important role for MCs also 
in other airway diseases such as 
chronic obstructive pulmonary 
disease, respiratory infections 
and lung fibrosis. While their roles 
mainly include immune-modula-
tory, pro-inflammatory and pro-fi-
brotic activities, MCs can also 
downregulate inflammation and 
participate in the defense against 
respiratory infections.
Human MCs were classified into 
two phenotypically distinct sub-
populations based on the type of 
neutral proteases they express, 
namely MC (T) that contain only 
tryptase, and MC (TC) that con-
tain chymase, cathepsin G and 
carboxypeptidase in addition to 
tryptase. In patients with AR, MC 
(T) are found to abundantly accu-
mulate in the epithelial compart-
ment of the nasal mucosa. Among 
the factors that induce the selec-
tive accumulation of MCsls into 
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Mast cell in allergic rhinitis
resulting in the enhancement of 
the production of immunomodu-
latory cytokines and chemical me-
diators, leading to a positive-feed-
back amplification loop involving 
the IgE-IgE receptor mast cell cas-
cade. More recently, it has been 
shown that oxidative stress may 
upregulate the IL-4 gene expres-
sion in mast MCs. MCs can also in-
teract with structural cells, such as 
epithelial cells and activate these 
cells or be activated by these cells 
via cytokines like IL-25, IL-33 and 
chemokines like RANTES.
There are several therapies target-
ing MCs for AR. With MCs being 
the major producers of histamine, 
leukotrienes and prostaglandins 
(e.g. prostaglandin D2), the clini-
cal efficacy of antihistamines, an-
ti-leukotrienes in AR can be inter-
preted as a strong indication of a 
significant mast cell role in AR. The 
pioneering drug in this context, 
the anti-IgE monoclonal antibody 
omalizumab, has been shown to 
reduce both inflammatory param-
eters, as well as patient-related 
outcomes (e.g. symptom scores 
and quality of life) in asthmatics 
and in patients with AR (although 
omalizumab is not indicated in AR 
alone).
KEY REFERENCES
1. Irani AA, Schechter NM, Craig 
SS, DeBlois G, Schwartz LB. Two 
types of human mast cells that 
have distinct neutral protease 
compositions. Proc Natl Acad Sci 
U S A 1986;83:4464-4468.
2. Nilsson G, Hjertson M, Anders-
son M, Greiff L, Svensson C, Nils-
son K, et al. Demonstration of 
mast-cell chemotactic activity in 
Figure 1 Mast cells and the immediate hypersensitivity reaction.
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Figure 2 Mast cells orchestrate the ongoing allergic inflammation in AR: under allergic inflammatory conditions, 
"primed" MCs produce IL-4 and IL-13 and express high levels of the high affinity receptor for IgE and the ligand for 
the surface antigen CD40, involved in T/B cell interactions leading to IgE production. IL-4 from MCs cells can direct 
uncommitted helper T lymphocytes toward Th2 and also upregulate the FcεRI expression in MCs and basophils.
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• Basophils infiltrate the nasal mucosa during the inflammatory 
process in allergic rhinitis (AR)
• Products released by basophils in the nasal mucosa retain the 
inflammatory process
• Treatment of AR directly or indirectly affects basophils 
activation and presence in nasal mucosa
Basophils are rare leukocytes that 
mature in the bone marrow and 
are released as mature cells in the 
peripheral blood. Basophils share 
many properties with mast cells, 
but are from a different lineage 
and, in general, are more respon-
sive to different types and lower 
concentrations of stimuli. Most 
importantly, mast cells are tis-
sue-bound, while basophils rep-
resent a population of rapidly mi-
grating leukocytes that infiltrate 
tissue sites when needed.
BASOPHIL PRESENCE IN 
NASAL MUCOSA IN ALLERGIC 
RHINITIS
Several studies have demonstrated 
basophils in the nasal mucosa in 
allergic rhinitis (AR) patients. The 
research group at Johns Hopkins 
University under supervision of 
Lawrence Lichtenstein, claiming 
that the nose was the only organ 
in which you could sample with a 
pipette, has been pioneering in this 
area by thorough analysis of medi-
ators and cells in nasal mucosa. In 
the allergen-induced late-phase re-
action, a typical basophil mediator 
profile and cells representing baso-
phils were found. Other groups us-
ing the basophil-specific antibod-
ies BB1 and 2D7 confirmed this 
increased basophil numbers (Fig-
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Basophils in allergic rhinitis
Figure 1 Photomicrograph of basophils (BB1-positive cells (red)) in the 
epithelium and lamina propria of a nasal mucosa biopsy section obtained 
from an allergic patient before (A) and 24 hours after (B) allergen provocation. 
(Adapted from KleinJan A, McEuen AR, Dijkstra MD, et al. Basophil and eosinophil 
accumulation and mast cell degranulation in the nasal mucosa of patients with hay 
fever after local allergen provocation. J Allergy Clin Immunol 2000;106:677-686.)
B
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Basophils in allergic rhinitis
ure 1). Importantly, basophil pres-
ence is reduced upon successfully 
treatment with local steroids or af-
ter immunotherapy. Production of 
chemokines in the nasal mucosa is 
most likely responsible for the ba-
sophil infiltration. The nasal appli-
cation of the chemokine RANTES/
CCL5 leads to influx of basophils.
BASOPHIL PRODUCTS
Basophils are supposed to play an 
important role via their products 
released. Next to histamine, baso-
phils can release many pre-formed 
and newly formed mediators, such 
as leukotriene C4 and platelet-acti-
vating factor. In addition, basophils 
are potent sources of cytokines 
and chemokines. An additional 
mechanism that basophils might 
use is the stimulation of cells via 
co-stimulatory molecules. CD40L 
on basophils will activate local B 
cells via binding to their CD40 and 
via simultaneous release of IL-4 
might drive local IgE production.
STIMULATION OF BASOPHILS
Although it is unlikely that high 
levels of allergens will still be 
present when basophils infiltrate 
the nasal mucosa, there are sev-
eral allergen-independent ways 
that activate basophils (Figure 
2). Chemokines are not only im-
portant to attract basophils, but 
also induce their degranulation in 
higher concentration. Locally pro-
duced cytokines will stimulate ba-
sophils, either on their own or in 
combination with other cytokines 
and mediators, including innate 
cytokines such as IL-33.
Human basophils, in contrast to 
their murine counterpart, lack 
PAR2 receptors, so it is unlikely, if 
proteases derived from allergens 
can activate. On the other hand, 
bacterial products, such as cell 
wall proteins from Staphylococ-
cus aureus and Peptostreptococcus 
magnum can activate basophils via 
crosslinking IgE, while formyl-me-
Figure 2 Basophils activation by different type of stimuli. The most prominent 
activation is via allergen interacting with IgE causing crosslinking of FcεRI. 
Bacterial products can crosslink IgE independent of its antigen specificity. 
Other stimuli can stimulate the cells via binding to specific receptors. 
Activation of basophils results in release of several types of mediators and 
cytokines/chemokines that are important in allergic diseases, as well as 
expression of co-stimulatory molecules.
thionine-containing tripeptides 
from microbes can directly acti-
vate basophils.
PERIPHERAL BLOOD 
BASOPHILS IN AR
After nasal allergen challenge ba-
sophils from the peripheral blood 
are stimulated indicating that the 
local allergic inflammatory process 
affects also systemically. In addi-
tion, AR patients have increased 
numbers of basophil progenitors 
in their blood, probably due to 
continuous release of basophil dif-
ferentiation factors in the tissue.
In conclusion, basophils and their 
products can be found in nasal mu-
cosa of AR patients. It is tempting 
to believe that these cells are im-
portant for the pathomechanism 
in this disease. However, the pres-
ence of many other inflammatory 
cells and their products makes it a 
challenge to dissect the exact role 
of basophils in this disease.
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population of lineage-negative lymphocytes that produce Th2 
cytokines
• ILC2s have been detected in human sinonasal tissue and are 
enriched in eosinophilic nasal polyps from chronic rhinosinusitis 
patients
• Cat allergen challenge in allergic rhinitis subjects resulted in 
increased peripheral blood ILC2s
• Peripheral blood ILC2s are increased in pollen-allergic rhinitis 
patients during pollen season and decreased by subcutaneous 
immunotherapy
Group 2 innate lymphoid cells 
(ILC2s) are a recently-discov-
ered population of lymphocytes 
that produce high levels of Th2 
cytokines (IL-4, IL-5, IL-9, IL-13) 
that promote allergic inflamma-
tory responses in animal models. 
Human ILC2s are defined by ex-
pression of the prostaglandin D2 
(PGD2) receptor DP2 (also known 
as CRTH2) in addition to being 
lineage-negative (lack surface ex-
pression for B, T, NK, and NKT cell 
as well as mast cell and basophil 
markers). ILC2s are enriched in 
nasal polyps from patients with 
chronic rhinosinusitis (CRS) and 
are increased in eosinophilic com-
pared with non-eosinophilic polyp 
endotypes. Unlike conventional T 
cells, ILC2s are not antigen spe-
cific and are activated by sever-
al mediators including cytokines 
TSLP and IL-33, as well as lipid 
mediators prostaglandin D2 and 
cysteinyl leukotrienes (Figure 1). 
Importantly, these mediators have 
been detected at higher levels in 
CRS patients and are thus availa-
ble for ILC2 activation.
Two studies have investigated the 
effects of allergen exposure on 
peripheral blood ILC2s in patients 
with allergic rhinitis (AR). In the 
first study, changes in peripheral 
Taylor A. Doherty  
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blood ILC2s were assessed four 
hours after cat allergen challenge in 
AR subjects with positive cat chal-
lenges. The percent of CRTH2+ 
ILC2s was increased 2-fold after 
cat allergen challenge compared 
to diluent control challenge given 
to the same subjects at a separate 
visit. The second report demon-
strated that peripheral blood ILC2s 
were increased during grass pollen 
season in pollen AR patients. In-
terestingly, the levels of peripher-
al blood ILC2s were also reduced 
by subcutaneous immunotherapy. 
The function of peripheral blood 
ILC2s after allergen exposure in AR 
is not known, but may involve re-
cruitment of ILC2s from the bone 
marrow that are bound for tissues. 
Importantly, ILC2s express CRTH2 
that binds to PGD2 and is known 
to promote chemotaxis of immune 
cells including ILC2s. High levels 
of PGD2 are rapidly produced af-
ter airway allergen challenge and 
could thus promote ILC2 recruit-
ment in AR.
There are currently no studies ad-
dressing the role of tissue ILC2s 
in AR. Whether sinonasal ILC2s 
are activated after allergen expo-
sure is so far not reported. How-
ever, given the capacity for ILC2s 
to generate large amounts of Th2 
cytokines that could propagate 
chronic inflammation in AR, ILC2s 
may be a target of future therapy. 
Additionally, whether human tis-
sue ILC2s are corticosteroid sensi-
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tive is also not known and has sig-
nificant implications for improved 
treatment for patients.
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Figure 1 Proposed ILC2 responses in AR. Epithelial damage and activation may occur after exposure to allergens, 
viruses, or irritants. ILC2s are activated by epithelial cytokines TSLP, IL-33, and IL-25 as well as prostaglandin D2 
(PGD2) and cysteinyl leukotrienes (CysLTs) produced by mast cells and eosinophils. In turn, ILC2s produce Th2 cytokines 
including IL-4, IL-5, IL-9, and IL-13. ILC2 IL-4 production may contribute to differentiation of Th2 cells and promote IgE 
production by B cells. IL-5 secretion induces recruitment, activation and survival of eosinophils. IL-9 promotes mast 
cell accumulation and mucus production and IL-13 induces immune cell influx, tissue remodeling and further enhances 
mucus production. (Adapted from Doherty TA. At the Bench: Understanding group 2 innate lymphoid cells in disease. J Leukoc 
Biol 2014;97:455-467.)
Innate lymphoid cells in allergic rhinitis
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innate immune system
• In vivo existence of type 2 cytokine-producing NK cells and 
increased NK - cytotoxic capacity in patients with AR support 
the role of NK cells in AR
• Limited findings in NK-T cells suggest that NK-T cells are not 
directly related to the development of AR, but they may play 
important roles in the development of chronic sinusitis
Alterations in the innate immune 
system cells, as natural killer (NK) 
cells, NK-T (NK-T) cells, γδ T cells, 
dendritic cells, and innate lym-
phoid cells, play a pivotal role in 
the development and immuno-
modulation of allergic rhinitis (AR).
NK-CELLS
NK cells not only exert cytotox-
ic activity against tumor cells or 
infected cells but also act to reg-
ulate the function of other im-
mune cells through secretion of 
cytokines and chemokines or cell 
contact-dependent mechanisms. 
Human NK cells have the capacity 
to differentiate into two function-
al distinct subsets, NK1 or NK2, 
which are analogous to the T-cell 
subsets Th1 or Th2. In addition, 
a regulatory NK cell subset has 
been described that secretes IL-
10, shows antigen-specific T-cell 
suppression, and suppresses IgE 
production.
The percentage of NK cells and 
their cytotoxic activity are high-
er in patients with AR compared 
with non-atopic subjects. Addi-
tionally, patients with atopic res-
piratory diseases have a higher 
activity of NK cells. The role of 
type 2 cytokines in allergic dis-
eases has been established, and 
NK cells are possibly the source of 
Günnur Deniz  
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Natural killer (NK) and NK-T cells in allergic rhinitis
Th2 cytokines. IL-4+ NK cells were 
significantly higher while IFN-γ+ 
NK cells were non-significantly 
lower in AR patients compared to 
healthy non-atopic subjects. IL-13 
secretion from NK cells was also 
significantly higher. These findings 
confirm the existence of type 2 
cytokine-secreting NK cells in AR 
and show their increased number 
and enhanced cytotoxicity com-
pared to normal individuals.
In chronic rhinosinusitis, de-
creased NK cell functions were 
associated with some poor prog-
nostic factors such as peripheral 
blood eosinophilia. Thus, NK cells 
may play an important role in reg-
ulating inflammatory process also 
in chronic sinusitis pathogenesis.
NK-T CELLS
NK-T cells are a unique CD1d-re-
stricted T cells with NK cell sur-
face markers and play important 
roles in innate immunity. The 
NK-T cells were detected with 
varying degrees in the sinus mu-
cosa from asthmatic patients with 
chronic sinusitis, but not in the na-
sal mucosa of non-asthmatics nor 
in the nasal mucosa of patients 
with AR. NK-T cells might play im-
portant roles in the enhanced Th2 
cytokine expression and increased 
infiltration of Th2 cells and eosin-
ophils observed in the sinus mu-
cosa of asthmatic patients with 
chronic sinusitis through MHC-in-
dependent mechanisms. There is 
evidence that alterations of the 
NK and NK-T cells are relate to 
the development and immuno-
modulation of AR.
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Figure 1 The diagram shows a hypothetical scheme of the potential role of NK cells in the network of immune cells. 
NK cells play an important role in innate and adaptive immunity, and they can influence the development of dendritic 
cells (DC) & macrophages (M) and adaptive T- & B-cell immune responses. Cytokines, such as interferon IFN-γ, which 
are produced by activated NK cells, activate cytotoxic T lymphocytes (CTL) and helper T cell (Th) responses. This leads to 
the proliferation of helper T cells and cytokine production. Cytokines that are produced by NK cells might also regulate 
antibody production of B cells. (Reprinted from J Allergy Clin Immunol, 132/3, Deniz G, van de Veen W, Akdis M. Natural killer 
cells in patients with allergic diseases, 527-535, Copyright 2013, with permission from Elsevier.)
Natural killer (NK) and NK-T cells in allergic rhinitis
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directly investigate allergen/antigen-specific immune response 
development
• Functional allergen-specific FOXP3+ Treg cells are identified in 
tonsils
• Certain innate immune response signals and pro-inflammatory 
cytokines break allergen-specific CD4+ T-cell tolerance in tonsils
• Tonsillar immune response profile can be influenced by 
respiratory virus infections, allergic conditions and age and 
show distinct clusters of immune activation/regulatory versus 
anti-viral immune response
New human in vivo models are 
needed for allergy and asthma re-
search. Tonsils are secondary lym-
phoid organs and primary naso-
pharyngeal lymphoid tissue. The 
four areas of tonsil tissue in the 
naso- and oropharynx are shown 
in Figure 1. Their highly cryptic 
structure is ideal for sequester-
ing food- and aeroallergens and 
infectious agents for their first 
contact with the immune system 
(Table 1, Figure 2). Palatine ton-
sils are removed by tonsillectomy 
without disturbing the integrity of 
the relatively big lingual tonsil as 
well as tubal tonsils. Due to their 
anatomic location, tonsils provide 
a new in vivo model for the under-
standing of immune response de-
velopment and immune tolerance 
induction.
INDUCTION AND 
MAINTENANCE OF ALLERGEN-
SPECIFIC FOXP3 TREG CELLS IN 
HUMAN TONSILS
Active regulation of peripheral T-cell 
repertoire is an essential mecha-
nism for inducing and maintaining 
tolerance to allergens. The genera-
tion of regulatory T (Treg) cells con-
stitutes a main component of oral 
tolerance induction. Allergen-spe-
cific CD4+FOXP3+ T reg cells with 
suppressive activity exist in human 
Tuomas Jartti  
Turku University Hospital 
Turku, Finland
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TABLE 1
Facts about tonsil immunology
Tonsils represent first line lymphatic organs, a fully organized lymphoid tissue 
with high exposure to aeroallergens, food antigens and to infectious agents
The highly cryptic structure of tonsils sequesters all swallowed or inhaled par-
ticles and allows long-term exposure of antigens. The pressure of swallowing 
further squeezes these particles against tonsil tissue
Tonsils express high levels of allergen-specific T cells, T regulatory cells, plas-
mocytoid dendritic cells and innate lymphoid cells
Tonsillectomy only removes the palatine tonsils and sometimes adenoids. The 
lingual tonsil, which is anatomically big, remains intact and is immunologically 
active lifelong
palatine and lingual tonsils. Their 
frequency is approximately 3 times 
higher in tonsils compared to pe-
ripheral blood. Thus, tonsils have an 
active role in the first step of oral 
tolerance induction.
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TRIGGERING OF SPECIFIC 
TOLL-LIKE RECEPTORS 
AND PRO-INFLAMMATORY 
CYTOKINES BREAKS 
ALLERGEN-SPECIFIC T-CELL 
TOLERANCE IN HUMAN 
TONSILS
Human tonsils show very low lev-
els of allergen-induced T cell pro-
liferation, thus representing a very 
suitable in vivo model to assess 
mechanisms of breaking aller-
gen-specific T cell tolerance. Dur-
ing these events dendritic cells 
(DCs) can control the suppressive 
activity of Treg cells. Plasmocytoid 
DCs dominate in both lingual and 
palatine tonsils. CD4+FOXP3+ Treg 
cells co-localize with plasmocyto-
id DCs and proliferate in T cell are-
as of tonsils. Triggering of TLR4 or 
TLR8, as well as IL-1β or IL-6 are 
able to enhance allergen-specific 
CD4+ T-cell responses in human 
tonsils. Myeloid DCs is the main 
DC subset mediating such effects, 
whereas plasmocytoid DCs or 
other innate stimuli (such as stim-
ulation of TLR-7 and TLR-9) do 
not show any tolerance-breaking 
effect.
DISTINCT REGULATION 
OF TONSILLAR IMMUNE 
RESPONSE IN RESPIRATORY 
VIRAL INFECTIONS
Susceptibility to certain viral infec-
tions and defects in viral clearance 
could play a role in pulmonary in-
flammatory processes. Deficient 
innate and adaptive immune re-
sponses contribute to the morbid-
ity and mortality of viral infections. 
Tonsillar cytokine expression is 
closely related to existing viral in-
fections, age and allergic diseases 
and show distinct clusters be-
tween anti-viral and immune reg-
ulatory genes (Figure 3).
Figure 1 The 4 areas of tonsil tissue: the paired palatine tonsils (at both sides 
in the back of the mouth), the nasopharyngeal or adenoid tonsil (attached 
to the roof of the pharynx), the paired tubal tonsils (at the openings of the 
Eustachian tubes), and the lingual tonsil (located at the back of the tongue).
Figure 2 Age-dependent decrease in intratonsillar virus detections. (Adapted 
from Jartti T, Palomares O, Waris M, et al. Distinct regulation of tonsillar immune 
response in virus infection. Allergy 2014;69:658-667.)
The immune response in tonsils
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Figure 3 Age-dependent adjusted network representation of the significant intratonsillar gene correlations according 
to intratonsillar virus infection and allergic status. Nodes indicate genes. Lines indicate presence of significant 
correlations. Positive correlations are displayed as red and negative correlations as blue. The line thickness is 
proportional to the magnitude of the correlation coefficient. (Adapted from Jartti T, Palomares O, Waris M, et al. Distinct 
regulation of tonsillar immune response in virus infection. Allergy 2014;69:658-667.)
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• allergen-specific IgE and eosinophilic inflammation are key 
features that distinguish allergic rhinitis (AR) from other forms 
of rhinitis
• the presence of eosinophilia in the nasal mucosa of AR patients 
has been long established and has been related to disease 
severity and to the occurrence of co-morbidities such as nasal 
polyps and chronic rhino-sinusitis
• exposure to allergen increases nasal eosinophilia, while steroids 
and allergen immunotherapy significantly diminishes it
Allergic rhinitis (AR), or allergic in-
flammation of the nasal airways, 
is the most prevalent chronic 
non-communicable disease, af-
fecting 10–25% of people annu-
ally. The characteristic symptoms 
of AR are rhinorrhea (excess nasal 
secretion), itching, sneezing, na-
sal congestion and obstruction. 
The immune response in AR is 
initiated by T cell production of 
Th2 cytokines, which drive IgE 
cross-linking on surface of mast 
cells resulting in release of pre-
formed mediators such as his-
tamine, leukotrienes and pros-
taglandins (early response). This 
is followed by recruitment of 
inflammatory cells, namely eo-
sinophils and CD4+ T cells to the 
nose resulting in nasal edema and 
obstruction (late phase). The key 
features of AR (which distinguish 
AR from other forms of rhinitis 
such as non-allergic rhinosinusitis) 
include allergen-specific IgE and 
eosinophilic inflammation.
The presence of eosinophilia in 
the nasal mucosa of AR patients 
has been long established (Figure 
1A). Nasal allergen provocation 
in AR patients leads to increase 
in tissue eosinophilia (Figure 1C 
and D), as well as expression of 
pro-eosinophilic cytokines such 
EOSINOPHILS IN 
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as IL-5 and GM-CSF. Following 
allergen challenge, there is a local 
increase of eosinophil precursors 
and progenitors in the nasal tissue 
as well as local eosinophil differ-
entiation. In seasonal AR, there is 
an accumulation of activated eo-
sinophils during natural grass-pol-
len exposure. Eosinophil counts as 
well as eosinophil cationic protein 
(ECP) in nasal secretions were re-
lated to the severity of symptoms 
in seasonal AR and can be used for 
the diagnosis and management of 
AR.
Chronic and/or untreated AR may 
result in complications which in-
clude recurrent chronic sinusitis 
and formation of nasal polyps. 
There is a large accumulation of 
eosinophils and their cytokines in 
both of these cases. These effects 
can be largely attributed to IL-5 
and eotaxin (Figure 2), an eosino-
phil chemo-attractant, whose pro-
duction is significantly increased 
in the nasal mucosa, although 
others including GM-CSF and 
RANTES are likely to contribute.
In grass-sensitive patients, aller-
gen immunotherapy effectively 
inhibits allergen-induced infiltra-
tion of eosinophilia. Steroids ef-
fectively reduce activated eosino-
phils in seasonal AR (Figure 1B), in 
patients with nasal polyps or with 
severe chronic sinusitis. Together 
these data suggest that eosino-
phil is a critical cell involved in the 
pathogenesis of AR.
Meri K. Tulic  
University of Nice Sophia Antipolis 
Nice, France
Qutayba Hamid  
McGill University 
Montreal, Canada
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Figure 1 Increased eosinophil numbers in biopsies from patients with 
allergic rhinitis (A) is inhibited with use of steroids (B). Increased presence 
of eosinophils in the nasal inferior turbinate in allergic rhinitis (C) is further 
augmented after (D) allergen challenge.
Figure 2 Eotaxin immunoreactivity (A) and mRNA (B) (in situ hybridization) in 
the nasal mucosa of a patient with allergic rhinitis (A). Eotaxin co-localises with 
cytokeratin (C) in the nasal epithelium as well as with local inflammatory cells.
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• Antigen-presenting cells act at the interface of innate and 
adaptive immunity and are crucial in determining whether 
allergic sensitization or tolerance develops
• The most important antigen-presenting cells the in nasal mucosa 
in allergic rhinitis are myeloid and plasmacytoid dendritic cells 
and Langerhans cells
• Dendritic cells process the allergen into small peptides that are 
presented onto MHCI and MHCII to T cells
• Dendritic cells can induce, maintain and propagate allergic 
inflammation and represent relevant therapeutic targets
The processing and presentation 
of allergens by antigen-present-
ing cells (APC) to T-lymphocytes 
is a prerequisite for allergic sen-
sitization and thus for the allergic 
reaction per se. However such a 
reaction will develop, only under 
specific conditions, while the nor-
mal response that is induced is im-
mune tolerance to allergens. The 
type and amount of allergen as well 
as the context in which APCs come 
into contact with antigens is crucial 
for the final fate of the immunolog-
ic reaction toward the antigen.
A number of different cell types 
are capable of acting as APCs, but 
the most important and effective 
are dendritic cells (DC). Mainly, 
three different types of dendritic 
cells are present in the human na-
sal mucosa: CD11c+ myeloid DCs 
(mDCs) and CD123+ plasmacytoid 
DCs (pDCs), and Langerhans cells 
(CD1a+, CD207+) that have differ-
ent properties and ontogeny. In the 
human nasal mucosa, dendritic cells 
have first been described by Haas, 
and Langerhans cells by Fokkens. 
Recent literature has furthermore 
demonstrated that mDCs and pDCs 
are both present in the mucosa of al-
lergic rhinitis (AR) patients and that 
their reaction after allergen contact 
might promote inflammation.
ANTIGEN PRESENTING 
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DCs process the allergen into 
small peptides that are presented 
onto MHCI and MHCII to T cells. 
They act at the interface of innate 
and adaptive immunity and can 
set the course toward a Th2-type 
allergic reaction or - under differ-
ent circumstances - toward Th1-, 
Th17-, or T regulatory reactions. 
Generally, antigen presentation by 
pDCs will lead to tolerance while 
engagement of mature DCs will 
promote allergic reactions. Impor-
tant determinants for the type of 
immunologic reaction are the cy-
tokine milieu at the site, the time 
of contact and the concurrent ex-
posure to adjuvants, such as diesel 
exhaust particles or enzymatically 
active allergen components.
Apart from their essential role in 
the pathogenesis of allergic re-
actions, dendritic cells have also 
been demonstrated to be relevant 
in the maintenance and propaga-
tion of allergic inflammation and 
thus in the development of clinical 
symptoms.
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Figure 1 Dendritic cells (DC) control the type of the T-cell response. DCs collect allergens at the epithelium, process 
the allergen into peptide fragments and migrate to lymphoid tissue. DCs present the peptides onto MHCII to CD4+ 
lymphocytes. Dependent on the cytokine milieu T-cells differentiate to different phenotypes.
Figure 2 Interaction between 
epithelium, dendritic cells and 
T-lymphocytes. Cofactors and 
protease components of allergen 
activate the innate receptors on 
the epithelium leading to cytokine 
release (TSLP, IL-33, GM-CSF, IL-1) 
by epithelial cells. These cytokines 
activate DCs, induce recruitment of 
basophils, mast cells, and Th2 cells 
who also contribute to a cytokine 
milieu that favors the differentiation 
of naïve T-cells into Th2-lymphocytes.
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• Allergic disease is a case of mistaken identity, where a parasitic T 
and B cell response is triggered against harmless environmental 
molecules
• In allergic disease not only eosinophils of prototypical Th2 
responses are recruited, but also neutrophils of the Th17 type 
and macrophages of the Th1 type play roles
• Plasticity of pro-inflammatory and regulatory T and B cells adds 
a new layer of complexity to the immune response
• Understanding regulatory networks that control T and B cell 
differentiation could potentially identify molecular targets for 
intervention
The general role of T and B lym-
phocytes in the adaptive immune 
response is well established (Fig-
ure 1). Depending on the specific 
microbiological threat the immune 
system encounters a dedicated 
subclass of CD4 T helper cells is 
induced by the interaction and ac-
tivation of dendritic cells. These 
T helper cells in turn may induce 
and activate effector cells such as 
eosinophils or neutrophils, or may 
activate B cells to become plasma 
cells that produce pathogen specif-
ic immunoglobulins.
In the case of allergy, harmless en-
vironmental molecules like grass 
or tree pollen, animal dander, or 
house dust mite droppings are 
mistaken for parasites and the 
immune system elicits a strong 
Th2 and IgE-driven response that 
fails to remove these “irrelevant 
threats” yet does induce the clin-
ical symptoms of rhinorrhoea, 
nasal congestion, and itching. An-
other specific class of T cells, the 
regulatory T cells (Tregs) is able to 
dampen immune responses. Dis-
tinct subclasses of Tregs can be 
discerned that differ in their origin 
(naturally occurring and produced 
in the thymus or induced in the pe-
riphery) and/or expression of the 
differentiation markers Foxp3 and 
THE ROLE OF T- AND 
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The role of T- and B-lymphocytes in allergic disease
CD25, or the expression of the ef-
fector cytokines IL-10 and TGF-be-
ta. Just like the expression of effec-
tor cytokines define and mediate 
the downstream effects of T helper 
cells, the induced or constitutive 
expression of IL-10 and TGF-beta 
by Tregs inhibits the activation of 
other T-, B-, and dendritic cells, or 
the antigen driven activation of 
mast cells. In the case of Foxp3-
CD25 positive Tregs that do not 
produce IL-10 or TGF-beta, a di-
rect physical interaction with other 
T cells blocks the T cell receptor 
mediated activation. Interestingly, 
these Tregs have been shown to be 
part of the mechanism by which al-
lergen immunotherapy suppresses 
symptoms.
T and B cells have been used in 
many in vivo, in vitro, or animal mod-
el systems to study specific diseas-
es like allergy. Current interests try 
to link specific genomic mutations 
(SNPs), expression profiles, or epi-
genetic changes in T and B cells to 
the risk of individuals to develop 
allergy or to study the regulatory 
network that controls the activity 
and functionality of these cells.
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Figure 1 Overview of T and B cells differentiation in relation to potential microbiological threats.
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• Cytokines ensure communication between the immune system 
cells and with other cells of the body and act as a network 
governing the elicitation, amplification and resolution of 
inflammation
• Several subtypes of cytokines are described according to their 
main biological effect: sensing cytokines, T-cell instructing 
cytokines, effector cytokines and resolving cytokines
• Chemokines create a gradient (chemotaxis) that decides which 
type of inflammatory cells and which type of T and B cells are 
recruited in the nasal mucosa in allergic rhinitis
Cytokines are soluble proteins or 
peptides that act as the hormones 
- messengers - of the immune 
system. They confer cell-to-cell 
communication, which may take 
place between adjacent cells (jux-
tacrine) or cells in different organs 
of the body (para- or endocrine). 
A cytokine signal is delivered via 
a receptor on the surface of a 
cell, and since different cells may 
express the same receptor, a cy-
tokine can have several functions 
(pleiotropy) depending on the tar-
get cell.
A special subgroup of cytokines 
is constituted of the so-called 
chemokines that attract leuko-
cytes to the site of inflammation, 
and the immune system uses 
these to move leukocytes in the 
tissues, when they have left the 
bloodstream. The chemokines are 
key players in attracting the leu-
kocytes to inflamed areas such as 
the nose in allergic rhinitis (AR). 
The chemokines have a fairly sim-
ilar biochemical structure, and are 
divided according to the place-
ment of two intramolecular cys-
tin-bridges (Figure 1) into groups: 
CC, CXC or CX3C, where X de-
notes a non-cystein amino acid 
residue.
Various groups of cytokines are 
responsible for the different phas-
es of the allergic sensitization 
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Cytokines and chemokines in allergic rhinitis
(building up the allergic immune 
response) and elicitation (reac-
tions upon exposure to an aller-
gen):
The sensing cytokines (Figure 2, 
yellow), IL-33, IL-25 and TSLP are 
released from the epithelial cells 
of the nasal mucosa and signal to 
the allergen-presenting dendritic 
cells to take up incoming aller-
gens and bring them to the lymph 
nodes.
The T-cell instructing cytokines 
(Figure 2, green) will instruct un-
differentiated T-helper (CD4+) 
cells to develop into differ-
ent kinds of cells, each of them 
equipped for different kinds of im-
mune response: IL-12 and γ-inter-
feron will produce type 1 T-helper 
cells (Th1) that helps fighting bac-
teria and virus, IL-4 leads to Th2 
cells which fights large multicel-
lular parasites like worms, but un-
fortunately also create the allergic 
immune response. Other Th-cell 
types such as Th17 (believed to be 
active in fighting bacterial fungal 
infections, but unfortunately also 
involved in autoimmune diseases), 
and Tregulatory (dampening the 
inflammation) also exists.
T-cell effector cytokines (Figure 
2, red) are the cytokines by which 
T helper cells exerts their action: 
Th2 cells release IL-4 and IL-13, 
which instructs B-cells to produce 
the allergy antibody IgE, IL-5 that 
causes the bone marrow to form 
the eosinophilic granulocyte, and 
IL-9 that together with IL-13 cre-
ates the allergic inflammation e.g. 
in the nose as is the case in allergic 
rhinitis.
Lars K. Poulsen  
National University Hospital 
Copenhagen, Denmark
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Figure 1 Chemokine classes according to their structure. (Copyright Kohidai, L.)
Cytokines and chemokines in allergic rhinitis
Chemokines (Figure 2, purple). 
When chemokines are secreted 
from inflammatory cells, a gradient 
builds up, where the highest con-
centration is closest to the secret-
ing cell, and in this way different 
leukocytes may sense instructions 
about direction. The movement of 
cells up against a gradient is called 
chemotaxis, and the large number 
of chemokines and their corre-
sponding receptors, constitute an 
elaborate system, that can decide 
which inflammatory leukocytes, 
e.g. eosinophils, neutrophils, ba-
sophils or T- and B-cell subpopu-
lations are attracted to a certain 
site in the nasal mucosa. It is likely 
that the organ in which the aller-
gic reaction takes place: the nose, 
the lungs or the skin make use of 
different chemokines, thus also 
transferring organ specificity to 
the inflammatory response. Some 
chemokines may also - at higher 
concentrations - activate leuko-
cytes to release mediators, and in 
this way they become important 
the important directing players 
in the allergic reaction. The most 
important chemokines in the al-
lergic inflammation are eotaxin-1 
(CCL11), eotaxin -2 (CCL24) and 
eotaxin -3 (CCL26) all of which 
act via the CCR3-receptor present 
on eosinophils, basophils and cer-
tain T helper-cell populations. An-
other, more generally acting Th2 
chemokine, is RANTES (CCL5) 
that acts via the CCR5-receptor.
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Figure 2 The complex interplay of cytokines and chemokines inducing, augmenting or resolving inflammation in the 
nasal mucosa in allergic rhinitis
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patients develop rhinitis, others asthma or eczema alone or in 
combination. Conversely the absence of local IgE may explain 
why up to 50% of the population who demonstrate positive 
skin tests/IgE have no clinical manifestations of allergy
• In a minority of patients, typical symptoms of allergic rhinitis 
(AR) are described, but systemic IgE and skin prick tests are 
uninformative. These patients previously labelled as having 
‘non allergic’ or ‘idiopathic’ rhinitis may potentially have a local 
IgE-dependent rhinitis
• Local IgE synthesis in AR was suggested by the detection of 
interleukin 4 and epsilon gene transcripts by in situ hybridization 
in B cells in the nasal mucosa and confirmed in supernatants of 
nasal biopsies cultured in vitro with IL-4 and CD40 ligand
The diagnosis of allergic rhinitis 
(AR) depends upon symptoms of 
nasal itching/sneezing, watery dis-
charge and congestion following 
relevant aeroallergen exposure 
accompanied by objective evi-
dence of IgE sensitivity commen-
surate with the history. However, 
there is a minority of patients, 
who describe typical symptoms 
of AR in whom systemic IgE is un-
detectable and skin prick tests are 
negative.
Huggins and Brostoff were the 
first to demonstrate this phenom-
enon by positive nasal provoca-
tion tests with house dust mite 
extract in patients with perenni-
al symptoms on dust exposure 
but negative skin tests/serum 
IgE concentrations. Subsequent-
ly, local IgE synthesis in AR was 
suggested by the detection of in-
terleukin 4 and epsilon gene tran-
scripts by in situ hybridization in B 
cells in the nasal mucosa (Figure 
1). Local IgE protein production 
was confirmed in supernatants 
of nasal biopsies cultured in vitro 
with IL-4 and CD40 ligand. Actual 
heavy chain gene switch recom-
bination occurring locally, rather 
than as a consequence of recruit-
ment of already-switched B cells, 
was strongly supported by the de-
Stephen R. Durham  
Imperial College 
London, United Kingdom
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tection of local heavy chain DNA 
switch circles and activation-in-
duced cytidine deaminase (AID) 
RNA necessary for local switch 
recombination to occur.
Whereas allergy is regarded as a 
systemic disease, the local pro-
duction of IgE in target organs 
may explain why some patients 
get rhinitis, others asthma or ec-
zema alone or in combination. 
Conversely the absence of local 
IgE may explain why up to 50% of 
the population, who demonstrate 
positive skin tests/IgE have no 
clinical manifestations of allergy, 
although this remains to be test-
ed. Patients previously labelled as 
having ‘non allergic’ or ‘idiopathic’ 
rhinitis may potentially also have a 
local IgE-dependent rhinitis.
In an elegant series of studies 
Rondon, Blanca and colleagues 
have characterised such ‘local al-
lergic rhinitis’ (LAR) in a Spanish 
population. The allergens respon-
sible include house dust mite, 
grass pollen and olive pollen. In 
such patients, serum specific IgE 
and skin tests are uninformative 
and nasal provocation testing with 
the relevant allergen(s) is needed. 
In addition to early and late phase 
symptoms, nasal allergen provo-
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cation in LAR resulted in imme-
diate tryptase release and a more 
delayed release of eosinophil cat-
ionic protein and Th2 cytokines 
in nasal lavage. Somewhat sur-
prisingly they were able to detect 
local IgE in nasal lavage in only a 
proportion of subjects although 
attributed this to low IgE concen-
trations and to the effects of dilu-
tion by nasal lavage.
Outstanding issues include the 
need to establish the prevalence 
of LAR in different countries, the 
natural history of LAR and wheth-
er LAR may respond to usual nasal 
therapies including allergen im-
munotherapy – possibly delivered 
by the nasal route? Nasal provoca-
tion tests require standardisation 
with careful consideration of rel-
evant threshold allergen concen-
trations. Meanwhile the mainstay 
of diagnosis of AR remains a care-
ful history with skin tests and/or 
serum specific IgE, whereas nasal 
provocation has assumed an in-
creasingly important role, not only 
for research, but also for use in 
patients with a clear-cut history in 
whom conventional IgE tests are 
negative (Figure 2).
KEY REFERENCES
1. Huggins KG, Brostoff J. Local pro-
duction of specific IgE antibodies 
in allergic-rhinitis patients with 
negative skin tests. Lancet 1975; 
2:148-150.
2. Durham SR, Gould HJ, Thienes CP, 
Jacobson MR, Masuyama K, Rak S, 
et al. Expression of epsilon germ-
line gene transcripts and mRNA 
for the epsilon heavy chain of IgE 
in nasal B cells and the effects of 
topical corticosteroid. Eur J Immu-
nol 1997;27:2899-2906.
3. Takhar P, Smurthwaite L, Coker HA, 
Fear DJ, Banfield GK, Carr VA, et al. 
Allergen drives class switching to 
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Figure 2 Diagnostic approach in patients with local allergic rhinitis (LAR). (Reprinted from J Allergy Clin Immunol, 
129/6, Rondón C, Campo P, Togias A, Fokkens WJ, Durham SR, Powe DG, Mullol J, Blanca M. Local allergic rhinitis: concept, 
pathophysiology, and management, 1460-1467, Copyright 2012, with permission from Elsevier.)
IgE in the nasal mucosa in aller-
gic rhinitis. J Immunol 2005;174: 
5024-5032.
4. Powe DG, Jagger C, Kleinjan A, 
Carney AS, Jenkins D, Jones NS. 
'Entopy': localized mucosal allergic 
disease in the absence of systemic 
responses for atopy. Clin Exp Aller-
gy 2003;33:1374-1379.
5. Rondón C, Campo P, Herrera R, 
Blanca-Lopez N, Melendez L, Can-
to G, et al. Nasal allergen provoca-
tion test with multiple aeroaller-
gens detects polysensitization in 
local allergic rhinitis. J Allergy Clin 
Immunol 2011;128:1192-1197.
6. Rondón C, Campo P, Togias A, Fok-
kens WJ, Durham SR, Powe DG, et 
al. Local allergic rhinitis: concept, 
pathophysiology, and manage-
ment. J Allergy Clin Immunol 2012; 
129:1460-1467.
Local and systemic IgE in allergic rhinitis
35
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 A
 - A
llergic rhiniti
s - m
echanism
s 
• Humans have the potential to produce at least 1011 antibody 
specificities with five antibody classes that perform different 
functions
• Antibody (immunoglobulin) genes may undergo somatic hyper-
mutation, class switch recombination and affinity maturation to 
generate diversity in the B cell or antibody repertoire
• In sensitised individuals, IgE antibodies enable a rapid and po-
tent immune response (immediate hypersensitivity) to aller-
gens; in allergic rhinitis (AR) this response takes place at the 
initial site of allergen exposure in the nasal mucosa
• Next generation sequencing of expressed immunoglobulin 
genes in AR has revealed the clonal amplification, diversifica-
tion and selection of IgE-expressing B cells in the nasal mucosa
B cells are generated in the bone 
marrow, where they acquire ‘re-
combinatorial diversity’ by the 
random recombination of immu-
noglobulin gene fragments and 
‘junctional diversity’ by the dele-
tion or addition of nucleotides at 
recombination junctions (Figure 
1). Upon activation by antigen, 
mature cells may be further mod-
ified by somatic hypermutation 
(SHM) during affinity maturation. 
Competition for antigen results in 
selective survival and proliferation 
of high affinity clones. In parallel, 
the cells undergo class switch re-
combination (CSR) from IgM to 
IgG, IgA or IgE (direct switching). 
IgG- and IgA- expressing B cells 
can also switch to IgE (sequential 
switching) and this may be the 
predominant pathway for local IgE 
production in allergic rhinitis (AR). 
Sequential switching is correlated 
with affinity maturation in IgE.
Every B cell clone expresses a 
unique immunoglobulin. Diver-
sification of a B cell clone during 
an immune response generates 
clonally related progeny. Clones 
are associated with a hierarchy of 
mutations derived from the orig-
inal immunoglobulin sequence 
assembled in the bone marrow. 
The entire population of B cells in 
IgE REPERTOIRES IN 
ALLERGIC RHINITIS14
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an individual is termed the B cell 
repertoire. Until recently, analy-
sis of the antibody repertoire was 
very labour intensive and limited 
to tens or hundreds of antibody 
sequences. This science has been 
revolutionized by the “next gener-
ation sequencing” (NGS) methods 
in which the sequences of millions 
of DNA molecules can be deter-
mined in parallel in a single exper-
iment, approaching the complete 
repertoire of the B cell population 
in an individual. Pioneering stud-
ies of IgE repertoires by NGS in AR 
have provided valuable insights 
into the ontogeny of IgE-express-
ing cells. Analysis of matched 
blood and nasal biopsy samples 
in rhinitis patients demonstrat-
ed trafficking of B cells between 
blood and the nasal mucosa, sup-
porting previous evidence that 
the nasal mucosa enhances the 
diversification of IgE-producing B 
cells (Figure 2).
In patients with AR, IgE repertoires 
have greater inter- and intra-clonal 
diversity and increased SHM com-
pared to IgE from healthy controls 
(Figure 3). The level of SHM with-
in the ‘allergic’ IgE repertoire was 
strongly influenced by seasonal 
exposure to allergen, particular-
ly in local nasal tissue compared 
to the blood (Figure 4). The close 
Louisa K. James Yu-Chang B. Wu Hannah J Gould
King’s College 
London, United Kingdom
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Figure 1 Diversity and selection of antibody repertoire. In the bone marrow, B cells acquire recombinatorial diversity 
by random shuffling of VDJ segments for the IgM (μ) heavy chain (VH), and VJ for the kappa- (Vk) and lambda- (Vk) 
light-chains. Junctional diversity is simultaneously introduced by addition or deletion of nucleotides at breaks in the 
DNA before end-joining. Antigen exposure may induce SHM and CSR to IgE during affinity maturation of B cells 
in the germinal center of peripheral lymphoid tissue. In allergic patients, the production of IgE contributes to the 
allergic response by sensitising IgE effector cells and antigen-presenting cells for antigen-induced activation. Selection 
checkpoints are imposed to regulate clonal expansion and affinity maturation of B cells.
Figure 2 Formation of IgE lineage 
trees. IgE sequences that share a 
common ancestor are identified by 
alignment to germline sequences. 
Sequences that are more mutated 
are indicated by a darker shade. A 
& C highlight IgE clones that can 
be identified in both blood and 
nasal mucosa. B shows that IgE 
sequences can diversify within 
the nasal mucosal via SHM. Red 
circles indicate blood sequences, 
green circles indicate nasal 
sequences, open white circles 
indicate germline sequences and 
grey circles indicate theoretical 
intermediates that are not 
experimentally sampled.
IgE repertoires in allergic rhinitis
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Figure 3 IgE repertoire differences between healthy controls (left column) and allergic rhinitis (right column). A & B: 
The IgE repertoire in AR encompasses a greater number of clones (i.e. more branches in the phylogenic tree) expressing 
different immunoglobulin genes (VH1-6) compared with healthy controls. C & D: IgE clones in AR contain more mutat-
ed family members as result of intra-clonal diversification. E: IgE sequences (green) share the same ancestors with IgM 
(red), IgA (blue) or IgG (purple) sequences in AR but only with IgM or IgA in healthy controls. C-E: Sequences with darker 
shades of colors are more mutated.
IgE repertoires in allergic rhinitis
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association between SHM and an-
tibody affinity suggests that aller-
gen exposure drives affinity mat-
uration of B cells resulting in high 
affinity IgE that is central to the 
inflammatory allergic response. In 
contrast, in healthy individuals the 
IgE repertoire was less mutated.
Analysis of IgE repertoires in AR 
have provided valuable insights 
into the mechanisms of this dis-
ease and further support the con-
cept that the nasal mucosa is an 
important source of local IgE.
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Figure 4 Increased mutation of IgE in response to seasonal allergen exposure. Seasonal pollen exposure increases SHM 
of IgE clones in the blood (red) and nasal mucosa (blue). The relative proportion of Mutated IgE versus Unmutated IgE 
clones was also altered in AR during the pollen season.
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• A variety of miRs are abnormally expressed in both allergic 
rhinitis (AR) and chronic rhinosinusitis (CRS)
• Inflammation and immune imbalance in AR and CRS may be 
promoted by miRs
• miRNAs have the potential to act as biomarkers of AR and CRS
• The miR expression profiles from different studies in AR have 
displayed a considerable discrepancy
• Functional pathways for miRs in AR and CRS need to be further 
studied
MicroRNAs (miRs) are evolutionally 
conserved small non-coding RNA 
molecules, only 18-22 nucleotides 
in length, which represent one of 
the fundamental epigenetic regu-
latory mechanisms used by cells. 
miRs are transcripted from genomic 
DNA and mature miRNAs are gen-
erated through multiple processes 
controlled by a set of enzymes (Fig-
ure 1). Mature miR is incorporated 
into the RNA-Induced Silencing 
Complex (RISC) and regulates gene 
expression by base pairing of the 
seed sequence to the 3’-UTR of 
target mRNA (Figure 1). Depending 
on the level of complementarity be-
tween miR and its target site, target 
mRNA degradation, translational 
repression, or both occur.
miRNAs are involved in diverse bi-
ologic processes including allergic 
responses. Several miRNAs have 
been found to target a number of 
immune genes such as IL-12p35, 
IL-13, IL-13Rα, Cytotoxic T Lym-
phocyte–associated Antigen 4 
(CTLA-4) and Signal Transducer 
and Activator of Transcription-1 
(STAT-1), as well as to modulate 
the function of various immune 
cells including T cells, dendritic 
cells, and macrophages which in 
turn affects the Th1/Th2 balance 
state (Figure 2).
MicroRNAs IN ALLERGIC 
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miR IN RHINITIS AND 
RHINOSINUSITIS
Particularly in allergic rhinitis (AR), 
the miR profiles in nasal mucosa of 
AR patients have been explored. 
The results from different studies 
are inconsistent and the functions 
of most aberrantly expressed miRs 
remain undefined. MiR-224, miR-
187, miR-143, and Let-7e have 
been reported to be down-regu-
lated, whereas miR-155, miR-205, 
and miR-498 have been demon-
strated to be up-regulated.
Cord blood IgE is associated with 
the development of aeroallergen 
sensitization. Decreased miR-21 
expression in blood mononuclear 
cells has been associated with ele-
vated IgE levels in cord blood and 
AR development. Since it is able 
to suppress Transforming Growth 
Factor beta (TGF-β) receptor 2 
expression in monocytes, miR-21 
has the potential to serve as early 
predictor of AR.
A variety of miR expression profiles 
have been found in patients with 
chronic rhinosinusitis (CRS) with 
nasal polyps (CRSwNP) and with-
out nasal polyps (CRSsNP) in com-
parison with controls. miR-125b 
has been found up-regulated in 
eosinophilic CRSwNP. miR-125b 
is able to induce the production of 
type I interferon (IFN) via silenc-
ing human eukaryotic Initiation 
Factor 4E (eIF4E)-binding protein 
1, which is a translational repres-
sor of interferon regulatory factor 
MicroRNAs in allergic rhinitis and chronic rhinosinusitis
Zheng Liu  
Huazhong University  
of Science and Technology  
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Figure 1 Biogenesis and mechanism of action of miRNAs. Primary miRs (pri-miRNAs) are transcribed by RNA 
polymerase II or III from specific genomic DNA and are processed by the RNase III endonuclease, Drosha, with its 
partner, DiGeorge syndrome critical region gene 8 (DGCR8), into 60-70-nucleotide hairpin miRNA precursors (pre-
miRNAs) in the nucleus. The resulting pre-miRNAs are exported into the cytoplasm and then further processed by 
another RNase III enzyme, Dicer, into the mature miRNAs. One strand of mature miRNA duplex is assembled into 
the RNA-induced silencing complex (RISC). MiRNAs regulate gene expression by repressing translation or directing 
sequence-specific degradation of complementary mRNA. (From: Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr 
Res 2007; 61: 24R-29R).
7. Since type I IFN may promote 
mucosal eosinophilia in CRS, the 
overexpression of miR-125b may 
contribute to eosinophilic inflam-
mation in nasal mucosa (Figure 3).
Overall, the research on miRNAs 
in AR and CRS is still in its early 
stages. The results from differ-
ent studies are inconsistent, the 
functions of most miRs have not 
been well established, and the 
therapeutic effects of miRNAs in 
CRS and AR are still unknown. It 
remains as an unmet need to ad-
dress these important challenges 
in future studies.
MicroRNAs in allergic rhinitis and chronic rhinosinusitis
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Figure 3 The role of miR-125b in eosinophilic inflammation of chronic rhinosinusitis (CRS). MiR-125b-eukaryotic 
translation initiation factor 4E binding protein 1 (4E-BP1)-type I IFN pathway lead to increased production of type I 
IFN which induce B cell-activating factor (BAFF) secretion from epithelial cells and subsequent IgA production and local 
activation of eosinophils. (From: Zhang XH, Zhang YN, Liu Z. MicroRNA in chronic rhinosinusitis and allergic rhinitis. Curr 
Allergy Asthma Rep 2014; 14: 415).
Figure 2 Sketch map depicting the recognized functions of miRNAs and their targets in allergic inflammation. miRs 
inhibit immune genes and cells which in turn affect Th1/Th2 balance in the allergic response. (Reprinted from J Allergy Clin 
Immunol, 132/1, Lu TX, Rothenberg ME. Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases, 3-13, 
Copyright 2013, with permission from Elsevier.)
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• Delayed eosinophil apoptosis contributes to tissue eosinophilia 
and is driven by IL-5
• Eosinophil activation leads to eosinophil cytolysis, a non-
apoptotic type of cell death
• Successful therapies delete eosinophils from tissues
• Specific cell death pathways should be considered as targets 
for anti-allergic therapies
The regulation of cell death in 
allergic rhinitis (AR) has been rel-
atively little investigated and its 
possible contribution to patho-
genesis largely ignored. As with 
other types of inflammatory re-
sponses, the local accumulation of 
different subgroups of leukocytes 
occurs during the initiation and 
maintenance phases, whereas in-
flammatory cell numbers decline 
in the resolution phase of allergic 
inflammation. The changes in cell 
numbers during inflammation are 
largely due to changes in rates, 
both of cell recruitment and of 
cell death. Important leukocyte 
subgroups believed to play criti-
cal roles in the pathophysiology of 
AR are the dendritic cells, T cells, 
mast cells, and eosinophils.
The contribution of cell death to 
the pathogenesis of allergic dis-
eases has recently been summa-
rized elsewhere. Although most 
of the reports published so far 
have not been studies with AR 
patients or animal models, one 
could expect that these findings 
should have relevance for AR. 
For instance, it is likely that epi-
thelial cell damage accompanies 
the allergic inflammation of the 
nasal mucosa. Moreover, the sus-
ceptibility of T cells for undergo-
REGULATION OF 
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ing apoptosis might be regulated 
similarly to other inflammatory 
responses.
The mode of cell death in eosino-
phils has been the subject of most 
studies on cell death regulation 
and inflammation in AR. Eosino-
phils accumulate in the nasal mu-
cosa not only owing to increased 
recruitment, but also as a conse-
quence of delayed apoptosis. The 
major eosinophil survival factor 
seems to be IL-5. Interestingly, 
allergen-specific immunotherapy 
reduced IL-5 production by CD4+ 
T cells in AR patients and anti-IL-5 
antibody therapy has been effec-
tive in patients with nasal polypo-
sis. The beneficial effect of topical 
corticosteroid therapy in AR is 
probably also largely a conse-
quence of the reduced expression 
of Th2 cytokines, including IL-5. 
Besides delayed eosinophil ap-
optosis, eosinophil degranulation 
and cytolysis, which represents a 
form of non-apoptotic cell death, 
have also been observed in AR. It 
has been suggested that eosino-
phil cytolysis occurs without prior 
extensive degranulation and is the 
result of major activation mecha-
nisms distinct from degranulation. 
The molecular mechanisms of eo-
sinophil activation resulting in cy-
tolysis remain to be investigated.
A look at the molecular basis of 
many allergic diseases reveals a 
cell death component that either 
accounts for the disease or con-
tributes to disease progression. 
For instance, following eosinophil 
activation in AR, signaling path-
ways mediating both cell survival 
and cell death are activated. Re-
gardless the cellular response, the 
inflammation is maintained (Fig. 
1). Therefore, current and future 
Regulation of inflammation by cell death in allergic rhinitis
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Delayed apoptosis
Granule protein release
Cytokine release
Lipid mediator production
Reactive oxygen species
Metalloproteinases
Extracellular DNA traps
Cell free granules
Granule protein release
Inflammation & tissue damage
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DAMPs
Activation
Figure 1 Eosinophil activation and their cellular life span. The activation of eosinophils can change their cellular life 
span. Either eosinophils exhibit a prolonged life span owing to cytokine-mediated delayed apoptosis or they undergo 
cytolysis. With delayed apoptosis, eosinophils contribute to the maintenance of inflammation by multiple mechanisms. 
Cytolysis, on the other hand, is associated with massive granule protein secretion. Moreover, cytolysis most likely results 
in the release of damage-associated molecular pattern molecules (DAMPs), which are known to trigger inflammatory 
responses. The release of DAMPs from cytolytic eosinophils remains to be further studied; hence, this pathway is 
indicated with dashed arrows.
anti-allergic therapies should also 
be analyzed with respect to their 
impact on cell death pathways.
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• Allergen-specific Th2 responses are essential for induction of 
allergic rhinitis
• Allergen-specific immunotherapy is the only available curative 
treatment for allergic rhinitis
• Allergen-tolerance is mediated by tolerogenic dendritic cells 
(DCs), regulatory T cells and regulatory B cells
• IL-10 and TGF-beta play a key role in tolerance induction 
through suppression of Th2 responses and basophil/mast cell 
activation, as well as by skewing B cells from IgE production 
towards IgG4 and IgA production
Immune tolerance induction 
through allergen-specific immuno-
therapy (AIT) is currently the only 
curative therapy for several allergic 
diseases including allergic rhinitis 
(AR). The principle for AIT is to in-
duce immune tolerance to an aller-
gen through high-dose exposure 
for prolonged periods of time.
The mechanisms that underlie 
allergen tolerance include chang-
es in dendritic cells (DCs), aller-
gen-specific B- and T- cells, and 
reduced activation of effector 
cells such as basophils, mast cells 
and eosinophils. This results in 
suppression of both immediate 
and late phase responses trig-
gered by allergen exposure.
Already within hours after the first 
injection of the allergenic extract 
used for AIT the level of mast cell 
and basophil degranulation in re-
sponse to allergen exposure is re-
duced. This effect may be attrib-
uted to the gradual inhibition of 
degranulation that may take place 
during the buildup phase of AIT 
and to changes in histamine re-
ceptor 2 expression on basophils.
While Th2 cells are key drivers of 
allergic sensitization, one of the 
hallmarks of allergen tolerance is 
the induction of allergen-specific 
Tregs. Both inducible T regulato-
MECHANISMS OF IMMUNE 
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ry type 1 (TR1) cells and FoxP3+ 
natural Tregs increase during aller-
gen tolerance induction. Through 
the secretion of IL-10 and TGF-β, 
regulatory T cells can suppress 
T helper cell responses and the 
activation and migration of mast 
cells, basophils and eosinophils. 
IL-10 also limits maturation and 
antigen-presentation capacity 
and maturation of DCs. Imma-
ture plasmacytoid DCs can induce 
IL-10-producing TR1 cells, there-
by fueling a positive feedback 
loop promoting tolerance. TGF-β 
is a pluripotent cytokine, which 
can suppress Th1, Th2 and B cell 
responses as well as IgE produc-
tion, while promoting Treg re-
sponses and IgA production by B 
cells (Figure 1).
Dendritic cells (DCs) are key reg-
ulators of allergen-specific im-
mune responses. In response to 
epithelium-derived cytokines 
such as IL-25, IL-33 and TSLP, al-
lergen-loaded DCs promote Th2 
differentiation. Other signals, in-
cluding IL-10, vitamin D3 metabo-
lites, retinoic acid, adenosine and 
histamine can prime immature or 
conditioned mature DCs to induce 
regulatory T cells (Tregs) (Figure 2).
The predominant Th2 response 
during allergic sensitization drives 
B cells to produce allergen-specif-
ic IgE. However, during tolerance 
induction, the production of spe-
cific IgG4 (an immunoglobulin iso-
type that has anti-inflammatory 
properties) rapidly increases. IL-10 
plays an essential role in this pro-
Mechanisms of immune regulation in allergic rhinitis
Willem van de Veen Hideaki Morita Mübeccel Akdis
Swiss Institute of Allergy and Asthma Research 
Davos, Switzerland
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Figure 1 Role of Treg and Breg cells in the suppression of allergic inflammation. Treg cells and their cytokines mainly IL-
10 and TGF-β suppress Th2 type immune responses and control allergic inflammation in many ways. Blue arrows show 
the regulatory and suppressive effects of Treg and Breg cells on: B cells by inducing IgG4 and IgA and suppressing IgE; 
on Th2 cell by suppressing proliferation and homing to tissues; on mast cells, basophils and eosinophils via direct and 
indirect suppressive effects.
Mechanisms of immune regulation in allergic rhinitis
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Th2
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Adenosine
Histamine
TReg
DC Figure 2 Distinct role of the micromilieu of dendritic cells in 
driving T cells differentiation. IL-33, 
IL-25 and TSLP promote Th2 cells 
differentiation through DCs. In 
contrast, other signals such as vitamin 
D3 metabolites, IL-10, retinoic acid, 
adenosine and histamine induce Treg 
cells through DCs.
cess through suppressing IgE pro-
duction and enhancing IgG4 pro-
duction. In addition to Treg cells, 
IL-10-producing B regulatory cells 
can potently suppress T cell prolif-
eration and upregulate IgG4 pro-
duction. The frequency of these 
cells is upregulated during AIT 
(in a bee venom immunotherapy 
study). Their role in the regulation 
of respiratory allergies remains 
to be determined. Thus, IL-10, 
which can be produced both by 
T- and B-cells, modulates the al-
lergen-specific humoral response 
from IgE towards IgG4. The role 
of the recently described innate 
lymphoid cells (ILCs) in this intri-
cate cellular interplay is largely 
unknown. A recent study demon-
strated a reduction of peripheral 
ILC2s during the pollen season 
in AR patients who received AIT 
(Figure 1).
In conclusion, many cells and mol-
ecules play their part in the regu-
lation of immune responses in AR 
and many processes remain to be 
further elucidated.
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pathogenesis of allergic rhinitis (AR)
• Cysteinyl leukotrienes (CysLT) and prostaglandin D2 (PGD2) 
are potent proinflammatory mediators that are released into 
nasal secretions of patients with AR. The role of prostaglandin 
E2 in AR remains to be clarified
• Lipoxins are released into nasal secretions of patients with AR 
and appear to exert anti-inflammatory effects
• Antagonists of the CysLT1 receptor improve symptoms in 
patients with AR. The potential therapeutic effect of antagonist 
of the DP2 receptor of PGD2 and of lipoxin analogs remains to 
be demonstrated
Arachidonic acid (AA) is released 
from the cell membrane phospho-
lipids by activated phospholipas-
es A2. When AA is metabolized 
through the 5-lipoxygenase (5-
LO) enzyme pathway leukotrienes 
(LT) B4 (LTB4) and cysteinyl leu-
kotrienes (CysLT), LTC4, LTD4 and 
LTE4 are generated (Figure 1).
Five G protein-coupled recep-
tors (GPCR) receptors for LT have 
been cloned: BLT1 and BLT2 
which bind LTB4, CysLT1 and 
CysLT2 which bind CysLTC4 and 
LTD4 and CysLT3R receptor se-
lective for LTE4 (Figure 1). Neu-
trophils preferentially generate 
LTB4, whereas mast cells, baso-
phils and eosinophils preferen-
tially generate CysLT.
CysLT exert multiple biological 
activities including recruitment 
of eosinophils, stimulation of air-
way mucus secretion and up-reg-
ulation of the inflammatory cy-
tokines.
AA can also be converted via the 
cyclooxygenase (COX) pathway 
into prostaglandins (PG), PGE2, 
PGD2, PGF2alpha, PGI (prostacy-
clin), and TXA2 (tromboxane). Mast 
cells preferentially generate PGD2. 
There are two isoforms of COX, a 
basal or constitutive form (COX-
1) and an inducible form (COX-2). 
LIPID MEDIATORS IN ALLERGIC 
RHINITIS: INFLAMMATION AND 
RESOLUTION OF INFLAMMATION
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The role of PGs in the inflammato-
ry response is often ambiguous. In 
certain settings, PGs exert inflam-
matory functions (PGE2, PGD2, 
PG2alpha, TXA2), but in others, 
they appear to act as anti-inflam-
matory endogenous molecules 
(PGE2, PGD2) (Figure 2).
Lipoxin A4 (LXA4) can be generat-
ed either by the sequential lipox-
ygenation of AA by the 15-lipox-
ygenase (15-LO) in epithelial cells 
and 5-LO in leukocytes, or by the 
production of LTA4 by 5-LO in leu-
kocytes, which is converted into 
LXA4 by a platelet 12-LO. Lipox-
ins exert anti-inflammatory and 
pro-resolution effects through the 
activation of their GPCR FPRL-1.
CysLT and PGD2 are elevated in 
nasal fluids from symptomatic al-
lergic rhinitis (AR) patients com-
pared with healthy controls. In 
contrast, LTE4 and PGD2 levels 
measured in nasal biopsies were 
found significantly lower in AR 
than in controls.
Allergen nasal provocation in-
creases CysLT, LTB4 and PGD2 re-
lease during the early phase of the 
nasal allergic response (1-2). Cys-
LT concentrations also increase 
during the late phase response. 
Treatment with CysLT1 receptor 
Lipid mediators in allergic rhinitis: inflammation and resolution of inflammation
César Picado  
Hospital Clinic. University of Barcelona 
Barcelona, Spain
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antagonists reduces nasal symp-
toms (congestion, rhinorrhea, pru-
ritus and itching). Various DP2 an-
tagonists are currently in clinical 
development to treat AR.
PGE2 levels in nasal lavage flu-
id have been found higher, simi-
lar and lower in symptomatic AR 
compared to healthy controls. No 
changes or increased release of 
PGE2 have been reported after 
allergen nasal challenge.
Concentrations of LXA4 in lavage 
nasal fluid are higher in patients 
with AR rhinitis compared with 
controls. LXA4 inhibits release of 
inflammatory mediators such as 
interleukin 8 and tumor necrosis 
alpha. LXA4 analogs can be po-
tential regulators of inflammation 
in AR.
Membrane phospholipids
PLA2
Arachidonic acid
5-LO
FLAP
LTB4
LTA4
LTB4R2LTB4R
LTC4
CYSLT1R CYSLT2R
CYSLT3R
LTD4
LTE4
LTA4
Hydrolase
LTA4
Synthase
Figure 1 Arachidonic acid (AA) released from cell membrane phospholipids by phopholipase 2 can be converted by 
the 5-lipoxygenase-activating protein (FLAP) and the 5-lipoxygenase (5-LO) into leukotrienes (LT) A4 (LTA4), which 
can be further metabolized either into leukotriene B4 (LTB4) in cells that express the LTA hydrolase enzyme, such as 
neutrophils, or into the cysteinyl leukotrienes, LTC4, LTD4 and TLE4 in cells equipped with the LTC4 synthase such as 
eosinophils and mast cells. BLT1 and BLT2 receptors bind LTB4. CysLT1, CysLT2 bind CysLTC4, LTD4 and and CysLT3R 
binds LTE4. CysLTs are chemotactic factors for eosinophils and play an important role in the pathogenesis of allergic 
rhinitis especially in nasal obstruction. CysLT1 receptor antagonists can modulate nasal inflammation by inhibiting 
allergen-induced influx of eosinophils into the nasal mucosa.
Lipid mediators in allergic rhinitis: inflammation and resolution of inflammation
50
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 A
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
m
ec
ha
ni
sm
s  
EP1
Membrane phospholipids
PLA2
Arachidonic acid
COX-1
COX-2
TXA2 PGF2α PGE2 PGI2 PGD2
EP2 EP3 EP4 IP DP1 DP2TP FP
NSAIDs
Coxibs
Figure 2 Prostanoids are derived from AA by the action of cyclooxygenases (COX). COX-1 exerts physiological 
functions while COX-2 is upregulated in inflammation. Prostanoids can be subdivided into three groups: prostaglandins, 
prostacyclins and thromboxanes. They are synthesized by specific enzymes and interact with nine PG receptors named 
by the letter “P” and a prefix of “D”, “E”, “F”, “I”, or “T” to signify preference for PG. Four subtypes receptors (EP1-EP4) 
are described for PGE2, two for PGD2 (DP1 and DP2), one for PGF2alpha (FP), prostacyclin (IP), and thromboxane A2 
(TXA2) respectively. PG receptors belong to G protein-coupled receptors. Under normal conditions prostanoid levels in 
cells are low but during inflammation the nature and concentrations of protanoids can change dramatically. Prostanoids 
are viewed as part of complex regulatory networks of inflammation. The potential therapeutic effects of DP2 receptor 
antagonist in allergic rhinitis is currently being investigated.
 KEY REFERENCES
1. Shirasaki H. Cysteinyl leukotrine re-
ceptor CysLT1 as a novel therapeu-
tic target for allergic rhinitis. Ex-
pert Opin Ther Targets 2008;12: 
415-423.
2. Sugimoto M, Sugiyama S, Yanag-
ita N, Ozawa T. Laser high per-
formance liquid chromatography 
determination of prostaglandins in 
nasal lavage fluid in allergic rhini-
tis. Clin Exp Allergy 1994;24:324-
329.
3. Shahab R, Phillips DE, Jones AS. 
Prostaglandins, leukotrienes 
and perennial rhinitis. J Laryngol 
Otol 2004;118:500-507.
4. Prat J, Mullol J, Ramis I, 
Roselló-Catafau J, Xaubet A, Nerin 
I, et al. Release of chemical medi-
ators and inflammatory cells influx 
during early allergic reaction in the 
nose: effect of furosemide. J Aller-
gy Clin Immunol 1993;92:248-254.
5. Shimizu S, Ogawa T, Seno S, Kou-
zaki H, Shimizu T. Pro-resolution 
mediator lipoxin A4 and ist re-
ceptot in upper airway inflam-
mation. Ann Otol Rhinol Laryn-
gol 2013;122:683-689.
Lipid mediators in allergic rhinitis: inflammation and resolution of inflammation
51
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 A
 - A
llergic rhiniti
s - m
echanism
s 
• The epithelium in upper airways is the first line of defence 
against extrinsic agents including bacteria, pollen and other 
pathogens
• The epithelial barrier may become disrupted by different agents 
including pollens and proinflammatory cytokines
• The epithelial-derived thymic stromal lymphopoietin (TSLP) 
may preserve the epithelial barrier and induce tight junctions 
between dendritic cells during the early stage of allergic rhinitis 
(AR) 
• In severe AR, marked upregulation of TSLP and disruption of 
the epithelial barrier are observed 
The epithelial barrier in upper and 
lower airways forms the first line 
of defence against intruding aller-
gens, pollutants and pathogens. 
It is therefore a prerequisite to 
maintain an intact and functioning 
epithelium in order to keep the 
submucosal equilibrium balanced 
and not to promote inflammation. 
The epithelial barrier in the nose 
and paranasal sinuses consists of 
a pseudostratified, ciliated, epi-
thelium that is held together by 
structures like tight junctions, 
desmosomes, adherens junctions 
and gap junctions. Furthermore, 
barrier function is promoted by 
proteins that have antimicrobi-
al properties such as defensins, 
cathelicidins, lysozyme and lacto-
ferrin, as well as others. The S-100 
protein family contributes to 
these antimicrobial effects, while 
influencing innate immunity and 
Toll-like receptors (Figure 1).
One of the main contributors to 
the barrier function is the tight 
junctional belt. Tight junctions are 
formed by the integral membrane 
proteins Claudins, Occludin, lipol-
ysis-stimulated lipoprotein recep-
tor (LSR) and junctional adhesion 
molecules (JAMs,) and by many 
peripheral membrane proteins, 
including the scaffold PSD95-Dlg-
THE EPITHELIAL BARRIER 
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The epithelial barrier in the nose
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ZO1 (PDZ)-expression proteins 
Zonula occludens and the non-
PDZ  -expressing proteins. These 
tight junctions are controlled by 
various cytokines and growth fac-
tors via distinct signal transduc-
tion pathways. The tight junction 
molecules are expressed in both 
membranous or microfold cells 
(M cells) and dendritic cells (DCs) 
as well as by the epithelial cells of 
upper airways (Figure 2). Various 
antigens are sampled, transport-
ed, and released to lymphocytes 
through the cells in nasal mucosa, 
while they maintain the integrity 
of the barrier. Expression of tight 
junction molecules and the barri-
er function in normal human na-
sal epithelial cells (HNECs) are af-
fected by various stimuli including 
growth factors, TLR ligands and 
cytokines etc (Table 1). In addition, 
epithelial-derived thymic stromal 
lymphopoietin (TSLP) which is a 
key factor for allergic inflammato-
ry diseases including allergic rhini-
tis (AR), enhances the barrier func-
tion together with an increase of 
tight junction molecules in HNECs 
and DCs (Figure 3).  In severe or 
chronic AR, marked upregulation 
of TSLP and disruption of tight 
junctions are observed (Figure 3). 
Pollens and their proteolytic en-
zymatic properties are capable of 
disrupting tight junctions facilitat-
ing their intrusion.  Upper airway 
epithelium has been shown to 
have an increased permeability in 
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Figure 1 The nasal epithelial barrier and influencing agents.
Figure 2 Putative sealing intercellular spaces by tight junction molecules 
in the upper airway epithelium including epithelial cells, M cells and 
dendritic cells. (From Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi 
J, et al. Regulation of tight junctions in upper airway epithelium. Biomed Res 
Int 2013;2013:947072.)
The epithelial barrier in the nose
Th2 driven inflammation of chron-
ic rhinosinusitis with polyps and 
leakiness of sino-nasal epithelial 
cell cultures was promoted by IL-4 
and IFN-g. This is in line with oth-
er research results from Th2 driv-
en inflammatory conditions such 
as asthma. Further studies of the 
epithelial barrier in upper airways 
should provide new insights not 
only into pathological conditions 
in AR but also to provide new 
therapeutic targets.
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TABLE 1
Changes of tight junction proteins and barrier function in HNECs in vitro
Intervention Tight junction proteins Barrier function
Fetal bovine serum CLDN-1↑; CLDN-4↑ upregulation
Growth factor TGF-β CLDN-4↑ no change
PKC activator TPA CLDN-1↑; OCLN↑; ZO-1↑; ZO-2↑ upregulation
PPARγ ligands
Rosiglitazone CLDN-1↑; CLDN-4↑; OCLN↑; TRIC↑
upregulation
Troglitazone CLDN-1↑; CLDN-4↑; OCLN↑
TLR3 ligand Poly I:C JAM-A↓ no change
Allergen Der P 1 CLDN-1↓, JAM-A↓ downregulation
Virus RSV CLDN-4↑; OCLN↑ upregulation
Bacteria Pseudomonas aeruginosa elastase CLDN-1↓; CLDN-4↓; OCLN↓; TRIC↓ downregulation
microRNA miR-146a mimic CLDN-1↑; OCLN↑; JAM-A↑ upregulation
GJIC activator Irsogladine maleate CLDN-1↑; CLDN-4↑; JAM-A↑ upregulation
Cytokine IL-4 OCLN↓, ZO↓ downregulation
Cytokine IL-17a no changes observed no change
Cytokine IFN-g stratification downregulation
Cytokine TSLP CLDN-1↑; CLDN-4↑; CLDN-7↑; OCLN↑ upregulation
Abbreviations: CLDN = claudin; Der p = Dermatophagoides pteronyssimus; GJIC = Gap junction intercellular communication; IFN = in-
terferon; IL= interleukin; JAM = junctional adhesion molecules; OCLN = occluding; PKC = protein-kinase C; PPAR = Peroxisome prolifera-
tor-activated receptor; RSV = respiratory syncytial virus; TLR = Toll-like receptor; TSLP = epithelial-derived thymic stromal lymphopoietin; 
TGF-β= transforming growth factor β; TPA= 12-O-tetradecanoyl-Phorbol-13-acetate; TRIC = tricellulin; ZO = zonula occludens
Figure 3 Regulation of the epithelial-derived TSLP 
and tight junctions of epithelial and dendritic cells 
in allergic rhinitis.
The epithelial barrier in the nose
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s  • The sensory innervation of the nose conveys sensations of itch, 
airflow (epithelial cooling), irritation (nociception), and possibly 
congestion due to venous sinusoid dilation
• Histamine stimulates H1 receptors on type C neurons to induce 
itch
• Histamine – independent itch may contribute to persistent 
allergic rhinitis
• Itch is mediated by a subset of pain neurons
• Allergic inflammation is likely to modify afferent receptors, 
combinations of neurotransmitters, and spinal cord dorsal horn 
central sensitization that mediates neuropathic itch
• Itch pathways can interfere with cognition leading to disability 
and allergic fatigue
ITCH – PAIN NERVES
Unmyelinated Type C trigeminal 
neurons innerve the nasal epi-
thelium (Figure 1). These highly 
branched nerve endings also ex-
tend to submucosal gland acini. 
Arteriovenous anastomoses of 
venous sinusoids are innervated 
by sympathetic neurons. Sinusoi-
dal walls are richly innervated but 
their neural regulation is poorly 
understood. Filling of sinusoids 
determines obstruction to airflow 
and the nasal cycle.
Histamine stimulates H1-re-
ceptors to depolarize an “itch” 
sub-population of pain-conveying 
(nociceptive) neurons to cause the 
pruritus of allergic rhinitis (AR). 
Histamine – independent itch in-
duced by protease activated re-
ceptors and other mediators oc-
curs in chronic diseases including 
eczema, but this mechanism is not 
well studied in the human nose.
Co-localized neurotransmitters in-
clude calcitonin gene related pep-
tide (CGRP), a potent vasodilator; 
neuromedin B (NMB, closely re-
lated to gastrin releasing peptide 
(GRP); the tachykinins neurokinin 
A (NKA) and substance P (SP) 
that are more potent for glandu-
lar exocytosis; and possibly glu-
tamate, an excitatory amino acid 
NEURO - IMMUNE 
MECHANISMS IN ALLERGIC 
RHINITIS
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Neuro - immune mechanisms in allergic rhinitis
neurotransmitter. In human nasal 
mucosa, neural depolarization by 
hypertonic saline stimulates ax-
onal transmission of pain to the 
spinal cord and local release of 
neuropeptides from the branched 
nerve endings. This axon response 
stimulated seromucous gland ex-
ocytosis. Local CGRP release may 
stimulate plasma exudation from 
the most superficial sub-base-
ment membrane vessels, but does 
not appear to cause venous sinu-
soid filling or nasal obstruction. 
This is unlike rodents that have 
few glands and stronger vascular 
responses to neuropeptides.
Patterns of immune and epithelial 
cell gene expression and allergic 
mediator release differ between 
seasonal and perennial AR. Medi-
ators such as leukotriene B4 and 
nerve growth factor significantly 
influence sensory receptor, neu-
rotransmitter, and inhibitory au-
toreceptor expression. The range 
of afferent sensitivity is increased 
by expression of endothelin and 
bradykinin receptors, and the trio 
of transient receptor potential 
vanilloid 1 (TRPV1), purinergic 
P2X receptors and acid sensing 
ion channel 3 (ASIC3). The trio 
responds to ATP, adenosine, H+, 
James N. Baraniuk  
Georgetown University 
Washington DC, USA
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K+, and Ca+2 released from injured 
cells. Neural plasticity may also 
contribute to mucosal hyperal-
gesia in idiopathic nonallergic 
rhinopathy. Glucocorticoids may 
reverse some neuronal plasticity 
effects indirectly by inhibiting cy-
tokine and mediator release.
Aδ NEURONS
Thinly myelinated Aδ neurons 
express “cool,” menthol-sensitive 
transient polarization receptor 
melanostatin 8 (TPM8) ion chan-
nels. Inhalation of ambient air 
evaporates water from the epi-
thelial lining fluid. This cools the 
epithelium and activates Aδ affer-
ents. Their brainstem connections 
help control the work of breathing 
and sense of dyspnea.
CENTRAL CONNECTIONS
Itch and nociceptive neurons en-
ter the pons, turn caudally in the 
trigeminal spinal tract and termi-
nate on dorsal horn pars cauda-
lis interneurons of the first three 
cervical segments. Glutamate 
may depolarize the interneurons 
via N-methyl-D-aspartic acid 
(NMDA) receptors. Under normal 
conditions, these interneurons are 
difficult to depolarize. However, 
prolonged glutaminergic depolar-
ization of AMPA (α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropi-
onic acid) ion channels overcomes 
the normal “blocked gate” activity, 
and allows interneuron depolar-
ization and increased respon-
siveness to co-released peptide 
neurotransmitters. This subacute 
process of “central sensitization” 
also attenuates the ability of 
brainstem descending opioid and 
noradrenergic anti-prurinergic 
neurons to prevent interneuron 
depolarization.
Itch interneurons may use GRP as 
a neurotransmitter. They cross the 
midline, enter the lateral trigemi-
nothalamic tract, and terminate 
in the medial thalamus. Axonal 
branches innerve the superior sal-
ivatory nucleus and recruit bilater-
al parasympathetic reflexes. These 
reflexes stimulate muscarinic M3 
receptor-mediated gland exocy-
tosis and seromucous rhinorrhea 
in AR, and explain the benefits of 
anticholinergic nasal drugs. The 
sneeze reflex is a complexly or-
chestrated response to clear the 
nasal airway of irritants (Figure 2).
The concept of “Allergic Fatigue” 
is attributed to Melvyn Danzig 
(1989). Tertiary thalamic nerves 
convey mucosal sensations to 
the “interoceptive cortex” in the 
posterior insula. Based on pain 
models, summation of prurito-
genic messages eventually leads 
to activation of the anterior insula 
where the sensation of nasal itch 
becomes perceived by the con-
Figure 1 Histamine-sensitive itch nerves in nasal mucosa. Itch-pain Type C neurons (black line) are depolarized in the 
epithelium by histamine and other mediators. They release co-localized CGRP, SP, NKA and NMB in the mucosa by 
the axon response that leads to glandular exocytosis in humans. Glutamate is likely the predominant neurotransmitter 
at secondary spinal cord dorsal horn neurons. Sensation is conveyed via spino-thalamic and thalamo-cortical tracts. 
Itch enters conscious perception in the anterior insula, that in turn leads to cognitive dysfunction and allergic fatigue. 
Significant reflexes include the brainstem parasympathetic arc causing seromucous rhinorrhea, and supratentorial itch - 
sneeze reflex.
Neuro - immune mechanisms in allergic rhinitis
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scious mind. These perceptions 
interfere with salience and exec-
utive control brain networks, and 
explain the negative impact of AR 
on school or work performance 
and on other cognitive functions. 
Anterior insula efferent pathways 
activate brainstem sympathetic 
(right insula) and parasympathetic 
(left insula) autonomic discharges.
KEY REFERENCES
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nociception and pruritus. Curr 
Allergy Asthma Rep 2012;12:104-
114.
2. Liu T, Ji RR. New insights into the 
mechanisms of itch: are pain and 
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1671-1685.
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4. Ständer S, Raap U, Weisshaar E, 
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er H, et al. Pathogenesis of pruri-
tus. J Dtsch Dermatol Ges 2011; 
9:456-463.
Figure 2 The sneeze. Irritation of nasal afferents (1) leads to a large inhalation (2). The soft palate, uvula and 
tongue move to occlude the hypopharynx and occlude the efflux of air (3) as thoracic muscles contract and increase 
intrathoracic pressure (4.). The uvula is suddenly depressed (5) and the column of air is forcefully expelled with high 
speed and shearing forces through the nasopharynx and cavities. Applying pressure to the nasal columella early in the 
sequence can abort the sneeze reflex.
Neuro - immune mechanisms in allergic rhinitis
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• Nasal hyperreactivity is defined as ‘increased sensitivity of the 
nasal mucosa to commonly encountered nonspecific stimuli’
• Nasal mucosal epithelial cells, nasal vascular and glandular 
tissues, and neuromodulatory systems as well as other different 
mechanisms are involved in nasal hyperreactivity
• Cold dry air provocation tests are useful adjunct tools for the 
evaluation of nasal hyperreactivity
CONCEPT AND DEFINITIONS
Many patients with rhinitis often 
suffer from aggravation of their 
nasal symptoms after exposure 
not only to allergenic stimuli, 
such as house dust mites, pets, or 
fungi, but also to non-allergenic, 
non-specific stimuli, such as cig-
arette smoke, cold air, perfume, 
or air pollutants. This increased 
sensitivity of the nasal mucosa to 
commonly encountered nonspe-
cific stimuli is defined as “nasal 
hyperreactivity.”
PATHOPHYSIOLOGIC 
MECHANISMS
Although there is still much to be 
elucidated, it is assumed that dif-
ferent tissues such as the nasal 
mucosal epithelial cells, nasal vas-
cular and glandular tissues, and 
neuromodulatory systems as well 
as other different mechanisms are 
involved in nasal hyperreactivity. 
As the first step, damage to the 
epithelium and increased epitheli-
al permeability affect the afferent 
sensory nerve endings and trigger 
the release of several mediators 
(such as histamine) from mucosal 
mast cells. Increased sensitivity 
of the sensory nerve ending itself 
augments hyperreactivity. Addi-
tionally, the increase in the levels 
of non-adrenergic non-cholin-
NASAL 
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Nasal hyperreactivity
ergic neurotransmitters (such as 
neuropeptide Y and vasoactive 
intestinal peptide) may activate 
the cholinergic system and cause 
vasodilation of the nasal vascula-
ture, increasing secretion from na-
sal glands and aggravating symp-
toms such as nasal stuffiness and 
post-nasal drip.
CLINICAL ASSESSMENT
Provocation tests using various 
substances have been used to eva-
laute nasal hyperreactivity. Phar-
macologically active substances 
used for nasal provocation include 
histamine and methacholine. 
Cold dry air (CDA) is an example 
of a non-pharmacologic physical 
stimulus. In order to quantify the 
changes induced by provocation 
inside the nasal cavity various 
methods can be used, ranging 
from nasal symptoms scores to 
rhinomanometry, peak flowmetry, 
and acoustic rhinometry. Howev-
er, there is still no widely accepted 
single provocation method or di-
agnostic standard.
CDA provocation has been proven 
to be superior to histamine provo-
cation in clinical settings and cor-
relates well the provocation tests 
using histamine or methacholine. 
The machinery for creating CDA 
could be simply made using a re-
frigerator, a pressure regulator, 
and a mist separator (Figure 1). By 
performing acoustic rhinometry 
before and after the provocation, 
changes in the volume and dimen-
sions of the nasal cavity induced 
by CDA can be measured. and are 
reliable diagnostic criteria for the 
diagnosis of nasal hyperreactivity.
Young Hyo Kim Tae Young Jang
Inha University College of Medicine 
Incheon, Republic of Korea
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CONCLUSION
Nasal hyperreactivity is a very 
common phenomenon among pa-
tients with allergic or non-allergic 
rhinitis. Although it significant-
ly impairs their quality of life, we 
know very little about its mech-
anism and there are no standard 
diagnostic criteria or therapeutic 
strategies. Therefore, more stud-
ies are needed to better under-
stand this phenomenon.
KEY REFERENCES
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Head Neck Surg 2011;144:91-95.
Figure 1 Cold dry air (0°C, <10% of relative humidity) can be produced by passing air through a refrigerator, a mist 
separator, and filters. Cold dry air is supplied to patients’ nose using pediatric CPAP (Continuous Positive Airway 
Pressure) masks (approximately 400 L in 6 minutes).
Nasal hyperreactivity
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• New and improved animal models are being established for 
allergic rhinitis (AR)
• Animal models are particularly useful for identifying novel 
cellular and molecular immunological mechanisms of AR
• No single animal model completely recreates all the aspects of 
AR
Animal models have been devel-
oped for almost all types of aller-
gic disease such as allergic rhinitis 
(AR), asthma, food allergy and ana-
phylaxis, atopic dermatitis and al-
lergic conjunctivitis. These animal 
models are important to examine 
the mechanism of the disease and 
define the pathogenic pathways, 
such as the activity of genes and 
cellular pathways, explore the role 
of environmental factors (such as 
the microbiota), suggest new ther-
apeutic options and predict the 
safety of new drugs or chemicals 
before being used in clinical stud-
ies, The ideal animal model should 
reflect the disease pathophysiolo-
gy as closely as possible and new 
models are essential for the devel-
opment of new therapies.
Laboratory mice do not spontane-
ously develop AR and a range of 
sensitization and challenge pro-
tocols have been developed. The 
number of sensitizations and chal-
lenges can vary, but typically ani-
mals are sensitized to the allergen 
via intraperitoneal injection fol-
lowed by intranasal allergen chal-
lenge. Disease severity measures 
include sneezing frequency, nose 
rubbing motion frequency and na-
sal tissue histology. Nasal lavage 
fluid and nasal tissue are utilized 
ANIMAL MODELS OF 
ALLERGIC RHINITIS22
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Animal models of allergic rhinitis
to determine local cytokine levels 
and analyze the type of inflam-
matory infiltrate and lymphocyte 
polarization. AR can be influenced 
by the genetic background of the 
mice, the allergen, type of the sen-
sitization and challenge protocol 
and contamination of the allergen 
with stimulating substances (e.g. 
LPS). Certain protocols require 
the combination of allergen with 
an adjuvant, for example alumin-
ium hydroxide (ALOH3, Alum). Of 
note, the dosage form of Alum 
adjuvant is decisive. The inclusion 
of Staphylococcus aureus entero-
toxin B is thought to support the 
formation of nasal polypoid le-
sions. The sensitization, challenge 
and analysis parameters of murine 
allergy models are summarized in 
Figure 1.
Although murine models of AR 
provide important insights into 
the disease mechanisms, there 
are some limitations that should 
be considered. In addition to the 
genetic and physiological differ-
ences between humans and mice, 
rats or rabbits, there are also lim-
itations due to complexity of this 
disease. One can replicate impor-
tant components of the disease, 
but no single model accurately 
models all the features of AR. This 
is very important to take into ac-
count when choosing the correct 
model to address the specific ex-
perimental question. For example, 
chronic exposure to the allergen 
may be required to examine many 
of the structural changes associ-
ated with AR. Notwithstanding 
the limitations of these models, 
several studies carried out in an-
imal models have given important 
clues that explain the pathophys-
iological conditions related to the 
disease status. For instance, the 
role of Th2 type cytokines and T 
Liam O’Mahony  
Swiss Institute of Allergy and Asthma Research 
Davos, Switzerland
60
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 A
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
m
ec
ha
ni
sm
s  
regulatory cells in the pathogene-
sis of allergy have been particular-
ly well-studied in animal models.
Human clinical studies remain the 
gold standard for determining the 
clinical efficacy of new therapeu-
tic approaches. Murine models 
will continue to provide important 
mechanistic clues, while improved 
models may extend our under-
standing of the basic mechanisms 
for examining new therapeutic 
options.
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Figure 1 Overview of the experimental steps commonly used in allergic rhinitis models. Animal models typically 
comprise a sensitization, a challenge, and an analyses phase. After sensitization, allergic responses are provoked by 
intranasal application of the allergen. The severity and mechanisms of the allergic response are determined using a 
variety of approaches.
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s • Global rising trend of allergic rhinitis (AR) has been observed 
in the past decades. The prevalence vary widely particularly in 
the developing nations. One- quarter of the global population 
may be affected
• Increased urbanization and improvement in living standards 
contributed to an increased exposure to a variety of indoor and 
outdoor pollutants and allergens, hence the raise in prevalence
• Most studies are based on data collection for seasonal AR. True 
prevalence of AR is being underestimated
• Large scale coordinated studies specifically designed to estimate 
the prevalence of AR in regions with different environmental 
factors and climates are needed
Allergic rhinitis (AR) affects up to 
40% of the population worldwide. 
High prevalence is being record-
ed in the developed nations of 
the Northern Hemisphere, with 
23-30% affected population in 
Europe and 12-30% in the USA. 
Great diversity of prevalence is 
found in the non-Western popula-
tions of the Southern Hemisphere, 
with wide inter- and intra-regional 
variations ranging from 2.9% to 
54.1% between countries. Figure 
1 shows the reported prevalences 
of different countries, albeit with-
out a uniform definition of AR.
FACTORS INFLUENCING THE 
PREVALENCE OF AR
The prevalence of seasonal AR 
is higher in children and adoles-
cents, while perennial AR seems 
to be more common in adults. In 
children, boys outnumber girls in 
terms of prevalence but tendency 
reverses in puberty and by adult-
hood, both sexes are being equally 
affected. This observed trend may 
be due to the female personality 
of self-reporting diseases or to 
a true impact of female sex hor-
mones on disease development.
There is very little inter-racial var-
iations implying that environmen-
tal factors seem have a greater 
influence than genetic differenc-
EPIDEMIOLOGY OF ALLERGIC 
RHINITIS THROUGHOUT THE 
WORLD
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es. Increased urbanization and 
improvement in living standards 
especially in the developing re-
gions have increased exposure to 
a variety of indoor and outdoor 
pollutants and allergens, all con-
tributing to the increased preva-
lence. Climatic factors may direct-
ly affect the presenting symptoms 
or indirectly through allergens, 
sensitizing agents and population 
lifestyle.
PREVALENCE OF AR IN 
CHILDREN
The International Study of Asth-
ma and Allergies in Childhood 
(ISAAC) program phases I, II and 
III held in more than 237 centers 
in 98 countries worldwide using 
standardized methodology, have 
demonstrated major worldwide 
variations for AR prevalence in 
children, with the lowest preva-
lence being observed mainly in 
centers from middle/low income 
countries, particularly in Africa/
Latin America. ISAAC phase III 
repeated the same questionnaire 
to assess the time trends 5-10 
years after the initial phase I, and 
showed that the prevalence of AR 
is increasing in most of the areas 
with a few exceptions. Some of 
the highest increases were ob-
served mainly in the non-Western 
region, particularly Asia-Pacific, 
as opposed to the western pop-
Epidemiology of allergic rhinitis throughout the world
Michael C.F. Tong Janice S.C. Lin
The Chinese University of Hong Kong 
Hong Kong
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ulation like North America where 
AR prevalence tends to gradually 
decline.
PREVALENCE OF AR IN ADULTS
Global coordinated studies such 
as ISAAC in children are lacking. 
Population based cohort studies 
reported in Asia Pacific, Australia 
and Eastern Europe have demon-
strated variations in prevalence of 
the AR in adults between the sur-
veyed region. Self-administered, 
locally custom designed and Eu-
ropean Community Respiratory 
Health Survey (ECRHS) question-
naires have been used, with vari-
ations ranging from 8.7-24.1% in 
China and 11.4-22.7% in Turkey.
Large scale studies specifically de-
signed to estimate the prevalence of 
allergic rhinitis in regions with differ-
ent climates are needed.
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Figure 1 Prevalence of allergic rhinitis in different regions of the world, using ISAAC standardized methodology.
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stronger association to male sex
• In pre-school years, rhinitis is primarily non-allergic and 
transient
• In boys, non-allergic rhinitis decreases in prevalence during 
adolescence, while in girls it increases consistently from 4 to 
18 years, resulting in a female dominance of this condition in 
early adult life
• Gender and atopy are two major factors influencing the natural 
history of rhinitis
Allergy rhinitis (AR), with its’ con-
stellation of symptoms is a clini-
cal diagnosis and hence reported 
prevalence and natural history var-
ies widely. Cross-sectional studies 
across the globe, using standard-
ized questionnaires, shows sub-
stantial average global prevalence 
of rhinitis, which increases from 
childhood (8.5% at 6-7 years) to 
14.6% at 13-14 years. Keil et al, 
recently showed that prevalence 
of AR quadrupled from 6% at 
3-years to 24% at 13-years in chil-
dren with non-allergic parents and 
tripled from 13% to 44% for chil-
dren with at least one allergic par-
ent.. In the Isle of Wight Birth Co-
hort rhinitis prevalence increased 
7-fold from 5.4% at 4-years to 
35.8% at 18-years. This rise was 
seen in children of both allergic 
and non-allergic parents. There is 
very little information available re-
garding the course of AR through 
adult life. However, clinical expe-
rience and a few studies that have 
been done suggest that it takes a 
chronic course with significant re-
mission and relapse.
The classical “atopic march” por-
trays a characteristic evolution of 
allergic disease from one state to 
another through childhood, which 
typically suggested that rhinitis 
NATURAL HISTORY OF 
ALLERGIC RHINITIS2
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follows asthma, mostly appearing 
in later childhood or adolescence. 
However, it is likely that in reality, 
allergic diseases, especially asth-
ma and rhinitis, exist together due 
to common underlying immune 
and epithelial dysregulation lead-
ing to airway inflammation and 
giving rise to the “one airway one 
disease” concept.
Atopy, as defined by positive skin 
test or presence of specific IgE, 
significantly influences the natu-
ral course of the disease. Rhinitis 
is conventionally regarded as an 
allergic disorder but similar con-
stellation of symptoms can oc-
cur without evidence of allergic 
sensitization in the non-allergic 
rhinitis. There is a male prepon-
derance in AR during childhood, 
which persists up to young adult 
life. Non-allergic rhinitis behaves 
differently. It is often transient 
during early childhood. It then in-
creases in prevalence during later 
childhood with no clear sex dom-
inance but acquired a female pre-
dominance by the age of 18-years 
as girls “grew into” it while boys 
“grew out of” rhinitis during ado-
lescence. The different dynamic 
for allergic and non-allergic rhinitis 
in males and females is illustrated 
in Figures 1and 2. Similar gender 
switch during adolescence is seen 
in non-allergic asthma which is 
more common in boys but women 
acquire more non-allergic asthma 
during adolescence. Given the 
common underlying pathophysi-
ology and adolescence period, it is 
Natural history of allergic rhinitis
S. Hasan Arshad  
University of Southampton 
United Kingdom
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plausible that factors such as sex, 
puberty/ hormones and obesity 
influence the natural course of 
both asthma and rhinitis.
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Figure 1 Changes in Atopic and 
Non-atopic Rhinitis Prevalence for 
Boys over the First 18-years of Life. 
Figures indicate rhinitis prevalence 
(percentage with 95% confidence 
intervals) at each assessment for 
boys, stratified by atopic status. 
(Adapted from Kurukulaaratchy RJ, 
Karmaus W, Raza A, et al. The influence 
of gender and atopy on the natural 
history of rhinitis in the first 18 years 
of life. Clin Exp Allergy 2011;41:851-
859.)
Figure 2 Changes in Atopic and 
Non-atopic Rhinitis Prevalence for 
Girls over the First 18-years of Life. 
Figures indicate rhinitis prevalence 
(percentage with 95% confidence 
intervals) at each assessment for girls, 
stratified by atopic status. (Adapted 
from Kurukulaaratchy RJ, Karmaus W, 
Raza A, et al. The influence of gender 
and atopy on the natural history of 
rhinitis in the first 18 years of life. Clin 
Exp Allergy 2011;41:851-859.)
Natural history of allergic rhinitis
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rhinitis (AR) and showed a steep increase in the prevalence and 
the severity of AR
• The direct relation with atopy as part of the “allergic march” is 
confirmed by most but not by all studies
• Birth cohort studies also evaluated the imapct of genetic 
variants and of the effect modifiers, such as pollution
• Molecular diagnosis in the preclinical phase of the AR could 
provide a window of opportunity for primary prevention
Several birth cohorts studied the 
natural course of atopic diseases. 
Especially for asthma, allergic rhi-
nitis (AR), eczema and sensitisa-
tion to inhalant and food allergens 
we have European data on approx-
imately 20.000 children. Common 
data analyses were performed as 
meta analyses or pooled analy-
ses. There are certain limitations 
as different cohort studies have 
slightly different designs, howev-
er, many of them used the same 
validated questionaires (ISAAC) 
and performed similar assays for 
the determination of specific se-
rum IgE. Thus they appear to be 
comparable in an acceptable way.
In the Multicentre Allergy Study 
MAS-90 ARIA criteria were used 
to define rhinitis in children and 
young adults. Symptoms were 
defined as “severe” (impairment 
of daily activities) or “mild” (no 
impairment), “persistent” (dura-
tion >1 month) or “intermittent” 
(≤1 month) using annual ques-
tionnaires. The 12-months preva-
lence of AR quadrupled from 6% 
(at age 3y) to 24% (at age 13y) in 
children with non-allergic parents, 
and more than tripled from 13% 
(3y) to 44% (13y) in children with 
at least 1 allergic parent (figure 
1). Boys were more frequently af-
BIRTH COHORTS STUDIES IN 
ALLERGIC RHINITIS3
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fected than girls (figure 2). Half or 
more of the children with AR had 
“severe persistent” symptoms. At 
age 13, these children were signif-
icantly more often sensitized than 
those with “mild persistent” dis-
ease: 91% vs. 70% (p=0.015). Sen-
sitization to aero-allergens (ad-
justed OR 18.9; 95%CI 9.3-38.4), 
and having 2 allergic parents (3.1; 
1.1-9.3) were significantly asso-
ciated with AR. According to the 
ARIA criteria, the impact of AR 
seems to be substantial; the vast 
majority of affected children suf-
fered persistently for periods of 
2 months or more annually, and 
most of the children with persis-
tent AR were impaired in their 
daily activities. At 7 years of age, 
seasonal allergic rhinitis (SAR) de-
veloped in 15% of the children. 
Children with SAR already in the 
second year of life were all born in 
spring or early summer. Risk fac-
tors for SAR were male sex, atopic 
parents having SAR themselves, 
first-born child, early sensitization 
to food and atopic dermatitis.
The Follow-up of the German 
MAS at 20 years of age showed 
that rhinitis was still the most 
frequent outcome observed. 290 
individuals developed ‘allergic rhi-
nitis’ within 13,179 person years 
observed. The risk to develop AR 
was higher with parents’ history 
of AR (adjusted hazard ratio [95% 
confidence interval]: 2.52 [1.94; 
3.27]), urticaria (1.32 [1.00;1.74]) 
or asthma (1.29 [0.95;1.75]). 
Early allergic sensitization (4.50 
[3.30;6.13]), eczema within the 
first three years (1.88 [1.43;2.48]), 
Birth cohorts studies in allergic rhinitis
Susanne Lau  
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male sex (1.28 [1.01;1.61]) and 
birthday in summer or autumn 
(1.26 [1.00;1.59]) were independ-
ent predictors of AR up to age 
20. The secondary outcome ‘AR 
and asthma’ was linked to several 
modifiable risk factors (smoking 
in pregnancy; starting day-care 
before age 18 months, or after 
age 36 months). Receiving recom-
mended vaccinations was associ-
ated with lower incidence of rhini-
tis combined with current asthma.
In the Swedish BAMSE study 
13.8% of the participating chil-
dren had AR, while 6.4% had 
non-allergic rhinitis at age 8 years, 
while at age 4 years, 5% had AR 
and 8% had non-allergic rhinitis. 
Remission was much higher for 
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Figure 1 Heredity and prevalence of allergic rhinitis symptoms in the German MAS. (Reproduced from Keil T, Bockelbrink 
A, Reich A, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol 2010;21:962-969, with permission 
from Wiley-Blackwell.)
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non-allergic rhinitis than for AR 
(73% versus 12%). Of the sensi-
tized 4-year-old individuals with-
out rhinitis, 56% had developed 
AR at age 8 years. Parental hay 
fever increased the odds of AR in 
offsprings (OR 2.2; 95% CI 1.6-
3.2), whereas isolated parental ec-
zema or asthma did not. The odds 
for non-allergic rhinitis increased 
when one parent had two or more 
allergy-related diseases.
In the Isle of Wight cohort, over-
all rhinitis prevalence increased 
from 5.4% at age 4 years to 35.% 
at 18 years (p<0.001), without 
gender difference. AR prevalence 
increased steadily from 3.4% 
Birth cohorts studies in allergic rhinitis
Figure 2 Influence of gender and heredity for the prevalence of allergic rhinitis in the German MAS. (Reproduced from 
Keil T, Bockelbrink A, Reich A, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol 2010;21:962-
969, with permission from Wiley-Blackwell.)
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at 4 years to 27.3% at 18 years 
(p<0.001). AR was commoner 
in boys at 18 years (p=0.02) and 
associated with greater positive 
transition in boys from 10 to 18 
years (p=0.01). Prevalence of 
non-atopic rhinitis also increased 
from 4 to 18 years (p=0.003) and 
was greater in girls at 18 years 
(p<0.001) reflecting higher female 
positive transition from 10-18 
years (p<0.001). Non-atopic rhini-
tis remission was highest in early 
life and reduced in later child-
hood/adolescence.
In the Norwegian Environment 
and Childhood Asthma Study cur-
rent rhinitis was reported in 254 
of 1019 children (25%) at age 10 
years. Children with rhinitis and 
allergic sensitization had more fre-
quently bronchial hyperreactivity.
IS ALLERGIC RHINITIS PART OF 
THE ATOPIC MARCH?
In European birth cohort studies 
AR is found in 10-25% of children 
and adolescents depending on the 
recruitment area. While in some 
cohorts it appears that early atop-
ic eczema and early sensitisation 
to foods and inhalant allergens 
appears to be a risk factor for lat-
er airway disease, other cohorts 
have reported a heterogeneous 
developmental profile for eczema, 
wheeze and rhinitis. In the British 
ALSPAC and MAAS cohorts, ap-
plying Bayesian machine learning 
methods in order to identify dis-
tinct latent classes only 7% of chil-
dren were found to follow trajec-
tory profiles resembling the atopic 
march.
An analysis of 12 ongoing Euro-
pean birth cohort studies partici-
pating in MeDALL (Mechanisms in 
the Development of ALLergy) in-
cluded over 16.000 children aged 
4 years and 11080 aged 8 years. 
Comorbidity of eczema, rhinitis 
and asthma was investigated and 
defined as coexistence of two or 
three diseases in the same child. 
1.6% of children were found to 
have comorbidity at age 4 years 
and 2.2% of the children at age 
8 years. Strikingly, IgE sensitisa-
tion was not the dominant causal 
mechanism of comorbidity.
In a Swedish publication, 32.7% 
of children with mild eczema 
and 45% of children with mod-
erate-to-severe eczema showed 
also rhinitis, favouring the conclu-
sion, that severity of eczema is as-
sociated with rhinitis and allergic 
airway disease. Furthermore, at 
age 12 years, 7.5% of the children 
in the BAMSE cohort were affect-
ed by at least two allergy-related 
diseases.
In the German MAS AR until the 
age of 5 years was found to be a 
predictor for developing wheez-
ing between the ages of 5 and 13 
years, with an adjusted relative 
risk of 3.82 (p<0.001). This asso-
ciation was not attributable to the 
type of sensitization, the severity 
of sensitization, or atopic dermati-
tis during the first 2 years of life. In 
this group of children, 41.5% of all 
new cases of wheezing occurred 
among children with preceding AR 
(figure 3).
ALLERGIC RHINITIS AND 
OTITIS MEDIA
In the Danish COPSAC birth co-
hort (Copenhagen Prospective 
Studies on Asthma in Childhood) 
291 children in the 6th year of 
life were evaluated for asthma, 
allergic and non-allergic rhinitis, 
eczema and also for otitis media 
with effusion. Otitis media with 
effusion was diagnosed in 39% of 
the cohort and this was associated 
with AR (aOR 3.36; CI 1.26-8.96; 
p=0.02) but not with non-allergic 
rhinitis, asthma or eczema.
GENETIC VARIANTS AND 
EFFECT MODIFICATION
Filaggrin gene variants are associ-
ated with severer atopic eczema 
and skin barrier dysfunction, with 
asthma and poor lung function 
at school age and in some stud-
ies also with rhinitis. In the Isle of 
Wight study, filaggrin gene vari-
ants increased the risk of asthma 
(RR 1.3; 95% CI 1.06-1.80) and 
rhinitis (RR 1.37; 95% CI 1.16-
1.63). While eczema and allergic 
sensitisation modulated and in-
creased the risk for asthma, this 
could not be shown for rhinitis. 
This supports the interpretation, 
that rhinitis and asthma in child-
hood and adolescence do not nec-
essarily follow a common pathway 
in the group of children carrying 
the filaggrin mutations.
In another pooled analyses certain 
single nucleotide polymorphisms 
within the TLR4 and TNF genes 
increased the risk of AR in chil-
dren. Traffic related air pollution 
was not a relevant effect modifier.
MOLECULAR SPREADING IN 
THE PRECLINICAL PHASE OF AR
The development of AR seems to 
be determined by the develop-
ment of specific sensitization. In 
the case of grass pollen sensitiza-
tion in the German MAS, an initial 
IgE response to an initiator mole-
cule, in > 75% of cases Phl p1 in a 
preclinical phase, precedes a more 
complex sensitization to several 
molecules: Phl p 4, Phl p 5, Phl p 
2, Phl p 6 and Phl p 11 and later 
Phl p 12 and Phl p 7. Sensitization 
at age 3 predicted SAR by age 12 
years (PPV 68%; 95% CI, 80-87%). 
At this early preclinical prediction 
time, the number of recognized 
molecules and the serum levels of 
IgE to Phleum pratense were sig-
nificantly lower than at 3 or more 
years after the clinical onset of 
Birth cohorts studies in allergic rhinitis
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Figure 3 The risk of wheezing is determined by preceding allergic rhinitis in the German MAS. (Reprinted from J Allergy 
Clin Immunol, 126/6, Rochat MK, Illi S, Ege MJ, Lau S, Keil T, Wahn U, von Mutius E; Multicentre Allergy Study (MAS) group. 
Allergic rhinitis as a predictor for wheezing onset in school-aged children, 1170-1175.e2, Copyright 2010, with permission 
from Elsevier.)
SAR and could thus be a potential 
window of opportunity for pre-
ventive early intervention.
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• Only 4 genome-wide association studies (GWAS) studies of 
allergic rhinitis have been performed
• Genes for mitochondrial function, B cells and regulatory T cells 
have been identified
• The next steps are further integrative omics studies of AR using 
GWAS, gene expression, microRNA, and metabolomics
Genome-wide association studies 
(GWAS) utilize the natural correla-
tion of single nucleotide polymor-
phisms (SNPs) with one another 
to allow genotyping of a reduced 
subset of SNPs across the genome. 
These SNPs are then associated 
with the phenotype of allergic rhi-
nitis (AR) in either a family-based 
or a case control study design.
AR is an IgE-mediated inflammato-
ry disease of the nasal mucosa. It 
can occur with or without asthma 
or eczema, the two other primary 
allergic conditions. Relatively few 
GWAS studies have been reported 
in AR. The initial paper documented 
MRPL4 (Mitochondrial ribosomal 
protein L4, chr 19p13.2) and BCAP 
(B-cell adaptor for phosphatidy-
linositol 3 Kinase, Chr10q24.1) 
as having suggestive associations 
without genome-wide signifi-
cance. A large European study then 
identified one genome-wide signif-
icant locus for AR: chromosome 11 
open reading frame 30 (C11orf30). 
A meta-analysis of genome-wide 
associations with self-reported 
cat, dust-mite, and pollen allergies 
among Europeans identified 16 
shared susceptibility loci, including 
8 previously associated with asth-
ma. Most recently, a North Amer-
ican integrative genomics study 
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(figure 1) utilizing both GWAS and 
gene expression identified a locus 
near transcription factor FER3-Like 
(FERDL3) on chromosome 7p21.1 
as a genome-wide significant AR 
susceptibility locus across ethnic 
groups, in addition to four ge-
nome-wide significant loci among 
Latinos specifically. The integrative 
analysis with gene expression data 
implicated a gene module enriched 
for mitochondrial pathway genes 
(figure 2). Although other studies 
have examined AR and asthma or 
AR and atopic dermatitis, these 4 
studies are the only ones that fo-
cus exclusively on AR as a disease. 
Methodologically these studies 
seem sound in that they have some 
form of replication, are of large 
sample size, and all have addressed 
the major validity threat of popula-
tion stratification.
The existing literature supports 
the involvement of mitochondri-
al genes, genes related to B cells 
and epithelial barrier function and 
regulatory T cell function as being 
of prime importance in AR. Future 
directions will need to go in the 
direction of the recently published 
integrative genomics paper where 
gene expression and GWAS data 
were integrated in one analysis 
and a systems genomics approach 
using pathway models was imple-
mented. This methodology holds 
great promise in helping to deter-
mine the underlying pathobiology 
of AR. One of the positive advan-
tages that are available in AR is 
that investigators can obtain nasal 
cells from lavage or biopsy and 
use these cells to perform multi 
Omic studies including metabolo-
mics and microRNA studies.
Genome-wide association studies in allergic rhinitis
Scott T. Weiss  
Harvard Medical School 
Boston, USA
Supinda Bunyavanich  
Icahn School of Medicine at Mount Sinai 
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Figure 1 Study flow for the integrated genome-wide association, coexpression network, and expression single 
nucleotide polymorphism analysis of allergic rhinitis. CHS = Children’s Health Study, CAMP = Childhood Asthma 
Management Program, CAG = Chicago Asthma Genetics Study, CSGA = Collaborative Studies on the Genetics of 
Asthma, SARP = Severe Asthma Research Program, GALA1 = Genetics of Asthma in Latinos, MCCAS = Mexico City 
Childhood Asthma Study, GRAAD = Genomic Research on Asthma in the African Diaspora and Barbados, SAPPHIRE 
= Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity. (From Bunyavanich S, Schadt EE, 
Himes BE, Lasky-Su J, Qiu W, Lazarus R, et al. Integrated genome-wide association, coexpression network, and expression single 
nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis. BMC Med Genomics 2014;7:48.)
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It is quite likely that the next steps 
here are further integrative Omics 
studies of AR using GWAS, gene 
expression, microRNA, and me-
tabolomics. If these studies are 
performed on subjects before and 
after allergen exposure using the 
subject as his or her own control, 
it is likely that even a small sample 
size will yield positive results and 
further refine the biology of the 
disease.
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Figure 2 CD4+ lymphocyte coexpression network with detail of the brown coexpression module. A. Each circle 
represents a gene. Weighted gene coexpression analysis identified groups of genes with similar patterns of gene 
expression and interconnectivity (coexpression modules). The 41 coexpression modules identified are labeled by color. 
Pathways associated with the largest coexpression modules are denoted in the legend. B. Interconnectivity of the 
brown coexpression module is shown in detail. Tagged by 6 allergic rhinitis GWAS loci, this coexpression module was 
highly enriched for allergic rhinitis-associated eSNPs (3.4-fold enrichment, FDR-adjusted P value = 2.6 × 10−24) and 
also highly enriched for pathways related to mitochondrial function (8.6-fold enrichment, FDR-adjusted P value = 4.5 
× 10−72). Genes containing allergic rhinitis-associated eSNPs are marked in brown, with those containing eSNPs with 
lowest P-value for association between genotype and gene expression marked with greatest brown saturation. Genes in 
pathways related to mitochondrial function are marked by diamonds with blue outline. Higher correlation between gene 
expression is shown with thicker and darker edges. (From Bunyavanich S, Schadt EE, Himes BE, Lasky-Su J, Qiu W, Lazarus 
R, et al. Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis 
identifies novel pathway in allergic rhinitis. BMC Med Genomics 2014;7:48.)
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EPIGENETIC MECHANISMS 
IN ALLERGIC RHINITIS
• Genetics alone cannot explain the increasing prevalence of 
allergic rhinitis (AR)
• Epigenetics is likely to be involved in the pathology of AR
• DNA methylation patterns differ between patients and healthy 
individuals, and between patients before and after allergen 
immunotherapy
• DNA methylation may be a useful predictive marker and 
therapeutic target in AR
The modest effects of genetic var-
iants and increasing prevalence of 
common diseases like asthma and 
seasonal allergic rhinitis (SAR) sug-
gest the pathogenic importance 
of environmental factors and the 
involvement of epigenetic mech-
anisms. Epigenetic mechanisms 
include DNA methylation, which 
in general inhibits mRNA expres-
sion and modifications of chro-
matin structure, such as histone 
proteins, which may either deny 
or facilitate binding of transcrip-
tion factors to promoter regions. 
Several studies have shown the 
importance of DNA methylation 
in T-cell differentiation as well 
as indifferent T-cell subsets from 
asthmatic patients, as recently re-
viewed.
SAR is an excellent model to study 
such mechanisms, because the 
main environmental trigger, pol-
len, is known and the effects of 
allergen exposure can be studied 
in vitro by allergen challenge of pe-
ripheral blood mononuclear cells 
(PBMCs) from patients outside of 
the season. Moreover, changes 
during tolerance induction by al-
lergen immunotherapy (3) can also 
be studied. However, there are rel-
atively few studies of epigenetic 
mechanisms in SAR. One recent 
KE Y MESSAGES
study suggests that the beneficial 
effects of AIT may be due to in 
part to reduced DNA methylation 
of the FoxP3 promoter region in T 
regulatory cells. Several studies in 
mouse models of SAR have also 
observed changes in DNA meth-
ylation as key regulatory of genes 
expression in CD4+ T-cells (Figure 
1).
To identify changes in DNA meth-
ylation in SAR patients, we gener-
ated genome-wide DNA methyla-
tion and gene expression profiles 
of ex vivo CD4+ T-cells from SAR 
patients and healthy controls. 
DNA methylation profiles clearly 
separated SAR patients from con-
trols, during and outside the pol-
len season. Moreover, a significant 
correlation between symptom 
scores and DNA methylation was 
found. Conversely, gene expres-
sion profiles of the same samples 
failed to separate patients and 
controls. Separation by methyla-
tion but not by gene expression 
was also observed in an in vitro 
model system in which purified 
PBMCs from patients and healthy 
controls were challenged with al-
lergen. These findings highlight 
the potential of DNA methylation 
as a biomarker useful for the strat-
ification of SAR. DNA methyla-
tion has also diagnostic potential, 
since it's more stable and easy to 
measure than mRNA and perhaps 
proteins.
Finally, unlike genetic changes, 
epigenetic enzyme activity and 
epigenetic profiles are readily al-
tered by several approved drugs 
and nutrients, such as vitamins C 
or D. Thus, epigenetic alterations 
in immune disease may not only 
Epigenetic mechanisms in allergic rhinitis
Colm E. Nestor Mikael Benson
Linkoping University 
Sweden
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serve as predictive markers, but 
also as potential targets for novel 
epigenetic-taregeted therapies.
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Figure 1 DNA methylation dynamics in CD4+ T-cells. (A) Several key loci undergo loss of promoter DNA methylation 
during CD4+ T-cell differentiation. Naïve CD4+ T-cells (NTs) can be differentiated in vitro into several T effector (T-helper 
type 1, type 2, and type 17) and T regulatory (Treg) cell types; an in vitro polarisation assay. Changes in locus specific or 
genome-wide methylation can then be assessed during this process. (B) Increased promoter DNA methylation in allergic 
rhinitis patients are partially reversed after allergen immunotherapy (AIT). SAR = seasonal allergic rhinitis.
Epigenetic mechanisms in allergic rhinitis
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FROM GENE EXPRESSION 
MEASUREMENTS TO 
EPIDEMIOLOGIC STUDIES
• Measuring gene expression, RNA stability and quality require 
special attention
• Expression of pattern-recognition receptors and regulatory 
cytokines might play a role in the immunological mechanisms 
of the hygiene hypothesis
• Gene- environment interaction deserves particular attention in 
the context of the epidemic rise of allergic diseases
• Gene expression measurements in the context of epidemiological 
studies are a useful tool to reproduce in humans the findings 
from cell cultures and from mouse models
MEASURING GENE 
EXPRESSION
Gene expression measurements 
became an attractive tool to as-
sess biological responses in epide-
miological studies, as they might 
reflect both genetic and environ-
mental influences. However, col-
lection of blood samples for gene 
expression assessment poses var-
ious technical pitfalls. Collecting 
blood samples into tubes contain-
ing an RNA-stabilizing solution in-
creases RNA yield and reduces its 
variability. Long-term storage of 
samples may lead to RNA degra-
dation, requiring special attention 
in longitudinal studies.
THE HYGIENE HYPOTHESIS 
AND GENE EXPRESSION
In epidemiological studies, immu-
nological mechanisms underpin-
ning the hygiene hypothesis have 
been extensively studied using 
gene expression (Figure 1). The 
hygiene hypothesis states that 
environmental exposures to high 
levels of microbial components, 
such as occurring in the tradition-
al farming setting, are one of the 
major preventive factors for the 
development of allergic diseases, 
such as allergic rhinitis (AR) and 
or for the sensitization to inhalant 
allergens. In fact such environ-
KE Y MESSAGES
ments up-regulate the expression 
of pattern-recognition receptor 
genes such as Toll-like receptors 
(TLR) and the expression of genes 
of their signaling cascade. Fur-
thermore, the gene expression of 
regulatory cytokines such as IL-10 
and TGF-β in blood leukocytes is 
strongly induced among farmers’ 
children (Figure 2).
There are evidences that the pro-
tective effect of farm exposures 
against the occurrence of allergic 
diseases could already be effec-
tive during pregnancy. Exposure 
of pregnant mothers to farm sta-
bles is associated with an increase 
of gene expression of receptors of 
the innate immunity, TLR2, TLR4 
and CD14 (Figure 2). Results from 
a birth cohort show that an in-
creased gene expression of innate 
immunity receptors at birth is pro-
tective against the development 
of atopic dermatitis.
CHRONIC RHINOSINUSITIS 
AND GENE EXPRESSION
Evidence for a defective barrier 
function is shown in patients with 
chronic rhinosinusitis (CRS). Bi-
opsies of patients with CRS have 
a decreased gene expression of 
tight junction (TJ) genes occludin 
and zonula occludens 1 that is as-
sociated with a disruption of the 
epithelial integrity. The relative 
importance of primary (genetic) vs 
secondary (inflammatory) changes 
in TJ gene expression needs fur-
ther study.
From gene expression measurements to epidemiologic studies
Caroline Roduit  
Zurich University Children’s 
Hospital 
Zurich, Switzerland
Remo Frei 
Swiss Institute of Allergy 
and Asthma Research, 
Davos, Switzerland
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GENE-ENVIRONMENT 
INTERACTION
The levels of expression of certain 
genes are not influenced by envi-
ronmental exposures alone, but 
they depend also on the type of 
alleles interacting with the envi-
ronment. As shown by farm stud-
ies raw milk consumption is asso-
ciated with increased expression 
of the CD14 gene only if a certain 
polymorphism of the CD14 gene 
is present.
CONCLUSION
Gene expression measurements 
in the context of epidemiological 
studies are a useful tool to repro-
duce in humans the findings from 
cell cultures and mouse models. 
The availability of new technolo-
gies such as RNA sequencing will 
boost the findings in this research 
area.
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Figure 1 T helper cell differentiation and B cell activation by the innate immune system. Schematic overview showing 
how microbes activate the innate immune system leading to T helper cell differentiation and proliferation and how 
immunoglobulin class switching recombination is induced via a T helper cell-dependent and independent pathway. 
In red, genes whose expression levels have been intensively studied in the context of epidemiological studies. APC, 
antigen-presenting cell; red, gene expression of these marker molecules was measured in this study. Abbreviations: APC 
= antigen presenting cell; APRIL = a proliferation inducing ligand; BAFF= B cell activating factor; CCR = CC-chemokine 
receptor; IL= interleukin; TGF=transforming growth factor; Th = T helper cell. (From Frei R, Roduit C, Bieli C, Loeliger 
S, Waser M, Scheynius A, et al. Expression of genes related to anti-inflammatory pathways are modified among farmers' 
children. PLoS One 2014;9:e91097.)
From gene expression measurements to epidemiologic studies
79
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 B - A
llergic rhiniti
s - epidem
iology and risk factors
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- Pets
- Nutrition
- Pets
- Farm milk
- Farm animals
- Siblings
- Day care 
- Infection
- Helminthes
- TLR2, TLR4, CD14
- IL-10
- TGF-β
- Less IFN-γ and IL-4
- SOCS-3
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- IFN-γ
- TLRs
Pregnancy
- BCG 
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Immunity
Figure 2 Overview of environmental factors reducing the risk of developing allergies in children over time and 
the associated immunological mechanisms described by gene expression measurements. Abbreviations for figure 
2: IFN=interferon; IL= interleukin; IRAK = IL1 receptor-associated kinase; SOCS = suppressor of cytokine signaling 
proteins; TLR=Toll-like receptor; TGF = transforming growth factor
From gene expression measurements to epidemiologic studies
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PERINATAL INFLUENCES 
ON THE DEVELOPMENT OF 
ALLERGIC RHINITIS
• Parental atopy, genetics and epigenetics influence development 
of allergic rhinitis (AR) in childhood
• Early life exposure to a farming environment protects against 
development of atopic diseases including AR later in life
• Microbial and nutritional diversity are associated with a lower 
risk of developing AR.
DEVELOPMENT OF ALLERGIC 
RHINITIS IN CHILDHOOD
Allergic rhinitis (AR), one of the 
most common allergic diseases in 
childhood, shows a shift of onset 
to younger ages with further in-
creasing prevalence until adoles-
cence. AR has an impact on qual-
ity of life, performance at school/
work and socioeconomic burden. 
The onset of this IgE-mediated 
disease in children usually suc-
ceeds the development of atop-
ic dermatitis (AD) and childhood 
asthma, being often related to 
one or both. Different phenotypes 
were described differentiating be-
tween local and systemic AR.
EARLY LIFE DETERMINANTS OF 
ALLERGIC RHINITIS
While several studies have shown 
that perinatal influences alter 
immune regulation early in life 
and subsequent development of 
allergic diseases such as child-
hood asthma, studies on early life 
mechanisms for AR alone are rare. 
This is due to its interrelation with 
AD and asthma, to partly shared 
mechanisms, and to its’ later on-
set mostly succeeding AD and 
asthma. A variety of underlying 
factors are relevant during a peri-
natal “window”, where disease de-
velopment may be originated with 
KE Y MESSAGES
symptoms succeeding later in life. 
In the following, primarily studies 
on early life determinants of AR 
are included (Figure 1).
Role of family history, infections 
and environmental exposure for 
AR development
A family history of atopy is a known 
risk factor for AR development. In 
two German studies (Multicenter 
Allergy cohort with 820 children, 
PAULA study with 526 children), 
parental hay fever or maternal at-
opy, infections, and bacterial expo-
sure, respectively, were related to 
higher risk of AR in the offspring, 
importantly before the onset of 
symptoms, potentially acting as 
immunomodulators enhancing or 
inhibiting the development of AR. 
Farm exposure early in life protect-
ing from AR is certainly one of the 
strongest factors shown repetitive-
ly, similar to asthma prevention.
Recent studies on the microbiome 
indicate that reduced bacterial 
diversity of the infants’ intesti-
nal flora was associated with in-
creased risk of AR, but not with 
asthma or AD.
Genetics and epigenetics in the 
development of AR
Genetics are partially impor-
tant in AR development, how-
ever not necessarily sharing the 
same susceptibility loci. Despite 
the high prevalence of AR, only 
three GWASs of AR have been 
reported identifying key genes 
such as MRPL4, BCAP, C11orf30/
LRRC32 and FERD3L (Table 1). 
C11orf30/LRRC32 was relevant 
in GWAS for AR, asthma and AD. 
While overlapping loci may in-
dicate a progression of allergic 
diseases from childhood AD to 
AR and asthma (“atopic march), a 
close relationship between AR and 
Perinatal influences on the development of allergic rhinitis
Bianca Schaub  
University Children´s Hospital Munich 
Munich, Germany
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asthma may indicate the concept 
of „united airways“ from early life 
onwards. Certainly, epigenetic ef-
fects, gene–gene interactions and 
gene–environment interactions 
have to be investigated in future 
genetic studies on AR.
Epigenetics, namely acquired 
and potentially reversible modi-
fications that do not include al-
terations in the primary DNA se-
quence, comprise regulation via 
DNA methylation, histone modifi-
cation, and non-coding RNAs and 
are likely to contribute to the en-
vironmental origins of asthma and 
its phenotypic variability. For AR 
alone, very few studies have been 
reported, with one differentiating 
AR vs controls by epigenetics fo-
cusing on promoter CpGs of PIE-
ZO1, RPP21 and HLA-DMA.
Early life nutrition and supple-
mentation
Maternal vitamin D intake during 
pregnancy increased the risk for 
asthma and had no effect for AR 
in the offspring. Early introduc-
tion of fish has repetitively been 
shown to decrease the risk of AR, 
and also of asthma, besides other 
foods (e.g. wheat, rye, oats, barley 
cereals, egg). A murine birch pol-
len allergy model suggests that 
administration of L. paracasei, a 
probiotic bacteria during pregnan-
cy/lactation protects the offspring 
against airway inflammation via 
TLR2/4-signalling. Human studies 
are controversial, lately showing 
no effect of probiotic mixtures for 
AR incidence until age 5, solely in 
the group of offspring delivered 
via caesarian section.
Viral 
infections
Allergic
rhinitis
Airway
epithelium
TSLP   IL-33  IL-25
Th2/17 immune 
response
IL-5, 13, 4
IL-17, 21
Th2
B
Atopic
sensitization
e.g. maternal Vit. D, 
fish
Allergen
Nutrition
Family 
history, 
infections
Environment;
Microbiome
Genetics
MRPL4, BACP, 
C11orf30/LR 
RC32, FERD3L
Epigenetics
Promoter CpGs
of Piezo1, 
RPP21, HLA-
DMA
Figure 1 Early life determinants of AR. (Adapted from Raedler D, Schaub B. Immune mechanisms and development of 
childhood asthma. The Lancet Respiratory medicine. 2014;2(8):647-56.)
Perinatal influences on the development of allergic rhinitis
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TABLE 1
Genetic and epigenetic studies in allergic rhinitis
Allergic rhinitis Chromosome Gene Possible allergic mechanism
Genetics 
(GWAS)
19p13 MRPL4 Involved in inflammatory adhesion process
10q24 BCAP Involved in activation, development and maturation of B cells
11q13 C11orf30/LRRC32
Epithelial barrier function/regulatory 
T-cell functions and immune tolerance
7p21 FERD3L Unknown
Epigenetics
Selection of relevant CpGs confirmed by pyrosequencing: Function
PIEZO1 promoter CpG, RPP21 promoter CpG, HLA-DMA promoter CpG
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THE FARM EFFECT AND 
ALLERGIC RHINITIS
• The association between exposure to a traditional farming 
environment and protection from allergic disease is extremely 
robust across studies, countries and continents
• Exposure to cows, straw, and farm milk explains the farm effect 
for asthma, and exposure to fodder storage rooms and manure 
explains it for atopic dermatitis. However the farm effect for 
hay fever and atopic sensitization could not be completely 
accounted for by these exposure and remains partially 
unexplained
• The relationship between farm exposure and allergy/hay fever 
prevalence is extremely dynamic over time, pointing to the 
impact of rapidly changing environments on allergy risk
• Continued exposure might be a critical component of the 
protective effects of farming
The association between expo-
sure to a farming environment 
and protection from allergic dis-
ease (among which allergic rhini-
tis/hay fever is paradigmatic) has 
proven extremely robust across 
studies, countries and continents, 
especially in work focusing on 
truly traditional farms. A recent, 
large (>8,000 children) study that 
sought to identify distinct expo-
sures that account for the protec-
tive effect of farming found that 
children living on a farm were at 
significantly reduced risk of hay 
fever (aOR, 0.43; 95% CI, 0.36-
0.52; P< .001) and atopic sensiti-
zation (aOR, 0.54; 95% CI, 0.48-
0.61; P< .001) compared with 
nonfarm children. Of note, where-
as this overall farm effect could be 
explained by specific exposures 
to cows, straw, and farm milk for 
asthma, and exposure to fodder 
storage rooms and manure for at-
opic dermatitis, the farm effect on 
hay fever and atopic sensitization 
could not be completely explained 
by the questionnaire items them-
selves or their diversity. Therefore, 
the link for hay fever and atopy is 
still missing. Interestingly, a high 
number of siblings, especially old-
er siblings, reduces hay fever risk 
in childhood, and farming families 
are typically larger in size. Howev-
KE Y MESSAGES
er, an inverse association between 
farm exposure and hay fever was 
found in all sizes of family, with 
no substantial tendency to satu-
ration or synergism. This suggests 
that these two protective factors 
may act through distinct biological 
mechanisms.
How strikingly dynamic the rela-
tionship between prevalence of 
allergy and farming can be is elo-
quently illustrated by the results 
of two surveys performed in 2003 
and 2012 in lower Silesia, Poland 
(Figure 1). In 2003, among those 
living in Sobótka (a town of just 
4000 inhabitants) the prevalence 
of atopy was 20%, that is, similar 
to that observed in the United 
Kingdom and similar to Europe-
an countries. In contrast, among 
those living in any of seven small 
villages, each no more than 10 km 
from the town, the prevalence of 
atopy was just 7%, that is, lower 
than any recorded elsewhere in 
Europe. At that time, 55% of vil-
lagers (but <1% of those living in 
Sobótka) described themselves 
as living on farms. A quarter had 
regular or occasional contact with 
cows, a third had regular or occa-
sional contact with pigs, and 35% 
reported that they drank unpas-
The farm effect and allergic rhinitis
Donata Vercelli  
University of Arizona 
USA
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The farm effect and allergic rhinitis
teurized cow’s milk.. In 2004, Po-
land joined the European Union 
and consequently adopted the 
Common Agricultural Policy. As a 
result, it immediately became une-
conomic for village farmers in Sile-
sia to keep small numbers of cows 
or other large farm animals. The 
number of cows and pigs kept by 
households in the seven villages 
decreased by 80%. When, in 2012, 
a second survey of the same area 
was undertaken, the results were 
impressive. Far fewer villagers had 
contact with cows (4% vs 24.3% 
in 2003) or pigs (14% vs 33.5%), 
milked cows (2.7% vs 12.7%), or 
drank unpasteurized milk (9% vs 
35%). In parallel, the prevalence 
of atopy significantly increased 
among the villagers (7.3% vs 
19.6%, P < .0001) but not among 
the townspeople (20% vs 19.9%). 
Hay fever increased over 2-fold in 
the villages (3.0% vs 7.7%) but not 
in the town (7.1% vs 7.2% (Figure 
1). It is especially noteworthy that 
increased allergy prevalence was 
detected across all ages.
The dramatic increase in the prev-
alence of allergies observed in 
Poland within 9 years, and similar 
findings from urban Germany af-
ter reunification (where the prev-
alence of atopy doubled within 
3 years), suggest that the atopic 
state is more plastic than many 
believe in both childhood and 
adulthood, and highlight the im-
pact of rapidly changing environ-
ments on allergy risk. They also 
suggest that continued exposure 
might be a critical component of 
the protective effects of farming.
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Sobótka
POLAND
Figure 1
Figure 1 Effects of changing environments on the prevalence of atopy and allergic rhinitis: Results from the 2003 and 
2012 Sobotka studies.
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VITAMIN D AND 
ALLERGIC DISEASES
• Vitamin D is synthesised following sunlight exposure, but small 
quantities can be ingested
• Vitamin D deficiency is a global problem and has increased 
markedly in recent decades
• Observational studies highlight an association between vitamin 
D deficiency and increased incidence of allergic sensitization 
and disease
• Effects of vitamin D on airways and immune cells are likely 
to underpin associations between low vitamin D status and 
allergic sensitization
• Interventional studies are needed to determine whether 
restoring vitamin D sufficiency improves disease management 
and reduces the incidence of disease
Environmental factors, such as vi-
tamin D deficiency, are proposed 
to contribute to the increase in al-
lergic diseases reported in the last 
half-century. Vitamin D is synthe-
sized following exposure of skin to 
UVB radiation, and is also present 
in certain foods and dietary supple-
ments (Figure 1). Vitamin D status 
is assessed as circulating levels of 
the major metabolite, 25-hydrox-
yvitamin D3 (Table 1). Vitamin D 
deficiency has increased dramat-
ically in recent decades related to 
changes in lifestyle, including re-
duced sun exposure.
Vitamin D deficiency, particular-
ly in pregnancy and childhood, 
is associated with increased al-
lergic sensitization and levels of 
aeroallergen specific IgE, as well 
as increased incidence of atopic 
dermatitis (AD), allergic rhinitis 
(AR), food allergy (FA) and asthma. 
However, these data remain con-
tentious since examples of lack, 
or even inverse correlations, also 
exist. A non-linear relationship 
exists between vitamin D status 
and IgE levels, which may partially 
explain this discrepancy.. In preg-
nancy vitamin D assessments are 
variously made by food-frequency 
questionnaire, or by single meas-
urements of serum 25-hydroxyvi-
KE Y MESSAGES
tamin D3 in late pregnancy or in 
cord blood. The associations are 
strongest with food-frequency 
questionnaire, which may repre-
sent a more accurate measure of 
long-term dietary intake.
Vitamin D classically mediates cal-
cium homeostasis and bone me-
tabolism.
The vitamin D receptor is expressed 
essentially by all immune cells. Fur-
thermore, innate immune cells (e.g. 
epithelial cells, macrophages, den-
dritic cells) can convert the precur-
sor 25-hydroxyvitamin D3 to the 
active metabolite 1α,25-dihydrox-
yvitamin D3 (Figure 1), supporting 
a role for extra-renal synthesis of 
vitamin D and regulation of im-
mune function.
Vitamin D modulates many as-
pects of immune function (Figure 
2). Vitamin D enhances innate 
antimicrobial mechanisms that 
aid pathogen clearance, increas-
es the frequency of CD4+IL-10+ 
and CD4+Foxp3+ regulatory T cell 
subsets, and inhibits pro-inflam-
matory Th1 and Th17 responses, 
both directly and via effects on 
antigen presenting cells. How-
ever, vitamin D can enhance al-
lergy-associated Th2 responses 
experimentally, even though ob-
servational studies demonstrate 
Catherine M. Hawrylowicz  
King’s College London 
London, United Kingdom
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7-dehydrocholesterol Vitamin D3
25-hydroxyvitamin D3
25(OH)D3
1α,25-dihydroxyvitamin D3
1,25(OH)2D3
Skin                            Liver                                              Kidney
UVB                         25-hydroxylase
CYP27A1
1α-hydroxylase
CYP27B1
Serum levels used to assess 
vitamin D status CYP24A1
Active form
1,24,25(OH)3D3
Calcitroic acid
VDRE
1,25(OH)2D3
VDR
RXR
Gene transcription
Nucleus
Figure 1 Scheme of the vitamin D metabolic pathway. Vitamin D3 is obtained from dietary sources, or more commonly 
metabolized following ultraviolet B (UVB) irradiation (from sunshine) of 7-dehydrocholesterol in skin. The enzyme 
25-hydroxylase (CYP27A1) in the liver converts vitamin D3 to the major circulating metabolite 25-hydroxyvitamin 
D3 (25(OH)D3), and then 1α-hydroxylase (CYP27B1), in the kidney and locally in tissues, to the active moiety 1α,25-
dihydroxyvitamin D3 (1α,25(OH)2D3). 1α,25-dihydroxyvitamin D3 binds to the vitamin D receptor (VDR), which forms 
a heterodimer with members of the retinoic acid (RXR) family; this complex translocates to the nucleus and engages the 
vitamin D response element (VDRE) to mediate gene transcription. 1α,25-dihydroxyvitamin D3 is rapidly inactivated by 
CYP24A1 to 1,24,25(OH)3D3 and calcitroic acid.
TABLE 1
Vitamin D status
Vitamin D 
status
ng/ml 25-hydrox-
yvitamin D3
nmol/L 25-hydrox-
yvitamin D3
Clinical associations
Deficiency Less than 20 Less than 50 Rickets, osteomalacia
Insufficiency 20-30 50-75
Wide range of im-
mune-mediated condi-
tions including allergic 
sensitization, allergic rhi-
nitis & asthma
Sufficiency Greater than 30 Greater than 75
Vitamin D status is measured as circu-
lating levels of the major metabolite, 
25-hydroxyvitamin D3. Levels below 
50nmnl/L (<20ng/ml) are commonly 
considered as deficient, 50-75nmol/L 
(20-30ng/ml) insufficient, and between 
75-120nmol/L as sufficient. There is an 
ongoing debate about the precise levels 
that constitute sufficiency, however there 
is consensus that a high prevalence of 
deficiency and insufficiency exists glo-
bally. Vitamin D status is also influenced 
by skin colour, obesity, season and 
lifestyle, as well as by genetic diversity.
Vitamin D and allergic diseases
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IL-10, inhibitory receptors e.g. ILT3
IL-10, IgG4
IgE
Foxp3, IL-10, CTLA4, PD-1
CD200, CD39, soluble ST2
Th1, Th17 responses
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Treg
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Antimicrobial peptides
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Corticosteroid responsiveness
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Goblet cell hyperplasia
Figure 2 Effects of vitamin D on innate 
and adaptive immune function. Vitamin 
D promotes antimicrobial pathways 
on innate and structural cells that 
enhance pathogen clearance. On the 
adaptive immune response vitamin D 
promotes a tolerogenic dendritic cell 
(DC) phenotype, enhances regulatory T 
cells and their activity, and dampens pro-
inflammatory Th1 and Th17 responses. In 
a range of allergic conditions the capacity 
of vitamin D to enhance the clinical 
response to corticosteroids is likely to be 
beneficial, whilst reducing the incidence 
of infections and airway remodelling is 
relevant to airway disease.
an inverse association between 
vitamin D status and Th2-associ-
ated allergic diseases. The capac-
ity to enhance regulatory mech-
anisms, including Th2-specific 
inhibitory pathways such as solu-
ble ST2, may explain this apparent 
paradox. Vitamin D also enhanc-
es the effects of corticosteroids, 
which are a primary treatment for 
many allergic conditions.
Interventional studies are be-
ginning to emerge, and although 
highly variable in design and out-
comes measured, will be essen-
tial in evaluating the potential of 
vitamin D to prevent and control 
allergic disease.
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THE ENVIRONMENT-
PATHOGEN-HOST AXIS IN 
ALLERGIC RHINITIS
• Allergic rhinitis (AR) is the most common clinical manifestation 
of atopy
• Development of AR is controlled by a complex interaction of 
genetic, environmental and life-style factors
• Environment-environment interactions and climate change 
related effects are likely to result in higher prevalence of AR
• Early life crosstalk of innate immune receptors with pathogens 
and the body s´ own microbiome contribute to the decision 
between tolerance and disease
ALLERGIC RHINITIS: THE MOST 
COMMON MANIFESTATION OF 
ATOPY
According to WAO estimates, the 
incidence of allergic rhinitis (AR) 
ranges from 10-30% worldwide. 
The tremendous rise in incidence 
during the last decades emphasiz-
es the importance of environmen-
tal factors in the manifestation of 
the disease. In order to develop 
prevention measures for people at 
risk, effort has been put into the 
identification of genetic and envi-
ronmental risk factors.
GENETIC PREDISPOSITION
In genome-wide association stud-
ies (GWAS), single nucleotide 
polymorphisms (SNPs) associat-
ed with AR were identified. The 
respective genes – among them 
IL-18, LRRC32, TLR6, TSLP and 
NOD1 – govern mechanisms in-
volved in innate immunity, im-
mune regulation and crosstalk of 
epithelial cells and immune cells 
(figure 1). Epithelial barrier genes 
were not identified. This implies 
that they might play a more prom-
inent role in atopic eczema and 
in asthma than in AR. In contrast 
to other atopic traits, the genet-
ic susceptibility to AR seems less 
clear. This is likely due to fact that 
patients with AR often develop 
KE Y MESSAGES
asthma, resulting in an overlap 
of phenotypes. In line with this, 
some results were not replicated 
in meta-analyses.
ANTHROPOGENIC 
ENVIRONMENTAL FACTORS
Anthropogenic environmental 
factors, such as air pollutants, can 
impact directly on human health, 
but can also indirectly influence 
patients via their interaction 
with allergens (environment-en-
vironment interactions) (figure 
2). For the direct effects, popula-
tion-based studies show relation-
ships between allergic sensitiza-
tion/AR symptoms and long-term 
exposure to traffic-related air 
pollutants, such as Diesel exhaust 
particles, fine particulate matter, 
NO2 and ozone. However, a re-
cent meta-analysis did not show 
any clear correlation between AR 
and anthropogenic pollutants. 
These inconsistencies likely re-
flect methodological differences. 
in study design, measurement of 
pollutant exposure or differences 
in outcome between short-term 
and long-term exposure. For the 
indirect effects on human health, 
ozone was shown to enhance 
the allergenicity of birch pollen, 
a highly relevant allergen for AR. 
Moreover, prolonged flowering 
seasons and increases in pollen 
load as a consequence of global 
warming might increase AR bur-
den.
The environment-pathogen-host axis in allergic rhinitis
Stefanie Gilles Claudia Traidl-Hoffmann
 Institute for environmental medicine, UNIKA-T 
Augsburg, Germany
10
89
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 B - A
llergic rhiniti
s - epidem
iology and risk factors
Innate 
immune 
receptors 
Th2 
Th1 
T cell  
differentitaion 
Epithelial- 
immune cell 
crosstalk 
Chemotaxis 
Treg 
IL-27, IL13, LRRC32,  
CTLA4, HLA genes 
TSLP, 
IL33 
TLR6, NOD1 
RANTES, CXCL9, 
CXCL10, CXCL11 
Figure 1 Genes associated with the allergic rhinitis phenotype. Genome-wide association studies identified 
polymorphisms in several genes that may be linked to allergic rhinitis (AR). These genes are involved in different steps 
of the pathomechanism of AR, i.e. recognition of pathogen-associated molecular patterns, epithelial cell-immune 
cell crosstalk, T helper cell differentiation and immune cell chemotaxis. Legend for figure 1: CTLA4 = cytotoxic 
T-lymphocyte-associated protein 4; CXCL= the CXC-chemokine ligand; IL = interleukin; LLRC = Leucine-Rich Repeat-
Containing Protein 2; NOD = nucleotide oligomerization domain; RANTES = Regulated on Activation, Normal T Cell 
Expressed and Secreted; Th = T-helper cell; TLR = Toll-like receptor; Treg = T regulatory cell; TSLP = Thymic stromal 
lymphopoietin.
BIOGENIC ENVIRONMENTAL 
FACTORS
The world-wide rise in allergic 
diseases parallels the “western-
ized” life-style, characterized by 
increasing urbanization, smaller 
family sizes with fewer siblings, 
improved hygiene standards, in-
creasing numbers of cesarean 
sections, changed dietary habits 
and excessive use of antibiotics. 
This association gave birth to the 
“hygiene hypothesis”, which states 
that early life exposure to certain 
environmental microbes or path-
ogens confers protection against 
allergic diseases later in life. How-
ever, to be protective, an environ-
mental factor has to encounter 
a susceptible genotype (figure 
3). This is exemplified by a study 
The environment-pathogen-host axis in allergic rhinitis
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ANTHROPOGENIC FACTORS 
 
•  PM 2.5, PM10 
•  DEP 
•  NO2 
•  O3 
•  Climate change 
Predisposing factors ?  
HUMANS 
•  Pollen 
BIOGENIC FACTORS 
Allergic 
rhinitis 
Environment – 
environment 
interactions 
Prevention 
Health 
Allergen, 
adjuvats 
Figure 2 Effect of anthropogenic air pollution and climate change on allergic rhinitis. Traffic-related air pollutants 
associated with the development of AR include particulate matter (PM), Diesel exhaust particles (DEP), nitrogen dioxide 
(NO2), and ozone (O3). These pollutants have a direct effect on asthma and cardiovascular diseases. Their effect on AR 
remains ambiguous. However, air pollutants enhance the expression of allergenic proteins and adjuvants in pollen, and 
can therefore influence AR patients indirectly. Global warming might contribute to the rising trend in allergies due to 
increases in allergenic pollen load. Legend figure 2: DEP = Diesel exhaust particle; PM = particulate matter.
demonstrating that the protective 
effect of early life farm milk con-
sumption on allergic diseases was 
stronger in children carrying a cer-
tain allele for the innate immune 
receptor CD14.
CONCLUSIONS
Like other diseases linked to atopy, 
AR is caused by genetic as well as 
environmental and life style factors. 
By revisiting the “hygiene hypoth-
esis”, it becomes increasingly clear 
that the developing immune system 
is shaped by pre-natal or early life 
exposure to pathogens and coloniz-
ing microbiota. In genetically pre-
disposed individuals, disturbance 
of this intricate crosstalk causes 
immune dysregulation, resulting in 
autoimmunity or allergy.
The environment-pathogen-host axis in allergic rhinitis
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•  Intact gut/airway microbiome 
•  Early exposure to microbes 
HUMANS 
PROTECTIVE FACTORS 
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Figure 3 Harmful and protective environmental factors for the development of allergic rhinitis. AR is a complex disease 
triggered by genetic and environmental factors. Protection is conferred early in life when a favorable genetic background 
encounters protective environmental factors, such as an intact microbial flora and certain microbial pathogens. In 
contrast, allergen exposure induces allergic disease if an unfavorable genetic background meets harmful environmental 
factors, such as an imbalanced microbial flora. Cesarean section delivery and excessive antibiotic use can alter the 
body´s microflora and might therefore cause immune dysregulation.
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THE NASAL 
MICROBIOME
• Microbes start to colonize all of our body surfaces after birth
• The microbiota changes with age and is shaped by environmental 
exposures, lifestyle and inflammation
• Many bacterial ‘pathogens’ are normal components of the 
microbiota, which under certain circumstances outgrow and 
can cause disease
• New approaches that target interactions between the 
microbiota and host inflammatory pathways could help reduce 
the global burden of allergic diseases
THE “HUMAN 
SUPERORGANISM”
Microbes reside in niches 
throughout our body (Figure 1), 
and host-microbe interactions 
play a fundamental role in im-
mune and disease development. 
Indeed, the ‘human superorgan-
ism’, consists of 1% human DNA 
and 99% microbial DNA. The 
nasopharyngeal microbiota has 
been well described, is considered 
distinct from other body sites, 
and amongst its constituents are 
bacteria that are considered path-
ogens, for example, Streptococcus 
pneumonia, Haemophilius influen-
za, Staphylococcus aureus and Mo-
raxella catarrahlis. However, overt 
disease is typically not evident 
unless these bacterial species be-
come dominant at the expense of 
other resident microbes. This is 
a state of ‘dysbiosis’ and is often 
associated with inflammation. The 
factors that allow this microbial 
dysbiosis to develop could be key 
to a deeper understanding of dis-
ease aetiology, susceptibility and 
future therapeutic or prevention 
strategies.
FACTORS SHAPING THE 
CONSTITUENTS OF THE 
MICROBIOTA
Many factors can modulate the 
KE Y MESSAGES
composition of the nasopharyn-
geal microbiota, such as vacci-
nation strategies and exposure 
to microbes present in different 
environments/ climates/ sea-
sons. As examples, studies have 
shown that respiratory tract viral 
infections can profoundly impact 
on local bacterial populations, 
and that the microbiota is differ-
ent between summer and winter. 
Recently, the development of the 
upper respiratory tract microbiota 
was tracked over the first 2 years 
of life, and found to develop and 
cluster into certain groups. For ex-
ample, breast-feeding was associ-
ated with a more stable microbiota 
with high abundance of Moraxella 
and Corynebacterium/ Dolosigran-
ulum, and lower incidences of pa-
rental-reported respiratory infec-
tions. Comparatively, less stable 
microbial profiles were linked with 
high abundance of Haemophilus or 
Streptococcus. Studies of the na-
sal microbiota of individuals with 
or without allergic rhinitis have 
clearly showed that this disease 
is associated with changes in mi-
crobial diversity and constituents. 
Is this cause or effect? Do certain 
microbes predispose to allergies, 
or do allergies create tissue envi-
ronments suitable for these mi-
crobes?
OUTLOOK
Further studies are required to 
distinguish cause-and-effect from 
simple associations, however an 
emerging theme is that bacteria, 
classically considered pathogens, 
are normal residents of the res-
The nasal microbiome
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Figure 1 Microbes colonize 
all body surfaces starting from 
birth. (Reprinted from Marsland BJ, 
Gollwitzer ES. Host-microorganism 
interactions in lung diseases. Nat Rev 
Immunol 2014;14:827-835.)
The nasal microbiome
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Figure 1 Cross-talk between inflammatory pathways and microbes can create a tissue environment suitable for 
outgrowth of resident pathogens that further increase inflammation and disease pathology. (Adapted from Marsland BJ, 
Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol 2014;14:827-835.)
piratory tract and that certain 
events may change this habitat 
allowing for them to expand and 
promote disease. There is clear 
crosstalk between microbes and 
inflammatory pathways (Figure 2); 
a greater appreciation and under-
standing of the interactions be-
tween the tissue environment, mi-
crobes and inflammation may lead 
us to approaches that will reduce 
the global burden of allergies.
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UPPER RESPIRATORY TRACT INFECTIONS 
IN CHILDHOOD ARE LINKED TO THE 
DEVELOPMENT OF ALLERGIC RHINITIS IN 
ATOPIC CHILDREN
• Upper respiratory tract infections in early childhood may be 
protective against the development of allergic rhinitis (AR) in 
the general population
• However, upper respiratory tract infections are associated with 
the development of AR in children with atopic family histories
• Children with an atopic phenotype have decreased virus-
induced interferon-alpha production. This reduction in innate 
immune anti-viral responses may predispose them to develop 
AR that results from frequent URTIs
Many clinicians and parents ques-
tion whether frequent upper res-
piratory tract infections (URTIs) in 
early childhood can increase the 
risk for the development of aller-
gic rhinitis (AR). Frequent URTIs 
are defined as viral infections of 
the nose or ears occurring more 
then six times per year. AR is a 
combination of congestion, sneez-
ing, and rhinorrhea with associat-
ed pruritus of the nose and eyes 
due to demonstrable aeroallergen 
sensitivity.
The link between infection and 
the development of AR is com-
plex, exemplified by the incon-
sistent and conflicting results of 
various epidemiologic studies. 
These observed discrepancies 
appear to be due to variability of 
host factors. Some studies show 
an inverse association between 
URTIs and AR, while others show 
no association. Interestingly, any 
observed association or increased 
risk appears to be greater in chil-
dren with a family history of atop-
ic disease. Indeed, these children 
show increased rates of atopy if 
they experience early URTIs.
In observations supporting the 
hygiene hypothesis, Svanes et al 
found the number of siblings at 
home and day care enrollment 
KE Y MESSAGES
was inversely proportional to the 
risk of AR development. Assuming 
that the number of siblings and 
day care could be surrogate mark-
ers for URTI frequency, this study 
suggested that frequent URTIs in 
childhood are inversely related to 
the development of AR.
However, a more recent pro-
spective birth cohort study by 
Balemans et al found no associa-
tion between recurrent URTIs in 
childhood and the development 
of AR. The authors concluded that 
URTI in childhood do not reduce 
the risk of AR in young adulthood. 
Conversely, Lee et al found that 
high-risk children with a family 
history of asthma or atopic sen-
sitization have increased rates of 
AR when exposed to parainflu-
enza virus and picornavirus in the 
first year of life.
The discrepancy in research find-
ings among the various studies 
may be due to differences in im-
munologic response profiles in the 
children experiencing these viral 
illnesses. For example, children 
with an atopic phenotype have 
been shown to have decreased vi-
rus-induced interferon (IFN)-alpha 
production compared to healthy 
controls. Since IFN-alpha is both 
antiviral and immunoregulatory, 
any observed differences could be 
attributed to differences in these 
host response patterns. Thus, if 
a child has an atopic phenotype, 
their innate immunoinflammatory 
responses may predispose them 
to the development of AR.
Upper respiratory tract infections in childhood are linked to the development of allergic rhinitis in atopic children
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Upper respiratory tract infections in childhood are linked to the development of allergic rhinitis in atopic children
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Figure 1 the complex interplay between the host and viral infections is modulated by host factors such as atopic status 
and by several environmental factors.
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THE COMMON COLD IN 
ALLERGIC INDIVIDUALS
• Numerous viruses manifest with common cold symptoms, the 
most prominent of which is human rhinovirus (HRV)
• Allergic rhinitis (AR) and the common cold in allergic individuals 
have in common their symptoms and their pathophysiologies 
are interconnected
• HRV infection is often more severe in atopic individuals, as 
infection-induced, interferon-mediated innate responses are 
differentially regulated and viral replication is increased in a Th2 
environment
• Conversely allergen exposure concurrent to infection can lead 
to an exaggerated allergic reaction
The common cold is a pre-em-
inent phenotype of infectious 
rhinitis with high incidence and 
prevalence, associated with con-
siderable burden and socioec-
onomic costs. Numerous virus-
es manifest with common cold 
symptoms, the most prominent of 
which is human rhinovirus (HRV), 
a heterogeneous virus segregated 
in three groups (HRV-A, B and C) 
and with over 100 serotypes (Fig-
ure 1).
Allergic rhinitis (AR) is often con-
trasted to infectious rhinitis/
common cold, as a rhinitis entity 
whose pathophysiological mech-
anism is driven by atopy instead 
of infection. Although the under-
lying pathophysiology of common 
cold and AR is viewed as radically 
different, their clinical manifes-
tations do not differ much and it 
is often challenging to set apart 
these two conditions by clinical 
criteria. In addition, it appears that 
allergen-driven and virus-driven 
inflammation considerably over-
lap (Figure 2).
HRV infections often interact with 
AR, or -more appropriately- with 
the atopic state that underpins 
AR. Indeed, viral infections can 
trigger bronchial – and apparent-
ly nasal – hyperresponsivenes 
KE Y MESSAGES
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Figure 1 Human rhinovirus type 16. (Accesed from http://www.virology.wisc.
edu/virusworld/ICTV8/r16-human-rhinovirus-16-ictv8.jpg on May 11, 2015.)
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and increased recruitment and 
activation of eosinophils in at-
opic subjects. HRV in particular, 
causes both bronchial and nasal 
eosinophilia, which – important-
ly – is prolonged in asthmatic and 
rhinitic patients (Figure 3). HRV 
infection is often more severe in 
atopic individuals, as infection-in-
duced, interferon-mediated in-
nate responses are differentially 
regulated in these patients and 
viral replication is increased in a 
Th2 environment. Also, the de-
gree of antibody-mediated pro-
tection from HRV infection may 
be suboptimal in atopic subjects. 
In fact, it appears that the interac-
tions between HRV and the atopic 
state could be so robust that the 
actual presence of allergen is not 
required for the increased sever-
ity of the symptoms of infection. 
Nevertheless, if a sensitized indi-
vidual is exposed to the allergen in 
the context of an HRV infection, 
an augmented reaction could en-
sue. Indeed, in AR patients, aller-
gen challenge after an HRV infec-
tion leads to increased bronchial 
eosinophil accumulation and en-
hanced and persistent release of 
histamine.
In all, atopy appears to be a risk 
factor for increased severity of the 
common cold infection. Inversely, 
allergen exposure concurrent to 
infection can lead to an exagger-
ated allergic reaction. These are 
important interactions between 
two pathophysiological mecha-
nisms that, at first look, appear to 
be different.
AR and the common cold in aller-
gic individuals have more in com-
mon than initially meets the eye: 
their symptoms tend to overlap 
(as is especially true for rhinor-
rhoea and sneezing and less so for 
obstruction and itching) and their 
pathophysiologies, albeit didacti-
cally distinct, are interconnected.
Figure 2 Mucosal response following Rhinovirus (RV) infection. (Reproduced from Papadopoulos NG, Xepapadaki P, Mallia 
P, et al. Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document. Allergy 
2007;62:457-470, with permission from Wiley-Blackwell.)
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Figure 3 Nasal brush samples following common cold infection, stained for A. MBP (eosinophils). B. Eotaxin C. CD68 
(Macrophages) D. CD3 (T cells). (Reproduced from van Benten IJ, KleinJan A, Neijens HJ, et al. Prolonged nasal eosinophilia in 
allergic patients after common cold. Allergy 2001;56:949-956, with permission from Wiley-Blackwell.)
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FURRY ANIMALS – RISK OR 
PROTECTIVE FACTOR FOR 
ALLERGIC RHINITIS?
• Tolerance to animal dander can be seen either as lack of IgE 
production or as progressive decrease in symptoms with 
prolonged exposure
• Community prevalence of animal ownership is an important 
determinant of the levels of cat allergen in schools and homes 
without a cat
• The impact of a dog in the house is complex because they 
introduce a wide range of bacteria into the house as well as 
being a source of allergen
The significance of skin tests or IgE 
antibodies for cat or dog allergens 
has been appreciated by physicians 
who were interested in allergic dis-
ease for many years. However, the 
relationship between exposure 
to animal allergens and sensitiza-
tion has been less clear. For many 
years, it was assumed that cat or 
dog ownership was the prima-
ry factor in specific sensitization. 
Many allergists in practice went 
further and say that a positive skin 
test for cat was only relevant to 
asthma or allergic rhinitis (AR) if 
the patient had an animal at home. 
It was therefore a surprise when 
Hesselmar et al. reported that sub-
jects living in a house with a cat 
were less likely to become sensi-
tized to cat allergens. Subsequent 
studies rapidly confirmed this find-
ing for cats and dogs (Figure 1). At 
the same time, it became clear that 
animal dander allergens not only 
remained airborne in the home but 
were present in homes without a 
cat as well as in schools, offices and 
other public places.
One of the problems with assess-
ing the role of cat allergens in AR 
is that exposure is perennial and 
that there are very few studies that 
have successfully decreased expo-
sure sufficiently to answer ques-
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tions about the role of cat allergens 
induced-symptoms. In addition, 
controlled trials of cat allergen 
immunotherapy (AIT) for AR have 
generally not been carried out on 
allergic subjects who do not have 
an animal in their house. Investiga-
tion of the effects of animal own-
ership has given different results 
in different communities. In some 
studies, the protective effect of cat 
ownership appeared to be at least 
partly explained by the removal of 
pets by families with allergic chil-
dren. However many studies have 
confirmed a strong protective ef-
fect of early dog or cat ownership.
Since it is clear than many patients 
who do not live in a house with a 
cat become sensitized it is impor-
tant to consider what influences 
the quantity of cat allergens in 
schools or homes without a cat. 
The best data comes from schools 
in Stockholm, where it has been 
clearly shown that the quantity of 
cat allergen in a room is directly 
related to the number of children 
in the class who have a cat at 
home. The obvious implication is 
that the quantity of cat allergen in 
homes without a cat is likely to be 
influenced by the number of the 
homes in the community where 
animals are kept. Indeed, in some 
areas of the United States animals 
are not kept at all or are kept out-
side only. In these predominantly, 
African-American communities, 
the prevalence of cat allergy is 
generally very low. Equally keep-
ing any animal that is rare in the 
community i.e. <2% is not likely to 
sensitize a significant number of 
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Figure 1 Sensitization to 
Cat Allergens in Relation 
to the Prevalence of 
Cat Ownership in the 
Community
Figure 2 Prevalence 
of Sensitization and IgG 
Antibodies to Fel d 1 in 
11-year-old Children in 
Relation to Home Exposure.
(Reprinted from The Lancet, 
357, Platts-Mills T, Vaughan J, 
Squillace S, et al, Sensitisation, 
asthma, and a modified Th2 
response in children exposed 
to cat allergen: a population-
based cross-sectional study, 
752-756, Copyright 2001, 
with permission from Elsevier.)
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children outside the home where 
the animals is kept.
CONCLUSIONS
All animals produce allergens and 
can induce specific sensitization. 
However, a large range of studies 
shows that in a community where 
20% to 40% of the families have a 
cat, those children without a cat at 
home are equally if not more likely 
to be sensitized. Even if the prev-
alence of sensitization is equal 
among children without a cat, 80% 
to 60% of the allergic children 
will not have an animal at home. 
Thus the presence of animals in a 
community can be the or a major 
risk factor for sensitization even 
though children who are exposed 
from early childhood are less likely 
to become sensitized. By contrast 
for animals such as rabbits which 
are much less common in homes, 
it is the patients who live with the 
animals that have the main risk. It 
is clear that the current situation 
is not simple and not surprising-
ly it is not easy to make a simple 
case about the clinical relevance 
of a positive skin test to animal 
dander.
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ALLERGIC RHINITIS PREVALENCE 
AND CLIMATE CHANGE: A 
GLOBAL ECOLOGIC ANALYSIS
• Climate change is measurably altering the timing, distribution, 
quality and quantity of allergenic plants and aeroallergens
• These changes may affect the global distribution of allergic 
rhinitis (AR) incidence and prevalence as well as symptom 
severity, but additional research is needed
• Several spatial associations between climatic factors and the 
prevalence of both intermittent and persistent rhinitis symptoms 
in children were identified in a recent global ecological study, 
providing suggestive evidence that climate influences the 
prevalence of rhinitis symptoms
• Further large multi-country studies that consider climatic effects 
on different AR phenotypes, and the potential interacting role 
of air pollutants, are needed
A major potential indirect effect of 
climate change on public health is 
predicted to arise via climate-in-
duced changes in aeroallergens, 
the primary risk factor for aller-
gic rhinitis (AR). There is already 
a significant body of evidence 
indicating that climate change is 
measurably altering the timing, 
distribution, quality, and quantity 
of allergenic plants and aeroaller-
gens. Such changes are occurring 
via meteorological factors and 
through interactions with green-
house gases and air pollutants, 
and may affect both the incidence 
and prevalence of AR, as well as 
the severity of symptoms.
Despite the strong evidence 
demonstrating climate-induced 
changes on allergenic plants and 
aeroallergens and the known 
causal relationship between aer-
oallergens and AR onset and 
prevalence, studies examining as-
sociations between climatic fac-
tors and AR have yielded mostly 
inconsistent results. This may be 
because climatic effects on aer-
oallergens and thus presumably 
on AR are likely to vary by geogra-
phy and vegetation type. Studies 
that incorporate data from several 
geographical areas and climates 
are required. However, to date, 
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only very few studies have exam-
ined associations between climat-
ic factors and AR using data from 
more than one country.
The most recent effort utilized 
data collected by the worldwide 
International Study of Asthma and 
Allergies in Childhood survey (3). 
In addition to identifying variation 
in the global distribution of both 
intermittent (Figure 1) and persis-
tent rhinitis symptom prevalences 
among children, this ecological 
study reported on several spatial 
associations between climatic fac-
tors and the prevalence of these 
allergic conditions on a global 
scale. Associations appeared most 
consistent for intermittent rhi-
nitis symptoms when examining 
country-level (between-country, 
Figure 2) associations, whereas 
associations with persistent rhi-
nitis symptoms were more con-
sistent at the center-level (with-
in-country associations, Figure 3). 
The overall trend reported in this 
paper was a generally positive as-
sociation between mean monthly 
temperature and vapor pressure 
(which were highly correlated) and 
several measures of precipitation, 
with rhinitis symptom prevalence. 
Elaine Fuertes  
University of British Columbia 
Canada
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Allergic rhinitis prevalence and climate change: a global ecologic analysis
Figure 1 World map showing the center prevalence of intermittent rhinitis symptoms for the centers with 13- to 
14-year-olds. (Reprinted from Ann Allergy Asthma Immunol, 113/4, Fuertes E, Butland BK, Anderson HR, Carlsten C, Strachan 
DP, Brauer M, Childhood intermittent and persistent rhinitis prevalence and climate and vegetation: a global ecologic analysis, 
386-392, Copyright 2014, with permission from Elsevier.)
Figure 2 Between-country associations for intermittent and persistent rhinitis prevalence with select environmental 
factors for the centers with 13- to 14-year-olds. All models were adjusted for center mean exposure of interest, as well 
as the center and country mean population density, country gross national income per capita, and climate type. (Created 
from values presented in Table 3 in Fuertes E, Butland BK, Anderson HR, et al. Childhood intermittent and persistent rhinitis 
prevalence and climate and vegetation: a global ecologic analysis. Ann Allergy Asthma Immunol 2014;113:386-392.e9. Note: 
effect estimates in original table are presented per one unit increase whereas effect estimates in the current figure are presented 
per one interquartile range increase.)
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Although not conclusive, this eco-
logical study represents a first 
step in investigating how future 
changes in climate change may af-
fect rhinitis symptom prevalence 
on a global scale.
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Figure 3 Within-country associations for intermittent and persistent rhinitis prevalence with select environmental 
factors for the centers with 13- to 14-year-olds. All models were adjusted for country mean exposure of interest, as 
well as the center and country mean population density, country gross national income per capita, and climate type. 
(Created from values presented in Table 4 in Fuertes E, Butland BK, Anderson HR, et al. Childhood intermittent and persistent 
rhinitis prevalence and climate and vegetation: a global ecologic analysis. Ann Allergy Asthma Immunol 2014;113:386-392.
e9. Note: effect estimates in original table are presented per one unit increase whereas effect estimates in the current figure are 
presented per one interquartile range increase.)
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ENVIRONMENTAL RISK FACTORS 
FOR ALLERGIC RHINITIS – HOME 
ENVIRONMENT
• Allergens from house dust mites and furry pet allergens is 
ubiquitous in homes and furry pet allergens can be transported 
by clothes and hair from other indoor environments. Cockroach 
allergens can be an important risk factors for allergic rhinitis 
(AR) in some parts of the world
• Cleaning and other hygienic measures can reduce allergen 
exposure but it is more unclear if they reduce allergic symptoms
• Dampness and indoor mould growth are well-established 
risk factors for AR, but the causative factors are not clearly 
identified and can differ between different climate zones
• Chemical emissions from recent redecoration and new building 
materials can be a risk factor for AR but the mechanisms are not 
well understood
• A sufficient ventilation flow in homes is important to reduce the 
exposure to particles and volatile organic compounds and to 
reduce the risk for building dampness and indoor mould growth
Allergic rhinitis (AR) occurs when 
an allergen triggers nasal symp-
toms in a sensitized individual, 
while non-allergic rhinitis (NAR) 
is triggered by non-allergic and 
non-infectious agents. In epide-
miological studies, it is often diffi-
cult to distinguish between these 
two types of rhinitis and moreover 
non-allergic indoor factors can act 
as adjuvant factors for AR. House 
dust mites (HDM) allergy is a com-
mon cause of allergic asthma and 
AR, affecting 65-130 million per-
sons globally, but the translation 
of the silent sensitization into 
symptomatic disease is still not 
well understood. Allergen sources 
are common in the home environ-
ment, including furry pets (cat and 
dogs), rats and mice, cockroaches, 
house dust mites, tropical storage 
mite (Bloomia tropicalis), fungal 
allergens (e.g. from Penicillium sp, 
Cladosporium sp. and Alternaria sp.) 
and allergenic pot plants (e.g. Ficus 
benjamina and Yucca elephantipes) 
(Table 1). Non-allergic factors in-
cludes particle pollutants (PM10 
and PM2.5), environmental to-
bacco smoke (ETS), formaldehyde, 
volatile organic compounds (VOC) 
from new building materials and 
consumer products (Table 1 and 
Figure 1).
KE Y MESSAGES
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Building dampness and mould 
growth on indoor surfaces or in 
the construction are common in 
homes and could cause rhinitis in 
children and adults. Recently large 
studies in children and adults on 
AR have been published, e.g. from 
Asia. Presence of cockroaches was 
associated with AR in studies from 
China and France and with current 
rhinitis in China. In studies from 
China and Korea, recent redeco-
ration and moving to a new home 
was associated with AR. However, 
one study from France found that 
new particle board in the home, 
a well-known source of formal-
dehyde emissions, was associat-
ed only with NAR. Windowpane 
condensation in wintertime is an 
indicator of a combination of poor 
ventilation and high air humidity 
and has been associated with AR 
in China and Sweden. Finally, daily 
cleaning of the homes was asso-
ciated with a lower prevalence of 
AR in China.
The indoor environment in homes 
is complex and contains a large 
number of allergens and non-al-
Dan Norbäck Juan Wang
Uppsala University 
Uppsala, Sweden
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lergenic factors that can affect 
AR. Use of low-emission building 
materials and consumer products, 
reduction of tobacco smoke and 
other indoor combustion sources 
and sufficient air exchange is im-
portant, as well as sufficient clean-
ing. Moreover it is important to 
construct and maintain buildings 
in such a way that building damp-
ness and indoor microbial growth 
is avoided to reduce the risk for 
AR.
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TABLE 1
Common sources of indoor pollution in the home environment
Allergenic source Main allergens
Cats Der p 1
Dogs Can f 1
Horse Ecu cx
Rats/mice Mus m 1, Rat n 1
House dust mites (HDM) Der p 1, Der f 1, Der m 1
Tropical storage mite (Bloomia tropicalis) Blo t
Cockroaches  Per a 1, Bla g 1
Mould (e.g. Penicillium sp. Cladosporium 
sp, Alternaria sp.) various allergens
Pot plants (e.g. Ficus benjamina, Yucca 
elephantipes, Dieffenbachia picta and 
Euphorbia pulcherrima)
various allergens
Other indoor factors Type of emissions
New building materials formaldehyde, various VOC
New chip board formaldehyde
Environmental tobacco smoke (ETS) nicotin, aldehydes, particles, VOC
Biomass and wood combustion aldehydes, particles, VOC
Low ventilation flow (poor ventilation) Increased levels of all pollutants
Building dampness
aldehydes, VOC, microbial VOC 
(MVOC), mycotoxins, endotoxin, 
mould, bacteria, microbial compounds
Figure 1 The complexity of the 
indoor environment in homes.
Environmental risk factors for allergic rhinitis – home environment
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ENVIRONMENTAL RISK FACTORS 
FOR ALLERGIC RHINITIS - WORK 
ENVIRONMENT
• Sensitizers (HMW and LMW allergens) and irritants may lead 
to occupational rhinitis (OR). There is an overlap between the 
different categories of eliciting agents. Sensitizers may also 
have irritating properties. Irritants may lead to new onset OR, 
but also to worsening of pre-existing disease
• The level of exposure, atopy and smoking are considered as the 
main potential determinants for the development of OR
• OR is a risk factor for the development of asthma. Work-related 
ocular-nasal symptoms are also a strong predictor of work 
exacerbated asthma
• Occupational exposures may also be involved in more severe 
forms of chronic rhinosinusitis
OCCUPATIONAL AND WORK-
EXACERBATED RHINITIS
Environmental agents at the work 
place may lead to work-related 
rhinitis. Work-related rhinitis can 
be caused by work - occupational 
rhinitis (OR) – or exacerbated by 
work (work-exacerbated rhinitis). 
OR can be divided into allergic 
and non-allergic OR.
In general, allergic OR is charac-
terized by a latency period i.e. a 
period between the start of expo-
sure and the onset of symptoms 
whereas non-allergic OR might 
develop shortly after exposure 
(figure 1). Sensitizing agents - in 
most cases high molecular weight 
(HMW) allergens and sometimes 
low molecular weight (LMW) al-
lergens – may induce an IgE medi-
ated allergic reaction, responsible 
for allergic OR. Less frequently, 
single or multiple exposures to 
irritants will lead to non-allergic 
irritant-induced OR. Corrosive rhi-
nitis is considered as the most se-
vere form of irritant induced OR, 
characterized by persistent in-
flammation. Ulcerations and per-
foration of the nasal septum may 
be attributed to OR, but are more 
frequently seen in the context of 
cocaine sniffing and/or nose pick-
ing.
KE Y MESSAGES
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Apart from these occupational 
diseases caused by work, environ-
mental stimuli at work may also 
lead to worsening of pre-existent 
rhinitis.
There is some overlap between 
the different categories of eliciting 
agents. Sensitizers may also have 
irritating properties. Irritants may 
lead to OR, but also to worsen-
ing of pre-existing rhinitis. Table 1 
shows some examples of allergens 
and the corresponding occupa-
tions responsible for OR. The level 
of exposure, atopy and smoking 
are considered as the main poten-
tial determinants for the develop-
ment of OR.
CHRONIC RHINOSINISITIS
Recent studies provide evidence 
that occupational exposures may 
also be involved in more severe 
forms of chronic rhinosinusitis 
(CRS). Exposures at work appear 
to be a risk factor for the occur-
rence, recurrence and persistence 
of CRS. Moreover, patients with 
job exposures appear to be less 
satisfied with the outcome of sur-
gical procedures.
WORK RELATED RHINITIS AND 
ASTHMA
There is a close relationship be-
tween the presence of OR and 
the development of occupation-
al asthma (OA). It has been esti-
Environmental risk factors for allergic rhinitis - work environment
Roy-Gerth van Wijk  
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mated that the relative risk of OA 
amounts to 4.8 in workers with 
OR. Vice versa OR can be found 
in three-quarters of the patients 
with OA. Work-related ocular-na-
sal symptoms are also a strong 
predictor of work -exacerbated 
asthma (OR 6.7; CI 2.4-19.1)
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TABLE 1
type of exposure leading to work-related rhinitis
Agents Occupation Prevalence (%)
High molecular weight agents
Laboratory animals Laboratory workers 6–33
Other animal-de-
rived allergens Swine confinement workers 8–23
Insects & mites Laboratory workers, farm workers 2–60
Grain dust Grain elevators 28–64
Flour Bakers 18–29
Latex Hospital workers, textile factory 9–20
Other plant aller-
gens
Tobacco, carpet, hot pepper, tea, coffee, 
cocoa, dried fruit and saffron workers 5–36
Biological enzymes Pharmaceutical & detergent industries 3–87
Fish and seafood 
protein
Trout, prawn, shrimp, crab & clam work-
ers; aquarists & fish-food factory workers 5–24
Low molecular weight agents
Diisocyanates Painters, urethane mould workers 36–42
Anhydrides Epoxy resin production, chemical work-ers, electric condenser workers 10–48
Wood dust Carpentry & furniture making 10–36
Metals (platinum) Platinum refinery 43
Drugs (psyllium, spira-
mycin, piperacillin) Health care & pharmaceutical workers 9–41
Chemicals
Reactive dye, synthetic fibre, cotton, 
persulphate, hairdressing, pulp & paper, 
shoe manufacturing
3–30
Data from Moscato G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, Quirce S, et 
al. EAACI position paper on occupational rhinitis. Respir Res 2009;10:16.
Figure 1 Rhinitis symptoms occurring in the work 
place can be induced by substances present in the 
work place (occupational rhinitis) or preexisting and 
aggravated by exposure to substances present in the 
work place (work-aggravated rhinitis). (From Moscato 
G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, 
Quirce S, et al. EAACI position paper on occupational 
rhinitis. Respir Res 2009;10:16.)
Environmental risk factors for allergic rhinitis - work environment
Work related rhinitis
Rhinitis caused by work:
Occupational rhinitis
Rhinitis exacerbated by work:
Work exacerbated rhinitis
Allergic rhinitis
With latency period
Non-allergic rhinitis
Without latency
IgE mediated
Non IgE 
mediated
Single expo-
sure RUDS
Multiple 
exposures: 
Irritant induced
Corrosive 
rhinitis
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ENVIRONMENTAL RISK FACTORS 
FOR ALLERGIC RHINITIS - INDOOR 
AND OUTDOOR POLLUTION
• Diesel-burning engines emit particulate matter which has been 
demonstrated to cause and aggravate asthma and enhance 
allergic sensitization leading to allergic rhinitis (AR) in children 
living in close proximity to high-traffic areas
• Volatile organic compounds are derived from chemical 
or microbial sources and at high levels can cause mucous 
membrane irritation resulting in non-specific upper respiratory 
symptoms as well as fatigue, and difficulty concentrating
• Solid biomass fuels are also a major source of indoor air 
pollution especially in underdeveloped countries dependent on 
this energy for heating and cooking
• Polyaromatic hydrocarbons from residential heating and 
gas appliances can impact the immunologic development of 
newborns and increase the number and duration of respiratory 
episodes in infants with prenatal exposure
OUTDOOR POLLUTION
Air pollution and global warming 
have significant health and eco-
nomic effects on society. Outdoor 
pollution includes gases such as 
sulfur dioxide, ozone, nitrogen 
species, carbon monoxide, and 
particulate matter (PM) (coarse 
PM10, fine PM2.5, and ultrafine) 
and may contribute to the rising 
prevalence of allergic rhinitis (AR) 
and asthma in westernized coun-
tries (Table I). Air pollutants can be 
classified as primary/secondary, 
indoor/outdoor and as gaseous 
particulate (Table II). Studies have 
found that increased outdoor CO2 
levels combined with increased 
temperatures cause ragweed 
plants to grow larger and produce 
increased pollen. Diesel-burning 
engines emit PM which has been 
demonstrated to cause and aggra-
vate asthma and enhance allergic 
sensitization in children living in 
close proximity to high-traffic ar-
eas. Ozone, a byproduct of die-
sel exhaust, can increase inflam-
mation in the airways of asthma 
patients. A study of school-aged 
children in Germany found an as-
sociation with atopy but only in 
children living in homes exposed 
to air pollution from high motor 
vehicle traffic and environmen-
tal tobacco smoke. A longitudi-
KE Y MESSAGES
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nal study evaluated the effect of 
air pollution in causing atopy and 
asthma based on the child’s geo-
graphic location over seven years 
using exposure modeling and 
found that PM2.5 was associated 
with asthma, whereas nitrogen 
dioxide was associated with ecze-
ma, and living a distance less than 
50 m to the nearest road was as-
sociated with asthma symptoms. 
In addition, another similar lon-
gitudinal study found that diesel 
exhaust particles (DEP) exposure 
enhances the risk of early aeroal-
lergen sensitization and was as-
sociated with allergic rhinitis at 4 
years of age.
INDOOR POLLUTION
Examples of indoor pollution in-
clude cigarette smoke, carbon 
monoxide, carbon dioxide, and vol-
atile organic compounds (VOCs) 
(Table 2). VOCs are derived from 
chemical or microbial sources. 
Chemical VOCs include ketones 
and aldehydes like formaldehyde 
which emanate from building ma-
terials including adhesives, carpet, 
cleaners, linoleum, furniture, paint, 
printers, textiles, personal care 
Environmental risk factors for allergic rhinitis - indoor and outdoor pollution
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ed clothing. High VOC levels (> 
3000 μg/m3) can cause mucous 
membrane irritation resulting in 
non-specific upper respiratory 
symptoms as well as fatigue, and 
difficulty concentrating.
Use of solid biomass fuels is also 
a major source of indoor air pol-
lution. This is especially true in 
underdeveloped countries where 
heating and cooking depends on 
these biomass fuels and when 
combined with poor ventilation 
results in repeated periods of 
emissions that have been asso-
ciated with increased childhood 
respiratory infections and devel-
opment of chronic obstructive 
pulmonary disease, asthma, and 
malignancy.
Studies have also investigated 
the health effects of air pollution 
during pregnancy and found that 
moderate- to long-term high air 
pollution exposure can alter T-cell 
production in neonates. Polyaro-
matic hydrocarbons (PAHs), emit-
ted from residential heating and 
gas appliances, may also impact 
the immunologic development 
of newborns. Studies have found 
that the number and duration of 
respiratory episodes were greater 
in infants exposed prenatally to 
higher levels of PAHs.
In summary, there is overwhelm-
ing evidence to support the health 
effects of air pollution on respira-
tory health. However, many ques-
tions remain unanswered which 
require further investigation.
TABLE 1
National Ambient Air Quality Standards (adapted from http://www.epa.gov/air/criteria.html) *
Pollutant Primary standards Averaging times Secondary standards
CO 9 ppm (10 mg/m3) 8-Hour † None
35 ppm (40 mg/m3) 1-Hour † None
NO2 0.053 ppm (100 μg/m
3) Annual (arithmetic mean) Same as primary
PM10 Revoked‡ Annual ‡ (arithmetic mean) Revoked‡
150 μg/m3 24-Hour § Same as primary
PM2.5 15.0 μg/m3 Annual ‖ (arithmetic mean) Same as primary
35 μg/m3 24-Hour ¶ Same as primary
O3 0.08 ppm 8-Hour # Same as primary
0.12 ppm 1-Hour** (applies only in limited areas) Same as primary
Sulfur oxides 0.03 ppm Annual (arithmetic mean) —
0.14 ppm 24-hour † —
— 3-hour † 0.5 ppm (1300 μg/m3)
* Primary standards, limits set to protect public health, especially sensitive subpopulations such as patients with asthma, the 
elderly, and children. Secondary standards, limits set to protect public welfare such as visibility and damage to crops, animals, 
and buildings. Levels for VOCs have not been established.
†Not to be exceeded more than once per year.
‡Because of a lack of evidence linking health problems to long-term exposure to coarse particle pollution, the agency revoked 
the annual PM10 standard in 2006 (effective December 17, 2006).
§Not to be exceeded more than once per year on average over a period of 3 years.
‖To attain this standard, the 3-year average of the weighted annual mean PM2.5 concentrations from single or multiple com-
munity-oriented monitors must not exceed 15.0 μg/m3.
¶To attain this standard, the 3-year average of the 98th percentile of 24-hour concentrations at each population-oriented 
monitor within an area must not exceed 35 μg/m3 (effective December 17, 2006).
#To attain this standard, the 3-year average of the fourth-highest daily maximum 8-hour average O3 concentrations measured 
at each monitor within an area over each year must not exceed 0.08 ppm.
** (1) The standard is attained when the expected number of days per calendar year with maximum hourly average concentra-
tions above 0.12 ppm is ≤1. (2) As of June 15, 2005, the Environmental Protection Agency revoked the 1-hour O3 standard in 
all areas except the fourteen 8-hour O3 nonattainment Early Action Compact (EAC) areas.
Environmental risk factors for allergic rhinitis - indoor and outdoor pollution
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TABLE 2
Classification of air pollutants
A. Primary-secondary pollutants
(i) Primary: pollutants emitted directly into the atmosphere (eg, SO2, some NOx species, CO, PM)
(ii) Secondary: pollutants that form in the air as a result of chemical reactions with other pollutants and gases (eg, 
ozone, NOx, and some particulates)
B. Indoor-outdoor pollutants
(i) Indoor pollutants
(a) Sources: cooking and combustion, particle resuspension, building materials, air conditioning, consumer products, 
smoking, heating, biologic agents
(b) Products: Combustion products (eg, tobacco and wood smoke), CO, CO2, SVOC (eg, aldehydes, alcohols, alkanes, 
and ketones), microbial agents and organic dusts, radon, manmade vitreous fibers
(ii) Outdoor pollutants
(a) Sources: industrial, commercial, mobile, urban, regional, agricultural, natural
(b) Products: SO2, ozone, NOx, CO, PM, SVOC
C. Gaseous-particulate pollutants
(i) Gaseous: SO2, NOx, ozone, CO, SVOC (eg, PAH, dioxins, benzene, aldehydes, 1,3-butadiene)
(ii) Particulate: coarse PM (2.5-10 μm; regulatory standard = PM10), fine PM (0.1-2.5 μm; regulatory standard = PM2.5); 
ultrafine PM (<0.1 μm; not regulated)
NOx, Nitrogen oxides; SVOC, specific volatile organic compounds.
(Data from J Allergy Clin Immunol, 114/5, Bernstein JA, Alexis N, Barnes C, Bernstein IL, Bernstein JA, Nel A, Peden D, Di-
az-Sanchez D, Tarlo SM, Williams PB. Health effects of air pollution, 1116-1123, Copyright 2004, with permission from 
Elsevier.)
Section C
* Clinical features of allergic rhinitis
* Triggers of allergic rhinitis: inhalant allergens
* Triggers of allergic rhinitis – cross-reactive allergens
* Triggers of allergic rhinitis - work-related allergens
* Co-morbidities of allergic rhinitis: nasal polyposis
* Co-morbidities of allergic rhinitis: ocular allergy
* Co-morbidities of allergic rhinitis: eosinophilic otitis 
media
* Co-morbidities of allergic rhinitis: eosinophilic 
esophagitis
* The united airway disease
* Atopic dermatitis and allergic rhinitis: Where is the 
evidence for comorbidity?
* Allergic rhinitis and food allergy
* The link between the skin and the airways
* Allergic rhinitis and angioedema
* Allergic rhinitis and sleep apnea
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es • Common symptoms of allergic rhinitis involve the nose and 
extend beyond to affect the eyes, ears, sinuses, and lungs
• Nasal symptoms include nasal itching and congestion, runny 
nose, and paroxysmal sneezing
• Additional symptoms include ear fullness, itching and tearful 
eyes, post-nasal drip, and cough
• Classic physical exam findings include swollen nasal turbinates, 
pale nasal cavity lining, and cobblestoning
While allergic rhinitis (AR) refers 
to an inflammatory process of 
the nasal passages, symptoms in-
volve the nose and may extend 
beyond to affect the eyes, ears, 
sinuses, and lungs. Commonly 
reported nasal symptoms include 
nasal itching and congestion, run-
ny nose, and sneezing. Patients 
may also complain of ear symp-
toms including ear fullness and 
popping. Often AR will involve the 
conjunctiva and as such patients 
may experience itching, burning, 
or tearful eyes. Other frequently 
associated symptoms are throat 
itching and post-nasal drip.
Severe persistent AR may lead 
to snoring, mouth breathing, and 
sinus pressure symptoms. With 
chronic symptoms, children may 
often sniff, snort, and repeatedly 
clear their throats. While scratch-
ing their itchy palates, children 
may also make a clicking sound 
called the “palatal click.” Table 1 
provides an overview of common 
clinical features of AR.
AR is often associated with classic 
physical findings as well. On nasal 
examination, the nasal cavity lin-
ing will often appear pale or have a 
bluish hue in contrast to its normal 
pinkish hue. Nasal turbinates may 
be enlarged and swollen. Clear 
CLINICAL FEATURES OF 
ALLERGIC RHINITIS1
KE Y MESSAGES
nasal discharge may also be seen 
(Figure 1). Patients may also have 
“cobblestoning” on exam, which 
refers to the cobblestone-like or 
bumps often seen in the back of 
the throat.
Other physical features include 
lines below the lower eyelid re-
ferred to as Dennie-Morgan lines. 
Patients may have dark circles 
around the eyes referred to as 
allergic shiners (Figure 2). In ad-
Clinical features of allergic rhinitis
Megan Motosue James T. Li
Mayo Clinic 
Rochester, USA
Figure 1 Typical 
nasal exam findings 
of allergic rhinitis 
with clear nasal 
drainage and swollen 
inferior turbinate. 
(From Onerci TM. 
Rhinitis. Diagnosis in 
Otorhinolaryngology. 
2010; pp 60-64.)
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dition, children will often perform 
the “allergic salute,” a rubbing mo-
tion performed by using the palm 
of their hand to relieve their nasal 
itching (Figure 3). Over time, this 
can lead to a transverse crease 
along the nose.
Symptoms of AR are caused by 
an allergic reaction to allergens in 
the air. Depending on the allergen, 
symptoms may occur seasonally 
or year round. Common seasonal 
allergens include grasses, trees, 
weeds, and molds. Common year 
round or perennial allergens in-
clude animal dander, molds, and 
dust mites. While seasonal allergic 
rhinitis tends to predominate in 
children and perennial in adults, 
individuals can have both types.
AR is a global health problem. In 
addition to appropriate treatment, 
symptom recognition is important 
in managing and reducing morbid-
ity in this increasingly prevalent 
disease.
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Clinical features of allergic rhinitis
TABLE 1
Clinical features of allergic rhinitis
System Symptoms
Nose Sneezing, runny nose, and nasal congestion
Ears Tearful, burning, and itching eyes
Ears Ear popping and fullness
Sinus Pressure over the cheeks and forehead
Throat Itchy throat and post nasal drip
Lungs Cough and symptoms of asthma
Figure 2 Pediatric patient with allergic rhinitis 
demonstrating “allergic shiners” and mouth breathing 
(source UptoDate)
Figure 3 The Allergic Salute. (From Marks M: Physical 
Signs of Allergy of the Respiratory Tract in Children. New 
York, American College of Allergy, Asthma and Immunology, 
1990.)
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es • Inhalant allergens are plant and animal derived proteins that 
have the capacity to generate IgE responses and allergic disease 
in susceptible individuals; they cause rhinitis, conjunctivitis,
• asthma and atopic dermatitis
• The preferred nomenclature for inhalant allergens is intermittent 
and persistent
• The diagnosis of inhalant allergy requires the presence of 
sensitization and timing of disease to exposure to the inhalant 
allergens
INTRODUCTION
Inhalant allergens are plant and an-
imal derived proteins that have the 
capacity to generate IgE responses 
and allergic disease in susceptible 
individuals. Sensitization to inhal-
ant allergens is the main risk fac-
tor for allergic rhinitis (AR), asthma 
and allergic conjunctivitis. In addi-
tion to the adaptive IgE immune 
response, many allergens engage 
adaptive immune responses via 
proteolytic actions to destroy pro-
tective mucous layers in the air-
ways or activate the protease ac-
tivate receptor PAR2 to contribute 
to epithelial inflammation.
CLASSIFICATION
Inhalant allergens were tradi-
tionally classified as seasonal or 
perennial, however the allergic 
rhinitis and its impact on asthma 
(ARIA) report has suggested a 
classification that relates to the 
duration of impact than an aller-
gen has on allergic disease. For 
example grass pollen can be sea-
sonal in a temperate region, but 
causes perennial disease in the 
tropics and sub-tropics. The pre-
ferred nomenclature for inhalant 
allergens is intermittent and per-
sistent.
TRIGGERS OF ALLERGIC 
RHINITIS: INHALANT 
ALLERGENS
2a
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HOUSE DUST MITES
Two common mites from the Der-
matophagoides (Latin for ‘skin eat-
er’) genus can cause allergic dis-
ease: the European house dust mite 
(HDM) (Dermatophagoides pteron-
yssinus) (Figure 1) and the American 
HDM (Dermatophagoides farinae); 
however these are not confined to 
their geographic titles and are pres-
ent worldwide. In tropical regions, 
the tropical mite Blomia tropicalis is 
the major mite allergen. Der P1, a 
cysteine protease is the most char-
acterised, and is a digestive enzyme 
that is excreted in mite faeces. Mites 
inhabit and thrive in conditions 
where there is skin and humidity, 
particularly bedding, but may in-
habit furniture and carpet. Pillows 
can contain up to 2000 mites per 
gram of dust. Dust mites require 
moulds for digestion. In their life 
cycle, mites can lay about 70 eggs 
and produce 2000 allergenic faecal 
particles. Most mite reduction trials 
have methodological issues and a 
Cochrane review summarised that 
extensive bedroom-based environ-
mental control measures may be 
of use in reducing perennial rhinitis 
symptoms.
POLLENS
Pollens are the male spores of 
plant seeds from trees, grasses and 
weeds. Pollen grains have a stur-
dy outer shell and inner spores. As 
plants have evolved, pollens have 
developed a more complex outer 
structure (Figures 2 & 3). Tree pol-
lens (e.g, birch, elm, olive, acacia, 
ash, cedar, pine) have a shorter and 
earlier duration of pollination and 
Triggers of allergic rhinitis: inhalant allergens
Pete Smith  
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Queensland Australia
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may release pollen for only a few 
weeks in spring. Grasses (e.g. Rye, 
Timothy, Orchard, Bermuda) have 
late spring and summer peaks and 
weeds (Ragweed/Ambrosia, Plan-
tain, Sorrel) follow a similar release 
pattern, but also continue pollen 
release into autumn. In temperate 
zones weeds generally cease pollen 
release with the first freeze. Pollens 
can travel for miles, although some 
pollens (e.g. plantain and birch) are 
quite heavy and are not widely 
dispersed. Grass pollen release is 
increased 8-20 fold with the atmos-
pheric changes of thunderstorms.
MOULD
Moulds are the major component 
found in environmental allergen 
traps. They thrive and reproduce in 
moist, dark environments such as 
dirt, wood, food, plant matter and 
animal matter. Common inhalant 
allergen species include, Alternaria, 
Aspergillus, Helminthosporium, Cla-
dosporium and Penicillium. Inhalant 
allergic disease has been associated 
with fungal dermatophytes includ-
ing Trichophyton spp, Candida albi-
cans and Epidermophyton. Most fun-
gi have branching threads (hyphae, 
Figure 4). A mycelium is a cluster 
of hyphae. In addition to allergic 
disease several moulds (e.g. asper-
gillus) cause invasive disease and 
are capable of producing volatile or-
ganic compounds that cause airway 
irritation. Moulds are regarded as 
persistent allergens however spore 
release can increase dramatically 
with thunderstorms to produce an 
intermittent clinical disease pattern.
DANDER
Domestic cats and dogs are the 
most characterized pet allergens, 
although dander from a wide range 
of animals may cause inhalant al-
lergic disease. The most important 
cat allergens are the glycoproteins 
Fel d1 (from sebaceous glands) 
Triggers of allergic rhinitis: inhalant allergens
Figure 1 Scanning electron microscopy (false colour) of the common house 
dust mite. Dermatophagoides pteronyssinus.
Figure 2 Scanning electron microscopy (false colour) of Bermuda grass 
Cynodon dactylon.
Figure 3 Scanning electron microscopy (false colour) demonstrating a 
complex sulci (furrow) pattern of acacia pollen grains.
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Triggers of allergic rhinitis: inhalant allergens
and Fel d4 (in saliva). Cat allergens 
are very pervasive and resistant to 
elimination measures. Dog hair and 
saliva can provoke allergic symp-
toms in sensitised individuals.
OTHER INHALANT ALLERGENS
A wide range of biological materi-
als including feathers, insect ma-
terials (e.g. cockroach, housefly) 
and latex can provoke inhalant 
allergic disease.
DIAGNOSIS OF ALLERGY
The clinical diagnosis of allergic 
disease requires symptomatolo-
gy in the presence of the allergen 
and the presence of IgE on testing 
(skin prick, RAST 
and/or provoca-
tion). Pollen maps 
(Figure 5) can 
be helpful when 
correlating dis-
ease with posi-
tive tests. Clinical 
disease caused by 
inhalant allergens 
can be enhanced 
by the presence 
of high ozone lev-
els and pollutants 
including smoke 
and diesel ex-
haust particles.
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Figure 5 European pollen map of birch (Betulla pendula in early May and ragweed (Ambrosia 
artemisiifolia) in mid-end August (Code: white nil, green low, yellow moderate, orange high and red 
very high) Image courtesy of EAN (European Aeroallergen Network) Medical University Vienna, 
Austria.
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• Cross-reactivity is common in allergic rhinitis
• Cross-reactivity allows simplification of diagnostic and 
therapeutic strategies
• Taxonomic family-specific marker allergens help identifying the 
source of primary sensitization
• Pan-allergens can assist in excluding primary sensitization
Allergic rhinitis (AR) is a disease 
triggered by the interaction be-
tween mast cell-bound specific 
IgE antibodies and inhaled aller-
gens. The most common triggers 
are house dust mites, and grass, 
tree and weed pollen. In all cases, 
multiple species have been impli-
cated, e.g. Dermatophagoides pter-
onyssinus and Dermatophagoides 
farinae, and Blomia tropicalis for 
mites, a long list of grass species 
including Phleum pratense, Lolium 
perenne and Poa pratensis, various 
trees from the order of the Fagales 
to which the Betulaceae (birch, 
alder and hazel) and the Juglan-
daceae (walnut) families belong, 
and the order of the Lamiales with 
the family of the Oleaceae (olive 
and ash), and finally a variety of 
allergenic weeds such as the As-
teraceae (mugwort and ragweed), 
the Urticaceae (Parietaria judaica), 
the Plantaginaceae (plantain) and 
the Amaranthaceae (Russian this-
tle). Depending on climatic and 
socio-economic characteristics of 
the domicile of a patient, the ac-
tual combined exposure to these 
potential triggers differs widely in 
composition.
Establishing the exact composi-
tion of exposure to the level of 
individual species is in fact im-
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possible, e.g. because pollen of 
different species within plant fam-
ilies can hardly if at all be distin-
guished microscopically. Antibody 
responses as a read-out for expo-
sure usually do not really give the 
answer either, because there is a 
high degree of antibody cross-re-
activity between homologous al-
lergens of different species of pol-
len or of house dust mites, within 
a family or even across family (or 
even order) boundaries.
The degree of cross-reactivity is 
correlated with the percentage of 
structural homology, which is de-
termined by adjacency in the fam-
ily tree (genealogical relationship). 
Both from a diagnostic and a ther-
apeutic perspective it is important 
to be aware of cross-reactivity. 
Within a family, cross-reactivity 
is usually so extensive that both 
for diagnosis and for allergen im-
munotherapy (AIT), a single high 
IgE-binding species is sufficient, 
e.g. Pheum pratense for grass pol-
len, Betula verrucosa for the birch 
family, or Dermatophagoides ptero-
nyssinus for mites. There is no con-
vincing evidence that patients are 
selectively allergic to just one spe-
cies of grass or tree pollen or one 
species of mites. A mix of allergen 
extracts for diagnosis or AIT may 
seem more comprehensive but in 
fact only complicates production 
and standardization.
Cross-reactivity outside gene-
alogical families caused by so-
called pan-allergens may lead 
to confusion about the primary 
source of sensitization. For pol-
len, profilins and cross-reactive 
carbohydrate determinants (CCD), 
and for arthropods tropomyosins 
are responsible for such broader 
cross-reactivity. Molecular aller-
gology now offers the opportunity 
to establish whether sensitization 
Triggers of allergic rhinitis – cross-reactive allergens
Ronald van Ree  
University of Amsterdam 
Amsterdam, The Netherlands
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is the true primary sensitization or 
cross-reactivity that started with 
another primary sensitizer. For 
allergenically important genealog-
ical families, marker allergens for 
primary sensitization have been 
identified (Table 1). If these are 
negative, and only pan-allergens 
are responsible for IgE reactivity, 
clinical relevance is unlikely and 
AIT not warranted.
KEY REFERENCES
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TABLE 1
Marker allergens for primary sensitization to a member of a genealogical family
House dust mite
Dermatophagoides pteronyssinus Der p 1
Dermatophagoides farinae Der p 2
Blomia tropicalis Blo t 5
Grass pollen Gramineae or Poaceae Phl p 1, Phl p 5
Tree pollen
Fagales Bet v 1
Lamiales Ole e 1
Mugwort pollen Artemisia vulgaris Art v 1
Ragweed pollen Ambrosia artemisifolia Amb a 1
Pellitory pollen Parietaria judaica Par j 1
Plantain pollen Plantago lanceolata Pla l 1
Russian thistle Salsola kali Sal k 1
olive           ash
OLIVE FAMILY
birch        alder          hazel
BIRCH FAMILY
Bet v 1     Aln g 1       Cor a 1
Ole e 1 Fra a 1
timothy   rye   meadow
GRASS FAMILY
Phl p 1   Lol p 1  Poa p 1
Phl p 5   Lol p 5  Poa p 5
WEED FAMILIES
mugwort ragweed         pellitory plantain Russian thistle
Art v 1  Amb a 1             Par j 1                    Pla l 1                      Sal k 1
profilin
CCD
Figure 1 Cross-reactivities of most dominant allergenic pollen. Arrows indicate cross reactivity. The circular arrows 
imply that profilin and CCD are pan-allergens present in all pollen and cause cross-reactivity across family borders. The 
major allergens of the weeds essentially do not cross-react.
3. Santos A, Van Ree R. Profilins: 
mimickers of allergy or relevant 
allergens? Int Arch Allergy Immu-
nol 2011;155:191-204.
4. van Ree R. Carbohydrate epitopes 
and their relevance for the diag-
nosis and treatment of allergic 
diseases. Int Arch Allergy Immu-
nol 2002;129:189-197.
5. Jeong KY, Hong CS, Yong TS. Al-
lergenic tropomyosins and their 
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Lett 2006;13:835-845.
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• Work-related rhinitis includes occupational rhinitis (OR), i.e. an 
inflammatory disease of the nose due to causes and conditions 
attributable to a particular work environment, and work-
exacerbated rhinitis, that is pre-existing or concurrent rhinitis 
exacerbated by workplace exposures
• Allergic OR may be induced by high-molecular-weight (HMW) 
agents (i.e. glycoproteins from vegetal and animal origin) and by 
some low-molecular-weight (LMW) agents acting through an 
IgE-mediated mechanism, or can be induced by LMW-agents 
acting by non-IgE, immunological mechanisms
• Non-allergic OR is caused by the work environment through 
irritant, non-immunological mechanisms
• Simultaneous multiple exposure to irritants and sensitizers can 
also induce work-related rhinitis
Work-related rhinitis (WRR) in-
cludes occupational rhinitis (OR), 
that is an inflammatory disease of 
the nose due to causes and con-
ditions attributable to a particular 
work environment, and work-ex-
acerbated rhinitis, that is pre-ex-
isting or concurrent rhinitis exac-
erbated by workplace exposures 
(Figure 1).
OCCUPATIONAL RHINITIS
OR is the most frequent and rec-
ognised form of WRR and can be 
allergic, i.e. immunologically medi-
ated, and non-allergic, i.e. mediat-
ed by irritant mechanisms.
Occupational exposures inducing 
allergic OR are the same as for 
occupational asthma. High-mo-
lecular-weight (HMW) agents 
such as glycoproteins from veg-
etal and animal origin (e.g. flours, 
latex, animal-derived allergens) 
and some low-molecular-weight 
(LMW) compounds (e.g. platinum 
salts, anhydrides) can cause aller-
gic OR through an IgE-mediated 
mechanism. Some LMW agents, 
e.g. isocyanates, can act with non-
IgE, cell-mediated immunological 
mechanisms, which have not yet 
been fully characterized. (Figure 2)
Non-allergic OR is caused by the 
work environment through irritant, 
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Gianna Moscato  
Experimental and Forensic Medicine 
of the University of Pavia, Italy
Santiago Quirce  
Hospital La Paz Institute for Health 
Research (IdiPAZ), Madrid, Spain
non-immunological mechanisms. 
An acute form of irritant-induced 
OR occurring without a latency 
period, after a single exposure 
to high levels of irritants at work 
is called ‘reactive upper airways 
dysfunction syndrome’ (RUDS). 
Exposure to volatile organic sol-
vents and pesticides has been 
associated to the development of 
RUDS. Symptoms of rhinitis may 
also present in subjects repeat-
edly exposed at work to irritants 
(vapors, fumes, smokes, dusts), 
without any identifiable exposure 
to high concentration of irritants. 
This entity is recognized as multi-
ple exposure irritant-induced OR. 
A variety of occupational expo-
sures have been associated with 
this type of OR, including ozone, 
volatile organic compounds, fuel 
oil ash, grain and cotton dust, for-
maldehyde, chlorine, wood dust, 
thermal degradation products of 
polyurethanes, and waste han-
dling. The term ‘corrosive rhinitis’ 
describes the most severe form 
of irritant-induced OR, which is 
characterized by permanent in-
flammation of the nasal mucosa, 
sometimes associated with ulcer-
ations and perforation of the na-
sal septum, that may develop after 
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Figure 2 Occupational agents inducing occupational rhinitis according to their etiopathogenesis. (Reproduced with 
permission from Hox V, Steelant B, Fokkens W, et al. Occupational upper airway disease: how work affects the nose. Allergy 
2014;69:282-291, with permission from Willey Blackwell.)
 Occupational rhinitis
due to causes and conditions attributable to 
a particular work environment
o Allergic (IgE-mediated or non-IgE-
mediated)
o Non-allergic (RUDS, irritant-induced)
 Work-exacerbated rhinitis
o that is pre-existing or concurrent 
rhinitis exacerbated by workplace 
exposures
WORK-RELATED RHINITIS
Figure 1
Figure 1 Classification 
of work related rhinitis. 
(Modified from EAACI Task 
Force on Occupational Rhinitis, 
Moscato G, Vandenplas O, 
et al. Occupational Rhinitis. 
Allergy 2008;63:969-980.)
Triggers of allergic rhinitis - work-related allergens
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TABLE 1
Work-related rhinitis related to exposure to multiple agents
Occupation Agents
Cleaners Various cleaning agents (Chlorine/bleach, dust)
Grape farmers Various pesticides (Bipyrifyl herbicides -paraquat, diquat-, dithiocarbamate fungicides, carbamate insecticides)
Greenhouse workers Inhalant allergens, endotoxins, pesticides
Construction painters Paints
Automotive piston ring 
manufacturing workers Metal working fluid aerosol (microbes, endotoxins, metals)
Modified from Siracusa A, Folletti I, Moscato G. Nonallergic work-related rhinitis. Review 
article. Curr Opin Allergy Clin Immunol 2013;13:159-166.
exposure to high concentrations 
of irritating and soluble chemicals 
like, for instance, chromium.
WORK-EXACERBATED 
RHINITIS
A wide variety of conditions at 
work, including irritant agents 
(e.g., chemicals, dusts, fumes), 
physical factors (e.g., temperature 
changes), emotions, second-hand 
smoke, and strong smells (e.g., 
perfumes) can trigger or wors-
en symptoms of a pre-existing or 
concurrent personal rhinitis.
EXPOSURE TO MULTIPLE 
AGENTS
A high prevalence of rhinitis in 
working populations that were si-
multaneously exposed to several 
potentially irritant and sensitiz-
ing agents, both LMW and HMW 
agents, has recently been report-
ed (Table 1). Cleaners, farmers, 
greenhouse workers, construction 
painters, automotive piston ring 
manufacturing workers have been 
described.
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es • IgE is involved in both AR and CRSwNP, although in AR it is 
allergen-specific and in CRSwNP it is polyclonal
• It is not clear whether atopy contributes to the development of 
CRSwNP
• CRSwNP are often colonized with S. aureus and IgE to S aureus 
superantigens are related to disease severity
• Nasal polyps are frequently associated with (non-atopic, late 
onset) asthma and aspirin intolerance
• The treatment of nasal polyps is indispensable in the control of 
asthma
Allergic rhinitis (AR) and chronic 
rhinosinusitis with nasal polyps 
(CRSwNP) are both T helper 2 
mediated inflammatory diseas-
es of the nasal mucosa with high 
concentrations of IgE. AR affects 
30 % of the population and al-
lergen-specific IgE plays a well-
known central role. CRSwNP af-
fects 4% of the population and 
is frequently associated with late 
onset intrinsic asthma. IgE in AR is 
monoclonal allergen-specific and 
polyclonal in CRSwNP.. Although 
this polyclonal IgE is functional, 
it does not point to comorbid al-
lergic disease. The prevalence of 
allergy in CRSwNP, diagnosed by 
skin prick tests, has been report-
ed to vary from 10 to 54%.. In-
terestingly, allergen exposure in 
atopic nasal polyp (NP) patients 
does not clearly enhance disease 
expression, in contrast to patients 
with AR. The monoclonal IgE in 
AR reflects the allergic constitu-
tion. The polyclonal IgE in atopic 
NP patients however suppresses 
atopic symptoms. AR does prob-
ably not predispose to the devel-
opment of NP, as their prevalence 
in the atopic population is similar 
to the general population, which 
in a French study was estimat-
ed 2,11% of the adult popula-
tion. The treatment of NP is still 
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Co-morbidities of allergic rhinitis: nasal polyposis
problematic because there are 
no effective medical treatments 
available and because of a high re-
currence rate after surgical NP re-
moval. Anti-IgE treatment appears 
to be effective in both atopic and 
non-atopic patients with CRSwNP 
and comorbid asthma, suggesting 
this ‘non-atopic’ IgE plays a pivotal 
role in CRSwNP.
CRSwNP is frequently associated 
with late onset intrinsic asthma, 
and can be associated with aspirin 
intolerance. The triad CRSwNP, 
asthma and aspirin intolerance 
was termed Samter’s triad and is 
actually known as aspirin-exac-
erbated respiratory disease.. NP 
in Samter’s triad are typically re-
calcitrant and hard to treat, and 
asthma is likewise severe. Fur-
thermore, asthma control is un-
likely in uncontrolled CRSwNP. In 
contrast to AR associated asthma, 
co-morbid asthma in NP disease 
is mostly non-atopic and its onset 
is generally in the adult life. Thus, 
atopy cannot explain the pres-
ence of co-morbid asthma in NP 
patients. It is thought that many 
factors contribute in the patho-
genesis of CRSwNP, including col-
onization with Staphylococcus au-
reus. Their enterotoxins can act as 
superantigens resulting in an im-
mune response of increased mag-
nitude and a massive IgE response 
(Figure 1). The overexpression of 
IgE and IL5, and the presence of 
SE-specific IgE in CRSwNP is as-
sociated with an increased risk of 
asthma (Figure 2).
Philippe Gevaert  
Ghent University Hospital 
Ghent, Belgium
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Co-morbidities of allergic rhinitis: nasal polyposis
Figure 1 Enterotoxins derived from Staphylococcus aureus act as superantigens, resulting in high levels of polyclonal IgE.
Figure 2 Higher levels of IgE 
are found in nasal polyp tissue 
when patients suffer from co-
morbid asthma. Elevated local 
IgE seems to be a risk factor 
for asthma development in 
patients with nasal polyps.
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CRSwNP and asthma are associat-
ed with high morbidity and socio-
economic cost. Control is essential 
in the prevention of exacerba-
tions. Treatment of CRSwNP fol-
lowing the evidence-based EPOS 
management scheme (Figure 3) is 
indispensable to achieve control 
of co-morbid asthma. Recognition 
of aspirin intolerance in patients 
with CRSwNP is important to ed-
ucate patients and to prevent life 
threatening responses.
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Figure 3 The evidence-based management scheme for nasal polyps in the adult population as described by the EPOS 
guidelines. (From Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis 
and Nasal Polyps 2012. Rhinol Suppl 2012;(23):3 p preceding table of contents, 1-298.)
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• Allergic conjunctivitis is one of the most common comorbidities 
of allergic diseases, especially of allergic rhinitis
• Allergic rhinoconjunctivitis can be seasonal or perennial
• Symptoms can considerably affect quality of life
• New therapeutic approaches are improving rhinoconjunctivitis 
management
Allergic rhinoconjunctivitis (ARC) 
is a very common manifestation 
of allergy affecting approximately 
10-30% of adults and up to 40% 
of children. Allergic conjunctivitis 
(AC) is a comorbidity of other al-
lergic diseases in more than 90% 
of cases. Specifically, in allergic 
rhinitis (AR) sufferers the preva-
lence of AC varies between 50-90 
%. As noted by the Phase III ISAAC 
Study the prevalence of ARC in 
children is increasing worldwide 
and rises through childhood (8.5% 
at 6-7 years and 14.6% at 13-14 
years). No significant gender dif-
ferences have been described in 
the prevalence of ARC. AC can be 
seasonal (SAC) or perennial (PAC). 
SAC and PAC are the most com-
mon forms of ocular allergy.
AC is characterized by itching, hy-
peremia, watering and chemosis. 
Vision is not affected, but symp-
toms can be highly bothersome 
with a significant impact on pro-
ductivity and quality of life. AC 
is related to both direct allergen 
contact with conjunctival mucosa 
as well as indirect contact via a na-
sal-ocular reflex. In SAC and PAC 
common environmental allergens 
lead to an inappropriate immuno-
globulin E production and immu-
nological sensitization. When sub-
CO-MORBIDITIES OF 
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Co-morbidities of allergic rhinitis: ocular allergy
sequently exposed to the allergen, 
these antibodies can initiate mast 
cell degranulation and the entire 
allergic response. SAC and PAC in-
volve an immediate (type I) hyper-
sensitivity response. In SAC mast 
cells (MC) are the main infiltrat-
ing cells in the conjunctiva, with 
secreted products primarily or-
chestrating the inflammatory re-
sponse. In PAC the inflammation 
is more chronic, with involvement 
of activated MC, eosinophils, neu-
trophils and some T cells.
SAC (Figure 1) occurs at the same 
time each year and recurs season-
ally with the changes in pollens 
and allergens present. Symptoms 
tend to last a few weeks each 
year and may vary with the pollen 
count. Grass pollens tend to cause 
symptoms in early summer, usual-
ly from April through to July. Oth-
er pollens may cause symptoms 
as early as February or March or 
as late as September. PAC (Figure 
2) persists throughout the year. 
It is most commonly due to an 
allergy to house dust mite. PAC 
is becoming more frequent that 
SAC, probably due to new peren-
nial airborne allergens or irritants, 
such as pollutants.
Traditional therapy for SAC and 
PAC has been topical administra-
tion of antihistamines or mast cells 
stabilizers. In the last few years 
therapeutic approach has evolved 
toward more specific therapies 
(allergen immunotherapy, topical 
immunosuppressants) improving 
its management, especially for se-
vere cases.
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Figure 1 Acute seasonal allergic conjunctivitis
Figure 2 Perennial allergic conjunctivitis
Co-morbidities of allergic rhinitis: ocular allergy
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• Eosinophilic otitis media (EOM) is an intractable otitis media 
characterized by the presence of a highly viscous yellow 
effusion containing eosinophils. It mainly occurs in patients 
with asthma
• High level of eosinophil cationic protein in middle ear effusion 
and many EG2 immunopositive cells in the middle ear mucosa 
are detected in EOM patients, indicating active eosinophilic 
inflammation
• EOM causes deterioration of bone conduction hearing levels, 
particularly for high frequencies
• Systemic or topical administration of corticosteroids is the most 
effective treatment for patients with EOM
Eosinophilic otitis media (EOM) 
is a newly recognized middle ear 
disease, which was first reported 
by Tomioka et al. in 1994. EOM is 
an intractable otitis media charac-
terized by the presence of a highly 
viscous yellow effusion contain-
ing many eosinophils (Figure 1). 
It mainly occurs in patients with 
asthma and is resistant to conven-
tional treatments for otitis media.
PATHOGENESIS
In the middle ear of patients with 
EOM, active eosinophilic inflam-
mation appears to be present 
because high levels of eosinophil 
cationic protein in middle ear effu-
sion (MEE) and many EG2 immu-
nopositive cells in the middle ear 
mucosa are detected. EOM pa-
tients show a significantly longer 
Eustachian tube opening duration 
compared with that of control pa-
tients allowing antigenic materials 
to enter the middle ear, causing 
eosinophilic inflammation in asso-
ciation with an atopic predisposi-
tion. Antigen-specific IgEs against 
inhalant and bacterial antigens 
were detected in EOM, suggest-
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Figure 1 Histological findings of the 
middle ear effusion of eosinophilic 
otitis media. Numerous eosinophils 
are seen in the effusion. ( HE stain)
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ing local sensitization (middle ear) 
against fungi and bacteria such as 
Staphylococcus aureus.
DIAGNOSIS
Diagnostic criteria were estab-
lished in 2011 by the EOM study 
group. The major diagnostic crite-
rion is otitis media with effusion 
or chronic otitis media with eosin-
ophil-dominant effusion. The mi-
nor criteria are: 1) highly viscous 
MEE; 2) resistance to convention-
al treatment for otitis media; 3) 
association with asthma; and 4) 
association with nasal polyposis 
(NP). Definite cases are defined 
as the presence of the major cri-
terion plus two or more of the 
minor criteria. In addition eosin-
ophilic granulomatous polyangitis 
(Churg-Strauss syndrome) and hy-
pereosinophilic syndrome need to 
be excluded.
CLINICAL FEATURES
EOM can be roughly divided into 
effusion type otitis media and 
chronic type otitis media. The lat-
ter is further divided into two sub-
types: simple perforation subtype 
and granulation tissue formation 
subtype (Figure 2). About 90 % of 
EOM patients have asthma. As-
sociation of chronic rhinosinusitis 
(CRS) was also found in 75% of 
the patients (2). In these patients, 
massive infiltration of eosinophils 
is observed in NP or in the sinus 
mucosa. This condition is called 
eosinophil-dominant NP or eosin-
ophilic CRS.
EOM causes deterioration of 
bone conduction hearing levels, 
particularly for high frequencies. 
The risk factors of deteriorating 
bone conduction hearing levels 
include high levels of IgE and eo-
sinophil cationic protein in MEE, 
male sex, the duration of EOM, 
the severity of middle ear mucosa 
inflammation, and the presence of 
bacterial infection.
TREATMENT
Currently, the most reliable treat-
ment for EOM is systemic and 
topical administration of corticos-
teroids. The instillation of triamci-
nolone acetonide into the middle 
ear is very effective for the control 
of eosinophilic inflammation.
In addition, omalizumab, a recom-
binant humanized monoclonal an-
ti-IgE antibody, has been reported 
to be efficacious for some patients 
with EOM.
The control of bacterial infection 
is also important for the treatment 
for EOM superinfected with path-
ogens.
KEY REFERENCES
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Figure 2 Otoscopic findings of EOM, chronic otitis media type (granulation tissue 
formation subtype), left ear.
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• Eosinophilic Esophagitis (EoE) is a rapidly occurring disease with 
symptoms of esophageal dysfunction with isolated eosinophils 
infiltrating the esophagus
• The diagnosis of EoE increases during pollen season
• Esophageal eosinophilia is seen in patients with allergic rhinitis 
and increases during pollen season to the range seen in food 
induced EoE
• Patients with EoE need to be treated for their allergic rhinitis
WHAT IS EOSINOPHILIC 
ESOPHAGITIS?
Eosinophilic Esophagitis (EoE) is a 
chronic immune and antigen me-
diated disease (Figure 1), which 
is characterized by eosinophil in-
filtration into the esophageal epi-
thelium and results in esophageal 
fibrosis and dysfunction. EoE af-
fects children and adults through-
out the world, and has been 
reported in all continents. The 
prevalence of EoE is 56.7/100,000 
and is increasing throughout the 
world. Current consensus diag-
nostic guidelines for EoE recom-
mend a minimum threshold of 15 
eosinophils per high power field 
on at least one esophageal biopsy 
specimen, with eosinophilia lim-
ited to the esophagus. Common 
macroscopic endoscopic findings 
include furrowing, white mucosal 
plaques, esophageal trachealiza-
tion, esophageal narrowing, stric-
ture, and mucosal tearing.
EoE is known to be a food anti-
gen-driven, chronic allergic dis-
ease. There are two main cur-
rently accepted clinical treatment 
strategies for EoE: dietary elimina-
tion and corticosteroid treatment. 
Food avoidance by elemental diet 
or specific food elimination diet 
leads to resolution of his symp-
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toms and normalization of esoph-
ageal biopsy.
Patients with EoE often have a 
history of atopy, such as elevated 
serum IgE, peripheral eosinophilia, 
allergic diseases (including asth-
ma, atopic dermatitis, or allergic 
rhinitis, IgE mediated foods aller-
gies), and sensitization to foods 
and aeroallergens as demonstrat-
ed by a positive skin test result. 
Allergic rhinitis (AR) was seen up 
to 75% of the patients.
Evidence suggests that aeroaller-
gens may play a causative role in 
the development of EoE. Circum-
stantial evidence shows an in-
crease in EoE diagnosis in pollen 
seasons. During pollen season, 
there is an increased numbers of 
eosinophils in esophagus com-
pared to non-atopic controls, al-
though the number of eosinophils 
observed was lower than values 
typically seen in patients who 
have EoE. In addition, we have 
seasonal variation of symptoms 
and eosinophils in esophagus in 
about 25% of our patients. Sea-
sonal variation was confirmed in 
a case report on one 20 year old, 
full disease control was achieved 
only during non–pollen seasons.
Additional evidence comes from 
trials of allergen immunotherapy 
(AIT) as EoE occurred when one 
patient started on sublingual im-
munotherapy. Two recent case 
reports have show improvement 
in EoE with birch pollen and dust 
mites subcutaneous immunother-
apy suggesting a role for aeroal-
lergens in a select group of EoE 
patients.
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Nevertheless, food elimination is 
the mainstay of therapy for the 
treatment of EoE. For the season-
al induced EoE, either intranasal 
steroids or subcutaneous immu-
notherapy are available treatment 
options.
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Figure 1 In genetically susceptible individuals, antigens (i.e. foods or aeroallergens) and irritants (i.e. acid reflux) induce 
esophageal epithelium to produce thymic stromal lymphopoietin (TSLP) and Eotaxin 3 (CCL26). Eotaxin 3 (CCL26) recruits 
eosinophils to the esophageal epithelium, whereas TSLP leads to dendritic cell and basophil activation as well as Th2 
polarization. This results in Th2 cytokine ( IL-4, IL-5 and IL-13) secretion and the development of typical Th2 inflammation 
characterized by eosinophils, mast cells and T cells. IL-13 further promotes expansion and survival of the recruited 
eosinophils. Diet therapy removes the allergen, while swallowed corticosteroids decrease pro-inflammatory cytokines. 
(Figure revised from Rothenberg et al, Gastroenterol 2009 and Merves et al, Annual Allergy Asthma Immunol, 2014.)
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• The respiratory tract starts with the nose and ends with the 
peripheral small airways
• Nervous triggers and inflammatory changes in the upper 
airways relate to changes in the lower airways, mediated 
through a nervous, direct and systemic route
• Optimal control of asthma involves proper treatment of the 
associated rhinitis or rhinosinusitis
The airways start with the nose 
and end with the peripheral small 
airways. Thus the nose has an im-
portant role as gatekeeper pro-
tecting the lower airways from 
exogenous pro-inflammatory trig-
gers. The nose and bronchi form 
one respiratory unit (Figure 1).
Anatomically there are both simi-
larities and differences. The nose 
is being formed by the ectoderm, 
while the lower airways derive 
from the mesoderm, with the 
paranasal sinuses representing a 
mix of these two. Thus the nose 
keep some features from the skin 
being more resistant to external 
stress compared to mucosa of the 
lower airways. One common fea-
ture of the facial skin and the nose 
and the lung is the innervation.
THE NERVOUS LINK
Both the face and the nose are 
sensitive to external stimuli po-
tentially harmful for the lower air-
ways. Koskela described in a study 
on cold air sensitive asthmatics 
that facial cooling was enough to 
induce a bronchial obstruction in 
subjects inhaling humidified room 
tempered air. The magnitude of 
response was the same as when 
the subjects inhaled cool dry air 
to the lower airways.. However, 
not only the face but also the nose 
THE UNITED AIRWAY 
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share the same pattern with ef-
ferent sensory nerves mediating a 
response in the lower airways. In a 
study by Millqvist, cold air stimuli 
in the nose induced increased re-
sistance of the lower airways. This 
naso-bronchial reflex could be sup-
pressed by local anesthesia applied 
in the nose. A third evidence of a 
nervous link between the upper 
and lower airways was the study 
by LIttell showing that methacho-
line but not histamine applied in 
the nose, increased both nasal and 
lower airway resistance.
THE DIRECT AIRWAY LINK
During inspiration the air is fil-
tered, tempered, humidified and 
supplied with nitric oxide (NO) 
before entering the lower airways. 
Thus the nose serve as an impor-
tant conditioner of the air that is 
tracked down into the airways. 
Nose breathing can prevent bron-
choconstriction induced by inhala-
tion of cold dry air, and increased 
mouth breathing due to a blocked 
nose is likely to be one reason for 
the worsening of asthma. In nor-
mal controls almost all NO found 
in exhaled air is derived from the 
upper airways, mainly produced in 
the paranasal sinuses. During deep 
nasal inhalation, NO in physiologi-
cal concentrations is being tracked 
down to the lower airways. This is 
believed to be an important factor 
that helps to improve matching be-
tween ventilation and perfusion.
A SYSTEMIC LINK
Allergen challenge in the nose 
is know to induce inflammatory 
changes in the bronchi, measured 
as increased numbers of eosino-
phils in bronchial mucosa. The final 
proof that the reaction was due to 
The united airway disease
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systemic mechanisms came from 
the revert study applying allergens 
by endoscopy in the lower airways, 
and than 24 hours later, showing 
increased inflammation in the na-
sal mucosa. The link between the 
paranasal sinuses and the lower 
airways is probably even more in-
teresting. Sharing the same germ 
layer origin, there are similarities 
not only regarding cellular inflam-
mation but also in tissue inflam-
mation and remodelling. A chronic 
sinusitis harboring fungal or staph-
ylococcal superantigens has been 
associated with a more extensive 
and difficult to treat asthma. Also 
in other non-asthmatic conditions, 
a definite link exist, i.e. chronic 
lower airway infection with bron-
chiectasis is associated with an 
increased prevalence of chronic 
sinusitis with polyps.
IMPLICATION FOR TREATMENT
The link between the upper and 
the lower airways is so obvious 
that it should be regarded as mis-
conduct not to consider both com-
partments as treatment targets in 
order to achieve optimal disease 
control. Thus patients with asth-
ma and more severe rhinitis or 
rhinosinusitis have a greater risk 
of worsening asthma control and 
getting severe asthma exacerba-
tions. In parallel, severe asthma 
barely exists without concomitant 
rhinosinusitis. In the traditional 
asthma studies, severe rhinitis pa-
tients have been excluded. There-
fore, we need to explore different 
treatment alternatives, how to 
best treat and control asthma and 
rhinitis simultaneously. This can 
be done either as optimal local 
treatment by the two compart-
ments or by the systemic route. As 
new biologics with anti-cytokine 
treatment are entering the scene, 
it is important that these aspects 
are being addressed from the ear-
ly start.
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Figure 2 There is a consistent link 
between the nose and the lower 
airways, forming one functional unit. 
A direct link, a systemic link and a 
nervous link have been documented.
The united airway disease
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• There is clear evidence for comorbidity between atopic 
dermatitis (AD) and allergic rhinitis (AR)
• AD usually precedes AR and the association strongly depends 
on the stage of the course of AD
• Future early prevention strategies may decrease the incidence 
of both AD and AR
Atopic dermatitis (1), allergic rhi-
nitis (AR) and allergic asthma (AA) 
(2) represent the three allergic dis-
eases within the context of the at-
opic diathesis. Interestingly, while 
the issue of comorbidity between 
AD and AA has been analyzed 
thoroughly from a genetic, epi-
demiological and clinical aspect, 
data related to the comorbidity 
between AD and AR are more 
scarce. In principle, this could be 
mainly due to the fact that the age 
of onset of both diseases differs 
substantially. Indeed in our clas-
sical view, AD starts rather early 
in childhood and typically much 
longer before AR and AA emerge. 
However, epidemiological studies 
seem to show that the combina-
tion of AD and AR is a risk factor 
for AA. Moreover, the issue of the 
severity of AD and its possible im-
plication for the appearance of AR 
has not been studied in detail.
In some epidemiological stud-
ies looking at the prevalence of 
AD, AA and AR, the percentage 
of subjects with both AD and AR 
was about 9%. Interestingly, this 
prevalence of comorbidity de-
creased afterwards with age. The 
BAMSE cohort reported a high-
er incidence: at 12 years, 58% of 
the children had eczema, asthma 
ATOPIC DERMATITIS AND 
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and/or rhinitis (Figure 1) at some 
time. Disease turnover was high 
for all three diseases throughout 
the study (Figure 2). Comorbid-
ity increased with age, and at 12 
years, 7.5% of all the children 
were affected by at least two al-
lergy-related diseases. This fur-
ther illustrates how important it 
is to consider the age of the pa-
tients and disease turnover with 
regard to this particular kind of as-
sociation. It is well accepted that 
patients with AD are significantly 
more likely to have other atopic 
diseases, compared to patients 
without AD (22% versus 17%). 
In such studies, which are not 
primarily considering the age of 
the patients, the comorbidity be-
tween AD and AR was quite high 
(76 %). In other studies a higher 
percentage of patients with AD 
had reported to have rhinitis but 
again these studies did not con-
sider differences in terms of age 
of the patients. Interestingly from 
a genetic point of view, there is 
no evidence for a clear overlap in 
terms of genetic linkage analyses 
or by the means of other genet-
ic investigations such as genome 
wide association studies.
Moreover there are no clear-cut 
validated biomarkers identified so 
far which may predict, that a given 
patients with AD will develop AR 
in the course of the natural histo-
ry of its skin disease. On the oth-
er hand, it has been reported that 
individuals with AD clearly show a 
predisposition for allergic comor-
bidities by the age of 3y and that 
this seems to correlate with the 
severity and poor disease control 
of AD.
This is again confirmed by more re-
cent studies looking at the severity 
of AD in relationship with other 
Atopic dermatitis and allergic rhinitis: where is the evidence for comorbidity?
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chronic health disorders including 
AA, AR and food allergies. Hence 
addressing the question of comor-
bidity of AD and AR seems to be 
tightly related to the time point at 
which the patients are observed 
during the course of AD. Indeed, 
beside the real comorbidity, se-
quential association between AD 
and AR is probably the more often 
situation than the single occur-
rence of both allergic diseases.
The lessons learned from these 
observations as 3 fold:
1. The heterogeneity of the clin-
ical phenotype of AD has so 
far been underestimated. New 
epidemiological studies with 
regard to the question of the 
comorbidity should consider 
this particular aspect.
2. In terms of prevention, there 
are currently new develop-
ments aimed to prevent the 
appearance of AD as the first 
manifestation of the atopic 
march by a very early interven-
tion using emollients directly 
after birth. Only a few studies 
have addressed this key issue 
so far and it will be interesting 
to see whether a successful 
prevention of AD in the context 
of this early intervention may 
also prevent the appearance of 
AR in children with high risk to 
develop the atopic march.
3. From a therapeutic point of 
view it is well accepted that 
- in contrast to AR -antihista-
mines have only poor effects 
in the control of AD, particu-
larly with regards to the pruri-
tus. On the other hand, there 
is some evidence that allergen 
immunotherapy (AIT) targeting 
for example house dust mite as 
a classical trigger for AR could 
be of interest in the context of 
the management of the severe 
forms of AD. Clearly, for such 
studies we needed to explore 
the clinical benefit but also the 
immunological mechanisms pu-
tatively involved in a positive 
clinical respond for both AD 
and AR to AIT.
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Figure 1 Prevalence rates of allergy-related diseases up to 12 years in the BAMSE birth cohort. Twelve-month prevalence 
of eczema, asthma, rhinitis and any symptom at age 1, 2, 4, 8 and 12 years. Empty bars show the cumulative prevalence at 
12 years (n=2916). (Reproduced with permission from Ballardini N, Kull I, Lind T, et al. Development and comorbidity of eczema, 
asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy, 2012;67:537-544, with permission from Willey 
Blackwell.)
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Figure 2 Disease turnover and persistence up to 12 years of age in the BAMSE birth cohort. Turnover indicates the 
percentage in the population (n = 2916) of new and remitting cases at each observation point. New cases were defined 
as onset of disease that had not been present at any previous observation point, and remission was defined as not having 
a disease that had been present at the previous observation point. Persistence indicates the proportion of children who 
had a disease at one, two, three or more observation points among the children who had ever had the same disease. 
(Reproduced with permission from Ballardini N, Kull I, Lind T, et al. Development and comorbidity of eczema, asthma and rhinitis to 
age 12: data from the BAMSE birth cohort. Allergy, 2012;67:537-544, with permission from Willey Blackwell.)
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develop oral symptoms to raw fruits and vegetables. This syn-
drome is called pollen–food syndrome or oral allergy syndrome. 
It is characterized by an IgE-mediated, immediate reaction in-
duced by prior sensitization to pollen rather than primary sensi-
tization to a food allergen. Cross-reactivity depends on specific 
epitopes shared by food allergens and pollen
• Pathogenesis-related proteins (PR) are usually responsible for these 
reactions. 17 families of PR have been identified according to their 
function. The most relevant to pollen food allergy syndrome are 
profilins (PR-10), lipid–transfer–protein (LT; PR-14 and PR-15)
• Profilins in birch pollen cross –reacts commonly with foods of 
the Rosacee family i.e for fruit: apple, pear, peach, cherry, apri-
cot. Bet v 1 shows homologous protein with Mal d 1, a major 
antigenic protein in apple
• The clinical manifestations are usually mild and transient (pru-
ritus of the lip, tongue and mouth, throat tightness). Systemic 
reactions are uncommon, but may happen depending on the 
specific epitope that is involved
• Symptoms are triggered by fresh vegetables and fruits. The 
cooked forms are usually tolerated
• The prevalence is related to sensitivity patterns varying with 
exposure and is associated to geographical areas i.e Northern 
Europe: birch pollen/apple, Southern Europe: grass pollen/ 
apricot, pear, apple
Food allergy is an overlooked 
co-morbidity of allergic rhinitis 
(AR), however the upper respirato-
ry tract can be a target of IgE-me-
diated food allergy. Symptoms 
may include nasal congestion, rhi-
norrhoea, sneezing and pruritus. 
Although prevalence seems to be 
low in clinical presentation, pa-
tients who present with IgE-medi-
ated food allergy have nasal symp-
toms during oral food challenges.
A peculiar form of co-morbid food 
allergy, highly prevalent in patients 
with pollen-induced AR, is the 
so called “pollen food syndrome” 
(PFS), which is also termed “oral 
allergy syndrome” (OAS). This is 
an immediate hypersensitivity re-
action mediated by IgE following 
sensitization to pollens. Patients 
will experience local oral symp-
toms of pruritus and swelling with 
fresh fruits (e.g. apple, pear, peach), 
vegetables or spices that cross-re-
act with pollens (Figure 1 and Table 
1). The suggested mechanism is IgE 
cross-reactivity between the impli-
cated plant-derived food and the 
primary sensitizing pollen(s) that 
occurs as consequence of common 
epitopes between pollen and food 
allergens.
The pathogen-related proteins 
(PR) are the plant allergens re-
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sponsible for this peculiar form 
of food allergy. Some of them 
are heat–resistant and account 
for some more severe reactions. 
Two main families of heat-labile 
PR have been identified as more 
prevalent in inducing clinical reac-
tions: the Bet v 1 family (birch pol-
len major allergens that are highly 
cross reactive with several plant 
food allergens) and the profilins 
(which includes the Bet v 2 minor 
Allergic rhinitis and food allergy
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Figure 1 Cross-reactive pollens and foods
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birch pollen allergen, also highly 
cross reactive with other pollen 
and plant derived food allergens).
The prevalence and pattern of the 
triggering food can vary widely 
in relation to the specific region-
al pattern of sensitization. Oral 
symptoms related to birch pol-
len are more prevalent in North-
ern and Central Europe, while in 
Southern Europe grass pollen is 
the usual trigger.
Diagnosis (Figure 2) relies on a 
history of pruritus at the lip and 
tongue, sometimes with oral and 
facial angioedema and throat 
tightness following the ingestion 
of fruit and vegetable. Skin prick 
testing with the raw fruit and veg-
etable is more accountable than 
using commercial extract, as the 
allergens are usually labile and are 
easily destroyed by cooking. The 
use of component–resolved–di-
agnostics has recently allowed to 
better profile the sensitizations of 
these patients and to add some 
probabilistic information on the 
severity of the reactions. The only 
treatment is avoidance of the 
triggering food; the role of inhal-
ant allergen immunotherapy as 
treatment of the clinical reactions 
to related foods is still debated. 
TABLE 1
Cross-reactive pollens and foods
Birch
Apple, pear, cherry, peach, nectarine, apricot, tomato, kiwi, car-
rots, potato, parsnip, green pepper, fresh spices, celery, peanuts, 
hazelnut, walnut, almond, lentil, beans, peas, soybean
Grass Melon, water melon, oranges, tomato, potato, kiwi, Peanut, carrot
Mugwort
Celery, carrot, spices (parsley, caraway seeds, fennel seed, cori-
ander seeds, aniseed, paprika, garlic, onion) pepper, mango, leek, 
mustard, broccoli, cabbage, cauliflower, chamomile, kiwi
Ragweed Melon, Zucchini, Cucumber, Banana
Pellitory Pistachio, Swiss chard
Olive Pollen Peach, pear, melon, kiwi
Prevention of PFS avoiding all the 
possible cross-reactive foods in 
pollen allergic patients has not be 
shown to be effective.
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Ask about
any oral pruritus, swelling of 
lips with symptoms with raw fruit 
i.e apples or vegetables i.e celery. 
Investigate if symptoms occur with 
cooked and frozen foods
Skin prick tests
 it should be by prick-prick test 
with fresh foods and only with the 
incriminated fruit as nonclinically 
relevant positivity could be elicited
Component-resolved diagnostics 
can provide a profile of relevant 
sensitizations: profilins, LTP
Pollen–food 
syndrome
Figure 2 Recognizing the pollen-food syndrome.
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• Non-specific mast cell mediator symptoms, including fatigue, 
arthralgia and hyperacidity may be experienced by patients 
with severe chronic urticaria, but symptoms in the respiratory 
tract resulting from local mast cell degranulation are not usually 
described
• By contrast, involvement of the respiratory tract in allergen-
induced anaphylaxis with urticarial rash is well known
• There is limited evidence for bronchial hyperreactivity and 
subclinical asthma in patients with spontaneous and inducible 
types of chronic urticaria. Studies are required to look for 
evidence of subclinical rhinitis in severely affected chronic 
urticaria patients
The cutaneous mast cell is con-
sidered to be the primary effector 
cell in urticaria and histamine to 
be the major mediator, although 
there is clinical and histological 
evidence that other inflammatory 
events are important. Histamine 
is also considered to be a key me-
diator of allergic rhinitis (AR). Un-
like chronic urticaria (CU), where 
IgE-mediated allergy is rarely the 
cause, a high proportion of AR pa-
tients are allergic to inhalant aller-
gens and will develop symptoms 
on exposure.
It might be anticipated that CU 
patients would have features of 
generalized mast cell degranula-
tion if the autoimmune hypothesis 
of causation is correct. Although 
patients with severe urticaria may 
complain of non-specific fatigue, 
arthralgia and indigestion due to 
mediator release into the circula-
tion, it is exceptional for patients 
to experience respiratory or gas-
trointestinal symptoms during at-
tacks. A possible explanation for 
this is the need for co-stimulation 
of cutaneous mast cells by C5a at 
the time of activation by function-
al autoantibodes against IgE or 
its receptor. By contrast, resident 
mast cells of the respiratory tract 
do not express the C5a receptor 
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and therefore do not respond to 
direct or indirect cross-linking of 
the high affinity IgE receptor by 
autoantibodies. This is in contrast 
to acute urticaria, which may be 
caused by immediate hypersensi-
tivity reactions to food or drug al-
lergens with a risk of progression 
to anaphylaxis. Symptoms result 
from generalized mast cell degran-
ulation, including local release of 
histamine and other mediators 
in the respiratory tract leading to 
rhinitis and/or asthma.
There is some evidence for bron-
chial hyperreactivity in different 
subtypes of CU although overt 
asthma is rare. One study con-
cluded that bronchial hyperres-
ponsiveness is a common feature 
in patients with active CU. Twenty 
six adults with chronic spontane-
ous urticaria were assessed with 
respiratory function tests and 
methacholine provocation. Two 
had asthma on baseline pulmo-
nary function tests and twenty 
others (77%) showed bronchial 
hyperresponsiveness on metha-
choline challenge. Bronchial hy-
perresponsiveness has also been 
demonstrated in patients with 
cholinergic urticaria and symp-
tomatic dermographism. A ret-
rospective questionnaire sent to 
parents of children presenting to 
a paediatric allergy centre identi-
fied respiratory symptoms during 
The link between the skin and the airways
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attacks in 6/45 children (13%) al-
though the authors did not detail 
whether they related to the upper 
or lower respiratory tract. It seems 
possible therefore that evidence 
for subclinical upper respiratory 
tract involvement in severe chron-
ic urticaria may be found with ap-
propriate studies.
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The link between the skin and the airways
?
??
Respiratory tract
Gastrointestinal tract
Figure 1 Urticaria results from mast cell mediator release in the skin. Systemic features in severe chronic urticaria may 
include hyperacidity in the gut and bronchial hyper-responsiveness of the airways. These may result from distant effects of 
circulating mediators from cutaneous mast cell degranulation, including histamine, rather than local tissue degranulation in 
gut and lung.
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• Angioedema is a severe and potentially life- threatening 
condition
• Angioedema with urticaria is common, mostly histamine-
induced and responds to systemic antihistamines and steroids
• Bradykinin-mediated forms are rare and mosty induced by 
hereditary or acquired deficiency in C1-Inhibitor (function) or 
by drugs, namely ACE inhibitors. Treatment of acute attacks is 
based on C-1 Inhibitors or bradykinin receptor antagonist
• Little is known about mutual between allergic rhinitis and 
angioedema; worsening by cumulative effects may occur
Angioedema is often a severe and 
potentially life- threatening con-
dition with substantial impact on 
the patients’ quality of life. Se-
vere symptoms such as laryngeal 
blockage but also disabling swell-
ings or strong abdominal pain due 
to intestinal angioedema require 
immediate, specific and fast act-
ing therapy. Thus every physician 
caring for patients with diseases 
in the oro-pharyngeal area should 
be familiar with a basic knowledge 
on the management of angioede-
ma. There are 2 different forms 
of angioedema based on different 
mediators and partly also clinical 
features: Histamine- mediated 
forms and non-histamine, brady-
kinin-mediated diseases (Figure 1).
HISTAMINE-AND OTHER MAST 
CELL MEDIATOR MEDIATED 
FORMS OF ANGIOEDEMA
Histamine-mediated forms are 
mostly associated with urticar-
ial, itch and/or systemic allergic 
symptoms such as asthma or an-
aphylactic shock; untreated they 
lasts often mostly for a few hours 
before spontaneously resolving. 
Acute forms are often para-infec-
tious or due to immediate allergic 
reactions to causes such as drugs 
(aspirin, NSAIDS and others), hy-
menoptera venom (honey bees, 
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wasps) or foods. Accordingly to 
the severity treatment is based 
on antihistamines (H1-blockers), 
steroids and in severe cases in-
tramuscular adrenaline. Chron-
ic forms with a duration of more 
than 6 weeks are often so-called 
spontaneously with no definite 
underlying cause. Treatment is 
similar as in chronic spontaneous 
urticaria involving updosing 2nd 
or 3rd generation antihistamines 
(H1- blockers) and in non-re-
sponding cases increasingly also 
Omalizumab.
BRADYKININ-MEDIATED 
FORMS OF ANGIOEDEMA
Bradykinin-mediated angioedema 
are characterized by recurrent ep-
isodes of non-pruritic subcutane-
ous or submucosal edema with no 
associated wheals and urticarial 
and involving extremities, bowel 
or facial-oropharyngeal-laryngeal 
region. Hereditary angioedema 
(HAE) due to C1 esterase inhibitor 
(C1-INH) deficiency and HAE with 
normal C1-INH and acquired C1-
INH deficiency are all rare but im-
portant diseases with significant 
morbidity and also mortality. The 
swelling is induced often by minor 
trauma or stress and may wors-
en slowly but often last several 
days. HAE has to be separated 
from drug-induced angioedema: 
frequently by Angiotensin-Con-
verting-Enzyme-Inhibitors (ACE—
Inhibitors), but also by some 
glyptins, thrombolytic and immu-
nosuppressive agents ; drug-in-
Allergic rhinitis and angioedema
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duced forms preferentially involve 
the facial-oropharyngeal region.
Diagnosis is based on clinical his-
tory and complement analyses 
(C1-INH value and function, Com-
plement C4, genetics). Treatment 
of the acute attacks include plas-
ma-derived C1-INH concentrates, 
recombinant human C1-INH and a 
bradykinin receptor antagonist. All 
are highly efficient and fast work-
ing. Typically systemic antihista-
mines and steroids do not work in 
bradykinin-mediated angioedema.
ALLERGIC RHINITIS AND 
ANGIOEDEMA AS MUTUALLY 
EXACERBATING FACTORS
Mainly acute histamine-mediated 
forms of angioedema in patients 
with allergic rhinitis e.g. with as-
sociated food allergy can lead to 
severe comorbidity and cumula-
tive worsening of both diseases. 
Little is known about allergies as 
an exacerbating factor of brady-
kinin-mediated angioedema; how-
ever recently a certain exacerba-
tion of ACE-I induced angioedema 
during pollen season has been 
reported.
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Angioedema: Forms and Management
Histamine-induced forms
Common
Often with Urticaria/ hives
Present
A few hours
As in urticaria limited 
(Blood cell count, CRP, evtl Tryptase) 
Further assays only based on associated
symptoms and geographic background
Antihistamines (po/iv)
Systemic steroids (po/iv)
(Epinephrine im  if assoc anaphylaxis)
Bradykinin-induced forms
Hereditary forms (HAE Type I-III)
Acquired forms (AAE)
Drug-induced (ACE-Inhibitors)
Rare
Mostly without skin symptoms
Rarely present, often painful
Often several days
C1-Inhibitor (incl Function) 
Complement C4 
(Genetic analyses)
C1-Inhibitor (iv)
Bradykinin recept. antagonist (sc)
Stop of potential culprit drug
Background
Frequency
Skin symptoms
Itch
Duation of swelling
Laboratory
Treatment
Figure 1 Distinct forms of angioedema due to different pathophysiologic background. (Adapted from Maurer M, Magerl M, 
Metz M, et al. Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013;68:816-819.)
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Figure 2 Different manifestations of angioedema with facial involvement (A-C), hand (D) and genitalia (E) due to NSAID 
hypersensitivity (A), ACE Inhibitor induced (B) and HAE with C1-Inh deficiency (C, D, E)
A B C
D E
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sleep apnea syndrome (OSAS) due to elevated inspiratory 
breathing workload
• Nocturnal allergic rhinitis and asthma can mimic symptoms of 
OSAS
• Patients with OSAS present with nocturnal snoring, choking, 
and stops of breathing. In addition, they suffer from chronic 
excessive sleepiness and nonrestorative sleep
• OSAS is diagnosed by polysomnography; a cardiorespiratory 
polygraphy can render first information about nocturnal 
breathing in patients suspected to suffer from OSAS
• Positive airway pressure therapy applied by a nasal mask is 
standard-therapy in OSAS, thus nasal breathing needs to be 
optimized
INTRODUCTION
Nasal obstruction results in patho-
logic changes in airflow velocity 
and resistance and has been asso-
ciated with obstructive sleep ap-
nea syndrome (OSAS) as a poten-
tial etiologic factor by promoting 
more negative intraluminal pres-
sure in the pharynx predisposing to 
pharyngeal occlusion and thus ob-
structive apnea events. Although 
clinical research examining the cor-
relation between nasal obstruction 
and sleep-disordered breathing is 
limited, studies evaluating patients 
with either naturally occuring par-
tial nasal obstruction (e.g. allergic 
rhinitis, septal deviation) or exper-
imentally induced nasal occlusion 
show a clear relationship between 
nasal obstruction and nocturnal 
appearance of snoring, hypopneas, 
and apneas. In a population-based 
sample (n=4927), participants who 
often or almost always experi-
enced nighttime symptoms of rhi-
nitis were significantly more likely 
to report habitual snoring, chronic 
excessive sleepiness, or nonrestor-
ative sleep than those who rarely 
or never had symptoms.
NASAL RESISTANCE AND SLEEP 
APNEA
Rhinitis is a risk factor for 
sleep-disordered breathing on the 
ALLERGIC RHINITIS 
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basis of the Bernoulli principle 
(stating that the wider the begin-
ning of a duct is, the less the risk 
of collapse is and viceversa) and 
the Venturi effect (postulating 
that air must pass through a small 
tube faster than through a large 
tube if the passing volume of air 
and time remain constant). From 
this perspective upper airways 
behave like a Starling resistor: the 
obstruction at the inlet induces 
collapsing forces that manifest 
downstream in the collapsible 
segment, the pharynx.
SLEEP APNEA AS A 
DIFFERENTIAL DIAGNOSIS 
TO NOCTURNAL ALLERGIC 
RHINITIS AND ASTHMA
Allergic rhinitis and allergic asth-
ma often show a worsening of 
symptoms during sleep, especially 
when a house dust mite sensitiza-
tion is present. This leads to a poor 
sleep quality and daytime somno-
lence. In contrast to these symp-
toms, patients with OSAS present 
with habitual snoring, choking and 
stops of breathing (apneas) during 
sleep. In addition, patients with 
Fulvio Braido  
University of Genoa 
Genoa, Italy
Hans-Werner Duchna  
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OSAS suffer from chronic exces-
sive sleepiness and nonrestora-
tive sleep. In most cases, talking 
with the patient`s partner can 
help differentiating the underlying 
diseases. OSAS can effectively be 
diagnosed by polysomnography 
in a sleep lab. A non-laboratory 
monitoring of sleep by cardiores-
piratory polygraphy can render 
first information about nocturnal 
breathing in patients suspected to 
suffer from OSAS.
NASAL RESISTANCE AND CPAP 
THERAPY
CPAP (Figure 1) is, the most ef-
fective treatment for OSAS. with 
a compliance rate for CPAP of ap-
proximately 60%. Nasal conges-
tion, irritation or runny nose can 
be caused by the use of CPAP but, 
when concomitant rhinitis is pres-
ent, its symptoms may intereferes 
with CPAP adherence. Symptoms 
can be often alleviated by the use 
of a humidifier but a proper treat-
ment of concomitant allergies, 
chronic sinus problems or a devi-
ated septum must be considered.
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snoring
Upper airway dilator muscle activity
suction pressure
Splinting of upper airway
Hypoxemia
Nasal CPAP
Diaphragm efficiency
end expiratory 
lung volume
Upper airway 
collapse
Pharyngeal cross-
sectional area
Excessive 
daytime 
sleepness
Upper airway mucosal EdemaSplinting of upper airway
Figure 1 Potential physiological effect of nasal CPAP in patients with OSAS. (From Breathing Disorders in Sleep Mc Nicholas 
WT and Philipson Saunders Elsevier Science Limited 2002 pag.118)
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Section D
ALLERGIC RHINITIS - DIAGNOSIS
* Allergic rhinitis diagnostic work-up overview
* Diagnosis of allergic rhinitis - rhinoscopy and endoscopy
* Non-invasive evaluation of nasal inflammation (NO, nasal 
cytology and mediators)
* Skin testing in the diagnostic workup of rhinitis
* Provocation tests
* Specific IgE and diagnosis of allergic rhinitis
* Component resolved diagnosis
* Dıagnosıs of allergıc rhınıtıs - cellular tests
* New diagnostic and research techniques in allergic 
rhinitis and chronic rhinosinusitis
* Measuring allergen exposure
* Diagnosis of allergic rhinitis-measuring health-related 
quality of life
* Biotechnology for the diagnosis of allergic rhinitis
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allergic rhinitis from different types of non-allergic rhinitis, 
but allergy testing is needed to make a reliable diagnosis, 
particularly when year round nasal symptoms are present
• Demonstration of sensitisation by testing is not sufficient alone 
to make the diagnosis of allergic rhinitis and must be correlated 
with clinical history
• Differential considerations for allergic rhinitis include various 
types of non-allergic rhinitis, rhinosinusitis and anatomic 
problems
To correctly diagnose allergic and 
non-allergic rhinitis, rhinosinusitis 
and other conditions that may af-
fect the nose and sinuses, history, 
physical exam and when appropri-
ate, testing should be performed.
Some symptoms of allergic rhinitis 
(nasal drainage, nasal congestion, 
sneezing, and nasal itching) over-
lap with some symptoms associ-
ated with non-allergic rhinitis, rhi-
nosinusitis, (Table 1) or with other 
disorders that may involve the 
nose and sinuses. (Table 2).
By history, allergic rhinitis (AR) 
is more likely than non-allergic 
rhinitis if there are nasal itch-
ing and sneezing, associated eye 
symptoms (itchy, watery eyes), 
and nasal symptoms that devel-
op or worsen with exposure to 
furry pets or seasonally in asso-
ciation with regional allergy pol-
len seasons (Table 1). Year round 
symptoms make it more difficult 
to distinguish AR from non-AR, 
or even chronic rhinosinusitis, 
on the basis of history alone. Al-
lergy testing then is needed for a 
correct diagnosis. However, the 
mere presence of sensitisation as 
identified by skin testing or blood 
testing is not sufficient and must 
be correlated with the clinical his-
tory. Unilateral nasal symptoms 
ALLERGIC RHINITIS 
DIAGNOSTIC WORK-UP 
OVERVIEW
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suggest that an anatomic issue is 
present (Table 2).
Physical examination of the nose 
should be performed, in part to 
identify complicating or alternative 
nasal conditions (e.g, nasal polyps, 
septal deviation). In AR, inflamed 
mucosa classically has a bluish/
pale hue, but appearance may vary 
and may not reliably differentiate 
between AR and non-AR.
Rhinosinusitis (including nasal 
polyps) is characterized by two 
or more symptoms, one of which 
should be either a) nasal block-
age/ obstruction/congestion or b) 
nasal discharge (anterior/posterior 
nasal drip). Other symptoms may 
be c) facial pain/pressure, and/or 
d) reduction or loss of smell. Dis-
colored nasal drainage may occur 
in AR and some types of non-AR, 
so its presence does not necessar-
ily indicate bacterial rhinosinusitis. 
The common cold from respirato-
ry viruses has an acute onset of 
rhinosinusitis symptoms typically 
lasting for less than 10 days or 
getting better after 5 days. The 
common cold and rhinosinusitis 
are not typically associated with 
nasal itching or ocular symptoms 
that may be seen in AR.
KEY REFERENCES
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Allergic rhinitis diagnostic work-up overview
TABLE 1
Differential Diagnostic Features of History, Physical Exam, Testing
Medical History Physical examination In vitro - in vivo tests
Allergic 
rhinitis
• Symptoms: obstruction/conges-
tion, nasal drainage, sneezing, itch-
ing
• Seasonal symptoms may be pres-
ent with prominent nasal itching 
and sneezing
• Concurrent allergic conjunctivitis 
(itchy, watery eyes) common
• Early onset (age <20 years) com-
mon
• May be associated with atopic der-
matitis, asthma, food allergy, ob-
structive sleep apnea syndrome
• Variable appearance 
of mucosa: mucosal 
pallor, edema, hyper-
emia
• Allergic shiners: dark 
discolorations of the 
periorbital skin
• Dennie–Morgan lines: 
folds of the low––er 
eyelid in children
• Allergic crease: hori-
zontal wrinkle near the 
tip of the nose
• Skin-prick tests (SPTs) 
with allergen
• Serum allergen-specific 
IgE tests
• Nasal smears for eosino-
phils (>10%) (not routine-
ly employed clinically)
Nonallergic 
rhinitis & 
infectious 
rhinosinusitis
• Idiopathic rhinitis (IR: sneezing, 
pruritus and ocular involvement 
uncommon
• NARES,C RSwNP, and atrophic rhi-
nitis: Hyposmia/anosmia common
• Rhinosinusitis: headache and facial 
pain common
• NARES, CRSwNP, and IR: usually 
adult onset
• Gustatory rhinitis: food related 
symptoms at any age, but more 
likely with increasing age. Sneez-
ing, pruritus, ocular involvement 
uncommon.
• Rhinitis of pregnancy: mainly con-
gestion during the last 6 weeks 
of pregnancy and up to 2 weeks 
post-partum
• Atrophic rhinitis: mu-
cosal atrophy, foetor, 
crusts and perceived 
congestion inconsist-
ent with observed na-
sal patency
• Rhinosinusitis: Endo-
scopic findings of pol-
yps and/or mucopuru-
lent discharge, edema, 
mucosal obstruction 
primarily in middle 
meatus, are prerequi-
site for diagnosis
• CRS: CT findings are a 
prerequisite for the diag-
nosis if endoscopic find-
ings inconclusive
• NARES: Nasal smears for 
eosinophils (any amount 
from >5% to >20%) (not 
routinely employed)
• NARES, atrophic rhini-
tis and rhinoshinusitis: 
Objective and subjective 
olfactory evaluation to 
demonstrate hypoosmia/
anosmia.
• AERD: Oral aspirin chal-
lenges to demonstrate 
sensitivity
AERD (aspirin exacerbated respiratory disease); CRSwNP (chronic rhinosinusitis with nasal polyps); IR (idiopathic rhinitis), NAR-
ES (nonallergic rhinitis and eosinophilia syndrome)
Modified from Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. Phenotypes and Endo-
types of Rhinitis and Their Impact on Management: A PRACTALL Report. Allergy 2015;70:474-494.
ican Academy of Allergy, Asthma & 
Immunology. J Allergy Clin Immu-
nol 2013;131:1479-1490.
2. Brozek JL, Bousquet J, Baena-Cag-
nani CE, Bonini S, Canonica GW, 
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Clin Immunol 2010;126:466-476.
3. Papadopoulos NG, Bernstein JA, 
Demoly P, Dykewicz M, Fokkens W, 
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pact on Management: A PRACTALL 
Report. Allergy 2015;70:474-494.
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Khan DA, et al. The diagnosis and 
management of rhinitis: an updat-
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paper on rhinosinusitis and na-
sal polyps 2012. A summary for 
otorhinolaryngologists. Rhinolo-
gy 2012;50:1-12.
152
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 D
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
di
ag
no
si
s
Allergic rhinitis diagnostic work-up overview
TABLE 2
Rhinitis differential diagnosis: other disorders
Structural/Mechanical abnormalities Systemic disease
• Septal deviation
Unilateral obstruction, sleep apnea, epistaxis
• Primary ciliary dyskinesia (PCD)
Recurrent respiratory infections; Kartageners syndrome (si-
tus inversus, chronic rhinosinusitis and bronchiectasis), low 
nasal and tidally exhaled NO, diagnosis through biopsy and 
electron microscopy examination of cilia
• Turbinate hypertrophy
Often contralateral to septal deviation
• Nasal tumors
Epistaxis, hypoosmia/anosmia, facial pain, 
otalgia, recurrent ear infections, unilateral ob-
struction
• Cystic fibrosis
Thick, viscous secretions, recurrent infection, often radio-
logic evidence of sinus disease and concurrent nasal polyps. 
Diagnosis through genetic and sweat testing•  Adenoidal hypertrophy
congestion, mouth breathing, nasal speech and 
sleep apneic episodes/snoring
• Pharyngonasal reflux
apneic spells, secondary rhinitis (caused by re-
turn of ingested liquids) and recurrent pneumo-
nia due to aspiration
• Churg–Strauss syndrome
Asthma, blood eosinophilia, mononeuropathy/polyneuropa-
thy, migratory pulmonary infiltrates, paranasal sinus disease, 
tissue eosinophilia
• Choanal atresia
Mild symptoms if unilateral, severe symptoms 
if bilateral (often involving generalized cyanosis
• Granulomatosis with polyangiitis
Obstruction, rhinorrhea, crusting, ulcerations and epistaxis, 
often secondary bacterial sinusitis
• Nasal trauma/foreign object
May present with unilateral obstruction, 
epistaxis, olfactory impairment
• Sarcoidosis
Obstruction, nasal crusting, anosmia, epistaxis, lymphade-
nopathy, malaise
• Cerebrospinal fluid rhinorhea
Clear watery secretion – often unilateral, head-
aches and olfactory impairment, β-2 transfer-
rin protein elevated in nasal discharge
• Amyloidosis
Obstruction, nasal discharge, epistaxis and post nasal drip
• Relapsing polychondritis
Chondritis (auricular, nasal, and laryngotracheal, including 
ocular inflammation, audio vestibular damage, or seronega-
tive inflammatory arthritis.
Modified from Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW, et al. Phenotypes and Endo-
types of Rhinitis and Their Impact on Management: A PRACTALL Report. Allergy 2015;70:474-494.
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• Visualizing the nasal cavity is an important evaluation in 
patients with nasal symptoms
• There are no definitive signs of allergic rhinitis
• Rhinoscopy visualizes the anterior third of the nasal cavity
• Nasal endoscopy visualizes the entire nasal cavity, and allows 
the differential diagnosis of mucosal vs structural endonasal 
pathology
One of the great advances in di-
agnosing and understanding nasal 
and sinus diseases has been the 
ability to visualize the entire na-
sal cavity. The advances primarily 
relate to the development of ritig 
and flexible endoscopes.
Traditional approaches of using a 
nasal speculum and a light source 
or an otoscope, referred to as rhi-
noscopy, investigate the anterior 
part of the nose prior to the level 
of the middle turbinates. Although 
the experienced examiner might be 
able to visualize the middle turbi-
nate with this technique, the view 
is limited. The anterior part of the 
nose contains the nasal vestibule, 
where the epithelium transitions 
from squamous to pseudostrati-
fied columnar ciliated. One can also 
easily visualize the anterior septum, 
inferior turbinates, and nasal valve. 
The nasal valve is formed by the 
junction between the anterior na-
sal septum medially and the most 
caudal margin of the upper lateral 
cartilage of the nose superiorly and 
laterally. This valve is the narrow-
est portion of the airway between 
the external environment and the 
alveoli. Deflections of the anterior 
septum have a marked impact on 
airflow and can be diagnosed by 
anterior rhinoscopy.
DIAGNOSIS OF ALLERGIC 
RHINITIS - RHINOSCOPY 
AND ENDOSCOPY
2
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Other salient findings that can be 
visualized by rhinoscopy are hyper-
trophia (Figure 1) or congestion of 
the inferior turbinates. Most sep-
tal perforations involve this area. 
Large nasal polyps (NP) can also 
be seen, but novice clinicians of-
ten mistake the anterior tip of the 
middle turbinate or a large inferior 
turbinate for a polyp. Eighty-five 
percent of nose bleeds occur in the 
anterior septum in the area that 
is the confluence of the anterior 
ethmoid artery, the facial artery, 
and the septal artery, which form 
a rich plexus of vessels, called the 
Keisselbach’s plexus.
There are no definitive signs of al-
lergic rhinitis (AR) on anterior rhi-
noscopy; however, visualization 
by rhinoscopy helps to rule out 
other causes of similar symptoms 
such as nasal congestion due to 
anatomic causes.
Although anterior rhinoscopy is 
helpful, it does not provide visu-
alization of the entire nasal cavity. 
Specifically it does not provide a 
good view of the middle meatus, 
where the sinuses (which are com-
monly involved in patients with 
AR) drain. Adenoid hypertrophy, 
NP, tumors, posterior epistaxis, 
septal deviations obstructing the 
sinus ostia, and sinus infections 
are common and form part of the 
differential diagnosis of rhinop-
athy. Nasal endoscopy provides 
not only visualization to enhance 
diagnostic abilities (Figures 2, 3 
and 4), but also the opportunity to 
work inside the nose under direct 
visualization.
Nasal endoscopy can be per-
formed with a rigid or a flexible 
endoscope. Both can be attached 
to cameras for educating observ-
ers and patients and documenting 
Diagnosis of allergic rhinitis - rhinoscopy and endoscopy
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the examination. Both examina-
tions are usually performed after 
the administration of a topical 
decongestant and anesthetic. The 
response to the nasal decongest-
ant sometimes provides clues to 
the underlying problem. Patients 
with AR often decongest well with 
oxymetazoline because the con-
gestion of the inferior turbinates 
is caused by inflammatory medi-
ators released during an allergic 
reaction that subsequently dilate 
the cavernous veins in the inferior 
turbinates.
Flexible endoscopy is easier to 
perform and can also be used for 
visualizing the nasopharynx and 
larynx. Rigid endoscopy provides 
better image definition, and the 
endoscope can be held with one 
hand, freeing the other hand to 
intervene in the nasal cavity. Such 
interventions include lysis of ad-
hesions, obtaining guided cultures 
(Figure 5), performing biopsies, 
and cauterizing nosebleeds. Di-
rected middle meatal cultures cor-
relate highly with maxillary sinus 
Figure 1 Left panel: Endoscopic view of an antrochoanal polyp (originating from the maxillary sinus and protruding into 
the nasal cavity) of the right nostril in a teenage male who presented with a unilateral nasal obstruction. Right panel: 
closeup view. One can see the nasal septum (*), the middle turbinate (#), and the polyp (arrowhead).
Figure 2 Anterior rhinoscopy with use of a nasal 
speculum and headlight showing a hypertrophied right 
inferior turbinate.
Figure 3 Endoscopic view showing a small polyp (*) 
in the osteomeatal unit.
∗

#
∗

#
∗
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Figure 4 Left panel shows an endoscopic view of a posterior septal deviation impacting the inferior turbinate and heading 
to the osteomeatal unit. Right panel is an intraoperative photo following removal of the septal deviation showing multiple 
accessory ostia believed to be secondary to prior acute infections.
puncture cultures in patients with 
acute bacterial rhinosinusitis.
When should nasal endoscopy be 
performed in a patient who has a 
nasal complaint? One could argue 
that it should be done in every-
one, but that would be too cost-
ly. A more reasonable approach is 
to perform endoscopy in subjects 
who have symptoms that are not 
explained by rhinoscopy and who 
did not respond to initial treat-
ment.
Figure 5 View of the right middle turbinate (#) and the right 
osteomeatal unit (arrowhead) with some purulent drainage. This 
view was obtained with the use of a rigid scope, allowing the 
introduction of a Calgae swab (*) to obtain a culture.
∗

#
KEY REFERENCES
1. Stammberger H. Functional Endo-
scopic Sinus Surgery. Decker. Phil-
adelphia, Pennsylvania, 1991.
2. Benninger MS, Appelbaum PC, 
Denneny JC, Osguthorpe DJ, 
Stankiewicz JA. Maxillary sinus 
puncture and culture in the diagno-
sis of acute rhinosinusitis: the case 
for pursuing alternative culture 
methods. Otolaryngol Head Neck 
Surg 2002;127:7-12.
3. Psaltis AJ, Li G, Vaezeafshar R, Cho 
KS, Hwang PH. Modification of the 
Lund-Kennedy endoscopic scoring 
system improves its reliability and 
correlation with patient-report-
ed outcome measures. Laryngo-
scope 2014;124:2216-2223.
4. Stankiewicz JA, Chow JM. Na-
sal endoscopy and the definition 
and diagnosis of chronic rhinosi-
nusitis. Otolaryngol Head Neck 
Surg 2002;126:623-627.
Diagnosis of allergic rhinitis - rhinoscopy and endoscopy
156
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 D
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
di
ag
no
si
s • Allergic rhinitis (AR) is a complex allergen-driven mucosal 
inflammation caused by the interplay between local and 
infiltrating inflammatory cells and many vasoactive and 
inflammatory mediators
• Increased Nasal Nitric Oxide (nNO) levels are associated with 
nasal inflammation; however, results should be interpreted 
with caution in patients with severe or persistent AR, which 
may reduce nNO levels
• Nasal cytology is performed to help differentiate AR (predom-
inantly) from infectious rhinitis (predominantly neutrophils), al-
though it is relatively nonspecific and insensitive
• Non-invasive sampling of mediators by nasal lavage is an 
emerging method to monitor AR
In allergic rhinitis (AR), the ear-
ly-phase reaction due to IgE-me-
diated mast cell degranulation 
and mediator release is rapid and 
leads to sneezing and rhinorrhea. 
The late-phase reaction involves 
an eosinophilic infiltrate, leading 
to nasal inflammation.
Nasal nitric oxide (nNO) is pro-
duced continuously in the parana-
sal sinuses without inflammatory 
stimuli and plays a role in airway 
homeostasis. AR may be associ-
ated with elevated nNO levels, by 
the increase in inducible nitric ox-
ide synthase (iNOS) expression in 
respiratory epithelial cells. While 
the level of nNO may be increased 
by nasal inflammation, nasal swell-
ing and secretions may occlude 
the ostia of the paranasal sinuses 
thereby lowering nNO levels. A 
high nNO may be a useful mark-
er of eosinophilic inflammation of 
the nasal cavity and indicate open 
sinus ostia. nNO measurements 
may be an alternative to diagnose 
AR in patients who are not able to 
undergo allergic tests or invasive 
procedures.
Infiltrating eosinophils are the 
hallmark of nasal inflammation in 
AR. Nasal smears for eosinophils 
are not recommended for rou-
tine use in diagnosing AR when 
NON-INVASIVE EVALUATION OF 
NASAL INFLAMMATION (NO, NASAL 
CYTOLOGY AND MEDIATORS)
3
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the diagnosis is clearly supported, 
but may be a useful adjunct when 
there remains a high clinical sus-
picion of allergy in a history-pos-
itive, skin test-negative patient. 
Nasal cytology can not only be 
utilized to establish the diagno-
sis of AR, but is also useful in the 
follow-up of treated patients with 
this condition. The technique al-
lows clinicians to detect the cel-
lular modifications of the nasal 
epithelium during allergen expo-
sure (Figure 1) and by subsequent 
treatment with corticosteroids.
Many different mediators, cy-
tokines, and chemokines have 
been measured in nasal lavage (NL) 
studies (Figure 2). Certain proin-
flammatory mediators including 
eosinophilic major basic protein 
and neutrophil elastase have been 
identified in allergic mucin. Eosin-
ophil cationic protein (ECP) is one 
of the most studied inflammatory 
markers and is considered a gen-
eral marker of mucosal inflamma-
tion, both in processes of eosin-
ophil and neutrophil activation. 
Another key feature of mucosal 
inflammation is the exudation of 
plasma proteins such as albumin, 
a2-macroglobulin, and others, 
which can be monitored by analy-
sis of plasma proteins in NL. While 
histamine is rapidly degraded by 
Non-invasive evaluation of nasal inflammation (NO, nasal cytology and mediators)
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Non-invasive evaluation of nasal inflammation (NO, nasal cytology and mediators)
histaminases and N-methyl trans-
ferase, the more stable mast cell 
degranulation products, tryptase 
and prostaglandin PGD2 are rec-
ommended as markers of mast cell 
activation. The choice of which 
inflammatory marker to probe in 
AR depends on the purpose of the 
investigation and the manner of 
monitoring therapy.
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Figure 1 Nasal inflammation 
occurring in seasonal allergic rhinitis. 
(From Gelardi M, Luigi Marseglia 
G, Licari A, Landi M, Dell'Albani I, 
Incorvaia C, et al. Nasal cytology 
in children: recent advances. Ital J 
Pediatr 2012;25;38:51.)
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established in the diagnostic work-up of allergic rhinitis (AR) to 
demonstrate IgE mediated sensitizations
• The quality of allergen extracts is critical. False negative results 
can occur if minor allergens or instable allergenic proteins are 
underrepresented in an extract
• Well-standardized allergen extracts are available for many 
inhalant allergens
• The best established skin test is the skin prick test (SPT). 
The more sensitive intradermal tests are recommended after 
negative SPT in some situations, but can lead to false positive 
reactions and are associated with a higher risk of systemic side 
effects
Skin testing is well established in 
the diagnostic work-up of aller-
gic rhinitis (AR) to demonstrate 
IgE mediated sensitizations. It is 
mainly performed with protein al-
lergens and only rarely with small 
molecules. A positive skin test 
usually indicates sensitization but 
not necessarily clinically relevant 
allergy. The latter has to be proven 
either by a very convincing history 
or with further steps in the algo-
rithm of in vivo diagnosis (i.e. nasal 
challenge tests).
SKIN PRICK TEST
The skin prick test (SPT) is the 
best established skin test and rec-
ommended as first diagnostic test 
in patients with AR. SPT can be 
performed in patients of any age 
although the reactivity may pos-
sibly be lower in the elderly. The 
quality of allergen extracts used 
for SPT is critical. False negative 
results can occur if minor allergens 
or instable allergenic proteins are 
underrepresented in an extract. 
However, well-standardized al-
lergen extracts are available for 
many inhalant allergens. EU leg-
islation makes it currently difficult 
to have new and optimized diag-
nostic products approved due to 
very high standard requirements.
SKIN TESTING IN THE 
DIAGNOSTIC WORKUP OF 
RHINITIS
4
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The major advantage of SPT as 
compared to an in vitro measure-
ment of specific IgE antibodies is 
the fact that the test can be inter-
preted within 15 to 20 minutes 
(Figure 1). A further advantage 
is that the test gives a visual in-
dication of the sensitivity to the 
patient which may have impact 
on the patient’s behavior. Usual-
ly prick tests are performed with 
panels of allergens of interest; a 
standard set is proposed for inhal-
ant allergens (Table 1).
Some studies show discordances 
between serum-specific IgE and 
SPT results. In a recent meta-anal-
ysis on studies with SPT with in-
halant allergens, every fourth sen-
sitized patient would have been 
misdiagnosed as non-sensitized 
for a particular allergen if only 
serum specific IgE testing had 
been done. This has leads to the 
suggestion that the two methods 
complement each other and can-
not be used interchangeably.
OTHER SKIN TESTS
Intradermal tests are recom-
mended after negative SPT in 
some clinical situations. They are 
considered to be more sensitive 
than the SPT but can lead to false 
positive reactions and they are as-
sociated with a higher risk of sys-
Skin testing in the diagnostic workup of rhinitis
Thomas Werfel  
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temic side effects. Therefore ex-
tracts utilized for intradermal skin 
testing are less concentrated than 
those utilized for SPT. 
Patch testing is the mainstay in 
the diagnosis of allergic contact 
dermatitis – it is not recommend-
ed for the diagnosis of AR.
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Figure 1 SPT is usually performed on the forearm 
with a negative (saline 0.9%) and positive (histamine 
10mg/ml) control. A reaction is considered to be 
positive with a wheal diameter ≥ 3mm after 15 
minutes.
TABLE 1
Proposal for a standard prick test panel for Europe for 
inhalants
Hazel Corylus avellana
Alder Alnus incana
Birch Betula alba
Plane Platanus vulgaris
Cypress Cupressus sempervirens
Grass mix
Poa pratensis, Dactilis glomerata, Lolium 
perenne, Phleum pratense, Festuca 
pratensis, Helictotrichon pretense
Olive Olea europaea
Mugwort Artemisia vulgaris
Ragweed Ambrosia artemisiifolia
Alternaria alternata (tenuis), Cladospori-
um herbarum, Aspergillus fumigatus
Parietaria
Cat
Dog
Dermatophagoides pteronyssinus, 
Dermatophagoides farinae,
Cockroach Blatella germanica
Skin testing in the diagnostic workup of rhinitis
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mucosa to allergen(s) or non-specific triggers in order to elicit a 
measurable response
• Provocations have been essential in delineating patho-
mechanisms of (allergic) rhinitis
• Applications in clinical practice include identification of 
predominant allergens in polysensitised patients, proof of 
causation of symptoms for novel or occupational allergens, and 
investigation of local allergic rhinitis
• Several different approaches to provocation exist, universal 
consensus on optimal methods is lacking
Nasal provocation testing is the 
use of various stimuli – typical-
ly specific allergen(s), but also 
non-specific triggers including 
irritants, chemicals and physical 
stressors – to elicit a measurable 
response from the nose. Out-
comes include symptom scores, 
measures of nasal airway patency, 
cellular influx and inflammatory 
mediators in nasal fluid.
Applications of provocation tests 
are outlined in Table 1. In clinical 
practice, provocations may help 
differentiate between sensitisa-
tion and allergy, and identify indi-
viduals with local allergic rhinitis 
(AR). In research settings, prov-
ocations have demonstrated the 
efficacy of pharmacotherapies 
including anti-histamines and in-
tranasal corticosteroids, and iden-
tified basic immunological and 
neural mechanisms.
A reliable, reproducible means of 
delivering allergen to the nasal 
mucosa is required. Various deliv-
ery systems used are outlined in 
Table 2, alongside different provo-
cation protocols. The latter include 
up-dosing/titration provocations, 
providing dose-response profiles 
and allowing tailoring of future 
doses to each individual. Repeat 
challenges, usually every 24 hours 
PROVOCATION TESTS5
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for several days, may provide an 
approximation to real-life allergen 
exposures and allow investigation 
of ‘priming’ of the mucosa.
For research, participants are se-
lected on the basis of typical al-
lergic symptoms and evidence of 
systemic sensitisation to the aller-
gen in question. Allergen provoca-
tions are usually performed out-
side of usual seasonal exposure 
and in the absence of symptoms 
induced by alternative/perennial 
allergens, infection, nasal polyps 
or structural pathologies. Whilst 
provocations are extremely safe, 
individuals with poorly controlled 
asthma or FEV1 <70% predicted 
should be excluded; other con-
traindications include pregnancy 
or a history of anaphylaxis to the 
allergen in question. Anti-allergic 
medications need to be stopped 
for a sufficient wash-out period 
prior to provocations.
Clinical and laboratory outcomes 
of nasal provocations are given in 
Table 3. Typically, provocation is 
preceded by nasal lavage to pro-
vide a clean baseline. An example 
of the time-course of symptom 
and peak nasal inspiratory flow re-
sponses to a single dose nasal al-
lergen challenge is given in Figure 
1. In contrast to bronchial allergen 
provocation, a distinct late phase 
response is seldom seen, although 
nasal obstruction typically persists 
for some hours after provocation. 
Conversely, clear immunological 
Provocation tests
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TABLE 1
Clinical and research uses of nasal provocations
Clinical Practice Research
Confirmation of clinical relevance in cases of 
polysensitisation to aeroallergens
Assessment of mechanisms of (allergic) 
rhinitis:
• Cellular influx
• Early and late phase mediators
• Neural pathways
• Gene expression
• Naso-ocular, naso-bronchial interaction
Selection of patients for allergen immunotherapy 
(e.g. for house dust mite)
Investigation of symptoms in the absence of 
evidence of systemic allergen sensitisation (local 
allergic rhinitis)
Proof of symptom causation for novel and 
occupational allergens
Assessment of therapeutic interventions:
• Efficacy
• Onset
• Duration
Investigation of aspirin hypersensitivity
Assessment of non-specific nasal hyperreactivity
TABLE 2
Methods of nasal allergen provocation
Delivery System Challenge Protocol
Allergen in aqueous solution, administered by 
nasal spray, drops, pipette Up-dosing/titration protocol - half-log 
increments, every 10 minutes, ending at 
maximum dose or threshold responseFilter discs with adsorbed allergen, placed 
directly onto nasal mucosa
Allergen as dry powder insufflated or nebulised Single fixed dose challenge (standard or determined by titration challenge)
Allergen administered in high volume nasal 
lavage
Repeat dosing, usually daily, to mimic seasonal 
priming effect
TABLE 3
Clinical and laboratory outcome measures of nasal provocation.
Clinical Outcomes Laboratory Outcomes
Total nasal symptom score: 0-3 for each of 
sneezing, rhinorrhoea, itching, blocking/
congestion; maximum score 12.
Nasal mucosal fluid, collected by lavage 
or direct absorption (synthetic filters, 
polyurethane sponges), immunoassay for:
• Early phase mediators, e.g. tryptase, 
histamine, leukotrienes
• Cytokines and chemokines
• Allergen-specific antibodies
• Eosinophil products, e.g. ECP
• Neuropeptides
• Vascular, glandular proteins
Visual analogue scale (0-100mm; none – 
maximal symptoms)
Collected secretion weight
Nasal airflow/patency:
• Peak inspiratory flow
• rhinomanometry
Nasal cross-sectional area:
• acoustic rhinometry Nasal brushings for cytology, mRNA
Eosinophilic inflammation:
• nasal FeNO
Nasal (turbinate) biopsy for 
immunohistochemistry, in situ hybridisation
Nasal lavage for cytology
Provocation tests
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late phase responses are seen for 
both cellular influx (eosinophilic) 
and nasal fluid cytokines/chemok-
ines (Th2 predominant).
Whilst allergen provocations are 
more frequently used, non-specif-
ic provocations, described in Table 
4, have also been used to identify 
nasal hyperreactivity, investigate 
the effect of environmental pol-
lutants, and elucidate basic mech-
anisms of rhinitis.
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TABLE 4
Non specific nasal challenges
Biochemical Irritant/inflammatory Physical
Histamine – ipsilateral 
and contralateral effects
Capsaicin - Activates 
TRPV-1 receptors on 
sensory nerve endings; 
increased response in al-
lergic rhinitics
Cold dry air - rhinor-
rhoea and congestion 
in susceptible individ-
uals, associated with 
increased histamine, 
PGD2 and kinins.
Superior to histamine 
in identifying patients 
with non-allergic rhini-
tis from controls.
Methacholine – ipsilater-
al effect only
AMP – non-specific mast 
cell activation
Environmental tobacco 
smoke - rhinitis in sus-
ceptible individuals
Neuropeptides – stimula-
tion of sensory nerves
Diesel exhaust particles 
– may augment response 
to allergen
Bradykinin, leukotrienes 
– investigation of effects 
of individual components 
of mast cell granules
Ozone (in challenge 
chamber) - neutrophilic 
inflammation
Hyperosmolar solu-
tions, e.g. mannitol, 
hypertonic saline - in-
duces fluid shift into 
the nasal lumen and 
increases in mediators 
including mast cell, ep-
ithelial and neuronal 
factors.
Aspirin – diagnosis of hy-
perreactivity and desen-
sitisation
Chlorine – increases in 
nasal resistance
0
1
2
3
4
5
6
7
8
9
10
Total nasal symptom score : time course
Allergen 
Diluent 
-140
-120
-100
-80
-60
-40
-20
0
20
40
Δpeak nasal inspiratory flow: time-course
Figure 1 Time course of total nasal symptom score (0-12) and change from baseline peak nasal inspiratory flow (L/min) in 
19 cat-allergic individuals after single dose cat allergen challenge and diluent-only challenge. (Adapted from Scadding GW, 
Eifan A, Penagos M, et al. Local and systemic effects of cat allergen nasal provocation. Clin Exp Allergy 2015;45:613-623.)
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• Elevated allergen-specific IgE serum levels are indicative for an 
allergy
• Determination of allergen-specific IgE in serum allows rapid 
screening of the sensitization spectrum of a patient
• Screening panels of allergen-specific IgE without previous 
consideration of the history of the patient is not recommended
• A negative skin prick or serum IgE test does not entirely 
exclude a diagnosis of AR especially if they are in contrast with 
a convincing clinical history
• The diagnosis of AR with discordant clinical history and elevated 
allergen-specific serum IgE levels needs to be confirmed by 
provocation tests
Allergic rhinitis (AR) is a very com-
mon inflammatory chronic condi-
tion affecting the upper airways. It 
occurs in predisposed individuals 
when allergens such as pollens, 
dust, or animal dander are inhaled. 
Its incidence is rising in parallel 
with other IgE-mediated diseas-
es, affecting 10 to 30% of adults 
and up to 40% of children in in-
dustrialised countries. Seasonal 
AR is mainly elicited by exposure 
to pollens during the pollination 
period, while perennial AR is elic-
ited by allergens present in the 
environment throughout the year 
like those from house dust mite 
allergens or fungal spores. The 
disease is often associated with 
other IgE-mediated diseases like 
allergic asthma, or atopic derma-
titis. The characteristic symptoms 
of AR are excess nasal secretion, 
itching, sneezing, nasal conges-
tion and obstruction associated 
with eosinophilic inflammation of 
the mucosa. To confirm the diag-
nosis of AR, sensitisation (specific 
IgE reactivity) needs to be record-
ed and should be concordant with 
the clinical history.
The prototype for the in vitro 
detection of serum IgE (the radi-
oallergosorbent test, RAST) first 
described in 1967 used a paper 
SPECIFIC IgE AND DIAGNOSIS 
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disc as a solid phase to covalently 
immobilize the allergen followed 
by the addition of patient’s serum. 
After different washing proce-
dures to remove unbound serum 
proteins and antibodies, bounded 
IgE was detected with 125I-la-
belled polyclonal anti-human IgE 
(Figure 1). Modern assays for the 
detection of allergen-specific IgE 
have undergone impressive im-
provements including the calibra-
tion against the WHO Standard 
72/502, allowing quantitative de-
terminations, and the implemen-
tation of fully automated devices 
(Figure 2). To date the most com-
monly used system to determine 
allergen-specific IgE is the Immu-
noCAP system (Thermo Fisher 
Scientific, Uppsala) considered as 
the “gold standard” for the in vit-
ro diagnosis of allergic conditions. 
More recently, novel diagnostic 
tests based on allergen microar-
rays have been introduced both 
in research and clinical practice. 
Multiplex-based in vitro tools for 
allergy diagnosis allow a compo-
nent resolved diagnostics of the 
atopy status of a patient in a cost 
effective way.
In vitro tests for allergen-specific 
serum IgE are excellent for iden-
tifying a sensitization state of a 
patient and can be recommended 
at any age and without wash-out 
for antiallergic medication. How-
Specific IgE and diagnosis of allergic rhinitis
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ever, a positive in vitro test for al-
lergen-specific IgE in serum does 
not always equate with clinical 
allergy, and a negative test does 
not completely exclude the dis-
ease. For a clinical manifestation 
of any allergy the only biological-
ly relevant allergen-specific IgE is 
those immobilized on the surface 
of effector cells through the high 
affinity FcεRI receptors. This can, 
through cross-linking of 
the IgE molecules after 
allergen exposure and the 
resulting mediator release 
from effector cells, elic-
it local symptoms of AR 
also in the absence of sol-
uble allergen-specific IgE 
in serum. Therefore, the 
best tool for the diagno-
sis of AR is by correlating 
the patient’s history and 
physical exam with the 
presence of aeroallergen 
specific IgE determined 
by skin testing or by in 
vitro assays. Like skin test-
ing, limitations of in vitro 
specific IgE measurement 
include the availability of 
fully standardized aller-
genic extracts, particularly 
for foods, drugs, and occu-
pational agents.
New perspectives for the 
diagnosis of AR have been 
opened by in vitro diagnostic tests 
based on molecular approach-
es, which allow a component 
resolved diagnosis of hundreds 
of the offending allergens. Multi-
plex measurement platforms like 
the Immuno-Solid phase Allergen 
Chip (ISAC) allows discrimination 
between genuine and cross-reac-
tive sensitization thereby reducing 
unnecessary allergen challenges, 
and facilitating the identification 
of patients with a good prognosis 
for a successful allergen immuno-
therapy.
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Figure 1 Mechanism of the first radioallergosorbent assay (RAST).
Figure 2 Example of a fully automated device 
for the determination of allergen-specific IgE 
(PhadiaTM Immunoassay Analyzer).
Specific IgE and diagnosis of allergic rhinitis
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• The IgE response usually evolves from a monomolecular to 
an oligo- and poly-molecular stage (“molecular spreading” 
phenomenon) and can involve both, highly specific and highly 
cross-reactive molecules
• Allergic patients reacting to the same allergenic source (e.g. 
grass pollen) can be highly different in their molecular profile of 
IgE sensitization to that allergenic source
• Component resolved diagnosis (based on single or multiplex 
assays) allows discriminating whether a patient is truly or only 
apparently sensitized to an allergenic source (e.g. pollen)
• Component resolved diagnosis has a strong impact on the 
precision of allergen immunotherapy (AIT) prescription, which 
might imply to a better AIT efficacy and cost-effectiveness. Ad 
hoc Diagnostic Algorithms have been proposed
The number of allergenic mol-
ecules cloned and available for 
diagnostic tests grows year after 
year. We can nowadays precisely 
define the patient’s IgE repertoire 
and distinguish, in polysensitized 
patients, true sensitization (IgE to 
major, “species-specific” allergen-
ic molecules) from apparent sen-
sitization, due to cross-reactive 
molecules (e.g. profilin, serum al-
bumin, tropomyosin, CCD) shared 
by many allergenic sources.
This molecular approach, also 
called ‘component-resolved diag-
nosis’ (CRD), can rely upon clas-
sical ‘singleplex’ or newer ‘multi-
plex’ methods. By the singleplex 
method, single molecules are sep-
arately analyzed and the operator 
can select, with an inductive ap-
proach, those to be tested in the 
individual patient. By the multi-
plex method, fixed arrays of mole-
cules are tested in the same assay 
and the response is interpreted 
with a deductive approach.
CRD applies to all IgE-mediated 
allergic diseases and it is of para-
mount importance in the correct 
diagnosis of pollen-food syn-
dromes. In patients with seasonal 
allergic rhinitis (SAR), CRD may in-
fluence therapeutic decisions, by 
helping the selection of sources 
COMPONENT 
RESOLVED DIAGNOSIS7
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for allergen immunotherapy (AIT). 
Indeed, the IgE response against 
grass pollen (e.g. Phleum pratense) 
usually evolves from a simple, 
monomolecular stage to an oli-
gomolecular stage and eventually 
to a polymolecular sensitization 
stage. This phenomenon has been 
defined as ‘molecular spreading’, 
that is, “The sequential develop-
ment of antibody (IgE) response to 
distinct non-cross-reacting mole-
cules from the same antigenic (al-
lergenic) source, starting with an 
“initiator” (allergenic) molecule.” 
Phl p 1 is the probable ‘initiator’ 
molecule in most patients, and the 
response involves then Phl p 4 or 
Phl p 5, thereafter also Phl p 2 and 
Phl p 11 and at a later stage Phl 
p 12 or Phl p 7 (Figure 1). Inter-
estingly, the molecular spreading 
process follows different sequenc-
es in different children: some pa-
tients remain sensitized only to 
the “initiator” molecule while a 
few patients become sensitized to 
most or all allergenic molecules. 
Consequently, a population of 
grass-pollen allergic patients “ap-
parently” homogeneous if exam-
ined with an allergen extract, is 
Component resolved diagnosis
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Component resolved diagnosis
Figure 1 IgE to Phleum pratense allergenic molecules from the onset of grass-related seasonal allergic rhinitis (SAR). 
Lines show the prevalence of IgE sensitization (ISAC class >_1) to the 8 Pheum pratense allergenic molecules in children 
whose sera were available at each time point. The number of children examined at each time point is indicated under the 
x-axis. Clinical stages of SAR are also indicated. (Adapted from J Allergy Clin Immunol 130/4, Hatzler L, Panetta V, Lau S, et 
al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. 894-901.
e5, Copyright 2012, with permission from Elsevier.)
remarkably heterogeneous when 
examined with allergenic mole-
cules (Figure 2).
A consistent proportion of pollen 
allergic patients are sensitized to 
profilin and other highly cross-re-
acting molecules. When tested 
with extracts-based skin prick 
tests or IgE assays, these patients 
with SAR appear sensitized to 
many different pollens which of-
ten share, especially at warmer lat-
itudes (e.g. Mediterranean coun-
tries), overlapping season. In vitro 
molecular assays can discriminate 
true IgE sensitization from co-rec-
ognition and allow refining the di-
agnosis made with extract-based 
SPT or IgE assays. Not surpris-
ingly, a precise molecular diagno-
sis can play a strong influence on 
AIT prescription in Mediterranean 
countries (Figure 3) and this might 
imply a better AIT efficacy and 
cost-effectiveness. Accordingly, 
new diagnostic algorithms for an 
improved prescription of AIT in 
patients with pollen-related al-
lergic rhinitis have been recently 
proposed (Figure 4).
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Figure 3 The impact of CRD on 
AIT prescription. CRD impact on 
AIT prescription based on SPT 
with extract, by SPT cut-point and 
prescription model. (Reprinted from J 
Allergy Clin Immunol, 134/1, Stringari 
G, Tripodi S, Caffarelli C, et al. The 
effect of component-resolved diagnosis 
on specific immunotherapy prescription 
in children with hay fever. 75-81, 
Copyright 2014, with permission from 
Elsevier.)
Figure 2 Profiles of IgE sensitization 
to eight Phleum pratense molecules in 
176 sensitized children. Profiles of IgE 
sensitization to eight Phleum pratense 
molecules in 176 children with an 
IgE reaction to Phleum pratense and 
complete data-set. The APCS code 
and the absolute and cumulative 
frequency are shown. The profiles 
are ordered by declining frequency 
and the point at which the arbitrary 
threshold of 80% of the patient 
population has been reached is 
marked in red. (Reprinted from J Allergy 
Clin Immunol, 129/3, Tripodi S, Frediani 
T, Lucarelli S, et al. Molecular profiles of 
IgE to Phleum pratense in children with 
grass pollen allergy: implications for 
specific immunotherapy. 834-839.e8, 
Copyright 2012, with permission from 
Elsevier.)
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Figure 4 Proposal for a basic CRD work-up for pollen AIT candidates in southern Europe. For the purposes of the current 
figure, component allergens' names denote the detection of corresponding specific IgE. * In cases with nCyn d 1 (+) > rPhl 
p 1 (+) and negative species-specific allergen markers for Timothy grass (e.g. rPhl p 2, rPhl p 5 and rPhl p 6), a Bermuda 
grass standardized extract may be sufficient for the treatment of clinical allergy to grass pollen (please refer to text). ** Both 
natural nOle e 1 and recombinant rOle e 1 are commercially available in Europe. *** For optimal AIT efficacy, the use of 
standardized extracts containing the species-specific major allergen at high-dose concentration may be required. **** rPhl p 
7, as a polcalcin marker and rPhl p 12, as a profilin marker are typically used. In areas with a high prevalence of birch pollen 
allergy (not typical of the Mediterranean region), rBet v 4 and rBet v 2 may respectively be used, along with the essential 
rBet v 1 birch pollen major allergen. (Reproduced with permission from Douladiris N, Savvatianos S, Roumpedaki I, et
al. A molecular diagnostic algorithm to guide pollen immunotherapy in southern Europe: towards component-resolved 
management of allergic diseases. Int Arch Allergy Immunol 2013;162:163–172; with permission from Karger Publishers.)
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• Allergic rhinitis (AR) symptoms are significantly associated 
with allergen specific basophil sensitivity. Evaluation of cellular 
allergen sensitivity may be a useful tool for mirroring clinical 
allergen sensitivity
• The basophil activation test (BAT) is considered as an effective 
in vitro diagnostic test to identify difficult allergic cases and also 
can be used in monitoring immunotherapy
• Flow cytometry to measure basophils that express activation 
markers, including CD63, CD203c or both have been proven to 
be a useful tool for the assessment of the immediate response 
to allergens mediated by IgE
• BAT also might be used in the diagnosis of local AR
Cellular allergy tests are used to 
diagnose and follow up allergic 
diseases. They have advantages 
of detecting antigen-dependent 
cellular processes without any risk 
to the patient. Several studies also 
support its usefulness in monitor-
ing allergen immunotherapy (AIT).
Allergic rhinitis (AR) symptoms are 
significantly associated with ele-
vated basophil sensitivity. Evalu-
ation of allergen-specific basophil 
sensitivity could be a useful tool 
for distinguishing allergic sensiti-
sation. Effector cell based in vitro 
tests might help in defining the 
allergic state in sensitized individ-
uals.
The most common cellular test 
is basophil activation by allergen 
(BAT). BAT evaluating histamine, 
sulfidoleukotriene and cytokine 
release upon allergen exposure 
has been used in the diagnosis 
of allergy for many years (Figure 
1). However, the measurement 
of allergen-induced histamine re-
lease from patient’s basophils can 
not be used widely, because it is 
expensive and time consuming. 
In recent years, flowcytometric 
analysis based on the detection of 
allergen-induced basophil surface 
markers has been used (Figure 
2). CD63 expression or CD203c 
DIAGNOSIS OF ALLERGIC 
RHINITIS - CELLULAR TESTS8
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upregulation on basophil surface 
have been reported as new diag-
nostic markers for allergic diseas-
es (Figure 3). In several studies 
the BAT based on the occurence 
of CD63 (gp53) in the presence 
of allergen was found sensitive 
(80-100%) and specific (100%) for 
the in vitro diagnosis of pollen al-
lergy. The expression of CD63 has 
a good correlation with basophil 
degranulation and histamine re-
lease. Using grass pollen or mite 
(Dermatophagoides pteronyssinus) 
allergens, IgE-dependent acti-
vation of basophils is associated 
with upregulation of basophil sur-
face markers. Measurement of 
CD203c upregulation on baso-
phils in response to specific aller-
gens as a specific basophil activa-
tion marker has been shown to be 
a reliable and effective in vitro di-
agnostic test as CD63 expression.
BATs are considered to identify 
difficult IgE-mediated allergic cas-
es especially when patient history, 
skin tests or specific IgE results 
are discordant. In contrast to skin 
testing, CD203c-based BAT can 
be performed in patients without 
wash-out for antiallergic treat-
ment.
BAT is found to be more sensitive 
than detection of nasal specific 
IgE and less time consuming com-
pared to nasal provocation tests in 
Diagnosis of allergic rhinitis - cellular tests
Zeynep Mısırlıgil  
University of Ankara 
Ankara, Turkey
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Figure 1 Measurement methods of secreted mediators after the basophil activation by allergens. (Modified from Ebo 
DG, Saninte-Laudy J, Bridts CH, et al. Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 
2006;61:1028-1039 and MacGlashan DW Jr. Basophil activation testing. J Allergy Clin Immunol 2013;132:777-787.)
Figure 2 Identification of 
increased or newly expressed 
basophil surface proteins by 
using polychromatic flow 
cytometry. (Modified from Ebo 
DG, Saninte-Laudy J, Bridts 
CH, et al. Flow-assisted allergy 
diagnosis: current applications 
and future perspectives. Allergy 
2006;61:1028-1039 and 
MacGlashan DW Jr. Basophil 
activation testing. J Allergy Clin 
Immunol 2013;132:777-787.)
Diagnosis of allergic rhinitis - cellular tests
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local AR. The use of higher doses 
of allergen stimulation may be re-
quired because of low amounts of 
specific IgE in these cases.
Recently, it has been suggested 
that increased CD63 expression 
or CD203c upregulation might be 
useful tools for early monitoring 
of the development of protective 
immune response induced by AIT.
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Diagnosis of allergic rhinitis - cellular tests
Figure 3 Flow cytometric detection in healthy control ( A) and a patient with seasonal allergic rhinitis (B) ; 
Representative increased expression of CD203c on the basophil surface by pollen allergen stimulaton. A1, B1 ; negative 
control, A2, B2 ; positive control, A3, B3; stimulation with 45,1 µg/ml of pheleum pratensis concentration. (Modified 
from Özdemir SK, Güloglu D, Sin BA, Elhan H, İkinciogulları A, Misirligil Z. Reliability of basophil activation test using CD203c 
expression in diagnosis of polen allergy. Am J Rhinol Allergy 2011;25:e225-e231.)
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focus on the universal detection of genes (genomics), mRNA 
(transcriptomics), DNA methylation, histone modifications or 
non-coding RNA (epigenetics), proteins (proteomics), lipids 
(lipidomics) and small molecule metabolites (metabolomics) in a 
specific biological sample
• ‘Omic’ experiment is hypothesis-free; generates unbiased 
results by an extensive bioinformatic analysis and should be 
validated in the functional experiments
• Next Generation Sequencing (NGS) is a high-throughput, 
multiplexed sequencing method, which is used in genomics, 
transcriptomics and epigenetics, while mass spectrometry 
is used for detection of analytes in proteomic, lipidomic and 
metabolomic research
• International evidence-based guidelines help patients and 
clinicians in allergic rhinitis and chronic rhinosinusitis diagnosis 
and management
• Omics technologies do not have a place in routine diagnosis so 
far
We are witnessing the fast accel-
eration of research technologies, 
including ‘omic’ and others, which 
are currently being implemented 
in the studies on allergic rhinitis 
(AR) and chronic rhinosinusitis 
(CRS) pathogenesis, diagnosis and 
management (Figure 1). Several of 
these techniques will soon devel-
op into the standard clinical tools. 
‘Omic’ technologies and their in-
tegration are referred as systems 
biology. These experiments differ 
from traditional studies, which 
are largely focused around a hy-
pothesis. By contrast, the goal of 
an ‘omic’ experiment is to create 
an hypothesis-free, holistic view 
of the molecules involved in the 
functional and/or structural alter-
ations within the cells and tissues. 
In such an experiment, all data are 
simultaneously acquired and ana-
lyzed to further define a specific 
hypothesis for testing. Together 
with the progress in the primary 
cell culture techniques, combined 
with the molecular biology and cell 
imaging tools, ‘omic’ techniques 
are becoming crucial in under-
standing etiology of the disease, 
screening, diagnosis and progno-
sis (so-called biomarkers discov-
ery) (Figure 2). Moreover, they are 
increasingly being used in drug 
discovery and assessment of their 
NEW DIAGNOSTIC AND RESEARCH 
TECHNIQUES IN ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS
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toxicity and efficacy. Most of these 
technologies are being developed 
into high-throughput and multi-
plexed assays, which significantly 
lower the costs and decrease time 
to obtain the enormous amount 
of data. Because of that, in parallel 
with the ‘omic’ technology, there 
is a fast improvement in the data 
analysis and bioinformatic tools to 
comprehend and understand the 
results.
Genomics was the first ‘omic’ tech-
nologies to be developed, which 
progressed beyond DNA sequenc-
ing (structural genomics) to identi-
fying the function of the encod-
ed genes (functional genomics). 
Genomics has been focused on 
detecting structural variations in 
the coding and non-coding parts 
of DNA such as single nucleotide 
polymorphisms (SNPs) in different 
tissues and their associations with 
Milena Sokolowska Cezmi A. Akdis
Swiss Institute of Allergy and Asthma Research 
Davos, Switzerland
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the disease occurrence or with the 
different response to treatment 
(pharmacogenomics). Genomics 
is currently frequently used in the 
studies, identifying DNA of micro-
organisms that are inhibiting hu-
man body, which are referred as 
microbiome. Nasal mucosa is one 
of the tissues in which interaction 
between the microbiome and the 
host might shape the mucosal 
barrier function and response to 
allergens and irritants. With the 
progress of the genomics a glob-
al concept developed, suggest-
ing that not only the DNA/gene 
structure, but the gene expression 
might reflect the functional state 
of the organisms. Transcriptomics 
is the study of the total mRNA, re-
flecting the genes that are active-
ly expressed at any given moment. 
Since viral infections of the nose 
are extremely popular, they might 
also modulate the AR and other 
diseases of the nose and connect-
ed organs. Therefore, it is increas-
ingly more common to identify 
viral strains invading the nasal 
mucosa by genomic and transcrip-
tomic methods. Epigenetic chang-
es reflecting the influence of the 
environment on the nasal mucosa 
and leading to the non-genetic 
changes of chromatin or DNA are 
also currently studied by means 
of ‘omic’ technologies. Chromatin 
changes, histone modifications 
are studied by DNAse-seq and 
ChIP-seq, while DNA methylation 
and non-coding RNA expression 
(miRNA, lncRNA, etc.) are stud-
ied by sequencing. Most of these 
‘omic’ technologies described 
above have been developed on 
Standard diagnosis Research methods 
Additional diagnostic 
methods 
History 
Symptoms reported, 
QoL questionnaire 
Physical 
examination; 
rhinoscopy 
sIgE tests 
(skin/blood) 
Co-morbidities 
assessment 
(allergic asthma, 
atopic dermatitis, 
conjunctivitis) 
Differential diagnosis 
Nasal nitric oxide 
Nasal allergen 
provocation test 
Acoustic rhinometry 
Olfactory testing 
Genomics 
Transcriptomics 
Epigenetics 
Microbiome, virome 
Lipidomics 
Allergic rhinitis 
diagnostic spectrum 
Metabolomics 
Primary cell culture 
Cellular Imaging 
Molecular biology 
techniques 
Proteomics 
Figure 1 Current, novel diagnostic and research methods in allergic rhinitis.
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Hypothesis-free 
Experiment 
RNA extraction 
cDNA library preparation 
Next Generation 
Sequencing 
Literature & Pathway 
databases 
Bioinformatics  & 
Functional annotations 
Functional experiment 
Discovery validation 
Figure 2 Transcriptomics experiment sequential flow-chart.
the basis of DNA or RNA microar-
ray chips and are currently be-
ing accessible on the platform of 
high-throughput and multiplexing 
technique called next-generation 
sequencing. Proteomics and lipi-
domics are large-scale studies of 
proteins or lipids, respectively, in-
cluding their structure, functions, 
pathways and networks within 
the cell, tissue and organism. In 
nasal settings, proteomics and li-
pidomics focus on cells of mucosal 
lining, as well as on the secretome 
of nasal fluid. Proteomics and li-
pidomics hold special promise in 
the AR biomarker discovery, as 
the local nasal allergic inflamma-
tion reflects full spectrum of the 
disease, biomarker are likely to oc-
cur here in higher concentrations 
than in the blood, and the nose is 
easily accessible. Metabolomics 
is a study of global low molecular 
weight compounds (metabolites) 
present in a cell or organism that 
participate in metabolic reactions. 
The metabolome contains many 
different biological molecules 
which are physically and chemi-
cally very complex. Proteomics, 
lipidomics and metabolomics re-
quire sample fractionation by e.g. 
chromatography and further anal-
ysis by using a mass spectrometry. 
Finally, hypothesis generated due 
to the ‘omic’ technology and bio-
informatic processing can be now 
tested experimentally due to the 
advancement of primary nasal ep-
ithelial cell and sinus cell culture 
techniques, such as air-liquid in-
terphase cultures. International 
evidence-based guidelines help 
patients and clinicians in allergic 
New diagnostic and research techniques in allergic rhinitis and chronic rhinosinusitis
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rhinitis and chronic rhinosinusitis 
diagnosis and management (Ta-
ble 1). Omics technologies do not 
have a place in routine diagnosis 
so far.
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TABLE 1
Current diagnostic procedures in allergic rhinitis
Standard diagnosis in AR should include all of the following points:
a. History and quality of life assessment
b. Nasal symptoms reported (sneezing, rhinorrhea, itching of nose, eyes, palate; postnatal drip, frequent throat clear-
ing, cough, malaise or fatigue (esp. in children)
c. Physical examination including anterior rhinoscopy (clear rhinorrhea, bluish or pale swelling of nasal mucosa, oc-
ular findings e.g. watery discharge, swollen conjunctivae, scleral injection; allergic shiners, nasal crease, frequent 
throat clearing; absence of foreign body, tumor, purulence suggesting infection)
d. sIgE (skin or blood tests)
e. Common co-morbidities diagnostic approach (atopic dermatitis, allergic asthma, otitis media, conjunctivitis; pos-
sibility of coexistence of allergic and non-allergic causes of rhinitis)
f. Differential diagnosis (vasomotor rhinitis, non-allergic chronic rhinosinusitis, infections, hormonal drug-related, 
occupational rhinitis; CSF rhinorrhea, tumors, nasal polyps)
Additional diagnostic tools, not used as standard methods
a. Nasal allergen provocation test
b. Nasal nitric oxide
c. Acoustic rhinometry
d. Olfactory testing
New diagnostic and research techniques in allergic rhinitis and chronic rhinosinusitis
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major allergen released per pollen (pollen potency)
• Pollen allergen release potency is not geographical fixed and 
changes between years
• Pollen allergen release potency is probably determined in the 
week before pollination by two simultaneous competing ripening 
processes: anther development governing pollen emission and 
individual pollen ripening determining the allergen content of pollen
• Measuring exposure by determining the evoking factor on 
a molecular level (molecular aerobiology) will provide a more 
reliable measure of exposure
Allergy against pollen is the most 
frequent allergic airway disease. 
The prevalence of grass pollen 
sensitizations has surpassed house 
dust mite sensitizations, and if 
sensitizations to birch and other 
pollen are added, allergy against 
pollen is clearly the number one al-
lergic airway disease. It is therefore 
no surprise that monitoring pollen 
is the only voluntarily performed 
air quality monitoring in Europe, 
whereas air quality monitoring of 
PM10, carbon black, NO2 and O3 
are governmental funded activities 
to reduce man-made pollution. 
Measuring pollen is a major en-
deavor as many sites need to be 
monitored daily and manually, and 
no satisfactory automated pollen 
monitors are functionally availa-
ble. Currently, a network of about 
350 pollen monitoring stations is 
spread over Europe.
Monitoring pollen is a good pre-
dictor of allergy symptoms. How-
ever, the human immune system 
does not react to the pollen but to 
substances released by pollen, the 
most important ones being the al-
lergens. Most pollen release a ma-
jor allergen like Bet v 1 from birch 
pollen or Ole e 1 from olive pollen.
Monitoring airborne allergens in-
stead of airborne pollen is tedious 
MEASURING 
ALLERGEN EXPOSURE10
KE Y MESSAGES
and not frequently done. How-
ever, in all cases reported pollen 
counts varied widely in their ma-
jor allergen release per pollen i.e. 
in their allergen release potency. 
In Figure 1 the release of Ole e 
1 from olive pollen in Portugal is 
displayed. At the end of the olive 
pollen season a low number of air-
borne olive pollen was counted, 
but the major olive pollen allergen 
Ole e 1 was highest of the whole 
season. Thus pollen counts may 
underestimate allergen exposure. 
In Figure 2 a similar story is told 
for birch pollen: both airborne Bet 
v 1 and birch pollen were moni-
tored. Expected was that the pol-
len potency, i.e. the amount of Bet 
v 1 calculated per pollen, would be 
constant. Thus the curve for pol-
len potency should be a straight 
line parallel to the x-axis. This was 
however seldom the case in Eu-
rope and only during brief periods. 
In Figure 2A only the example of 
Munich in Germany is shown. Cal-
culating the origin of the pollen 
revealed that pollen with a deviat-
ing potency stemmed from differ-
ent regions. In general however, 
already the same pollen from the 
same region vary up to 10-fold in 
their potency to release the major 
allergen (Figure 2B). Unpublished 
observations showed that the 
same holds true for grass pollen.
In older investigations house dust 
mite exposure was measured by 
counting the number of house 
Measuring allergen exposure
Jeroen Buters  
Technische Universität München and Helmholtzzentrum 
Munich, Germany
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Figure 1 (A) Concomitant monitoring of airborne olive pollen and major olive pollen 
allergen Ole e 1. At the end of the season when pollen counts (grey bars) were low, 
high Ole e 1 levels (green curve is Ole e 1 in PM>10µm, the red curve is Ole e 1 in 
10µm>PM>2.5µm) were detected. (B) Pollen counts versus airborne Ole e 1. The slope (α) of 
the curve represents pollen potency. The pollen potency was much higher at the end of the 
pollen season in Evora, Portugal, 2009. (Reproduced with permission from Galan C, Antunes C, 
Brandao R, et al. Airborne olive pollen counts are not representative of exposure to the major olive 
allergen Ole e 1. Allergy, 2013;68:809-812, with permission from Willey Blackwell.)
Measuring allergen exposure
dust mite per surface 
area. Nowadays expo-
sure is determined by 
measuring the amount 
of house dust mite al-
lergen Der p 1, Der p 2, 
Der f 1 and Der f 2 per 
surface area instead. 
We now can do the 
same for pollen.
From the above exam-
ples we can deduce 
that probably any al-
lergen from natural 
sources has a variability 
in releasing major (and 
probably also minor) 
allergens. As most aller-
gens are natural prod-
ucts, we expect this to 
hold true for all aller-
gens. Thus, measuring 
exposure by determin-
ing the evoking factor 
on a molecular level 
(molecular aerobiology) 
should have advantag-
es. Until that is estab-
lished, the measuring of 
airborne whole pollen 
grains remains a good 
alternative.
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Figure 2 (A) Birch pollen flight (grey bars) and airborne birch allergen Bet v 
1 (the pink curve is allergen per pollen grain i.e. potency) in Munich, Germany 
2009. (B) Histogram of pollen potency (allergen release per pollen) for Munich, 
Germany in the years 2007-2011. The same amount of pollen may release 
over 10-fold different amounts of Bet v 1. (From Buters JTM, Thibaudon M, 
Smith M, Kennedy R, Rantio-Lehtimaaki A, Albertini R, et al. Release of Bet v 1 from 
birch pollen from 5 European countries. Results from the HIALINE study. Atmos 
Environ 2012;55:496-505.)
Measuring allergen exposure
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• Health-related quality of life (HRQOL) instruments were 
introduced because clinical symptoms correlate only moderately 
with patient perceptions
• To evaluate HRQOL in allergic rhinitis (AR), generic and specific 
questionnaires have been validated
• HRQOL questionnaires in AR are useful in clinical trials, in 
epidemiological studies and in clinical practice
• AR have a significant impact on HRQOL in comparison with 
healthy subjects or even in comparison with other diseases 
such as asthma
Health-related quality of life 
(HRQOL) is usually defined as a 
multidimensional concept encom-
passing the physical, mental, and 
social components associated 
with an illness or its treatment.
The reason to introduce HRQOL 
instruments in clinical practice 
or in clinical research is that the 
personal burden of any illness, as 
perceived by the patient, cannot 
be fully assessed by traditional 
clinical symptoms and signs since 
they are correlating only moder-
ately with patient perceptions and 
functional capabilities on a daily 
basis. The importance of HRQOL 
in allergic rhinitis (AR) is demon-
strated by the fact that in the last 
years the term AR and quality of 
life appeared cited in Pubmed 
more than 1,500 times.
Both generic and disease-specif-
ic instruments have been used to 
evaluate the impact of AR and its 
treatment on patients’ HRQOL. 
Such instruments are useful for 
assessing treatment efficacy in 
clinical trials, for measuring the 
burden of disease in epidemiologi-
cal studies, or as monitoring tool in 
clinical practice. Both generic and 
disease specific tools are useful, 
but their properties must be kept 
in mind. Generic instruments (Ta-
DIAGNOSIS OF ALLERGIC 
RHINITIS-MEASURING HEALTH-
RELATED QUALITY OF LIFE
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Diagnosis of allergic rhinitis-measuring health-related quality of life
Joaquín Sastre  
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TABLE 1
Generic instruments measuring 
the Health-related quality of life
• MOS SF-36/12 Generic health-
related quality of life measure
• SAT-P Daily life satisfaction 
profile
• Profile of Mood States (POMS)
• VAS Appraisal of General Health
• VAS-QoL
• Munich Life Dimension List
• The Nottingham Health Profile
• The Sickness Impact Profile
• The EQ-5D
• 15-dimensional instrument for 
measuring HRQL (15D)
ble 1) have the advantage of com-
paring unrelated diseases but are 
less sensitive to detect the burden 
of the disease. They are based on 
general health issues and include 
items on physical activity, physio-
logic status, capability of self-care, 
level of pain/stress and social in-
tegration. Generic instruments are 
also useful to compare cost-effica-
cy interventions. Disease specific 
questionnaires (Table 2) are more 
sensitive to changes and focus 
on items related to the disease, 
without the possibility to allow 
comparison between diseases. In 
the 90´s, several authors, using 
generic questionnaires, demon-
strated that AR has a significant 
impact on HRQOL in comparison 
with healthy subjects (Figure 1) 
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Diagnosis of allergic rhinitis-measuring health-related quality of life
Figure 2 QOL scores in adults with perennial allergic rhinitis and healthy control subjects. (Data from Bousquet J, 
Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the 
SF-36 Health Status Questionnaire. J Allergy Clin Immunol. 1994;94:182-188.)
TABLE 2
Disease specific questionnaires for Health-related quality of life in:
A. Allergic rhinitis
RQLQ - Rhinoconjunctivitis Quality of Life Questionnaire
RQLQ(S) - Standardised Rhinoconjunctivitis Quality of Life Questionnaire
MiniRQLQ - Mini Rhinoconjunctivitis Quality of Life Questionnaire
RhinQLQ - Rhinitis Quality of Life Questionnaire
AdolRQLQ - Adolescent Rhinoconjunctivitis Quality of Life Questionnaire
PRQLQ - Pediatric Rhinoconjunctivitis Quality of Life Questionnaire
Perceived control of rhinitis questionnaire
RSDI - Rhinosinusitis Disability Index
ESPRINT 28 & ESPRINT 15
B. Allergic rhinitis and other diseases
PADQLQ - Pediatric Allergic Disease Quality of Life Questionnaire
Rhiniasthma Quality of Life Questionnaire for patients with asthma and rhi-
nitis
PAR-ENT to assess the impact of children’s recurrent otolaryngologic infec-
tions on their parents’ QOL
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Diagnosis of allergic rhinitis-measuring health-related quality of life
TABLE 3
Main Characteristics of two Health-related quality of life questionnaires in used in allergic rinitis (ESPRINT-15 and 
the MiniRQLQ)
Number 
of items
Number of 
dimensions Dimensions
Overall and 
dimension scores Score ranges
MiniRQLQ 14 5 Activity limitations
Practical problems
Nose symptoms
Eye symptoms
Other symptoms
Yes Overall and dimension scores 
from 0 (no impairment) to 6 
(greatest impairment)
ESPRINT-15 15 4 Symptoms
Daily activities
Sleep
Psychological 
impact
Yes Overall score from 0 (minimum 
impact in HRQOL) to 5.8 
(maximum impact in HRQOL)
Dimension scores from 0 
(minimum impact in HRQOL) to 
6 (maximum impact in HRQOL)
(Reproduced with permission from Valero A, Alonso J, Antépara I,, et al. Health-related quality of life in allergic rhinitis: 
comparing the short form ESPRINT-15 and MiniRQLQ questionnaires. Allergy, 2007;62:1372-1378, with permission from 
Willey Blackwell.)
or even compared with other dis-
eases such as asthma. Also in the 
90´s the first questionnaires spe-
cific for AR were developed.
Any questionnaire of HRQOL 
measurement requires meeting 
some psychometric characteris-
tics before it can be used in clin-
ical practice. The validation of the 
questionnaires must evaluate its’ 
feasibility (ease to use), reliabili-
ty (internal consistency), validity 
(good correlation with symptoms 
related to the disease and with 
other questionnaires), the floor 
and ceiling effects (the propor-
tion of patients with the worst 
and best possible scores), sensi-
tivity to change (the size effect) 
and the minimal important dif-
ference. Other characteristic that 
must keep into consideration is 
the cultural adaptation since each 
questionnaire must be adapted 
and validated for use in different 
cultures and/or countries and for 
different age groups of patients.
HRQOL questionnaires in AR in-
clude dimensions (or domains) 
related to the disease such as 
nasal and non-nasal symptoms, 
activities of daily life, practical 
problems, energy/vitality, envi-
ronmental aspects, sleep prob-
lems and mood. In general, they 
include around 25 to 30 domains, 
but some questionnaires have the 
so call “short version” including 12 
to 15 domains (Table 3).
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last decades that have significantly contributed to improve 
diagnosis of allergic diseases
• The identification of the clinically relevant allergenic molecules 
is nowadays possible by combining biotechnological procedures 
(i.e. phage display, proteomic tools, mass spectrometry, etc.) 
with bioinformatics and databases
• The availability of well-defined purified allergens produced as 
recombinant proteins or directly obtained from the allergenic 
sources, has facilitated the implementation of the allergen-
based concept of component-resolved diagnosis (CRD)
• Biotechnology contributed to the elucidation of individual 
sensitization patterns and the identification of patients suffering 
from local allergic rhinitis (AR) without systemic atopy, which 
constitute major goals achieved in diagnosis of AR
 “Biotechnology is the use of living 
systems and organisms to develop 
or make useful products, or any 
technological application that uses 
biological systems, living organisms 
or derivatives thereof, to make or 
modify products or processes for 
specific use” (UN Convention on 
Biological Diversity, Art. 2). Bio-
technology and the diagnosis of al-
lergic rhinitis (AR) are closely linked 
via the most prominent clinical pa-
rameter in AR, specific IgE (sIgE) 
Specific IgE and thus the allergen 
sensitization profile of the patient 
is the key parameter for the diag-
nosis of AR and allergic diseases in 
general. The first read-out in daily 
practice is a positive skin-prick test 
for aeroallergens, followed by in 
depth determination of the sen-
sitization pattern in terms of sIgE 
in serum, locally in nasal biopsies, 
or bound on effector cells. A high 
sensitivity, specificity, reproduci-
bility and thus a high reliability of 
diagnostic tests for sIgE depends 
on the identification and availabili-
ty of the relevant allergens.
The most straightforward ap-
proach is the collection of the al-
lergenic sources, or parts of it, or 
the cultivation of the allergenic 
organisms to subsequently extract 
the allergenic molecules for diag-
BIOTECHNOLOGY FOR THE 
DIAGNOSIS OF ALLERGIC 
RHINITIS
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Biotechnology for the diagnosis of allergic rhinitis
nostic purposes. These already 
constitutes by definition biotech-
nological processes. The main pit-
falls here encompasses the notori-
ous difficulties in standardization 
of extracts and the possible under 
representation of important aller-
genic molecules in them, which 
might lead to false positive and 
negative results, thus hampering 
proper diagnosis of AR.
The incredible progress expe-
rienced by biotechnology over 
the last decades has significantly 
contributed to overcome some 
of these problems. First of all, bi-
otechnological processes such as 
phage surface display of comple-
mentary DNA libraries, selections 
by yeast two hybrid systems or the 
use of proteomics tools together 
with bioinformatics and databas-
es have significantly improved the 
identification of relevant aller-
gens (Figure 1). These identified 
molecules, usually proteins, are 
generated and/or modified using 
molecular biology techniques like 
polymerase-chain reaction (PCR), 
site directed mutagenesis or de 
novo gene synthesis and used to 
clone and express large amounts 
Oscar Palomares  
Complutense University of Madrid 
Spain
Claudio Rhyner  
Swiss Institute of Allergy and Asthma 
Research, Davos, Switzerland
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of allergens in heterologous hosts 
and to purify them to homogeneity 
using chromatographic and/or oth-
er biochemical methods and tech-
niques. Alternatively, if these al-
lergens are contained in sufficient 
amount, they can also be directly 
purified to homogeneity from the 
allergenic source (Figure 2).
The endpoint of this process is the 
availability of well characterized di-
agnostic agents fulfilling the needs 
of clinical practice to diagnose and 
distinguish AR from NAR, as well 
as the relevant regulations for the 
diagnostic industry (e.g ISO 13485, 
23640). The use of purified natural 
and recombinant allergens for the 
diagnosis of AR has established 
the new allergen-based concept 
of component resolved diagnosis 
(CRD). The CRD together with the 
other above described advances in 
biotechnology has certainly con-
tributed to improve the diagnosis 
of AR, for example, with the iden-
tification of patients with local al-
lergic rhinitis suffering from local 
nasal allergic responses without 
systemic atopy.
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Biotechnology for the diagnosis of allergic rhinitis
Figure 1 Different methodologies can be used for the identification of IgE binding molecules, either isolated or in 
iterative interplay. Technologies like the display of cDNA libraries derived from allergenic organisms on the surface 
of bacteriophage and selection of binders on immobilized IgE from allergic patients led to identification of a plethora 
of novel allergens. Recent progress in the resolution of mass spectrometry facilitated the identification of IgE binding 
proteins. This approach is strongly depended on the availability of large protein databases. In addition, in silico discovery 
of allergens by rational examination of structures and primary sequences by expert systems and pattern recognition 
facilitated the discovery of novel allergens.
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Figure 2 The production of pure allergens is mainly pursued by two approaches: a) the coding sequence of the allergen 
is amplified by PCR, cloned in a suitable vector for expression in heterologous hosts and sometimes supplemented with 
a polypeptide tag for purification. Commonly used hosts for the production include e.g. Escherichia coli, Pichia pastoris 
and mammalian cell lines. Allergens from natural sources are collected either from the whole organism or dedicated parts 
of it e.g. pollen or fruits. In both cases the proteins of interest are extracted with biochemical methods and purified using 
chromatography (affinity, SEC, IEX etc.). A very important aspect after the preparation of allergens or allergen extracts is 
the verification and determination of the biological relevance by serology and/or in vivo tests.
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t • Ideally, allergic rhinitis (AR) treatment should restore and enable 
the patient to achieve normal social function, olfaction, taste, 
and restful and peaceful sleep
• Controlling AR is of paramount importance for quality of life issues 
and to decrease the severity of co-morbidities associated with AR
• The rationale and methods to treat AR are much the same today 
as they were 40 to 50 years ago, however, today, treatment is 
more scientifically based and effective and associated with less 
side effects
• Elimination of an offending allergen from a patient’s environment 
is an effective method to control symptoms of AR
• Second generation antihistamines are not only effective to 
control the symptoms of AR, but are mostly devoid of major 
side effects. Topical (intranasal) glucocorticosteroids are 
perhaps one of the most effective modes of therapy since they 
control nasal congestion, one of the most difficult symptoms 
associated with AR to resolve
• Properly prescribed subcutaneous or sublingual allergen 
immunotherapy (AIT) is another cost -effective treatment for AR
Ambient air, as it enters the nose, 
whatever its temperature and 
humidity, is warmed and humidi-
fied almost to body temperature 
by the time it reaches the laryn-
gopharynx. Likewise, a normal 
anatomy and intact and normally 
functioning mucosal and muco-
cilliary transport system results in 
filtration of most particles greater 
than 4.5 microns. Allergic rhinitis 
(AR) disrupts the normal function 
of the upper airway causing con-
siderable disability, comorbidities, 
and loss of quality-of-life (QoL).
GOALS OF TREATMENT
The primary goal of a physician or 
other healthcare professional di-
agnosing and treating any upper 
airway disease is to restore nor-
mal function to the upper airway. 
To do so, an understanding of nor-
mal anatomy, physiology, local and 
systemic defense systems, and 
various diseases which affect the 
upper airway (Figure 1) is of par-
amount importance. For example, 
nasal obstruction not only occurs 
from nasal mucosal edema associ-
ated with AR, but also, to mention 
a few, from a severely deviated na-
sal septum, nasal polyposis (NP), 
various medications and large ad-
enoids and tonsils. Likewise, other 
symptoms of AR such as sneezing, 
TREATMENT OF ALLERGIC 
RHINITIS - OVERVIEW1
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itching, and rhinorrhea can be as-
sociated with a variety of different 
upper airway diseases, such as lar-
yngopharyngeal esophageal reflux 
disease, non-allergic rhinitis, and 
acute and chronic rhinosinusitis.
Thus, restoring normal nasal phys-
iologic function, in other words 
patency of the upper airway and 
resolution of excessive rhinorrhea 
and irritation of the nose mani-
fested by sneezing and nasal pru-
ritus is the primary goal of treating 
AR. Ideally, AR treatment should 
restore and enable the patient to 
achieve normal social function, 
olfaction, taste, and restful and 
peaceful sleep.
Controlling AR is of paramount 
importance for QoL issues and to 
decrease the severity of co-mor-
bidities associated with AR. A de-
creased QoL associated with AR 
is often greater than with many 
Treatment of allergic rhinitis - overview
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Treatment of allergic rhinitis - overview
other diseases, including asthma. 
This is not only because of the 
symptoms primarily associated 
with AR rhinitis but also because 
of associated symptoms such as 
post-nasal drip, red, itchy, watery 
eyes, headaches, facial discom-
fort, and ear discomfort (Figure 2). 
Mostly, AR patients feel tired, ir-
ritable, and sometimes depressed, 
not to mention the fact that they 
are often embarrassed because of 
symptoms associated with their 
malfunctioning upper airway (Fig-
ure 3). Co-morbidities of AR in-
clude asthma, atopic dermatitis 
(AD), allergic conjunctivitis, acute 
rhinosinusitis, chronic rhinosinus-
itis with/without nasal polyps, 
frequent upper respiratory tract 
infections, otitis media and oth-
ers. Secondary problems can re-
sult, for example sleep disorders, 
learning disabilities, and dental 
malocclusion (Table 1). In addition 
the financial burden is a consider-
able problem as measured by the 
direct and indirect costs derived 
from absenteeism from work and 
school, as well as from decreased 
productivity.
RATIONALE AND METHODS TO 
TREAT
Treatment of AR is more scientif-
ically based and effective than it 
has been in the past.
For example, elimination of an of-
fending allergen from a patient’s 
environment al-
ways has been an 
effective method 
to control symp-
toms of AR. How-
ever, today, there 
is a better rationale 
and more knowl-
edge about how 
to eliminate one 
allergen versus 
another and the 
time it takes to do 
so. It is now rec-
ognized that dif-
ferent dust mites 
affect different 
geographic popu-
lations throughout the world and 
that it takes up to five to six months 
to eliminate pet dander from the 
home. Cockroach allergens may af-
fect those who live in the inner city.
Second generation antihistamines 
are not more effective to control 
the symptoms of AR than first gen-
eration antihistamines, but they are 
Figure 1 The complexity of the upper airways – the lateral nasal wall.
TABLE 1
Comorbidities of Allergic Rhinitis
Primary Secondary
Allergic asthma
Atopic dermatitis
Allergic conjunctivitis
Acute and chronic sinusitis
Nasal polyps (rare)
Increased upper respiratory 
tract viral infections
Otitis media
Food allergy
Sleep apnea
Dental malocclusion
Occupational rhinitis
Sleep deprivation
Social dysfunction
Decreased productivity
Absenteeism
Increased fatigability
Learning impairment
Attention deficit
Snoring
Depression
Irritability
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mostly devoid of major side effects. 
Topical (intranasal) glucocorticos-
teroids are one of the most effec-
tive modes of therapy for the ma-
jority of symptoms of AR. Intranasal 
dexamethasone was used over 40 
to 50 years ago, however, today, in-
halational corticosteroids, appropri-
ately prescribed, are equally effec-
tive to dexamethasone and devoid 
of short- and long-term side effects. 
New to the repertoire of treatments 
available is a combined glucocorti-
costeroid - antihistamine for intra-
nasal use, with superior effects than 
each molecule in isolation. Topical 
ipratropium bromide, is an excellent 
medication to control rhinorrhea 
and is mostly devoid of significant 
side effects. Other treatment mo-
dalities, including improved meth-
ods to administer intranasal saline, 
leukotriene inhibitors and blockers, 
as well as oral sympathomimetics 
can be of benefit to certain patients.
Sophisticated newer treatments, 
such as the use of monoclonal an-
tibodies, may  also benefit AR 
patients but will only be useful if 
costs are reduced.
Another treatment strategy is to 
induce tolerance to the allergens 
by allergen-specific subcutaneous 
or sublingual allergen immuno-
therapy (AIT). The aim of AIT is to 
induce tolerance to the allergens, 
with resolution of allergen-induced 
inflammation and symptoms.
CONCLUSION
In summary, appropriate treat-
ment of AR is of paramount im-
portance for the patient who suf-
fers from this disease. The primary 
goal for any physician is to restore 
normal upper airway function and 
thereby control or prevent comor-
bidities and assure a normal qual-
ity-of-life. There is an old cliché 
which states “As goes the nose, 
so goes the chest”; if you appro-
priately treat AR, asthma is more 
easily controlled.
Figure 2 Allergies in America. A telephone survey conducted in 2500 adults with allergic rhinitis. Healthstar 
Communications, Inc., in partnership with Shulman, Ronca and Bucuvalas, Inc. Allergies in America: A landmark survey 
on nasal allergy sufferers. Executive summary. Florham Park, NJ: Altana Pharma US, Inc., 2006.
Treatment of allergic rhinitis - overview
189
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 E - A
llergic rhiniti
s - treatm
ent
KEY REFERENCES
1. Theodoropoulos DS, Ledford DK, 
Lockey RF, Pecoraro DL, Rodriguez 
JA, Johnson MC. Prevalence of up-
per respiratory symptoms in patients 
with symptomatic gastroesophageal 
reflux disease. Am J Respir Crit Care 
Med 2001;164:72-76.
2. Allergies in America. A telephone 
survey conducted in 2500 adults 
with allergic rhinitis. Healthstar 
Communications, Inc., in partner-
ship with Shulman, Ronca and Bu-
cuvalas, Inc. Allergies in America: 
A landmark survey on nasal aller-
gy sufferers. Executive summary. 
Florham Park, NJ: Altana Pharma 
US, Inc., 2006.
3. Stuck BA, Czajkowski J, Hagner 
AE, Klimek L, Verse T, Hörmann 
K. Changes in daytime sleepiness, 
quality of life and objective sleep 
patterns in seasonal allergic rhinitis: 
A controlled clinical trial. J Allergy 
Clin Immunol 2004;113:663-668.
4. Lamb CE, Ratner PH, Johnson 
CE, Ambegaonkar AJ, Joshi AV, 
Day D. Economic impact of work-
place productivity losses due to 
allergic rhinitis compared with 
select medical conditions in the 
United States from an employ-
er’s perspective. Curr Med Res 
Opin 2006;22:1203-1210.
5. Norman PS, Cluff LE. Disorders 
Caused by Antigens and Other For-
eign Substances. In: Harrison TR, 
Adams RD, Bennett Jr IL, Resnik 
WH, Thorn GW, Wintrobe MM, 
editors. Principles of Internal Med-
icine. 5th Edition: McGraw-Hill 
Book Company, New York;1966. p. 
1451-1457.
6. Rael E, Ramey J, Lockey R. Oxym-
etazoline hydrochloride combined 
with mometasone nasal spray for 
persistent nasal congestion (pilot 
study). WAO Journal 2011;4:65-67.
7. Baroody FM, Brown D, Gavanes-
cu L, DeTineo M, Naclerio RM. 
Oxymetazoline adds to the effec-
tiveness of fluticasone furoate in 
the treatment of perennial aller-
gic rhinitis. J Allergy Clin Immu-
nol 2011;127:927-934.
Figure 3 Allergies in America. A telephone survey conducted in 2500 adults with allergic rhinitis. Healthstar 
Communications, Inc., in partnership with Shulman, Ronca and Bucuvalas, Inc. Allergies in America: A landmark survey 
on nasal allergy sufferers. Executive summary. Florham Park, NJ: Altana Pharma US, Inc., 2006.
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t • During season one cannot avoid exposure to pollen allergens
• Exposure to mite allergen can be lowered but total avoidance 
is impossible
• Allergens of cats and dogs are ubiquitous
• Hypoallergenic animals do not exist
One of the components of aller-
gy treatment is allergen avoid-
ance, with total allergen avoid-
ance leading to resolution of the 
allergen-driven inflammation and 
symptoms. Most environmental 
allergens are almost impossible 
to avoid, because they are either 
too prevalent or because it would 
seriously hamper professional or 
social life.
TREE, GRASS AND WEED 
POLLEN
Symptoms of pollen-induced AR 
occur upon exposure to pollen 
at the beginning of the season 
and disappear once the pollen 
season has finished. During the 
pollen season, total avoidance of 
exposure to pollen is hardly pos-
sible, unless patients emigrate to 
a country where the trees, grasses 
or weeds are not in bloom. Per-
sonal protection such as wearing 
sun glasses may reduce exposure 
in pollen allergic patients but most 
patients will be dependent on 
medication for symptom relief.
HOUSE DUST MITE
Dust mite allergen is present not 
only at home in beds, carpets and 
furniture but also in public spac-
es such as hospitals, public buses 
and cinemas (Figure 1). Total erad-
MANAGEMENT OF ALLERGIC 
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ication is impossible. Encasings 
for mattresses, pillows and duvets 
reduce the amount of mite aller-
gen but do not diminish symp-
toms. Special vacuum cleaners do 
contain the allergens but the user 
will be exposed to allergens while 
vacuum cleaning. Other measures 
such as washing on high temper-
atures kill house dust mites but 
do not prevent repossession of 
the fabric by the house dust mite. 
Essentially, the optimal situation 
at home will be a reduction of 
exposure by choosing non-fabric 
flooring and furniture, cleaning 
regularly and washing as much as 
possible at 55 degrees or higher. 
However, even if one manages to 
keep mite exposure at home to a 
minimum, exposure outside the 
home occurs and can evoke symp-
toms.
ANIMAL ALLERGENS
Animal allergens are to be found 
everywhere including the homes of 
people who themselves don't keep 
them. Exposure is also present in 
public transport and public places 
such as hospitals, buses, schools 
and pubs (Figure 1). Reducing al-
lergen production by washing the 
animal has in case of cats been 
shown ineffective. The so called 
hypoallergenic animals such as the 
Labradoodle have been proven a 
myth: research showed that this 
dog produces normal amounts of 
allergen and that the allergen can 
be found in dust samples of the 
homes of their owners (Figure 2). 
Allergy to animals can not only 
hamper social life, it can force pa-
tients to change jobs, for instance 
laboratory workers developing al-
lergies to rats or mice, with serious 
effects on income.
Management of allergic rhinitis – allergen avoidance
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Figure 1 Levels of Dermatophagoides pteronyssinus (Der p 1), Dermatophagoides farinae (Der f 1), and Felis domesticus (Fel 
d 1) allergens in public transport vehicles. Dust samples were collected from front, middle, and rear seats in 60 natural-
ventilation buses (A) and 60 artificial-ventilation buses (B) and from driver’s, passenger’s front, and passenger’s rear seats in 
60 taxis (C). Horizontal bars indicate geometric means (GMs); asterisks, P <.05; double asterisks, P <.01; and triple asterisks, 
P <.001. (Reprinted from Ann Allergy Asthma Immunol, 93/2, Pereira FL, Silva DA, Sopelete MC, Sung SS, Taketomi EA. Mite and 
cat allergen exposure in Brazilian public transport vehicles. 179-184, Copyright 2004, with permission from Elsevier.)
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• H1-antihistamines are inverse agonists which ‘turn off’ the H1-
receptor and prevent its activation by histamine
• In allergic rhinitis, H1-antihistamines are particularly effective 
in relieving histamine-mediated rhinorrhoea, itching, sneezing 
and vasodilation
• When used as monotherapy, H1-antihistamines should be 
administered continuously while symptoms are present
• First-generation oral H1-antihistamines, which readily diffuse 
into the brain, should not be used because of their detrimental 
central nervous system (CNS) effects. Second generation H1-
antihistamines have little or no CNS effects but somnolence 
may occur with some drugs in some cases
H1-antihistamines are inverse ag-
onists of the histamine H1-recep-
tor. The H1-receptor, like other 
G-protein coupled receptors, is 
essentially like an electric switch 
that is turned on by histamine 
and off by antihistamines. At the 
molecular level, the proportion of 
H1-histamine receptors that are 
in the ‘turned off’ configuration, 
which is never 100%, is depend-
ent on the local H1-antihistamine 
drug concentration.
To understand the potential role of 
H1-antihistamines in allergic rhini-
tis (1) it is necessary to recap the ef-
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fects of histamine in this condition. 
The initial event in AR is the inter-
action of allergen, with mast cell 
bound IgE. The histamine released 
in the resultant degranulation is 
primarily responsible for the ear-
ly phase symptoms. These symp-
toms, shown in green in Figure 1, 
are rhinorrhoea, itching, sneezing 
and vasodilation. Mast cell-derived 
cytokines initiate allergic inflam-
mation in which the influx and 
activation of eosinophils results 
in accentuation of local nerve re-
flexes to cause nasal blockage (red 
in Figure 1) and reflex mediated 
conjunctival symptoms. Consider-
ing these mechanisms, H1-antihis-
tamines are particularly effective 
against the histamine-mediated 
early phase symptoms of AR. All 
H1-antihistamines also have weak 
anti-inflammatory activity and so 
have some effect on nasal block-
age. However, this is slow in onset 
(weeks) and weak compared with 
nasal corticosteroids.
ARIA recommends avoidance of 
first-generation oral H1-antihista-
mines which readily diffuse into 
the brain. Histamine is an impor-
tant neurotransmitter in the brain 
where it increases arousal in the 
circadian sleep/wake cycle and 
reinforces learning and memo-
ry. These effects are blocked by 
first-generation H1-antihista-
mines, which also reduce the du-
Antihistamines in the treatment of allergic rhinitis
Martin K Church  
Charité Medical University 
Berlin, Germany
TABLE 1
Common H1-Antihistamines
1st Generation Antihistamines
Diphenhydramine
Chlorpheniramine
Hydroxyzine
2nd Generation Antihistamines
Cetirizie
Loratadine
Fexofenadine
Desloratadine
Levocetirizine
Rupatadine
Bilastine
Topical Antihistamines
Azelastine
Olopatadine
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ration of REM sleep when taken 
at night (Figure 2). Furthermore, 
the long half-lives of drugs such 
as diphenhydramine, chlorphe-
niramine and hydroxyzine, ≈24 
hours, mean that these effects are 
still present next morning leading 
to daytime somnolence, increased 
traffic accidents, decreased pro-
ductivity at work and reduced 
children’s learning. Second-gener-
ation H1-antihistamines are large-
ly devoid of these effects.
H1-antihistamines may be adminis-
tered either orally or topically. Giv-
en orally, their onset of action is in 
1–4 hours and once a day dosage 
is usually sufficient. Most second 
generation H1-antihistamines have 
little or no central nervous system 
effects but somnolence may occur 
with some drugs in some patients. 
Intranasal antihistamines have the 
advantage of rarely causing system-
ic effects but have the disadvantag-
es of twice-daily dosage and being 
less convenient than tablets. Used 
as monotherapy, H1-antihistamines 
should be administered continu-
ously while symptoms are present. 
Alternatively, the may be used in-
termittently for symptom exacer-
bations in individuals being treated 
with intranasal corticosteroids.
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Figure 1 Diagrammatic representation of the symptoms of allergic rhinitis 
showing mucus secretion, sensory nerve activation and vasodilatation. In and 
close to the post-venular capillary below the mucous gland, inflammatory 
leukocytes, particularly eosinophils are accumulating to initiate allergic 
inflammation. On the right is a list of the main symptoms of allergic rhinitis. 
Those in green, alongside the figure of a mast cell, are primarily histamine-
induced and particularly sensitive to blockade by H1-antihistamines. Nasal 
blockage, in red alongside the figure of an eosinophil, is not histamine-
mediated and is only weakly blocked by H1-antihistamines.
Symptoms of Allergic Rhinitis
- venous congestion
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Figure 2 Diagrammatic representation of the effect of first-generation H1-
antihistamines on the electrical activity of the brain. There are approximately 
64,000 histamine-producing neurones, located in the tuberomamillary nucleus 
of the human brain that influence arousal in the circadian sleep/ wake cycle. 
Blockade of this system results in delayed and reduced rapid eye movement (2) 
sleep and subsequent daytime somnolence
Antihistamines in the treatment of allergic rhinitis
and its Impact on Asthma (ARIA) 
guidelines: 2010 revision. J Allergy 
Clin Immunol 2010;126:466-476.
5. Church MK, Maurer M, Simons FE, 
Bindslev-Jensen C, van Cauwen-
berge P, Bousquet J, et al. Risk of 
first-generation H(1)-antihista-
mines: a GA(2)LEN position pa-
per. Allergy 2010; 65:459-466.
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• Intranasal steroids (INS) are the most effective medication class 
in controlling the symptoms of allergic rhinitis (AR)
• INS may provide significant relief of symptoms of intermittent 
or persistent AR
• The overall clinical response does not appear to vary significantly 
between available INS, irrespective of the differences in topical 
potency, lipid solubility, and binding affinity
• When given in recommended doses INS are not associated 
with clinically significant systemic side effects
The main mechanism by which in-
tranasal steroids (INS) relieve the 
symptoms of allergic rhinitis (AR) 
is through their anti-inflammatory 
activity, although it is possible that 
they may exert an effect through 
other non genomic mechanisms. 
The rationale for using INS in the 
treatment of AR is that high drug 
concentrations can be achieved at 
receptor sites in the nasal mucosa 
with a minimal risk of systemic ad-
verse effects.
INS are effective in controlling all 
the four major symptoms of AR: 
sneezing, itching, rhinorrhea and 
especially nasal congestion. They 
also control the ocular symptoms 
of rhinoconjunctivitis.
Meta-analyses confirmed that INS 
are the most effective therapeutic 
agents for AR (Table 1). INS are su-
perior or equal to the combination 
of an antihistamine and an antileu-
kotriene. ARIA Guidelines 2010 
recommend INS for treatment of 
AR in adults (strong recommen-
dation | high quality evidence) 
and suggest INS in children with 
AR (conditional recommendation 
| moderate quality evidence). This 
recommendation places a relative-
ly high value on the efficacy of INS, 
and a relatively low value on avoid-
ing their possible adverse effects.
TREATMENT OF ALLERGIC 
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Due to their mechanism of action, 
efficacy appears after 7–8 h of 
dosing, but maximum efficacy may 
require up to 2 weeks. However, 
some patients benefit within the 
first 2 hours.
The general characteristics of 
the formulations of INS and rec-
ommended doses in children and 
adults are shown in Table 2.
Systematic reviews compared INS 
to other active treatments and re-
ported a low incidence of adverse 
effects. Epistaxis, headache, ab-
normal taste, and pharyngitis were 
the most frequently reported side 
effects. None of the short-term 
treatment studies analyzed in the 
reviews reported systemic side ef-
fects from INS, although there has 
been concern that their prolonged 
use may be associated with sys-
temic adverse effects including 
suppression of the hypothalam-
ic-pituitary-adrenal axis and sup-
pression of growth in children. 
Recently, it has been shown that 
fluticasone furoate administered 
over 52 weeks in prepubescent 
children resulted in a small reduc-
tion in growth velocity compared 
with placebo.
Patient education on the proper 
administration technique is very 
important since the incorrect use 
leads to treatment failure or ad-
verse events such as epistaxis (in 
10-15% of patients).
Treatment of allergic rhinitis – nasal steroids
Hugo Neffen  
Children Hospital “Orlando Alassia” 
Santa Fe, Argentina
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TABLE 1
Benefits and harms of treatments for allergic rhinitis
Benefit NNT Harm NNH
Antihistamine
Class mean 0.07 15.2 0.02 51
Nasal corticosteroid spray
Class mean 0.23 4.4 0.02 48
Nasal antihistamines
Azelastine (daily) 0.16 6.3 0.03 32
Azelastine (twice daily) 0.20 5.0 0.05 22
Other
Montelukast 0.07 14.3 0.01 167
Omalizumab 0.08 12.3 0.08 13
Immunotherapy 0.22 4.6 0.07 14
NNT=number needed to treat to make one person better. NNH=number needed 
to harm to make one adverse event arise. A high number in the benefit section 
indicates a great benefit. A high number in the harm section indicates the most 
harm. The major adverse events were epistaxis for nasal steroids and sedation for 
antihistamines.
Data from Greiner A, Hellings P, Rotiroti G, Scadding G. Allergic rhinitis. Lan-
cet 2011;378:2112–2122.
TABLE 2
General characteristics of the formulations of intranasal steroids, age from which they can be used in allergic rhinitis, 
and corresponding dosages for children and adults.
Name Formulation Minimum age Dose per spray 
mcg*/nostril
Maximum dose/
children mcg/day
Dose/adults 
mcg/day
Triamcinolone acetonide Isotonic 4 years 55 110 220
Budesonide Isotonic 6 years 32, 50, 64, 100 100 200
Ciclesonide Hypotonic 6 years 50 100 200
Beclomethasone 
dipropionate Isotonic 6 years 50 100 200
Mometasone furoate Isotonic 2 years 50 100 200
Fluticasone propionate Isotonic 2 years 50 100 200
Fluticasone furoate Isotonic 4 years 27.5 52.5 105
*mcg micrograms. Source: Medication inserts.
Modified from Mello Jr JF, Mion Ode G, Andrade NA, Anselmo-Lima WT, Stamm AE, Almeida WL, et al. Brazilian Academy of 
Rhinology position paper on topical intranasal therapy. Braz J Otorhinolaryngol 2013;79:391-400.
Rhinitis. J Allergy Clin Immunol 
Pract 2014;2:421-427.
6. Brozek JL, Bousquet J, Baena-Cag-
nani CE, Bonini S, Canonica GW, 
Casale TB, et al. Allergic Rhinitis 
and its Impact on Asthma (ARIA) 
guidelines: 2010 revision. J Allergy 
Clin Immunol 2010;126:466-476.
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• Cysteinyl leukotrienes are released during early and late allergic 
inflammation of the nasal mucosa from mast cells and eosinophils
• Many nasal symptoms of oedema, congestion, secretion and 
infiltration are mediated by the activation of CYSLT1 receptor 
but other receptors to cysteinyl leukotrienes are postulated
• Currently, only CYSLT1 receptor antagonist are recommended 
as add-on therapy of allergic rhinitis (AR); montelukast is the 
best studied one and its efficacy seems better for moderate to 
severe persistent disease
• Novel inhibitors of 5-lipoxygenase or its activating protein 
(FLAP) are under development which may improve benefits of 
antileukotriene therapy in AR
Cysteinyl leukotrienes (CysLTs) 
were discovered as potent media-
tors in asthma but participate also 
in the early and late allergic allergic 
inflammation of the nasal mucosa 
(Figure 1). This family of oxylip-
ins produced by 5-lipoxygenation 
(5-LO) of arachidonic acid include 
peptide derivatives (LTC4, LTD4 
and LTE4) and the chemoattractant 
LTB4 (Figure 2). CysLTs are synthe-
sized by activated mast cells and 
eosinophils. However, a transcel-
lular synthesis is also possible by 
neutrophils releasing the unstable 
intermediate LTA4 and by neutro-
phil-adhered platelets expressing 
leukotriene C4 synthase. CysLTs are 
pro-inflammatory mediators lead-
ing to increased vascular permea-
bility and oedema of nasal mucosa, 
mucus secretion, and chemoat-
traction of eosinophils and lym-
phocytes T. CysLTs also constrict 
the bronchial tree and augment 
airway hyperreactivity and remod-
elling. Many respiratory symptoms 
elicited by CysLTs are mediated by 
the activation of type-1 receptor 
(CysLT1R), although the presence 
of other receptors for CysLT in the 
respiratory system has been postu-
lated.
Two classes of leukotriene modi-
fying drugs are currently available 
ANTILEUKOTRIENES IN THE 
TREATMENT OF ALLERGIC 
RHINITIS
5
KE Y MESSAGES
(Figure 2). 5-lipoxygenase inhibitor 
zileuton prevents LTA4 production, 
whereas antagonists of CysLTR1 
(zafirlukast, pranlukast and mon-
telukast) abates CysLTs signalling 
by CysLT1R (Table 1). Inhibition 
of 5-lipoxygenase was found ben-
eficial in AR as early as in 1990, 
however, randomized control tri-
als (RCTs) were published only 
on montelukast. A comprehen-
sive review described a decrease 
in daytime nasal symptoms in AR 
patients treated with montelukast 
versus placebo in 5 out of 6 RCTs. 
In addition, combined therapy 
with montelukast and lorata-
dine or with topical steroids also 
showed improvement of daytime 
AR symptoms. Beneficial effects 
were experienced both by pa-
tients with seasonal and perennial 
AR. The 6th RCT included in the 
analysis, comparing montelukast 
as add-on to intranasal fluticasone 
propionate monotherapy, failed to 
show advantages in patients with 
intermittent AR during 6 weeks of 
treatment. Currently, montelukast 
is recommended in moderate to 
severe AR as a combination with 
intranasal corticosteroids and/
or oral antihistamines. The indi-
cation is supported by a recent 
RCT on subjects sensitized to 
perennial mites allergen showing 
benefits of add-on montelukast 
over nasal fluticasone propionate 
Antileukotrienes in the treatment of allergic rhinitis
Marek Sanak  
Jagiellonian University Medical College 
Krakow, Poland
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Figure 2 Arachidonic acid is released from cell membranes by calcium-dependent cytosolic phospholipases and 
transported by FLAP to 5-lipoxygenase present at nuclear envelope. Only some myeloid cells are capable to release high 
amounts of CysLTs due to expression of leukotriene C4 synthase. Many nasal symptoms are mediated by the activation of 
CYSLT1R, including the autocrine activation of mast cells. Novel inhibitors of FLAP (1: licofelone, veliflapon), 5-lipoxygenase 
(2: atreleuton, setileuton, flavocoxid), LTC4 synthase (3: TK04) are under development in addition to CYSLT1R antagonists.
Figure 1 Exposure to aeroallergens 
perpetuates allergic inflammation by 
continuous production of specific IgE, 
degranulation of mucosal mast cells 
(early phase) and release of chemical 
mediators (chemokines, CysLTs) by 
activated mast cells, eosinophils and 
lymphocytes-T. Since CysLTs act in 
concert with other cytokines, no 
significant impact on AR is expected 
using antileukotrienes monotherapy.
Antileukotrienes in the treatment of allergic rhinitis
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Antileukotrienes in the treatment of allergic rhinitis
monotherapy, measured not only 
as a decrease in symptoms score 
but also as an improvement in 
the Rhinoconjunctivitis Quality 
of Life Questionnaire and lorata-
dine rescue self-administration. 
In addition eye symptoms and 
night-symptoms improved, with 
the greatest effect by the end of 
the two-months trial.
In summary, selective targeting of 
the CysLTs pathway is not expect-
ed to bring spectacular improve-
ment in AR. However, addition of 
a CysLT1R antagonist is effective 
in moderate/severe persistent AR 
following regular treatment during 
at least two months. The inhibition 
of 5-LO or 5-LO activating protein 
(FLAP) might potentiate the effects 
of antileukotriene therapy of AR, 
however, drugs with a satisfacto-
ry pharmacokinetics are still under 
development (Figure 2, Table 2).
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TABLE 1
Antileukotriene drugs currently available on the market
Name Mechanism of action Indications Age limit Administration Adverse effects
Zileuton (Zyflo) 15-LO inhibitor asthma adults
b.i.d  (extended 
release version) 
or q.i.d
dyspepsia (8.2%), 
transaminases eleva-
tion (1.9%)
Montelukast (Singu-
lair, Pluralair, Monte-
carlo, Lovetas)
CysLT1 antagonist asthma, rhinitis
adults and children 
from 6 months on q.d not observed
Pranlukast (Onon, 
Azlaire) CysLT1 antagonist
asthma, 
rhinitis
adults and children 
from 1 year on b.i.d not observed
Zafirlukast (Accolate) CysLT1 antagonist asthma, rhinitis
adults children 
from 5 years on b.i.d
not observed (hepa-
toxicity single reports)
Abbreviations: bid = twice per day, qd = once daily; qid = four times per day; LO = lipoxygenase; LT = leukotrienes
TABLE 2
Novel antileukotriene drugs under investigation in clinical trials
Name Action Indications Develop-
ment stage
Adverse effects
Veliflapon FLAP inhibitor myocardial infarc-tion, stroke
phase III 
suspended
serum LDL, cre-
atinine elevations
Licofelone FLAP inhibitor/COX inhibitor osteoarthritis phase III not observed
GSK2190915 FLAP inhibitor asthma phase II not observed
Atreleuton 15-LO inhibitor atheromatosis, car-diovascular disease phase II not observed
Setileuton 15-LO inhibitor asthma, COPD, car-diovascular disease phase II
transaminases 
elevation
Flavocoxid 
(pharmaceutical 
plant flavonoid)
15-LO in-
hibitor/COX 
inhibitor
arthritis phase II hepatotoxicity
TH04 LTC4 synthase inhibitor preclinical preclinical unknown
Abbreviations: COX = cyclooxygenase; FLAP = 5-lipoxygenase activating protein
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t • Due to inadequate response to regular medical treatment, up to 
20 percent of allergic rhinitis (AR) patients may need additional 
medical treatment to control their symptoms
• In AR with persistent nasal obstruction despite topical steroids, 
a short course of nasal decongestants or oral steroids may be 
recommended
• In patients with persisting rhinorrhea, add-on topical 
anticholinergics are the treatment of choice
• Nasal cromones may be an alternative choice in small children 
and in pregnancy, where adherence to standard treatment is 
questionable
Allergic rhinitis (AR) is not well 
controlled in up to 20% of the 
patients despite adequate med-
ical treatment. Lack of control is 
commonly related to the poor ad-
herence to treatment, however, 
non-specific nasal hyperreactivity, 
upper airways comorbidities and 
insufficient control of environ-
mental/endogenous factors may 
also play a role.
In uncontrolled patients addition-
al drug treatment options, aiming 
to improve control of remaining 
symptoms include oral and nasal 
decongestants, nasal anticholiner-
gics, cromones and systemic ster-
oids (Figure 1 and Table 1).
Nasal and oral decongestants 
markedly improve nasal obstruc-
tion, however, due to mainly local 
adverse effects, treatment with 
decongestants is limited to a very 
short course treatment.
Topical mast cell stabilizers, like cro-
mones, have been proven higher 
efficacy for the treatment of ocular 
rather than nasal symptoms. Topical 
nasal cromones can safely be pres-
ribed to small children and in preg-
nancy, however, due to low efficacy 
compared to topical and oral H1 
antihistamines, they are not strong-
ly recommended as the first line 
treatment of AR. Cromones taken 
ADDITIONAL DRUG 
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several hours prior to to allergen 
exposure may prevent symptoms 
of the early phase reaction. As they 
should be taken 4 times daily, ad-
herence to cromones is poor.
Nasal anticholinergics, like iprat-
ropium bromide, has proven effi-
cacy in the control of rhinorrhea, 
however, as it is the only symp-
tom which is significantly reduced 
compared to placebo, topical an-
ticholinergics are considered as an 
additional treatment when control 
of rhinorrhea is not achieved by 
maximal standard treatment with 
the combination of topical ster-
oids and H1 antihistamines.
Systemic steroid treatment in pa-
tients unresponsive to maximal 
standard medical treatment is lim-
ited to a short course of oral corti-
costeroids, and avoidance of intra-
muscular administration is strongly 
recommended due to risk of local 
and systemic side effects. The ad-
verse events of a short course of 
oral steroids is acceptable in most 
of uncontrolled patients. Its effica-
cy was not adequately evaluated in 
high quality trials. Major improve-
ment after oral steroid treatment 
are the reduction of nasal obstruc-
tion and smell improvement in 
patients unresponsive to topical 
steroids, including those who have 
been on prolonged treatment with 
decongestants.
In patients with uncontrolled AR 
despite adherence to nasal steroids, 
Additional drug treatment options for allergic rhinitis
Livije Kalogjera  
University of Zagreb 
Zagreb, Croatia
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Additional drug treatment options for allergic rhinitis
a short course of nasal/oral decon-
gestants followed by short course 
of oral steroids may be prescribed. 
In patients with persisting rhinor-
rhea, added topical anticholinergics 
are the treatment of choice. Nasal 
cromones may be an alternative 
choice in small children and in preg-
nancy, where adherence to stand-
ard treatment is questionable (Fig-
ure 1 and Table 1).
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Allergic rhini s
VAS ≥ 5 for TNS
Or NEED of treatment
Controlled AR Uncontrolled AR
VAS < 5
First-line treatment for 2–4 weeks
Avoid irritants and allergens if possible
VAS ≥ 5
Con nue treatment as needed
Consider I.T.
Uncontrolled ARControlled AR
Second-line treatment for 2–4 weeks
Avoid irritants and allergens if possible
Consider I.T.
VAS ≥ 5VAS < 5
Con nue treatment as needed
Consider I.T.
RECONSIDER DIAGNOSIS
EXCLUDE CONCOMITANT PATHOLOGY
Consider I.T.
Consider surgery
Figure 1 Modified treatment algorithm 
for allergic rhinitis to achieve disease 
control. Drugs mentioned in this chapter 
may be considered as the second line 
treatment. (Reproduced with permission 
from Hellings PW, Fokkens WJ, Akdis 
C, et al. Uncontrolled allergic rhinitis 
and chronic rhinosinusitis: where do we 
stand today?. Allergy, 2013;68:1-7, with 
permission from Willey Blackwell.)
TABLE 1
Efficacy and safety of additional treatments in allergic rhinitis. Safety is estimated in 
terms of short-term treatment
congestion rhinorrhea sneezing nasal itch ocular itch safety
nasal decongestant ++ 0 0 0 0 +
oral decongestant ++ 0 0 0 0 +
nasal cromone + + + + + +++
ocular cromone 0 0 0 0 + +++
nasal anticholinergic + +++ 0 0 0 ++
oral steroid +++ +++ +++ ++ ++ +
Efficacy of different drugs is adapted according to the ARIA 2001 recommendations.
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popularity and may be applied alone or complementarily
• Apart from isotonic and hypertonic nasal sprays, which are 
already widely used, alternative methods, such as thermal 
water applications, endonasal phototherapy or acupuncture 
are available and have been investigated in clinical trials
• Although the exact mechanism of action is not yet fully 
understood, clinical evidence assigns similar efficacy to 
nonpharmacological treatments compared to traditional agents 
with hardly any side effects
Giving credit to a worldwide grow-
ing acceptance of herbal products 
and simultaneously limited effica-
cy of conservative pharmacolog-
ical agents, nonpharmacological 
treatment options – alone or com-
plementary – have become popu-
lar and widely investigated in clini-
cal trials in allergic rhinitis (AR).
While isotonic and hypertonic na-
sal sprays, based on a great varie-
ty of active agents such as lipos-
omes, ectoine, herbal compounds, 
cellulose, and vaseline are already 
widely used, alternative methods 
such as thermal water applica-
tions, endonasal phototherapy or 
even acupuncture are also gain-
ing more importance. The mech-
anisms of action are of different 
nature (Figures 1 and 2). Nasal 
sprays and nasal irrigations un-
fold their effect by implementing 
by creating a hydrofilm as a me-
chanical barrier. They thus aim to 
strengthen resistance to airborn 
allergens and iritants.
Saline nasal irrigation belongs to 
those complementary non-phar-
macologic treatment options with 
a relieving effect on symptoms 
of the AR. A meta-analysis of 10 
studies investigated its’ effect as 
adjuvant therapy. Nasal symp-
toms were reduced by 27.66%, 
CONSERVATIVE NON-DRUG 
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while simultaneously less rescue 
medication (-62.1%) was applied 
and the patient’s quality of life 
was improved (+27.88%).
Likewise, in a meta-analysis, an 
ectoine-based nasal spray has 
been shown to reduce the severity 
for all relevant rhinitis symptoms 
to the same extent as traditional 
agents. Nasal obstruction, rhinor-
rhea, and itching eyes improved 
by 29.94%, 31.49%, and 33.49%.
Similarly, the nasal administration 
of liposomes was also compared 
with guideline-recommended 
therapeutic regimes in several 
small open-label trials. The liposo-
mal sprays showed good results in 
clinical tolerability as well as in re-
ducing typical rhinitis symptoms.
Thermal water irrigations and in-
halations offer a new additional 
approach in AR despite having a 
century-old tradition in Roman 
practices. A systematic review 
revealed that nasal flow, nasal re-
sistance and mucociliary clearing 
time were significantly improved 
using thermal water applications 
while only little side effects were 
documented.
A fairly new concept is an endona-
sal phototherapy with rhinolight, 
utilizing the immunosuppressive 
effects of UV radiation by direct-
ing UV-A, UV-B and visible light 
into the nasal cavity (Figure 3). Al-
though its effectiveness has been 
demonstrated in clinical studies, 
the risk of damaging the mucosa 
has not been assessed sufficiently.
Conservative non-drug treatment for allergic rhinitis
Mehregan Nematian-Samani  
Hospital Maria Hilf, 
Mönchengladbach, Germany
Andrea Eichel Ralph Mösges
 University of Cologne 
 Cologne, Germany
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In summary, compared to stand-
ard therapy, alternative therapies 
have shown efficacy with limited 
or no side effects. Nevertheless, 
the operating principles of new 
therapeutic approaches must be 
further explored and evaluated 
in the future. Comparing the effi-
cacy of alternative therapies with 
standard effective treatment is 
warranted.
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Isotonic nasal spray 
/ nasal douches
Ectoine
Liposome
Cellulose
Rhinolight
Thermal water
Acupuncture
Improvement of nasal mucosa
functioning
Stabilisation / Revocery of surfacant / 
Protection against pathogens
Prevention of allergen contact with
mucosa
Stimulation of cellular activity / Activation
of breathing and blood circulation / 
Reduction of inflammation
Prevention of inflammation of the lung / 
Reduction of the programmed celldeath / 
Stabilisation of membrane and proteins
Immunomodulatory effect
Immunosuppressive effects / local
and systemic immunomodulation
Induction of DNA damage
in the irradiated cells
Exact mechanism unknown
Preferential hydration due to
solvophobic effects / Increase
of the surface tension of water
Breaking of disulphild bonds
of the mucin / Reduction of
eosinophils
Integration into damaged
cell membranes
Moisturising, thinning
of mucus
Moisten the mucous
membrane / protective barrier
Figure 1 Mechanism of action for different non-pharmacological treatment agents.
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Lung
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Cell
membrane
Release of 
stress mediators
Water loss
Membrane 
damage
Increase of Hydration
Decrease of 
second 
messenger
release
stabilisation
Ectoin Hydro 
Complex
Water structure 
forming effect
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Water shell
Intracellular
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stabilisation
Figure 2 Protective and hydrating properties of ectoine. (From bitop AG-Extremolytes for Life, Ectoin – mode of action; 
reprinted with permission of bitop AG, Germany.)
Figure 3 Application of endonasal phototherapy 
with rhinolight® device. (From Rhinolight Ltd. rhinolight 
broschure – Clinically proven phototherapy of allergic 
rhinitis, p.3; reprinted with permission of Rhinolight Ltd., 
Hungary.)
Conservative non-drug treatment for allergic rhinitis
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• Allergen immunotherapy (AIT) is an immune-modulating 
therapy aiming at restoring normal immunity against allergens
• The balance between IL-4-secreting T helper 2 cells and IL-
10-secreting inducible T regulatory cells is central for the AIT-
induced long-term immune tolerance of allergens
• AIT is indicated for the treatment of moderate-to-severe 
intermittent or persistent allergic rhinitis (AR)
• AIT shows pharmacoeconomic advantages over other 
treatments for AR and plays a key role in the prevention of new 
sensitisations and asthma
MECHANISMS
Allergen immunotherapy (AIT), 
which represents the only spe-
cific approach to the treatment 
of allergic rhinitis (AR) provides a 
unique opportunity to specifically 
restore normal immunity against 
allergens and affect the long term 
course of AR. AIT triggers multi-
ple sequentially activated mech-
anisms, which work in concert 
leading to clinical events eliciting 
rapid desensitization to allergen, 
long-term allergen-specific im-
mune tolerance as well as the sup-
pression of allergic inflammation.
AIT induces a shift in the propor-
tion of IL-4-secreting T helper (Th) 
2 cells in favor of IL-10-secreting 
inducible T regulatory cells (iTreg) 
specific for the same allergenic 
epitope, which increase in number 
and function. Different types of 
iTreg control several facets of al-
lergic inflammation. They are com-
posed of FOXP3+ (Forkhead box 
protein 3) adaptive T regulatory 
(Treg) cells and FOXP3 negative, 
but IL-10-producing Tr1 cells. A 
significant correlation is found be-
tween improvement of symptoms 
and the increase in Treg cell num-
bers during AIT. Recently the B 
regulatory cells (B reg) character-
ized as CD73-CD25+CD71+ cells 
ALLERGEN IMMUNOTHERAPY 
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were found in increased numbers 
in subjects undergoing AIT. Breg 
cells regulate IgG4 versus IgE and 
induce allergen-specific antibod-
ies towards the non-anaphylactic 
and non-inflammatory type. The 
shift in isotype production cannot 
however, explain the therapeutic 
effect of AIT probably due to a 
very long IgE lifespan. iTregs sup-
press allergen-specific T cells in 
both their regulatory and effector 
functions. T cell suppression can 
take place both in the secondary 
lymphoid organs and in the affect-
ed tissues. iTreg are also capable 
of suppression of innate effec-
tor cells of allergic inflammation 
(mast cells, basophils) and induce 
decrease of eosinophils in the mu-
cosal tissues. The understanding 
of the AIT mechanisms helps in 
elaboration of early and late di-
agnostic biomarkers to select the 
best responders and to optimize 
the treatment.
INDICATIONS AND EFFICACY
AIT is indicated for the treatment 
of moderate-to-severe intermit-
tent or persistent symptoms of 
AR. Usually AIT is recommended 
in subjects over 5 years of age, 
however sublingual AIT is safe 
and effective even in children as 
young as 3 years of age. The rec-
ommended duration of AIT for AR 
is 3 years, both for the subcutane-
ous and the sublingual routes.
Significant improvement in na-
sal and ocular symptom scores, 
reduced need for symptomatic 
Allergen immunotherapy for allergic rhinitis - overview
Marek Jutel  
Wroclaw Medical University 
Wrocław, Poland
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medication and improved qual-
ity of life both during and after 
discontinuation of AIT has been 
consistently demonstrated in dou-
ble-blind placebo-controlled stud-
ies. The major advantage of AIT in 
the treatment of AR is the preven-
tion of asthma and the reduction 
of new sensitizations.
AIT should only be performed 
with standardized allergen ex-
tracts, which are currently availa-
ble for grass, tree, and weed (rag-
weed, mugwort) pollens; house 
dust mites; several mold species 
and animal dander. Pharmacoeco-
nomic studies demonstrated a 
clear advantage of AIT over phar-
macologic therapies.
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Figure 1 After the first administration of the AIT vaccine, there is an early decrease in mast cell and basophil 
degranulation. Treg cells are generated and there is suppression of allergen-specific Th2 cells and other effector cells. 
Suppression of IgE production, endothelial cell activation and Th2 cell homing to tissues, mucus production by the 
epithelium, and tissue migration, priming and survival of mast cells, eosinophils and basophils appears. IL-10 and TGF-β 
directly and indirectly regulate B cells and effector cells. A decrease in tissue mast cells and eosinophils and release of 
their mediators and decrease in late phase response is observed in the affected tissues (red arrows: suppression, black 
arrows: induction). AIT = allergen immunotherapy; IL= interleukin; TGF= transforming growth factor; Th= T helper cells; 
Treg = T regulatory cells
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Figure 2 AIT triggers multiple mechanisms, which are sequentially activated. These events lead to multifaceted clinical 
improvement. Rapid desensitization to allergen, long-term allergen-specific immune tolerance as well as the suppression 
of allergic inflammation appears. AIT – allergen immunotherapy; Breg = B regulatory cell; Th = T helper cell; T reg = T 
regulatory cell.
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seasonal and perennial allergic rhinitis
• Clinical effectiveness requires several years of treatment
• SCIT modifies the course of allergic disease, evidenced by 
reduced rates of new allergic sensitizations and prevention of 
progression from rhinitis to asthma
• The clinical effect of SCIT persists for years after it is 
discontinued
Allergic rhinitis (AR) is common 
and often poorly controlled by 
standard drug therapy. In subcu-
taneous allergen immunotherapy 
(SCIT) patients receive a course 
of injections of allergen extracts, 
which desensitize them, reduc-
ing symptoms and medication 
requirements. The dose is built 
up over 7-12 weekly injections; 
if maintenance injections are re-
quired these are given every 4-6 
weeks for about 3 years.
CLINICAL EFFICACY
The value of SCIT for seasonal AR 
has been confirmed in many ran-
domized placebo-controlled trials. 
Improvement is expected in about 
80% of patients; symptoms are re-
duced rather than abolished, with 
a marked reduction in the number 
of days with very bad symptoms 
compared to untreated or place-
bo-treated controls.
In patients with perennial AR, it 
can be difficult to work out how 
much of their symptoms are due 
to allergy. SCIT with HDM ex-
tracts can be effective in con-
trolling symptoms of perennial AR 
but patient selection is critical. If 
there is no benefit after 6 months, 
SCIT is unlikely to be effective and 
alternative strategies should be 
considered. SCIT can be used in 
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cat allergy but is usually restricted 
to people with occupational ex-
posure. There is no corresponding 
data for dog allergy.
EVIDENCE OF DISEASE 
MODIFICATION
SCIT may have long term benefits 
by modifying the course of the 
disease, whereas drug therapies 
only suppress the symptoms while 
they are taken. Two outcomes of-
fer evidence of disease modifica-
tion – the prevention of asthma 
in patients treated for AR and the 
prevention of new allergic sensiti-
sations (Figure 1). After cessation 
of SCIT treatment, there is a slow 
recurrence of symptoms over the 
first 3 years after completing SCIT, 
but no appreciable increase there-
after.
ADVERSE REACTIONS TO SCIT
Localized and systemic reactions 
may occur after SCIT. Local reac-
tions are commoner during the 
build-up phase than during main-
tenance, but do not predict sub-
sequent occurrence of systemic 
reactions. Systemic reactions are 
more serious and can very rarely 
prove fatal. Consequently, SCIT 
injections should only be given in 
clinics familiar with SCIT and by 
clinicians able to deal with ana-
phylactic side-effects.
FUTURE DIRECTIONS
Given the time, cost and risks of 
conventional SCIT, there is in-
terest in modifications that may 
increase efficacy, simplify the re-
gime or improve safety (Table 1).
Subcutaneous allergen immunotherapy for allergic rhinitis
Anthony J. Frew  
Royal Sussex County Hospital 
Brighton, UK
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Subcutaneous allergen immunotherapy for allergic rhinitis
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TABLE 1
Future developments
modified natural allergens
recombinant allergens
modified recombinant allergens (hypoallergenic variants)
immunological adjuvants (CpG-DNA; LPS derivatives)
alternative routes of administration (Sublingual, intralymphatic, liposomes etc).
Figure 1 Pollen SCIT reduces asthma in children with seasonal rhinitis. (Reprinted from J Allergy Clin Immunol, 109/2, 
Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, 
Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis 
(the PAT-study), 251-256, Copyright 2002, with permission from Elsevier.)
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considered an alternative treatment to the subcutaneous 
route and has been included in international guidelines for the 
treatment of allergic rhinitis (AR)
• SLIT significantly reduces symptoms scores and the use of 
rescue medication in both adults and children with AR
• A disease modification effect was proved 2 years after the 
completion of 3 years of treatment with SLIT-tablets for grass 
pollen allergy
• The safety profile of SLIT is extremely good; therefore, SLIT can 
be self-administrated by the patients in their homes
Sublingual allergen immunother-
apy (SLIT) is currently considered 
an alternative treatment to the 
subcutaneous route. The use of 
SLIT has been included in inter-
national guidelines for the treat-
ment of allergic rhinitis (AR) with 
or without conjunctivitis. SLIT can 
be administered as drops or tab-
lets for respiratory allergies due 
to grass, tree, ragweed pollens 
and house dust mites. At present, 
SLIT is commercialised and rou-
tinely used in some countries in 
Europe (e.g., France and Italy) and 
is becoming popular in many other 
countries around the world. Some 
SLIT products have also been re-
cently approved by the FDA in the 
USA.
CLINICAL EFFICACY
The clinical efficacy of SLIT is 
well documented in different 
double-blind, placebo-controlled, 
randomised clinical trials (DBPC 
RCTs) and meta-analyses (Tables 1 
and 2). SLIT significantly reduces 
symptoms scores and the use of 
rescue medication in both adults 
and children. Large clinical and 
methodological heterogeneity 
was detected in these analyses. 
New well-powered well-designed 
multinational DBPC RCTs using 
almost comparable clinical out-
SUBLINGUAL 
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comes and properly standardised 
sublingual products have demon-
strated sustained clinical effica-
cy in the active group relative to 
placebo. These studies have also 
indicated a disease modification 
effect observed 2 years after the 
completion of 3 years of treat-
ment with SLIT-tablets for grass 
pollen allergy.
SAFETY
The safety profile of SLIT is ex-
tremely good; therefore, SLIT can 
be self-administrated by the pa-
tients in their homes. However, 
it is recommended that the first 
dose should always be given to 
the patient in the presence of a 
physician. This is to re-assure the 
patient about the expected local 
symptoms he/she can experience 
while taking the medication. Most 
reported symptoms are self-lim-
ited, mild in severity and do not 
require any other relief medica-
tion. Local symptoms are itching/
tingling of the lips, mouth or/and 
oral mucosa; mild local swelling 
of lips, sublingual area or tongue. 
Very rarely, systemic reactions ap-
pear. Few so-called anaphylactic 
cases have been globally reported. 
No fatalities are related to SLIT. 
Good adherence to SLIT is critical 
for its success, at least 3-4 visits 
per year should be programmed 
to evaluate adherence and clinical 
response to SLIT.
Sublingual immunotherapy for allergic rhinitis
Moisés A. Calderon  
Imperial College 
London, UK
Oliver Pfaar  
University Hospital 
Mannheim, Germany
Pascal Demoly  
University Hospital 
Montpellier, France
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TABLE 1
The clinical efficacy of SLIT – decrease in symptom scores
Participants
Disease Author Studies 
(no.)
Population Active 
(no.)
Placebo 
(no.)
Effect size, 
SMD (95% CI)*
Heteroge-
neity I2†
SCIT
Rhinitis Calderon, 2007 15 Adults 597 466 -0.73 (-0.97 to -0.50) 63%
Asthma Abramson, 2010 34 Adults and children 727 557 -0.59 (-0.83 to -0.35) 73%
SLIT
Rhinitis Wilson, 2003 21 Adults and children 484 475 -0.42 (-0.69 to -0.15) 73%
Rhinitis Penagos, 2006 10 Children 245 239 -0.56 (-1.01 to -0.10) 81%
Rhinitis Radulovic, 2011 49 Adults and children 2333 2256 -0.49 (-0.64 to -0.34) 81%
Asthma Calamita, 2006 9 Adults and children 150 153 -0.38 (-0.79 to 0.03) 64%
Asthma Penagos, 2008 9 Children 232 209 -1.14 (-2.10 to -0.18) 94%
Conjunctivitis Calderon, 2011 36 Adults and children 1725 1674 -0.41 (-0.53 to -0.28) 59%
House dust mites Compalati, 2009 8 Adults and children 194 188 -0.95 (-1.77 to -0.14) 92%
Grass allergens Di Bona, 2010 19 Adults and children 1518 1453 -0.32 (-0.44 to -0.21) 56%
*Effect size (SMD): poor, <20.20; medium, 20.50; high, >20.80.
†Heterogeneity (I2) 5 0% to 40%, might not be important; 30% to 60%, might represent moderate heterogeneity; 50% to 90%, 
might represent substantial heterogeneity; 75% to 100%, considerable heterogeneity
TABLE 2
The clinical efficacy of SLIT – decrease in medication
Participants
Disease Author Studies 
(no.)
Population Active 
(no.)
Placebo 
(no.)
Effect size, 
SMD (95% CI)*
Heteroge-
neity I2†
SCIT
Rhinitis Calderon, 2007 13 Adults 549 414 -0.57 (-0.82 to -0.33) 64%
Asthma Abramson, 2010 20 Adults and children 485 384 -0.53 (-0.80 to -0.27) 67%
SLIT
Rhinitis Wilson, 2003 17 Adults and children 405 398 -0.43 (-0.63 to -0.23) 44%
Rhinitis Penagos, 2006 7 Children 141 138 -0.76 (-1.46 to -0.06) 86%
Rhinitis Radulovic, 2011 38 Adults and children 1737 1642 -0.32 (-0.43 to -0.21) 50%
Asthma Calamita, 2006 6 Adults and children 132 122 -0.91 (-1.94 to 0.12) 92%
Asthma Penagos, 2008 7 Children 192 174 -1.63 (-2.83 to -0.44) 95%
Conjunctivitis Calderon, 2011 13 Adults and children 560 478 -0.10 (-0.22 to 0.03) 34%
House dust mites Compalati, 2009 4 Adults and children 89 86 -1.88 (-3.65 to -0.12) 95%
Grass allergens Di Bona, 2010 17 Adults and children 1428 1358 -0.33 (-0.50 to -0.16) 78%
*Effect size (SMD): poor, <20.20; medium, 20.50; high, >20.80.
†Heterogeneity (I2) 5 0% to 40%, might not be important; 30% to 60%, might represent moderate heterogeneity; 50% to 90%, 
might represent substantial heterogeneity; 75% to 100%, considerable heterogeneity.
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MECHANISMS
The mechanisms of SLIT are less 
well understood than those of 
subcutaneous immunotherapy. 
SLIT products should be placed 
under the tongue, allowing the al-
lergen to be in contact for at least 
2 minutes with the oral mucosa 
through dendritic cells. The aller-
gens cross the mucosa in 15 - 30 
minutes. They are then captured 
by tolerogenic dendritic cells 
and processed as small peptides. 
Then, via the lymphatic system a 
systemic immune response is cre-
ated, aiming to produce an early 
decrease in mast cell and basophil 
degranulation. This is followed 
by generation of allergen-specific 
Treg cells and suppression of al-
lergen-specific Th1 and Th2 cells 
and possibly other effector cells. 
An early increase and a very late 
decrease in specific IgE levels are 
observed. IgG4 levels show a rel-
atively early increase that is dose 
dependent. A significant decrease 
in the allergen-specific IgE/ IgG4 
ratio occurs after several months.
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• A short, safe and effective intradermal injection regimen that 
confers long-lasting clinical benefit would be an appealing 
alternative to current AIT which necessitates a prolonged 3-5 
year treatment regimen
• Synthetic peptide immuno-regulatory epitopes (SPIREs) 
represent a new class of therapeutics for allergen 
immunotherapy (AIT) that afford the potential to suppress 
the IgE-mediated allergic cascade through induction of T-cell 
tolerance
• Dose-ranging and safety studies, cat allergen provocation 
studies, and environmental exposure chamber studies have 
demonstrated a therapeutic effect for cat, ragweed, grass, and 
house dust mite synthetic peptide constructs
• Several novel approaches such as B cell epitopes combined 
with Pre S antigen of hepatitis B virus, modular allergen-
translocating vaccines, combined recombinant allergens are 
underway
The focus of specific allergen im-
munotherapy (AIT) is to effec-
tively control the allergic cascade 
and thereby suppress the allergic 
inflammatory response and atten-
uate, if not completely abrogate, 
the clinical symptomatology that 
otherwise manifests as allergic rhi-
noconjunctivitis and/or asthma.
The ability to prevent the allerr-
gic immune response is a primary 
goal of AIT, and new advances in 
immunotherapeutics directed at 
inducing T-cell tolerance, shifting 
the balance in Th2 vs Th1 cellular 
subtypes, or upregulating T-reg-
ulatory cells are at the stage of 
promising Phase 2-3 clinical de-
velopment.
T-CELL-TOLERIZING PEPTIDES
A therapeutic approach in AIT 
uses T-cell-tolerizing peptides 
to induce immune tolerance and 
thereby suppress IgE-mediated 
diseases. Early work in this re-
search area was carried out by 
Gefter and colleagues in the mid-
1990s, and these studies provided 
the first evidence that synthetic 
T-cell-tolerising peptides could in-
duce tolerance and thereby open 
a treatment pathway to suppress 
IgE-mediated allergic diseases 
such as cat and ragweed-induced 
rhinitis and asthma. Gefter’s lab 
NEW VACCINES 
FOR ALLERGEN 
IMMUNOTHERAPY
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developed both cat (two 27 amino 
acid peptides derived from Fel d 1) 
and ragweed (derived from Amb a 
1), T-cell-tolerizing peptides, and 
in collaborative work with Nor-
man and Creticos, demonstrated 
that administration of these pep-
tides, in various subcutaneous 
treatment regimens, resulted in 
significant improvement in cat-in-
duced clinical symptoms in studies 
utilizing cat broncho-provocation 
or natural cat room challenges 
and in multicenter field trials of 
the ragweed vaccine.
However, these first-generation 
peptides were not optimal when 
compared to conventional AIT, 
as they were longer sequenced 
peptides (potentially exposing 
IgE epitopes), too few in number 
(hence, not providing a more com-
plete immune protection), and 
required administration of higher 
subcutaneous doses which were 
associated with late-onset ad-
verse events.
New vaccines for allergen immunotherapy
Peter Socrates Creticos  
Johns Hopkins Division of Allergy & Clinical Immunology 
Baltimore, USA
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SYNTHETIC PEPTIDE IMMUNO-
REGULATORY EPITOPES
New research into peptide 
epitopes initiated at Imperial Col-
lege by Mark Larché and Barry Kay 
has resulted in the development of 
a second generation of these mol-
ecules - Synthetic Peptide Immu-
no-Regulatory Epitopes (SPIREs). 
These synthetic T-cell-tolerizing 
peptides are comprised of small-
er peptide units (e.g.: cat: seven 
peptides; 13-17 amino acids in 
length), administered in much 
smaller quantities (75 μg vs. 750 
μg), assembled from different 
T-cell epitopes, and administered 
intradermally to more efficiently 
access antigen-presenting cells.
These novel peptides are specifi-
cally designed to induce immuno-
logic tolerance through binding to 
MHC class II molecules on anti-
gen-presenting cells, with subse-
quent up-regulation of regulatory 
T-cells (Figure 1). A key advantage 
of these peptides lies in their 
smaller size; i.e., molecules that 
are of insufficient length to trigger 
cross-linking of IgE on mast cells 
and basophils, thus significantly 
reducing the risk of IgE-mediated 
allergic reactions (e.g., asthma, an-
gioedema/urticaria, or anaphylax-
is).
MECHANISTIC STUDIES
The leading SPIRE construct is the 
cat peptide derived from Fel d 1, 
the major cat allergenic moiety. 
Mechanistic studies with these 
peptides in mice have demon-
strated reduction in BAL total 
cells and eosinophils, pulmonary 
and systemic Th-2 inflammato-
ry cytokines, recruitment of Th-2 
cells to the lungs, and of prolif-
Figure 1 Mechanistic schematic representation of synthetic peptide immune-regulatory epitopes. (This figure 
reproduced with permission from: BioMed Central; published in: Creticos PS. Advances in synthetic peptide immune-regulatory 
epitopes. World Allergy Organ J 2014; 7:30.)
New vaccines for allergen immunotherapy
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Figure 2 Delta changes in total 
rhinoconjunctivitis symptom scores 
for the treatment effect observed 
with Cat-SPIRE in the environmental 
exposure chamber. In this DBPC 
study, 202 cat-allergic subjects were 
randomized to either: a) 4 doses of 
6-nmol 4 weeks apart (n=66); b) 8 
administrations of 3 nmol 2 weeks 
apart (n=67); or c) placebo (n=69). 
Subjects underwent a baseline 
challenge (4 consecutive days of 
3 hours in the EEC) and patients 
returned for the identical challenge 
protocol in the EEC at 18-22 weeks 
and at 50-54 weeks after the start 
of treatment. The primary endpoint 
was defined as the change in TRSS, 
(post-treatment vs. baseline EEC 
challenges) at 1-3 hours on days 
2-4. The results of this 1-year study 
demonstrated a persistent treatment 
effect in the pre-specified statistical 
analysis at time points after 1 hour on 
Days 2-4 of EEC at the 50-54 week 
EEC challenge in the non-asthmatic 
population for the 6 nmol x 4 dose 
regimen vs. placebo [median change: 
-6.80 (vs. -3.27); mean change: 
-3.89 +/-5.56 (vs. -2.91 +/-5.56); 
LS means: -7.074, -4.077; 95% CIs: 
-7.165 to -0.989; p value =0.0104]. 
Analysis of the data at all time-points, 
on all days, showed similar results. 
The challenge performed at 1-year 
demonstrated the treatment effect 
was observed to be stronger on 
successive days in the EEC.
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erative responses to Fel d 1. Fur-
thermore, evidence for the role 
of IL-10 in the underlying mecha-
nism of action is provided by the 
observation that administration of 
anti-IL-10 monoclonal antibody, 
immediately post-treatment with 
the peptide, blocked the positive 
peptide-inducing effects. Subse-
quently, initial safety and efficacy 
work was published which defined 
the optimal peptide construct and 
the applicability of a short intra-
dermal injection regimen.
SALIENT CLINICAL STUDIES
Utilizing a controlled cat allergen 
environmental exposure chamber 
(EEC) model, dose-ranging and 
dose-dependent clinical efficacy 
and safety studies have demon-
strated that a long-lasting persis-
tence of effect [i.e., improvement 
in total rhinitis clinical symptoms 
(TRSS)] can be demonstrated as 
far out as 1-year after comple-
tion of a concise injection regi-
men (6 nmol x 4 ID injs x 4 wks 
apart) (Figure 2). A subgroup of 
subjects followed for 2 years has 
now shown a similar magnitude 
of effect upon chamber expo-
sure. The magnitude of change in 
TRSS scores in the EEC model (~4 
TRSS units vs placebo) compares 
favorably with chamber studies 
performed with cat SCIT (3u), cat 
SLIT-drops (1.6u), or an antihis-
tamine (1.3u). Furthermore, the 
evidence for a long-lasting effect 
parallels that observed with SCIT 
and SLIT in which 3-year courses 
of treatment are necessitated to 
obtain a sustained treatment ef-
fect in the 2-years post-cessation 
of treatment.
A large Phase 3 multicenter rand-
omized DBPC clinical field trial is 
currently underway with the cat 
construct, and the findings from 
this trial should further elucidate 
the potential for this novel immu-
notherapeutic in the treatment of 
cat allergy. In addition, the SPIRE 
platform has further branched 
into ragweed, grass, and house 
dust mite development programs.
CONCLUSION
Synthetic peptides comprised 
of T-cell epitopes, derived from 
known amino acid sequences of 
specific relevant allergens, afford 
a unique opportunity through a 
short intradermal injection regi-
men to safely and effectively in-
duce immunologic tolerance and 
hence initiate long-lasting clinical 
efficacy.
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• Allergen immunotherapy (AIT) works by stimulating DCs, T- 
and B-cells. In contrast, side effects are mediated by mast cells 
and via blood vessels
• The ideal route for AIT is characterized by high density of DCs, 
T- and B-cells, but low density of mast cells and blood vessels
• Lymph nodes contain masses of DCs, T- and B-cells, but few 
mast cells. Intralymphatic AIT (ILIT) was safe and the number of 
allergen injections cold be reduced to three
• The epidermis contains dense DCs and no mast cells or blood 
vessels. Epicutaneous AIT (EPIT) was safe and the allergen 
administrations could be reduced to 6 patches
For allergic rhinitis (AR) allergen 
specific immunotherapy (AIT) is 
the only causal treatment with 
long-term efficacy that in ad-
dition prevents progression to 
asthma. Current AIT suffers from 
two short-comings. First, allergen 
administration causes allergic ad-
verse effects. Local adverse ef-
fects are mediated by mast cells at 
the site of allergen administration, 
whereas systemic adverse effects 
occur when allergen reaches blood 
vessels and activates basophils or 
gets distributed systemically to 
tissue resident mast cells (Figure 
1). The second short coming is 
that current AIT requires numer-
ous allergen administrations over 
three to five years and thus is time 
consuming. Due to these two dis-
advantages few allergic patients 
opt to undergo AIT and treatment 
adherence is poor.
HOW TO IMPROVE SAFETY?
Local and systemic allergic side 
effects can be prevented by re-
ducing the IgE binding capacity 
of the therapeutic allergen, either 
by chemical or recombinant mod-
ification, or by use of oligopep-
tides representing merely T cell 
epitopes. Another strategy to re-
duce local side effects is choosing 
a route of allergen delivery, which 
AIT FOR ALLERGIC RHINITIS - 
NEW DELIVERY OPTIONS8e
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is characterized by low density or 
absence of mast cells. Also, sys-
temic side effects should be pre-
ventable, when choosing a route 
characterized by low density or 
absence of blood vessels, mini-
mizing risk for systemic allergen 
distribution.
HOW TO REDUCE THE 
NUMBER OF ALLERGEN 
ADMINISTRATIONS?
The number of allergen admin-
istrations can be reduced by en-
hancing the immunological effects 
of each administration. AIT works 
by inducing blocking antibodies, 
T helper 1- and regulatory T cells, 
orchestrated by dendritic cells 
(DCs). Immunological effects are 
classically enhanced by adjuvants. 
Replacing alum by bacterial prod-
ucts such the lipopolysaccharides 
derivative monophosphoryl lipid 
A (MPLA) or bacterial DNA allows 
reducing the number of injec-
tions to 4 or 6. Another strategy is 
choosing an administration route 
which is characterized by high 
density of DCs, B- and T-cells.
INTRALYMPHATIC 
IMMUNOTHERAPY (ILIT)
In lymph nodes, the density of 
DCs, B- and T-cells is maximal, 
whereas the density of mast cells 
is low. We could demonstrate that 
direct injection of allergen into a 
AIT for allergic rhinitis - new delivery options
Gabriela Senti Thomas M. Kündig
University Hospital Zurich 
Zurich, Switzerland
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subcutaneous lymph node was 
safe and ameliorated symptoms of 
AR already after three injections.
EPICUTANEOUS 
IMMUNOTHERAPY (EPIT)
The epidermis is characterized by 
high density of potent DCs and ab-
sence of blood vessels. AIT admin-
istered via this route should there-
fore be more efficient and safer. In 
fact, we could demonstrate that 
EPIT was safe and ameliorated 
symptoms of AR already after 6 
allergen patch applications
The above mentioned two prom-
ising allergen delivery routes have 
been clinically developed by us 
and others.
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Figure 1 Cells mediating the therapeutic effect of AIT vs. cells mediating adverse effects. While the therapeutic 
effects of AIT are mediated by DCs, T-cells and B-cells, the local adverse effects are mediated by mast cells at the site of 
injection and the systemic adverse effects are mediated when allergen accidentally reaches the blood circulation so that 
it can activate basophils and/or tissue resident mast cells. Therefore the ideal route for allergen administration should be 
characterized by a high density of DCs, T- and B-cells, but a low density of mast cells and blood vessels.
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• Allergenic products for allergen immunotherapy (AIT) are 
biologics that require a marketing authorization (MA) in the EU 
and the US
• The regulatory process consists of scientific advice, review, and 
regulation of clinical trials and the MA procedure;
• Authorization is granted on the basis of quality, safety and effica-
cy, and a benefit-risk assessment; the regulatory process contin-
ues after authorization and may include additional clinical trials
• The quality of natural allergen extracts depends on the 
source material and the production process and is difficult to 
standardize
• Standardization is based on FDA standards in the US and on In 
House References in the EU
• For many products, potency of standardized extracts is still 
based on allergen binding by IgE antibodies from allergic 
subjects
• Novel approaches to allergenic product testing include purified 
recombinant allergens as international reference standards, 
sandwich ELISAs for major allergen quantification, and mass 
spectrometry
Licensed allergen products for al-
lergen immunotherapy (AIT) are 
extracts derived from biological 
source materials such as pollen 
or house dust mites. They are bi-
omedicines requiring a marketing 
authorization both in the EU and 
the US. The quality and consist-
ency of biomedicines strongly 
depends on the standardization 
of the production process. More-
over, due to natural biovariability 
of the composition of source ma-
terials, AIT extracts are difficult to 
standardize.
In the US, clinical development 
begins with an investigation-
al new drug (IND) application. 
While not mandatory, US Food 
and Drug Administration (FDA) 
encourages a Pre-IND meeting, 
for which supporting documen-
tation includes the investigational 
plan and an outline of chemistry, 
manufacturing and control (CMC) 
information. The subsequent IND 
application includes a Phase 1 
protocol to support safety. Phase 
2 studies determine proper dos-
ing range and support efficacy, 
after which the sponsor is en-
couraged to request an End of 
Phase 2 (EOP2) meeting to dis-
cuss criteria for successful Phase 
3 studies. Within 60 days of the 
REGULATION AND 
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EOP2 meeting a sponsor should 
submit their initial pediatric study 
plan (iPSP). The iPSP must in-
clude plans for pediatric studies, 
and any plans to request waivers 
or deferrals of the requirement 
to submit data to support use of 
the product in pediatric popula-
tions at the time of submission 
of a biologics license application. 
Phase 3 protocols should include 
comprehensive CMC information 
and (ideally) a Statistical Analysis 
Plan. The product used for Phase 
3 studies should be manufactured 
in the same facilities and using 
the same process intended for 
the licensed product. After com-
pletion of Phase 3, the sponsor is 
encouraged to request a pre-BLA 
meeting to discuss the proposed 
content of a BLA, which should 
Regulation and standardization of AIT extracts
Ronald L. Rabin  
Center for Biologics Evaluation and Research, US Food 
and Drug Administration, Silver Spring, MD, USA
Stefan Vieths  
Paul-Ehrlich-Institut 
Langen, Germany
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include an agreed upon PSP. Af-
ter approval of a BLA, the manu-
facturer is authorized to market a 
product for interstate commerce 
in the US (Figure 1).
In the EU allergen extracts are au-
thorized at the level of individual 
member states (MS). Once a prod-
uct is authorized in one MS the 
license can be extended to other 
MS by a mutual recognition proce-
dure. Moreover, the decentralized 
procedure, in which one MS acts 
as reference member state (RMS) 
allows to simultaneously obtain a 
marketing authorization in two to 
all MS. The system of clinical test-
ing is similar to the US, and medi-
cal agencies offer scientific advice 
to pharmaceutical companies and 
other sponsors (similar to Pre-IND 
meetings). Approval of a pediatric 
investigation plan by the Europe-
an Medicines Agency is required 
before an authorization of the 
products for use in adults can be 
granted (Figure 2).
In the EU, biological allergen 
standardisation is mainly based 
on skin testing during develop-
ment of a new product and on 
IgE inhibition tests comparing a 
given extract batch with a refer-
ence preparation for evaluating 
batch to batch consistency. In the 
US, FDA allergen standards and 
allergic human reference sera are 
used, while the system in the EU 
is based on In House Reference 
Preparations (extracts) and human 
sera pools that are manufacturer 
specific. Recent progress in aller-
gen standardisation are the devel-
opment and validation of purified 
recombinant allergen standards 
and the use of sandwich ELISA 
systems for determination of indi-
vidual allergens in extracts, as well 
as proteomic tools such as mass 
spectrometry.
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Figure 1 Steps in the development of an allergenic vaccine following the rules of an investigational new drug in the US.
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Figure 2 Steps in the development of an allergenic vaccine following the rules of an investigational new drug in the EU.
4. Becker WM, Vogel L, Vieths S. 
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tracts for immunotherapy: where 
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BloodVaccines/GuidanceCompli-
anceRegulatoryInformation/Guid-
ances/General/ucm218518.htm, 
accessed May 19, 2015.
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symptom control of allergic rhinitis (AR) in an allergen-
nonspecific fashion
• In contrast to allergen-specific immunotherapy treatment of 
AR with anti-IgE is probably not disease modifying
• As a proof of concept, other biologicals (antibodies anti IL5, IL4 
or IL13) should be studied in AR
Since allergic rhinitis (AR) is proba-
bly the most classical IgE mediated 
part of all atopic manifestations, 
it is quite tempting to utilize the 
recently developed pathogenesis 
oriented interventions as “a proof 
of concept” in this disease. How-
ever, most of the modern tools are 
currently studied and will proba-
bly be marketed only for asthma 
for non-scientific but mainly eco-
nomic reasons: disease related 
costs as well as impairment for the 
quality of life in patients suffering 
from asthma is much more rele-
vant compared to AR which is by 
many physicians and health care 
providers still considered trivial, 
transient and relatively “cheap” 
disease.
Studies have indicated, however, 
that around 50 % of the patients 
affected have to be categorized as 
persistent AR with severe impair-
ment which means that the dai-
ly life of the affected patients in 
school or work is markedly affect-
ed. Still the aspect of cost effec-
tiveness with modern antiallergic 
biologicals and monoclonal anti-
bodies will be discussed not only 
within the scientific society but 
also by health of authorities and 
payers.
TREATMENT OF ALLERGIC 
RHINITIS WITH BIOLOGICALS AND 
MONOCLONAL ANTIBODIES
9
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So far in most countries patients 
with AR are treated according to 
international or national guide-
lines, primarily with modern 
antihistamines (oral or topical) 
and topical corticosteroids. The 
treatment effect of this pharma-
cotherapeutic approach is well 
documented, but not really im-
pressive. Allergen immunotherapy 
(AIT) is applied by the subcuta-
neous or sublingual route. It can 
be assumed that the AIT disease 
modifying effect is stronger than 
drug treatments, although head-
to-head comparisons are not real-
ly available for final and conclusive 
judgments.
Since anti-IgE has become avail-
able, a number of studies have 
been performed in seasonal AR. 
anti-IgE was applied either alone 
or together with AIT (Figure 1). 
A recent metaanalysis concludes 
that in seasonal and perenial AR 
treatment with Omalizumab pro-
vides an improvement of daily 
nasal symptoms severity score or 
reduction of anti-allergic medi-
cation, compared with placebo. 
Looking at the different trials it 
is obvious, that not all of these 
studies are adequately powered 
so that larger clinical trials and 
economic studies are still needed 
to address the issues of rare ad-
verse events occurrence or cost 
effectiveness respectively. So far 
one can conclude that Omalizum-
ab as the only biological which 
has so far been investigated in 
AR is significantly associated with 
symptom relief, decreased rescue 
medication use and improve qual-
ity of life in patients with inade-
quately controlled AR or rhinosi-
nusitis refractory to conventional 
treatment. The more recently de-
Treatment of allergic rhinitis with biologicals and monoclonal antibodies
Ulrich Wahn  
Charité Medical University 
Berlin, Germany
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Treatment of allergic rhinitis with biologicals and monoclonal antibodies
veloped biologicals like anti-IL5, 
combined antibodies to IL4 and 
IL 13 or their receptor have so far 
only been used for asthma trials.
Given the fact that in atopic dis-
eases, particularly in children and 
adolescents, the majority of pa-
tients develop IgE-mediated co-
morbidities in the lower airways, 
the skin or the gastrointestinal 
tract, it is mandatory, that future 
pathogenesis oriented systemic 
intervention will also carefully as-
sess the effect of the treatment 
with biologicals on AR. In addition 
AR patients with a broad spec-
trum of relevant seasonal or per-
ennial allergies may benefit better 
from a nonspecific antiallergic 
approach using monoclonal anti-
bodies, if they are not sufficiently 
controlled by standard treatment, 
rather though AIT.
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and G, Rosenhall L, Zetterstrom 
O, et al. Recombinant humanized 
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nol 2000;106:253-259.
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Figure 1 Treatment of polyallergic (birch and grass pollen) children with allergic rhinitis. Effect of intervention with 
allergen immunotherapy (either birch or grass pollen) or Omalizumab documented during the grass pollen season. 
(Reprinted from J Allergy Clin Immunol, 109/2, Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, 
Bergmann KC, Rolinck-Werninghaus C, Gräve M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus 
specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis, 274-280, Copyright 2002, 
with permission from Elsevier.)
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factors involved in allergic diseases suggest new therapeutic 
avenues for the treatment of allergic rhinitis
• Toll like receptor agonists, which mimic the beneficial 
modulation of viruses and bacteria on the allergic inflammation
• CRTH2 (or DP2) receptor antagonists, which block the effects 
of the mast cell derived mediator prostaglandin D2
• MicroRNA inhibitors which might posttranscriptionally regulate 
key pathogenetic mechanisms in allergic inflammation
Allergic rhinitis (AR) is an immuno-
globulin E (IgE)-mediated disease, 
whereby inhaled allergens cause a 
type 1 hypersensitivity reaction. 
Inflammation in AR is driven by a 
variety of cell types including mast 
cell activation, the infiltration of 
sensitized tissues by eosinophils 
and T helper type 2 (Th2) lym-
phocytes. Recent advances in the 
understanding of new pathways 
and factors involved in allergic 
diseases suggest new therapeutic 
avenues for the treatment of AR.
Toll-like receptors (TLR) belong to 
a large family of pattern recogni-
tion receptors known as the an-
cient 'gatekeepers' of the immune 
system. TLRs are located at the 
first line of defense against invad-
ing pathogens (bacteria and virus-
es) as well as aeroallergens. They 
can modulate the Th2 specific al-
lergic immune response towards a 
Th1 response, which make them 
appropriate adjuvants for allergy 
vaccines, as well as as stand-alone 
therapeutics to treat symptoms 
of AR patients. Using oligonucle-
otides enriched in CpG motifs as 
a TLR-9 agonist or other TLR ago-
nist against like TLR-4, TLR-7 and 
TLR-8 have been successfully in-
vestigated in early clinical trials in 
AR (Table 1).
OTHER TARGETED 
TREATMENT OPTIONS FOR 
ALLERGIC RHINITIS
10
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Prostaglandin D2 (PGD2), an ara-
chidonic acid metabolite, is a key 
mediator in inflammation after al-
lergen exposure and is released by 
IgE-activated mast cells and by oth-
er inflammatory cell types. PGD2 
helps in recruiting and activating 
Th2 lymphocytes, eosinophils and 
basophils (Figure 1). Nasal challenge 
with PGD2 induces a greater de-
gree of nasal congestion than that 
induced by histamine. The proin-
flammatory effects of PGD2 occur 
through interactions with the che-
moattractant receptor homologous 
molecule on Th2 cells (CRTH2), 
a 7-transmembrane type G pro-
tein–coupled receptor selectively 
expressed on Th2 cells, T cytotoxic 
type 2 cells, eosinophils, and baso-
phils (Figure 1). Around 20 CRTH2 
(or DP2 receptor) antagonists have 
been developed into clinical devel-
opment with different effectivity 
for systemic treatment of AR. A re-
duction in nasal allergic symptoms 
as well as in local nasal biomarkers 
has been shown in patients with AR 
exposed to grass pollen.
MicroRNAs (miRNAs) are a class 
of short single stranded RNA mol-
ecules that posttranscriptionally 
silence gene expression and have 
been shown to fine-tune gene 
transcriptional networks. Specif-
ic miRNAs have been found to 
have critical roles in regulating key 
pathogenic mechanisms in models 
of preclinical allergic inflamma-
tion (eg, miR-21). Therefore, they 
might have perspectives as dis-
ease biomarkers and therapeutic 
targets when new miRNA mimics/
antagomiRs, and novel small-mol-
Other targeted treatment options for allergic rhinitis
Norbert Krug  
Fraunhofer Institute for Toxicology and Experimental Medicine 
Hannover, Germany
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ecule miRNA inhibitors become 
available for human use.
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TABLE 1
Toll-like receptors (TLR) and TLR agonists under clinical development in al-
lergic diseases
TLR Exogenous and Endogenous Ligands TLR Agonists
TLR1 Bacterial lipopeptides
TLR2 Bacterial lipoproteins and glycolipids
TLR2/TLR1 Bacterial diacyl lipopeptides
TLR2/TLR6 Bacterial triacyl lipopeptides
TLR3 Viral double-stranded RNA Vaccine adjuvant (Poly I:C )
TLR4 Bacterial LPS Allergy
TLR5 Bacterial flagellin
TLR6 Bacterial triacyl lipopeptides
TLR7 Viral single-stranded RNA Asthma, allergic rhinitis
TLR8 Viral single-stranded RNA Allergic rhinitis
TLR9 Bacterial and viral CpG-DNA Asthma, AR; vaccine adjuvant
TLR10 Unknown
TLR11 Profilin
Figure 1 Prostaglandin D2 (PGD2), an arachidonic acid metabolite, is a key mediator in inflammation after allergen 
exposure and is released by IgE-activated mast cells and other inflammatory cell types. PGD2 helps in recruiting and 
activating Th2 lymphocytes, eosinophils and basophils. (From Arima M, Fukuda T. Prostaglandin D₂ and Th2 inflammation in 
the pathogenesis of bronchial asthma. Korean J Intern Med. 2011; 26:8-18.)
Other targeted treatment options for allergic rhinitis
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and understudied
• Pharmacogenetic studies in AR are largely missing
• Pharmacogenetic studies investigating response to allergen 
immunotherapy are needed
• Strategies to identify patients with severe AR to profit from 
biologicals is needed
Within the “big three” allergic dis-
eases (asthma, atopic dermatitis 
and allergic rhinitis), allergic rhi-
nitis (AR) is the disease the least 
targeted and defined by genetic 
studies. While genome wide anal-
yses are history in asthma and at-
opic dermatitis (Figure 1) and the 
field moves on to whole exome 
and whole genome sequencing, 
genome wide association stud-
ies are still sparse in AR. When it 
comes to pharmacogenetic stud-
ies of AR, current knowledge is al-
most non-existing. Potential rea-
sons may be that (a) all patients are 
perfectly treated or even cured by 
current medication and treatment 
or that (b) there are no side effects 
with current therapy so that phar-
macogenetic studies to optimize 
treatment are not needed. Neither 
(a) nor (b) seems likely the case. 
Current standard therapy for AR 
in most cases and countries is sys-
temic and/or local antihistamines, 
topic steroids or AIT.
For histamine receptors and genes 
within histamine related pathway 
genes, knowledge on common 
and rare mutations exists, but 
studies investigating their effects 
in patients with AR under these 
therapies is lacking. For steroids, 
pharmacogenetic studies have 
PHARMACOGENETICS 
OF ALLERGIC RHINITIS11
KE Y MESSAGES
been performed, but not consid-
ering topic nasally applied steroids 
in patients with AR. Pharmacoge-
netic (and pharmacoepigenetic) 
studies in AIT have never been 
performed so far, but could be 
of greatest interest to the whole 
allergy field as these may lead to 
the identification of mechanisms 
related to tolerance induction and 
individual susceptibility to allergy 
or tolerance development.
There is a new wave of treatment 
options on the horizon that may 
eventually also change clinical 
practice in AR. With biologicals 
reaching severe asthma therapy, 
also patients with AR (at least with 
an asthma/AR overlap syndrome) 
will be treated with these targeted 
approaches. Thus, profiling these 
patients for mutations in IL13, IL5 
and other specific targets of bio-
logicals will be necessary in the 
future. Obviously, there is a big 
unmet need for pharmacogenet-
ics in AR to tailor and individualize 
therapy.
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Pharmacogenetics of allergic rhinitis
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ment in adults with asthma. N Engl 
J Med 2011;365:1088-1098.
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Figure 1 Venn diagram illustrating genes identified through genome-wide association studies as associated with the 
allergic diseases asthma, atopic dermatitis and allergic rhinitis. Genes highlighted in black identify those discovered in 
Caucasian populations, with italics defining promising genes that nearly achieved genome-wide significance. Genes 
highlighted in blue identify those genes discovered in non-Caucasian populations, while those in red identify those 
genes discovered in both Caucasian and populations of other ancestry. (Reproduced with permission from Portelli MA1, 
Hodge E, Sayers I. Genetic risk factors for the development of allergic disease identified by genome-wide association. Clin Exp 
Allergy, 2015;45:21-31, with permission from Willey Blackwell.)
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allergic medication drive more patients to seek complementary 
and alternative medicine (CAM) for help
• Acupuncture and herbal therapies are current the most popular 
CAM strategies for allergic rhinitis (AR). They are supposed to 
be therapeutic effective via affecting the balance between the 
Th1 and Th2 response
• Acupuncture can be recommended as adjunct therapy for AR. 
Other therapies have shown some clinical promise
• In spite of an increasing use of CAMs for AR, both the patients 
and the medical providers should be fully aware of the 
limitations of CAMs and to avoid relying too much on CAMs
Allergic rhinitis (AR) is one of the 
most common health problems 
worldwide. Pharmacologic treat-
ment and allergen immunotherapy 
(AIT) are the two primary choices 
in the conventional approach to 
AR. Outside of these options lies 
complementary and alternative 
medicine (CAM). Worries about 
concurrent side effects of con-
ventional anti-allergic medication 
could be one of the major reasons 
for more AR patients to seek help 
from CAM (Figure 1).
Acupuncture and herbal thera-
pies are current the most popular 
CAM strategies for AR, followed 
by vitamin therapy, tea therapy, 
massage and Ayurveda etc (Table 
1). Some of these methods have 
shown great efficacy in treating 
AR and others have not. CAMs are 
supposed to be therapeutic effec-
tive via modulating the immune 
system, by affecting the balance 
between the Th1 and Th2 cell-de-
rived cytokines.
Acupuncture (Figure 2) and acu-
pressure work via stimulating spe-
cific points on the human body. 
Based on the latest meta-anal-
ysis of the studies published 
from 1980 to 2013, acupuncture 
appears to be a safe, valid and 
cost-effective option for allergy 
COMPLEMENTARY AND 
ALTERNATIVE MEDICINE FOR 
ALLERGIC RHINITIS
12
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Complementary and alternative medicine for allergic rhinitis
Wei Zhang  
Beijing Tongren Hospital 
Beijing, China
TABLE 1
Major complementary and alternative approaches for allergic rhinitis
Categories Examples
Accupuncture sphenopalatine ganglion stimulation 
acupoint moxibustion 
acupoint catgut implantation
ear accupuncture
Herbal medicine herbal formula 
acupoint herbal patching
Vitamin complements Vitamin D
Others tea therapy
massage
* only major approaches are stated here 
* based on database on www.gopubmed.org 
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Complementary and alternative medicine for allergic rhinitis
relief, and can be recommended 
as adjunct therapy for AR. Acu-
puncture decreases nasal symp-
tom scores and improves quality 
of life with no serious systemic re-
action or side effects. Its efficien-
cy and safety heavily depends on 
the clinical experiences and skills 
of the acupuncturists.
Some herbal therapies and an-
tioxidants demonstrate a trend 
toward some clinical efficacy. A 
few therapies, including spiruline, 
butterbur, phototherapy and acu-
point herbal patching hold some 
promise. Herbal medicine, though 
is widely used for treating AR in 
China and Asia, is not yet qualified 
and recommended by the inter-
national peers since large studies 
with appropriate randomization, 
blinding and control are lacking.
Tea therapy is becoming an easy 
to take self-care method for AR 
patients in Asia. Japanese green 
tea with methylated catechin as 
an active ingredient has been sug-
gested beneficial for AR patients 
sensitised to cedar by relieving 
symptoms, improving quality of 
life, and by reducing peripheral 
eosinophil as well.
In conclusion, the popularity of 
CAM among the general public 
Figure 2 Acupuncturist in practice 
at AR clinic Beijing Tongren Hospital, 
China.
Figure 1 CAM classifications. CAM comprises 5 domains: alternative 
medical systems, biologically based therapies, manipulative therapies, 
mind-body therapies, and energy therapies. The alternative medical system 
involves whole medical systems that are built on other theories and practices 
including acupuncture, Ayurveda, homeopathic treatment, and naturopathy. 
Manipulative therapies include chiropractic care and massage. Mind-body 
therapies use a variety of techniques designed to enhance the mind’s capacity 
to affect bodily function and symptoms and include biofeedback, meditation, 
guided imagery, progressive relaxation, deep breathing, hypnosis, yoga, Tai Chi, 
Qi-gong, Reiki, and prayer. The biologically based therapies use substances 
found in nature, such as herbs, foods, and vitamins and include megavitamin 
therapy, various diet-based therapies, folk medicine, chelation therapy, and 
herbal medicines.3 Energy therapies are essentially made up of biofield 
therapies that are intended to affect energy fields that purportedly surround 
and penetrate the human body, whereas bioelectromagnetic based therapies 
involve the unconventional use of electromagnetic fields. (Reprinted from J 
Allergy Clin Immunol, 123/2, Mainardi T, Kapoor S, Bielory L. Complementary and 
alternative medicine: herbs, phytochemicals and vitamins and their immunologic 
effects, 283-294, Copyright 2009, with permission from Elsevier.)
is increasing, but CAMs have not 
been integrated into the guide-
lined for AR treatment yet. Rig-
orous studies of CAM for AR are 
very few. Both the AR patients 
and the medical providers should 
be fully aware of the limitation of 
CAMs in order to avoid relying too 
much on CAM.
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Section F
ALLERGIC RHINITIS - SPECIAL CONSIDERATIONS
* Aspirin-exacerbated respiratory disease
* Nonallergic rhinitis
* Local allergic rhinitis
* Conditions mimicking allergic rhinitis
* Primary ciliary dyskinesia
* Oral allergy syndrome
* Non-allergic, mastocytosis-associated rhinitis (NAMAR)
* Occupational irritant and allergic rhinitis
* Allergic rhinitis in the elderly
* Management of allergic rhinitis during pregnancy
* Allergic rhinitis in children
* Allergic rhinitis in elite athletes
* Rhinitis in a tropical environment
* Severity and control in allergic rhinitis
* Phenotypes and endotypes of allergic rhinitis
* The burden of allergic rhinitis on patients' quality of life
* Adherence to the management plan of allergic rhinitis
* Illness perception, mood and coping in patients with 
rhinitis
* Pharmacoeconomics of allergic rhinitis
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the gold diagnostic test is aspirin 
challenge tests via variable routes, 
including bronchial provocation 
which proved safe and is wide-
ly used. Serum periostin and the 
serin protease dipeptidyl pepti-
dase 10 (DPP10) were suggested 
as potential serum biomarkers 
for predicting the phenotype of 
AERD.
MANAGEMENT
Patients with AERD should be 
recommended to avoid ingestion 
of aspirin/NSAIDs. Highly selec-
tive COX-2 inhibitors are safer 
alternatives, although their abso-
lute safety has not been proven 
yet. Pharmacological treatment 
is needed to control the severe 
eosinophilic inflammation of the 
upper and lower airways. Intrana-
sal steroids, inhaled corticosteroid 
with/without long acting beta2 
agonist and leukotriene receptor 
antagonists are recommended as 
controller medications. Sinus sur-
gery is considered as a next treat-
ment option after the medical 
treatment fails. Aspirin desensiti-
zation can be recommended for 
the CRSwNP patients with AERD 
who are refractory to medical and 
surgical treatments.
In conclusion, further efforts are 
needed to investigate diagnostic 
biomarkers for early diagnosis of 
AERD and to evaluate the efficacy 
of new biologics such as anti-IL-5, 
anti-IL5R or anti-IgE antibodies.
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Aspirin-exacerbated respiratory disease
Figure 1 The pathogenic mechanisms and future therapeutic intervention for aspirin exacerbated respiratory disease.
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Figure 1 The complex network of Type 2 endotype in allergic diseases involves the interaction between innate immune 
response and Th2 cells. Three major downstream effector pathways can be described: the IgE pathway, the IL-5/eotaxin 
pathway, and the IL- 4/IL-13 pathway. Additional modulators of the Th2 endotype can be described such as the IL-9/
mast cell axis, Th17 or Th1 cells, activation of the metabolic pathways (Reproduced with permission from Agache I, Sugita 
K, Morita H, et al. The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside. Curr Allergy Asthma Rep. 
2015, in press.)
TABLE 1
Type 2 inflammation biomarkers in allergic diseases
Biomarker Clinical Utility Reproducibility
Nasal eosinophils Clinical setting ?
Blood eosinophils Clinical setting No
Serum periostin Research setting Yes
The Th2 gene signature (serpin B2, 
periostin, CLCA1 or CLC, CPA3, 
DNA- SE1L3) in nasal epithelial cells
Research setting Yes
The salivary inflammatory profile. Research setting ?
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ment of Asthma. Curr Treat Options 
Allergy 2014;1:198–212.
5. Agache I, Sugita K, Morita H, Akdis 
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Options in Allergy. The Com-
plex Type 2 Endotype in Allergy 
and Asthma: From Laboratory 
to Bedside. Curr Allergy Asthma 
Rep 2015;in press.
6. Papadopoulos NG, Bernstein JA, 
Demoly P, Dykewicz M, Fokkens W, 
Hellings PW, et al., Phenotypes and 
endotypes of rhinitis and their im-
pact on management: a PRACTALL 
report. Allergy 2015;70:474-94.
Phenotypes and endotypes of allergic rhinitis
Th17 
(neutrophilic inflammation)
Th1 
(apoptosis/granuloma)
IL-9 / mast cells / PGD2
Remodelling phenotype Metabolic pathways (eicosanoids; L-Arg/ADMA)
Innate immune response 
(TSLP, IL-33, ILC2, iNKT, Eos) 
Th2 cells
IgE  
(atopic and non-atopic) IL-4 / IL-13
IL-5 / 
eotaxin
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s • Aspirin-exacerbated respiratory diseases (AERD) are 
characterized by intense eosinophilic inflammation of upper and 
lower airways, which leads to more severe airway inflammation 
and a need for more aggressive medical and surgical interventions
• Dysregulation of arachidonic acid metabolism, overproduction 
of cysteinyl leukotrienes with reduction of PGE2 is a major 
pathogenic mechanism of AERD, in which genetic mechanisms 
regulating with leukotriene synthesis and eosinophil-related 
genetic polymorphisms are involved
• Local and systemic IgE responses to Staphylococcal 
superantigens contribute to eosinophil activation in the upper 
and lower airway inflammation
• Inhaled and intranasal steroid, and leukotriene receptor 
antagonists are recommended as controller medications. Sinus 
surgery is considered as a next treatment option if medical 
treatment fails
• Aspirin desensitization can be recommended, if the upper and 
lower airway symptoms are refractory to medical and surgical 
treatments. Biologics such as anti-IgE and anti-IL-5 antibodies 
are suggested as future therapeutic options
Aspirin-exacerbated respiratory 
diseases (AERD) is a distinct syn-
drome characterized by moderate 
to severe asthma, chronic rhinosi-
nusitis (CRS) with nasal polyps 
(CRSwNP), and hypersensitivity to 
aspirin/non-steroidal anti-inflam-
matory drugs (NSAIDs). It affects 
10-20% of asthmatic patients 
and about 8-26% of patients di-
agnosed with CRSwNP. AERD is 
common in middle-aged women 
and usually presents with severe 
CRS and asthma symptoms.
PATHOGENIC MECHANISMS
The key features of AERD are the 
intense eosinophilic infiltration of 
the upper and lower airway mu-
cosa and the refractory nature 
to routine pharmacological treat-
ment. Major pathogenic mecha-
nisms are represented by the as-
sociation between a susceptible 
genetic background with overpro-
duction of cysteinyl leukotrienes 
and increased local and systemic 
IgE (Figure 1). Overproduction of 
cysteinyl leukotrienes (CysLTs) oc-
curs via activation of 5-lipoxygen-
ase (LO) pathway with decreased 
level of PGE2. Increased number 
of platelet-adherent leukocytes 
was noted, which results in in-
creased production of CysLTs. Lo-
cal and systemic IgE responses to 
ASPIRIN-EXACERBATED 
RESPIRATORY DISEASE1
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Staphylococcal superantigens con-
tribute to eosinophil activation via 
polyclonal T and B cell activation 
with induction of Th2 cytokines 
and polyclonal IgE production. Ge-
netic studies indicated that HLA 
DPB1*0301 is a strong genetic 
marker for AERD. The genetic pol-
ymorphisms of leukotriene related 
genes (CysLTR1, 5-LO,15-LO) and 
of eosinophil related genes (CCR3, 
CRTH2, IL-5, IL5R, P2RY12) were 
reported to be associated with 
AERD.
DIAGNOSIS
A history of an asthmatic at-
tack after ingestion of aspirin/
NSAIDs, or the association of CR-
SwNP with asthma is suggestive 
of AERD. A definite in vitro diag-
nostic test is not available, thus 
Aspirin-exacerbated respiratory disease
Hae-Sim Park  
Ajou University School of Medicine 
Suwon, South Korea
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the gold diagnostic test is aspirin 
challenge tests via variable routes, 
including bronchial provocation 
which proved safe and is wide-
ly used. Serum periostin and the 
serin protease dipeptidyl pepti-
dase 10 (DPP10) were suggested 
as potential serum biomarkers 
for predicting the phenotype of 
AERD.
MANAGEMENT
Patients with AERD should be 
recommended to avoid ingestion 
of aspirin/NSAIDs. Highly selec-
tive COX-2 inhibitors are safer 
alternatives, although their abso-
lute safety has not been proven 
yet. Pharmacological treatment 
is needed to control the severe 
eosinophilic inflammation of the 
upper and lower airways. Intrana-
sal steroids, inhaled corticosteroid 
with/without long acting beta2 
agonist and leukotriene receptor 
antagonists are recommended as 
controller medications. Sinus sur-
gery is considered as a next treat-
ment option after the medical 
treatment fails. Aspirin desensiti-
zation can be recommended for 
the CRSwNP patients with AERD 
who are refractory to medical and 
surgical treatments.
In conclusion, further efforts are 
needed to investigate diagnostic 
biomarkers for early diagnosis of 
AERD and to evaluate the efficacy 
of new biologics such as anti-IL-5, 
anti-IL5R or anti-IgE antibodies.
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Aspirin-exacerbated respiratory disease
Figure 1 The pathogenic mechanisms and future therapeutic intervention for aspirin exacerbated respiratory disease.
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several syndromes
• Approximately 50% of patients with chronic rhinitis are non-
allergic
• The pathophysiology of the most common form of NAR is 
unknown (idiopathic rhinitis)
• Management of NAR is not optimal; most commonly used 
medications include intranasal corticosteroids, azelastine and 
ipratropium
Non-allergic rhinitis (NAR) is de-
fined as chronic or episodic nasal 
symptoms in the absence of any 
evidence of an allergic etiology. It 
is a diagnosis of exclusion and not a 
distinct nosologic entity. A number 
of syndromes have been defined on 
the basis of clinical characteristics 
(Table 1), but the pathophysiologic 
mechanisms behind most of these 
syndromes have not been elucidat-
ed. Infectious rhinitis, including the 
common cold, and chronic rhinosi-
nusitis are generally not considered 
under the umbrella of NAR.
When all syndromes are consid-
ered, close to 50% of patients, 
who complain of chronic or epi-
sodic nasal symptoms fall under 
the NAR category. The relative 
prevalence of NAR, compared 
to allergic rhinitis (AR), increases 
with age. Idiopathic rhinitis is the 
most common NAR syndrome.
Patients with NAR can present 
with the full constellation of rhi-
nitis symptoms, including rhinor-
rhea, nasal congestion, posterior 
nasal drainage, local pruritus and 
sneezing, but the latter two are 
less prominent, compared to AR. 
Also, conjunctival symptoms and 
asthma co-morbidity are less com-
mon in NAR. Another difference 
between AR and NAR is that pa-
NONALLERGIC 
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tients with the latter condition 
have lower prevalence of family 
history of rhinitis or asthma. How-
ever, none of these differences can 
be used as a reliable diagnostic 
characteristic for NAR. The only 
diagnostic approach to NAR is the 
exclusion of allergy either through 
skin testing or allergen-specific 
serum IgE measurements. Even 
when skin testing is negative and 
allergen-specific serum IgE is un-
detectable or very low, the possi-
bility exists that local production 
of IgE at the nasal mucosa may be 
responsible for a patient’s condi-
tion. In this instance, and as long as 
a nasal allergen challenge confirms 
it, the diagnosis of local allergic rhi-
nitis (LAR) can be given. Ongoing 
debate as to the prevalence of LAR 
and the fact that LAR responds 
well to conventional AR treatment 
makes it difficult to recommend 
routine nasal allergen challenge for 
the differential diagnosis of NAR.
Management of NAR is summa-
rized in Table 1. For syndromes in 
which the etiology is known (e.g. 
drug-induced rhinitis), removal of 
the offending agent is the most 
logical and effective intervention. 
In the case of idiopathic rhinitis, 
treatment should aim towards 
controlling symptoms since cur-
ing the condition is not an option 
at this point. Azelastine, an intra-
nasal antihistamine, or intranasal 
corticosteroids should be tried 
first; intranasal capsaicin may be 
used in some specialized centers. 
For patients with excessive rhin-
orrhea, intranasal ipratropium can 
offer adequate relief.
Nonallergic rhinitis
Alkis Togias  
Institute of Allergy and Infectious Diseases 
Bethesda, Maryland, USA
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TABLE 1
Nonallergic Rhinitis Syndromes: Characteristics, Mechanisms and Management
Nonallergic Rhinitis 
Syndromes Subphenotypes Clinical Characteristics Mechanisms/Endotypes Management
Idiopathic Rhinitis
Alternative Terms:
• Nonallergic, 
noninfectious 
perennial rhinitis 
(NANIPER)
• Intrinsic rhinitis
• Vasomotor 
rhinitis
• Nonallergic 
rhinopathy
None identified • Most prevalent form 
of NAR
• Most common symp-
toms: nasal conges-
tion, rhinorrhea
• Triggers: irritants and/
or weather chang-
es (but also chronic 
symptoms without 
identifiable triggers)
• Uncertain role of inflamma-
tion
• Sensorineural hyperreactivity 
(neurogenic rhinitis)?
• Irritant avoidance
• Oral antihistamines 
ineffective
• Nasal antihistamines 
(azelastine): effective
• Intranasal corticos-
teroids: conflicting 
results
• Capsaicin: effective 
(small studies)
Nonallergic Rhi-
nitis with Eosino-
philia Syndrome 
(NARES)
None identified • Most common symp-
toms: nasal con-
gestion, rhinorrhea, 
sneezing, pruritus
• Nasal secretion eo-
sinophilia
• Related to local allergic rhini-
tis?
• A prodrome to chronic rhi-
nosinusitis?
• Intranasal corticos-
teroids: effective
Hormonal Rhinitis • Rhinitis of 
pregnancy
• Menstrual 
cycle-associ-
ated rhinitis
• Most common symp-
tom: nasal congestion
• Rhinitis of pregnancy: 
most common during 
late pregnancy; smok-
ing is a risk factor
• Estrogen effects on nasal vas-
culature?
• Rhinitis of pregnan-
cy: Minimal possi-
ble intervention for 
symptom relief
Rhinitis of the 
Elderly
None identified • Most common symp-
tom: watery rhinor-
rhea
• Triggers: spontane-
ous
• Cholinergic nasal hyperreac-
tivity?
• Anticholinergics
Gustatory Rhinitis None identified • Most common symp-
tom: watery rhinor-
rhea
• Triggers: hot and 
spicy foods
• Cholinergic nasal hyperreac-
tivity?
• Post-traumatic
• Post-surgical
• Cranial nerve neuropathy-as-
sociated
• Idiopathic (most common)
• Avoidance of spicy 
food
• Anticholinergics pri-
or to spicy food
Atrophic Rhinitis • Primary 
(warm cli-
mates)
• Secondary
• Mucosal and glandu-
lar atrophy
• Bacterial colonization
• Perceived nasal con-
gestion
• Crusting
• Foetor
• Hyposmia
• Primary: unclear
• Secondary: extensive sur-
gery, chronic granulomatous 
disorders
• Nasal irrigation
• Antibiotics as need-
ed
Cold air-Induced 
Rhinitis
(Skiers’ Nose)
None identified • Most common symp-
toms: rhinorrhea, nasal 
congestion, burning
• Trigger: cold, windy 
conditions
• Nasal nociceptor activation 
by hyperosmolarity and, pos-
sibly, low temperature
• Anticholinergics pri-
or to cold air expo-
sure
Nonallergic rhinitis
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TABLE 1
Nonallergic Rhinitis Syndromes: Characteristics, Mechanisms and Management (continued)
Nonallergic Rhinitis 
Syndromes Subphenotypes Clinical Characteristics Mechanisms/Endotypes Management
Drug-Induced 
Rhinitis
• Rhinitis me-
dicamentosa
• Aspirin-Exac-
erbated Res-
piratory Dis-
ease (AERD)
• Rhinitis in-
duced by sys-
temic alpha 
and beta-adr-
energic an-
tagonists
• Rhinitis in-
duced by 
phosphodi-
e s t e r a s e 
(PDE) V inhib-
itors
• Rhinitis in-
duced by oth-
er drugs (ACE 
inhibitors, cal-
cium channel 
blockers, an-
tipsychotics)
• AERD includes nasal 
polyposis and asth-
ma; diagnostic aspirin 
challenge
• Most common symp-
tom of other pheno-
types: nasal conges-
tion
• Rhinitis medicamentosa: ex-
cessive use of intranasal de-
congestants (alpha adrener-
gic agonists) downregulating 
alpha-adrenergic receptor 
function
• AERD: overproduction of leu-
kotrienes and dysregulation 
of enzymes and receptors re-
sponsible for the production 
and function of protective 
lipid mediators
• Systemic alpha and beta-adr-
energic antagonists: down-
regulation of nasal sympa-
thetic tone
• PDE V inhibitors: increased 
local concentrations of nitric 
oxide causing vascular dilata-
tion and congestion
• Other drug-induced rhinitis: 
mechanisms unclear
• Removal of offend-
ing drug (if clinically 
possible)
• Rhinitis medicamen-
tosa may be avoid-
able if nasal corti-
costeroids are used 
concomitantly; nasal 
corticosteroids can 
be used to facilitate 
withdrawal of de-
congestants
• AERD: aspirin de-
sensitization fol-
lowed by long-term 
aspirin treatment
Occupational 
Nonallergic Rhi-
nitis
• Irritant-in-
duced rhinitis
• Corrosive 
rhinitis
• Irritant-induced: 
symptoms subside 
after a few days away 
from work
• Irritant-induced: can be as-
sociated with neutrophilic in-
flammation, possibly caused 
by neuropeptides released 
locally from sensory nerves
• Corrosive: diffuse mucosal 
damage induced by toxic 
chemical gases
• Avoidance of causa-
tive exposures
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• Local allergic rhinitis (LAR) is a new phenotype of allergic rhinitis 
(AR) characterized by a localized nasal allergic response in 
patients with negative skin prick-test (SPT) and non-detectable 
serum specific IgE (sIgE) antibodies
• LAR is an under/misdiagnosed disease that may affect patients 
from different countries, ethnic groups and ages
• The diagnosis of LAR is based on a clinical history, a positive 
response to nasal allergen provocation test and/or the detection 
of nasal sIgE
• SPT and serum sIgE are not sufficient to differentiate between 
LAR and non-AR
• Subcutaneous allergen immunotherapy has demonstrated to 
be an effective treatment in LAR
Local allergic rhinitis (LAR) is a 
clinical entity characterized by 
nasal itching, sneezing, rhinorrea 
and obstruction caused by a nasal 
allergic response to aeroallergens 
in the absence of systemic atopy 
(negative skin prick test (SPT) and 
undetectable sIgE in serum) (Fig-
ure 1). LAR is a newly described 
phenotype of allergic rhinitis (AR) 
that may starts early in life and 
persists throughout the years, 
with a tendency towards clinical 
worsening and the development 
of asthma. It is a common respira-
tory disease, affecting patients 
from different countries, ethnic 
groups and ages, with impairment 
of the quality of life and frequent 
association to conjunctivitis and 
asthma. Every physician can see 
patients with LAR every day dur-
ing practice and should be pre-
pared to differentiate these pa-
tients from non-AR.
Immunologically the nasal muco-
sa inflammation of LAR patients 
presents a Th2 cytokine profile 
with local production of sIgE and 
increased levels of eosinophils, 
mast-cells and T cells. Typical-
ly there is a positive response to 
nasal allergen provocation test 
(NAPT) and NAPT induces the im-
mediate and late phases of the al-
LOCAL ALLERGIC 
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lergic inflammatory response with 
nasal production of tryptase, eo-
sinophil cationic protein, and sIgE 
antibodies (Figure 2).
The diagnosis of LAR is based on a 
clinical history of allergen induced 
rhinitis symptoms in patients with 
negative SPT and undetectable se-
rum sIgE followed by the demon-
stration of an allergic response to 
aeroallergens by NAPT and/or the 
detection of nasal sIgE (Figure 3). 
A detailed clinical history is cru-
cial for identifying patients with 
LAR. The majority of patients are 
non-smoking young women, who 
have moderate to severe rhinitis 
associated with conjunctivitis and 
asthma. The onset of the disease 
in childhood and a family history 
of atopy are also common in LAR 
(Table 1). The NAPT is the gold 
standard for the diagnosis of LAR. 
It is safe, sensitive, specific, and 
reproducible, although time-con-
suming. Fortunately, a new pro-
tocol for NAPT with multiple 
aeroallergens in one session has 
shortened the diagnosis. The de-
termination of nasal sIgE and the 
basophil activation test (BAT) are 
very specific in vitro techniques 
useful for confirming LAR.
LAR patients have a good re-
Local allergic rhinitis
Carmen Rondon  
Regional University Hospital of Málaga 
Malaga, Spain
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Figure 1 Local 
allergic rhinitis (LAR) 
is characterized 
by a nasal Th2 
inflammatory 
response with local 
production of sIgE 
antibodies and 
positive response to 
NAPT (green arrow) 
in patients with a 
negative skin prick 
test and absence 
of IgE antibody in 
peripheral blood (red 
arrows). (Reprinted 
from J Allergy Clin 
Immunol, 129/6, 
Rondón C, Campo P, 
Togias A, Fokkens WJ, 
Durham SR, Powe 
DG, Mullol J, Blanca 
M. Local allergic 
rhinitis: concept, 
pathophysiology, and 
management, 1460-
1467, Copyright 2012, 
with permission from 
Elsevier.)
Figure 2 Kinetic of nasal 
production of inflammatory 
mediators (tryptase and 
eosinophil cationic protein 
(ECP)) after nasal allergen 
provocation test with grass 
pollen (figure 2A) and D. 
pteronyssinus (figure 2 B). 
(Figure 2A reprinted from J 
Allergy Clin Immunol, 124/5, 
Rondón C, Fernández J, López 
S, Campo P, Doña I, Torres MJ, 
Mayorga C, Blanca M. Nasal 
inflammatory mediators and 
specific IgE production after 
nasal challenge with grass pollen 
in local allergic rhinitis, 1005-
1011.e1, Copyright 2009, with 
permission from Elsevier. Figure 
2B reproduced with permission 
from López S, Rondón C, Torres 
MJ, et al. Immediate and dual 
response to nasal challenge with 
Dermatophagoides pteronyssinus 
in local allergic rhinitis. Clin Exp 
Allergy 2010;40:1007-1014, 
with permission from Willey 
Blackwell.)
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Clinical suspicion 
of allergic rhinitis
Routine allergy test:
SPT and/or sIgE
Allergic Rhinitis
Positive & concordant 
with clinical history
Negative
Specialized allergy tests: 
NAPT (gold standard) 
Nasal sIgE
Basophil Activation Test
Positive
Local Allergic Rhinitis Non Allergic Rhinitis
Negative
Positive but 
discordant with 
clinical history
Figure 3 In suggestive cases of AR 
with negative SPT and serum sIgE, 
a thorough allergological evaluation 
(nasal allergen provocation test 
and/or nasal detection of sIgE and 
basophil activation test) should be 
considered to differentiate between 
LAR and non-allergic rhinitis. 
(Adapted from Campo P, Rondón C, 
Gould HJ, Barrionuevo E, Gevaert P, 
Blanca M. Local IgE in Non-Allergic 
Rhinitis. Clin Exp Allergy. 2015 
May;45(5):872-81.)
Figure 4. Specific immunotherapy in LAR
AIT group Control 
group
AIT group                 Control 
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AIT group                 Control 
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A) Nasal tolerance to grass pollen
B) Clinical response to grass-AIT
Figure 4 Allergen immunotherapy (AIT) for LAR. The treatment of LAR patients with a course of 6 months of grass 
specific subcutaneous AIT induced increased tolerance to allergen with negative NAPT in three patients (A), and 
a clinical improvement in the following spring (B), with reduction in daily rhinoconjunctivitis symptom and rescue 
medication scores and an increase of the number of medication-free days compared with the control group treated 
with oral antihistamines and intranasal corticosteroids. (Adapted from Rondón C, Blanca-López N, Aranda A, et al. Local 
allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. J Allergy Clin 
Immunol. 2011 Apr;127(4):1069-71)
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TABLE 1
Demographic and clinical differences between LAR and non-allergc rhinitis 
(NAR)
LAR NAR p value
Number of patients 110 48
Age (y) 29* 42 0.001
Onset age (y) 21* 36 0.001
Onset in childhood (%) 36* 9 0.001
Women (%) 78* 52 0.001
Non-smoking habit (%) 81 83 >0.05
Family history of atopy (%) 44* 21 0.005
Rhinitis classification (%)
Persistent symptoms 91 85 >0.05
Perennial symptoms 71 77 >0.05
Severity of symptoms
Mild 5 8 ND
Moderate 36 57 ND
Severe 59* 35 0.006
Nasal symptom (%)
Itching 86* 71 0.031
Sneezing 80 71 >0.05
Nasal obstruction 60 90* 0.001
Mucous rhinorrea 22 71* 0.001
Main trigger factors (%)
House dust 47* 19 0.001
Irritant 19 46* 0.001
Comorbidites (%)
Conjunctivitis 65 50 >0.05
Asthma 31 18 >0.05
Continuous variable are expressed as mean
LAR: local allergic rhinitis; NAR: non-allergic rhinitis; y: years * p <0.05. (Table 
adapted from Rondón C, Campo P, Galindo L, Blanca-López N, Cassinello MS, 
Rodriguez-Bada JL, Torres MJ, Blanca M. Prevalence and clinical relevance of local 
allergic rhinitis. Allergy. 2012 Oct;67(10):1282-8.)
sponse to allergen avoidance 
measures, and pharmacological 
treatment with intranasal cor-
ticosteroids and oral antihista-
mines. Ongoing evidence indicate 
that subcutaneous allergen immu-
notherapy with grass and house 
dust mite is beneficial for LAR by 
reducing the symptoms and the 
use of rescue medication, and by 
increasing immune tolerance to-
wards the allergen.
KEY REFERENCES
1. Rondón C, Campo P, Togias A, 
Fokkens WJ, Durham SR, Powe 
DG, et al. Local allergic rhinitis: 
concept, pathophysiology, and 
management. J Allergy Clin Immu-
nol 2012;129:1460-1467.
2. Rondón C, Campo P, Zambonino 
MA, Blanca-Lopez N, Torres MJ, 
Melendez L, et al. Follow-up study 
in local allergic rhinitis shows a 
consistent entity not evolving to 
systemic allergic rhinitis. J Aller-
gy Clin Immunol 2014;133:1026-
1031.
3. Gómez E, Campo P, Rondón C, Bar-
rionuevo E, Blanca-López N, Torres 
MJ, et al. Role of the basophil acti-
vation test in the diagnosis of local 
allergic rhinitis. J Allergy Clin Immu-
nol 2013;132:975-976.e1-5.
4. Rondón C, Blanca-López N, Aran-
da A, Herrera R, Rodriguez-Bada 
JL, Canto G, et al. Local allergic 
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• Several conditions that are mimicking allergic rhinitis (AR), 
such as chronic rhinosinusitis (CRS), are partly associated with 
rhinitis symptoms
• The prevalence of rhinitis symptoms or skin prick test positivity 
are high, which might lead to delay in diagnosing a condition 
mimicking AR
• Some conditions mimicking AR need fast detection and 
treatment such as nasal foreign body, tumor and cerebrospinal 
fluid leakage
Several conditions mimick aller-
gic rhinitis (AR) (Table 1). The in-
flammation of the nasal mucosa 
may or may not associate these 
conditions. Rhinitis is a prevalent 
disorder, whereas some mimick-
ing conditions are rare. This may 
cause delayed diagnosis of the 
mimicking disorders.
Inflammation close to the nasal 
cavity usually leads to inflamma-
tion of the nasal mucosa. Exam-
ples include rhinosinusitis, inflam-
mation of the oral cavity, such 
as dental caries and periodontal 
disease, rare infections such as tu-
berculosis, fungal sinusitis, Lyme 
disease, meningitis and autoim-
mune diseases such as Wegen-
er´s granulomatosis and Sjogren’s 
syndrome. In children, the most 
common disorders mimicking rhi-
nitis are adenoid hypertrophy and 
intranasal foreign body.
Sniffling, a habit rhinitis may de-
velop in children after a cold or 
other irritant. These rhinitis symp-
toms disappear during sleep. Dys-
function of autonomous nervous 
system may lead to rhinitis. Psy-
chosocial stress may affect rhinitis 
via the neuro-endocrine system. 
Depression and other psychiatric 
disorders may generate or modify 
rhinitis symptoms.
CONDITIONS MIMICKING 
ALLERGIC RHINITIS4
KE Y MESSAGES
Tumors and congenital defects, 
such as choanal atresia, primary 
ciliary dyskinesia or cystic fibrosis 
are rarely associated with rhinitis 
symptoms. It is important to avoid 
delayed diagnosis of benign and 
malignant tumors. Treatment-re-
sistant or unilateral rhinitis symp-
toms should raise suspicion of a 
tumour. Such tumors include in-
verted papilloma, olfactory neuro-
blastoma, juvenile angiofibroma, 
hemangioma, squamous cell car-
cinoma, lymphoma, tumors irritat-
ing trigeminal nerve, and central 
lesions.
Structural abnormalities, such as 
nasal septum deviation, hyper-
trophic inferior turbinate and val-
vular insufficiency, often exist to-
gether with rhinitis. Spontaneous 
or traumatic defect of the skull 
base may cause cerebrospinal rhi-
norrhea.
Head and facial pain, headache 
and decreased olfaction are im-
portant signs in the differential 
diagnosis between AR and chron-
ic rhinosinusitis. Other important 
signs to exclude mimickers are 
muco-purulent discharge, na-
sal bleeding, systemic symptoms 
such as low grade fever and ma-
laise, severe and treatment resist-
ant rhinitis symptoms or unilateral 
symptoms.
In conclusion, several rhini-
tis-mimicking conditions may ex-
ist with or without inflammation 
of the nasal mucosa. Their early 
detection will essentially improve 
health.
Conditions mimicking allergic rhinitis
Sanna Toppila-Salmi  
Haartman Institute, University of Helsinki 
Helsinki, Finland
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TABLE 1
Conditions mimicking rhinitis
Congenital defects Primary ciliary dyskinesia
Cystic fibrosis
Choanal atresia
Other
Structural 
abnormalities
Adenoid hypertrophy
Septum deviation
Septal perforation
Hypertrophic inferior turbinate
Valvular insufficiency
Other
Inflammation in 
neighboring organs
Sinusitis
Otitis
Tonsillitis
Dental caries
Periodontal disease
Pharyngitis
Laryngitis
Bronchitis
Pneumonia
Esophagitis
Other
Autoimmune and 
autoinflammatory 
diseases
Eosinophilic granulomatosis with 
polyangiitis (allergic granulomatosis or 
Churg Strauss syndrome)
Wegener´s granulomatosis
Sarcoidosis
Amyloidosis
Sjogren’s syndrome
Chronic fatigue syndrome
Thyroiditis
Other
Rare infection Fungal sinusitis
Tuberculosis
Lyme disease
Syphilis
Meningitis
Encephalitis
Other
Tumors
Benign Inverted papilloma
Hemangioma
Osteoma
Fibrous dysplasia
Angiofibroma
Meningioma
Other
Malignant Squamous cell carcinoma
Transitional cell carcinoma
Adenocarcinoma
Adenoid cystic carcinoma
Melanoma
Olfactory neuroblastoma
Undifferentiated carcinoma
Soft-tissue sarcoma
Rhabdomyosarcoma
Leiomyosarcoma
Fibrosarcoma
Liposarcoma
Angiosarcoma
Myxosarcoma
Hemangiopericytoma
Connective tissue sarcoma
Chondrosarcoma
Osteosarcoma
Synovial sarcoma
Lymphoma
Plasmacytoma
Giant cell tumor
Metastatic carcinoma
Glioma
Tumor affecting trigeminal nerve or orbit
Neurological 
conditions
Migraine
Tension headache
Cluster headache
Neuropathic pain (trigeminal neuralgia)
Atypical facial pain
Autonomous nerve dysfunction
Repeated facial spasm (Tic)
Parkinson’s disease
Multiple sclerosis
Syringobulbia
Other
Psychosocial 
disorders
Psychogenic rhinitis (Habit rhinitis)
Psychosocial stress
Anxiety disorders
Depression
Bipolar disorder
Psychosomatic syndrome
Psychosis
Other
Other Trauma
Foreign body
Cerebrospinal fluid leak
Rhinolith
Prominent nasal cycle
Gastro esophageal reflux disease
Temporo-mandibular joint dysfunction
Disease or irritation of the orbit
Obstructive sleep apnea
Conditions mimicking allergic rhinitis
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• Primary ciliary dyskinesia (PCD) is a genetically heterogeneous 
recessive disorder of motile cilia that leads to sino-pulmonary 
disease, serous otitis media and infertility. Organ laterality 
defects occur in ~50% of cases
• Respiratory and nasal symptoms typically start in infancy
• There is no single ‘gold standard’ diagnostic test. Patients 
require referral to highly specialised centres where a panel of 
complimentary sophisticated investigations is available
• The evidence base for treating PCD is limited, and approach is 
largely based on local experience
Primary ciliary dyskinesia (PCD) is 
a rare, genetically heterogeneous 
recessive disorder of biogenesis, 
structure and/or function of motile 
cilia. Ciliated epithelial cells line the 
airways, nasal and sinus cavities 
and Eustachian tube. In healthy 
individuals, mucociliary clearance 
(MCC) occurs as cilia beat in a co-
ordinated pattern, propelling mu-
cus to the oropharynx where it can 
be swallowed (Figure 1). Impaired 
MCC in patients with PCD is a con-
sequence of abnormal ciliary beat 
function, which is usually but not 
always associated with abnormal 
ciliary axoneme structure as seen 
with transmission electron micros-
copy (TEM) (Figure 2). Mutations 
in over 30 genes, accounting for 
≈65% of cases, have been pub-
lished to date.
Estimates of prevalence vary 
widely due to the broad range of 
non-specific clinical symptoms, 
variation of mutations in different 
populations and under-diagnosis. 
It has been estimated that PCD 
occurs in approximately 1:10,000 
Europeans, and is higher in certain 
consanguineous populations.
SYMPTOMS OF PCD
Clinicians should refer patients 
with symptoms suggestive of PCD 
(Table 1) to a specialist diagnostic 
PRIMARY CILIARY 
DYSKINESIA5
KE Y MESSAGES
centre. Early onset of daily res-
piratory symptoms is a key feature 
of PCD. Patients typically present 
as neonates with respiratory dis-
tress, which may range from mild 
transient tachypnoea to respirato-
ry failure requiring prolonged ven-
tilatory support. Neonatal rhinitis 
is also common. A persistent wet 
cough and recurrent respiratory 
infections continue throughout 
childhood and adulthood, often 
with exacerbations during infec-
tions. Bronchiectasis can present 
in infancy and is almost invariable 
by adulthood, predominantly af-
fecting lower and middle lobes.
Most patients have persistent rhi-
nitis, and radiographic evidence of 
chronic pan-sinusitis is apparent 
in childhood. Serous otitis media 
often fluctuates and frequently 
is associated with transient im-
paired hearing that rarely evolves 
into permanent hearing loss. The 
structure of sperm flagella is simi-
lar to the ultrastructure of cilia, ac-
counting for male infertility, which 
is common in PCD. Dysfunction 
of nodal cilia, important for left-
right asymmetry during embryon-
ic development, accounts for situs 
inversus in ≈50% and situs ambigu-
ous in ~10% of patients.
DIAGNOSIS
Diagnosis of PCD is challenging, 
with no ‘gold standard’. The com-
posite of tests contributing to the 
diagnosis include measurement of 
nasal nitric oxide, assessment of 
ciliary function by high-speed vid-
Primary ciliary dyskinesia
Jane S. Lucas  
University of Southampton 
Southampton, UK
Margaret W. Leigh  
University of North Carolina 
Chapel Hill, USA
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eo microscopy, ciliary ultrastruc-
ture by TEM and genetics testing. 
Performance and interpretation of 
these tests is not straightforward 
and should be conducted in cen-
tres with extensive experience of 
normal and abnormal findings.
MANAGEMENT
There is a lack of evidence for the 
optimal management of PCD with 
no long-term randomised trials 
of treatment. As a result, patient 
care is usually based local expe-
rience with other diseases (eg. 
cystic fibrosis or sinus disease) de-
spite differing underlying patho-
physiology. Specialists agree that 
multi-disciplinary care, with an ag-
gressive approach to airway clear-
ance and management of infec-
tions is important for prognosis. 
However, wide variations in ap-
proach to specific treatment exist, 
for example ventilation tubes are 
commonly used in some countries 
to manage serous otitis media.
KEY REFERENCES
1. Knowles MR, Daniels LA, Davis 
SD, Zariwala MA, Leigh MW. Pri-
mary ciliary dyskinesia. Recent 
advances in diagnostics, genet-
ics, and characterization of clini-
TABLE 1
Who to refer for diagnostic testing
Refer if >2 of these symptoms or, in isolation if other reasons for higher index 
of suspicion eg. very early onset of symptoms, consanguineous background.
Neonatal respiratory distress of unknown cause
Sibling with PCD, particularly if symptomatic
Situs inversus totalis or other laterality defect, including cardiac disease asso-
ciated with heterotaxy (situs ambiguous)
Daily wet cough starting in early childhood
Unexplained bronchiectasis
Persistent serous otitis media
Persistent rhinitis and/ or sinusitis
Male infertility
Figure 1 Cilia lining the upper and lower airway of healthy individuals beat in a coordinated sweeping pattern, 
moving mucus with entrapped particles including pathogens and debris towards the oropharynx for swallowing or 
expectorating. In PCD cilia do not beat effectively, and mucus and debris fail to be cleared by mucociliary clearance 
(MCC). (Image provided by Robert Scott)
Primary ciliary dyskinesia
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Figure 2 Transverse section of a respiratory cilium as seen by TEM. a) motile cilia in the respiratory tract have a highly 
organized “9+2” arrangement with nine peripheral microtubule doublets surrounding a central pair of single microtubules 
running the length of the ciliary axoneme. Nexin and radial spokes support the structure. Attached to the peripheral 
microtubules are inner and outer dynein arms. Dynein is a mechano-chemical ATPase responsible for generating the 
force for ciliary beating. Abnormalities of the dynein arms, or of the structures maintaining the 9+2 arrangement impair 
normal ciliary beating, preventing normal mucociliary clearance. b) TEM of motile cilia from patients with PCD due to an 
outer dynein arm defect and (c) disorganized ciliary structure. (Schematic image provided by Robert Scott; EM images 
obtained using FEI Tecnai 12 transmission electron microscope (FEI UK Limited, Cambridge, UK) at80 kV). Scale bars580 
nm. EM images provided by P. Goggin (Primary Ciliary Dyskinesia Group, University Hospitals Southampton NHS Foundation 
Trust, Southampton, UK).
cal disease. Am J Respir Crit Care 
Med 2013;188:913-922.
2. Lucas JS, Burgess A, Mitchison HM, 
Moya E, Williamson M, Hogg C, et 
al. Diagnosis and management of 
primary ciliary dyskinesia. Arch Dis 
Child 2014;99:850-856.
3. Campbell RG, Birman CS, Morgan 
L. Management of otitis media 
with effusion in children with pri-
mary ciliary dyskinesia: a literature 
review. Int J Pediatr Otorhinolaryn-
gol 2009;73:1630-1638.
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disorder frequently associated with allergic rhinitis with 
sensitisation to pollen allergens
• Usually symptoms are rather mild and restricted to the oral 
mucosa
• Most of OAS reactions are mediated by the pan-allergens PR 
10 (Bet v 1) and profilin (Bet v 2) and linked with pollen allergies
The oral allergy syndrome, (OAS) 
is an IgE-mediated food allergic 
disorder frequently associated 
with allergic rhinitis (AR) with 
sensitisation to pollen allergens. 
A subgroup of pollen allergic pa-
tients, are sensitized to profilin 
(a pan-allergen present in all veg-
etables), and are prone to suffer 
from OAS. These patients are fre-
quently encountered in areas with 
intense grass pollinization.
In Northern and Central Europe, 
birch pollen allergic patients may 
develop OAS with symptoms in-
duced by apple, hazelnut, kiwi-
fruit, pear, carrot, celery and raw 
potato. In the Mediterranean area, 
pollen allergic patients may expe-
rience OAS with fruits of Rosace-
ae family (peach, apricot, plum, 
strawberry, cherry, nectarine, 
pear, apple) (Figure 1). Sometimes, 
patients allergic to nuts, legumes, 
animal foods such as cow’s milk, 
egg, fish and shellfish can suffer 
OAS.
The observed cross-reactivity 
between pollen and plant foods 
causing OAS can be correlated 
with sensitization to a small num-
ber of well known allergens (Table 
1). Homologues from the major 
birch pollen allergen, Bet v 1 and 
profilin, Bet v 2, are present in a 
ORAL ALLERGY 
SYNDROME6
KE Y MESSAGES
Oral allergy syndrome
Tomas Chivato  
School of Medicine CEU San 
Pablo of Madrid, Spain
Karin Hoffmann-Sommergruber  
Medical University of Vienna 
Austria
Figure 1 Fruits of Rosaceae family (peach, apricot, plum, strawberry, cherry, 
nectarine, pear, apple) inducing oral allergy syndrome in pollen allergic patients 
in the Mediterranean region. (Image from Banco de imágenes en Alergología - 
Spanish Society of Allergology and Clinical Immunology (SEAIC).)
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range of fruits, nuts, tree nuts and 
vegetables causing the birch pol-
len-fruit syndrome. For melon and 
banana allergy profilin sensitiza-
tion is the predominant sensitizer. 
In contrast, for the Mediterranean 
Rosaceae fruit allergy, sensitiza-
tion to profilin may account for 
OAS linked symptoms, while for 
more severe food allergy symp-
toms the non-specific lipid trans-
fer proteins are the main inducers 
allergens. Many raw plant foods 
contain allergens belonging to 
these three pan-allergen groups. 
Normally the patient’s sensitiza-
tion profile follows the geographi-
cal distribution mentioned above.
The symptoms of OAS include 
pruritus, tingling, and erythema 
or angioedema of the lips, tongue, 
palate and throat. Sometimes, 
pruritus appears in the ears or 
tightness in the throat is present. 
Symptoms appear within 15 min-
utes after ingestion of foods, nor-
mally fresh fruits or vegetables, 
and are usually mild and disappear 
spontaneously without any kind 
of treatment.
Occasionally, OAS may be the 
first symptom of other food al-
lergy manifestations (cutaneous, 
digestives, respiratory), even ana-
phylaxis.
TABLE 1
Difference between basophils and mast cells
PR10 associated food allergies Profilin associated food allergies
Rosaceae
Apple Mal d 1 Apple Mal d 4
Peach Pru p 1 Peach Pru p 4
Cherry Pru av 1 Cherry Pru av 4
Pear Pyr c 1 Pear Pyr c 4
Apiaceae
Carrot Dau c 1 Carrot Dau c 4
Celeriac Api g 1 Celeriac Api g 4
Corylaceae
Hazelnut Cor a 1.04 Hazelnut Cor a 2
Others
Kiwifruit Act d 8 Kiwifruit Act d 9
Peanut Ara h 8 Peanut Ara h 5
Soybean Gly m 4 Soybean Gly m 3
Melon Cuc m 2
Orange Cit s 2
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Table 1: Allerg ns frequently involved in OAS (Bet v 1 structur :pdb:1bv1; Bet v 2 
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Table 1: Allergens frequ ntly i volved in OAS (Bet v 1 structure:pdb:1bv1; Bet v 2 
structure:pdb:1CQA). 
Diagnosis of OAS is based on case 
history, skin prick testing prefer-
ably performed as prick to prick 
with raw food sources, and deter-
mination of specific IgE by in vitro 
tests. Assessment of sensitization 
patterns to inhalant allergens/
pollens can be helpful. Compo-
nent resolved diagnosis to pan-al-
lergens (Bet v 1, Bet v 2, Pru p 3) 
could provide valuable additional 
information. If the patient’s his-
tory is unclear, a mucosal and/or 
oral challenge test should be per-
formed, especially for patients at 
risk to develop severe food allergy 
symptoms such as anaphylaxis.
An elimination diet of the causa-
tive food is recommended based 
on conclusive diagnosis, discrim-
inating between sensitization 
patterns with and without clinical 
symptoms. Dietetic counseling 
should be offered to the patient 
how to avoid the incriminating 
food and if necessary to supple-
ment with vitamins. Usually no 
symptomatic treatment is re-
quired for OAS. Symptoms may 
improve with pollen allergen im-
munotherapy, but no solid clinical 
evidence is available.
KEY REFERENCES
1. Muraro A, Werfel T, Hoff-
mann-Sommergruber K, Roberts 
G, Beyer K, Bindslev-Jensen C, et 
al. EAACI food allergy and ana-
phylaxis guidelines: diagnosis and 
management of food allergy. Aller-
gy 2014;69:1008-1025.
2. Sampson H, Burks W. Adverse re-
actions to foods. In: Adkinson ND 
Jr, Bochner BS, Busse WW, Hol-
gate ST, Lemanske RF Jr, Simons 
FER, editors. Middleton's allergy: 
principles and practice. 7th edn. 
Vol. 2. St Louis: Mosby, Inc; 2009. 
p.1139-1167.
3. Fernández Rivas M. Food Allergy in 
Alergológica-2005. J Invest Allergol 
Clin Immunol 2009;19:37-44.
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mastocytosis
• Nasal itching, sneezing, and rhinorrhoea are the predominant 
nasal symptoms in this patient group
• The level of nasal tryptase correlates strongly with the main 
symptoms and could link up the individual local mast cell burden 
with the individual nasal complaints
• Based on the significance of this mastocytosis-associated 
symptom complex and elevated nasal tryptase levels, this 
entity is defined as non-allergic, mastocytosis-associated 
rhinitis (NAMAR)
Systemic mastocytosis (SM) is a 
clonal proliferative disorder of 
mast cells (MC) that causes patho-
logical accumulation of mast cells 
in various tissues, which results in 
a multitude of clinical symptoms 
due to MC mediator release. Nasal 
complaints in SM have been de-
scribed in previous studies as the 
most frequent allergy-suggesting 
symptoms. Evidence of allergy 
could only be found in approxi-
mately one half of the patients. 
Therefore, non-allergic rhinitis 
symptoms in SM patients have 
been assumed to be due to an in-
creased nasal mast cell burden. To 
prove this hypothesis, we investi-
gated whether nasal complaints in 
non-allergic SM patients are cor-
related with objective measures 
of nasal mast cell burden. Eleven 
adult patients with systemic mas-
tocytosis underwent a compre-
hensive rhinologic work-up. All 
patients fulfilled the clinical ARIA 
criteria for rhinitis. The allergo-
logic work-up included skin prick 
testing, testing for serum specif-
ic IgE, determination of tryptase 
levels (serum and nasal secretion), 
and nasal provocation testing. Ten 
out of eleven SM patients with 
clinical persistent allergic rhinitis 
were found to be non-allergic.
NON-ALLERGIC, 
MASTOCYTOSIS-ASSOCIATED 
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The clinical symptom pattern in 
SM patients with non-allergic 
persistent rhinitis was quite in 
contrast with the usually predomi-
nant symptoms in persistent aller-
gic rhinitis (AR): nasal obstruction 
was almost negligible, 
while itching, sneez-
ing, and rhinorrhea 
were the predominant 
symptoms in this pa-
tient group. All three 
predominant symp-
toms were strongly 
correlated with the 
nasal tryptase level, 
but not with the lev-
el of serum tryptase 
(Figure 1 and Table 
1). The level of na-
sal tryptase correlated strongly 
with the above mentioned main 
symptoms and provided the link 
between the individual local mast 
cell burden and the individual nasal 
complaints. The correlations be-
TABLE 1
Mastocytosis-associated nasal complaints
Nasal symptom Correlation (significance) with 
nasal tryptase level (p values)
Rhinorrhea p = 0.017
Sneezing p = 0.001
Itching p = 0.003
Obstruction p = 0.51
Data from Dollner R, Taraldsrud E, Iversen K, et al. 
Non-allergic, mastocytosis-associated rhinitis. Clin 
Exp Allergy 2013;43:406-412.
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tween nasal tryptase and median 
nasal symptom score respectively 
rhinorrhea, sneezing, and itching 
point to mast cell degranulation 
as the causal factor for rhinitis in 
MC patients. Thus, elevated nasal 
tryptase can be recommended as 
an indicator for mastocytosis-as-
sociated non-allergic rhinitis.
The clinically relevant complex 
of mastocytosis-associated nasal 
complaints are characterized by:
1) Persistent non-allergic nasal 
complaints, such as watery rhi-
norrhea, sneezing, and itching.
2) Elevated nasal tryptase as an 
objective measure.
Based on the demonstrated signif-
icance of this mastocytosis-asso-
ciated symptom complex, we pro-
posed these criteria to tentatively 
define the entity of non-allergic 
mastocytosis-associated rhinitis 
(NAMAR).
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Figure 1 Immunohistochemical staining (tryptase) for mast cells in the nasal mucosa (magnification 40x). (Picture by 
courtesy of Dr. Svetlana Tafjord, Oslo University Hospital, Oslo, Norway.)
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(OR) and work-exacerbated rhinitis
• Allergic OR is characterized by nasal and ocular symptoms 
due to IgE-mediated sensitization to a high molecular weight 
allergens or low molecular weight chemical sensitizers acting as 
haptens, through exposure in the work environment
• Risk factors for development of OR include level and length of 
exposure, atopy, and smoking
Work related rhinitis (WRR) de-
scribes a variety of conditions, 
where nasal symptoms are trig-
gered from exposure to allergens, 
chemical sensitizers, and/or ir-
ritants encountered in the work 
environment. WRR can be further 
classified into occupational rhinitis 
(OR) and work-exacerbated rhini-
tis (WER) (Figure 1). OR is defined 
as rhinitis triggered by a specific 
substance or exposure encoun-
tered in the work environment. 
Reactive upper airways dysfunc-
tion syndrome (RUDS), a non-al-
lergic form of OR, is induced by 
accidental exposure to high levels 
of irritants or chemical fumes in 
the workplace. OR should be dis-
tinguished from WER, a preexist-
ing rhinitis condition (e.g. allergic 
rhinitis), that is worsened by expo-
sures in the work environment.
OR may be due to both allergic and 
non-allergic mechanisms. It is most 
often associated with allergic sen-
sitization to high molecular weight 
(HMW) protein allergens. Less 
commonly, low molecular weight 
(LMW) chemical sensitizers can 
form haptens with respiratory pro-
teins and elicit typical allergic rhino-
conjunctivitis symptoms at work.
Allergic OR is characterized by 
nasal and ocular symptoms due to 
OCCUPATIONAL IRRITANT 
AND ALLERGIC RHINITIS8
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Occupational irritant and allergic rhinitis
an agent in the workplace, which 
has induced IgE-mediated sensi-
tization. Development of allergic 
OR symptoms may be preceded 
by a latency period of exposure 
of months to years. Demonstra-
tion of allergic sensitization is 
necessary to confirm allergic OR 
by a positive skin prick test and/
or elevated serum-specific IgE to 
the suspect workplace allergen(s). 
A few reactive chemicals, such as 
the acid anhydrides and platinum 
salts, have the capacity to hap-
tenize, forming allergenic epitopes 
and specific IgE responses. After 
a latency period of exposure to 
these chemicals, affected workers 
develop IgE-mediated OR and oc-
cupational asthma symptoms.
RUDS, a phenotype of non-aller-
gic OR, is chronic rhinitis related 
to an acute exposure to a chem-
ical irritant or combustion prod-
ucts. RUDS is not preceded by a 
latency period. Nasal pathology 
in RUDS is characterized by fo-
cal epithelial desquamation, glan-
dular hypertrophy, lymphocytic 
infiltrates, and sensory nerve fib-
er proliferation. Substance P re-
leased from sensory nerves, and 
not histamine, is the hypothesized 
as the major mediator involved.
Risk factors for development of 
OR include level and length of 
exposure, atopy, and smoking. 
Occupational asthma (OA) and 
OR are closely associated and 
coexist 76% to 92% of the time. 
OR symptoms typically precede 
those of OA in workers exposed 
to HMW agents or LMW agents.
A diagnosis of OR can be estab-
lished by a consistent medical 
J. Wesley Sublett James L. Sublett
Family Allergy and Asthma, Louisville 
Kentucky, USA
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history of WRR combined with 
demonstration of allergic sensi-
tization to specific substance(s) 
encountered in the workplace. 
Typical rhinitis and eye symptoms 
exacerbated by the work environ-
ment and resolving over week-
ends and/or during vacations are 
highly consistent with allergic OR. 
Patients presenting with rhinitis 
symptoms at work should be eval-
uated for non–work-related aller-
gic rhinitis caused by common en-
vironmental allergens, which may 
be confused with OR, but is more 
consistent with nonspecific WER. 
An accurate diagnosis of OR and 
the ability to distinguished it from 
WER may have important medico-
legal consequences.
The principles of management of 
WRR follow the same principles 
as for allergic rhinitis: avoidance 
of exposure, pharmacothera-
py and allergen immunotherapy 
(AIT). Steps to modify the work-
place could include: improved 
ventilation to remove offending 
exposures, using less hazardous 
materials, and creating closed-cir-
cuit manufacturing processes. 
Workers should be supplied with 
high-efficiency personal respira-
tors. Nasal steroids are first line 
therapy for persistent symptoms. 
Antihistamines are used for inter-
mittent symptoms or as ancillary 
agents to nasal steroids. AIT can 
be considered in patients with OR 
who fail pharmacotherapy and 
cannot avoid the causative aller-
gen. Due to the limited availability 
of commercial allergen extracts 
for AIT for many forms of allergic 
OR, indications for AIT are limited.
KEY REFERENCES
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and determinants. Clin Exp Aller-
gy 2000;30:1519-1534.
2. Moscato G, Vandenplas O, Van 
Wijk RG, Malo JL, Perfetti L, Quirce 
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Res 2009;10:16.
3. Sublett JW, Bernstein DI. Occupa-
tional rhinitis. Curr Allergy Asthma 
Rep 2010;10:99-104.
4. Castano R, Theriault G. Defining 
and classifying occupational rhini-
tis. J Laryngol Otol 2006;120:812-
817.
5. Malo JL1, Lemière C, Desjardins A, 
Cartier A. Prevalence and intensity 
of rhinoconjunctivitis in subjects 
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Occupational irritant and allergic rhinitis
 
Work Related Rhinitis
Occupational 
Rhinitis
caused by a specific 
substance only 
encountered in work 
environment
Allergic OR 
IgE-mediated  sensitization to  
protein or chemical sensitizers
Reactive Upper Airways 
Dysfunction Syndrome
acute exposure to a chemical 
irritant or combustion product
Work 
Exacerbated 
Rhinitis
pre-existing allergic or 
non-allergic rhinitis 
worsened by exposures 
in the work environment
Figure 1 Classification of work related rhinitis.
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professionals will need to address the growing number of 
elderly with allergic rhinitis (AR)
• Understanding the pathophysiology of AR in the aging nose is 
important to properly manage the condition
• In elderly patients with atopic conditions, serum IgE levels stay 
increased into advanced age
• Two relevant differentials for AR in the elderly are drug-induced 
rhinitis and common neurologic disorders such as Parkinson’s 
and Alzheimer’s
• Treatment involves avoidance of exposure, pharmacotherapy 
and allergen immunotherapy
The world’s geriatric population 
(65 and older) is estimated to in-
crease from 601 million in 2015 
to 1.5 billion by 2050. As this 
population continues to increase, 
healthcare professionals will need 
to address the growing number of 
elderly with allergic rhinitis (AR).
In 2005, the prevalence of AR in 
the US for ages 65-75 was 7.8%; 
over 75 was 5.4%. By 2013, Swiss 
aged 60+ had an atopic rate of 
26% for men and 18% for women; 
AR rates of 13% and 15% respec-
tively. In Poland (2013), similar 
percentages were found for atopy 
(26.7%), seasonal AR (12.6%), and 
perennial AR (17.1%).
Understanding the pathophys-
iology of AR in the aging nose is 
important to properly manage 
the condition and its deleterious 
affects on quality of life. With in-
creasing age, the nose undergoes 
changes in its structural compo-
nents. These normal aging pro-
cesses of the nose can manifest as 
rhinologic dysfunction and result 
in symptoms of postnasal drip-
ping, nasal drainage, sneezing, and 
olfactory loss (Table 1). In geriatric 
individuals without atopic condi-
tions, total and specific IgE pro-
ductions are reduced. However, 
this is not the case in elderly pa-
ALLERGIC RHINITIS IN 
THE ELDERLY9
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Allergic rhinitis in the elderly
tients with atopic conditions, and 
serum IgE levels stay increased 
into advanced age. It is important, 
therefore, to assess elderly pa-
tients for AR if their history and 
physical examination findings are 
consistent with the disease.
Clinical evaluation of older pa-
tients with AR should begin with 
a complete history. Physical ex-
amination is also essential and 
includes assessment of nasal pa-
tency, turbinates, straightness of 
septum, signs of inflammation, 
and presence of polyps. In addi-
tion to the normal changes pro-
duced by aging, rhinitis in the 
aging nose may also include vaso-
motor, primary atrophic, and gus-
tatory rhinitis. If the history and 
physical exam raises a suspicion 
for AR, in vivo (skin prick test) or in 
vitro tests may be utilized. Meas-
ures of allergic sensitization, such 
as those seen in in vivo or in vitro 
studies, decline with age; howev-
er, there is a robust association 
between allergic sensitization and 
allergic disease in the elderly.
Two relevant differentials of in-
creasing importance in the elderly 
are polypharmacy and drug-in-
duced rhinitis, including anti-hy-
pertensives, anti-cholinergics, 
beta-blockers, and psychotropics. 
Common neurologic disorders 
such as Parkinson’s and Alzheim-
er’s can initially present as rhinitis, 
Eric R. Yoo  
University of Illinois College of 
Medicine, Chicago, USA
Jacquelynne P. Corey  
University of Chicago 
Chicago, USA
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particularly olfactory dysfunction.
Treatment involves three compo-
nents: avoidance of exposure to 
known allergens, pharmacother-
apy, and allergen immunotherapy 
(AIT). Pharmacotherapy includes 
humidification, antihistamines, in-
tranasal steroids, ipratropium bro-
mide, and leukotriene inhibitors. 
Although the efficacy of AIT in the 
elderly has not been widely stud-
ied, there are some supportive 
findings. Surgical treatment is a 
safe and effective option that may 
include nasal tip, lateral cartilage, 
and endoscopic sinus procedures, 
and is associated with improve-
ments in quality of life.
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1/31/15.
2. Wüthrich B, Schmid-Grendelmeier 
P, Schindler C, Imboden M, Bircher 
A, Zemp E, et al. Prevalence of ato-
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and the SAPALDIA team. Int Arch 
Allergy Immunol 2013;162:143-
148.
3. Bozek A, Jarzab J. Epidemiology 
of IgE-dependent allergic diseases 
in elderly patients in Poland. Am J 
Rhinol Allergy 2013;27:e140-145.
4. Sahin Yilmaz AA, Corey JP. Rhinitis 
in the Elderly. Curr Allergy Asthma 
Rep 2006;6:125-131.
5. Pinto JM, Jeswani S. Rhinitis in the 
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Rep 2011;11:427-433.
TABLE 1
Symptoms and pathophysiology associated with the normal aging nose
Symptoms Pathophysiology
Nasal obstruction
Loss of nasal tip support secondary to fibrous connec-
tive tissue weakening in lateral cartilages
Decrease in nasal cavity volume secondary to septal 
cartilage weakening and retraction of nasal columella
Increased airway resist-
ance
Decrease in nasal mucosal softness and elasticity sec-
ondary to decrease in mucosal estrogen content
Nasal irritation
Decreased intranasal temperature and humidity of in-
spired air secondary to decrease in submucosal vessel 
patency
Olfactory dysfunction Nasal obstruction and inflammation in the olfactory cleft; central and peripheral nerve disorders
Postnasal drip, coughing, 
and sneezing
Thickened mucus secondary to mucosal epithelium 
atrophy
Decrease mucociliary clearance caused by decreased 
Decreased frequency of cilia movement and thickened 
mucus
Allergic rhinitis in the elderly
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during pregnancy
• Allergen avoidance is an important part of the treatment of AR
• Skin testing should be deferred until after delivery
• Antihistamines are less effective for the treatment of AR 
compared with intranasal glucocorticoids
Allergic rhinitis (AR) is usually pre-
existing, although it may develop 
or be recognized for the first time 
during pregnancy. Patients with 
AR often report prominent sneez-
ing, nasal pruritus, and watery rhi-
norrhea, and some have concom-
itant ocular itching and irritation. 
Common triggers for allergic rhini-
tis include dust mites, animal dan-
ders, molds, and pollens (Table 1).
If allergy testing was not per-
formed in the past, we recom-
mend that this evaluation should 
be deferred until after delivery, 
since skin testing has the poten-
tial to induce systemic allergic 
reactions in highly sensitive pa-
tients. Although skin testing is 
more sensitive for the diagnosis of 
sensitivities to inhaled allergens, 
in vitro tests for allergen-specific 
IgE are widely available and may 
be used for the diagnosis of AR 
during pregnancy.
TREATMENT
The mainstays of therapy for AR in 
pregnant patients are avoidance 
of triggers, oral antihistamines 
and intranasal glucocorticoids (Ta-
ble 2). No important differences in 
efficacy or safety appear to exist 
between the various intranasal 
glucocorticoid preparations. Some 
clinicians choose budesonide, if 
MANAGEMENT OF 
ALLERGIC RHINITIS DURING 
PREGNANCY
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Management of allergic rhinitis during pregnancy
starting intranasal glucocorticoids 
for the first time during pregnan-
cy, since it is classified as a catego-
ry B drug based on reassuring data 
available for its use as an inhaled 
preparation. Pregnant women 
who require antihistamines for AR 
should generally be treated with 
a second generation agent such 
as loratadine (10 mg once daily) 
or cetirizine (10 mg daily), since 
these drugs have reassuring ani-
mal and human data, are less se-
dating, and have fewer anticholin-
ergic side effects compared with 
first generation agents.
Intranasal cromolyn sodium may 
be considered a first-line therapy 
for mild AR in pregnancy because 
of its excellent safety profile. De-
congestants are vasoconstrictors 
that are available as both oral 
preparations and nasal sprays. 
Decongestant nasal sprays can be 
used very briefly (e.g., three days 
or less) for temporary relief of se-
vere nasal congestion, and some 
reassuring human data exist for 
use of intranasal oxymetazoline 
during pregnancy. However, as 
noted above, patients should be 
warned about dependence with 
prolonged use of decongestant 
nasal sprays. Oral decongestants 
are probably best avoided alto-
gether during the first trimester 
because of a possible increased 
risk of a rare birth defect, gastro-
schisis
KEY REFERENCES
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TABLE 1
Environmental Control Measures to reduce Exposure to Allergens
Indoor Allergens Instructions Level of Evidence
Animal dander
Remove pet from house; if removal 
not acceptable, keep pet out of bed-
room
Consensus judg-
ment
Dust mites
Encase pillow and mattress with im-
permeable covers; wash sheets and 
blankets in hot water weekly
Data from several 
randomized con-
trolled trials
Cockroaches
Do not leave food or garbage ex-
posed; use poison baits or traps rath-
er than chemical agents, which can 
aggravate asthma
Few randomized 
controlled trials
TABLE 2
Environmental Control Measures to reduce Exposure to Allergens
Drug Class Drug FDA Class Adverse perinatal Outcomes
Oral 
Antihistamines
Azelastine C No human data, animal studies show increase in teratogenicity, skeletal abnormalities and fetal death in high doses
Cetirizine B No increase in congenital malformation
Chlorpheniramine No increase in congenital malformation
Dexchlorpheniramine B No increase in congenital malformation
Fexofenadine C This active metabolite of terfenedine has been associated with dose related weight gain animal studies.
Diphenhydramine No increase in congenital malformation; withdrawal syndrome a risk
Hydroxyzine No increase in congenital malformations; withdrawal syndrome a risk
Loratadine B No increase in congenital malformations, low birth weight, or small for gestational age
Decongestants
Oxymetazoline No increase in congenital malformations; possible uteroplacental insufficiency with higher doses
Phenylephrine Associated with club foot, eye/ear malformations
Phenylpropanolamine Increase in total and specific congenital malformations in one study, association with gastroschisis and VSD in case-control studies
Pseudoephedrine Association with gastroschisis, hemifacial microsmia and small intestinal atresia in some case-control studies
Intranasal 
Antihistamines
Azelastine No controlled studies;
Olapatadine No controlled data; animal studies reassuring
Intranasal 
Corticosteroids
Budesonide B
 Substantial reassuring data for inhaled corticosteroids. Risk of 
increased malformations with high dose, but may be confounding by 
severity. Most data for budesonide.
Fluticasone C
Triamcinolone C
Mometasone C
Adapted from Schatz M, Zeiger RS, Falkoff R, et al. Asthma and allergic diseases during pregnancy. In: Adkinson NF, Yunginger-
JW, Busse WW, et al, editors. Middleton’ s Allergy: Principles and Practice 8th. St. Louis:Mosby, 2014; 951-969.
Management of allergic rhinitis during pregnancy
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impacts negatively on quality of life
• In children and adolescents, AR may present atypically with 
symptoms associated with comorbidities such as fatigue and 
snoring
• Non-sedating antihistamines are the first line therapy for mild 
to moderate AR; where symptoms are more problematical, 
nasal corticosteroids are likely to be more effective within or 
without concurrent antihistamine therapy
Allergic rhinitis (AR) is a common 
problem in childhood and adoles-
cence. While most experience the 
typical sneezing, itching, watery 
rhinorrhoea and nasal blockage 
(Figure 1), other children and ad-
olescents may present atypically 
with cough or snoring, due to co-
morbidities. AR impacts negative-
ly on physical, social and psycho-
logical well-being of children and 
adolescents. As well as direct im-
pact of symptoms, indirect effect 
of sleep disturbance gives daily 
fatigue and results in impaired 
school performance.
The differential diagnosis of rhi-
nitis is wide (Figure 2), commonly 
it needs to be differentiated from 
infectious rhinitis, typically caused 
by a viral infection. Less common 
is non-allergic, non-infectious rhi-
nitis, usually due to irritants such 
as cigarette smoke or pollution in 
this age group. Similar symptoms 
may occur with other conditions 
such as adenoidal hypertrophy, 
septal deviation and nasal polyps. 
Examination by anterior rhinosco-
py and allergy tests may help to 
substantiate a diagnosis of AR.
A wide range of allergens drive AR. 
Outdoor allergens, such as tree or 
grass pollens, are typically associ-
ated with seasonal AR while indoor 
ALLERGIC RHINITIS IN 
CHILDREN11
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Allergic rhinitis in children
ones, such as house dust mite and 
animal dander, are usually associ-
ated with perennial AR. Especially 
in new onset AR, skin prick testing 
and specific IgE may be negative 
to the likely allergen. Avoidance of 
relevant allergens, where possible 
may be helpful for AR.
Oral and intranasal antihistamines 
and nasal corticosteroids are both 
appropriate for first-line treatment 
of AR in children, although the lat-
ter are more effective (Figure 3). 
Once-daily forms of corticoster-
oids are preferred given their im-
proved safety profile. Potentially 
useful add-on therapies for AR in 
children include oral leukotriene 
receptor antagonists, short bursts 
of a nasal decongestant, saline 
douches and nasal anticholiner-
gics. Both sublingual and subcu-
taneous allergen immunotherapy 
(AIT) is effective for AR in children 
and teenagers. There is also some 
evidence to suggest that AIT may 
prevent the progression of AR to 
asthma. Compliance with AR ther-
apy has not been well studied in 
children and teenagers. It is likely 
to be suboptimal, particularly for 
nasal sprays or AIT, and deserves 
more attention.
The European Academy of Al-
lergy and Clinical Immunology 
Taskforce position paper on Rhi-
nitis in Children describes the ev-
idence-base for the diagnosis and 
management of paediatric allergic 
and non-allergic rhinitis. The po-
sition paper also outlines the are-
as that need to be clarified in the 
management of rhinitis in children 
and adolescents.
Graham Roberts  
University of Southampton 
UK
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Allergic rhinitis in children
Pre-school AdolescentSchool
Classic 
symptoms
and signs 
of rhinitis
Rhinorrhoea – clear or discoloured discharge, sniffing 
Congestion - mouth breathing, snoring, sleep apnoea, allergic shiners
Pruritus - nose rubbing, the “allergic salute”, “allergic crease”, 
“sneeze”, may be associated with complaints of an itchy mouth or 
throat in older children
atypical 
Potential 
presentations
Eustachian tube dysfunction - ear pain 
on pressure changes (eg flying), reduced 
hearing, chronic otitis media with effusion
Cough – often mislabelled as asthma 
Poorly controlled asthma – may co-exist with asthma
Sleep problems - tired, poor school performance, irritability
Prolonged and frequent respiratory tract infections
Rhinosinusitis - catarrh, headache, facial 
pain, halitosis, cough, hyposmia
Pollen-food syndrome, particularly with 
pollen driven allergic rhinitis
Diagnosis Pre-school School
Choanal atresia 
or stenosis 
Adolescent
Immuno-
deficiency 
Encephalocoele 
Persisting mucopurlent discharge
Obstruction without 
other features of 
allergic rhinitis
Unilateral nasal “polyp”
Adenoidal 
hypertrophy 
Foreign body 
Rhinosinusitis 
Unilateral discoloured 
nasal secretions,         
foul smell
Mouth breathing, discoloured nasal 
secretions, snoring in the absence 
of other features of allergic rhinitis
Cystic fibrosis 
Discoloured nasal secretions, headache, 
facial pain, poor smell,  halitosis, cough
Primary ciliary 
dyskinesia 
Bilateral nasal polyps, poor smell, chest symptoms, symptoms 
of malabsorption, failure to thrive
CSF leakage 
Coagulopathy 
Colourless nasal discharge often with a history of trauma 
Septal deviation 
Recurrent epistaxis with minimal trauma 
Persisting mucopurlent discharge without respite between “colds”, bilateral 
stasis of mucus and secretions at the nasal floor, symptoms from birth
Obstruction in the absence of other   
features of allergic rhinitis
Figure 1 Recognising allergic 
rhinitis in childhood and adolescence. 
(Reproduced with permission from 
Roberts G, Xatzipsalti M, Borrego 
LM, et al. Paediatric rhinitis: 
position paper of the European 
Academy of Allergy and Clinical 
Immunology. Allergy 2013;68:1102-
1116, with permission from Willey 
Blackwell.)
Figure 2 Differential diagnosis 
of allergic rhinitis in children and 
adolescents. (Reproduced with 
permission from Roberts G, Xatzipsalti 
M, Borrego LM, et al. Paediatric 
rhinitis: position paper of the European 
Academy of Allergy and Clinical 
Immunology. Allergy 2013;68:1102-
1116, with permission from Willey 
Blackwell.)
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Figure 3 Approach to therapy for allergic rhinitis in children and adolescents. ❶, ❷ and ❸ are potential entry points 
into therapeutic approach depending on the severity of the rhinitis symptoms. For seasonal disease, regular therapy 
should be commenced 2 weeks before the anticipated start of symptoms. *Oral antihistamines may be better tolerated 
while intranasal antihistamines have a more rapid onset of action. **Reconsider diagnosis if not controlled within 
1-2 weeks. If less than 2 year of age and do not respond to antihistamine within a week, reconsider diagnosis before 
stepping up therapy. If poorly controlled, consider a short rescue course of a decongestant or low dose oral prednisolone 
to gain symptom control; topical ipratropium may be useful for rhinorrhoea. (Reproduced with permission from Roberts 
G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical 
Immunology. Allergy 2013;68:1102-1116, with permission from Willey Blackwell.)
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• Rhinitis is particularly frequent in athletes and its incidence is on 
the increase, with symptoms occurring more often in subjects 
practicing swimming, cold and endurance disciplines
• Among different phenotypes described, allergic rhinitis (AR) is 
the most commonly observed variant
• AR often coexists with asthma and represents a risk factor for 
its onset
• Diagnosis is largely underestimated and should be made 
according to the ARIA guideline recommendations
• Special considerations should be taken into account during 
treatment for potential side-effects and anti-doping regulations
• Preventive measures should be undertaken to limit exposure 
to environmental factors that may trigger symptoms and affect 
performances
Rhinitis is often considered a triv-
ial disease and is largely underdi-
agnosed and self-managed in ath-
letes. However, it has been shown 
to significantly affect their qual-
ity-of-life and performance. The 
prevalence of rhinitis in athletes is 
particularly high and appears to be 
on a continuous increase (Table 1), 
with ranging prevalence in various 
studies depending on the criteria 
used for diagnosis. Athletes from 
winter, aquatic and endurance 
sport disciplines are more likely to 
have symptoms. Among different 
phenotypes described (vasomo-
tor, infectious, traumatic, neutro-
philic, NARES) the allergic variant 
is the most frequently observed. 
In our recent study performed in 
659 Italian Olympic athletes, al-
lergic rhinitis (AR) was found to be 
present in 26.2% of subjects.
Such increased occurrence has 
been reported to be ascribed to 
a global influence of the intense 
physical exercise on the immune 
system, inducing a transient im-
mune deviation with a prevalent 
Th2 response, as well as to its di-
rect trigger effect on target organs 
(Figure 1).
Furthermore, epidemiological 
data indicate that asthma and AR 
frequently coexist, with symp-
ALLERGIC RHINITIS IN 
ELITE ATHLETES12
KE Y MESSAGES
toms of rhinitis being reported in 
80–90% of asthma patients, and 
asthma symptoms in 19–38% of 
those with AR. In addition, sub-
jects with rhinitis alone often ex-
perience exercise-related airway 
symptoms which represent a risk 
factor for subsequent develop-
ment of asthma. With this regard, 
every athlete with rhinitis should 
be also screened for asthma and 
exercise-induced bronchocon-
striction according to the Allergic 
Rhinitis and its Impact on Asthma 
(ARIA) guidelines. The established 
clinical and functional assessment 
may also benefit of the comple-
mentary use of specific allergy 
questionnaires, such as the Al-
lergy Questionnaire for Athletes 
(AQUA).
In addition to ARIA recommen-
dations, special considerations 
should be taken into account for 
elite athletes for potential side-ef-
fects of some drugs, as well as to 
the limitations set by the World 
Anti-Doping Association - www.
wada-ama.org - (Table 2). Inhaled 
and nasal steroids represent the 
treatment of choice, being effec-
tive in controlling inflammation 
and symptoms of both upper and 
lower airways, while reducing 
Matteo Bonini  
Sapienza University of Rome 
Rome, Italy
Allergic rhinitis in elite athletes
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Allergic rhinitis in elite athletes
TABLE 1
Prevalence of rhinitis in athletes
Study population (n) Prevalence Diagnostic method Reference
Australian Olympics (185) 8.6% Medical records analysis Fitch, 1984
Australian Olympics (106) 7.5% Medical records analysis Fitch, 1984
Swiss athletes (2060) 16.8% Questionnaire Helbling et al, 1990
Swiss athletes (1530) 19.7% Questionnaire Kaelin et al, 1993
US swimmers (738) 19.0% Questionnaire Potts, 1996
Finish summer athletes (162) 29.6% Skin prick tests with medical diagnosis Helenius et al, 1998
US Olympic team (699) 16.9% Questionnaire Weiler et al, 1998
US winter Olympic team (196) 13.3% Questionnaire Weiler et al, 2000
Australian Olympic team (214) 41.0% Skin prick tests with medical diagnosis Katelaris et al, 2000
Italian Pre-Olympic team (265) 25.3% Skin prick tests with medical diagnosis Lapucci et al, 2003
Finnish Olympic athletes (446) 26.5% Self reported medical diagnosis Alaranta et al, 2005
Finnish marathon runners (141) 17.3% Self reported medical diagnosis Moreira et al, 2007
Italian preOlympics (98) 34.7% Skin prick tests with medical diagnosis Bonini et al, 2007
Italian Olympic athlets (659) 26.2% Skin prick tests with medical diagnosis Bonini et al, 2015
TABLE 2
2015 WADA international standard on drugs for treating rhinitis
Treatment WADA rules Notes
Inhaled steroids Permitted First-choice treatment
Antihistamines Permitted Second generation molecules should be preferred to avoid side effects
Leukotriene modifiers Permitted Particularly effective in subjects with concomitant asthma
Ephedrine and 
methylephedrine
Prohibited in 
competition A concentration >10 ug/ml represents an adverse analytical finding
Immunotherapy Permitted SCIT should not be performed close to physical exercise
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the need for rescue medications. 
Ephedrine and methylephedrine 
are prohibited in competition by 
the WADA, when their concen-
tration in urine exceeds the al-
lowed threshold. Although there 
are no restrictions for the use of 
antihistamines, it is well known 
that particularly first-generation 
molecules may have potential 
side-effects on the cardiovascu-
lar and nervous system and may 
induce sedation and fatigue. The 
use of second-generation mole-
cules must be therefore preferred 
in athletes, and the potential 
side-effects should be carefully 
monitored, in relation to the rel-
evant cardiovascular loads and 
the need for unaffected reaction 
times. Leukotriene modifiers and 
allergen immunotherapy are al-
ternative effective and safe treat-
ment strategies. Preventive meas-
ures should also be undertaken to 
limit exposure to environmental 
factors (air humidity and temper-
ature, content in pollutants and 
allergens responsible for sensi-
tization in allergic athletes) that 
may trigger symptoms and affect 
performances during training and 
competition. In view of this, lo-
cal pollen counts and forecasts 
should always be made available 
in advance to allergic athletes, 
their coaches and medical staff.
KEY REFERENCES
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et al. Exercise-induced hypersen-
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gy 2008;63:953-961.
2. Bonini M, Gramiccioni C, Fioret-
ti D, Ruckert B, Rinaldi M, Akdis 
C, et al. Asthma, allergy and the 
Olympics: a 12-year survey in elite 
athletes. Curr Opin Allergy Clin Im-
munol 2015;15:184-192.
3. Bonini M, Bachert C, Baena-Cag-
nani CE, Bedbrook A, Brozek JL, 
Canonica GW, et al. What we 
should learn from the London 
Olympics. Curr Opin Allergy Clin 
Immunol 2013;13:1-3.
4. Bonini M1, Braido F, Baiardini I, Del 
Giacco S, Gramiccioni C, Manara 
M, et al. AQUA: Allergy Question-
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Allergic rhinitis in elite athletes
Figure 1 Effect of physical exercise on the immune system and target organs.
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underdiagnosed and undertreated
• Major risk factors are sensitization to mites, cockroaches, 
moulds and pets, and less to pollens
• Economic shortages interfere with adequate care of AR patients 
in tropical countries
• More allergists are needed in order to meet the challenge 
represented by the large demand of care for AR in the tropics
In contrast to the general belief, 
allergies are highly prevalent in 
tropical countries. It is a region 
surrounding the Equator, limited 
in latitude by the Tropic of Cancer 
at 23° 26′ 16″ (or 23.4378°) N 
and the Tropic of Capricorn at 23° 
26′ 16″ (or 23.4378°) S (Figure 
1) with high biodiversity, variable 
climate, and abundant rainfall all 
year round with mean tempera-
tures above 18°C. More than half 
of the World’s population lives in 
the tropics.
EPIDEMIOLOGY AND RISK 
FACTORS
Allergic rhinitis (AR) incidence in 
the tropical areas is influenced 
by the environment, infections, 
and allergens. The prevalence of 
AR in the tropics is as high as in 
other regions. Anticipated protec-
tive factors, such as low hygienic 
conditions, do not seem to confer 
protection in poor communities. 
In Africa allergic rhinoconjuncti-
vitis (ARC) has a prevalence be-
tween 7.2 and 27.3%. Latin Amer-
ica, encompassing the territories 
from Mexico to Paraguay and Bra-
zil, has the greatest concentration 
of tropical rainforest in tropical 
countries, with temperatures be-
tween 20°C and 34°C, and hu-
midity between 77 and 88%. Latin 
RHINITIS IN A TROPICAL 
ENVIRONMENT13
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America is one of the regions with 
the highest prevalence of AR; ac-
cording to ISAAC phase III, the 
prevalence is 37.6%.
Sensitization to mites constitutes 
the most important risk factor for 
AR in the tropics. Humidity facili-
tates the proliferation of mites and 
perennial exposure to high allergen 
concentrations. In Venezuela 97.1 
% of AR patients are sensitized to 
mites (Table 1). In Mexico, 56% of 
patients are sensitized to mites, 
but this rate reaches 87% in trop-
ical regions (Figure 2). Cockroach 
allergen sensitisation represents 
another risk factor. In Caracas the 
rate of sensitisation to cockroach 
allergen is 83.1%, being more 
common in low socioeconomic 
groups. Allergy to cockroaches in 
Latin America is likely related to 
availability of food, humidity and 
heat, poor hygiene and ventilation, 
and low educational levels. In the 
tropics there are only two seasons. 
Pollen concentrations are not as 
high as in temperate climates. 
Bermuda grass (Cynodon dactylon) 
hypersensitivity has been associ-
ated to seasonal exacerbations of 
AR in Africa, and Maize (Zea mais) 
in Zimbawe. In Caracas, Cupressus, 
Cecropia, Gramineae, Acalypha, Urti-
caceae, Mimosa spp., Pinus radiate, 
Ulmaceae and Soroceae, Piperaceae, 
and Eucalyptus spp. are the pollens 
found in significant quantities. 
Mould spores are present all year 
round. In Venezuela sensitization 
rates of 56.4 to 67.4% have been 
reported, the most common spe-
cies reported being Aspergillus, 
Penicillium, Cladosporium, Alter-
naria, and Rhizopus.
Mario Sánchez-Borges  
Centro Médico-Docente La Trinidad 
Caracas, Venezuela
Rhinitis in a tropical environment
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Figure 1 Tropical climate zones of the Earth where all twelve months have mean temperatures above 18°C (64°F). Peel, 
M. C., Finlayson, B. L., and McMahon, T. A. (University of Melbourne).
Rhinitis in a tropical environment
TABLE 1
Rates of Sensitization to Aeroallergens in patients 
with Rhinitis and Rhinosinusitis*
Allergen % of positive skin tests
Mites 97.1
Dog 51.4
Cat 40.5
Cockroach 36.5
Moulds 22.8
Bermuda grass 21.1
Feathers 10.0
Weeds 9.8
Trees 2.9
*Modified from: Sánchez-Borges M, Fernández-Caldas E, 
Capriles-Hulett A, Caballero-Fonseca F. Mite hypersensi-
tivity in patients with rhinitis and rhinosinusitis living in 
a tropical environment. Allergol Immunopathol (Madr). 
2014; 42: 120-126.
SOCIAL DETERMINANTS AND 
SOCIOECONOMIC ASPECTS IN 
THE TROPICS
Allergic diseases represent an im-
portant burden for health servic-
es. Although there are variations 
among countries, most tropical 
countries are poor, and patients 
do not have access to medical 
assistance. Thus, although AR is 
frequent in the tropics it is often 
underdiagnosed and undertreat-
ed. Medical management is insuf-
ficient and medications are not 
available or unaffordable. In many 
countries allergology is not recog-
nized, or the number of allergists 
is low. In consequence, most pa-
tients are treated by primary care 
physicians. Potential risk factors 
for AR in this region are related 
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Rhinitis in a tropical environment
Figure 2 Allergen sensitivity throughout the Mexican Republic. (From Larenas-Linnemann D, Michels A, Dinger H, et al. 
Allergen sensitization linked to climate and age, not to intermittent-persistent rhinitis in a cross-sectional cohort study in the 
(sub)tropics. Clin Transl Allergy. 2014;4:20.)
to poverty, housing conditions, 
access to tap water, exposure to 
fumes, contact with animals, and 
large family size. In summary, 
weak economies and insufficient 
resources interfere with care for 
AR in tropical settings.
PREVENTION AND CONTROL
The number of patients undergo-
ing allergy testing in the tropics is 
low, and the utilization of allergen 
immunotherapy is nearly absent. 
The cost of medication, dose fre-
quency, fear of adverse effects, 
and low efficacy determine low 
treatment compliance. A higher 
number of physicians trained in 
allergology are needed in order to 
meet the increasing demand.
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• Guidelines for allergic rhinitis (AR) management are based on 
symptom severity assessed by simple questions regarding their 
impact on quality of life
• The management of AR should rather be based on control; new 
disease control-defined paradigms are emerging
• There is currently no single and universally accepted definition 
of AR control
• Control tools should include objective and subjective 
measurements of symptoms and their impact on daily activities
In order to enhance the effective-
ness and quality of management 
for allergic rhinitis (AR), a number 
of international guidelines and 
consensus statements have been 
developed and regularly adapted 
over the past two decades. The 
Allergic Rhinitis and its Impact on 
Asthma (ARIA) was the first evi-
dence-based guidelines, proposed 
in conjunction with the World 
Health Organization. It focus-
es on the assessment and treat-
ment of AR based on severity as 
assessed by simple quality of life 
(QoL) measurements. Although the 
treatment guidelines are now well 
established, treated patients may 
report poor levels of satisfaction 
and continue to be undertreated 
and at risk for acute exacerbations, 
resulting in reduced productivity 
at work, school performance and 
QoL, triggering increased health-
care costs and the use of oral cor-
ticosteroids. The level of AR’ con-
trol is often overestimated by both 
patients and physicians, resulting 
in failure to make the necessary 
adjustments to medication. Thus, 
a measure of AR control should be 
used to evaluate treatment out-
comes and simplify monitoring. 
As implement for asthma manage-
ment by the the Global Initiative 
for Asthma (GINA) guidelines, the 
SEVERITY AND CONTROL 
IN ALLERGIC RHINITIS14
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generalization of the term "con-
trol" is now being considered for 
the management of patients with 
AR, chronic rhinosinusitis, chronic 
urticaria and atopic dermatitis.
There is currently no single defini-
tion of AR control, since its deter-
mination depends on the variables 
taken into account by the different 
available tools. As a consequence, 
there is no universally agreed indi-
cation that AR control should be 
measured directly. Rhinitis control 
is essentially “absence of symp-
toms”. Most of the control tools 
developed so far focus on objec-
tive and subjective measurements 
of daily or nocturnal nasal and ocu-
lar symptoms (congestion, rhinor-
rhea, sneezing, pruritus, post-na-
sal drip), symptom magnitude (i.e., 
the patients’ perception of how 
bothersome their symptoms are), 
patient-reported metrics of QoL 
(i.e., impairment in sleep or daily 
activities) and satisfaction, and 
some objective measurements 
(e.g., peak nasal inspiratory flow, 
rhinomanometry, increased use 
of rescue medication). Many in-
struments, such as The Control 
of Allergic Rhinitis and Asthma 
Test (CARAT), Rhinitis Control As-
sessment Test (RCAT), The Aller-
gic Rhinitis Control Test (ARCT), 
a Visual Analog Scale (VAS) and 
other new questionnaires requir-
ing validation have appeared and 
have been used in the assessment 
of the patient’s clinical symptoms 
(Table 1). New approaches based 
on disease control are now emerg-
ing (Figure 1). They will need to be 
evaluated prospectively.
Pascal Demoly  
University Hospital of Montpellier 
Montpellier, France
Severity and control in allergic rhinitis
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Severity and control in allergic rhinitis
Figure 1 New proposal to manage allergic rhinitis based on control.  (Reproduced with permission from Papadopoulos 
NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. 
Allergy 2015;70:474-494, with permission from Willey Blackwell.)
Environmental control
Control medication steps
1 2 3 4 (Specialist care only)
One of: One of:
Combination of Intranasal 
corticosteroids with one or 
more of *: Consider omalizumab 
(not approved for rhinitis)
Consider surgical 
treatment of concurrent 
pathology
• Oral antihistamine
• Intranasal antihistamine
• Intranasal cromolyn/
nedocromyl
• Leukotriene receptor 
antagonist
• Intranasal corticosteroid 
(preferred)
• Oral antihistamine
• Intranasal antihistamine
• Leukotriene receptor 
antagonist
• Intranasal antihistamine
• Oral antihistamine
• Leukotriene receptor 
antagonist
Rescue medication
• Decongestants (oral/intranasal)
• Anticholinergics (Intranasal)
• Oral corticosteroids
Reassess diagnosis and/or adherence and evaluate potential comorbidities and/or anatomic abnormalities prior to 
considering step-up**
*There is little evidence of additional efficacy of these drugs to intranasal corticosteroids. 
** Step up is indicated if symptoms remain uncontrolled and step down if control is achieved with the employed regimen. Al-
though the control principle may be valid for other rhinitis phenotypes as well, specific medications should be adjusted accord-
ingly.
Immunotherapy
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TABLE 1
A comparison of three published allergic rhinitis control questionnaires
The Control of Allergic Rhini-
tis and Asthma Test (CARAT)
The Rhinitis Control Assessment 
Test (RCAT)
The Allergic Rhinitis Control 
Test (ARCT)
Administration 
mode self-questionnaire self-questionnaire self-questionnaire
Diseases 
considered allergic rhinitis and asthma allergic rhinitis allergic rhinitis
Period of 
evaluation The previous 4 weeks The- previous week The previous 2 weeks
Number of final 
items/questions
17 in development
10 in the final tool
26 in development
6 in the final tool
5 in the final tool
Response type 4-point frequency scale and some yes/no items 5-point Likert scale 5-point frequency scale
Validation status
Tested in 141 non-treated 
adult patients (CARAT17) and 
then 193 adults (CARAT10). 
Internal consistency over 
0.70. Longitudinal validation 
underway
Psychometric validation by 
410 patients consulting allergy 
specialists. God psychometric 
properties and reliable internal 
consistency (Cronbach alpha 
coefficient: 0.70)
Tested in 902 patients 
selected by 411 primary care 
physicians and allergists. 
Internal consistency: 0.77
Other comments Tested in patients consulting an allergist
Significant correlations with 
physician-rated disease 
severity, total nasal symptom 
score and physician-
recommended change in 
therapy
Based on the Asthma Control 
Questionnaire. Significant 
correlations with the clinical 
picture and the impact of 
allergic rhinitis on social and 
sports activities
(From Demoly P1, Calderon MA, Casale T, et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy. 2013;3:7; 
Reprinted with permission under the Creative Common Attribution License or equivalent.)
Severity and control in allergic rhinitis
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understanding of disease heterogeneity and mechanisms in 
relation to clinically significant outcomes
• Phenotypes describing observable clinical and morphologic 
characteristics and unique responses to treatment have been 
developed; however they do not relate to disease mechanisms
• Recently, extended heterogeneous and disease-related 
metabolic, inflammatory, immunological, and remodeling 
pathways have been described, and reproducible patterns are 
defined as disease endotypes
• An endotype might consist of several intricated mechanisms 
that cannot be clearly separated into “pure single molecular 
mechanism” thus being a “complex endotype”
• The Th2 type inflammation or aspirin exacerbated respiratory 
disease can be defined as complex endotypes
• The description of an endotype relies on biomarkers, which 
can be the signature of a complex underlying pathway or a key-
molecule for a role in a particular disease endotype
PHENOTYPES AND 
ENDOTYPES
The heterogeneity of allergic dis-
eases in relation to clinically signifi-
cant outcomes, including response 
to treatment has been established 
beyond any doubt. At first, pheno-
types describing clinical and mor-
phologic characteristics as well 
as unique responses to treatment 
have been developed to address 
the complexities of the disease. 
Several allergic rhinitis (AR) phe-
notypes can be described based 
on the predominant symptom 
(“runners” vs. “blockers”), occur-
rence of symptoms (“seasonal” vs 
“perennial” or “intermittent” versus 
“persistent”), pattern of sensitisa-
tion (“mono-“ vs. “polysensitised”) 
severity or response to treatment. 
The phenotype driven approach 
of AR is already in place for many 
years and acknowledged by the 
international guidelines such as 
ARIA, since we tend to use as first 
line treatment nasal steroids for 
blockers and antihistamines or an-
ticholinergics for runners, and we 
treat AR according to its severity. 
Even the elicitation of symptoms 
can separate different clusters of 
AR patients: for example the aer-
oallergen challenge chamber (ACC) 
exposure dichotomises patients 
into low versus high level of symp-
PHENOTYPES AND 
ENDOTYPES OF ALLERGIC 
RHINITIS
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toms developing slow or fast while 
natural exposure versus ACC di-
vides patients into concordant re-
sponders to both type of exposure 
or discordant responders, with a 
greater symptom score in the nat-
ural season.
Phenotypes may be clinically rel-
evant in terms of presentation, 
triggers, and treatment response, 
but do not necessarily relate to 
or give insights into the underly-
ing pathological mechanism. For 
example, the recently described 
local allergic rhinitis is certain-
ly an interesting AR phenotype 
posing several questions on the 
mechanisms involved in the lack 
of systemic atopy. For most of 
the allergic diseases extended 
heterogeneous disease-related 
inflammatory, immunological, and 
metabolic pathways have been 
described, and a reproducible un-
derlying mechanism is defined as 
a disease endotype. Classifying 
Ioana Agache  
Transylvania University 
Brasov, Romania
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AR based on underlying patho-
physiologic mechanisms, known 
as endotyping, offers a stratified 
approach for a better assessment 
of disease’ epidemiology, genetic 
background and environmental 
risk factors, for the development 
of new targeted therapies and for 
a better selection of responders to 
targeted treatment.
To become clinically relevant, the 
endotype should be related to 
validated biomarkers that corre-
spond to the underlying mecha-
nism. The purpose of the biomark-
er is to identify disease endotype, 
predict onset and prognosis of a 
disease, measure exposure, mon-
itor response to treatment and 
forecast unfavourable evolution. 
The biomarker can be the sig-
nature of a complex underlying 
pathway or a key-molecule of a 
particular disease endotype. To 
further complicate the picture, 
the predictive value of the same 
biomarker is highly variable across 
age groups, disease severity and 
in relation to the outcome. The 
ideal biomarker should be path-
way-specific, reproducible in the 
same individual and in an inde-
pendent prediction cohort and 
usable as a diagnostic test (easily 
measurable and affordable). New 
strategies for discovery and vali-
dation of biomarkers such as gene 
expression (microarrays) and om-
ics provide combined signatures 
as per systems medicine.
THE CONCEPT OF COMPLEX 
ENDOTYPES
Allergic diseases, such as asthma, 
AR or atopic dermatitis, manifest 
as heterogeneous syndromes that 
cover a broad spectrum of complex 
genetic, inflammatory, metabolic 
and remodelling networks that lead 
to several pathogenetic pathways. 
Single molecular mechanism-linked 
endotypes can be defined for an 
allergic disease, however most al-
lergic endotypes involve concomi-
tantly several pathways. Examples 
of such complex endotypes are 
Th2 inflammation or aspirin-exac-
erbated respiratory disease.
THE TYPE 2 COMPLEX 
ENDOTYPE
The type 2 complex endotype in al-
lergic diseases includes innate lym-
phoid cells, T helper 2 cells, tissue 
eosinophilia and systemic and local 
IgE production. The IL-9/mast cell/
PGD2 pathway activation, Th1 or 
Th17 cells may add to the Th2-driv-
en inflammation, with their role in 
apoptosis of the epithelium (Th1) 
and in promoting neutrophilic in-
flammation (Th17). Further influ-
ences may be added by the associ-
ated microbiota (superantigens) or 
by activation of peculiar metabolic 
pathways such as the eicosanoid 
pathway in aspirin-exacerbated 
respiratory disease or the L-Arg/
ADMA or the lectin pathway in 
obesity (Figure 1).
The type 2 inflammation is char-
acterized by a high cellular plas-
ticity that enables the cells to 
adapt to a specific inflammatory 
milieu. Innate cytokines such as 
IL-33 and TSLP modulate the mast 
cell phenotype, while type 2 cy-
tokines influence permissiveness 
of epithelium for allergens and of 
the endothelium for the recruit-
ment of inflammatory cells to in-
flamed tissues and are involved in 
the production of mucus.
The “Holy Grail” of endotyping is to 
pinpoint the essential nodes of the 
network that are unique for one 
endotype and relate to relevant 
clinical end-points such as disease 
severity or response to treatment. 
For Type 2 inflammation endotype, 
three such nodes can be described, 
each depicting a distinct subendo-
type: the IL-5 pathway, the IL-4/IL-
13 pathway and the IgE pathway 
(Figure 1). These pathways can be 
demonstrated for allergic asthma, 
where targeted intervention and 
the fast development of biomark-
ers allow such a separation. Since 
for AR the targeted treatment has 
not been fully developed one can 
just assume that given the simi-
larities between the Th2-driven 
inflammation in the nasal and the 
bronchial mucosa and the well es-
tablished systemic link between 
AR and asthma, the Th2 nasal en-
dotype to behave similar to asth-
ma. In addition, the well recognized 
link between rhinitis and asthma 
should be integrated and tackled 
within the framework provided by 
endotypes.
Several biomarkers for Type 2 
type inflammation have been de-
scribed (Table 1). Each biomarker 
reflects a compartment or a path-
way involved in type 2 inflamma-
tion, related to Th2 cells and ILC2. 
For non-specific interventions, 
such as topical corticosteroids, all 
described biomarkers can be used 
to predict response. However, for 
more targeted interventions, such 
as anti-IL-5 or anti-IL-13, each 
of these Th2 or ILC2 biomarkers 
needs to be related to the specifi-
cally targeted pathway.
KEY REFERENCES
1. Lötvall J1, Akdis CA, Bacharier LB, 
Bjermer L, Casale TB, Custovic A, 
et al. Asthma endotypes: a new 
approach to classification of dis-
ease entities within the asthma 
syndrome. J Allergy Clin Immu-
nol 2011;127:355-360.
2. Agache I, Akdis CA, Jutel M, Vir-
chow JC. Untangling asthma phe-
notypes and endotypes. Aller-
gy 2012;67:835–846.
3. Agache IO. From phenotypes 
to endotypes to asthma treat-
ment. Curr Opin Allergy Clin Immu-
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Figure 1 The complex network of Type 2 endotype in allergic diseases involves the interaction between innate immune 
response and Th2 cells. Three major downstream effector pathways can be described: the IgE pathway, the IL-5/eotaxin 
pathway, and the IL- 4/IL-13 pathway. Additional modulators of the Th2 endotype can be described such as the IL-9/
mast cell axis, Th17 or Th1 cells, activation of the metabolic pathways (Reproduced with permission from Agache I, Sugita 
K, Morita H, et al. The Complex Type 2 Endotype in Allergy and Asthma: From Laboratory to Bedside. Curr Allergy Asthma Rep. 
2015, in press.)
TABLE 1
Type 2 inflammation biomarkers in allergic diseases
Biomarker Clinical Utility Reproducibility
Nasal eosinophils Clinical setting ?
Blood eosinophils Clinical setting No
Serum periostin Research setting Yes
The Th2 gene signature (serpin B2, 
periostin, CLCA1 or CLC, CPA3, 
DNA- SE1L3) in nasal epithelial cells
Research setting Yes
The salivary inflammatory profile. Research setting ?
nol 2013;13:249–256.
4. Agache IO. Endotype Driven Treat-
ment of Asthma. Curr Treat Options 
Allergy 2014;1:198–212.
5. Agache I, Sugita K, Morita H, Akdis 
M, Akdis CA. Current Treatment 
Options in Allergy. The Com-
plex Type 2 Endotype in Allergy 
and Asthma: From Laboratory 
to Bedside. Curr Allergy Asthma 
Rep 2015;in press.
6. Papadopoulos NG, Bernstein JA, 
Demoly P, Dykewicz M, Fokkens W, 
Hellings PW, et al., Phenotypes and 
endotypes of rhinitis and their im-
pact on management: a PRACTALL 
report. Allergy 2015;70:474-94.
Phenotypes and endotypes of allergic rhinitis
Th17 
(neutrophilic inflammation)
Th1 
(apoptosis/granuloma)
IL-9 / mast cells / PGD2
Remodelling phenotype Metabolic pathways (eicosanoids; L-Arg/ADMA)
Innate immune response 
(TSLP, IL-33, ILC2, iNKT, Eos) 
Th2 cells
IgE  
(atopic and non-atopic) IL-4 / IL-13
IL-5 / 
eotaxin
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• Allergic rhinitis (AR) is a systemic disease affecting not only the 
nasal function, but general well-being as well (hay ‘fever’)
• Patients frequently consider their condition as being part of 
how they are, without seeking medical attention
• Automedication is common in patients with AR, resulting 
in adverse effects such as sedation from first generation 
antihistamines and rhinitis medicamentosa from misuse of 
topical vasoconstrictors
• As a chronic condition AR puts a considerable economic burden 
on sufferers
• Allergen immunotherapy, subcutaneous or sublingual, can 
improve quality of life and reduce the economic burden of AR
Allergic rhinitis (AR) is often con-
sidered a local condition caused 
by an allergic reaction to inhalant 
allergens in the nose. However, in 
patients suffering from AR apart 
from local immunologic changes, 
also a deviation of the systemic 
immune response has been docu-
mented. During allergen exposure 
serum levels of specific IgE, eosin-
ophil-derived proteases and cy-
tokines are all elevated. These are 
probably the cause of the feverish 
feeling and tiredness expressed 
by several patients, leading in the 
past to the term hay-fever.
AR patients often accept their 
condition as being part of how 
they are and as such do not seek 
medical attention. Even less often 
advice from a specialist is sought. 
It is common that patients refer af-
ter they have suffered from symp-
toms for years, before visiting the 
physician. During peaks of symp-
toms the burden of self-medica-
tion is frequent, often in the form 
of first generation antihistamines, 
alone or in a cold-mix. When the 
main symptom is nasal obstruc-
tion, the mostly used over the 
counter (OTC) medication is a top-
ical vasoconstrictor.
As such, AR affects the patient’s 
well-being in several ways (Figure 
THE BURDEN OF ALLERGIC 
RHINITIS ON PATIENTS' 
QUALITY OF LIFE
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1). Firstly, the local nasal condi-
tions such as rhinorrhea, sneezing 
and pruritus are bothersome and 
can interfere with the social func-
tioning of sufferers. At night, nasal 
obstruction reduces the quality of 
sleep and causes odynophagia in 
the morning, because of nocturnal 
oral respiration. Secondly, the sys-
temic immunologic reactions give 
the patient a feeling of malaise 
and unwell being and in some cas-
es even arthralgia has been doc-
umented, especially in children. 
Thirdly, side effects of the OTC, 
self-prescribed medication poses 
more burden on the AR patient. 
The sedative effect of first gen-
eration antihistamines can have 
deleterious consequences, be-
cause it not only reduces school 
and work performance, but intake 
of first generation antihistamines 
has even been linked to car and 
plane accidents. Misuse of topi-
cal decongestants in nasal sprays 
easily leads to a rebound nasal ob-
struction and finally rhinitis me-
dicamentosa.
Measuring quality of life in pa-
tients with allergic rhinitis has to 
take into account all these differ-
ent aspects. As such, a generic 
health-related quality of life ques-
tionnaire might not be the ideal 
instrument. Specific rhinitis, rhi-
noconjunctivitis and rhinosinusitis 
quality of life questionnaires have 
Désirée Larenas Linnemann  
Hospital Médica Sur 
Mexico City, Mexico
The burden of allergic rhinitis on patients' quality of life
272
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 F
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
Sp
ec
ia
l c
on
si
de
ra
ti
on
s
been developed for adults, adoles-
cents and children, e.g. the RQLQ. 
To select the best instrument, sev-
eral issues have to be considered 
(Table 1).
KEY REFERENCES
1. Ferreira MA. Cytokine expres-
sion in allergic inflammation: 
systematic review of in vivo 
challenge studies. Mediators In-
flamm 2003;12:259-267.
TABLE 1
Mesuring disease burden of allergic rhinoconjunctivitis (ARC): Issues to be 
taken into account for selection of patient-related outcomes
The phenotype of ARC 
being treated
seasonal and peren-
nial ARC
seasonality, timing of expo-
sure
Age of the patients
Adult
Pediatric
Pediatric patients: caretaker 
bias
The nature of the inter-
vention being evaluated
Pharmacotherapy
AIT
For AITthe effect should 
be measured after a longer 
time interval
Symptoms beyond ARC
Asthma, otitis media 
with efffusion, sinus-
itis
Symptoms of the co-mor-
bidity included in the ques-
tionnaire (eg RhinAsthma)
Figure 1 The complex interplay of factors decreasing quality of life in patients with allergic rhinitis.
2. Walker S, Khan-Wasti S, Fletcher 
M, Cullinan P, Harris J, Sheikh A. 
Seasonal allergic rhinitis is associ-
ated with a detrimental effect on 
examination performance in Unit-
ed Kingdom teenagers: case-con-
trol study. J Allergy Clin Immu-
nol 2007;120:381-387.
3. Röder E, Berger MY, Hop WC, de 
Groot H, van Wijk RG. The relevance 
of patient-reported outcomes in a 
grass pollen immunotherapy trial 
in children and adolescents with 
rhinoconjunctivitis. Pediatr Allergy 
Immunol 2013;24:39-48.
4. Larenas-Linnemann D, Pfaar O. Pa-
tient-reported outcomes and qual-
ity-of-life questionnaires in the as-
sessment of rhinoconjunctivitis in 
childhood. Curr Opin Allergy Clin 
Immunol 2014;14:192-199.
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• More than 50% of patients with allergic rhinitis (AR) do not 
fulfill their prescription. Many factors may negatively account 
for patient adherence to treatment
• Adherence is a multidimensional phenomenon determined by 
the interplay of different factors. Hence, it is a dynamic process 
that varies over treatment duration
• Targeted management plans, based on patient’s characteristics, 
symptoms, co-morbid conditions, and preferences, may 
increase adherence and patients’ perception of symptom relief
• Education is a key factor in promoting adherence and providing 
the best care for the patients with AR. Additional research to 
determine the best methods for education delivery is needed
Currently, management plan of al-
lergic rhinitis (AR) includes allergen 
avoidance, pharmacotherapy, aller-
gen immunotherapy (AIT) and pa-
tient’s education. The management 
of AR, same as many chronic diseas-
es, is affected by the adherence is-
sues, since at least one-third of pa-
tients may be non-adherent to their 
AR treatment regimen, and 40-80% 
of patients may discontinue the 
treatment after the first 6 weeks. 
Adherence is a multidimensional 
phenomenon, currently measured 
by variable methods. Figure 1 sum-
marizes five dimensions of deter-
minants for adherence, which may 
have also relevance for AR.
There are very few data on the 
adherence to allergen avoidance 
measures, available only for house 
dust mites and indicating a great 
adherence rate, when encasings 
are provided without costs. In clin-
ical trials involving both pharmaco-
logical treatments and AIT, where 
patients are strictly monitored, the 
adherence is obviously much bet-
ter compared to real life studies. 
Thus, for antihistamines, clinical 
trials report an overall long-term 
adherence of about 80%, where-
as real-life studies suggest a rate 
of less than 50%, with one third 
of patients adapting or modifying 
ADHERENCE TO THE 
MANAGEMENT PLAN OF 
ALLERGIC RHINITIS
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the prescribed treatment. An easy 
schedule and different drug for-
mulation as well as safety issues 
should be taken into consideration. 
For intranasal steroids (INS), low 
efficacy perception and bother-
some adverse effects contribute to 
lack of satisfaction with treatment 
and discontinuation of treatment 
in AR patients. The compliance has 
been formally assessed mainly on 
the basis of patient’s preference 
(i.e. INS smell, taste, type of for-
mulation), the preference being in-
versely correlated to the intensity 
of the sensorial attributes. The rate 
of adherence to AIT is currently 
low. Multiple predictors of non-ad-
herence have been identified, in 
particular the inconvenience and 
the occurrence of side effects for 
subcutaneous AIT, while the per-
ceived (vs. expected) efficacy and 
the costs seem to play a major role 
for the adherence to sublingual 
AIT. The reasons for non-adher-
ence might differ between children 
and adults (Table 1).
Therefore, the approach to AR 
management must be individual-
ized, considering many variable 
factors, such as patients’ age, fre-
quency and severity of symptoms, 
degree of impairment of QOL, 
patient preferences, response, 
tolerability and compliance to pre-
vious medications, presence of 
co-morbidities and costs. An ef-
M. Beatrice Bilò  
University Hospital Ospedali Riuniti 
Ancona, Italy
Adherence to the management plan of allergic rhinitis
274
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 F
 - 
A
lle
rg
ic
 r
hi
ni
ti
s 
- 
Sp
ec
ia
l c
on
si
de
ra
ti
on
s
fective AR management requires 
the development of a doctor/
patient/family partnership and 
tailored patient and family educa-
tion. In some studies, a structured 
educational programme has re-
sulted in enhanced adherence to 
AR treatment and follow-up care, 
improved patients’ perception of 
symptom relief, and decrease in 
prescribed medications.
Although there is a general agree-
ment that education is a key ele-
ment, the best delivery method, 
frequency, and educational set-
ting are still not established.
KEY REFERENCES
1. Sabaté E. World Health Organiza-
tion. Adherence to long-term ther-
apies: evidence for action. Switzer-
land: World Health Organization; 
2003.
2. Naclerio RM, Hadley JA, Stoloff S, 
Nelson HS. Patient and physician 
perspectives on the attributes of 
nasal allergy medications. Allergy 
Asthma Proc 2007;28:S11-17.
3. Marple BF, Fornadley JA, Patel 
AA, Fineman SM, Fromer L, Kro-
use JH, et al. Keys to successful 
management of patients with al-
lergic rhinitis: focus on patient 
confidence, compliance, and sat-
isfaction. Otolaryngol Head Neck 
Surg 2007;136:S107-124.
4. Bukstein D, Luskin AT, Farrar JR. 
The reality of adherence to rhinitis 
treatment: identifying and over-
coming the barriers. Allergy Asth-
ma Proc 2011;32:265-271.
5. Köberlein J, Kothe AC, Schaffert 
C. Determinants of patient com-
pliance in allergic rhinoconjuncti-
vitis. Curr Opin Allergy Clin Immu-
nol 2011;11:192-199.
6. Passalacqua G, Baiardini I, Sen-
na G, Canonica GW. Adherence 
to pharmacological treatment 
and specific immunotherapy in 
allergic rhinitis. Clin Exp Aller-
gy 2013;43:22-28.
COMPLIANCE
HEALTH SYSTEM-
RELATED FACTORS
CONDITION-
RELATED FACTORS
PATIENT-RELATED
FACTORS
THERAPY-RELATED
FACTORS
SOCIOECONOMIC 
FACTORS
State of education
Income
Race/cultural beliefs
Social and family support
Complexity of the regimen
Duration of therapy
Previous treatment failure
Efficacy
Side effects
Age, fear
Motivation, Expectations
Knowledge
Perception and misunderstanding
Severity of disease, cronicity
Symptom stability or absence
Level of disability, co-morbidities
Availability of effective treatments
Education and training
Patient-phycisian-relationship
Capacity of the system
Medical costs
Figure 1 Dimensions of adherence. (Modified from Sabaté E. World Health Organization. Adherence to long-term therapies: 
evidence for action. Switzerland: World Health Organization; 2003.)
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TABLE 1
Some common reasons for poor adherence to management plan in patients 
with allergic rhinitis*
ADULTS:
Feeling that the drug does not have a rapid-onset and long-lasting effect 
(drugs not effective)
Belief that the medication is no longer needed
Belief that medication is only needed intermittently or when symptoms are 
noticeable 
Forget to take the medication
Fear of side effects 
Inconvenience (complexity of the therapeutic regimen)
Difficulty taking the medication 
Cost 
CHILDREN:
Difficulty to take the medication
Do not want to feel different from other children (particularly at school) 
Fear of side effects (both child and parents)
Division of responsibility for treatment between child, school personnel, 
parents, and other caregivers
* Modified from Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse 
JH, et al. Keys to successful management of patients with allergic rhinitis: focus 
on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck 
Surg 2007;136:S107-124.
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social burden
• How patients perceive their rhinitis can differ widely and often 
challenges the understanding of the disease by professionals
• Adopting a bio-psychosocial approach in the consultation 
ensures that the wider impacts of rhinitis are recognised, and 
can then be taken into account when advising and prescribing
• Patient’s perceptions about their rhinitis appear to be 
independent of the severity and persistence of their disease, 
this may lead to under-diagnosis and under-treatment
ILLNESS PERCEPTIONS
Health psychologists have devel-
oped models to help us understand 
how patient’s perceptions about 
their illness links to the way they 
behave (e.g. self-care, medication 
adherence). A widely used model 
is the Leventhal’s Common Sense 
Model of self-regulation, which 
provides a framework for under-
standing how symptom-based 
and psychological factors com-
bine to form patient’s own mod-
el of illness, and how this in turn 
influences their coping strategies 
and outcomes. The model, devel-
oped in 1984, has been applied to 
many chronic illnesses (Figure 1), 
but only recently in rhinitis. One 
British study of adults with sea-
sonal allergic rhinitis (AR) found 
two distinct groups of patients, 
those with negative beliefs about 
hay fever and its treatment (ap-
proximately 40%), and those with 
more positive beliefs. Those with 
negative beliefs perceived control 
of their illness as minimal and their 
treatment ineffective.
Eliciting patients’ beliefs during 
the consultation can reveal as-
sumptions that differ from those 
of the clinician and these patient 
perceptions need to be consid-
ered when negotiating treatment 
ILLNESS PERCEPTION, MOOD 
AND COPING IN PATIENTS 
WITH RHINITIS
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plans. Interestingly, a recent Ital-
ian study found patient percep-
tions to be independent of sever-
ity or persistence of rhinitis. The 
authors suggested this may ex-
plain why AR is under-diagnosed 
and undertreated, even in its most 
severe forms.
COPING
Patients with rhinitis have to 
deal with multiple challenges; 
the feelings of having the disease 
(such as disappointment or an-
ger), the symptoms of rhinitis, the 
need and costs of seeking health 
care and the inconvenience and 
side-effects of treatment. From 
the general literature it is known 
that patients cope with adversity 
in numerous ways, ranging from 
the passive (e.g. acceptance, dis-
engagement) through to very ac-
tive strategies, for example use 
of support (e.g. social, religious). 
Coping can be measured with 
validated questionnaires and in 
Braido’s study the most frequent-
ly used coping mechanisms were 
positive reinterpretation, taking 
action, planning, use of social sup-
port and acceptance. These cop-
ing mechanisms can all be encour-
aged in the consultation (Table 1).
MOOD
Superficially rhinitis may be seen 
as a solely physical disorder; how-
ever it is well documented that 
it also impacts on psychological 
wellbeing, sometimes referred 
to as the “allergy blues”. Rhinitis 
Illness perception, mood and coping in patients with rhinitis
Helen Smith Christina J. Jones
Brighton and Sussex Medical School 
UK
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Figure 1 Leventhal’s Common Sense Model. This model is often used as a framework for examining individuals’ beliefs 
about their illness and health behaviours. Leventhal suggested that patients form beliefs about their illness (cognitive 
representations) and emotional responses (emotional representations) to their illness and together these influence their 
coping strategies. The processing of the information feeds back, modifying the patient’s beliefs and coping mechanisms.
TABLE 1
Tips for helping patients cope with their rhinitis
• Learn to accept your illness – acceptance is often the starting point for 
action, individuals are then better placed to move on, to plan, to seek sup-
port and do the things that can improve their quality of life
• Take action and be involved in your treatment – impact can be reduced by 
becoming actively involved in your care and establishing a good rapport 
with your health carers
• Planning - this can relate to avoiding the triggers and also planning the 
actions you want to take
• Seeking support – seek assistance, information and advice on what to 
do. Sources of advice are plentiful (e.g. books, internet, patient support 
groups)
• Reinterpretation of the situation – this is about viewing your rhinitis in 
a more positive light and looking for benefits in your situation (e.g. the 
things you have learnt or the people you have met).
Illness perception, mood and coping in patients with rhinitis
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Figure 2 Bio-psychosocial model of health and illness. Psychosocial factors, including beliefs, relationships and mood, 
impact on patient’s quality of life and ability to cope with their illness. Incorporating a holistic view in the consultation 
can ensure patient’s wellbeing is addressed in its entirety.
can interfere with sleep, and this 
can cause poor concentration and 
depression. There may also be a 
biological explanation; interest 
in this area was triggered by the 
observation that high tree pollen 
levels correlated with increased 
suicide rates. It has been hypoth-
esised that it is the cytokine re-
leased which affects brain func-
tion, triggering sadness, malaise, 
poor concentration, and increased 
sleepiness. This association re-
quires further exploration, but it 
supports the need to adopt a ho-
listic approach (Figure 2), when 
managing patients with rhinitis, 
and being attentive to their mood 
and psychological well-being, re-
ferring the patient to a mental 
health professional for evaluation 
if appropriate.
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• Allergic rhinitis (AR) is a common, chronic illness with a long 
duration of disease activity that can require many years of 
treatment
• AR is associated with considerable direct and indirect costs to 
the patient and healthcare system
• Poorly controlled AR can be associated with comorbid illnesses 
that can compound treatment costs, such as asthma or sinusitis
• In contrast to pharmacotherapy, allergen immunotherapy (AIT) 
can provide long-term clinical benefits after discontinuation. 
The sustained benefits of AIT can translate into significant cost-
savings over time
• Two systematic reviews concluded that both the sublingual and 
the subcutaneous routes for AIT delivery are cost-effective 
compared with standard drug treatment with no strong 
evidence favoring a particular route
• The cost-effective time point was about 6 years after AIT 
initiation in one systematic review, but as early as 3 months in 
large retrospective claims analyses studies
Allergic respiratory diseases rep-
resent some of the most common 
and costliest chronic conditions 
worldwide. Global estimates sug-
gest that allergic rhinitis (AR) af-
fects approximately 500 million 
people, with higher prevalence in 
westernized countries. Approxi-
mately 113 million people in Eu-
rope and 30 to 60 million in the 
United States (US) are affected 
by AR. Studies comparing AR 
prevalence in patient-reported 
questionnaires with subsequent 
clinically-confirmed AR, suggest 
AR is frequently underdiagnosed, 
often undertreated, and/or poor-
ly controlled. In addition to sig-
nificant patient discomfort, AR 
can be associated with a number 
of ‘secondary’ symptoms and co-
morbid conditions, such as asth-
ma, presenteeism, impaired sleep 
with subsequent daytime fatigue, 
otitis media, and sinusitis that sig-
nificantly impair quality of life, and 
increase the direct and indirect 
costs of AR.
The total indirect costs associated 
with AR can be considerable and 
may actually be greater than the 
direct costs. In addition to over-
the-counter medications, indirect 
costs include lost work productiv-
ity. The annual loss to employers 
PHARMACOECONOMICS OF 
ALLERGIC RHINITIS19
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related to untreated AR-related 
presenteeism has been estimated 
to be approximately €100 billion 
in Europe (2011 value). In a sur-
vey of U.S. employees, the total 
annual cost of lost productivity at-
tributable to AR was significantly 
higher than the cost for any other 
condition assessed including dia-
betes and coronary heart disease.
There are a number of second-
ary outcomes assessed in ran-
domized, controlled trials such 
as impact on quality of life via a 
validated questionnaire, but few 
studies directly assess economic 
outcomes. Cost comparisons can 
only be estimated by translating 
medication scores (use) and the 
secondary clinical outcomes re-
ported (e.g., hospitalizations, or 
unscheduled clinic or emergency 
visits) into actual costs based on 
the reimbursement fees of that 
particular healthcare system. An-
other limitation is that many do 
Linda Cox  
Nova Southeastern University 
Davie, USA
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not provide outcome information 
related to comorbid illnesses or 
the indirect costs of AR (e.g., last 
work days).
The management of AR is multi-
faceted and may include avoid-
ance measures, pharmacothera-
py, and allergen immunotherapy 
(AIT). Multiple controlled-trials 
and systematic reviews indicate 
the magnitude of AIT clinical ef-
ficacy is generally superior to 
pharmacotherapy, with only nasal 
corticosteroids approaching the 
20 to 30 percent improvement 
over placebo seen in most AIT 
trials. An additional consideration 
when evaluating the pharma-
coeconomic of AR, is that allergy 
medications provide no sustained 
benefits after discontinuation. In 
contrast, AIT can provide symp-
tomatic improvement during and 
years after discontinuation. Addi-
tionally, AIT may prevent the pro-
gression of the allergic rhinitis to 
asthma, which is a considerably 
more ‘expensive’ disease in terms 
of both costs and morbidity.
The economic benefit of AIT over 
standard drug treatment (SDT) 
has been confirmed from sever-
al different perspectives; soci-
etal, healthcare system, patient 
and private 3rd party payer, or 
some combination of these per-
spectives. This economic benefit 
would be even greater, if account-
ing for the persistent clinical im-
provement and preventive effect 
of AIT-outcomes that are not seen 
with SDT. One 6-year prospective 
study demonstrated 80% lower 
healthcare costs in the patients 
who received subcutaneous AIT 
(SCIT) compared with SDT, three 
years after the treatment discon-
tinuation.
Several systematic review and me-
ta-analysis of studies that evaluat-
ed the costs and benefits of SCIT 
and/or sublingual AIT (SLIT) and 
concluded that both forms of AIT 
may be cost-effective compared 
with SDT (Table 1). One analysis 
indicated AIT became cost-effec-
tive, as compared with SDT, after 6 
years of treatment initiation from 
the patient and National Health 
Services (NHS) perspectives and 
7 years from NHS perspective. 
In another analysis the cost-sav-
ings associated with AIT began 
TABLE 1
Systematic reviews evaluating allergen immunotherapy health economics
Author
(Number of 
studies included in 
economic analyses )
Inclusion 
criteria
Economic 
outcome SCIT vs SDT
SLIT tablets 
vs, SDT
SLIT drops vs 
SDT,
SCIT vs, SLIT 
vs SDT
Meadows
2013
(14)
All included 
EEs critically 
appraised 
using 
Cochrane 
Collaboration 
checklists
Both SCIT and 
SLIT may be 
cost-effective 
from around 6 
years
6
Cost-effective 
from 3, 6 
and 10 but 
varied with 
perspective
3
 Cost-effective 
at ~ 6 years 
and various 
ICER
2
All favored 
SLIT
3
SCIT more 
cost-effective 
over time
Hankin 2014
(24)
SR of Medline 
studies 
reporting 
health 
economic 
outcomes 
associated 
with AIT.
23
favored AIT 
over SDT
10
All favored 
SCIT
8
1 found higher 
costs with 
SLIT
1
reduced costs 
by year 4
4
All favored 
SLIT
SLIT 48% 
cost-savings 
from HCS 
perspective
SCIT=subcutaneous allergy immunotherapy; SLIT=sublingual allergy immunotherapy; SDT=standard drug treatment, EE=eco-
nomic evaluations, SR =systematic review
* included 3 studies that evaluated the actual total healthcare cost via claims analyses not included in the Meadows review
Adapted with permission from Cox L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck 
Surg 2015;23:247-254.
Pharmacoeconomics of allergic rhinitis
281
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 F - A
llergic rhiniti
s - Special considerati
ons
at 3 months and progressively in-
creased through 18-month evalu-
ation period. The reason(s) for this 
early treatment economic benefit 
can only be speculated but are 
likely multi-factorial and may in-
clude the benefits of an allergy 
specialist’s care
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CHRONIC RHINOSINUSITIS (CRS) – MECHANISMS, 
EPIDEMIOLOGY, RISK FACTORS AND CO-MORBIDITIES
* Chronic rhinosinusitis - mechanisms
* Innate and acquired immunity and epithelial cell function 
in chronic rhinosinustitis
* The role of superantigens in allergic rhinitis, asthma and 
chronic rhinosinusitis
* Host-microbial interactions in chronic rhinosinusitis
* Immunodeficiency and chronic rhinosinusitis
* T-cell regulation in chronic paranasal sinus disease
* Cytokine profiles in chronic rhinosinusitis
* Mucociliary transport in chronic rhinosinusitis
* Airway remodeling in chronic rhinosinusitis
* Epidemiology of chronic rhinosinusitis
* Risk factors for chronic rhinosinusitis
* Classification of chronic rhinosinusitis
* Clinical features of chronic rhinosinusitis
* Endotypes and phenotypes of chronic rhinosinusitis
* Eosinophilic chronic rhinosinusitis
* Fungal sinus disease
* Co-morbidities of chronic rhinosinusitis
* Uncontrolled rhinosinusitis
* The global burden of chronic rhinosinusitis
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es • Defects in the mucosal barrier and in the removal of allergens, 
microbes, mucus, and particulates from the air
• Frequent infections with bacteria, fungi, and viruses leading 
to clinical symptoms and either recurrent acute illnesses or 
chronic inflammation of the nose and sinuses
• Accumulation of immune cells including eosinophils, basophils, 
neutrophils, mast cells, T cells, and B cells that can produce 
mediators involved in immune cell recruitment, tissue injury, 
and perpetuation of the inflammatory response
• Growth of polyp tissue and/or widespread swelling and mucus 
production in the nose and sinuses
Chronic rhinosinusitis (CRS) is a 
complex disease associated with 
inflammation of nasal and sinus 
tissue. Currently, the cause of CRS 
remains unclear but researchers 
have proposed several mecha-
nisms. In healthy people, the nose 
and sinuses are lined with epithe-
lial cells and other specialized cells 
that form a mucosal barrier. This 
barrier serves to protect the un-
derlying tissues from the millions 
of allergens, microbes, and par-
ticulates inhaled regularly. Such 
inhaled particles can be trapped 
in mucus and cleared through the 
action of cilia on nasal epitheli-
al cells that move mucus out of 
the airways. In CRS, the mucosal 
barrier can be defective (Figure 
1). Epithelial cells do not function 
normally, leading to a weak and 
permeable barrier. This impaired 
barrier is exposed to more parti-
cles and does not repair itself as 
well as a healthy barrier. There is 
increased thick mucus produc-
tion in CRS that cannot be easily 
cleared away by nasal epithelial 
cilia.
Some people with CRS have per-
sistent growth of fungi or bacte-
ria such as Staphylococcus aureus 
in their nose and sinuses. In some 
cases, the organism does not 
CHRONIC RHINOSINUSITIS - 
MECHANISMS1
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cause significant damage to tis-
sue. However, problems can occur 
if an immune response is mounted 
against the colonising organism 
or to the toxins it makes. This im-
mune response can cause inflam-
mation and damage to the sinus 
and nasal tissues and worsen CRS 
(Figure 2).
There are many types of white 
blood cells that play a role in CRS 
inflammation. Special factors re-
leased by epithelial cells and other 
cells can cause immune cells to 
migrate outside of blood vessels 
into the sinus and nasal tissue. 
Eosinophils, neutrophils, baso-
phils, mast cells, innate lymphoid 
cells type-2, T cells, and B cells are 
elevated in CRS. These cells can 
be activated to release specific 
mediators that can recruit more 
immune cells, cause tissue injury, 
and perpetuate inflammation.
Inflammation in CRS can lead to 
the dilation of nasal and sinus 
blood vessels, tissue swelling, and 
increased mucus production (Fig-
ure 3). These features can produce 
common CRS symptoms including 
stuffy nose, runny nose, and sinus 
pressure. Finally, in certain types 
of CRS, nasal polyps can form 
which are not cancerous but are 
characterized by local swelling, 
fluid retention, and increased fi-
brin deposition.
In summary, many models have 
been proposed describing the 
Chronic rhinosinusitis - mechanisms
Whitney W. Stevens Robert P. Schleimer
Northwestern University Feinberg School of Medicine 
Chicago, Illinois, USA
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Chronic rhinosinusitis - mechanisms
Figure 1 Components of the mucosal barrier in CRS may be defective.
Figure 2 Colonization with microbes and accumulation of immune cells can lead to tissue injury, inflammation, and 
mucosal barrier loss in CRS.
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mechanisms of CRS. It is very like-
ly that mucosal barrier integrity, 
pathogen colonization, and the 
ensuing immune response all play 
important roles.
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Figure 3 Formation of nasal polyps involves tissue remodeling and enhanced inflammation.
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• The innate immune system represents the first line of immunity 
and host defense and can influence the specific acquired, 
adaptive immune response or the epithelial surface
• The innate immune system distinguishes microbes and other 
entities on a molecular basis. These molecular patterns that are 
recognized impinge on a variety of receptors
• The mechanisms of innate immunity in maintenance of the 
upper airway epithelium requires cellular functions that range 
from epithelium itself through a variety of resident immune 
cells and infiltrating inflammatory cells
• The T-lymphocytes may develop a specific type 2 adaptive 
immune response. The triggering of these specific cells by 
allergens, viral, and microbial proteins may trigger the symptoms 
of rhinosinustitis
Microbial pattern recognition is 
a major function of the innate 
immune system mediated by a 
variety of cells in the tissues pre-
dominately at the epithelial airway 
interface in the nose and sinuses. 
There are four types of receptor 
mechanisms activated in this kind 
of pattern recognition response 
(Table 1). The first involves mem-
brane bound receptors, such as 
the Toll like receptors (TLR) and 
C-type lectin receptors, all of 
which are involved in immune 
cell activation, cytokine produc-
tion and regulation and other 
mediator release. The second 
level response involves secreted 
membrane browned form of re-
ceptors from microbial proteins 
and other agents. These would in-
clude CD14 that binds endotoxin 
as does LPS-binding protein, and 
all of these secreted membrane 
browned material are potentially 
co-factors for TLR activation. The 
secreted forms of host defense in 
innate immunity involves the pro-
duction of anti-microbial peptides 
including the defensins, celliicidin, 
dermicidin and the collectins, sur-
factant proteins and C-reactive 
protein. Finally cytosolic recep-
tors that are NOD-like of which 
the genes coding for NOD1 and 2, 
and NLRP 1, 3 and 4. All pattern 
INNATE AND ACQUIRED IMMUNITY 
AND EPITHELIAL CELL FUNCTION IN 
CHRONIC RHINOSINUSTITIS
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recognition receptors play a role 
in the generation of an intact in-
flammasone that could be gener-
ated in response to innate immune 
response system activation. Once 
these innate processes are activat-
ed, a variety of signaling pathways 
generated by the various recep-
tors, membrane and cytosolic lead 
to a development of pro-inflamma-
tory cytokines and other proteins 
that are involved not only in direct 
host defense, but also in the initi-
ation and modulation of adaptive 
immunity, either locally within the 
submucosa, or within the draining 
lymphoid tissues (Figure 1).
These immune responses depend 
on a wide variety of factors rang-
ing from the microbiome identi-
fied in the upper airway depend-
ent on exposure and development 
of microbiological systems on oth-
er surfaces including the skin and 
gut. In the airways, these bacterial 
enviropathogens and/or commen-
sals do significant influence the 
type of immune response gener-
ated. Most functional immune re-
sponses that are adaptive derive 
from innate immune responses 
are Th1 and Th17 dependent re-
sponses, In those individuals, who 
have a genetic predisposition for 
Innate and acquired immunity and epithelial cell function in chronic rhinosinustitis
Lanny J. Rosenwasser  
University of Missouri-Kansas City School of Medicine 
Kansas City, USA
288
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 G
 - 
C
hr
on
ic
 r
hi
no
si
nu
si
ti
s 
(C
R
S)
 –
 m
ec
ha
ni
sm
s,
 e
pi
de
m
io
lo
gy
, r
is
k 
fa
ct
or
s 
an
d 
co
-m
or
bi
di
ti
es
type 2 immune responses, Th2 
responses can be developed and 
can influence the landscape of 
the epithelium. In the presence 
of increased IL4 and IL13, there 
is reduced production of antimi-
crobial peptides and defensins, as 
well altered barrier function of the 
epithelium.
Finally, it is entirely possible that 
the mechanisms of immune re-
sponses in chronic rhinosinusitis 
(CRS) could give a hint as to the 
organization and systems biology 
of innate immunity at the epithe-
lium border (Figure 2). So, there 
is an inference for excess mRNA 
production in response to an in-
Innate and acquired immunity and epithelial cell function in chronic rhinosinustitis
TABLE 1
Pattern Recognition Receptors
Membrane bound Toll like receptors, C-type lectin receptors
Membrane bound 
and sealed CD14, LPS binding protein
Secreted Antimicrobial peptides: defensins, celliicidin, dermicidin and the collectins, surfactant proteins and C-reactive protein
Cytosolic NOD1, NOD2, NLRP1, NLRP3
LPS = lipopolysaccharide; NOD= nucleotide-binding oligomerization domain; NLRP 
= NOD-like receptors
Microbes
Immune related innate defense
AMP, DC, Macrophage
Homeostasis and barrier of 
Epithelium
Infiltrated Cellular Response
EOS, Neutrophils, Mast Cells
Adaptive Acquired 
Response (T-cells, Ig)
nate and/or an adaptive trigger 
in which gene activation leads to 
increased mRNA. This increased 
mRNA activity can be correlated 
with excess protein of pro inflam-
matory nature that would be gen-
erated. Transcription factors, RNA 
binding proteins, and miRNA’s in-
fluence the mRNA output in terms 
of gene output, so those are im-
portant regulatory factors.
The innate immune system can be 
evaluated in a variety of pathway 
analysis that would identify po-
tential pathway commons and/
or unique aspects of innate adap-
tive immune interactions based 
on network evaluation of high 
throughput data such as after al-
lergen exposure, during allergen 
immunotherapy, or under influen-
za immunization and/or exposure 
to natural viruses. All of these 
activities across the respiratory 
upper airway epithelium can be 
assessed and measured. An iden-
tification of new potential mecha-
nisms for innate adaptive immune 
responses in CRS will be most in-
teresting and identify important 
models that can be developed for 
understanding the framework of 
allergic disease mechanisms.
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Figure 1 Innate Defense modulates the adaptive immune response. 
AMP = antimicrobial peptide; DC = dendritic cell, EOS = eosinophils; Ig = 
immunoglobulins.
Levels of Gene Expression in Innate Response in 
Tissues and Cells
Transcription Factors 
RNA Binding Proteins
miRNA 
Analysis of 
Transcription
Analysis of 
Proteomics
Figure 2  Investigation of the innate immune response by multiple omics.
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• Superantigens, best known those from Staphylococcus aureus, 
can stimulate the mucosal immune system and aggravate 
disease
• S. aureus frequently colonizes noses in children and is associated 
with an increased risk for asthma
• Allergic rhinitis and asthma patients frequently develop IgE 
against superantigens (SE-IgE)
• In chronic rhinosinusitis with nasal polyps, SE-IgE can be 
found in the tissue and are associated with severe disease and 
comorbid asthma
• Serum SE- IgE is associated with asthma, and specifically with 
severe asthma, hospitalisations and decreased lung function
• Omalizumab reduces polyps and symptoms also in non-atopic 
SE-IgE positive subjects
Staphylococcus aureus superan-
tigens were recognized by their 
unique property to stimulate 
T-cells via the T-cell receptor un-
restricted by its antigen speci-
ficity, and have been shown to 
broadly activate epithelial cells, 
dendritic cells, B-lymphocytes as 
well as mast cells and eosinophils. 
Although this interaction is not 
restricted to a mucosal Th2 bias, 
there is an association between 
S. aureus colonisation, formation 
of IgE antibodies to superanti-
gens (SE-IgE) and allergic airway 
disease (Figures 1 and 2). There 
is evidence that allergic mucosal 
sites show a deficit in defense 
against S. aureus partially due to 
the alternative activation of mac-
rophages (type 2 macrophages) 
in the upper and lower airways. 
Nasal colonisation with S. aureus 
is associated with increased risk 
of asthma prevalence, symptoms, 
and exacerbations in children and 
young adults. It has been recently 
speculated that the epidemic of S. 
aureus colonisation may drive the 
concurrent epidemic of asthma.
As superantigens also stimulate 
B-cells and induce receptor re-
vision and class switch recom-
bination, an increased and often 
polyclonal IgE formation is typ-
THE ROLE OF SUPERANTIGENS IN 
ALLERGIC RHINITIS, ASTHMA AND 
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ically found in the mucosal site, 
producing high concentrations of 
functional IgE antibodies. In sub-
jects with allergic rhinitis (AR), 
with or without allergic asthma, 
a significant increase in the prev-
alence and concentration of IgE 
antibodies to classical superanti-
gens vs. controls was found, like-
ly contributing to more severe 
symptoms. Europe-wide, the find-
ing of SE-IgE antibodies in serum 
is associated with higher total IgE 
concentrations and an increased 
risk of asthma (OR 2.10 [1.60–
2.76], P = 0.001) in a concentra-
tion-dependent manner in atopic 
and non-atopic subjects. In asth-
matics, serum SE-IgE is associated 
with asthma severity, oral corti-
costeroid use, hospital admissions 
and decrease in lung function.
Apart from AR and asthma, S. 
aureus and SE-IgE does also play 
a prominent role in chronic rhi-
nosinusitis (CRS), especially in 
the nasal polyp (NP) phenotype. 
In Europe, 85% of NP are Th2-bi-
ased and eosinophilic, with a low 
to medium expression of inter-
leukin-5 and IgE. S. aureus has 
been demonstrated to reside in-
tramucosally, and to release su-
perantigens locally, orchestrating 
The role of superantigens in allergic rhinitis, asthma and chronic rhinosinusitis
Claus Bachert Nan Zhang
Ghent University 
Belgium
290
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 G
 - 
C
hr
on
ic
 r
hi
no
si
nu
si
ti
s 
(C
R
S)
 –
 m
ec
ha
ni
sm
s,
 e
pi
de
m
io
lo
gy
, r
is
k 
fa
ct
or
s 
an
d 
co
-m
or
bi
di
ti
es
Figure 1 Mucosal effects of S. aureus superantigens on immune cells.
Figure 2 Impact of S. aureus and its superantigens on airway disease throughout lifetime.
The role of superantigens in allergic rhinitis, asthma and chronic rhinosinusitis
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a severe eosinophilic inflamma-
tory reaction with high total IgE 
concentrations (Figures 3 and 4). 
Tissue SE-IgE, which is found in 
up to 25% of NP patients, signif-
icantly increases the odds ratio to 
have comorbid asthma, and also is 
a predictor for NP recurrence after 
surgery. Of interest, Omalizumab 
has been demonstrated to sig-
nificantly reduce NP size and de-
crease symptoms in patients with 
NP and asthma, independent of 
the atopic status. These patients 
suffer from late-onset non-atopic 
disease, which is likely to be or-
chestrated by staphylococcal su-
perantigens.
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Figure 3 Intramucosal S. aureus in a 
polyp sample.
Figure 4 Follicle-like structures in a nasal polyp expressing IgE and binding the superantigen SEA.
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Host-microbial interactions in chronic rhinosinusitis
• Host-microbial interactions (HMI) are key to the pathogenesis 
of chronic rhinosinusitis (CRS) manifesting as: infection with 
or without biofilm formation, “dysbiosis” of the nasal/sinus 
microbiome or maladaptive immune responses to microbial 
colonization
• Multiple host functions protect against sinus infection and 
maintain a healthy sinus microbiome, including epithelial 
barrier, mucociliary clearance, microbial recognition through 
innate epithelial pattern-recognition receptors and production 
of antimicrobial proteins and nitric oxide (NO)
• A deficiency in local production of lactoferrin has been 
described in CRS
• A nonfunctioning polymorphism in the bitter taste receptor 
T2R38 fails to recognize a quorum-sensing molecule from 
Pseudomonas aeruginosa. CRS patients possessing this 
nonfunctioning polymorphism (TAS2R38) are more likely to 
have Pseudomonas sinus infection
• Staphylococcus aureus can contribute to CRS pathogenesis 
by several mechanisms: overt infection, mucosal biofilm, 
intraepithelial colonisation and by staphylococcal enterotoxins 
(SEA, SEB or TSST-1) that activate T lymphocytes to produce 
Th2 cytokines (IL-5 and IL-13) and elicit local maladaptive anti-
enterotoxin IgE antibodies in nasal polyps
• Certain colonising fungi also elicit maladaptive Th2 responses 
in CRS
Chronic rhinosinusitis (CRS), exists 
in 3 subtypes, namely CRS without 
nasal polyposis (CRSsNP), CRS with 
nasal polyposis (CRSwNP) and al-
lergic fungal rhinosinusitis (AFRS). 
Host-microbial interactions (HMI) 
are key to the pathogenesis of 
CRS manifesting as an unusual 
susceptibility to infection, biofilm 
formation, “dysbiosis” of the nasal/
sinus microbiome or “maladaptive” 
Th2-biased immune responses to 
microbial colonization. Defects in 
host innate immune responses po-
tentiate these phenomena.
Bacterial biofilm forms on sinus 
mucosa with an overall prevalence 
of 56.3% in surgical CRS series 
but less in CRSwNP. The pres-
ence of polymicrobial biofilm or 
biofilm containing Staphylococcus 
aureus has been associated with 
more severe sinus disease preop-
eratively and worse sinus symp-
tom and nasal endoscopy scores 
postoperatively. An intraepithelial 
reservoir of Staphylococcus aureus 
(IESA) has been demonstrated in 
CRS patients, but its significance is 
unclear. The key features of “dys-
biosis” of the sinus microbiome are 
summarized in Table 1. While the 
total bacterial burden in CRS tissue 
is similar to controls, there is an in-
creased “burden” of Staphylococcus 
HOST-MICROBIAL 
INTERACTIONS IN CHRONIC 
RHINOSINUSITIS
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aureus. Certain bacterial taxa or 
species may be protective against 
CRS, whereas others may be 
uniquely harmful, although these 
observations derive from only one 
study. There is debate regarding 
the importance of colonizing fun-
gi as drivers of maladaptive Th2 
inflammation in CRS, stemming 
in part from difficulties in staining 
fungal hyphae or culturing viable 
fungi from sinus mucus samples 
Daniel L. Hamilos  
Massachusetts General Hospital 
Boston, USA
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and in part from conflicting results 
regarding the immune stimulation 
afforded by colonizing fungi.
Table 2 summarizes the key com-
ponents involved in host-microbial 
interactions in the paranasal sinus-
es. Tight junction proteins, adher-
ens junction proteins and desmo-
somal proteins maintain normal 
epithelial barrier function. No 
primary defects in these proteins 
have been described in CRS or NP, 
although decreased occludin and 
zonula occludens 1 and decreased 
E-cadherin were described in NP, 
likely secondary to allergic tissue 
inflammation. CRS is associated 
with a transient reduction in mu-
cociliary clearance that normalizes 
following resolution of infection 
and restoration of sinus ostial pa-
tency. There is no evidence for 
a primary defect in mucociliary 
clearance in CRS except in the rare 
patients with primary ciliary dyski-
nesia (PCD) and cystic fibrosis (CF). 
A decreased level of the antimicro-
bial protein lactoferrin has been 
found in CRS, whereas the level 
of other antimicrobial proteins has 
been found to be normal. Nitric ox-
ide (NO) is constitutively produced 
at high levels in sinus epithelium by 
virtue of constitutive expression 
of inducible nitric oxide synthase 
(iNOS). The NO concentration in a 
healthy maxillary sinus (9.1 +/- 3.8 
ppm) exceeds that necessary for 
antibacterial effects in vitro and is 
vastly higher than that produced in 
the nose or lungs (exhaled NO nor-
mally < 50 ppb).
Figure 2 summarizes current 
knowledge about microbial trig-
gering of innate immune responses 
in CRS. Sino-nasal epithelial cells 
express Toll-like receptors (TRLs) 
that recognize pathogen-associ-
ated molecular patterns (PAMPs) 
leading to production of antimi-
crobial peptides and cytokines and 
chemokines that amplify innate 
and adaptive immune responses. 
No primary defects in sino-nasal 
TLRs have been described in CRS. 
Dectin and NOD-like receptors 
have not been studied in CRS. Bit-
ter taste receptors, such as TAS2R, 
recognize besides bitter taste a 
quorum-sensing molecule from 
Pseudomonas aeruginosa resulting 
in production of antimicrobial NO 
and β-defensin. A common pol-
ymorphism (TAS2R38 variant) is 
associated with reduced signaling 
and an increased frequency of P 
aeruginosa infection in CRS pa-
tients.
There is evidence that links colo-
nizing microorganisms to a mala-
daptive Th2-biased “local allergic” 
response in NP. Certain fungi, such 
as Alternaria, induce production of 
IL-5 and IL-13, as well as IFN-γ in 
peripheral blood lymphocytes from 
CRS patients and elicit modest pro-
duction of IL-5 and IL-13 from dis-
persed NP T lymphocytes. Mucosal 
colonization with Staphylococcus 
aureus occurs in 64% of patients 
with CRSwNP, compared with 30% 
in healthy individuals or patients 
with CRSsNP, and staphylococcal 
superantigens (such as SEB) cause 
local proliferation of T lympho-
cytes, local anti-SEB IgE antibody 
production and robust production 
of IL-5 and IL-13 in dispersed NP 
T lymphocytes. These studies sug-
gest that colonizing Staphylococcus 
aureus is a major driver of the local 
maladaptive Th2-biased inflamma-
tory response in CRSwNP. There is 
also evidence that links allergic in-
flammation with down-regulation 
of TLR-9 expression which may 
account for some of the increased 
susceptibility of NP toward bacteri-
al colonization.
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Rep 2014;14:485.
3. Soyka MB, Wawrzyniak P, Eiweg-
ger T, Holzmann D, Treis A, Wanke 
K, et al. Defective epithelial bar-
rier in chronic rhinosinusitis: The 
regulation of tight junctions by 
IFN-gamma and IL-4. J Allergy Clin 
Immunol 2012;130:1087-1096.
e10.
4. Lee RJ, Xiong G, Kofonow JM, 
Chen B, Lysenko A, Jiang P, et al. 
T2R38 taste receptor polymor-
phisms underlie susceptibility to 
upper respiratory infection. J Clin 
Invest 2012;122:4145-4159.
5. Tieu DD, Kern RC, Schleimer RP. Al-
terations in epithelial barrier func-
tion and host defense responses in 
chronic rhinosinusitis. J Allergy Clin 
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TABLE 1
Key findings regarding “dysbiosis” of the microbiome in CRS patients
• Less richness, evenness and diversity in CRS than controls.
• Total bacterial burden in CRS is similar to controls.
• Increased burden for certain organisms (e.g. Staphylococcus aureus).
• Certain bacterial taxa or species may be protective (e.g. the order Lactoba-
cillales or the species Lactobacillus sakei), although this has not been sup-
ported in all studies.
• Some taxa or species may be uniquely harmful (e.g. the family Corynebacte-
riaceae and the species Corynebacterium tuberculostearicum), although this 
has not been supported in all studies.
Host-microbial interactions in chronic rhinosinusitis
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Antimicrobial proteins/antimicrobial peptides: Lactoferrin, 
lysozyme, S100A7 (psoriasin) and S100A8/A9 (calprotectin), 
LPLUNC-1, short-PLUNC1, LPLUNC-2 (BPI), α-defensin, β-
defensins (HBD-1, HBD-2) and cathelicidin (LL-37).
Immunoglobulin-related proteins: Secretory IgA, secretory 
component (extracellular component of poly-Ig receptor), BAFF (B 
cell-activating factor)
Complement-related proteins: C3, Factor B, Factor H, serum 
amyloid A
Chitinases: Acidic mammalian chitinase (AmCase), chitotriosidase
Ficolins and collectins: SP-A, SP-D, uteroglobin (secretoglobin), 
statherin, mammaglobin B
Secretory proteins: Lipocalin-1, neutrophil gelatinase-associated 
lipocalin (NGAL)*
Phospholipases/Proteases/Protease inhibitors: Secretory 
phospholipase: sPLA(2)-IIA, -IID, -IIE; MASP1, MASP2, secretory 
leukocyte protease inhibitor (SLPI)
Antimicrobial reactive species: nitric oxide (NO)
Epithelium
Mucus goblet 
cells
Ductal 
epithelium
Submucosal 
seromucinous 
mixed glands
Bacterial dysbiosisFungal 
colonization
Bitter taste receptor
NO
Decrease in 
antimicrobial 
protein production 
(lactoferrin)
Activation 
of NFkB 
Toll-like receptors
Proinflammatory
response:
Cytokines, chemokines
defensins
cathelicidins
PLUNC proteins
beta-defensin-2
Bacterial biofilm
formation
Sinus epithelium
Figure 1 Structure of sinus epithelium, submucosal seromucinous mixed glands and stroma and summary of the most 
widely studied proteins and peptides and antimicrobial substances produced by sinus mucosal cells of relevance to CRS. 
Seromucinous glands are stained positively for CXCL1 (GRO-α). (Adapted from Hamilos DL. Host-microbial interactions in 
patients with chronic rhinosinusitis. J Allergy Clin Immunol 2014;133:640-653.)
Figure 2 Summary of pathologic features of CRS and important components of innate immunity of relevance to CRS. 
(Not all pathologic features need be present in all cases.). (Adapted from Hamilos DL. Host-microbial interactions in patients 
with chronic rhinosinusitis. J Allergy Clin Immunol 2014;133:640-653.)
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TABLE 2
Key components involved in host-microbial interactions in the paranasal*
Host 
function
Key innate components 
or receptors in airway 
epithelial cells
Specific receptors or 
proteins involved
Relevant pathogens Defects in CRS patients
Maintaining 
epithelial 
barrier
Tight junction proteins claudins, occludins
Bacteria, fungi
Decreased in NP epithelial 
cell cultures.
Adherens junction 
proteins E cadherin Decreased in NP.
Desmosomal proteins
desmoglein 2
desmoglein 3
Decreased in NP epithelial 
cells in response to IL-13.
Mucociliary 
clearance Cilia
Outer dynein arms, inner 
dynein arms, or both
Gram-positive and 
gram-negative bacteria CRS patients with PCD.
Mucus 
rheology
Epithelial chloride 
channels CFTR
Staphylococcus 
aureus, Pseudomonas 
aeruginosa, 
Burkholderia cepacia
CRS patients with CF.
Innate 
epithelial 
pattern-
recognition 
(cell 
membrane or 
intracellular 
TLR)
TLR 1-10 that recognize 
specific bacterial cell 
wall component, viral 
double-stranded RNA 
(dsRNA), and bacterial 
unmethylated CpG ODN 
sequences (CpG DNA) 1,2
TLR2
Gram-positive and 
Gram-negative 
bacteria; fungi
Normal function in CRS.
TLR3 Rhinovirus, other viruses Normal function in CRS.
TLR4 (recognizing LPS)3
Gram-negative 
bacteria; Candida and 
Aspergillus fumigatus
Normal function in CRS.
TLR9 Bacteria
Reduced TLR9 in cultured 
NP epithelial cells possibly 
due to Th2 cytokines.
Bitter taste 
receptors 
(e.g. T2R38, 
TAS2R)
G-protein coupled recep-
tors expressed on sinus 
epithelial cells that recog-
nize bitter tastes and quo-
rum-sensing molecules.
TAS2R38 Pseudomonas aeruginosa
Nonfunctional TAS2R38 
genotype correlated with P 
aeruginosa infection in CRS 
patients
Antimicrobial 
proteins
Produced in response to 
TLR ligation and to bitter 
taste receptor ligation
Lactoferrin, lysozyme Bacteria, fungi Decreased lactoferrin in CRS
Beta-defensins Bacteria Normal levels in CRS.
Cathelicidins Bacteria Normal levels in CRS.
Bactericidal/permeability 
increasing protein (BPI)
Gram-negative 
bacteria
Decreased in NP (likely 
reflecting less glands in NP).
Complement C3, serum 
amyloid A Bacteria, fungi Normal levels in CRS.
Psoriasin, calprotectin Bacteria, fungi Decreased in NP
1 TLR-1, -5, -6 and -10 are not included, because there are no reports of abnormalities in these TLRs associated with CRS.
2 CpG: bacterial deoxyribonucleic acid (DNA) containing unmethylated CpG dinulceotides.
3 LPS; lipopolysaccharide.
TLR ligand information sources: http://www.invivogen.com/tlr2-ligands
* Data from Hamilos DL. Host-microbial interactions in patients with chronic rhinosinusitis. J Allergy Clin Immunol 2014;133: 
640-653.
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Immunodeficiency and chronic rhinosinusitis
• Antibody deficiencies are the most common primary immunode-
ficiencies. Patients with antibody deficiencies are susceptible to 
bacterial pathogens and can develop recurrent or chronic upper 
and lower respiratory tract infections. It is important to recognize 
antibody deficiencies in patients with refractory rhinosinusitis
• Common variable immunodeficiency, selective IgA deficiency, and 
specific antibody deficiency account for the majority of antibody 
deficiencies observed in patients with chronic rhinosinusitis (CRS)
• Antibody deficiencies range in severity from mild to severe 
depending on the underlying pathology and levels of antibody 
production and function
• Treatment options of antibody deficiencies in patients with 
refractory CRS should be individualized and may include 
prophylactic antibiotics and immunoglobulin replacement
Chronic rhinosinusitis (CRS) is as-
sociated with significant morbid-
ity and a high healthcare burden. 
Risk factors associated with CRS 
include atopy, structural abnor-
malities and immune dysfunction. 
Thus, patients with CRS who are 
refractory to medical therapy, or 
those who present with recurrent 
sinus infections, are evaluated for 
immunodeficiency.
Antibody deficiencies, such as 
specific antibody deficiency (SAD), 
common variable immunodefi-
ciency (CVID), and selective IgA 
deficiency are among the primary 
immunodeficiencies (PID) that are 
associated with CRS (Tables 1,2). 
Antibody deficiencies should be 
considered in patients with CRS 
refractory to standard medical 
and surgical management.
COMMON VARIABLE 
IMMUNODEFICIENCY
Common variable Immunodefi-
ciency (CVID) is the most common 
symptomatic antibody deficiency. 
Typically there is a reduction in at 
least two of the three major immu-
noglobulin types: levels of IgG as 
well as IgA and/or IgM are reduced 
more than two standard deviations 
below the mean adjusted for age. 
In addition, there is an impaired an-
tibody response to immunization 
IMMUNODEFICIENCY AND 
CHRONIC RHINOSINUSITIS5
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with polysaccharide antigens and 
often to protein antigens. Quite 
often CVID is diagnosed in the 
second and third decade of life al-
though symptoms may precede the 
diagnosis by many years. Recurrent 
infections involving the upper and 
lower respiratory tracts are often 
observed in CVID. The prevalence 
of CVID in patients with CRS at 
academic institutions ranges from 
6-10%. In a European cohort study, 
CRS was present in 37% of CVID 
patients at diagnosis and increased 
to 54% after 11 years of follow up. 
CVID is a heterogeneous disorder 
with both infectious and noninfec-
Anju T. Peters  
Northwestern University Feinberg School of Medicine 
Chicago, USA
TABLE 1
Prevalence of common primary 
antibody immunodeficiencies in 
patients with chronic rhinosinusitis 
who were evaluated for Immunode-
ficiency at an academic institution
Immune Status Patients
Specific Antibody Defi-
ciency (SAD) 144 (24.2%)
Common Variable Im-
mune Deficiency (CVID) 35 (5.9%)
IgA deficiency 16 (2.7%)
No Immunodeficiency 402 (67.6%)
Total 597
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Immunodeficiency and chronic rhinosinusitis
tious comorbidities. Many patients 
with CVID have noninfectious 
complications including chronic 
lung disease, autoimmunity, lym-
phoma, granulomatous disease 
or inflammatory gastrointestinal 
disease. In addition, patients with 
CVID have a reduced lifespan 
when compared to the general 
population. These findings high-
light the importance of diagnosing 
CVID in at-risk patients, including 
those with recurrent sinus infec-
tions or refractory CRS.
SELECTIVE IgA DEFICIENCY
Prevalence of selective IgA defi-
ciency ranges from 1 in 173 to 1 
in 3024 persons. The prevalence 
may be increased in CRS and was 
reported in 3-6% of patients with 
CRS, who were evaluated for im-
munodeficiency. The majority of 
patients with IgA deficiency are 
asymptomatic, however a small 
subset develops recurrent sinus in-
fections or CRS. Atopy, asthma, and 
autoimmune diseases are also com-
mon in patients with IgA deficiency.
Patients with specific antibody de-
ficiency (SAD) form normal quanti-
ties of IgG antibodies, but the an-
tibodies don’t function well. SAD 
is diagnosed by demonstrating a 
poor response after a polysaccha-
ride vaccine: typically 50-70% of 
pneumococcal serotypes should 
be at or above a protective level 
(>1.3 mcg/mL) after an unconju-
gated pneumococcal polysaccha-
ride vaccine. In an academic set-
ting, up to 24% of patients with 
CRS, who were evaluated for im-
mune problems had SAD. These 
patients received more antibiotic 
courses compared to patients with 
CRS who had an intact immune 
system, had an increased incidence 
of pneumonia, and 18% of the pa-
tients with SAD were treated with 
immunoglobulins.
IgG SUBCLASS DEFICIENCY
IgG subclass deficiency is defined 
as one or more low IgG subclass-
es with normal total IgG levels. 
The clinical significance of an iso-
lated IgG subclass deficiency is 
controversial. Low levels of IgG 
subclasses have been reported in 
otherwise healthy individuals. It is 
believed that a lack of a functional 
response to a polysaccharide vac-
cine is more important than defi-
ciency in IgG subclasses. For this 
reason, routine determination of 
IgG subclasses is not recommend-
ed in the evaluation of immunode-
ficiency in patients with CRS.
TABLE 2
Phenotype and clinical features of common primary antibody deficiencies 
observed in patients with chronic rhinosinusitis
Subtype Clinical Features Immunological Features
Pan-hypogam-
maglobulinemia 
(CVID)
Upper and lower respiratory 
tracts bacterial infections, 
autoimmune diseases, in-
creased risk of malignancy
1. Decreased CD27+ memory 
B cells
2. Defective plasma cells
3. Decreased immunoglobulins
Selective IgA 
deficiency
Typically asymptomatic, 
may get recurrent bacterial 
respiratory tract infections
1. Pathogenesis not known
2. IgA < 0.07g/L, normal IgG 
and IgM
Specific anti-
body deficiency
Bacterial infections; most 
are asymptomatic
1. Normal immunoglobulins
2. Lack of functional response 
to polysaccharide vaccines
CVID, common variable immunodeficiency
THERAPY
Treatment options for patients 
with CRS and antibody deficiency 
should be individualized and may 
include the use of prophylactic an-
tibiotics as well as vaccination with 
a conjugated pneumococcal anti-
gen vaccine. Immunoglobulin re-
placement is reserved for patients 
with CVID or those who fail to 
respond to vaccinations and have 
persistent infections. The under-
lying CRS should be managed by 
medical therapy and if necessary 
by surgical intervention.
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T-cell regulation in chronic paranasal sinus disease
• The role of the specific immune system in the upper airways 
is particularly interesting as the large surface in combination 
with the innate immune components and the mucosal surface 
represents a first contact point of immune system and inhaled 
environment including certain antigens
• Upon allergen-airway challenge T cells start to express enzymes 
encoded by the recombination-activating genes that edit the 
germline genes of the B- and T cell receptors and also the 
switch of naïve, IgM+ B cells to IgE
• The analysis of T cells isolated from chronically affected patients 
show a diverse cytokine secreting phenotype that is thought to 
origin from a “plasticity” of T cells
• A possible explanation for the origin of this cytokine escalation 
is the constant and repetitive exposure of upper airway cells to 
bacterial superantigens
• Increased cytokine production by the T cells is followed by an 
extended mediator release of tissue cells
While the structure of the upper 
airways gives rise to all kind of 
speculations regarding the evolu-
tionary origin, it’s function as in-
terface to the environment is not 
in question. The role of the specif-
ic immune system is particularly 
interesting as the large surface in 
combination with the innate im-
mune components and the mu-
cosal surface represents a first 
contact point of immune system 
and inhaled environment includ-
ing certain antigens.
IMMUNE SYSTEM OF THE 
UPPER AIRWAYS
A key hypothesis in T cell biology 
is that the antigen is taken up by 
dendritic cells and /or drained into 
the next lymph node, where anti-
gens are presented in context with 
MHC class II to T cells and mobilize 
either de novo or memory respons-
es along with help to differentiat-
ing B cells. In contrast to the lower 
airways the existence of the nasal 
mucosa associated lymphoid tis-
sue (MALT) is less clear and there-
fore the turnover of lymphocytes 
is not fully known. However, it 
could be demonstrated that upon 
allergen-airway challenge T cells 
start to express enzymes encod-
ed by the recombination-activat-
ing genes. These enzymes are ex-
T-CELL REGULATION IN 
CHRONIC PARANASAL SINUS 
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pressed to edit the germline genes 
of the B- and T cell receptors and 
also the switch of naïve, IgM+ B 
cells to IgE. These studies demon-
strate that lymphoid tissues are 
not essential for the maturation of 
the immune system and raise the 
question to which degree the tis-
sue environment contribute to the 
maturation of the immune cells.
T CELL SUBSETS
While it is well established that T 
cells play a key role in the switch 
of uncommitted, IgM+ B cells into 
IgG+ or IgA+ or IgE+ memory phe-
notypes, it became apparent that 
T cells do also play a key role in the 
instruction of tissue cells such as 
epithelial cells. In fact IL-17 and IL-
22 represent two T cell cytokines 
which act primarily or even exclu-
sively on epithelial cells or kerat-
inocytes. This finding raised the 
hope that paranasal sinus diseases 
could be treated with biologicals 
to block these cytokines. Howev-
er, the analysis of T cells isolated 
Carsten B. Schmidt-Weber  
Technical University Munich and Helmholtz Center 
Munich, Germany
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from local inflammation opposed 
to those that have been classical-
ly isolated from peripheral blood 
displayed a phenotype that dif-
fers from classical Th1, Th2, Th17 
or Treg cells. While the classical T 
cell phenotypes express a narrow 
bandwidth of cytokines, the cells 
isolated from chronically affect-
ed patients show a more diverse 
phenotype that is thought to or-
igin from a “plasticity” of T cells. 
This plasticity has been report-
ed for Th1 cells from peripheral 
blood that are able to express IL-
17 or IL-4 or Th2 cells expressing 
IFN-g, however expression can 
be reversible at least upon in vit-
ro culture. Analysis of T cells from 
biopsies of patients suffering from 
chronic disease revealed that 
these T cells expressing multiple 
cytokines are not the exception, 
but rather a rule. In contrast to pe-
ripheral blood cells, these clones 
are remarkably stable, These cells 
do not show a particular polariza-
tion towards any of the effector 
phenotypes, but a depression of 
regulatory phenotypes.
ORIGIN OF THE CYTOKINE 
ESCALATION
A possible explanation for the or-
igin of this cytokine escalation is 
the constant and repetitive expo-
sure of upper airway cells to Staph-
ylococcal aureus and its superanti-
gens, which can activate the T cell 
receptor by cross-linking it with 
the MHC class II molecule, even in 
the absence of an antigen, which 
is normally located in the MHC-
grove. This superantigen function 
may stepwise extend the T cell rep-
ertoire to produce cytokines.
REBOUND OF THE TISSUE
The multitude of cytokines has 
functional consequences not only 
on other immune cells, but also 
on structural cells such as airway 
epithelial cells. At least from the 
pharmaceutical viewpoint most 
monovalent drugs targeting cy-
tokines were unsuccessful, while 
biologicals with broader specific-
ity that are hitting multiple tar-
gets appear to be more effective. 
In fact, it appears that structural 
cells require the exposition to 
multiple cytokines before becom-
ing themselves active in the ex-
pression of defence mechanisms. 
Consequently, increased cytokine 
production by the T cells will also 
be followed by an extended medi-
ator release of tissue cells. Taken 
together, it appears that future 
therapies may need to address im-
mune cells and tissue cells at the 
same time to revert excessive im-
mune activation and insufficient 
regulatory control.
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Cytokine profiles in chronic rhinosinusitis
• Cytokines profiles differ among different phenotypes of chronic 
rhinosinusitis (CRS)
• Different cytokine profiles may underline different CRS 
endotypes
• The pattern of inflammation differs considerably between 
CRS with nasal polyps (NP), CRS without NP and CRS with NP 
accompanying cystic fibrosis
• Characterization of cytokine-producing cells and the whole 
array of cytokines in this context is demanded to generate 
more precise therapeutic approaches
Chronic rhinosinusitis (CRS) is 
characterized by a complex pat-
tern of inflammation that differs 
considerably between CRS with 
nasal polyps (CRSwNP), CRS with-
out nasal polyps (CRSsNP) and 
CRSwNP accompanying cystic fi-
brosis (CF-CRSwNP). 
In CRSwNP tissue the frequency 
of eosinophils, B-cells, T-cells, mac-
rophages, neutrophils and dendrit-
ic cells is enhanced and these cells 
orchestrate, although not mutu-
ally exclusively, a T helper 2 (Th2) 
dominated inflammatory response. 
IL-5, IL-13, IL-25, thymic stromal 
lymphopoietin (TSLP) and also 
IL-32 and IL-33 are up-regulated in 
CRSwNP tissue. Th2-cells and type 
2 innate lymphoid populations 
(ILC) significantly contribute to IL-
13 and IL-5 production. Moreover, 
eotaxins, leukotrienes and prosta-
glandins are released by mast cells 
and eosinophils or basophils. Upon 
inflammation and exposure to in-
fectious or non-infectious trigger 
factors like allergens, IL-33, IL-25 
and TSLP are either secreted (IL-
25, TSLP) or released upon cell 
damage (IL-33). These cytokines 
are capable to activate residing 
ILCs, that boost IL-13 and IL-5 pro-
duction and further up-regulate 
Th2-driven inflammation and ac-
CYTOKINE PROFILES IN 
CHRONIC RHINOSINUSITIS7
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tivate effector cell types. IL-4 and 
IL-13 promote isotype switching of 
resident B-cells to generate local 
IgE with specificity to Staphylococ-
cus endotoxin B (SEB) and other, 
not yet specified antigens, which 
could be relevant trigger factors 
that contribute to chronic inflam-
mation. In addition chemokines 
that favor immune cell recruitment 
(CCL11, CCL18, CCL24, CCL26) 
and inflammatory cytokines like IL-
6, IL-8 and TNFα are up-regulated 
in CRSwNP and enhance local in-
flammation (Figure 1).
The heterogeneity according to en-
vironmental factors is underlined by 
data from nasal polyp tissue from 
a Chinese population. In this sub-
group, inflammation is neutrophil 
dominated, non-eosinophilic (90%) 
and devoid of IL-5 protein and more 
aligned with a Th1/Th17-type re-
sponse, with increased expression 
of IFNγ, IL-1ß, IL-6 and IL-17A.
CRSsNP is characterized by an in-
creased production of Th1/Th0- 
associated cytokines (IFNγ), in-
creased expression of TGF-ß1 and 
TGF-ß2 receptors on effector cell 
populations and an up-regulation 
of the TGF-ß pathways, which is 
in accordance with typical fea-
tures, such as fibrosis, basement 
membrane thickening, goblet cell 
hyperplasia, sub-epithelial mono-
nuclear inflammation and edema 
(Figure 2).
CF-CRSwNP can be considered an 
entity of its own characterized by 
Thomas Eiwegger  
Medical University of Vienna 
Vienna, Austria
301
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 G
 - C
hronic rhinosinusiti
s (C
R
S) – m
echanism
s, epidem
iology, risk factors and co-m
orbiditi
es
a neutrophil-mediated inflamma-
tion with increased IL-1β, TNFα, 
IL-8, IL-17A, myeloperoxidase and 
increased expression of innate de-
fense proteins such as surfactant 
proteins A, B and D.
Given the broad range of inflam-
matory mediators involved and 
the inter-patient variability, it is 
likely that numerous CRS endo-
types exist that need to be de-
fined in the future to generate tar-
geted therapies for CRS patients.
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Figure 1 The cytokine network in chronic rhinosinusitis with nasal polyps 
(CRSwNP). CRSwNP is dominated by a Th2-type inflammatory environment, 
which is insufficiently controlled by regulatory T-cells. The epithelium releases, 
either by secretion, or upon cell death and apoptosis, cytokines that activate 
innate lymphoid cells (ILCs) that produce large amounts of IL-5 and IL-13 in 
concert with Th2 cells. In addition, a number of chemokines are released that 
recruit Th2 cells. The Th2 cytokines recruit and activate eosinophils and mast 
cells, trigger their mediator release, promote local IgE production and activate 
alternatively-activated macrophages (AAM).
Figure 2 The cytokine network in chronic rhinosinusitis without nasal polyps 
(CRSsNP). CRSsNP is characterized by an increased production of the T helper 
1 (Th1) associated cytokines (IFNγ, TNFα) and an enhanced production of 
TGF-β, accompanied by a higher expression of TGFβ1 and TGFβ2 receptors on 
effector cell populations. Moreover, the epithelium significantly contributes to 
inflammation by enhanced production of IL-6, IL-8 and TNF-α. The frequency 
of neutrophils is higher in CRSsNP tissue as compared to controls. This leads 
to typical features like fibrosis, basement membrane thickening and goblet cell 
hyperplasia.
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Mucociliary transport in chronic rhinosinusitis
• Mucociliary transport is the primary physical defense of the 
airways against inhaled pathogens and irritants
• Genetic diseases that decrease mucociliary transport are 
characterized by increased incidences of upper and lower 
airway infections, including chronic rhinosinusitis (CRS)
• Environmental exposure to toxic substances or pathogens that 
affect ciliary beating or ion/fluid transport can also result in 
acquired defects in mucociliary transport
• Stasis of sinonasal secretions and failure to properly clear 
pathogens is an important part of CRS pathology
• Stimulation of mucociliary clearance an important therapeutic 
target for CRS treatment
The front line of respiratory de-
fense is the sinonasal cavity, 
which comes into contact with 
aerosolized fungal spores, bacte-
ria, and viruses with every breath. 
However, in most individuals, the 
airways remain free of patho-
logical infection, largely due to 
multiple first-line innate immune 
mechanisms working in concert 
to defend the sinonasal epitheli-
um. The primary physical defense 
is mucociliary transport (MCT), a 
specialized function of the airway 
epithelium, consisting of two com-
ponents: mucus production and 
mucus transport. The airway sur-
face liquid (ASL) lining the airways 
contains a top layer of mucus gel 
formed from mucin macromole-
cules secreted by goblet cells and 
submucosal glands. Mucins are 
coated by “sticky” carbohydrates 
that trap inhaled pathogens and 
particulates. Below the mucus is a 
watery periciliary layer (PCL). The 
lower viscosity of the PCL allows 
motile cilia (Figure 1) to beat rap-
idly in a spatially and temporally 
coordinated manner, transporting 
the debris- and pathogen-laden 
mucus toward the oropharynx 
(throat), where the mucus/path-
ogen/debris mixture is cleared 
by swallowing or expectoration 
(Figure 2). MCT is complement-
MUCOCILIARY 
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ed by secretion of antimicrobial 
peptides (lysozyme, lactoferrin, 
cathelicidins, and defensins) and 
reactive oxygen and nitrogen spe-
cies (hydrogen peroxide and nitric 
oxide) that directly kill pathogens. 
Epithelial cells can also secrete cy-
tokines that recruit immune cells 
to sites of infection.
The fundamental importance of 
MCT to airway health is high-
lighted by two genetic diseases. 
In cystic fibrosis, a disease of al-
tered ion transport, reduced PCL 
volume causes overly sticky mu-
cus that severely impairs MCT and 
results in persistent upper airway 
infections and often fatal lung in-
fections. Primary ciliary dyskine-
sia, a genetic multi-organ disorder 
of cilia dysfunction, also caus-
es severely impaired MCT and 
chronic airway infections. MCT 
can also be reduced by exposure 
to various environmental toxins or 
pathogens that produce ciliotoxic 
metabolites.
While multiple causes contribute 
to the development of chronic 
rhinosinusitis (CRS), a common 
pathophysiologic sequela is the in-
effective sinonasal MCT, resulting 
in stasis of sinonasal secretions 
and subsequent chronic infection 
and/or persistent inflammation. 
Studies have suggested that al-
terations of mucus viscosity, ion 
transport, or ciliary beating may 
Robert J. Lee Noam A. Cohan
University of Pennsylvania 
Philadelphia, USA
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Figure 2 Diagram of mucociliary transport (MCT) intervention in airway innate immunity. Inhaled pathogens are 
trapped by the sticky mucus layer overlaying the airway surface liquid (ASL). The mucus rides on top of the less viscous 
periciliary layer (PCL), propelled by the rapid (~8-15 Hz) beating of airway ciliated cells, which affect MCT by both 
regulating ciliary beat frequency, as well as transporting ions and fluid that affect the composition and viscosity of the 
PCL. Acquired or genetic defects in ciliary beating and/or ion transport can reduce MCT and lead to increased incidences 
of airway infections.
Figure 1 Scanning 
electron micrograph 
(SEM) of rabbit maxillary 
sinus mucosa showing 
the “carpet” of airway cilia 
(~7 µm high) found on 
specialized epithelial cells 
that line both the upper 
and lower airway. Paranasal 
sinus mucosa is made up of 
predominately ciliated cells, 
giving the appearance of a 
shag carpet. Non-ciliated 
goblet cells are interspersed 
among the ciliated cells. 
Goblet cells secrete airway 
mucin molecules and other 
protein components of 
airway mucus.
Mucociliary transport in chronic rhinosinusitis
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exist in CRS as either genetic or 
acquired defect (Figure 3). The 
presence of multiple pathophysio-
logical mechanisms existing under 
the umbrella of CRS complicates 
treatment, but it is commonly be-
lieved that increasing MCT in CRS 
patients is likely to be beneficial 
by promoting pathogen clearance, 
making the stimulation of sinon-
asal ciliary function an attractive 
therapeutic target in CRS.
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Figure 3 Ciliary loss in CRS. SEMs of sinonasal samples obtained from a 
normal patient with no sinonasal disease (Left) and a patient with CRS (Right). 
Note the significant ciliary loss in CRS mucosa with only the stubs of microvilli 
present. Loss of cilia and epithelial damage in CRS is one mechanism thought 
to result in decreased MCT and contribute to CRS pathology.
Mucociliary transport in chronic rhinosinusitis
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Airway remodeling in chronic rhinosinusitis
• Remodeling occurs in the sinuses of patients with chronic 
rhinosinusitis (CRS) and its pattern is mainly related to the CRS 
phenotype (with or without nasal polyps), but also probably 
correlates to the severity of inflammation
• The concept of “dysfunctional sinus”, described by various 
authors as a clinical observation, has no unified definition, and 
has not been yet linked to remodeling either histologically or 
ultrastructurally
• It is currently not known whether early steroid intervention in 
CRS could stop progression into a potentially irreversible state
• Radical surgical procedures that had been described to address 
dysfunctional sinuses include: Caldwell-Luc and Denker’s 
procedures; maxillary mega-antrostomy or a Draf-3 frontal 
drillout procedure
Airway remodeling is a broad term 
used to describe the set of struc-
tural modifications that occurs 
in the airways. It has been noted 
to occur in the lower airways in 
asthma. The sinuses in chron-
ic rhinosinusitis (CRS) have also 
been shown to exhibit features of 
remodeling (Table 1, Figure 1), de-
scribed as resembling those of the 
asthmatic lower airways. The two 
major clinical CRS phenotypes 
(CRS without polyps - CRSsNP 
and with polyps - CRSwNP) exhib-
it different remodeling patterns, 
as they exhibit different inflam-
matory profiles.
The clinical question that has re-
cently been raised is whether 
recent basic science knowledge 
about remodeling could alter the 
management of CRS patients. 
Current treatment philosophies 
for CRS revolve around a concept 
of disease reversibility: steroids 
are given to reverse inflamma-
tion; functional endoscopic sinus 
surgery (FESS) is performed to 
relieve ostial obstruction and re-
store ventilation. Consequently, 
the occurrence of potentially-ir-
reversible changes in the mucosa 
challenges this paradigm.
One of the most important po-
tentially-irreversible changes is 
AIRWAY REMODELING IN 
CHRONIC RHINOSINUSITIS9
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collagen deposition by myofibro-
blasts (activated fibroblasts), a 
process promoted mainly by the 
action of TGF-β. Collagen dep-
osition cannot be reversed by 
steroids (although some animal 
model studies, through measure-
ment of subepithelial basement 
membrane thickness, suggested 
otherwise). This knowledge could 
affect clinical decision making 
via two means: firstly through 
the early introduction of steroid 
therapy to stop the development 
Ahmed Bassiouni Peter-John Wormald
University of Adelaide 
Adelaide, Australia
TABLE 1
Remodeling features in the sinuses
Epithelial detachment, goblet cell hypertrophy
Myofibroblast accumulation and collagen deposition
Subepithelial basement membrane thickening
Edema, pseudocysts and extracellular matrix deposition → polyp growth
Osteitic changes (neo-osteogenesis or conversely, bone erosion)
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of this irreversible fibrosis; sec-
ondly through alternative more 
extensive surgical techniques. To 
our knowledge, early intervention 
with steroids has not been explic-
itly investigated in CRS. As for the 
second means, there exists some 
low-level evidence (in the form of 
case series reports) for successful 
radical/extensive procedures to 
salvage “dysfunctional sinuses” 
(i.e. sinuses clinically perceived as 
irreversibly-diseased). The philos-
ophy of these techniques is either 
a radical removal of dysfunctional 
mucosa (e.g. Caldwell-Luc or Den-
ker’s procedure) or the allowance 
of gravity-dependent mucociliary 
clearance through maximal os-
tium-widening procedures (e.g. 
mega-antrostomy for a maxillary 
sinus or a Draf-3 frontal drillout 
for a frontal sinus). But neither 
“dysfunctional sinuses” nor the 
benefit conferred by these tech-
niques have been studied in re-
lation to remodeling, which is a 
more recently described phenom-
enon.
In summary, the current level of 
evidence for a clinical value for 
remodeling in CRS is low (Level of 
Evidence: 5). Future studies need 
to ascertain whether remodeling 
actually plays a role in influencing 
the prognosis and/or treatment 
options. An initial good step is to 
investigate features of remodeling 
in a cohort of patients suffering 
from refractory CRS.
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Figure 1 A CRSwNP tissue section showing cross out marked subepithelial basement membrane thickening as well as 
florid eosinophilia. Evidence from murine model allergen provocation studies suggest a critical role of eosinophils in the 
remodeling process.
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Epidemiology of chronic rhinosinusitis
• Chronic rhinosinusitis (CRS) may affect 5% to 13% of the 
general population
• Pre-morbid conditions present before the diagnosis of CRS 
include atopic conditions, recurrent infections, gastro-
esophageal reflux disease, sleep apnea, anxiety and headaches
• Co-morbidities associated with CRS include allergic rhinitis, 
asthma, gastro-esophageal reflux disease, antibody deficiency, 
aspirin sensitivity, and sinus bacterial biofilms
• In the United States, the annual direct cost for CRS health care 
is $ 8.6 billion
PREVALENCE AND INCIDENCE
Measuring prevalence of chronic 
rhinosinusitis (CRS) in the general 
population is difficult because its 
symptoms overlap with symptoms 
of other common conditions such 
as allergic rhinitis (AR), non-AR and 
migraine. In addition, there is no 
distinct biological marker for CRS 
diagnosis and only a small propor-
tion of patients undergo the objec-
tive confirmatory diagnostic tests 
namely, computerized tomography 
(CT) scanning of paranasal sinuses 
and nasal endoscopy. As a result, 
CRS epidemiological surveys rely 
on self-report of CRS symptoms 
(the presence of two or more 
symptoms for > 12 weeks: nasal 
congestion, nasal discharge, facial 
pressure/pain, loss of smell. One 
of the symptoms must be either 
congestion, or discharge) and have 
excluded individuals who report 
physician-diagnosis of AR. These 
surveys have detected a preva-
lence of CRS of 5% to 13% in the 
United States (U.S.), Europe and 
China, which may be overestima-
tions due to the absence of confir-
mation by sinus CT or rhinoscopy.
CRS is most prevalent in adults, 
because sinuses are not fully 
formed until adolescence. Medi-
an age of diagnosis is 48.4 years 
EPIDEMIOLOGY OF 
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for CRS with nasal polyposis (CR-
SwNP) and 40.3 years for CRS 
without nasal polyposis (CRSsNP). 
Prevalence rates peak between 
35 and 64 years of age, and 20% 
of CRS patients have nasal polyps 
(NP). Males account for 54% of 
patients with CRSwNP and 42% 
of those with CRSsNP.
The incidence rates of CRSwNP 
and CRSsNP in a primary care pop-
ulation in the United States were 
83 and 1,048 cases per 100,000 
person-years, respectively. Pa-
tients with CRSwNP were older 
and more likely males compared 
with CRSsNP.
PRE-MORBID CONDITIONS
The cause of CRS is unknown. 
Pre-morbid conditions (Table 1) 
present before the onset of CRS 
may reveal clues to the pathogene-
sis of the disease in the future. Pri-
or to diagnosis of CRSsNP, patients 
experienced increased prevalence 
of infections of the respiratory 
tract, skin/soft tissue, and urinary 
tract compared to the general pop-
ulation. Before the initial CRS di-
agnosis, patients also have greater 
number of visits to physicians and 
of antibiotic prescriptions.
CO-MORBIDITIES
Patients with CRS may suffer 
several co-morbidities (Table 2). 
Those with CRSwNP have a high-
er prevalence of atopic conditions 
than those with CRSsNP.
Subtypes of CRS include eosino-
philic CRS, allergic fungal rhinosi-
Pedro C. Avila  
Feinberg School of Medicine, Northwestern University 
Chicago, USA
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nusitis (AFRS), and aspirin-exacer-
bated respiratory disease (AERD). 
AFRS can be present in 0-23% of 
all CRS patients with higher prev-
alence in warm and humid geo-
graphic regions, and also among 
the young, African Americans, and 
those of low socioeconomic status. 
AERD may also affect up to 23% of 
CRS patients, and is more common 
in women, and those with atopic 
diseases (asthma and AR).
In tertiary medical care centers, 
antibody deficiencies have been 
identified in up to 22% of adult 
CRS patients and up to 50% of 
children with CRS, and more so in 
those with CRSwNP. These defi-
ciencies are mainly functional an-
tibody deficiencies, selective IgG 
deficiency and common variable 
immunodeficiency. Children with 
cystic fibrosis are also at risk of 
developing CRSwNP.
Other co-morbidities include 
asthma, sinus mucosal bacterial 
biofilms, and aspirin sensitivity. 
Asthma is more prevalent in pa-
tients with CRSwNP and women, 
a combination often associated 
with severe forms of asthma.
HEALTH CARE COST AND 
UTILIZATION
CRS is associated with a large 
health burden to the patient and 
society (Table 3). It costs several 
billion dollars annually in direct 
health care costs in the United 
States. Patients with CRS miss 
a number of workdays similar to 
those experiencing an acute asth-
ma episode (5.79 days/year). Out 
of pocket expenses for patients 
with CRS are greater than that of 
patients with chronic bronchitis, 
asthma, or AR. About 50% of all 
sinus surgeries performed in CRS 
are nasal polypectomies. Up to 
69% of polypectomies are repeat 
surgeries because NP often recur.
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TABLE 1
Pre-morbid conditions before chronic rhinosinusitis (CRS) diagnosis
• Acute sinusitis
• Allergic rhinitis
• Chronic rhinitis
• Asthma
• Atopic dermatitis
• Conjunctivitis
• Gastroesophageal reflux disease
• Otitis media
• Adenotonsillitis
• Skin infections
• Sleep apnea
• Anxiety
• Headaches
TABLE 2
Co-morbidities associated with CRS
• Allergic rhinitis
• Asthma
• Atopic dermatitis
• Eosinophilic CRS
• AFRS
• AERD
• GERD
• Antibody deficiency
• Cystic fibrosis
• Sinus bacterial biofilms
Abbreviations: AFRS: allergic fungal rhinosinusitis AERD: aspirin-exacerbated res-
piratory disease. GERD: Gastroesophageal reflux disease.
TABLE 3
CRS health care utilization and costs per year in the U.S.
• 250,000 sinus surgeries
• 11.1 million medical visits
• 5.67 workdays missed/patient
• 7.1% of all adult outpatient antibiotic prescriptions
• $ 8.6 billion in direct cost
• Among the top 10 most costly conditions in the U.S.
Epidemiology of chronic rhinosinusitis
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Risk factors for chronic rhinosinusitis
• Distinguishing risk factors for chronic rhinosinusitis (CRS) from 
comorbidities remains difficult
• Allergy and asthma are regularly found as comorbid diseases and 
have been considered in several studies as risk factors of CRS
• Autoimmune inflammatory diseases or immune deficiencies 
should also be considered as potential disease modifiers in CRS
• Anatomical nasal or sinus abnormalities have regularly been 
suspected in the development of CRS, even strong evidence 
is lacking
• Environmental and occupational factors could also influence 
the development of inflammation of the paranasal cavities
Chronic rhinosinusitis (CRS) with 
(CRSwNP) or without nasal pol-
yps (CRSsNP) has a broad spec-
trum of associations ranging from 
genetics to comorbid diseases 
and environmental factors (Fig-
ure 1). Differentiation of risk fac-
tors from comorbidities remains 
difficult due to variable disease 
definitions, lack of longitudinal 
studies to establish temporal re-
lationships between exposure and 
disease onset and difficulty in the 
evaluation of the dose-effect size 
on the disease severity.
CILIARY IMPAIRMENT
Patients with Kartagener’s syn-
drome, primary ciliary dyskinesia, 
and cystic fibrosis have frequently 
a long history of CRS.
ALLERGY
Considering its frequent asso-
ciation with CRS and its similar 
increasing prevalence, atopy has 
been suspected to predispose to 
CRS, because the swelling of the 
nasal mucosa in allergic rhinitis 
may compromise ventilation at 
the site of the sinus ostia and, ad-
ditionally, the sinus inflammation 
could be induced through a local 
extension from the initial nasal in-
flammation.
RISK FACTORS FOR 
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ASTHMA
In a recent study on over 52,000 
adults, GA2LEN researchers con-
cluded that there was a strong as-
sociation of asthma with CRS. In 
another study, a highly significant 
and independent correlation was 
noted between the extent of dis-
ease and the peripheral eosinophil 
count, presence of asthma and of 
atopy.
ASPIRIN SENSITIVITY
In patients with aspirin sensitivi-
ty, up to 90% have CRS with ra-
diographic changes. Patients with 
aspirin sensitivity, asthma and CR-
SwNP are usually non-atopic.
IMMUNOCOMPROMISED 
STATE
Dysfunction of the immune sys-
tem such as abnormal T-lympho-
cyte proliferation or selective im-
munoglobulin deficiencies may be 
associated with CRS.
AUTOIMMUNE AND OTHER 
INFLAMMATORY DISEASES
Chronic granulomatous diseases 
may require extensive pharmaco-
logic and surgical treatment for 
their associated CRS.
GENETIC FACTORS
Although CRS has been observed 
in family members, no genetic 
background has formally been 
identified as to be linked to CRS.
Jean-Baptiste Watelet  
Ghent University 
Belgium
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ENVIRONMENTAL 
FACTORS
1. Organic
- pathogens: biofilm…
2. Inorganic
-Tobacco
-Socio-economic poverty
-Pollutants
-Toxics
-Occupations… 
Watelet JB, MD, PhD
PATIENT-RELATED FACTORS
1.Genetics
2.Metabolic changes:
e.g. pregnancy
3.Anatomical variants
4.Systemic disorders
1.Allergy
2.Ciliary disorders
3.Immune deficiencies
4.Aspirine sensitivity
5.Inflammatory and 
autoimmune diseases…
5.Comorbidities
1.Asthma
2.Reflux…
FIGURE 1
Major risk factors and comorbidities for Chronic Rhinosinusitis
FIGURE 2
Normal anatomy of the nasal and paranasal cavities
LEGEND:
1. Nasal septum
2. Inferior turbinate
3. Middle turbinate
4. Ethmoid sinus
5. Maxillary sinus
6. Frontal sinus
3.
2.
1.
4. 5. 6.
Watelet JB, MD, PhD
Figure 1 Major risk factors and comorbidities for chronic rhinosinusitis.
Figure 2 Normal anatomy of the nasal and paranasal cavities.
Risk factors for chronic rhinosinusitis
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LOCAL ANATOMICAL 
FACTORS
Although some authors have 
suggested that spontaneous or 
iatrogenic anatomical variations 
of the paranasal sinuses or na-
sal structure (Figures 2-3) can 
contribute to ostial obstruction, 
there are several studies that 
show the prevalence of anatom-
ical variations is not more com-
mon in patients with CRSsNP or 
CRSwNP than in controls.
ENVIRONMENTAL FACTORS
Cigarette smoking was associat-
ed with a higher prevalence of 
CRS in European countries. Oth-
er lifestyle-related factors can 
be involved in CRS such as low 
income, pollutants, toxins, oc-
cupations as plant or machinery 
operators, crafts, even if their 
precise role in CRS pathogenesis 
remains unclear.
GASTRO-, LARYNGO-
PHARYNGEAL REFLUX
There is not enough evidence to 
consider acid reflux as a signifi-
cant causal factor in CRSsNP.
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FIGURE 3
Examples of spontaneous or iatrogenic anatomic variants 
having been suspected to induce CRS
LEGEND:
1. Haller cell
2. Paradoxical middle turbinate
3. Septal deviation
4. Oronasal fistulas
5. Cocha bullosa
6. Pneumatized uncinate process
7. Hypoplastic sinus
Watelet JB, MD, PhD
4.
Figure 3 Examples of spontaneous or iatrogenic anatomic variants having been suspected to induce CRS.
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Classification of chronic rhinosinusitis
• A simple generic approach has been adopted to the classification 
and definition of chronic rhinosinusitis to facilitate its diagnosis 
in a range of clinical settings
• A combination of symptoms and their duration remain the 
mainstay, confirmed by endoscopic appearances and/or imaging
• Further classification relies on the presence or absence of nasal 
polyps, inflammatory profiling and co-morbidities
Chronic rhinosinusitis (CRS) in 
adults is defined as inflammation 
of the nose and the paranasal si-
nuses producing ≥12 weeks of 
symptoms without complete res-
olution. It is characterised by two 
or more symptoms, one of which 
should be either nasal blockage/
obstruction/congestion or nasal 
discharge (anterior/posterior na-
sal drip), ± facial pain/pressure, ± 
reduction or loss of smell. In a spe-
cialist/ENT setting, CRS diagnosis 
is supported by endoscopic signs 
of nasal polyps, and/or mucop-
urulent discharge primarily from 
middle meatus, and/or oedema/
mucosal obstruction primarily in 
middle meatus and by computer 
tomographic (CT) findings such 
mucosal changes within the osti-
omeatal complex and/or sinuses.
In children CSR is defined as for 
adults except that cough replaces 
reduced or loss of sense of smell. 
Both adults and children CRS may 
be classified based on the visual 
analogue scale (VAS) score (0 - 
10cm) as mild (VAS 0-3), moder-
ate (VAS between 3-7) or severe 
(VAS >7) (Figure 1). Further clas-
sifications of CRS have included 
anatomical features, inflammation 
or co-morbidities (Table 1). These 
have led to a closer consideration 
CLASSIFICATION OF 
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of endotyping and phenotyping 
CRS to facilitate its classification.
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University College London 
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TABLE 1
Criteria used for the classification of chronic rhinosinusitis
• The presence or absence of nasal polyps (NP) on endoscopic examination: 
CRS with NP (CRSwNP) and withouth NP (CRSsNP), which is a pragmatic 
choice of classification, largely reflecting the literature on management
• The predominance of eosinophils or of other inflammatory cells on 
histologic examination of sinonasal tissue
• Cytokine and other mediator profiling
• The presence or absence of co-morbidities eg asthma, aspirin exacerbated 
respiratory disease, cystic fibrosis
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Figure 1 Evaluation of the severity of chronic rhinosinusitis using the visual analogue scale score.
Classification of chronic rhinosinusitis
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Clinical features of chronic rhinosinusitis
• Loss of smell is a strong positive predictive factor for the 
presence of mucosal inflammation in chronic rhinosinusitis 
(CRS) and is uncommon in simple rhinitis
• Significant facial pain as a dominant presentation is rare. 
Inflammation of mucosal surfaces that produces pain also 
produces significant other sino-nasal symptoms
• Infective exacerbations of CRS usually last at least 1-2 weeks. 
Flare-ups that last only several days are likely to be rhinitis and 
not rhinosinusitis
• Cough and other regional symptoms such as dysphonia are 
more likely to represent broader airway involvement in a chronic 
inflammatory process than direct effects of sinus disease
The presenting symptoms of 
chronic rhinosinusitis (CRS) are 
broad. However, four cardinal 
features are often present: nasal 
congestion, nasal discharge, facial 
pressure and loss/distortion of 
smell. These are the ‘local’ symp-
toms of chronic sino-nasal disease 
(Figure 1). Regional symptoms 
include Eustachian tube dysfunc-
tion, cough, post-nasal drip and 
dysphonia. Although, these symp-
toms can be a result of direct ir-
ritation from secretions, they are 
more likely to represent broader 
involvement of the airway in the 
associated disease process. When 
it comes to chronic disease, com-
partmentalization of airway symp-
toms (upper, lower, middle) is the 
exception rather than the rule. 
Systemic features include malaise 
and minor depression.
The local features are important 
and current diagnostic criteria 
need to include the presence of 
nasal congestion or discharge 
with either pressure or smell loss 
in the setting of endoscopic or 
radiological evidence of mucosal 
inflammation (Figure 2).
Nasal congestion is very ambig-
uous and the term nasal obstruc-
tion is often avoided as the ques-
tion is raised as to why is the nose 
CLINICAL FEATURES OF 
CHRONIC RHINOSINUSITIS13
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blocked, if the inflammatory con-
dition is primarily in the sinuses? 
Although concomitant rhinitis can 
exist, this nasal congestion is seen 
even in simple localised forms of 
CRS (infected fungal ball, odonto-
genic CRS). Along with the vasodi-
lation that can occur from nearby 
inflammation, there is an ipsilateral 
nasal reflex with induced vascular 
dilation in response to sinus stimu-
lus. Thus, congestion is often used 
to describe this symptom in CRS, 
outside the direct involvement of 
the nasal cavity with nasal polyps.
Nasal discharge is a common fea-
ture in the setting of CRS. Ante-
rior mucoid discharge is common 
in inflammatory disease and is 
often green in appearance. The 
green pigment of mucus comes 
from the iron containing heme 
groups of myeloperoxidase. Mye-
loperoxidase comprises 5% of the 
dry weight of polymorphonuclear 
cells and it accumulates in ab-
sence of bacteria, rarely implying 
infection. Cachosmia associated 
with discharge is common feature 
of CRS of odontogenic origins and 
signals true bacteria contribution. 
Sticky or ‘chewing gum’ mucus is 
a common feature of eosinophil-
ic conditions that are associat-
ed with degranulated eosinophil 
products in mucin.
Richard J. Harvey  
University of New South Wales 
Sydney, Australia
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Facial pressure is a major feature 
of CRS, but it is rarely true facial 
pain. CRS is inherently a mucosal 
inflammatory condition and the 
presence of facial pressure (pain) 
needs to be proportionate to oth-
er symptoms that should exist if 
significant mucosa-based inflam-
mation were present. This is the 
basis for facial pain not being a 
primary presentation of CRS. If 
mucosal inflammation was caus-
ing significant pain, then it is axi-
omatic that other non-pain based 
symptoms would be present (con-
gestion, discharge). Patients with 
facial pain as major presenting 
complaint rarely have CRS as the 
Clinical features of chronic rhinosinusitis
Figure 1 The constellation of presenting symptoms between rhinitis and 
chronic rhinosinusitis (CRS) can at first appear very similar. However, the nasal 
obstruction (congestion) and rhinorrhoea (mucoid discharge) of rhinitis differ to 
CRS due to the underlying pathophysiological process in the sino-nasal cavity.
Figure 2 The accurate diagnosis of chronic rhinosinusitis involves a 
combination of symptoms with features of inflammation on endoscopy 
and radiology. The use of symptoms alone has a poor specificity even with 
specialist assessment.
cause. Loss or distortion of smell is 
a common finding in CRS, but not 
in rhinitis. Olfaction is sensitive to 
mucosal oedema (due to vascular 
congestion) and is a strong predic-
tive factor for CRS.
Finally, for CRS patients, the dis-
ease burden and impact on qual-
ity of life is high. Although not 
life-threatening, it causes loss of 
productivity, accounts for a signif-
icant proportion of presentations 
to primary care physicians and re-
sults in a large health expenditure 
cost.
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Endotypes and phenotypes of chronic rhinosinusitis
• Chronic rhinosinusitis (CRS) has a variety of overlapping 
phenotypes and endotypes
• CRS with nasal polyps may have an eosinophilic or neutrophilic 
pathogenesis, but the clinical appearance of polyps is similar in 
both
• Systemic diseases other than allergy are also associated with 
CRS
• Sampling at multiple nasal or sinus mucosal sites may show 
variability of endotypic markers, suggesting that the various 
endotypic categories share characteristics or are heterogeneous
• Treatment of CRS would be improved with endotypic specific 
or directed therapy
The accurate characterization of 
the endotypes (pathogenic mech-
anism) and of phenotypes (phys-
ical or clinical manifestations) of 
chronic rhinosinusitis (CRS) re-
quires a precise diagnosis, specific 
characteristics that are clinically 
identifiable and distinct pathoge-
netic mechanisms. Unfortunately, 
these requirements generally are 
not clearly fulfilled for CRS.
CRS is defined as 12 weeks of 
documented disease. However, 
the duration is difficult to verify 
as the onset of disease may not be 
recognized. The clinical criteria for 
CRS overlap with the more com-
mon forms of rhinitis and among 
the subtypes of CRS (Table 1). 
Most forms of chronic rhinitis in-
crease the likelihood of CRS since 
the sinus mucosa is contiguous 
with the nasal mucosa; therefore, 
there is overlap among the dis-
ease mechanisms for rhinitis and 
CRS. The typical symptoms of rhi-
nosinusitis, which help define the 
phenotype, are nonspecific and 
overlap with rhinitis. Recurrent 
acute rhinosinusitis (3 or more ep-
isodes per year) may be confused 
with CRS. Finally, sinusitis is often 
diagnosed clinically, which may 
result in over- or under-diagnosis. 
Ideally endoscopy or paranasal CT 
ENDOTYPES AND 
PHENOTYPES OF CHRONIC 
RHINOSINUSITIS
14
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imaging should confirm the diag-
nosis, if CRS is suspected. Thus, 
the clinical features of CRS limit 
the ability to accurately pheno-
type and endotype the disease.
CRS has multiple causes (Figure 1) 
and the partial ability to precise-
ly identify causal mechanisms re-
duces the likelihood to define the 
endotype (underlying pathobio-
logic mechanism), and to recog-
nize the unique phenotypic char-
acteristics. The CRS phenotypes 
generally accepted are presented 
in Table 2. These categories are 
not mutually exclusive. For ex-
ample, the CRS associated with 
allergic rhinitis (CRSwAR) may de-
velop into eosinophilc CRS with 
Dennis K. Ledford  
University of South Florida 
Tampa, USA
TABLE 1
Typical symptoms of chronic 
rhinitis and sinusitis
Symptoms of chronic rhinitis
• Rhinorrhea
• Nasal congestion
• Sneezing (less for chronic 
disease)
• Post-nasal drip
Symptoms of chronic sinusitis
• Hyposmia/Anosmia
• Nonspecific facial discomfort
• Fatigue
• Cough with post-nasal drip and 
throat clearing
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Endotypes and phenotypes of chronic rhinosinusitis
Figure 1 Pathogenic mechanisms of chronic rhinosinusitis, contrasting chronic rhinosinusitis with eosinophilic nasal polyps 
(CRSwNPe) [Panel A] and chronic rhinosinusitis without nasal polyps (CRSsNP) [Panel B]. Panel A. CRSwNPe in a Th2-type 
microenvironment with general lack of regulatory T cell (Treg) function, increased interleukin-5 (IL-5) with eosinophilia and 
increased IL-4 and IL-13 with resulting increased IgE production. Epithelial activation, possibly related to colonization with 
certain bacteria or fungi, results in the in release of proinflammatory and regulatory cytokines and chemokines such as thymic 
stromal lymphopoietin (TSLP) and IL-32. Activation and apoptosis of epithelial cells result in compromise of epithelial barriers 
and increased susceptibility to irritants and infectious agents. Panel B. In chronic rhinosinusitis without nasal polyps (CRSsNP), 
a Th1 or a mixed Th0 and Th1 response predominates rather than Th2. The result is an increase in mucosal neutrophils and 
expression of TGFβ and its receptors. (DC: dendritic cells). (Adapted from Akdis CA, Bachert C, et al. Endotypes and phenotypes 
of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American 
Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2013;131:1479-1490.)
318
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 G
 - 
C
hr
on
ic
 r
hi
no
si
nu
si
ti
s 
(C
R
S)
 –
 m
ec
ha
ni
sm
s,
 e
pi
de
m
io
lo
gy
, r
is
k 
fa
ct
or
s 
an
d 
co
-m
or
bi
di
ti
es
fungal hyphae (AFRS) or possibly 
CRS with nasal polyps (CRSwNP). 
Also, allergic fungal rhinosinusitis 
(AFRS) may demonstrate eosino-
philic nasal polyps (NP). Distinct 
phenotypes, for example CRSwNP 
and AFRS, may represent distinct 
diseases or different manifesta-
tions of a disease spectrum, that 
may change from one to another. 
Furthermore, the apparent endo-
type of mucosal inflammation, as 
recognized by selective cell ac-
tivation and/or cytokine profile, 
may vary with different mucosal 
samples from the same individual. 
Thus, the inflammatory response, 
which reflects the genetic and 
environmental interaction, may 
not be clearly distinguishable. The 
characteristics of mucosal inflam-
mation often may not be recog-
nized until surgical specimens are 
histologically and biochemically 
studied.
CRS is often treated by surgery, 
particularly for asymmetric dis-
ease or obstructive NP. However, 
CRS is usually a medical condition 
and successful outcomes invar-
iably require adequate medical 
evaluation and pre- and post-op-
erative therapy. Clinically useful 
sampling methods, other than 
surgery, are needed to better fa-
cilitate endotypic characteriza-
tion. Bacterial infection, other 
than staphylococcal colonization 
with endotoxin and protein A pro-
duction is not generally important 
to the pathogenesis of CRS, but 
could exacerbate CRS. Finally, 
multiple systemic diseases may 
have CRS as a component of the 
condition, and the endotypes of 
these forms of CRS are different, 
even though the phenotypic pres-
entation may be similar (Table 2).
Pathogenic mechanisms associ-
ated with each of the CRS phe-
notypes are not universally ac-
TABLE 2
Phenotypes and endotypes of chronic rhinosinusitis (CRS)
Phenotype 
Characteristics
Endotype 
Characteristics
Treatment 
Implications
Chronic allergic 
rhinitis with 
sinusitis (CR-
SwAR)
Eos ++
IL-4, 5,13 ++
IL-17, IFN-γ (--)
Th2++
Systemic 
s-IgE+++
Allergen avoidance or IT
INCS and INA
Antibiotics
?Omalizumab
Nasal polyposis 
with rhinosinus-
itis and mucosal 
eosinophilia 
(CRSwNPe)
Eos+++
Edematous 
polyps++++
IL-4, 5,13+++
IL-10 (-)
LT++++*
M2 mac-
rophages++
Th2++
SA/SE/SPA++
? Local s-IgE+
TGF-β (--)
Treg(-)
High dose INCS or OCS
LMA
Surgery
ASA desensitization & 
therapy*
?Omalizumab
??Mepoluzimab, reslizumab
Nasal polyposis 
with rhinosinus-
itis and mucosal 
neutrophilia 
(CRSwNPn)
Eos (-)
INF-γ++
IL-5 (--)
IL-17+
PMN+++
Th1++
Th17++
INCS
Surgery
?Macrolide antibiotics
Chronic rhinosi-
nusitis without 
nasal polyposis 
(CRSsNP)
Collagen++
PMN+++
SA/SE/SPA+
Th1++
TGF-β+
Treg++
INCS
Allergic fungal 
hypersensitivity 
rhinosinusitis 
(AFRS)
Eos+++
Fungal culture or histology++++
s-IgE++
Total IgE++++
OCS
INCS
??Antifungals
???Omalizumab
Chronic 
rhinosinusitis 
associated with 
other systemic 
diseases
Varies With Disease
• Eos++ and ANCA++ (EGPA)
• PMN+++ and ANCA+++ (GPA)
• PMN ++ with Culture ++ (ID)
• CFTR mutation++++ (CF)
• Mucosal granulomas (Sarcoid)
• Ciliary dyskinesia
• ANA/SSA/SSB++ (Sjögren’s)
OCS
Immunosuppressives
Immunomodulators
Antibioitcs
Gamma globulin 
replacement
*Aspirin intolerant subjects (Aspirin Exacerbated Respiratory Disease [AERD]).
Eos: Eosinophils; ASA: Aspirin; +: Increased; IL-4: Interleukin 4; INCS: Intranasal 
corticosteroid; PMN: Neutrophils; IL-5: Interleukin 5; OCS: Oral corticosteroid; (-): 
Decreased; s-IgE: Allergen specific-IgE; LT: Leukotrienes; LTM: Leukotriene modifi-
ers; INA: Intranasal antihistamine; LMA: Leukotriene modifiers; ID: immunodeficien-
cy; M2 macrophages: Macrophage subpopulation more involved in Th2 repsonses; 
Treg: Regulatory T lymphocytes;?: Limited, negative or conflicting data; SA/SE/SPA: 
Staphylococcal aureus colonization or infection and nasal detection of enterotoxins 
and staphylococcal protein A; ANCA: Antineutrophil cytoplasmic antibody; ANA/
SSA/SSB: Antinuclear antibody with or without specific antibody to SSA and/or 
SSB; EGPA: Eosinophilic granulomatosis with polyangiitis (Churg-Strauss vasculitis); 
GPA: Granulomatosis with polyangiitis (Wegener granulomatosis); CF: Cystic fibro-
sis; CFTR: Cystic fibrosis transmembrane conductance regulator; Sarcoid: Sarcoido-
sis; Sjögren’s: Sjögren’s disease or syndrome
Endotypes and phenotypes of chronic rhinosinusitis
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cepted, although a significant 
body of research suggests disease 
mechanisms or potential pathoge-
netic associations (Table 2). The 
mechanisms include epithelial 
barrier abnormalities, selective 
T cell subpopulation stimulation, 
local specific-IgE production, se-
lective growth of microorgan-
isms, enhanced leukotrienes and/
or prostaglandin concentrations, 
specific cytokine profiles, and pro-
duction of factors that regulate 
fibrosis or cell recruitment such as 
transforming growth factor beta 
(TGF-β). Identification of some of 
these mechanisms has resulted in 
improved therapeutic approaches 
or suggestions for more effective 
therapies (Table 2). The role of in-
fectious agents, very important in 
acute sinusitis or acute exacerba-
tions of chronic disease, is unclear 
with difficulties in interpreting 
culture or genetic identification 
of infectious organisms due to 
the possibility of nonspecific or 
secondary colonization. There is 
a sizeable literature on the role of 
Staphylococcus aureus in CRSwNP 
and possibly in CRS without NP 
(CRSsNP) and fungal organisms in 
AFRS. Thus, infectious agents are 
likely important in selecting the 
endotypes of CRS and definitely 
for exacerbations of CRS.
Tools generally available to the 
clinician to phenotype/endotype 
CRS are listed in Table 3. Research 
or surgical approaches for CRS 
characterization or measures of 
systemic diseases are listed in 
Table 4. The major limitation in 
utilizing endotypic assessment of 
CRS and therapies targeted to dis-
ease endotype (Table 2) is the lim-
ited availability of cost effective 
strategies to clinically characterize 
CRS and the lack of clinical trials 
of endotypically characterized 
CRS. The treatment of CRS will 
likely improve if these barriers to 
CRS endotyping are overcome.
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TABLE 3
Basic clinical tools to characterize 
chronic rhinosinusitis (CRS) 
endotypes and phenotypes
History (onset, sense of smell, 
association with allergens, family 
history)
Testing for specific-IgE
Fiberoptic or rigid (generally used 
by surgeons) rhinolaryngoscopy
Mucosal cytology
Paranasal sinus imaging
Nasal/sinus culture
Peripheral blood eosinophil count
Total IgE
Total IgG
TABLE 4
Advanced or research techniques to characterize chronic rhinosinusitis 
(CRS) endotypes
Surgical histology
Cell subtyping by immunofluorescence or flow cytometry
Cytokine assays from nasal lavage or biopsy
Gene expression
Specific-IgE in nasal or sinus mucosa
Ciliary functional assessment
Antineutrophil cytoplasmic antibody quantification in peripheral blood
Cystic fibrosis genetic testing or sweat chloride test
Bacterial protein expression (e.g. staphylococcal enterotoxin)
Immunologic response to vaccination or in vitro immunologic assessment
Endotypes and phenotypes of chronic rhinosinusitis
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Eosinophilic chronic rhinosinusitis
• Eosinophilic chronic rhinosinusitis (ECRS) is a recently described 
subtype of refractory chronic rhinosinusitis characterized by 
massive infiltration by eosinophils of the nasal polyps (NP)
• The most prevalent characteristic clinical features of ECRS 
are strong tendency for recurrence after sinus surgery and 
the effectiveness of oral (systemic) corticosteroids for the 
treatment of recurrent NP
• Two-thirds of ECRS patients have asthma, and most are non-
atopic with adult onset
• CT findings are useful for the diagnosis, with involvement of 
the posterior ethmoid sinus and olfactory cleft characteristic 
for ECRS
Chronic rhinosinusitis (CRS) com-
prises several subtypes. Most 
cases of CRS with nasal polyps 
(CRSwNP) in Western countries 
have been reported to exhibit eo-
sinophil-dominant inflammation. 
However, more than half of CR-
SwNP patients in Japan and East 
Asia have non-eosinophilic CR-
SwNP. Until 30 years ago, most in-
dividuals with CRS in Japan were 
shown to exhibit purulent rhinor-
rhea (including abundant neutro-
phils). This Japanese conventional 
CRS was well controlled by the 
combination of macrolide therapy 
(long-term, low-dose) and endo-
scopic sinus surgery (ESS). How-
ever, since the 1990s, the number 
of CRSwNP patients shown to be 
refractory to the combined ther-
apy has increased gradually. One 
of the histologic characteristics of 
the disease is massive infiltration 
by eosinophils of the nasal polyps 
(NP). Hence, “eosinophilic chron-
ic rhinosinusitis” (ECRS) has been 
used to classify this refractory 
subtype in Japan since 2001.
The most prevalent characteris-
tic clinical features of ECRS are 
a strong tendency for recurrence 
after ESS and the effectiveness 
of oral (systemic) corticosteroids 
for the treatment of recurrent 
EOSINOPHILIC CHRONIC 
RHINOSINUSITIS15
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NP. Clinical features of ECRS in 
comparison with Japanese con-
ventional CRS are listed in Table 
1. Anosmia appears early in the 
illness and is characteristic for 
ECRS. While NP are raised from 
the middle meatus in most non-
ECRS patients, ECRS patients can 
exhibit bilateral NP that are often 
found in both side of the middle 
turbinate. Two-thirds of ECRS pa-
tients have asthma, and most are 
non-atopic with adult onset.
CT findings are useful to distin-
guish ECRS from non-ECRS with 
involvement of the posterior 
ethmoid sinus and olfactory cleft 
characteristic for ECRS. Massive 
infiltration of eosinophils of NP 
and eosinophilia in peripheral 
blood are also characteristics of 
ECRS.
Eosinophilia in tissue and periph-
eral blood are closely correlated 
in most patients. Gene-expression 
studies have revealed the unique 
pathophysiologic features of 
ECRS compared with non-ECRS. 
From these characteristic features 
we proposed a diagnostic proce-
dure for ECRS (Table 2). A multi-
center study is underway for the 
definition and diagnostic criteria 
of ECRS in Japan.
CRSwNP with allergic rhinitis (AR) 
is often confused with ECRS. They 
both have eosinophilic infiltration 
Junichi Ishitoya  
Yokohama City University 
Yokohama, Japan
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of the NP, but the latter does not 
always recur after ESS. Therefore, 
the keyword for ECRS mentioned 
above is “refractory” and ECRS 
should be termed “refractory 
ECRS”.
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TABLE 1
Comparison Between ECRS and Japanese conventional CRS
Eosinophilic Chronic 
Rhinosinusitis (ECRS)
Japanese conventional 
chronic rhinosinusitis (CRS)
Characteristic symp-
toms
Reduction/loss of smell in 
early stages -
Endonasal findings Bilateral polyps, high vis-cous secretion
Mucopurulent discharge, 
nasal polyp in middle mea-
tus
CT findings Ethmoid predominance (in early stages)
Maxillary predominance (in 
early stages)
Hematology Eosinophilia –
Coexistence of asth-
ma Frequent Less frequent
Macrolide therapy Not effective Effective
Prevalence of recur-
rence of nasal polyps Very high Low
Systemic corticoster-
oids for recurrence Higher efficacy Not known
Histology of nasal 
polyps
Eosinophilia, lymphocyte 
infiltration, thickening of 
basement membrane (re-
modeling)
Lymphocyte infiltration, in-
crease in number of nasal 
glands
TABLE 2
Diagnosis of eosinophilic chronic rhinosinusitis
1) Clinical history
• Symptoms of chronic rhinosinusitis
• Reduction and/or loss of the sense of smell in the early stages
(2) Endonasal examination
• Bilateral polyps
• High viscous secretion
(3) Paraclinical examinations (sensitivity = 0.846; specificity = 0.923)
• Eosinophilia in peripheral blood
• CT findings (posterior ethmoid score ≥ 1, olfactory cleft score ≥ 1, graded 
according to the Lund-Mackay system)
(4) Postoperative course
• Strong tendency to recur after endoscopic nasal surgery (ESS)
• Effectiveness of systemic corticosteroids for treatment of recurrence
Eosinophilic chronic rhinosinusitis
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Fungal sinus disease
• Fungi are ubiquitous in the environment and their prevalence in 
the sinonasal tract of healthy individuals has been reported to 
be as high as 100%
• Fungal rhinosinusitis can be divided into non-invasive forms that 
are usually seen in immunocompetent patients, and invasive 
forms that are usually seen in immunocompromised patients
• Treatment of most forms of fungal rhinosinusitis is primarily 
surgical
The interaction between fungi 
and the sinonasal tract results in 
a diverse range of diseases with 
an equally broad spectrum of clin-
ical severity (Table 1). Fungi are 
ubiquitous in the environment 
and accordingly, they are very 
frequently detected on the nasal 
mucosa of healthy individuals and 
their presence only rarely causes 
disease. The interaction between 
fungi and nasal mucosa is deter-
mined largely by the host immune 
state. Fungal sinus disease can be 
divided into non-invasive forms, 
which are usually seen in immuno-
competent patients, and invasive 
forms usually seen in immuno-
compromised patients.
BIOLOGY OF FUNGI
The kingdom of fungi encompass-
es an enormous diversity of or-
ganisms from single-celled yeasts 
to large mushrooms. Moulds are 
mainly responsible for causing dis-
ease in the sinonasal tract and are 
fungi that grow in the form of mul-
ticellular filaments called hyphae. 
Moulds and their airborne sexual 
spores or asexual conidia are pres-
ent in all habitable environments 
and so human beings inhale them 
constantly.
FUNGAL SINUS 
DISEASE16
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NON-INVASIVE DISEASE
Fungal ball are dense accumula-
tions of fungal hyphae within the 
mucosal confines of a paranasal 
sinus or sinuses, without tissue 
invasion (Figure 1). As sinonasal 
symptoms and clinical signs are 
either absent or non-specific, the 
diagnosis is usually made radiolog-
ically, and often incidentally, when 
patients are scanned for non-rhi-
nologic indications. Treatment 
consists of endoscopic removal of 
all the fungal content within the in-
volved sinus and the maximal wid-
ening of its ostium. There is usual-
ly no need for topical or systemic 
antifungal therapy postoperatively.
Allergic fungal rhinosinusitis 
(AFRS) is a subtype of chronic rhi-
nosinusitis (CRS) triggered by a hy-
persensivity reaction to fungi col-
onizing the sinonasal tract. AFRS 
is characterized by intense eosin-
ophilic mucosal inflammation. It is 
unlikely that IgE-mediated hyper-
sensitivity is the major pathogenic 
factor of this condition and almost 
certainly other mechanisms of hy-
persensitivity are involved. AFRS 
typically affects young, atopic and 
immunocompetent patients. The 
resultant CRS with nasal poly-
posis (NP) is often recalcitrant to 
conventional treatment. Nasal 
mucus is characteristically thick, 
tenacious and coloured from tan 
to brown or black and is rich in 
eosinophils or eosinophil degrad-
ed products (Figure 2). Severe or 
neglected cases may present with 
facial deformity, hypertelorism 
and proptosis. AFRS has some dis-
tinctive radiological appearanc-
es both on CT and MRI scanning 
(Figure 3). The Bent and Kuhn cri-
Claudio A. Callejas  
Pontifical Catholic University of Chile 
Santiago, Chile
Richard G. Douglas  
The University of Auckland 
Auckland, New Zealand
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TABLE 1
Summary of key concepts in most prevalent forms of fungal rhinosinusitis
Fungal Ball AFRS AIFRS
Most common 
etiologic agent Aspergillus spp
Aspergillus spp and dematiaceous molds (Al-
ternaria spp, Bipolaris spp and Curvularia spp)
Aspergillus spp and Mucorales 
(Rhizopus spp and Mucor spp)
Immune state Immunocompetent
Immunocompetent Immunosuspresion
Atopic patient
(Neutropaenia or neutrophil dysfunction)
e.g. hematologic malignancies, organ 
transplant or diabetic ketoacidosis
Demographics
Most commonly af-
fects middle-aged 
and elderly females
Warm humid regions
e.g. south of North America and India
Inpatient
(Usually in critic care units)
Treatment Surgery
Surgery Surgical debridement
+
Ongoing medical therapy 
 (Steroids, nasal douches)
+
Systemic antifungals
+
Immunotherapy?
+
Immune reconstitution
+
Antifungal drugs?
Prognosis Excellent cure rate
Chronic, but fairly good control of disease 
is achievable by means of surgery(ies) and 
ongoing medical therapy +/- immunother-
apy +/- Antifungal drugs
High mortality rate, mostly related to ab-
sence of host immune reconstitution and 
the extent of involvement on recognition 
of the disease
AFRS: allergic fungal rhinosinusitis, AIFRS: acute invasive fungal rhinosinusitis. Modified from Callejas CA, Douglas RG. Fungal 
rhinosinusitis: what every allergist should know, Clin Exp Allergy, 2013;68:835-849, with permission from Wiley-Blackwell.)
Fungal sinus disease
Figure 1 A. An axial CT scan demonstrating a fungal ball in the left maxillary sinus (black arrowheads). Note the 
heterogeneous radiodensity that is characteristic of this condition. Frequently, discrete and very dense areas (even metallic 
densities) are seen due to local calcification in the centre of the hyphae masses. B. An intra-operative photograph of the same 
patient. Thick fungal debris is being removed through a middle meatal antrostomy. (Modified from Callejas CA, Douglas RG. 
Fungal rhinosinusitis: what every allergist should know, Clin Exp Allergy, 2013;68:835-849, with permission from Wiley-Blackwell.)
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Figure 2 Eosinophilic mucin being extracted from the sphenoid 
sinus with a grasping forceps. The thick and tenacious consistency 
can be appreciated.
Figure 3 A. Sinus 
CT scans of a patient 
with allergic fungal 
rhinosinusitis (AFRS): 
1. Medial orbital wall 
thinned and expaned 
laterally by the 
ethmoid sinus content 
(arrowheads), 2. Erosion 
of the skull base (arrow) 
and lateral expansion of 
the thinned medial orbital 
wall (arrowheads). B. MRI 
of the same patient:1. T1-
weighted image showing 
central hypointensity 
(asterisks) and peripheral 
enhancement of right 
side sinuses (arrowheads), 
2. T2-weighted image 
showing central void 
signal (asterisks) and 
peripheral enhancement 
of right side sinuses 
(arrowheads). (Reproduced 
with permission from 
Callejas CA, Douglas RG. 
Fungal rhinosinusitis: 
what every allergist should 
know, Clin Exp Allergy, 
2013;68:835-849, with 
permission from Wiley-
Blackwell.)
Fungal sinus disease
A1 A2
B1 B2
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TABLE 2
Bent and Kuhn diagnostic criteria for allergic fungal 
rhinosinusitis
1) Nasal polyposis
2) Presence of fungi on direct microscopy or culture of 
sinus content
3) Eosinophilic mucin without fungal invasion into si-
nus tissue
4) Type I hypersensitivity to fungi demonstrated by 
skin testing or in vitro testing
5) Characteristic computed tomographic findings, in-
cluding sinus expansion or heterogeneous opacifi-
cation
teria for diagnosis of AFRS are still 
widely accepted (Table 2). Howev-
er, identical clinical forms of CRS, 
but without type I hypersensitiv-
ity to fungi (eosinophilic fungal 
rhinosinusitis) or without proven 
presence of fungi (eosinophilic 
mucin rhinosinusitis) have been 
described, raising the question 
whether AFRS as defined by the 
Bent and Kuhn criteria represents 
just a subset of this condition. 
The treatment of AFRS is pre-
dominantly surgical and involves 
the removal of all fungal debris 
and associated NP. Postoperative 
topical medical therapy with sa-
line lavage and intranasal corti-
costeroids probably increases the 
chance of achieving a good long-
term outcome. In spite of these 
measures, some patients will need 
multiple surgeries to achieve con-
trol of their disease. Antifungal 
drugs and immunotherapy may 
have a role as adjuvant therapy, 
but no clinical trial has demon-
strated convincing efficacy.
Figure 4 Left orbital exenteration in a patient with acute invasive fungal 
rhinosinusitis.
Fungal sinus disease
INVASIVE DISEASE
Acute invasive fungal rhinosinus-
itis (AIFRS) is an acute life-threat-
ening condition, in which the 
fungal infection invades underly-
ing mucosal tissue, as a result of 
an impaired immune response. It 
tends to spread aggressively, and 
often has a fulminant course, pro-
gressing over hours. Eye, brain, 
palate and skin involvement can 
occur (Figure 4). The symptoms 
are often non-specific and a high 
index of suspicion in an immuno-
compromised patient with sinon-
asal symptoms and/or fever is 
mandatory to facilitate early diag-
nosis. Treatment of AIFS has three 
pillars: (1) urgent surgical debride-
ment of all the necrotic tissue, (2) 
immediate initiation of systemic 
antifungal therapy and (3) immune 
reconstitution (if possible). AIFS is 
still associated with high mortali-
ty rates (10% to 50%) determined 
mainly by the potential for host 
immune reconstitution and the 
extent of involvement at the time 
of recognition of the disease.
KEY REFERENCES
1. Ebbens FA, Georgalas C, Rinia AB, 
van Drunen CM, Lund VJ, Fokkens 
WJ. The fungal debate: where do 
we stand today? Rhinology 2007; 
45:178-89.
2. Callejas CA, Douglas RG. Fungal 
rhinosinusitis: what every aller-
gist should know. Clin Exp Aller-
gy 2013;43:835-849.
3. Fokkens WJ, van Drunen C, Geor-
galas C, Ebbens F. Role of fungi 
in pathogenesis of chronic rhi-
nosinusitis: the hypothesis reject-
ed. Curr Opin Otolaryngol Head 
Neck Surg 2012;20:19-23.
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Co-morbidities of chronic rhinosinusitis
• Chronic rhinosinusitis (CRS) with/without nasal polyposis (NP) 
and asthma are diseases that often occur together
• Allergic rhinitis is a common coexisting disease in patients with 
CRS
• Sinonasal inflammation is found in most cystic fibrosis (CF) 
patients
• The number of cases with a concomitant diagnosis of sinusitis 
is significantly higher in the children with gastro-esophageal 
reflux disease (GERD)
Chronic rhinosinusitis (CRS) with 
and without nasal polyps (NP) 
(Figure 1) represent different 
stages of one chronic inflamma-
tory disease of the mucosa of the 
nasal cavity and paranasal sinuses. 
Co-existence of CRS with NP and 
asthma and rather similar charac-
teristics of inflammation support 
assumption that all are, at least 
in part, the same disease pro-
cess. Nasal allergy is also related 
to inflammatory chronic sinusitis 
as a risk factor. There are a lot of 
co-morbidities which often occur 
with CRS (Table 1).
CRS AND ASTHMA: CRS with/
without NP and asthma are dis-
eases that often occur together. 
A recent large-scale European 
CO-MORBIDITIES OF 
CHRONIC RHINOSINUSITIS17
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survey confirmed the strong asso-
ciation between CRS and asthma. 
CRS in the absence of nasal aller-
gies was associated with late-on-
set asthma.
CRS AND ALLERGIC RHINITIS: 
Allergic rhinitis is a common co-
existing disease in patients with 
CRS. The data about the associ-
ation between the 2 diseases in 
children is variable. In a series of 
42 patients with CRS refracto-
ry to medical treatment in which 
a RAST test as well as a CT scan 
was available, 40% of the pa-
tients were atopic and 60% were 
non-atopic.
CRS AND CYSTIC FIBROSIS: Rhi-
nosinusitis may often be a pre-
senting symptom of the so-called 
atypical cystic fibrosis (CF) pa-
Cemal Cingi  
Eskişehir Osmangazi University 
Turkey
Nuray Bayar Muluk  
Kırıkkale University 
Turkey
TABLE 1
Co-morbidities of chronic 
rhinosinusitis
Asthma
Allergic rhinitis
Cystic fibrosis
Chronic Obstructive pulmonary 
disease
Aspirin Exacerbate Respiratory 
Disease
Immunodeficiency
Hypertrophied adenoids
Gastro-esophageal Reflux Disease
Primary Ciliary Dyskinesia
Figure 1 Endoscopic view of nasal 
polyps.
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tients, with normal or borderline 
sweat test result and carrying only 
one mild mutation of the CFTR 
gene. Sinonasal inflammation is 
found in most CF patients, with 
NP being present in 1/3 of CF pa-
tients.
CRS AND CHRONIC OBSTRUC-
TIVE PULMONARY DISEASE: A 
majority of chronic obstructive 
pulmonary disease (COPD) pa-
tients presenting at an academic 
unit of respiratory disease re-
port sinonasal symptoms. Sev-
eral pro-inflammatory mediators 
have been found increased in the 
nasal lavages of COPD patients. 
The presence of nasal symptoms 
is associated with the overall im-
pairment of the quality of life in 
COPD.
CRS AND ASPIRIN EXACERBAT-
ED RESPIRATORY DISEASE: The 
presence of hypersensitivity to as-
pirin or other NSAIDs in a patient 
with rhinosinusitis and NP is asso-
ciated with a particularly persis-
tent and treatment-resistant form 
of the disease, coexisting usually 
with severe asthma and referred 
to as the “aspirin triad”.
CRS AND IMMUNODEFICIEN-
CIES: There was an association 
between rhinosinusitis and pri-
mary immunodeficiencies. Among 
CRS patients, who are referred for 
immune evaluation, up to half may 
have T lymphocyte dysfunction, 
while roughly 20% have decreased 
IgG, IgA or IgM. In addition, nearly 
10% have common variable im-
mune deficiency (CVID).
CRS AND HYPERTROPHIC ADE-
NOIDS IN CHILDREN: Nasal dis-
charge could be due to adenoiditis 
alone and that the bacterial reser-
voir of the adenoids more than 
their size was important in the 
relationship between CRS and the 
hypertrophied adenoids (Figure 
2).
GASTROESOPHAGEAL REFLUX 
DISEASE: The number of cases 
with a concomitant diagnosis of 
sinusitis was significantly higher in 
the children with gastro-esopha-
geal reflux disease (GERD) (4.19%) 
compared to the control group 
(1.35%) (Figure 3).
PRIMARY CILIARY DYSKINESIA: 
Primary ciliary dyskinesia (PCD) is 
the most common cause of ciliary 
dysfunction. PCD is an autosomal 
recessive disorder present in 1 of 
15,000 of the population. Half the 
children with PCD also have situs 
inversus, bronchiectasis, and CRS 
and are known as Kartagener’s 
syndrome. The diagnosis should 
be suspected in a child with atypi-
cal asthma, bronchiectasis, chron-
ic wet cough and mucus produc-
tion, rhinosinusitis, chronic and 
severe otitis media (especially 
with chronic drainage in children 
with ear tubes).
KEY REFERENCES
1. Jarvis D, Newson R, Lotvall J, 
Hastan D, Tomassen P, Keil T, et 
al. Asthma in adults and its asso-
ciation with chronic rhinosinusitis: 
the GA2LEN survey in Europe. Al-
lergy 2012;67:91-98.
2. Ramadan HH, Fornelli R, Ortiz AO, 
Rodman S. Correlation of allergy 
and severity of sinus disease. Am J 
Rhinol 1999;13:345-347.
3. Marshak T, Rivlin Y, Bentur L, Ro-
nen O, Uri N. Prevalence of rhi-
nosinusitis among atypical cystic 
fibrosis patients. Eur Arch Otorhi-
nolaryngol 2011;268:519-524.
4. Fokkens WJ, Lund VJ, Mullol J, 
Bachert C, Alobid I, Baroody F, et 
al. European Position Paper on 
Rhinosinusitis and Nasal Polyps 
2012. Rhinol Suppl 2012:1-298.
5. Sleigh MA. Primary ciliary dyskine-
sia. Lancet 1981;2:476.
Co-morbidities of chronic rhinosinusitis
Figure 2 Endoscopic view of hypertrophied adenoids. Partial (A) and total (B) 
obstruction of choana by hypertrophied adenoids is shown.
Figure 3 Laryngeal findings of 
gastroesophageal reflux disease (GERD). 
Oedema, erythema, and hyperkeratosis 
were shown in the interarytenoid region.
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Uncontrolled rhinosinusitis
• A significant percentage of chronic rhinosinusitis (CRS) patients 
are uncontrolled
• A wide variety of factors can contribute to poor disease control
• Assessment of disease control should guide alterations in 
therapy in CRS
In general, the goal of treatment for 
any medical condition is to achieve 
and maintain clinical control. In 
contrast to asthma, the concept of 
control of disease has only recently 
been introduced in the field of al-
lergic rhinitis (AR) and chronic rhi-
nosinusitis (CRS). In asthma treat-
ment guidelines are based on the 
assessment of control.
A number of terms have been 
used in the past to describe un-
controlled disease. Bousquet et 
al. suggested the term SCUAD 
(severe chronic upper airway dis-
ease) to define those patients 
whose symptoms are inadequate-
ly controlled despite adequate (ie, 
effective, safe, and acceptable) 
treatment based on guidelines. 
The patients have impaired qual-
ity of life, social functioning, sleep, 
and school/work performance. 
SCUAD patients can have sever-
al phenotypes like severe uncon-
trolled AR, non-allergic rhinitis, or 
CRS with or without nasal polyps 
(NP). Other terms that can be 
found in the literature are recalci-
trant rhinosinusitis, treatment-re-
calcitrant rhinosinusitis, refractory 
rhinosinusitis, and difficult to treat 
rhinosinusitis.
The European Position Paper on 
Rhinosinusitis and Nasal Polyps 
UNCONTROLLED 
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(EPOS) defined in 2012 EPOS cri-
teria for difficult to treat and dis-
ease control in CRS. Disease con-
trol in CRS was defined a disease 
state in which the patients do not 
have symptoms or the symptoms 
are not bothersome, if possible 
combined with a healthy or almost 
healthy mucosa and only the need 
for local medication. Patients who 
do not reach an acceptable level of 
control, despite adequate surgery, 
intranasal corticosteroid treatment 
and up to 2 short courses of anti-
biotics or systemic corticosteroids 
in the last year can be considered 
to have difficult-to-treat rhinosi-
nusitis. In EPOS 2012 a method of 
evaluating control was proposed 
(Table 1). Recently a modification 
of the EPOS 2012 control method 
was proposed: the ‘‘NOSE’’ stag-
ing system measuring only nasal 
obstruction, systemic medication 
use, and endoscopic signs of in-
flammation.
It has been estimated that up to 
20% of CRS patients are not well 
controlled despite receiving com-
bination maximal medical therapy 
and endoscopic sinus surgery. A 
wide variety of factors can con-
tribute to poor disease control, 
including patient-related factors 
such as eosinophilic CRS, osteitis, 
biofilms, other underlying diseas-
es like cystic fibrosis and vasculitis 
and physician-related factors such 
as inappropriate sinus surgery or 
inaccessible topical therapy. Pe-
riodical assessment of disease 
control should guide alterations 
in therapy according to a stepwise 
approach and optimize CRS man-
agement. A stepwise approach 
based on the EPOS2012 guide-
lines is suggested in Figure 1.
KEY REFERENCES
1. Bousquet J, Bachert C, Canonica 
GW, Casale TB, Cruz AA, Lock-
ey RJ, et al. Unmet needs in se-
vere chronic upper airway disease 
Wytske J. Fokkens  
Academic Medical Centre 
Amsterdam, The Netherlands
Peter W. Hellings  
Leuven University 
Leuven, Belgium
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Uncontrolled rhinosinusitis
(SCUAD). J Allergy Clin Immu-
nol 2009;124:428-433.
2. Fokkens WJ, Lund VJ, Mullol J, 
Bachert C, Alobid I, Baroody F, et 
al. European Position Paper on 
Rhinosinusitis and Nasal Polyps 
2012. Rhinol Suppl 2012:1-298.
3. Snidvongs K, Heller GZ, Sacks R, 
Harvey RJ. Validity of European 
position paper on rhinosinusitis 
disease control assessment and 
modifications in chronic rhinosi-
nusitis. Otolaryngol Head Neck 
Surg 2014;150:479-486.
4. Hellings PW, Fokkens WJ, Akdis C, 
Bachert C, Cingi C, Dietz de Loos 
D, et al. Uncontrolled allergic rhi-
nitis and chronic rhinosinusitis: 
where do we stand today? Aller-
gy 2013;68:1-7.
TABLE 1
Assessment of current clinical control of CRS*
Characteristic Controlled 
(all of the following)
Partly Controlled 
 (at least one present)
Uncontrolled
Nasal blockage Not present or not bothersome Present on most days of the week
Three or more features of 
partly controlled CRS
Rhinorrhea/ 
Postnasal drip Little and mucous
Mucopurulent on most days 
of the week
Facial pain/headachec Not present or not bothersome Present
Smell Normal or only slightly impaired Impaired
Sleep disturbance or fatigue Not impaired Impaired
Nasal endoscopy 
(if available)
Healthy or almost healthy 
mucosa
Diseased mucosa (nasal 
pol-yps, mucopurulent 
secretions, inflamed mucosa)
Systemic medication 
needed to control disease Not needed
Need of a course of antibiotics 
or systemic corticosteroids in 
the last three months
Need of long term antibiotics 
or systemic corticosteroids in 
the last month
*Data from Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European Position Paper on Rhinosinusitis and 
Nasal Polyps 2012. Rhinol Suppl 2012:1-298.
Figure 1 Treatment of CRS based on 
control. (Reproduced with permission 
from Hellings PW, Fokkens WJ, Akdis 
C, et al. Uncontrolled allergic rhinitis 
and chronic rhinosinusitis: where do we 
stand today? Allergy 2013;68:1-7, with 
permission from Willey Blackwell.)
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The global burden of chronic rhinosinusitis
• Symptoms of chronic rhinosinusitis are reported by about 10% 
of the population, but there is considerable variation
• About 5% of the population report that they have been given a 
diagnosis of CRS
• CRS is associated with smoking and with late onset asthma, but 
not with early onset asthma
• People with CRS and people with asthma have an approximately 
equivalent detriment in their quality of life
Chronic rhinosinusitis (CRS) is a 
condition that has been largely 
ignored by epidemiologists. It is 
diagnosed by a combination of 
symptoms and further confirma-
tory tests using either endosco-
py or computed tomography. In 
epidemiological surveys reliance 
is generally placed on symptom 
questionnaires and occasionally 
on reported diagnoses; confirma-
tory tests are generally not feasi-
ble. Questionnaires based on in-
ternational diagnostic guidelines 
are not adequate to make a clin-
ical diagnosis but have had some 
validation as indicators of disease.
Studies of CRS in adults have 
given estimates of prevalence of 
around 8-10% but there is some 
variation, some of which is relat-
ed to differences in the way the 
condition is assessed. A multi-site 
survey in Europe (Figure 1) based 
on symptom questionnaires gave 
estimates between 6.9 and 21.7% 
and a similar multisite study in Chi-
na gave prevalences between 4.8 
and 9.7%. In general, prevalences 
based on self-reported diagnoses 
give figures about a half of these 
figures, but studies in north Amer-
ica have given estimates of 11% 
for sinusitis in the USA and 6.7% 
THE GLOBAL BURDEN OF 
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for rhinosinusitis in Canada based 
on self-reported diagnoses.
The European studies suggest 
that CRS is more common in old-
er age groups, though elsewhere 
the peak prevalence in is early 
adulthood. This difference may 
represent differences in disease 
between birth cohorts as well as 
differences in susceptibility as 
people age. Most studies agree 
that smoking is strongly associat-
ed with disease (Figure 2). CRS is, 
in turn, a risk factor for late onset 
asthma, though it is not associat-
ed with early onset asthma. In this 
respect, it is different from allergic 
rhinitis (Figure 3).
Studies using generic measures of 
quality of life suggest that the im-
pairment of QOL is similar in mag-
nitude for patients with asthma 
and patients with CRS (Figure 4). 
Those who have both conditions 
have a worse quality of life than 
those who just have one condi-
tion.
KEY REFERENCES
1. Tomassen P, Newson RB, Hoff-
mans R, Lotvall J, Cardell LO, Gun-
nbjornsdottir M, et al. Reliability of 
EP3OS symptom criteria and nasal 
endoscopy in the assessment of 
chronic rhinosinusitis - a GA2LEN 
study. Allergy 2011;66:556-561.
2. Hastan D, Fokkens WJ, Bachert C, 
Newson RB, Bislimovska J, Bockel-
brink A, et al. Chronic rhinosinusi-
tis in Europe - an underestimated 
disease. A GA2LEN study. Aller-
gy 2011;66:1216-1223.
3. Shi JB, Fu QL, Zhang H, Cheng L, 
Wang YJ, Zhu DD, et al. Epidemi-
ology of chronic rhinosinusitis: 
results from a cross-sectional sur-
Peter Burney  
Imperial College 
London, UK
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The global burden of chronic rhinosinusitis
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Figure 1 Prevalence (%) of symptoms of chronic rhinosinusitis and of a self-reported diagnosis of CRS in 17-70 year 
old populations across Europe. (Redrawn from Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe - an 
underestimated disease. A GA2LEN study. Allergy 2011;66:1216-1223.)
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Figure 2 Association of chronic rhinosinusits with smoking status (odds ratio and 95% confidence interval) in three 
surveys in Canada (ref 5) Europe (ref 2) and China (ref 3)
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4. Blackwell DL Lucas JW, Clarke TC. 
Summary health statistics for U.S. 
adults: National Health Interview 
Survey, 2012. Vital Health Stat 
10 2014:1-161.
5. Chen Y, Dales R, Lin M. The Ep-
idemiology of Chronic Rhinosi-
nusitis in Canadians. Laryngo-
scope 2003;113:1199-1205.
6. Jarvis D, Newson R, Lotvall J, 
Hastan D, Tomassen P, Keil T, et 
al. Asthma in adults and its asso-
ciation with chronic rhinosinusitis: 
The GA2LEN survey in Europe. Al-
lergy 2012;67:91-98.
7. Ek A, Middleveld R, Bertilsson H, 
Bjerg A, Ekerljung L, Malinovschi 
A, et al. Chronic rhinosinusitis in 
asthma is a negative predictor of 
quality of life: results from the 
Swedish GA2LEN survey. Aller-
gy 2013;68:1314-1321.
Figure 3 Risk of early and late onset asthma by upper airway disease (Adjusted relative risk ratio compared 
with participants with no nasal allergies and no chronic rhino-sinusitis) (Adapted from Jarvis D, Newson R, Lotvall J, 
Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: The GA2LEN survey in 
Europe. Allergy 2012;67:91-98.)
Figure 4 Relative reductions in quality of life [EQ-5D] in those with chronic 
rhinusitis, asthma or both conditions, compared with those with none of these 
conditions. (Drawn from data in Ek A, Middleveld R, Bertilsson H, et al. Chronic 
rhinosinusitis in asthma is a negative predictor of quality of life: results from the 
Swedish GA2LEN survey. Allergy 2013;68:1314-1321.)
Section H
CHRONIC RHINOSINUSITIS - 
 DIAGNOSIS AND MANAGEMENT
* Nasal endoscopy
* Imaging of the paranasal sinuses in chronic rhinosinusitis
* Smell testing in chronic rhinosinusitis
* Medical management of chronic rhinosinusitis
* Topical and systemic corticosteroids in chronic 
rhinosinusitis
* Long-term use of antibiotics in chronic rhinosinusitis
* Immune modulation in chronic rhinosinusitis
* Evidence – based surgery in chronic rhinosinusitis
* Surgery for chronic rhinosinusitis with nasal polyps
* Interfacing medical and surgical management of chronic 
rhinosinusitis
* The challenges of chronic rhinosinusitis management
↓ Eosinophil and Th2 cell 
numbers (apoptosis)
↓ Th2 cell cytokines (IL-4, IL-5)
↓ Mast cell numbers
↓ Mast cell degranulation and 
mediators
↓ Epithelial and goblet 
cell hyperplasia
↓ Mucus hyperproduction
↓ Epithelial inflammatory 
mediators
↑ Epithelial antimicrobial 
products 
Th2 
cell
Plasma 
cell
IgE
Mast cell
Eosinophil
Macrophage
↓ Fibroblast inflammatory 
mediators
↓ Edema
↑ Collagen content
↑ TGF-β
Nasal polyp 
tissue
Cytokines, chemokines
↓ Mucus gland 
hyperproduction
Vessel
Corticosteroids
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the sino-nasal mucosa with greater precision than imaging and 
permits accurate evaluation of the efficacy of medical therapy 
in chronic rhinosinusitis (CRS)
• In addition the method allows endoscopically directed cultures 
and/or biopsies
• Nasal endoscopy is essential to identify persistent inflammation 
following sinus surgery and hence guide appropriate therapy
Nasal endoscopy is an essential 
element of rhinologic examination 
of chronic sinonasal complaints. 
It has been well documented that 
symptoms of chronic rhinosinusitis 
(CRS) do not correlate well with CT 
findings, and that the sensation of 
nasal obstruction does not corre-
late well with nasal airflow alone.
Performed under topical anesthe-
sia and typically following decon-
gestion, it provides for a detailed 
examination of the nose, naso-
pharynx, middle meatus and sphe-
no-ethmoidal recess. A 2.7mm or 
4mm 300 or 450 endoscope is uti-
lized most commonly, although a 
700 endoscope may be required in 
some situations. As an alternative, 
flexible fiberoptic endoscopy can 
provide good visualization, but 
does not facilitate endoscopically 
directed culture or biopsy.
Following the application of a top-
ical xylocaine or tetracaine spray, 
usually combined with a topical 
decongestant (oxymetazaline), na-
sal endoscopy is best performed 
in a systematic fashion with three 
passes (below the inferior turbi-
nate, between the inferior and 
middle turbinate and, when possi-
ble, with direct examination of the 
middle meatus. For the latter, ad-
ditional anesthesia (such as with 
NASAL ENDOSCOPY1
KE Y MESSAGES
4% cocaine on nasal applicators) 
may be required.
The first pass of the endoscope 
provides an overview of the nasal 
anatomy, of the Hausner’s valve, 
the evaluation of the status of the 
inferior turbinate and the naso-
pharyngeal anatomy. Passing the 
endoscope between the inferior 
and middle turbinate allows visu-
alization of the uncinate process 
and anterior middle meatus, sphe-
noethmoidal recess and some vis-
ualization of the olfactory cleft 
(Figure 1). The middle meatus is 
often best entered inferiorly, there-
by permitting visualization of the 
ethmoidal bulla, and hiatus semi-
lunaris. Gentle pressure on the un-
cinate process may reveal edema 
within the ethmoidal infundibulum, 
frequently the initial area involved 
in inflammatory disease (Table 1).
Careful evaluation should be per-
formed for the presence of pol-
yps, edema, drainage throughout 
the examination (Figure 2). Endo-
scopically directed culture is per-
formed when indicated, and bi-
opsy of suspicious lesions can be 
performed under local anesthesia 
when indicated. For endoscopic 
biopsy, a 5cm 27G needle may 
be bent appropriately, and when 
attached to a 1cc syringe usually 
allows direct injection of the ma-
jority lesions within the nose. Bi-
opsy of possible juvenile angiofi-
broma lesions should be avoided, 
and careful consideration should 
be given prior to office biopsy of 
other vascular lesions.
Postoperatively, nasal endoscopy 
directs the duration and types of 
medical therapy, as well as the ne-
cessity for debridement. Following 
Nasal endoscopy
David W. Kennedy  
University of Pennsylvania 
Philadelphia, USA
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Nasal endoscopy
a complete endoscopic surgical 
procedure, it should be possible 
to visualize all the sinuses with ap-
propriately angled telescopes. In 
patients with persistent or recur-
rent disease, particular attention 
should be directed to the frontal 
recess and to the natural ostium 
of the maxillary sinus. Ensuring 
the natural ostium of maxillary si-
nus is truly open and not scarred 
anteriorly frequently requires uti-
lization of a 450 or 700 endoscope.
Thus nasal endoscopy comple-
ments the careful patient history 
in the diagnosis of CRS, augments 
the information which can be ob-
tained by imaging and provides 
objective evidence of the thera-
peutic response over time, espe-
cially in postoperative patients 
who are frequently essentially 
asymptomatic despite persistent 
inflammatory disease.
KEY REFERENCES
1. Kennedy DW, Zinreich SJ, Rosen-
baum AE, Johns ME. Functional 
endoscopic sinus surgery. Theory 
and diagnostic evaluation. Arch 
Otolaryngol 1985;111:576-582.
2. André RF, Vuyk HD, Ahmed A, 
Graamans K, Nolst Trenité GJ. Cor-
relation between subjective and 
objective evaluation of the nasal 
airway. A systematic review of the 
highest level of evidence. Clinical 
Otolaryngology 2009;34:518-525.
3. Stewart MG, Sicard MW, Piccirillo 
JF, Diaz-Marchan PJ. Severity Stag-
ing in Chronic Sinusitis: Are CT Scan 
Findings Related to Patient Symp-
toms? Am J Rhinol 1999;13:161-
167.
4. Joe SA, Bolger W, Kennedy D. 
Nasal Endoscopy, In: Kennedy D, 
Bolger W, Zinreich SJ, editors. Dis-
eases of the Sinuses: Diagnosis and 
Management. Hamilton, Ontario: 
BC Decker, Inc, 2001;119-128.
TABLE 1
Nasal endoscopy steps and what can be visualised
1st pass Along floor of the nose
Inferior turbinate
Hausner’s valve
Inferior meatal window
Posterior Choana
Nasopharynx
Eustachian tube
2nd pass Between middle and inferior turbinate
Anterior middle meatus
Uncinate process
Inferior middle meatus
Accessory ostia
Sphenoethmoidal recess
Superior turbinate
Sphenoid ostium
3rd pass Middle meatus
Hiatus semilunaris
Infundibular edema
Bulla
Frontal recess openings
Figure 1 Outpatient nasal 
endoscopy. The procedure is 
performed under local anesthesia 
with the patient seated or lying 
supine in an examination chair. A 300 
endoscope is usually chosen for the 
initial evaluation. The image on the 
monitor shows the left inferior and 
middle turbinate.
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Figure 2 Nasal endoscopic 
examination of the left nasal cavity of 
a patient with chronic rhinosinusitis 
with a 300 endoscope demonstrates 
polypoid mucosa within the middle 
meatus (arrow). MT= middle 
turbinate, IT= Inferior turbinate
Figure 3 Nasal endoscopy of 
the right middle meatus with 
300 endoscope in a patient with 
aspirin exacerbated respiratory 
disease (AERD) and prior surgery 
demonstrates a large polyp in the 
right ethmoid cavity (arrow). MT= 
Middle meatus
Figure 4 Nasal Endoscopy of 
the left nasal cavity with a 300 
telescope in a patient with a large 
nasopharyngeal tumor demonstrates 
the nasopharyngeal mass (arrow) 
and polypoid mucosa within the 
sphenoethmoid recess (star). It is 
important to note that the wide angle 
of view of nasal endoscopes makes 
extramucosal masses perpendicular 
to the endoscope more difficult to 
identify. IT= Inferior turbinate).
MT
IT
MT
IT
Nasal endoscopy
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• Computed tomography (CT) is the most commonly used imaging 
modality for evaluation of inflammatory sinus mucosal disease
• CT allows optimal evaluation of the bony anatomy of the 
paranasal sinuses, the drainage pathways, as well as the mucosal 
disease
• CT is an excellent complementary tool in displaying the extent 
of inflammatory disease beyond what is available with anterior 
rhinoscopy and nasal endoscopy
• Magnetic resonance imaging (MRI) provides better soft 
tissue resolution and is useful in certain instances including 
complications of sinusitis and in differentiating inflammatory 
mucosal disease from neoplasia
Computed tomography (CT) is 
the most commonly used imaging 
modality for evaluation of inflam-
matory sinus mucosal disease. CT 
allows optimal evaluation of the 
bony anatomy of the paranasal si-
nuses, the drainage pathways, as 
well as the mucosal disease (Fig-
ure 1). Volumetric scanning with a 
multi-detector CT scan, use of 0.5 
mm or 0.6 mm axial acquired CT 
images, and reformatted images 
in the axial, coronal, and sagittal 
planes afford an excellent display 
of the regional soft tissue and 
bone detail.
Chronic rhinosinusitis (CRS) is a 
clinical diagnosis made in the set-
ting of persistent sinus symptoms 
for greater than 12 consecutive 
weeks, and is the most common 
indication for sinus imaging. CT is 
an excellent complementary tool 
in displaying the extent of inflam-
matory disease beyond what is 
available with clinical inspection, 
anterior rhinoscopy and nasal en-
doscopy. Sinusitis often results 
from an obstruction of the drain-
age pathways of the sinuses, the 
ostiomeatal pathways. Obstruc-
tion of the frontal recess, middle 
meatus and maxillary infundibu-
lum as well as the sphenoethmoid 
recess and sphenoid sinus ostium 
IMAGING OF THE 
PARANASAL SINUSES IN 
CHRONIC RHINOSINUSITIS
2
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Imaging of the paranasal sinuses in chronic rhinosinusitis
Sachin K. Gujar S. James Zinreich
Johns Hopkins University School of Medicine 
Baltimore, USA
Figure 1 Coronal images of the paranasal sinuses through the region of the 
ostiomeatal units in bone (A) and soft tissue (B) windows. There is polyp in 
the right middle meatus with mucosal disease in the right maxillary sinus, with 
minimally hyper attenuating secretions within.
A B
338
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 H
 - 
C
hr
on
ic
 r
hi
no
si
nu
si
ti
s 
- 
di
ag
no
si
s 
an
d 
m
an
ag
em
en
t
will block the mucociliary drainage 
and air exchange within the sinus-
es resulting in an inflammatory 
process.
The secretions opacifying the si-
nus lumen have a variable appear-
ance. In the acute phase, the low 
viscosity secretions are of inter-
mediate to low attenuation on CT 
(10-25 Hounsfield units). There 
is a uniform mucosal thickening 
along the sinus walls accompanied 
by a fluid exudate that may result 
in an air-fluid level within the si-
nus. If the obstruction continues, 
the mucosal thickening will in-
crease and may proceed to totally 
occupy the obstructed sinus. With 
chronicity, the secretions become 
more viscous with increased CT 
densities (30-60 HU), resulting 
from the relative increase in the 
protein concentration as the wa-
ter component decreases. These 
changes are not always visually 
apparent, and therefore a distinc-
tion between acute,subacute and 
chronic inflammation inflamma-
tion cannot always be made on 
CT scans. With time, however, the 
inflammation may extend into the 
bony perimeter of the sinus, with 
sclerosis and thickening of the 
sinus walls representing osteitis, 
and a sign of chronicity (Figure 2).
Magnetic resonance imaging 
(MRI) provides better soft tissue 
resolution and is useful in cer-
tain instances including compli-
cations of sinusitis and in differ-
entiating inflammatory mucosal 
disease from neoplasia. On MRI, 
the chronic proteinaceous or in-
spissated secretions appear hy-
perintense on the T1-weighted 
images and hypointense on the 
T2-weighted images with periph-
eral rim of mucosal enhancement 
on the post contrast images. It is 
also useful to remember that the 
viscous secretions may restrict 
diffusion in the absence of frank 
purulent change.
In general, CRS is not associated 
with bone erosion. Should bone 
erosion be present, one needs to 
consider the presence of other 
pathologies such as a mucocele, 
invasive fungal sinusitis, granu-
lomatosis with polyangiitis, or a 
superimposing neoplasm. Should 
the bone erosion affect the skull 
base the possibility of a mucocele, 
meningocele, meningoencepha-
locele, or a neoplasm should be 
considered. Nasal septal destruc-
tion can also occur with rhinosinus-
itis due to cocaine use, lymphoma, 
and post unsuccessful septoplasty.
To reach a more focused diagnosis, 
MRI with and without intravenous 
gadolinium based contrast admin-
istration will be very helpful. Mu-
cocele (Figure 3) is a complication 
of CRS resulting from a persistent 
Figure 2 Coronal image in bone window images 
shows sclerotic osteitic thickening of the sphenoid 
sinus walls with chronic moderate sinus mucosal 
disease and punctate calcifications. Incidentally 
noted is an Onodi cell on the left superior to the left 
sphenoid sinus lumen.
Figure 3 Coronal bone window image 
demonstrating a large left ethmoid mucocele 
obstructing and partially occupying the left maxillary 
antrum. There is focal osseous disruption of the 
inferior portion of the lamina papyracea and bulging 
of the mucocele into the orbit.
Imaging of the paranasal sinuses in chronic rhinosinusitis
339
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 H
 - C
hronic rhinosinusiti
s - diagnosis and m
anagem
ent
obstruction of drainage pathway 
with subsequent expansion of the 
sinus lumen, and may be associat-
ed with bony erosion. These most 
commonly involve the ethmoid 
and frontal sinuses, although max-
illary and sphenoid sinuses may 
also be affected. Secondary infec-
tion of a mucocele may result in 
a mucopyocele. Granulomatosis 
with polyangiitis, formerly known 
as Wegener's granulomatosis is 
a systemic necrotizing vasculitic 
syndrome that involves the sinon-
asal structures with mucosal thick-
ening, osteitis, bony erosion, and 
extension into the orbits, and rare-
ly the intracranial compartment. 
Bone destruction may involve the 
medial maxillary walls, lamina pap-
yracea, with nasal septal destruc-
tion being a characteristic feature 
(Figure 4)
Punctate calcific densities within 
inspissated proteinaceous secre-
tions may be occasionally be vis-
ible on CT scans, and represent 
fungal concretions related to a 
superimposed fungal colonization 
without a frankly invasive fun-
gal sinusitis. Noninvasive fungal 
colonization occurs in the CRS 
or in conjunction with polyposis. 
The presence of trace metallic 
elements in the fungal filaments 
occasionally will result in a pro-
foundly hypointense signal on T2 
weighted images mimicking an 
aerated sinus.
Retention cysts are often seen as 
well-defined lesions within the 
sinuses, most commonly in the 
maxillary sinuses. These are usu-
ally incidental findings on imag-
ing studies although large cysts 
may interfere with the drainage 
pathways. These may also demon-
strate slightly increased protein 
content and related signal chang-
es on MRI.
Antrochoanal and sphenochoanal 
polyps appear as well-defined 
masses that arise from the maxil-
lary antrum or the sphenoid sinus 
respectively. The antrochoanal 
polyp extends through the ac-
cessory maxillary ostium into the 
middle meatus, extending through 
the posterior choana and present-
ing as a nasopharyngeal mass.
KEY REFERENCES:
1. Zinreich SJ, Kennedy DW, Rosen-
baum AE, Gayler BW, Kumar AJ, 
Stammberger H. Paranasal Si-
nuses: CT imaging requirements 
for endoscopic surgery. Radiolo-
gy 1987;163:769-775.
2. Campbell PD Jr, Zinreich SJ, Aygun 
N. Imaging of the Paranasal Sinus-
es and In-office CT. Otolaryngol 
Clin N Am 2009;42:753-764.
3. Zinreich SJ, Kennedy DW, Malat 
J, Curtin HD, Epstein JI, Huff LC, 
et al. Fungal Sinusitis: Diagnosis 
with CT and MR Imaging. Radiolo-
gy 1988;169:439-444.
Figure 4 Coronal bone window image demonstrating near complete 
opacification of the paranasal sinuses in a patient with Granulomatosis with 
polyangiitis (GPA). There is destruction of the medial right maxillary wall, the 
turbinated bilaterally and the nasal septum.
Imaging of the paranasal sinuses in chronic rhinosinusitis
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chronic rhinosinusitis (CRS) have impaired olfactory function, 
mainly those with nasal polyps (CSRwNP)
• Orthonasal and retronasal olfactory function may be explored 
for diagnostic purposes and give important guidance in the 
management of the CRS patients
• Chemosensory event related potentials are considered a more 
objective method for olfactory function
• CT scan of the paranasal sinuses confirms the diagnosis of CRS 
and magnetic resonance imaging may reveal olfactory bulb 
volume variations
Olfactory dysfunction is one of the 
symptoms included in the diag-
nostic criteria for chronic rhinosi-
nusitis (CRS) with or without nasal 
polyposis (CRSsNP or CRSwNP), 
underlining the importance of this 
specific symptom in patients with 
sino-nasal disease. Even if olfacto-
ry impairment is a common symp-
tom affecting 61-83% of patients 
with CRS, up to one quarter of the 
patients with CRS are unaware of 
their olfactory dysfunction.
Psychophysical tests results show 
that patients with CRSsNP or CR-
SwNP have quantitative disor-
ders (hyposmia more frequently 
then anosmia), report fluctuating 
symptoms and have fewer quali-
tative disorders such as parosmia 
(28%) and phantosmia (7%) than 
patients without sino-nasal aeti-
ology of smell pertubation. Also, 
it is widely accepted that patients 
with CRSwNP have lower olfac-
tory function than patients with 
CRSsNP (Figure 1). Psychophysical 
testing is important when medical 
and/or surgical treatments are not 
effective or when the dysfunction 
of the chemosensory perception 
is important for the patient (Fig-
ure 2).
Olfactory dysfunction in CRS 
is caused by swollen or hyper-
SMELL TESTING IN 
CHRONIC RHINOSINUSITIS3
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Smell testing in chronic rhinosinusitis
Philippe Rombaux  
Université Catholique de Louvain 
Brussels, Belgium
trophic nasal mucosa or nasal 
polyps, inducing an impaired ac-
cess of odorants to the olfactory 
cleft. However there is only little 
correlation between nasal resist-
ance and the degree of olfactory 
dysfunction. In addition, surgical 
therapy, although improving the 
nasal patency, has sometimes un-
certain results when considering 
the olfactory recovery. Biopsies 
of the olfactory nasal neuroep-
ithelium in patients suffering 
from CRS revealed inflammatory 
changes in the nasal mucosa and 
apoptotic pathological changes, 
including the olfactory receptor 
neurons and olfactory support-
ing cells. Infiltrating inflammatory 
cells release inflammatory media-
tors, which are known to trigger 
hypersecretion in respiratory and 
Bowman’s glands altering the ion 
concentrations of olfactory mucus 
and affecting the olfactory trans-
duction process. In addition, cy-
tokines and mediators, particular-
ly those released by eosinophils, 
may be toxic to olfactory receptor 
neurons and the degree of in-
flammation changes in the neuro-
pithelium is related to the severity 
of olfactory dysfunction.
Evaluation of the orthonasal func-
tion can be performed through 
many standardized tests. The Snif-
fin’ Sticks test and the University 
of Pennsylvania smell identifica-
tion test (UPSIT ) are the most 
frequently used (Figure 3). These 
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semi-objective tests require the 
collaboration of the patients and 
need to be age and sex-related 
to allow distinction between nor-
mosmia, hyposmia and anosmia. 
Retronasal olfactory performanc-
es can also be evaluated following 
a standardized method using pow-
der substances delivered inside 
the oral cavity using an identifica-
tion task. A more objective way to 
determine the olfactory function 
facilitated by electrophysiological 
techniques and by chemosensory 
evoked potentials recording. This 
technique is based on the fact 
that a brief olfactory stimulus elic-
it transient changes in the ongoing 
electrographic activity. To evalu-
ate the olfactory function a pure 
odorant substance (i.e. 2-pheny-
lethanol ) is delivered in the nose 
of the patients. Brain responses 
are then recorded and averaged 
and responses are transformed 
into a single waveform called the 
olfactory event-related potentials. 
In CRS, both orthonasal and ret-
ronasal scores can be decreased 
and chemosensory even related 
potentials may demonstrate sub-
tle changes in the amplitude and/
or latency in moderate cases and 
may be absent in severe cases. 
Because it is impossible to record 
olfactory event related potentials 
in up to one third of the normal 
subjects, electrophysiological 
studies need to be interpreted 
with caution.
Beside CT scanning of the nose 
and of the paranasal sinuses, the 
magnetic resonance (MRI) is the 
imaging modality of choice for the 
evaluation of the olfactory appa-
ratus since it allows examining the 
olfactory bulb, olfactory tract and 
central olfactory projection areas 
(Figure 4). The assessment of ol-
factory bulb volume is particularly 
useful in the evaluation of olfacto-
ry disorder with a non sino-nasal 
origin. For the sino-nasal related 
olfactory dysfunction MRI may 
demonstrate changes in the olfac-
tory bulb volume related to the re-
sidual olfactory function and more 
importantly some plasticity when 
the olfactory bulb volume is in-
creased after a surgical procedure.
Smell testing in chronic rhinosinusitis
Figure 1 Endoscopic examination; A: CRSsNP; B: secretions in the right olfactory cleft; C: CRSwNP (polyps in the 
olfactory cleft).
A B C
CRSsNP or CRSwNP
Treatment Psychophysical olfactory testing
when major symptom
when unclear diagnosis
when predisposed activities
Success Failure
MRI 
Olfactory bulb
(Chemosensory
Event Related
Potentials)
Olfactory dysfunction ; 
anamnesis, endoscopic endonasal evaluation
Figure 2 Algorithm for olfactory evaluation in patients with CRS.
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Topical corticosteroid (spray, 
drops, squirt, aerosol) and oral 
corticoid may help to restore the 
olfactory function in CRS patients. 
Usually, this positive effect is in-
complete and transient and more 
efficient when the drug reaches 
the olfactory. Surgery such as en-
doscopic endonasal surgery is also 
very helpful and “sandwich” treat-
ment (corticoid/surgery/corticoid) 
seems to have the better chance 
to help the patient with an olfac-
tory dysfunction and CRS.
KEY REFERENCES
1. Doty RL, Shaman P, Dann M. Devel-
opment of the University of Penn-
sylvania Smell Identification Test: 
a standardized microencapsulated 
test of olfactory function. Physiol 
Behav 1984;32:489-502.
2. Gudziol V, Buschhüter D, Abol-
maali N, Gerber J, Rombaux P, 
Hummel T. Increasing olfactory 
bulb volume due to treatment of 
chronic rhinosinusitis – a longitudi-
nal study. Brain 2009;132:3096-
3101.
3. Hummel T, Kobal G, Gudziol H, 
Mackay-Sim A. Normative data 
for the Sniffin Sticks including test 
of odor identification, odor dis-
crimination and odor thresholds: 
an upgrade based on a group of 
more than 3000 subjects. Eur Arch 
Otorhinolaryngol 2007;264:237-
243.
4. Kern RC. Chronic sinusitis and 
anosmia: pathologic changes in 
the olfactory mucosa. Laryngo-
scope 2000;110:1071-1077.
5. Litvack JR, Mace JC, Smith TL. Ol-
factory function and disease sever-
ity in chronic rhinosinusitis. Am J 
Rhinol Allergy 2009;23:139-144.
6. Rombaux P, Mouraux A, Collet 
S, Eloy P, Bertrand B. Usefulness 
and feasibility of psychophysical 
and electrophysiological olfactory 
testing in rhinology clinic. Rhinolo-
gy 2009;47:28-35.
Figure 3 A: Orthonasal test Sniffin’s stick test used for treshold, 
discrimination and identification tasks; B: Retronasal test and some others 
validated tests.
Figure 4 A: T2 coronal MRI showing the Olfactory bulb; B: T2 coronal MRI 
showing the olfactory bulb in CRS
A B
Smell testing in chronic rhinosinusitis
A B
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• Chronic rhinosinusitis (CRS) should be adequately managed for 
optimal disease control
• Topical corticosteroids and douching are the mainstay of 
medical treatment in CRS
• Systemic treatment is the second line treatment in CRS patients 
with severe symptoms
• Antihistamines have a beneficial effect in CRS patients with 
concomitant allergic rhinitis
• Following the current evolution in CRS phenotyping, more 
personalized treatments based on the underlying inflammation 
will most likely be considered in the future
• Treatment with biologicals can only be recommended when 
additional studies show beneficial effects in (sub)groups of 
patients with CRS
Chronic rhinosinusitis (CRS) is de-
fined as a symptomatic inflamma-
tory process of nasal cavity and 
paranasal sinuses with or with-
out the presence of nasal polyps 
(NP), for at least 12 weeks. The 
presence of nasal congestion or 
blockage, discolored rhinorrhea or 
postnasal drip, facial pain or pres-
sure, hyposmia or anosmia togeth-
er with consistent pathologic find-
ings during nasal endoscopy or on 
CT scan establishes the diagnosis. 
Currently, a variery of therapeutic 
protocols have been developed 
and recommended for CRS: top-
ical and systemic corticosteroids, 
short- or long-term antibiotics, 
nasal irrigation, decongestants, 
antihistamines and even allergen 
immunotherapy (when allergy is 
confirmed by specific IgE meas-
urement), antileukotrienes, (Fig-
ure 1, Figure 2).
Topical intranasal corticoster-
oids (INS) and nasal douching 
are first-line treatment for CRS. 
Nasal douching clears the sinon-
asal cavity from pathogens and 
pro-inflammatory mediators. INS 
target the inflammatory response 
underlying nasal congestion, pro-
mote osteomeatal complex drain-
age and occasionally improve the 
sense of smell. Moreover, a signifi-
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University of Crete School of Medicine 
Heraklio, Greece
cant reduction in polyp size in cas-
es of CRS with NP (CRSwNP) has 
been reported. Based on clinical 
experience, systemic corticoids 
remain important for the treat-
ment of CRSwNP, as they provide 
short-term symptom relief. Short 
term courses of oral corticoster-
oids are usually given two to three 
times yearly.
Oral antibiotics together with 
topical corticosteroids have been 
proven to act synergistically, 
though antibiotics are reserved 
for the acute exacerbations of 
CRS. Low-dose macrolides have 
been used as a long-term antibiot-
ic treatment in CRS, while topical 
antibiotics remain an option for 
refractory cases where traditional 
topical steroids and oral antibiot-
ics are ineffective.
Nasal irrigation (douching) is a safe, 
inexpensive method with benefi-
cial effects such as improvement 
in mucous clearance, enhanced 
ciliary beat activity, removal of 
antigens, biofilms or inflammatory 
mediators. Intranasal decongest-
ants like xylomethazoline improve 
sinus ventilation through nasal de-
congestion, though prolonged use 
may have an opposite effect re-
sulting in rhinitis medicamentosa.
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Antihistamine have a minimal 
beneficial in CRS patients with 
concomitant AR. According to the 
GAL2EN study, approximately, 
57% of patients with CRS report 
symptoms of allergic rhinitis (AR) 
as well. The correlation with asth-
ma is stronger in those patients 
with both CRS and AR symptoms. 
In the absence of AR, CRS has a 
positive correlation with a late 
onset asthma. To sum up, check-
ing for allergy is advocated in CRS 
patients. Antileukotrienes (mon-
telukast) might have a beneficial 
effect in patients with NP.
Following the current evolution 
in phenotyping, more personal-
ized treatments based on the un-
derlying inflammation will most 
likely be considered in the future. 
Recent insight into B cell differen-
tiation into IgE-secreting plasma 
cells in CRSwNP help to under-
stand the phenomenon of local-
ized IgE production in NP without 
correlation to systemic IgE levels 
or to SPT results.
The results of clinical trials sug-
gest that anti-IL-5 antibodies like 
reslizumab could play a role in the 
treatment of selected CRS pa-
tients with NP. Given the cost of 
targeted treatments with mono-
clonal antobodies, they will prob-
ably be used for severe recurrent 
NP associated with difficult to 
control asthma. Considering local 
production of IgE antibodies in NP, 
it appears that local IgE is func-
tional in the regulation of chron-
ic inflammation. So, methods to 
antagonize IgE antibodies could 
be of relevance. Omalizumab, a 
recombinant DNA-derived hu-
manized IgG monoclonal antibody 
has been studied and approved 
for asthmatic patients. Up to date 
omalizumab is not recommended 
for patients with NP. Future rand-
omized controlled trials for further 
evaluation of benefit of therapies 
with anti-IL-5 and anti-IgE are re-
quired.
Figure 1 Management scheme for adults with CRS without NP for ENT specialists.
Medical management of chronic rhinosinusitis
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Figure 2 Management scheme for adults with CRS with NP for ENT specialists.
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t • There is good evidence that intranasal corticosteroids (INS) 
are a beneficial treatment for both chronic rhinosinusitis (CRS) 
without nasal polyps (CRSsNP) and CRS with nasal polyps 
(CRSwNP)
• Oral corticosteroids are also effective for the management of 
CRSwNP, but the short-lived benefits of systemic corticosteroid 
therapy need to be balanced with the potential side effects
• Postoperative treatment with corticosteroids is strongly 
recommended in CRSwNP to prevent relapse
• The powerful anti-inflammatory effects of corticosteroids in 
CRS are mediated by the binding and activation of intracellular 
corticosteroid receptors expressed in all human cells and tissues
Corticosteroids (CS) are hormones 
essential for life that are synthe-
sised and released by the adre-
nal cortex in a circadian manner 
and in response to stress. Their 
secretion is controlled by the hy-
pothalamic-pituitary-adrenal axis. 
CS regulate numerous physiolog-
ic processes and aim to maintain 
homeostasis (Figure 1). CS have 
powerful anti-inflammatory and 
immunosuppressive actions. Syn-
thetic derivatives of these hor-
mones have been the mainstay 
for treating inflammatory diseases 
such as chronic rhinosinusitis (CRS) 
and asthma, autoimmune disor-
ders, and hematologic cancers.
USE OF CORTICOSTEROIDS IN 
CRS
European and international guide-
lines recommend intranasal cor-
ticosteroids (INS) as first-line 
treatment for CRS without nasal 
polyps (CRSsNP) and CRS with 
nasal polyps (CRSwNP). Several 
randomised studies have report-
ed that INS improve the control of 
sino-nasal symptoms compared to 
placebo in patients with CRSsNP. 
However, not all authors demon-
strate these findings. It has been 
reported that direct delivery of 
the CS to the sinuses has more 
beneficial effect than simple nasal 
TOPICAL AND SYSTEMIC 
CORTICOSTEROIDS IN 
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delivery. There is good evidence 
that INS are a beneficial treatment 
also for CRSwNP. They improve 
nasal symptoms, reduce polyp 
size and prevent polyp recurrence 
after surgery. The effect on the 
polyp size is greater when INS are 
used in patients who have previ-
ously undergone sinus surgery. 
Importantly, INS are a safe thera-
py with minimal adverse effects in 
the management of both CRSsNP 
and CRSwNP.
Systemic CS are effective for the 
management of CRSwNP but their 
use is limited to patients with se-
vere or uncontrolled symptoms. A 
short-term benefit of a short (two 
to four-week) course of oral CS 
(OCS) when compared to placebo 
has been reported, with an objec-
tive reduction of polyp size and a 
subjective improvement of nasal 
symptoms and quality of life. No 
significant adverse effects have 
been reported with a short course 
of OCS. However, systemic corti-
costeroid therapy may potentially 
provoke suppression of the hy-
pothalamic-pituitary-adrenal axis 
and affect bone mineral density. 
Thus, the short-lived benefits of 
systemic corticosteroid thera-
py need to be balanced with the 
long-term potential side effects.
Current guidelines strongly rec-
ommend continuing medical 
treatment with CS postopera-
Laura Pujols  
Institut d’Investigacions 
Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
Mauricio López-
Chacón  
Hospital Clínic i Universitari, 
Barcelona, Spain
Jordi Roca-Ferrer  
Institut d’Investigacions 
Biomèdiques August Pi i Sunyer 
(IDIBAPS), Barcelona, Spain
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Topical and systemic corticosteroids in chronic rhinosinusitis
cells
tissues
organs
hypothalamus
CRH
stress
pituitary 
gland 
ACTH
Circadian 
rhythm
Adrenal 
gland
Corticosteroids 
(cortisol)
Figure 1 Regulation of corticosteroid (CS) levels by the hypothalamic-pituitary-adrenal axis. Synthesis and release of CS 
(cortisol in humans) is under daily and dynamic circadian regulation by the periventricular nucleus of the hypothalamus. 
Corticotropin-releasing hormone (CRH) secreted by the hypothalamus stimulates the release of adrenocorticotropic 
hormone (ACTH) from the anterior pituitary gland. In turn, ACTH induces the synthesis and secretion of cortisol from 
the cortex of the adrenal glands into the bloodstream. CS have effects on numerous cells, tissues and organs. CS 
regulate their own production by the negative-feedback loop suppressing ACTH levels in the anterior pituitary and CRH 
levels in the hypothalamus.
tively in patients who have been 
submitted to endoscopic sinus 
surgery because they have failed 
to maximal medical treatment to 
prevent relapse of the disease.
MECHANISM OF CS ACTION
CS achieve the reduction of nasal 
symptoms in most patients with 
CRS because they have power-
ful anti-inflammatory effects. The 
clinical efficacy of CS depends in 
part on their ability to reduce air-
way eosinophil infiltration by pre-
venting their increased viability 
and activation. CS also have im-
portant effects on the sino-nasal 
epithelial cells with reduction of 
the secretion of chemotactic cy-
tokines and other proinflammato-
ry mediators (Figure 2).
The biological action of CS occurs 
after their binding to the intracel-
lular CS receptors (GR) expressed 
in all human cells and tissues, in-
cluding in the sinonasal mucosa. 
The CS-GR complex rapidly trans-
locates into the nucleus and mod-
ulates, either positively or neg-
atively, the expression of target 
genes (Figure 3). Thus, CS activate 
the expression of several anti-in-
flammatory genes, such as the 
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↓ Eosinophil and Th2 cell 
numbers (apoptosis)
↓ Th2 cell cytokines (IL-4, IL-5)
↓ Mast cell numbers
↓ Mast cell degranulation and 
mediators
↓ Epithelial and goblet 
cell hyperplasia
↓ Mucus hyperproduction
↓ Epithelial inflammatory 
mediators
↑ Epithelial antimicrobial 
products 
Th2 
cell
Plasma 
cell
IgE
Mast cell
Eosinophil
Macrophage
↓ Fibroblast inflammatory 
mediators
↓ Edema
↑ Collagen content
↑ TGF-β
Nasal polyp 
tissue
Cytokines, chemokines
↓ Mucus gland 
hyperproduction
Vessel
Corticosteroids
Figure 2 Schematic representation of the effect of corticosteroids (CS) on the epithelium and submucosa of an 
eosinophilic nasal polyp tissue. The effect of CS on the different cells and mediators involved in chronic rhinosinusitis 
with nasal polyps (CRSwNP) pathogenesis is shown in red boxes.
mitogen-activated protein kinase 
(MAPK) phosphatase-1 (MKP-1) 
and the glucocorticoid-induced 
leucine zipper (GILZ). The GR-CS 
complex also suppresses the tran-
scription of numerous cytokines, 
chemokines and other proin-
flammatory mediators through 
the blockade of proinflammatory 
transcription factors, such as acti-
vating protein-1 (AP-1) and nucle-
ar factor-κB (NF-κB).
Interestingly, a lower expression 
of the GR has been reported in 
nasal polyps from CRSwNP pa-
tients compared with the control 
nasal mucosa, and a lower anti-in-
flammatory activity of the GR has 
been reported in vitro for fibro-
blasts sampled from patients with 
CRSwNP and asthma compared 
with the control nasal mucosa fi-
broblasts.
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nucleus
cytoplasm
GRE
lipocortin-1, MKP-1, GILZ, IL-10+
nGRE
TSLP_
TF-RE
COX-2, TNFα, VEGF, CXCL8_
mRNA
inflammatory 
protein
GRα
HSP
Corticosteroids
Figure 3 Mechanisms of corticosteroid (CS) action. After passing the cell membrane by passive diffusion, corticosteroids 
bind to CS receptor α (GRα), associated heat-shock proteins (HSP) are released, and the CS-bound receptor translocates 
into the nucleus. The receptor can bind CS responsive elements (GRE) on the promoter region of target genes and activate 
gene transcription; it can bind to negative GRE (nGRE) and lead to transcriptional repression; it can physically interact with 
pro-inflammatory transcription factors such as NF-κB and AP-1 and repress the transcription of pro-inflammatory genes. 
The receptor can also alter the mRNA or protein stability of inflammatory mediators. TSLP: thymic stromal lymphopoietin, 
COX-2: cyclooxygenase-2, TNF-α: tumor necrosis factor, VEGF: vascular endothelial growth factor, CXCL8: chemokine 
(C-X-C motif) ligand 8 (or IL-8), TF-RE: transcription factor-response element. (Modified from Pujols L, Mullol J, Picado C. 
Glucocorticoid receptor in human respiratory epithelial cells. Neuroimmunomodulation 2009;16:290-299 and Pujols L, Mullol J, 
Picado C. Importance of glucocorticoid receptors in upper and lower airways. Front Biosci (Landmark Ed) 2010;15:789-800.)
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antibiotics in large and well defined populations with chronic 
rhinosinusitis (CRS) are lacking
• Patients with normal serum IgE and a low CT score are more 
likely to respond to macrolides
• The potential cardiotoxicity of macrolides in patients with long 
QT-syndrome should not be ignored
• Doxycycline and trimethroprim-sulfamethoxazole may provide 
an alternative to macrolide antibiotics, but randomised 
controlled trials are lacking
• The immuno-modulating properties of certain antibiotics 
need further studies and could provide an alternative to 
corticosteroids in the future
Although chronic rhinosinusitis 
(CRS) is mainly inflammatory in its’ 
nature, oral antibiotics have for 
decades been the mainstay treat-
ment.
Macrolide antibiotics such as 
erythromycin, clarithromycin, 
roxithromycin and azithromycin 
are the most studied antibiotics 
for CRS treatment. Apart from 
reducing the number of bacte-
ria considered pathogens, oth-
er mechanisms of action are not 
fully understood. Macrolide an-
tibiotics have exhibited in vitro 
strong anti-inflammatory effects, 
on parity with prednisolone. The 
anti-inflammatory effects can also 
be demonstrated by measuring 
inflammatory mediators in nasal 
lavage fluid of patients, but if this 
is secondary to reduced bacterial 
load or a primary anti-inflamma-
tory effect is not clear. A more 
speculative explanation is that an-
tibiotics in long-term use prevent 
pathogenic bacteria to invade the 
epithelium. Reducing the number 
of toxins, such as those released 
by some Staphylococci species is 
another possible explanation.
There are two placebo-controlled 
studies using long-term macrolide 
antibiotics in CRS with conflict-
ing results. Both studies are of 
LONG-TERM USE OF 
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the about the same size (n=64 vs 
60 patients included). One study 
showed significant effects on the 
Sino-Nasal Outcomes Test (SNOT-
20), nasal endoscopy, saccharine 
transit time and IL-8 in lavage fluid 
with a response rate of 67% in the 
roxithromycin group vs 22% in the 
placebo group. In the other study 
the response rate (44 % in the 
azithromycin group and 28 % in the 
placebo group) did not reach sig-
nificance. The difference between 
the results of the two studies can 
be explained by the inclusion cri-
teria, the positive one including 
only CRS without polyps, whereas 
the negative one included CRS pa-
tients with nasal polyps (CRSwNP) 
as well. The positive study showed 
that patients with normal serum 
IgE are more likely to respond to 
treatment (Figure 1).
Doxycycline has been compared 
to methylprednisolone or pla-
cebo in CRSwNP over a 20 days 
treatment period in 47 patients. 
Both treatments reduced the size 
of polyps, the effect more pro-
nounced with methylpredniso-
lone, but more long lasting with 
doxycycline. Cytokines in nasal 
lavage were affected in different 
ways suggesting different mecha-
nisms of action.
Anders Cervin  
University of Queensland 
Brisbane, Australia
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Another treatment option in-
cludes trimethroprim-sulfameth-
oxazole. A retrospective study in 
79 patients with difficult to treat 
CRS compared macrolides with 
trimethroprim-sulfamethoxazole 
and found after at least 6 months 
of treatment a response rate of 78 
% with no difference between the 
treatment groups. However a pla-
cebo arm is lacking.
To sum up, systemic antibiotics 
have shown effect on symptoms 
and inflammatory markers in sub-
groups of CRS patients, but the 
mechanism of action is unclear 
and choosing the responsive pa-
tient remains challenging. There 
are also concerns about antibiotic 
resistance and significant drug in-
teractions as well as a concern for 
cardiac events with macrolides, 
especially in patients with long QT 
syndrome (Figure 1).
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Symptoms dominated by purulent discharge/post nasal drip
Patient not responding to INCS
Purulence on endoscopy
Low CT score (Lund-Mackay or similar)
Serum IgE not elevated
Macrolide antibiotics Long QT interval
Beware interactions
Anticoagulant
Antiarrythmics
Terfenadine
Carbamezapine
Doxycycline
Figure 1 A more likely patient to respond to long-term antibiotic treatment have signs and symptoms dominated by a 
neutrophilic inflammation such as purulence, normal IgE and a low CT score. Interactions of macrolides with other drugs 
need to be taken into account and monitoring the serum levels of anticoagulants, carbamezapine etc., may be necessary. 
As a precaution macrolides should be avoided in patient with a long QT interval.
Long-term use of antibiotics in chronic rhinosinusitis
352
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 H
 - 
C
hr
on
ic
 r
hi
no
si
nu
si
ti
s 
- 
di
ag
no
si
s 
an
d 
m
an
ag
em
en
t • Aspirin desensitisation appears to be beneficial in aspirin 
sensitive chronic rhinosinunisitis with nasal polyps, but the high 
rate of adverse events limits its’ usage
• Limited evidence supports a role of immunotherapy for allergic 
fungal rhinosinusitis
• Monoclonal antibodies against IgE and IL5 have been found 
to reduce polyp size but high cost is likely to restrict the 
therapeutic use to severe CRSwNP
Chronic rhinosinusitis (CRS) with-
out nasal polyps (CRSsNP) incor-
porates a heterogeneous group of 
disorders differing in aetiological 
and exacerbating factors, while 
CRS with nasal polyps (CRSwNP) 
is a more distinct immunological 
disease with Th2 dominance ac-
companied by excess IL-5 expres-
sion and high levels of IgE and 
tissue eosinophilia. Allergic fungal 
rhinosinusitis (AFS) (Figure 1) is a 
distinct subset of CRSwNP, with 
both type 1 IgE mediated hyper-
sensitivity and type 3 IgG medi-
ated responses to fungal hyphae. 
Both CRSwNP and AFS have un-
derstandably received more focus 
in terms of the immunomodula-
tion.
In order to assess the role of im-
mune modulation in CRS Pu-
bmed/Embase and the Cochrane 
database were searched using 
the following terms: (Sinusitis or 
nasal polyp) and (aspirin or salicy-
late) and; (Sinusitis or nasal polyp) 
and (immunotherapy or immu-
nomodulation) and; (Sinusitis or 
nasal polyp) and (monoclonal or 
anti-IgE pr anti-IL5 or mepolizum-
ab or omalizumab). In total 1103 
abstracts were reviewed, and con-
trolled trials and systematic re-
views were retrieved.
IMMUNE MODULATION IN 
CHRONIC RHINOSINUSITIS7
KE Y MESSAGES
Immune modulation in chronic rhinosinusitis
ASPIRIN DESENSITISATION 
IN CRSwNP AND ASPIRIN 
EXACERBATED RESPIRATORY 
DISEASE
Aspirin-exacerbated respiratory 
disease (AERD) is an eosinophil 
dominated inflammatory disease 
characterized by CRSwNP and 
asthma, caused 
by abnormalities 
in arachidonic 
acid metabolic 
pathway. Aspirin 
desensitisation, 
achieved through 
repetitive dosing 
with oral or top-
ical nasal aspirin, 
has been used 
to reduce the re-
currence of nasal 
polyps, occurring 
frequently. A sys-
tematic review of the literature 
was published in 2013, summaris-
ing 11 studies, of which 7 (all ob-
servational cohort studies) recom-
mended aspirin desensitization. 
However, only one study was a 
randomized trial of nasal lysine as-
pirin and found no significant ben-
Claire Hopkins  
Guy’s and St Thomas’ Hospitals 
London, UK
Figure 1 CT scan demonstrating typical features of AFS.
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efit. Two randomized controlled 
trials have been published since 
2013 and both identified signifi-
cant benefit from desensitization 
compared with placebo in terms 
of symptom scores, and one found 
a benefit in terms of reduced pol-
yp recurrence and further surgery 
(the other did not report this). 
Both studies suffered from a high 
drop out rate (55 and 31%) in part 
due to adverse effects. The key 
outcomes of the trials reported 
are summarized in Table 1.
Aspirin dosages used in published 
studies vary from 100 – 1100 mg 
per day, and only one trial has com-
pared different dosages to date.
Given the evidence retrieved there 
is a low GRADE recommendation 
for the use of aspirin desensitiza-
tion for CRSwNP and AERD. The 
quality of evidence is high, howev-
er there is a high risk of harm with 
high rates of adverse effect leading 
to drug discontinuation.
IMMUNOTHERAPY IN 
ALLERGIC FUNGAL SINUSITIS
Even if a strong immunological ba-
sis for AFS was documented, there 
is a paucity of strong evidence 
supporting the use of immuno-
therapy, and to date there are no 
placebo-controlled randomized 
trials. Two case-control studies, 
comparing a total of 47 patients 
undergoing immunotherapy with 
35 controls, showed reduced cor-
ticosteroid usage, reduced polyp 
recurrence and decreased need 
for repeated interventions in AFS 
patients receiving immunother-
apy. A later study by the same 
group failed to detect a signifi-
cant difference between active 
and control groups, but may have 
been underpowered (n=17). There 
has been some concern reported 
of the potential for adverse ef-
fects due to immune complex 
deposition, however one recent 
small study found no difference in 
adverse events between AFS and 
CRS without fungal hypersensitiv-
ity following high-dose immuno-
TABLE 1
Summary of evidence for aspirin desensitization
Study LE (mg) Route Dose F/U Outcomes(mg)
Adverse effects 
discontinued RX Recommend
Swierczynska 
2014 1b po 625 0.5
Sig improvement in 
Symptom score and ACT 25% Yes
Fruth 
2013 1b po 100 3
sig imp on nasal polyp recurrence, 
polyp grade and symptom scores Yes
Havel 
2013 2 po 500 >1.5
sig imp in polyp grade and symptom 
scores 5% Yes
Forer 
2011 2 po 1050 1
sig imp in olfaction but high drop out 
rate lead to low power 37%
Katial 2010 2 po 1100 0.5 sig imp in symptom scores 0% Yes
Rozasi 
2008 2 po
100/ 
300 1
300 mg – sig imp in symptom scores 
polyp grade and decreased surgery
100 mg no benefit
0% Yes
Lee 
2007 2 po
1100/ 
650 1
Sig imp in symptom score, reduction in 
surgery and steroid usage
1100 mg=12% 
650 mg=20% Yes
Berges-Gi-
meno 2003 2  po 1100 1
Sig imp in symptom score, reduction in 
surgery and steroid usage 24% Yes
Gosepath 
2001 2 po 100 1 no statistical analysis 0% ?
Stevenson 
1996 2 po 1100 1
Sig imp in symptom score, reduction in 
surgery and steroid usage 13% ?
Ogata 
2007 2 nasal 0.25
Sig decrease in polyp size, insig 
Change in symptom scores
Parikh 2005 1b nasal 0.5 No sig differenve in symptom score No
Immune modulation in chronic rhinosinusitis
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therapy. Larger, randomized trials 
are required to assess both safety 
and efficacy. All studies to date 
have assessed the response to im-
munotherapy in the early post-op-
erative period, with the exception 
of one study in which 5 patients 
who received treatment prior to 
surgery underwent radiological 
and symptomatic deterioration 
during treatment. Therefore, im-
munotherapy should be seen as 
an adjunct to surgery, which re-
mains the primary treatment mo-
dality, removing the allergic mucin 
(Figure 2) and opening the sinuses 
to topical therapy.
Given the evidence retrieved 
there is a low GRADE recommen-
dation for the use of immunother-
apy for AFS based on low quality 
of evidence and low risk of harm.
ALLERGEN SPECIFIC 
IMMUNOTHERAPY IN 
PATIENTS WITH CRS AND 
ALLERGIC RHINITIS
Only 3 case control studies have 
evaluated the benefit of allergen 
specific immunotherapy (AIT) for 
inhalant allergens in patients with 
co-morbid CRS and allergic rhinitis 
(AR) with respect to CRS outcomes. 
All reported better CRS outcomes 
in patients receiving AIT 
for their AR after sur-
gery, but have significant 
methodological flaws or 
lack adequate statistical 
analysis, such that no 
conclusions on the ben-
efits of AIT on symptoms 
of CRS in patients with 
AR can be made.
Given the evidence re-
trieved there is a low 
GRADE recommenda-
tion to NOT recommend 
AIT in patients with CRS 
and AR for CRS out-
comes alone. The recom-
mendation is based on low quality 
of evidence and low risk of harm.
SPECIFIC 
IMMUNOMODULATION WITH 
MONOCLONAL ANTIBODIES
Omalizumab, an anti-IgE mono-
clonal antibody (mAb) has been 
used in 2 placebo controlled 
RCTs. One study randomised 14 
patients with CRS (12 of whom 
had CRSwNP) and a history of 
prior surgery to active or placebo 
treatment and found no benefit in 
terms of radiological or symptom 
scores at 6 months. The second 
study included 24 patients with 
CRSwNP and asthma, and found 
that polyp grade, symptom and ra-
diological scores improved signifi-
cantly with omalizumab compared 
with placebo. One patient receiv-
ing active treatment developed 
lymphoma one year after complet-
ing the trial, however pooled data 
form asthma trials do not support 
a causal link of omalizumab with 
malignancy. There is an isolated 
case-report supporting the use of 
omalizumab in AFS.
One placebo controlled ran-
domised controlled trial has 
demonstrated significantly great-
er reduction in polyp size and ra-
diological scores in patients with 
CRSwNP receiving mepolizumab, 
an anti-IL-5 mAb, when compared 
with placebo.
Long-term data on mAb safety is 
required, and patient selection 
needs to be better defined before 
recommending widespread use of 
an expensive drug.
Given the evidence retrieved 
there is a low GRADE recommen-
dation to NOT recommend mAbs 
for CRA outside of trials. The rec-
ommendation is based on high 
quality of evidence and unknown 
risk of harm in association with 
high cost of treatment
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Immune modulation in chronic rhinosinusitis
Figure 2 Fungal mucin being removed during 
surgery for AFS.
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• Systematic reviews of cohort studies, large outcomes studies 
consistently support the safety and efficacy of functional 
endoscopic sinus surgery (FESS) for chronic rhinosinusitis (CRS) 
with nasal polyps (Level of evidence II)
• However, long term follow up suggests a 15-20 % revision 
rate, with negative prognostic factors including aspririn 
hypersensitivity and asthma, cystic fibrosis, previous surgery 
and extensive disease (Level of evidence II)
• FESS is effective in managing most symptoms of CRS, with effect 
sizes ranging from 0.8 (hyposmia) to 1.7 (nasal obstruction) 
(Level of evidence III)
The available randomised con-
trolled trials (RCTs) comparing sur-
gical treatment (Figures 1 and 2) 
with medical treatment for chron-
ic rhinosinusitis (CRS) with nasal 
polyps CRSwNP are summarised 
in Table 1. We can state that all 
the RCT’s conclude that surgery 
is as effective as prolonged and 
maximal medical treatment; and 
hence should be reserved for pa-
tients who fail conservative man-
agement, including systemic and 
local corticosteroids as well as 
long term antibiotics.
In a review first published in 2003 
and updated in 2006 by Dalziel. he 
screened 632 articles and evaluat-
ed 42 articles published between 
1978 and 2005 on the effect of 
functional endoscopic sinus sur-
gery (FESS) on CRSwNP. A total of 
12 329 patients were enrolled in 
the included studies. As a consist-
ent finding patients judged their 
symptom 'improved' or 'great-
ly improved' in 75 to 95 percent 
(level IV evidence). The percent-
age of overall complications was 
1.4% for FESS compared to 0.8% 
to conventional procedures.
In 2000 the Clinical Effective-
ness Unit of the Royal College of 
Surgeons of England conducted 
a National Comparative Audit of 
EVIDENCE – BASED 
SURGERY IN CHRONIC 
RHINOSINUSITIS
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Figure 1 Setup for endoscopic sinus surgery for CRS with nasal polyps.
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the Surgery for Nasal Polyposis 
and CRS covering the work of 298 
consultants working in 87 hos-
pital sites in England and Wales. 
Patients undergoing sinus surgery 
were prospectively enrolled and 
followed up in this observation-
al study at 3, 12 and 36 months 
post-operatively using the Si-
no-Nasal Outcomes Test (SNOT-
22) as the main outcome measure. 
Two thirds of the 3128 patients 
participating in this study had CR-
SwNP. All forms of sinus surgery 
were included though the major-
ity were performed endoscopical-
ly. Overall there was a high level 
of satisfaction with the surgery 
and clinically significant improve-
ment in the SNOT-22 scores were 
demonstrated at 3, 12 and 36 
months. CRSwNP patients ben-
efited more from surgery than 
the CRS patients without polyps 
(CRSsNP). Revision surgery was 
indicated in 3.6% at 12 months 
and 11.8% at 36 months. Ma-
jor complications were rare. Five 
year follow up results from almost 
half of the patients of this audit 
were published in 2009: 19% of 
patients surveyed underwent re-
vision surgery during these five 
years, including 21% of patients 
with CRSwNP compared to 15% 
of patients with CRSsNP. The 
mean SNOT-22 score for all pa-
tients was 28.2, very similar to 
the results observed at 36 months 
TABLE 1
Randomized controlled studies comparing surgery with medical treatment in chronic rhinosinusitis with nasal polyps
Author N Follow 
up
Inclusion criteria Non ESS group ESS group Outcome
Lildholdt 
1988 53
52 
wks CRS with NP
14mg bethamesone 
injection followed by 
12 months intranasal 
steroids
Intranasal polypec-
tomy followed by 
12 months intrana-
sal steroids
No difference in 
symptom score
Fairley 
1993
33 
(29)
6-12 
wks
Sinusitis symptoms + 
endosopic or radi-
ological findings of 
sinustis
Intranasal antrostomy ESS
Both groups im-
proved, no difference 
between groups
Hartog 
1997
89 
(77)
12-52 
wks
Rhinorhea /obstruc-
tion/headache and 
radiological evidence 
of maxillary opacifi-
cation
Sinus irrigation + Lora-
carbef po 10 days
Sinus irrigation+ 
loracarbef po 10 
days + ESS
No difference in 
overall cure rates, ESS 
group improved more 
in postnaasal dis-
charge and hyposmia
Lidholdt 
1997 126
2 
years CRS with NP
14mg bethamesone 
injection followed by 
12 months intranasal 
steroids
Intranasal polypec-
tomy followed by 
12 months intrana-
sal steroids
No difference in total 
symptoms scores or 
need for medication
Blomqvist 
2001 32
52 
wks
Endoscopic evidence 
of CRS with NP Budesonide spray
Budesonide spray 
+ESS
Surgical group has 
bigger improvement 
in nasal obstruction 
and discharge, not 
hyposmia
Ragab 
2004
90 
(78)
52 
wks
2 major or one major 
and 2 minor symp-
toms and CT evidence 
of CRS
3 months of erythro-
mycin + nasal steroid + 
nasal douche
ESS+nasal steroid 
+ nasal douche
No difference in 
total symptom scores, 
greater improvement 
in nasal volume in 
surgical group
Blomqvist 
2009 32
52 
weeks
Endoscopic evidence 
of CRS with NP Budesonide spray
Unilateral ESS + 
budesonide spray
CT scores significant-
ly better in surgery 
group
Abbreviations: CRS = chronic rhinosinusitis; CT = computer tomography; EES = endoscopic sinus surgery; NP = nasal polyps;
Evidence – based surgery in chronic rhinosinusitis
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(27.7), and a consistent 14-point 
improvement over the baseline 
score was reported. Scores were 
better for CRSwNP (mean = 26.2) 
than for CRSsNP (mean = 33.3) 
(Level IIc evidence).
A smaller non randomised cohort 
assessed 180 patients who failed 
initial medical treatment: 75 of 
these patients chose to undergo 
surgery and 75 to continue with 
medical treatment. Patients who 
chose to undergo surgery had 
worse baseline scores but showed 
more significant improvement in 
most symptom areas, at one year 
of follow up, while the same was 
true for crossover patients.
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Figure 2 Endoscopic and navigation views of Draf 3 endoscopic sinus approach for extensive sinonasal polyposis.
Evidence – based surgery in chronic rhinosinusitis
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treatment for chronic rhinosinusitis with nasal polyps
• Complete removal of ethmoidal air cells as well as thorough 
cleaning of the mucosal pathology together with mucosal 
preservation are key steps for the success of the EES
• Post-operative care such as sinus rinse and/or topical steroids 
are required to prevent recurrence of the disease
Endoscopic sinus surgery (ESS) has 
become widespread as a standard 
and effective surgical method for 
chronic rhinosinisitis (CRS) (Fig-
ure 1). Outcome of ESS for CRS 
has been further improved by 
employing post-operative med-
ical therapy including intranasal 
corticosteroids and low-dose 
long-term macrolide therapy (Fig-
ure 2). Recently, the incidence of 
CRS with nasal polyps (CRSwNP), 
which relates to significant eosin-
ophilic infiltration on sinus muco-
sa, is increasing. CRSwNP tends to 
show post-operative recurrence 
of mucosal lesion accompanied by 
recurrent nasal polyposis (NP), al-
though patient’s subjective symp-
toms are usually improved.
To reduce the frequency of NP 
recurrence, thorough removal of 
pathological tissues, especially 
complete removal of ethmoidal air 
cells, is required in order to make 
post-operative local treatments, 
e.g., topical steroids and sinus 
rinse, easier. Residual ethmoidal 
air cells affects outcomes of ESS, 
because these cells may become 
a focus of persistent inflammation 
and/or polyp growth. Another key 
for better EES outcome is to do 
“mucosal preservation surgery“3) 
(Figure 3). Excision of whole mu-
SURGERY FOR CHRONIC 
RHINOSINUSITIS WITH 
NASAL POLYPS
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Surgery for chronic rhinosinusitis with nasal polyps
Nobuyoshi Otori  
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Minato-ku, Japan
Figure 1 Endoscopic sinus surgery.
cosa with cup-type forceps is to 
be avoided as much as possible. 
Even for irreversible mucosal le-
sions showing severe edema and 
hypertrophy, subepithelial lesions 
are excised with a through-cutting 
forceps and/or micro-debrider, 
and the mucoperiosteum should 
be left intact. Such treatment fa-
cilitates ciliated epithelialization 
of mucosa, and recovery of the cil-
iary function should occur.
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Surgery for chronic rhinosinusitis with nasal polyps
Through-cutting forceps Cup-type forceps
Figure 2 Chronic rhinosinusitis. A-before the surgery. B - after the surgery.
Figure 3 Mucosal preservation. A - mucosal preservation with through-cutting forceps. B - mucosa is not preserved 
with cup-type forceps.
A B
A
B
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Figure 4 Anatomical preparations of 
nose, sinus and orbit (right side).
Actual surgical steps are as fol-
lows:
1. Nasal polypectomy. NP often 
derive from the middle meatus 
and olfactory cleft. These NP 
should be removed from the 
bottom.
2. Ethmoidal surgery. Under-
standing of the location of unci-
nate process, bulla ethmoidalis, 
ground lamellae and superior 
turbinate is important since 
they serve as an anatomic land-
mark during the operation. The 
bone septa in the ethmoid air 
cells are sufficiently excised to 
make them as smooth as possi-
ble, and a unique cavity is cre-
ated.
3. Maxillary surgery. The maxillary 
sinus is inspected with an an-
gled endoscopy, then a curved 
forceps is inserted through 
widen maxillary fontanelle to 
remove the pathologic tissues.
4. Sphenoidal surgery. Entering 
the sphenoid sinus from natural 
ostium and posterior ethmoid 
sinus is recommended with 
removal of the pathological le-
sions in the sphenoid sinus, but 
it is not preferable to remove 
forcibly a mucosal lesion from 
lateral or posterior wall
5. Frontal surgery. The approach 
to a frontal sinus lesion is the 
most difficult step in ESS. The 
use of an angled endoscope to 
look up at frontal recess from 
below is recommended, since 
it allows the recognition of the 
drainage pathway. The angled 
forceps is inserted carefully 
to the frontal sinus, and the 
drainage pathway is enlarged 
as much as possible. Draf type 
II or III are chosen to the case 
of revision surgery or the case 
of short anterior-posterior di-
ameter.
Inappropriate and rough manip-
ulation during the surgery may 
cause major complications such 
as orbital injury and cerebrospi-
nal fluid leakage4. Medical orbital 
wall is especially thin like a paper 
(Figure 4). Care must be taken to 
prevent these complications
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• Endoscopic sinus surgery improves the delivery of topical 
treatment to the sinonasal mucosa
• In chronic rhinosinusitis with nasal polyps, surgically removed 
polyps have a high tendency for recurrence without aggressive 
postoperative medical management
• Douching and topical steroid therapy are recommended for 
control of postoperative mucosal inflammation and should be 
maintained following endoscopic sinus surgery
Many studies have demonstrated 
the effectiveness of endoscopic si-
nus surgery (ESS) for patients who 
have chronic rhinosinusitis (CRS) 
with (CRSwNP) or without nasal 
polyps (CRSsNP). Few studies have 
also compared medical versus sur-
gical treatment for chronic sinus 
disease. These studies, including a 
Cochrane review, show that medi-
cal and surgical treatment can lead 
to similar effects in improving qual-
ity of life. Although these trials pro-
vide us an interesting insight into 
the relative efficacies of medical 
versus surgical therapy they don’t 
provide us sufficient evidence. 
The comparison medical versus 
surgical therapy does not reflect 
current guidelines as it is general-
ly accepted that for both CRSwNP 
and CRSsNP surgical intervention 
is only considered in patients who 
fail to improve after a trial of maxi-
mal medical treatment.
If a patient with CRS is consid-
ered for surgery it should not be 
thought of as the only treatment. 
ESS is rather a surgical technique 
that decreases the amount of in-
flammation and creates acces-
sible sinus cavities so that the 
medical treatment may become 
more effective. This concept has 
been proven in CRSwNP patients 
INTERFACING MEDICAL AND 
SURGICAL MANAGEMENT OF 
CHRONIC RHINOSINUSITIS
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where patients with previous si-
nus surgery responded to topical 
steroid greater than patients with-
out sinus surgery for nasal polyp 
(NP) size reduction. Patients with 
NP appear to receive the most 
benefit of postoperative topical 
steroids as polyp recurrence rate 
was reduced and time to polyp 
recurrence was lengthened. For 
CRSsNP it is less clear if surgical 
intervention affects the sympto-
matic response to a topical ster-
oid. Recent evidence also sup-
ports the claim that ESS improves 
the delivery of topical medications 
to the sinonasal mucosa, however 
it should be noted that large vol-
ume squeeze bottles or passive 
flow devices appear to have the 
best sinus penetration rate.
The fact that there is an important 
interplay between medical and 
surgical therapy is also reflected 
during the immediate periopera-
tive period after ESS. Administra-
tion of systemic steroids in the 
perioperative period for patients 
who have polyps has a significant 
impact on their postoperative 
course. Topical steroids have been 
shown to improve wound healing 
after ESS. For antibiotics (both lo-
cal and systemic) there is conflict-
ing evidence. Two studies evalu-
ating a short and long course of 
postoperative antibiotics (2 days) 
demonstrated it had no effect on 
outcomes, while a third study with 
a long postoperative antibiotic 
protocol demonstrated showed 
a improvement in patient symp-
toms, endoscopic appearance and 
significant reduction in sinonasal 
crust formation.
Interfacing medical and surgical management of chronic rhinosinusitis
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• Treatment of chronic rhinosinusitis (CRS) is a challenge. Part of the 
challenge is that CRS represents the end point of multiple etiologic 
processes that are influenced by genes, environment and age
• The unifying theme for CRS treatment is that inflammation 
needs to be controlled, acute infections need to be treated with 
antibiotics, and surgery is reserved for medical failures
• There is large numbers of treatments mentioned in the 
literature, but there are limited evidence-based publications 
that support the various treatments
• Many patients do not respond to treatment as indicated by the 
guidelines
• CRS treatment guidelines are mostly based on expert opinion, do 
not consider the response to prior treatment or the management 
of exacerbations, tend to eliminate certain CRS subtypes and do 
not consider the underlying disease mechanisms
Current guidelines tend to divide 
chronic rhinosinusitis (CRS) into 
that with and that without na-
sal polyps (NP). The guidelines 
base treatment on the severity of 
the disease. Unfortunately, most 
guidelines do not consider the re-
sponse to prior treatment or the 
management of exacerbations 
(Table 1). They tend to eliminate 
certain subtypes such as cystic 
fibrosis (CF), antrochoanal polyps, 
aspirin exacerbated respiratory 
disease (AERD, fungal disease (al-
lergic and invasive) and complica-
tions. Furthermore, children differ 
from adults in their pathophysi-
ology and thus require different 
treatment strategies.
The goals of treatment are to 
eliminate or reduce NP size, re-
store nasal breathing, restore the 
sense of smell, reduce symptoms 
of rhinitis, reduce the number of 
bacterial infections, and prevent 
recurrence. In addition, there are 
suggestions that treatment of CRS 
improves asthma.
The unifying theme for CRS treat-
ment is that inflammation needs 
to be controlled, acute infections 
need to be treated with antibi-
otics, and surgery is reserved for 
medical failures (Figure 1).
THE CHALLENGES OF 
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Treatment with anti-inflamma-
tory drugs is the mainstay, with 
drugs being given either primarily 
or secondarily after surgery to slow 
the rate of recurrence. Because 
of their anti-inflammatory prop-
erties, corticosteroids have been 
the pillars of treatment. Topical 
intranasal corticosteroids (INS) are 
more effective for CRS with polyps 
than for CRS without polyps. Many 
clinicians call for more studies re-
garding the delivery system, to 
ensure a better distribution of the 
INS throughout the nose and si-
nuses. This has been highlighted by 
the delivery of corticosteroid nasal 
drops, which reduced the need for 
surgical intervention in a group of 
patients who had previously re-
ceived standard INS. Experience 
has led to the use of Pulmicort 
respules® in a Sinusrinse® bottle 
in the attempt to deliver a large 
volume of fluid containing a topi-
cal corticosteroid into previously 
operated sinuses and corticos-
teroid impregnated stents placed 
at the time of surgery. Oral ster-
oids given over 2 to 4 weeks have 
been shown to reduce NP size and 
symptoms, but the optimum dose 
The challenges of chronic rhinosinusitis management
Robert Naclerio Fuad Baroody
University of Chicago 
Chicago, USA
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has not been established. In chil-
dren, oral methylprednisolone add-
ed to amoxicillin/clavulanate in the 
treatment of CRS, improves symp-
toms and the inflammatory chang-
es on CT scans. The usual clinical 
treatment of NP is to give oral ster-
oids followed by INS. Intrapolyp 
injections of steroids were popu-
lar until the 1960s, when resulting 
cases of blindness were reported. 
Now, this approach has been revis-
ited because some authors report 
no incidence of blindness with the 
use of fine suspensions of steroid 
particles and pre-decongestion. 
The authors suggest some effec-
tiveness for 4 to 8 weeks and some 
systemic absorption.
Surgery is clearly indicated for 
intracranial and intraorbital com-
plications, mucoceles, anatomic 
variations, allergic fungal disease, 
massive polyps with bony remode-
ling, and antrochoanal polyps. The 
category leading to the majority of 
surgical interventions, however, is 
that of patients who remain symp-
tomatic despite medical treatment. 
Overall, the number of patients 
requiring surgery is very low. This 
conservative approach to surgi-
cal intervention followed a study 
showing no difference between 
medical treatment (INS, douching, 
and long-term erythromycin) and 
surgery followed by INS. In support 
of surgical intervention are the 
excellent subjective rates of im-
provement in long-term follow-up. 
Unilateral surgery showed better 
CT findings, olfaction, polyp score, 
and relief of symptoms on the op-
erated side. Several quality-of-life 
instruments showed better im-
provement in patients electing sur-
gery compared to those electing 
continued medical therapy. The 
best surgical approach has been 
debated. The currently favored 
procedure is an extensive surgical 
clean-out to provide access for 
topical medicines postoperatively. 
This concept builds upon the view 
that INS slow the rate of post sur-
gery recurrence. Surgical revision 
rates have increased for cases of 
AERD, asthma, and frontal-sinus 
disease. Surgery in children is al-
most done exclusively in patients 
with CF and those with orbital and 
intracranial complications. The first 
surgical approach for children is an 
adenoidectomy plus/minus a max-
illary sinus wash.
The goals of the use of antibiotics 
are to eliminate infection, reduce 
inflammation, and clear biofilms. 
The use of topical antibiotics lacks 
good studies on safety, particular-
ly regarding systemic effects: only 
1 of 7 randomized, placebo-con-
trolled studies showed a positive 
effect. Mupirocin, used in an open 
study, showed positive effects in 
Staphylococcus aureus-positive pa-
tients. Oral antibiotics have been 
used short-term for treatment of 
acute episodes of CRS. Studies of 
the long-term use of antibiotics 
for their anti-inflammatory prop-
erties have had mixed results. In 
total, topical antifungals have not 
been shown to be effective in the 
treatment of CRS.
Because patients have persistent 
symptoms, besides the above ap-
proaches a multitude of other 
strategies have been suggested. 
These include oral and topical an-
tihistamines, leukotriene receptor 
antagonists, 5 lipooxygenase inhib-
itors, anti-IgE and anti-IL 5 mono-
clonal antibodies, immunotherapy 
against fungus and other aeroaller-
gens, large-volume irrigations with 
or without drugs, methotrexate, 
topical and oral antifungal drugs, 
decongestants, mucolytics, photo-
therapy, protein pump inhibitors, 
capsaicin, furosemide, Vitamin D, 
Manuka honey, bromelain, N-ace-
tylcysteine, quercetin, undecylenic 
acid, urtica dioica, massage of sinus 
ostea with swabs of botanical es-
sential oils, air purifiers, and diets, 
as well as aspirin desensitization 
orally or intranasal The vast major-
ity of the use of these treatments 
is supported by individual experi-
ence, and they place emphasis on 
the group of patients for whom we 
do not have effective treatment.
In summary, the design and in-
terpretation of CRS clinical trials 
have been hindered by the inher-
ent heterogeneity of the disease, a 
lack of uniform definitions for the 
various subtypes, an incomplete 
understanding of the underlying 
pathologies, the use of rescue 
medications, and a lack of useful 
and standardized clinical and labo-
ratory endpoints for measurement 
of the response to therapy.
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TABLE 1
Questions abound for CRS
What phenotype, what treatment?
Do paranasal CT findings define 
subtypes?
Does allergy play a role?
Does the presence of asthma define 
a unique phenotype?
How do you define and manage a 
flare-up of CRS?
When surgery, antibiotics, and ster-
oids fail to resolve CRS, what do we 
do, (the true unmet need)?
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Chronic Rhinosinusitis
CRSwNP CRSsNP
Saline Irrigation Intranasal Steroids 
Antibiotics for Acute 
Bacterial Exacerbations
Response No response
Endoscopic Sinus Surgery
Saline Irrigation Intranasal steroids 
Continue as above
CT Scan
Consider:
Anti-IgE, Doxycycline for 
CRSwNP, oral steroids for 
for CRSsNP, and 
Mucolytics, LTRAs, etc.
Diagnostic Nasal Endoscopy
Systemic Steroids
Figure 1 The figure depicts the most supported modes of therapy for chronic rhinosinusitis. Evidence based studies support 
the use of systemic steroids followed by topical steroids and saline irrigations for patients with chronic rhinosinusitis with 
nasal polyps (CRSwNP). For patients without nasal polyps (CRSsNP), most evidence supports saline irrigations and intranasal 
steroids. Antibiotics are reserved for the treatment of acute bacterial exacerbations of the disease with less evidence to 
support the prolonged use of antibiotics for their anti-inflammatory properties. If the patients respond to the treatment 
regimen, it should be continued with close clinical follow up. If they do not respond, then a sinus CT scan followed by 
endoscopic sinus surgery is offered followed by maintenance of a disease free cavity postoperatively with the use of saline 
irrigations and intranasal steroids. Other less supported agents such as Anti-IgE and Doxycycline for CRSwNP, oral steroids for 
CRSsNP, and mucolytics, LTRAs, etc can be considered if conventional therapy does not lead to a response.
The challenges of chronic rhinosinusitis management

Section I
TOWARDS A COMPREHENSIVE GLOBAL STRATEGY FOR THE 
MANAGEMENT OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
* The European Union plan of the early diagnosis and control 
of chronic respiratory diseases
* ARIA: from a guideline to a care pathway (AIRWAYS ICPs)
* Severe chronic upper airway diseases
* Important research questions in chronic upper airways 
diseases
* Policies and strategies to facilitate access to diagnosis and 
treatment for chronic upper airway diseases
* Policies and strategies to reduce risk factors for allergic 
rhinitis and chronic rhinosinusitis
* The role of primary health care in the management of 
chronic upper airway diseases
* The role of Patient Organisations in the management of 
allergic rhinitis and chronic rhinosinusitis
* Comprehensive management plan in allergic rhinitis – 
Towards a patient-centered attitude
* The role of pharmacists in the management of chronic 
upper airway diseases
* The role of schools in the management of chronic upper 
airway disease
* Managing allergic rhinitis and chronic rhino-sinusitis in 
developing countries - focus on Latin America
* Managing allergic rhinitis and chronic rhinosinusitis in 
developing countries – focus on Eastern Europe
* Managing allergic rhinitis and chronic rhinosinusitis in 
developing countries - focus on Asia Pacific
* Management of allergic rhinitis and chronic rhinosinusitis in 
developing countries - focus on Africa
* Managing allergic rhinitis and chronic rhinosinusitis in 
developing and low income countries - focus on South Asia
* Managing allergic rhinitis and chronic rhinosinusitis in 
developing countries – focus on East Asia
* Best buys for allergic rhinitis and chronic rhinosinusitis 
prevention and control
* The role of the allergist in allergic rhinitis and chronic 
rhinosinusitis
* Web-based surveys and monitoring in the management of 
allergic rhinitis and chronic rhinosinusitis
* Vision, roadmap and land-marking event
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s • Article 168 of the “Treaty on the Functioning of the European 
Union” (EU) provides a basis for conducting international health 
policy
• On this basis, the Council Conclusions on "Prevention, early 
diagnosis and treatment of chronic respiratory diseases in 
children" was adopted, defining the strategy of the EU for the 
chronic respiratory diseases (CRD)
• The EU strategy recommends building national and international 
policies aimed at the proper prevention, diagnosis and treatment 
of CRD, science-based and involving international cooperation
• The CC refers to the important role of environmental risk 
factors such as smoking and air pollution and health inequalities. 
These factors must be fought. The education of patients and 
caregivers is also important. These activities aim to allow 
reducing the socio-economic burden of the disease
In accordance with Article 168 of 
the Treaty on the Functioning of 
the European Union (EU) for the 
protection of human health, doc-
uments relating to chronic res-
piratory diseases (CRD) have been 
accepted at the international level 
recognizing them as an important 
public health problem:
1. Council conclusions of 7 De-
cember 2010 on 'Innovative 
approaches for chronic diseas-
es in public health and health-
care systems
2. Council conclusions of 2 June 
2004 on childhood asthma
The EU was also a signatory to 
a number of other documents, 
especially “Political declaration 
of the High-level Meeting of the 
General Assembly on the Preven-
tion and Control of Non-commu-
nicable Diseases” adopted by the 
United Nations General Assembly 
on 19 September 2011.
The EU Council conclusions on 
“Prevention, early diagnosis and 
treatment of chronic respiratory 
diseases in children” prepared and 
accepted by 27 Ministers of Health 
of all European Union Countries 
during the Polish Presidency of EU 
in 2011 (Figure 1) play a special 
role among all mention above doc-
uments. This is the first political 
THE EUROPEAN UNION PLAN OF THE 
EARLY DIAGNOSIS AND CONTROL OF 
CHRONIC RESPIRATORY DISEASES
1
KE Y MESSAGES
declaration on so high level con-
cerning CRDs. Its basic contents 
are summarized as follows:
1. CRDs, especially allergic rhinitis 
(AR) and asthma, are the most 
common non-communicable 
diseases in children
2. CRDs cause lifelong health im-
pairment
3. Both AR and asthma are inter-
dependently and significantly 
worsen the quality of life of pa-
tients,
4. There is a growing number 
of studies showing that AR 
and asthma may lead to other 
chronic diseases (in particular 
COPD) highlighting the impor-
tance for life expectancy and 
life expectancy in good health
5. Prevention, early diagnosis and 
treatment by controlling the 
diseases, environmental factors 
have a positive impact on the 
quality of life and active and 
healthy aging
The Council Conclusions invite 
the Member States and the Com-
mission to:
• Draw attention to the need for 
early prevention, diagnosis and 
treatment of CRD
The European Union plan of the early diagnosis and control of chronic respiratory diseases
Bolesław Samoliński  
Medical University of Warsaw 
Poland
Jean Bousquet  
University of Montpellier 
France
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• Improve the knowledge and 
education of children, families, 
teachers and health profession-
als
• Strengthen the cooperation 
and support of the national 
centers, international research 
networks, patients and health-
care professionals' organiza-
tions at all levels of care, to pri-
mary and secondary prevention
• Find cost-effective procedures 
and using health technology to 
improve health care systems 
standards regarding to CRD, re-
duce air pollution and tobacco 
smoke, improve physically ac-
tivity, improve exchange best 
practices
• Encourage and support re-
search on the causative genetic 
and environmental factors of 
CRD to contribute to the de-
velopment of evidence-based 
policy approaches
• Promote a multisectoral ap-
proach across the social, envi-
ronment, research, education 
and employment sectors, to 
improve the impact of policy on 
respiratory health.
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Figure 1 Council conclusions of 2 December 2011 on “Prevention, early diagnosis and treatment of chronic respiratory 
diseases in children”.
The European Union plan of the early diagnosis and control of chronic respiratory diseases
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ARIA: from a guideline to a care pathway (AIRWAYS ICPs)
• ARIA (Allergic Rhinitis and its Impact on Asthma) represents 
the most widely used guideline for allergic rhinitis (AR) and 
asthma comorbidity
• The new ARIA strategy is to develop recommendations, which 
will be used globally and applicable to each individual region or 
country of Europe depending on the health system, the cultural 
barriers, the availability and reimbursement of treatments and 
diagnosis, patients and health care professionals views
• Active and Healthy Ageing is a major societal challenge common 
to all countries and populations
• Integrated care pathways for airways diseases (AIRWAYS 
ICPs) has been chosen as the model of chronic diseases by the 
European Innovation Partnerships
• One of the major actions of AIRWAYS ICPs is to launch care 
pathways for chronic respiratory diseases which can be applied 
at the national and regional levels in Europe
European Innovation Partner-
ships (EIP) attempt to enhance 
European Union competitiveness 
and tackle societal challenges by 
fostering innovation.. The Action 
Plan B3 of the EIP on AHA is de-
voted to integrated care pathways 
for chronic diseases across the life 
cycle. The integrated care path-
ways for airways diseases (AIR-
WAYS ICPs) has been chosen as 
the model of chronic diseases. Its 
goals are to launch a collabora-
tion to develop multisectoral care 
pathways for chronic respiratory 
diseases in European countries 
and regions, and beyond with the 
Global Alliance against respiratory 
diseases (GARD). One of the ma-
jor actions of AIRWAYS ICPs is to 
launch care pathways for chronic 
respiratory diseases, which can be 
applied at the national and region-
al levels in Europe.
ARIA (Allergic Rhinitis and its Im-
pact on Asthma) represents the 
most widely used guideline for 
allergic rhinitis (AR) and asthma 
comorbidity. ARIA comprises a 
study group of 350 members and 
has been disseminated in over 65 
countries to specialists, general 
practitioners, pharmacists, other 
health care professionals, social 
carers and, importantly, patients. 
ARIA: FROM A GUIDELINE 
TO A CARE PATHWAY 
(AIRWAYS ICPS)
2
KE Y MESSAGES
ARIA is disseminated in over 60 
countries and has been translated 
into over 50 languages. Further-
more, it has been used in several 
guidelines recommended by gov-
ernmental health agencies (e.g. 
Brazil Portugal, Singapore, and the 
Finnish Allergy Programme).
The importance of clinical guide-
lines is widely recognized, but 
confusion exists on terminologies 
used to describe various forms of 
evidence-based tools to inform 
clinical practice.
A best practice is a technique, 
method, process, activity, incen-
tive, or reward that is believed to 
be more effective at delivering a 
particular outcome than any oth-
er technique, method, process, 
etc. when applied to a particu-
lar condition or circumstance. A 
best practice can be adopted as a 
standard process or be used as a 
guideline (U.S. Dept. of Veterans 
Affairs).
A guideline is a statement to de-
termine a course of action. It aims 
to streamline particular process-
Jean Bousquet Pascal Demoly Jose Rosado Pinto  
Hospital da Luz 
Lisbon, Portugal
MACVIA-LR, Montpellier 
France
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es according to a set routine or 
sound practice. By definition, fol-
lowing a guideline is never man-
datory. Guidelines are not binding 
and are not enforced.
Clinical practice guidelines are 
systematically developed state-
ments to assist the practitioner 
and patient decisions about ap-
propriate health care for specific 
clinical circumstances. (Institute 
of Medicine, 1990). Clinical prac-
tice guidelines define the role of 
specific diagnostic and treatment 
modalities in the diagnosis and 
management of patients. The 
statements contain recommenda-
tions that are based on evidence 
derived from a rigorous systemat-
ic review and synthesis of the pub-
lished medical literature. Clinical 
practice guidelines are not fixed 
protocols that must be followed, 
but are intended for health care 
professionals and providers to 
consider. While they identify and 
describe generally recommended 
courses of intervention, they are 
not presented as a substitute for 
the advice of a physician or other 
knowledgeable health care pro-
fessional or provider.
The integrated care pathway 
(ICP) concept was initiated in 
1985 by Zander and Bower. ICPs 
are structured multidisciplinary 
care plans which detail essential 
steps in the care of patients with 
a specific clinical problem. They 
promote the translation of guide-
lines into local protocols and their 
subsequent application to clinical 
practice. An ICP forms all or part 
of the clinical record, documents 
the care given, and facilitates the 
evaluation of outcomes for contin-
uous quality improvement. ICPs 
can help empower patients and 
their carers (health and social). 
ICPs differ from clinical practice 
guidelines as they are utilized by 
a multidisciplinary team and have 
a focus on the quality and co-ordi-
nation of care. ICPs need to have 
a mechanism for recording vari-
ations/deviations from planned 
care. An ICP is intended to act as 
a guide to treatment. Clinicians 
are thus free to exercise their own 
professional judgments as appro-
priate. However, any alteration to 
the practice identified within this 
ICP must be noted as a variance. 
Variance analysis is a critical part 
of developing and using ICPs. The 
resulting analysis can be used to 
amend the ICP itself if, for the ma-
jority of patients, the practice is 
different to the pathway (Table 1).
The new ARIA strategy is to devel-
op recommendations which will 
be used globally and applicable 
to each individual region or coun-
try of Europe depending on the 
health system, the cultural barri-
ers, the availability and reimburse-
ment of treatments and diagnosis, 
patients and health care profes-
sionals views. They will therefore 
represent the link between guide-
lines and care pathways.
The ARIA care pathway document 
will be launched during a meeting 
at the Ministry of Health of Por-
tugal, July 1-2, 2015 organised by 
the Région Languedoc Roussillon, 
the Reference Site Network of the 
EIP on AHA and the Directorate 
General of Health of Portugal in 
collaboration with WHO GARD 
(Global Alliance against Chronic 
Respiratory Diseases). Scientific 
societies like EAACI will partici-
pate to this launch.
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ARIA: from a guideline to a care pathway (AIRWAYS ICPs)
TABLE 1
Definition of guidelines, practice protocols and ICPs *
Guideline  Clinical Practice Guidelines Integrated Care Pathway
Focus Specific clinical circumstances (SPC) Treatment and prevention
The quality and co-
ordination of care.
Definition
Systematically developed 
statements to assist practitioners 
and patient make decisions about 
appropriate health care.
A suggested course of treatment 
and/or treatment service for a 
specific diagnosis, functional 
deficit or problem area.
Structured, multi-
disciplinary plans of care.
Goals
Makes specific recommendations 
on health care and links these to 
research evidence.
Highlights major therapeutic 
intervention points.
Identifies choices of difference 
courses or paths of treatment.
Supports the 
implementation of clinical 
guidelines and protocols.
Outputs
Provides a summary and appraisal 
of the best available research 
evidence or expert consensus.
Highlights the strength of 
the evidence underlying each 
recommendation.
Provides a logical flow of 
interventions.
Provides detailed 
recommendations that build on 
those made in SPCs guidelines.
Provides detailed guidance 
for each stage in the 
management of a patient.
Users Clinicians, patients and third parties. All stakeholders
A multidisciplinary clinical 
team.
Components
1) Appraisal of literature (research 
evidence or expert consensus).
2) Summary of recommendations.
3) An outline of how guideline 
should be implemented and 
how adherence monitored.
1) List of major interventions.
2) Goals: When interventions 
should be achieved.
3) Options for different choices 
of interventions.
1) Timeline
2) Categories of care/ 
intervention.
3) Intermediate and long 
term outcome criteria.
4) A variance record
* Adapted from http://www.implementationcentral.com/guidelines_8.html, accessed May 27, 2015.
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Severe Chronic Upper Airway Diseases
• SCUAD is the acronym for Severe Chronic Upper Airway 
Diseases
• A great percentage of allergic rhinitis (AR) patients are not 
controlled and they need to use more then one or two drugs
• SCUAD is present in 10-20% of AR patients
• SCUADs have great impact for defining treatment for AR, 
including allergen immunotherapy
SCUAD is the acronym for Severe 
Chronic Upper Airway Diseas-
es suggested by Bousquet et al. 
in 2009. Actually the title of the 
paper was really self explaining, 
since it was devoted to identify 
the unmet needs in this pathologi-
cal condition. Among the different 
phenotypes of rhinitis, infectious 
and allergic rhinitis (AR) are those 
that are best characterized from a 
pathophysiologic point of view.
AR is sometimes considered a trivial 
disease and is neglected, although 
its economical burden is over 2000 
€ per patient per year. These costs 
should be multiplied by a remark-
able number of patients, since the 
prevalence of AR is quite relevant, 
so the real socioeconomic burden 
of AR is even higher. In real life, 
the majority of patients had per-
sistent symptoms (73%), and AR 
of moderate-severe degree (70%). 
The majority of patients with AR 
present with controlled symptoms 
during treatment, but many pa-
tients suffer from SCUAD. SCUAD 
defines those patients who remain 
uncontrolled despite adequate 
(i.e. effective, safe and acceptable) 
pharmacologic treatment based on 
guidelines (ARIA & EPOS). SCUAD 
accounts for 10-18% of AR pa-
tients ondergoing treatment.
SEVERE CHRONIC UPPER 
AIRWAY DISEASES3
KE Y MESSAGES
It can be envisaged that the di-
agnostic/therapeutic approach 
is not supporting a correct treat-
ment to AR patients, so they 
are worsening and developing a 
SCUAD. Patients may not under-
stand the benefits from treatment 
and compliance to treatment is 
poor. A substantial proportion of 
such patients do not reach opti-
mal pharmacological treatment.
SCUAD patients are likely to have 
impaired quality-of-life including 
social functioning, sleep, school 
and/or work performances.
Although quite a few patients 
with AR are not sufficiently con-
trolled by current treatments in 
clinical practice, the prevalence 
of uncontrolled rhinitis and its 
impact on quality-of-life or work 
are unknown. In reality, patients 
with AR reach optimal health-re-
lated quality of life (HRQoL) in just 
one third of cases, mainly due to 
comorbid asthma, while unsatis-
factory disease control was the 
primary reason why the individu-
als remaining from one third failed 
to attain optimal HRQoL.
Impacting limitations in daily life 
is reported for 45% of AR patients 
in a recent study in Italy, and 61% 
of AR patients are worried about 
possible unfavorable evolution of 
the disease. In real life, sadely, AR 
patients use automedications first, 
referring to the general practioner 
in a small percentage and of course 
even less to specialists. A recent 
survey conducted in Italy detected 
that the majority of AR patients use 
more then one single drug; 36% 
use two drugs; 13% three drugs 
and 6% more than three drugs. 
So, it is reasonable to suggest that 
quite a few SCUAD patients are 
Walter G. Canonica  
University of Genova 
Italy
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not even suspected or detected 
and that SCUAD is possibly under-
estimated in real life.
Recent data of the ISMAR study, 
performed in different parts of the 
world, suggested an extensive clin-
ical use of guidelines (Figure 1).
However, it was recently demon-
strated that although “ARIA in the 
Pharmacy” program was dissem-
inated, just 13% of pharmacists, 
are aware of the ARIA Guidelines. 
This approach is not anymore 
structured in real life as it was 
proposed in the educational pro-
grams. New initiatives are needed, 
such as the Contre les Maladies 
Chroniques pour un Vieillissement 
Actif en Languedoc Roussillon 
(MACVIA-LR) programme.
Nonetheless, because of their 
severity and socioeconomic con-
sequences, SCUADs need special 
attention to better define its prev-
alence and mechanisms. Priori-
ties for research in SCUADs can 
be listed as: definition of geno-
types/phenotypes in relation to 
disease heterogeneity, immune 
responses (innate and specific), 
and inflammation; assessment of 
prevalence, burden, and costs of 
different causes of SCUADs; as-
sessment of SCUAD comorbidi-
ties; development of new forms 
of treatment; longitudinal evalua-
tion of SCUADs to find preventive 
strategies.
Because of the economic impact, 
some Regulatory Bodies are re-
stricting the reimbursement of 
Allergen immunotherapy ( AIT) 
mainly to SCUAD. This is a further 
reason to promote phenotypic 
characterisation and stratifica-
tion of allergic patients, charac-
terisation of SCUAD patients and 
characterisation of AR patients 
to be treated by AIT. In this re-
spect, three innovative tools (AIR-
WAYS-ICP, the allergy sentinel 
network and AIRWAYS-CDSS) will 
be combined in the MACVIA-AR-
IA Sentinel NetworK (MASK) and 
will make it possible to assess 
some of the unmet needs in re-
search of AIT (Table 1).
The final remark should be con-
sistent with the previous data on 
SCUADs, since because of their 
severity and socioeconomic con-
sequences, SCUADs need special 
Figure 1 Use of guidelines reported by physicians [Number and percentage of physicians]. Physicians answered to 
the following question: Do you know ARIA, GINA or other guidelines? Do you find guidelines are useful in categorizing 
patients? Are guidelines useful to find the best treatment for your patients? (Reproduced from Baena-Cagnani CE, 
Canonica GW, Zaky Helal M, et al. The international survey on the management of allergic rhinitis by physicians and patients 
(ISMAR). World Allergy Organ J 2015;8:10.)
Severe Chronic Upper Airway Diseases
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TABLE 1
MASK innovative goals
Assessment of prevalence and severity of allergic diseases.
Phenotypic characterisation of allergic patients, stratification of patients, char-
acterisation of SCUAD patients and characterisation of patients to be treated 
by AIT.
Randomised controlled trials (placebo-controlled or real life cluster randomised 
trials): assessment of efficacy (during the allergen exposure) and the safety 
(during AIT administration)
Follow up of patients in clinical settings during AIT
Follow up of patients in clinical settings after AIT has been stopped.
attention in daily clinical practice 
and in research to better define 
their prevalence, risk factors, se-
verity, mechanisms and novel 
treatments.
KEY REFERENCES
1. Bousquet J, Bachert C, Canonica 
GW, Casale TB, Cruz AA, Lock-
ey RJ, et al. Unmet needs in se-
vere chronic upper airway disease 
(SCUAD). J Allergy Clin Immu-
nol 2009;124:428-433.
2. Petersen KD, Gyrd-Hansen D, 
Dahl R. Cost of illness of Aller-
gic Rhinitis. Allergol Immuno-
pathol 2005;33:296-302.
3. Hellings PW, Fokkens WJ, Akdis C, 
Bachert C, Cingi C, Dietz de Loos 
D, et al. Uncontrolled allergic rhi-
nitis and chronic rhinosinusitis: 
where do we stand today? Aller-
gy 2013;68:1–7.
4. Bousquet J, Addis A, Adcock I, 
Agache I, Agusti A, Alonso A, et al. 
Integrated care pathways for air-
way diseases (AIRWAYS-ICPs). Eur 
Respir J 2014;44:304-323.
5. Bousquet J, Michel J, Standberg T, 
Crooks G, Iakovidis I, Gomez M. 
The European Innovation Partner-
ship on Active and Healthy Ageing: 
the European Geriatric Medicine 
introduces the EIP on AHA Col-
umn. Eur Geriatr Med 2014;5:361-
362.
6. Baena-Cagnani CE, Canonica GW, 
Zaky Helal M, Gómez RM, Compa-
lati E, Zernotti ME, et al. The inter-
national survey on the management 
of allergic rhinitis by physicians and 
patients (ISMAR). World Allergy Or-
gan J 2015;8:10.
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Important research questions in chronic upper airways diseases
• Further research regarding the diagnostic, therapeutic and 
patient-related factors that are responsible for uncontrolled 
upper airway diseases are needed
• Endotypes and phenotypes of AR and CRS should be 
established with a consensus after better understanding of 
their mechanisms
• Evidence for the long-term effect for subcutaneous allergen 
immunotherapy (SCIT) are lacking as well as a head-to-head 
studies comparing SCIT to sublingual allergen immunotherapy 
(SLIT)
• There is need for further identification of potential obstacles 
and of measures that will enhance a better compliance for 
allergen immunotherapy
• Early biomarkers for SCUAD development, therapy responses 
in AR and CRS and patient selection for AIT are needed
• For non-allergic rhinitis (NAR) there is a need for better 
understanding of its pathophysiology and risk factors, as NAR 
is a heterogeneous disease
• For chronic rhinosinusitis with and without nasal polyps, there 
is a further need for larger randomised placebo-controlled trials 
investigating the effect of existing and novel medical therapy
State-of-the-art documents like 
Allergic Rhinitis and its Impact on 
Asthma (ARIA) and the European 
Position Paper on Rhinosinusitus 
and Nasal Polyps (EPOS) provide 
clinicians with evidence-based 
treatment algorithms for allergic 
rhinitis (AR) and chronic rhinosi-
nusitis (CRS). However, a signifi-
cant number of patients with AR 
and CRS continue to experience 
bothersome symptoms despite 
adequate treatment. This group, 
the so-called severe chronic up-
per airway disease (SCUAD) rep-
resents a continuous therapeutic 
challenge. Further research re-
garding the diagnostic, therapeu-
tic and patient-related factors that 
are responsible for uncontrolled 
upper airway diseases are needed.
Allergen immunotherapy (AIT) is 
already an available causal treat-
ment for AR. Subcutaneous immu-
notherapy (SCIT) is in most cases 
effective in the short term (3-4 
years). However, its long-term ef-
ficacy is still unclear. Recent data 
indicate that sublingual immuno-
therapy (SLIT) is an effective treat-
ment modality for seasonal AR but 
head-to-head studies comparing 
SLIT to SCIT are needed. SCIT and 
SLIT are both safe and effective 
treatments for AR, but strict com-
IMPORTANT RESEARCH 
QUESTIONS IN CHRONIC 
UPPER AIRWAYS DISEASES
4
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pliance is crucial to achieve good 
clinical effects. There is, conse-
quently, a need for further identi-
fication of potential obstacles and 
of measures that will enhance a 
better compliance in AIT.
Non-allergic rhinitis (NAR) can be 
defined as chronic nasal symp-
toms that are not caused by 
IgE-dependent mechanisms or re-
lated to structural anomalies. Sev-
eral causes include hormonal im-
balance, physical/chemical agents, 
psychological factors, air pollution 
and certain drugs. Taking into ac-
count the heterogeneity of NAR 
there is a need for better under-
standing of the pathophysiology 
of the disease and its risk factors, 
Paul Van Cauwenberge Hanne Vanmaele
Gent University 
Belgium
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to guide us toward an improved 
diagnosis and therapy.
Local allergic rhinitis (LAR) is char-
acterized by the presence of a 
nasal Th2 inflammatory response 
with local production of specific 
IgE antibodies and a positive re-
sponse to a nasal allergen prov-
ocation test without evidence 
of systemic atopy. According to 
one report the prevalence of LAR 
tends to be up to 25% in subjects 
affected with persistent rhinitis 
presenting a comorbidity and the 
clinical pattern similar to AR. The 
real prevalence of LAR in the gen-
eral population remains, however, 
unknown and is probably overes-
timated.
With regard to chronic rhinosinus-
itis (CRS) with and without nasal 
polyps, there is a further need for 
larger randomised placebo-con-
trolled trials investigating the ef-
fect of existing and novel medical 
therapy. A better understanding 
of the pathogenesis and factors 
enhancing mucosal inflammation 
is crucial for the development of 
new diagnostic and therapeutic 
tools. The main objective for fu-
ture research should be the iden-
tification of clinical parameters, 
infectious agents, inflammato-
ry mechanisms and remodelling 
processes in patients with upper 
airway disease, so that those pa-
tients can be categorized into clin-
ically relevant subgroups based on 
clinical phenotyping and biomark-
er profiles. Defining and predict-
ing response to therapy in individ-
ual CRS patients is a challenge for 
future research.
KEY REFERENCES
1. Bachert C, Van Bruaene N, Toska-
la E, Zhang N, Olze H, Scadding G, 
et al. Important research questions 
in allergy and related diseases: 
3-chronic rhinosinusitis and nasal 
polyposis - a GALEN study. Aller-
gy 2009;64:520-533.
2. Bousquet J, Schünemann HJ, 
Samolinski B, Demoly P, Bae-
na-Cagnani CE, Bachert C, et al. 
Allergic Rhinitis and its Impact on 
Asthma (ARIA): Achievements in 
10 years and future needs. J Aller-
gy Clin Immunol 2012;130:1049-
1062.
3. Fokkens WJ1, Lund VJ, Mullol J, 
Bachert C, Alobid I, Baroody F, et 
al. EPOS 2012: European position 
paper on rhinosinusitis and na-
sal polyps 2012. A summary for 
otorhinolaryngologists. Rhinolo-
gy 2012;50:1-12.
4. Rondón C1, Campo P, Galindo L, 
Blanca-López N, Cassinello MS, 
Rodriguez-Bada JL, et al. Prev-
alence and clinical relevance 
of local allergic rhinitis. Aller-
gy 2012;67:1282-1288.
5. Papadopoulos NG, Agache I, 
Bavbek S, Bilo BM, Braido F, Car-
dona V, et al. Research needs in al-
lergy: an EAACI position paper, in 
collaboration with EFA. Clin Transl 
Allergy 2012;2:21.
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Policies and strategies to facilitate access to diagnosis and treatment for chronic upper airway diseases
• More responsibility of upper airways´ allergy care is shifting 
to primary care. The Primary Care Physicians need organized 
education to improve their skills for the diagnostics and 
management of rhinoconjunctivitis and rhinosinusitis
• Allergy testing centers should be formed in public health care 
to serve all practitioners in the region. This is for better quality 
of the testing itself as well as for proper result interpretation
• National or regional Allergy Plans are recommended to improve 
the care of multifaceted allergic conditions. Local groups 
of experts and stakeholders decide the division of labour, 
supervise the management processes and follow up results as 
well as costs
PRACTITIONER LEVEL
The vast majority of all allergy 
patients are managed by the gen-
eral practitioners (GP) (or gen-
eral allergists) in the outpatient 
care. This work is supplemented 
by ENT-specialist -, and hospi-
tal based care, if extensive rhi-
noscopic examinations, CT-scan 
or surgery are needed. Every GP 
or general allergist should have 
the equipment to perform sim-
ple anterior rhinoscopy as well as 
otoscopy. The GPs should detect 
severe mucosal inflammation, 
infectious secretion, polyposis, 
obvious tumors and marked an-
atomical changes like septum 
deviation. The GPs should have 
an easy access to x-rays or ultra-
sound examination to diagnose 
sinusitis and mucosal swelling. 
Many GPs are also able to drain 
maxillary sinuses.
Management of allergic upper air-
ways conditions is not taking place 
in a vacuum. If the patient is atopic, 
often lung -, skin -, and sometimes 
gastrointestinal symptoms co-ex-
ist. These co-morbidities need at-
tention to control the common in-
flammatory condition (Table 1).
SOCIETAL LEVEL
There is no straightforward trend 
of worsening in allergy; mild symp-
POLICIES AND STRATEGIES TO 
FACILITATE ACCESS TO DIAGNOSIS AND 
TREATMENT FOR CHRONIC UPPER 
AIRWAY DISEASES
5
KE Y MESSAGES
toms often improve, even without 
treatment. For mild rhinoconjunc-
tivitis, guided self-management 
and follow-up are generally suffi-
cient. Extensive diagnostic exam-
inations should be performed if 
the symptoms continue, become 
more severe and cause disability 
or marked inconvenience.
Tari Haahtela  
Helsinki University Hospital 
Finland
TABLE 1
How to improve the management of rhinitis and asthma
Allergic rhinitis is treated 
better
Ask asthma symptoms in every rhinitis patient.
Measure lung function (PEF, spirometry) in chronic 
rhinitis patients
Look at the eye conjunctiva
Look at the skin
Guide the patient to self-management “Rhinitis 
Control Card” etc.
Asthma is treated better Ask rhinitis symptoms in every asthma patient
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Because of the high occurrence of 
allergies in the urbanized world, 
even the number of patients with 
severe upper airway symptoms is 
high, and the healthcare system 
should allocate resources to man-
age them. Severe symptoms cause 
the majority of costs, which can 
be considerably reduced by pre-
ventive and good symptom con-
trol (Figure 1).
Diagnostic allergy practices vary 
greatly between countries and 
even in the same country. The 
GPs should be able to refer their 
patients to simple skin prick test-
ing to common allergens. The test 
answers to two basic questions: 
1) does the patient have an atopic 
disposition (any positive, at least 
3 mm wheal reaction), 2) is there 
a causal relationship of any of the 
tested allergen and current symp-
toms?
In the Finnish Allergy Programme 
2008-2018 public health allergy 
testing is centralized to large hos-
pitals, which give testing service 
to the whole region, also to GPs. 
This strategy has considerably im-
proved the quality of testing and 
interpretation of results. Diag-
nosing the upper airway allergies 
needs precision and both under- 
and over-diagnostics should be 
watched. The former causes un-
necessary suffering and the latter 
overuse of drugs.
As improving immune tolerance is 
increasingly emphasized in mod-
ern allergy treatment, the patients 
should have a better access to 
allergen immunotherapy (AIT). 
This is now feasible when AIT in-
jections are more and more turn-
ing to sublingual immunotherapy 
(SLIT) with tablets and drops. An 
allergy trained GP should be able 
to start SLIT and follow it up.
It is crucial that the management 
chains and processes are regional-
ly thought over, written down and 
organized between GPs, allergy 
testing centers and specialist care 
units. Basically: who is doing what 
and when? A national or region-
al “Allergy Plan” is very useful in 
facilitating comprehensive allergy 
care and co-operation between 
different healthcare units with the 
aim of better management and 
less costs.
KEY REFERENCES
1. Teppo H, Revonta M, Haahtela T. 
Allergic rhinitis and asthma have 
generally good outcome and little 
effect on quality of life - a 20-year 
follow-up. Allergy 2011;66:1123-
1125.
2. Haahtela T, von Hertzen L, Mäkelä 
M, Hannuksela M; Allergy Pro-
gramme Working Group. Finnish 
Allergy Programme 2008-2018-
-time to act and change the 
course. Allergy 2008;63:634-645.
3. Haahtela T, Burbach GJ, Bachert 
C, Bindslev-Jensen C, Bonini S, 
Bousquet J, et al. Clinical relevance 
is associated with allergen-specific 
wheal size in skin prick testing. Clin 
Exp Allergy 2014;44:407-416.
4. Lodrup Carlsen K, Haahtela T, 
Carlsen KH, Smith A, Fosse AM, 
Bjerke M, et al. Integrated allergy 
and asthma prevention and care. 
Report of the MeDALL/AIRWAYA 
ICPs meeting at the Ministry of 
Health and Cere Services, Oslo, 
Norway. Int Arch Allergy Immu-
nol 2015;in press.
Figure 1 The schematic allergy pyramid. Most of the allergy symptoms are mild 
or intermittent, but due to high prevalence, severe symptoms are also common 
and cause majority of the costs.
Policies and strategies to facilitate access to diagnosis and treatment for chronic upper airway diseases
Mild symptoms 70%
Moderate 
symptoms 20%
Severe 
symptoms 
10%
Disease severity Costs
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Policies and strategies to reduce risk factors for allergic rhinitis and chronic rhinosinusitis
• Many factors are known to be associated with the development 
of allergic rhinitis (AR) and chronic rhinosinusitis in genetically 
predisposed individuals and these factors can be controlled by 
implementation of effective public policies
• Public policies in controlling outdoor environmental pollution, re-
ducing environmental tobacco smoke exposure and implementa-
tion of building codes may reduce the related environmental risk
• Global warming is likely to affect the environmental compo-
sition and distribution of pollen allergens resulting in possible 
increase in AR
• Proper environmental control in the workplace can limit occu-
pational exposure thereby reducing morbidity associated with 
occupational rhinitis
Many risk factors are known to 
be associated with manifestations 
of allergic conditions including 
allergic rhinitis (AR) and asthma. 
However, the exact roles of these 
factors in the inception of AR and 
chronic rhinosinusitis (CRS) are 
not clear. The rapid increase of AR 
with urbanization clearly suggests 
the importance of environmen-
tal factors in the development of 
AR. The implicated factors include 
indoor and outdoor allergen expo-
sure, environmental air pollutants 
including tobacco smoke expo-
sure, and indoor humidity (Figure 
1). The most important predispos-
ing factor for rhinosinusitis is AR 
and adequate treatment of AR will 
reduce the burden of rhinosinus-
itis. Effective implementation of 
public policies regarding pollution, 
building codes, city planning and 
planting practices many help to 
reduce the burden of AR and CRS.
OUTDOOR ENVIRONMENT
Many outdoor environmental pol-
lutants, including ozone, nitrogen 
dioxide, sulfur dioxide, and partic-
ulate matter, can induce sino-nasal 
mucosal irritation and inflamma-
tion. Much of these pollutants are 
generated from burning of bio-
mass fuels and exhausts of motor 
vehicles. There were many animal 
POLICIES AND STRATEGIES TO REDUCE 
RISK FACTORS FOR ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS6
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Gary W.K. Wong  
Chinese University of Hong Kong 
Hong Kong SAR, China
Figure 1 The complex interplay between the outdoor and indoor environment.
381
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 I - G
lobal strategy for the m
anagem
ent of allergic rhiniti
s and chronic rhinosinusiti
s
studies confirming the detrimental 
effects of environmental pollut-
ants on the nasal mucosa. Human 
studies corroborated the experi-
mental findings documenting the 
association of outdoor ozone con-
centration and leucocytes in nasal 
secretions in a dose-dependent 
manner. Exposure to particular 
matter related to diesel exposure 
has been shown to increase upper 
airway expression of inflammatory 
cytokines. As there are no clear-cut 
thresholds of safety level for vari-
ous pollutants in relation to airway 
diseases, public policies should aim 
to reduce these pollutants to the 
lowest possible levels (Table 1).
Exposure to pollen is another ma-
jor risk factor for the development 
of AR. Due the increasing demand 
for green space in modern cities 
careful consideration during ur-
ban planning is needed for the 
selection of plant species thereby 
minimizing aeroallergen concen-
tration. Due to the phenomenon 
of global warming, the distribution 
and dispersion of various grass or 
tree related pollens are likely to 
change and may result in increase 
of AR across the world. Detailed 
environmental monitoring will be 
needed to document the effects 
of global warming.
INDOOR ENVIRONMENT
Environmental tobacco smoke (ETS) 
can damage the sino-nasal mucosa 
by local irritation and immune-re-
lated effects. In human studies, ex-
posure to ETS has been found to 
be associated with increased prev-
alence of CRS. Active smoking has 
also been shown to increase the 
personal risk of developing chronic 
rhinitis. Public policies in reducing 
secondhand tobacco smoke expo-
sure will likely to be associated with 
benefits in subjects prone to devel-
op chronic rhinitis.
Indoor environmental allergens, 
including house dust mites, pet al-
lergens, and mold allergens, have 
been widely implicated to be the 
major factors associated with AR. 
Poor ventilation and excessive 
humidity in households result in 
excessive growth of indoor molds 
and house dust mites thereby af-
fecting susceptible individuals. 
Public policies governing building 
codes and control of indoor hu-
midity are likely to be translated 
into health benefits with reduc-
tion of morbidity due to AR.
OCCUPATIONAL EXPOSURE
Occupational rhinitis refers to 
symptoms of the upper airways 
due to exposure to irritants or 
allergens at the workplace. Al-
though it is not as well character-
ized as occupational asthma, it is 
more likely to be underdiagnosed 
and more research is needed in 
the area. The implicated occupa-
tional agents are usually classified 
as low (<5 kDa) or high (>5 kDa) 
molecular weight agents (HMW 
or LMW). HMW agents refer to 
biological substance such as latex, 
laboratory animals, or flour. LMW 
agents are usually synthetic chem-
icals such as those found in hair 
bleachings, epoxy resins, or drugs 
which can act as immune sensi-
tizer. Symptoms typically would 
improve during holidays but get 
worse upon return to work.
Public policies in setting standards 
at work places aiming to reduce 
exposure to the related occupa-
tional agents will help in the pri-
mary and secondary prevention of 
work related AR.
KEY REFERENCES
1. Shea KM, Truckner RT, Weber RW, 
Peden DB. Climate change and al-
lergic disease. J Allergy Clin Immu-
nol 2008;122:443-453;quiz 454-5.
2. Beggs PJ. Adaptation to impacts 
of climate change on aeroaller-
gens and allergic respiratory dis-
eases. Int J Environ Res Public 
Health 2010;7:3006-3021.
3. Saulyte J, Regueira C, Mon-
tes-Martínez A, Khudyakov P, 
Takkouche B. Active or passive 
exposure to tobacco smoking 
and allergic rhinitis, allergic der-
matitis, and food allergy in adults 
and children: a systematic re-
view and meta-analysis. PLoS 
Med 2014;11:e1001611.
4. Hox V, Steelant B, Fokkens W, 
Nemery B, Hellings PW. Occu-
pational upper airway disease: 
how work affects the nose. Aller-
gy 2014;69:282-291.
TABLE 1
European Ambient Air Quality Standards *
Pollutant Concentration (µg/m3) Averaging period
Fine articles (PM2.5) 25 1 year
Sulphur dioxide (SO2)
350 1 hour
125 24 hours
Nitrogen dioxide (NO2)
200 1 hour
40 1 year
PM10
50 24 hours
40 1 year
Carbon monoxide (CO) 10 Maximum daily 8 hour mean
Ozone 120 Maximum daily 8 hour mean
* From European Commission Ambient Air Quality Standards. http://ec.europa.eu/
environment/air/quality/standards.htm, accessed May 20, 2015.
Policies and strategies to reduce risk factors for allergic rhinitis and chronic rhinosinusitis
382
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 I 
- 
G
lo
ba
l s
tr
at
eg
y 
fo
r t
he
 m
an
ag
em
en
t 
of
 a
lle
rg
ic
 r
hi
ni
ti
s 
an
d 
ch
ro
ni
c 
rh
in
os
in
us
iti
s
The role of primary health care in the management of chronic upper airway diseases
• Chronic upper airways disease are a common problem in 
primary care
• The history is the key to diagnosis
• A holistic, patient centered approach is advocated
• Specialist referral is indicated for persistent or uncontrolled 
symptoms
Chronic upper airway disease (Ta-
ble 1) is an umbrella term covering 
a multitude of potential problems, 
the most common of which are 
allergic in nature, but which may 
co-exist with and exacerbate or be 
exacerbated by another disorder.
In the general population rhinitis 
is frequently under recognised 
and managed sub optimally. The 
pharmacist is often the first per-
son an individual encounters 
when seeking alleviation from the 
symptoms of chronic upper air-
ways problems, the most common 
varieties of which are persistent 
allergic and non - allergic rhinitis. 
Over the counter remedies com-
monly available include saline na-
sal douches, nasal decongestants, 
topical nasal steroids and anti-
histamines, but this varies from 
country to country. It is strongly 
recommended that first genera-
THE ROLE OF PRIMARY HEALTH 
CARE IN THE MANAGEMENT OF 
CHRONIC UPPER AIRWAY DISEASES
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tion antihistamines are no longer 
used because of their adverse side 
effects.
Should the patient not respond, it 
is suggested that he is signpost-
ed to his general practioner (GP). 
Mild allergic rhinitis (AR) is usual-
ly managed at pharmacy level the 
result of which is that the major-
ity of those presenting in prima-
ry care have moderate or severe 
disease (Figure 1). In all instances 
of airways disease, it is wise to en-
quire about the presence of lower 
airways symptoms and in particu-
lar asthma
A major confounding factor is the 
presence of non AR, which has a 
number of aetiologies, on which 
treatment success relies on iden-
tification and removal of the aeti-
ological agent (Figure 2).
The role of the GP is thus to take 
a comprehensive, allergy focused 
clinical history, which will include 
seeking a history of precipitating, 
exacerbating and relieving factors, 
any co-morbidities, in particu-
lar asthma and any medications 
which have been tried as well as 
prescriptions for other problems 
such as hypertension, contracep-
tion or pain relief; this will be ac-
companied by a relevant physical 
examination in particular search-
ing for signs of remediable prob-
lems such as deviated nasal sep-
tum and polyps, which may point 
to salicylate sensitivity.
In all instances, exposure to ciga-
rette smoke is deleterious and ces-
sation advice should be offered. 
Having made as precise a diag-
nosis as possible a management 
plan will be drawn up informed by 
relevant guidelines. It is important 
to recognize that AR and non AR 
may co exist. The majority of pa-
tients can be managed in primary 
Dermot Ryan  
University of Edinburgh 
UK
Elizabeth Angier  
Northern General Hospital 
Sheffield, UK
TABLE 1
Chronic Upper Airway Disease
Allergic rhinitis
Nonallergic rhinitis
Chronic rhinosinusitis
Aspirin exacerbated respiratory 
diseases
Occupational airway diseases
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The role of primary health care in the management of chronic upper airway diseases
care (PC). Blood tests ( specific 
IgE) or skin prick tests, guided by 
an appropriate clinical history can 
be helpful in determining manage-
ment for those with poorly con-
trolled or persistent symptoms. 
Results should be interpreted in 
the context of the clinical histo-
ry. Patient centered care, with 
shared decision making about the 
different treatment options, after 
exploring the patient’s ideas con-
cerns and expectations is encour-
aged to ensure good compliance 
and improve outcomes. Treatment 
should ideally be tailored to indi-
vidual needs.
The presence of facial pain or 
pressure, reduction or loss of 
sense of smell accompanied by 
symptoms of nasal obstruction or 
blockage should lead the clinician 
to consider the diagnosis of rhi-
nosinusitis. This is conveniently 
sub categorized into acute, for ep-
isodes which completely resolve, 
Figure 1 Symptom severity profiles of those presenting with allergic rhinitis to primary care.
SYMPTOMS SUGGESTIVE
OF ALLERGIC RHINITIS
SYMPTOMS USUALLY 
NOT ASSOCIATED WITH 
ALLERGIC RHINITIS
2 or more of the following 
symptoms for >1hr on most days
• Watery anterior rhinorrhea
• Sneezing ( esp. paroxysmal
• Nasal pruritis
• ± conjunctivitis
• Unilateral symptoms
• Isolated nasal obstruction 
without other symptoms
• Muco-purulent rhinorrhea
• Posterior nasal drip
• Pain
• Recurrent Epistaxis
• Anosmia
Figure 2 Criteria for separating allergic rhinitis from non-allergic rhinitis in 
primary care.
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and chronic, for periods of greater 
than 12 weeks or in which com-
plete resolution has not occurred. 
Chronic rhinosinusitis (CRS) may 
be subcategorized as with or with-
out polyps. Treatment options are 
best determined following special-
ist consultation. A full exploration 
of the approach to management 
of CRS is offered by the European 
Position Paper on Rhinosinusitis 
and Nasal Polyposis (EPOS) 2012.
It is likely that future models of 
care will implement management 
strategies with the patient at the 
center of any management path-
way facilitating the escalation of 
care to those with greater levels of 
expertise and resources needed, 
within an appropriate time frame 
if symptoms are failing to come 
under control (Figure 3).
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Pharmacist 
Specialist 
Self Management
Primary care 
Patient with allergic rhinitis symptoms 
OTC medication
Improvement
Failure
Improvement
Failure
Treatment
Incorrect 
diagnosis 
Severity
Incorrect 
diagnosis 
Severity
Figure 3 Integrated care pathway for allergic rhinitis.
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The role of Patient Organisations in the management of allergic rhinitis and chronic rhinosinusitis
• Unacceptable of reduction of quality of life should not be 
tolerated, there are several solutions for improvement
• Patient organisations traditionally provide peer support, 
information and education for patients and their carers to cope 
with their disease
• The EAACI Patient Organisation Committee offers a well-
organised and sustainable platform for communication and 
dissemination of guidelines and other key recommendations 
and educational programmes, enabling mutually beneficial 
interactions between patients and clinicians
• Patient organisations revolutionised advocacy and the political 
influence of patient organisations grows as they strive for 
action and change, with the inclusion of patient representatives 
in official bodies advising on health, care and research policies
• Education and a patient-centered attitude are key steps towards 
a better management of allergic diseases
Patient organisations provide tra-
ditionally peer support, informa-
tion and education for patients to 
support their journey through the 
health care system. Patient organ-
isations aim to promote practical 
prevention and improve the quali-
ty of life (QoL) for people affected 
by health conditions and for their 
families, through patient partici-
pation and empowerment.
Allergic rhinitis (AR) and chronic 
rhinosinusitis (CRS) affect millions 
of people in Europe, and billions 
in the world, in their QoL, with-
out them realising it. Not only the 
general public but also patients 
perceive “hay fever” as something 
that causes minor disruptions and 
bearable complaints, and the ones 
who suffer from this disease most-
ly accept the reduction in quality 
of life due to AR and CRS. It is per-
ceived as something that just be-
longs to life and we cope with the 
discomfort. In general the patient 
and the general public are not 
aware that they can live life to the 
fullest, just by treating the disease 
and managing its triggers.
These chronic inflammatory dis-
eases of the upper airways do have 
a significant impact on the individ-
ual, the family and work. On a soci-
etal level the impact lies in the loss 
THE ROLE OF PATIENT ORGANISATIONS 
IN THE MANAGEMENT OF 
ALLERGIC RHINITIS AND CHRONIC 
RHINOSINUSITIS
8
KE Y MESSAGES
of workdays due to absence and 
loss of work effectiveness, thus 
generating a significant economic 
burden of annually more than sev-
eral billions of Euros on employers 
and disease-related health care. 
The mean total productivity (ab-
senteeism + presenteeism) losses 
per employee per year were 540 
Euro for allergic rhinitis, 165 Euro 
for respiratory infections, The 
mean total productivity loss per 
employee per year due to caregiv-
ing was 93 Euro for pediatric res-
piratory infections.
Patient organisations within the 
EAACI Patient Organisation Com-
mittee (POC) platform are well 
equipped to assist clinicians in de-
veloping strategies in addressing 
issues to change policies on a na-
tional and European political level. 
The POC can make itself strong 
in bringing the unrecognised and 
hidden allergic burden into the 
political and societal spotlight to 
raise awareness and initiate ac-
tions with the ultimate goal to 
relieve the societal economic bur-
den and foremost to raise the QoL 
EAACI Patient Organisation Committee
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of patients with AR and/or CRS 
and other airway diseases.
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Comprehensive management plan in allergic rhinitis – towards a patient-centered attitude
• Patient organizations are non-profit organizations that 
represent centres of excellence in the allergy field
• The services they offer range from advising individuals and 
training courses, providing information, organizing self help 
groups through to prevention projects and campaigns for the 
population at large
• Most patient organizations work on the assumption that 
allergy sufferers are self-empowering and take responsibility 
for themselves
• Patient-centered measures are to be promoted to succesfully 
tackle the allergy epidemic
ALLERGY PATIENT 
ORGANIZATIONS
Patient organizations like aha! 
Swiss Allergy Centre are mostly 
non-profit organizations that rep-
resent centres of excellence in the 
allergy field. They focus on the re-
actions of the airways, digestive 
system and skin to environmental 
allergens and irritants, thus also on 
allergic rhinitis (AR). For the sake 
of creating awareness and take al-
lergy preventive messages to the 
population, they seek visible public 
presence. Patient organizations are 
independent contact points for al-
lergy sufferers and carers, but also 
for other interested groups such 
as the media, companies, training 
centres, politics, authorities and as-
sociations. The services they offer 
range from advising individuals and 
training courses, providing infor-
mation, organizing self help groups 
through to prevention projects 
and campaigns for the population 
at large. These offerings are often 
made possible by widespread na-
tional and international networks 
and close co-operations with lead-
ing experts and professional bod-
ies in the relevant spheres. Most 
patient organizations work on the 
assumption that allergy sufferers 
are self-empowering and take re-
sponsibility for themselves.
COMPREHENSIVE MANAGEMENT PLAN 
IN ALLERGIC RHINITIS – TOWARDS A 
PATIENT-CENTERED ATTITUDE
9
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AIMS
Patient organizations want allergy 
sufferers and their families to have 
access to relevant, up-to-date and 
sound knowledge at the time and 
in the complexity, depth and form 
they need it in their respective 
situation. Sufferers shall have the 
skills, life circumstances and sup-
port they need to live their lives 
as symptom-free as possible and 
with a consistently high quality of 
life. The stakeholders in society 
shall take on their share of respon-
sibility for the health-related living 
conditions and quality of life of all 
humans.
SERVICES
To achieve these aims, patient or-
ganizations offer sufferers, carers 
and other groups very well estab-
lished services in the field of res-
piratory allergies and AR which 
are listed below.
• Expert advice. The main topics 
in connection with rhinitis dis-
cussed in those advices are list-
ed in Figure 1.
• Interdisciplinary training cours-
es and camps for children and 
adolescents. Children spend 
one week in summer or win-
ter camps such as the one in 
Davos. They are regularly in-
structed in therapeutic meas-
ures and for example daily skin 
care and get answers to every-
day questions concerning their 
allergies. The aim for the chil-
Karin Stalder Sereina Maibach George Schäppi
aha! Swiss Allergy Centre 
Berne, Switzerland
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dren is to have quality time in 
the mountains and meet other 
children, always with respect 
to their individual therapy and 
special needs in food. Contin-
uous evaluation and quality as-
surance measures illustrate the 
effectiveness of those services: 
they clearly show the positive 
effect of the kids camp on in-
dependence and cooperation 
of participating children in the 
view of their parents.
• Publication of daily updates 
of pollen forecasts (14 pollen 
types) and pollen measure-
ments (including weekly news 
alert) in close collaboration 
with the Federal Office of Me-
teorology and Climatology Me-
teoSwiss: Over 310’000 visi-
tors on www.pollenundallergie.
ch per year
• Smartphone applications for 
pollen forecasts, asthma con-
trol and documentation of al-
lergic rhinitis and related trigger 
factors including studies about 
effectiveness of self monitoring
• Prevention and information 
campaigns on current topics
• Technical presentations on cur-
rent topics
• Information about the variety 
of products and services which 
are suitable for allergy sufferers
• high-quality documentation, 
publications and information 
about respiratory allergies
Therewith, patient organizations 
support the health and quality of 
life of allergy sufferers, their fam-
ilies and potential sufferers and 
promote preventive action by a 
wide diversity of players. They 
campaign for high-quality, broadly 
accessible services such as prima-
ry prevention, with focus on living 
conditions and lifestyle and sec-
ondary prevention by improving 
patients and career skills. Aided 
by modern quality development, 
they strive for best professional 
practice.
TOWARDS A PATIENT-
CENTERED ATTITUDE
In a global perspective, the num-
ber of sufferers from AR steadily 
increases. The diversity of known 
allergic diseases and allergens in-
creases. At the same time, there 
is growing evidence that person-
alized measures are key for suc-
cessful prevention and therapy 
of allergies. In parallel to this, it is 
increasingly difficult to raise funds 
for patient organization activi-
ties. Today, allergy patient organ-
izations are heavily challenged by 
these facts. By choosing the ideal 
mixture of mass media communi-
cation (online and print), smart-
phone applications and individual 
advising on a one-to-one or one-
to-few basis, this challenge has 
to be and will be mastered effi-
ciently. In addition, online-based 
self-monitoring tools and person-
alized website surfaces can sup-
port patient-centered measures 
against the AR epidemic (Figure 2).
Comprehensive management plan in allergic rhinitis – towards a patient-centered attitude
Figure 1 expert advices with indicated number of phone calls and e-mails in 2014.
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Figure 2 Health 2.0 and the patient 
centered attitude.
Comprehensive management plan in allergic rhinitis – towards a patient-centered attitude
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The role of pharmacists in the management of chronic upper airway diseases
• Pharmacists are trusted health professionals
• Many patients with allergic rhinitis (AR) are seen by pharmacists
• Pharmacists are able to identify, counsel and refer to a physician 
patients with AR
• The role of pharmacists in integrated care pathways for allergic 
diseases is essential
Rhinitis is a highly diverse chron-
ic disease spanning from mild 
intermittent rhinitis to chronic 
rhino-sinusitis with polyps and se-
vere chronic upper airway disease 
(SCUAD). Multidisciplinary inte-
grated care is necessary to reduce 
the burden of chronic diseases. A 
significant proportion of patients 
with rhinitis self-manage the con-
dition and often the pharmacist is 
the first healthcare professional 
that a person with nasal complains 
contacts. Pharmacists are trusted 
in the community and are easy to 
access. As such, pharmacists are 
an important part of the multidis-
ciplinary healthcare team acting 
at different steps of rhinitis care 
pathways.
Pharmacists are important in 
many areas of intervention in al-
lergic rhinitis (AR):
1) Recognizing (identification)
2) Risk assessment/stratification
3) Over-the-counter treatment
4) Patient education
5) Referral to a physician
6) Teaching the technique for 
topical treatment and ensur-
ing adherence to treatment
A good awareness of the phar-
macist for recognizing AR and its 
main co-morbidities is mandatory 
to offer to the patient stratifica-
THE ROLE OF PHARMACISTS IN 
THE MANAGEMENT OF CHRONIC 
UPPER AIRWAY DISEASES
10
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tion of risk severity, and co-mor-
bities assessment (e.g. asthma).
Simple algorithms and tools are 
essential to routine implementa-
tion of these steps. Standardized 
and validated tools are available to 
assess the diagnosis of AR, to rec-
ognize an urgent medical referral 
(eg unilateral bleeding), to assess 
rhinitis severity, impact on the pa-
tient’s quality of life and control 
(Figure 1). A simple visual ana-
logue scale (VAS) on the bother-
some of nasal symptoms has been 
shown to be a sensitive tool for 
quantitative evaluation of severity 
of AR. VAS is highly responsive to 
change during treatment and very 
quick to complete, making it ideal 
for daily or frequent monitoring 
of AR. In addition The Control of 
Allergic Rhinitis and Asthma Test 
(CARAT) can help identify patients 
with uncontrolled rhinitis and/
or asthma in pharmacy settings. 
These and other tools can help 
pharmacists to give optimal ad-
vice for patients with rhinitis. This 
advice can be over-the-counter 
treatment, topical treatment tech-
nique or referral to a physician, 
based on simple decision making 
algorithms (Figure 2).
Initiatives such as MACVIA–LR 
(Contre les Maladies Chroniques 
pour un Vieillissement Actif en 
Languedoc-Roussillon; Fighting 
Chronic Diseases for Active and 
Healthy Ageing)-ARIA (Allergic 
Rhinitis and its Impact on Asth-
ma) in the pharmacy will help 
pharmacists to implement good 
practices contributing to a com-
munity-based integrated care of 
patients with AR.
Joao A. Fonseca  
University of Porto 
Portugal
Olga Lourenço  
University of Beira 
Interior, Covilhã, Portugal
Jean Bousquet  
University Hospital 
Montpellier, France
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The role of pharmacists in the management of chronic upper airway diseases
Figure 1 Instruments to assess of severity, symptoms and control and in allergic rhinitis and rhinosinusitis.
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The role of pharmacists in the management of chronic upper airway diseases
Figure 2 Decision making 
algorithms for pharmacists in rhinitis: 
a) first visit; b) follow up.
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The role of schools in the management of chronic upper airway disease
• Students with chronic upper airway disease and comorbid 
diseases should be identified and recorded as part of the 
registration process in school
• Students with chronic upper airway disease are encouraged to 
have their medications readily available and safely stored at all 
time
• School staff should be knowledgeable about allergic rhinitis 
and its comorbidities, and should be able to handle worsening 
symptoms
• Good indoor air quality in the school must be provided by 
reducing indoor air pollutant sources, including allergens, and 
by improving indoor ventilation
Allergic rhinitis (AR), the most 
prevalent chronic allergic disease 
in children, and chronic rhinosi-
nusitis (CRS) can have consider-
able negative impact on children. 
They both affect children’s quality 
of life, cognitive function, learning 
ability and the decision making 
process, thus resulting in signif-
icant impairment of the school 
performance (presenteeism). Un-
der-diagnosed or untreated AR of-
ten exacerbates comorbid asthma 
and also causes school absentee-
ism or presenteeism.
Children spend most of their time 
in schools. Indoor and outdoor air 
quality is important, especially in 
children with vulnerable airways. 
Exposure to indoor allergens, such 
as house-dust mite, cat, dog, cock-
roach, fungi and mould can trigger 
symptoms in sensitized children 
with AR. Exposure to various in-
door pollutants at schools, such 
as volatile organic compounds 
(VOC), depending on the use of 
marker boards, to cleansing or dis-
infecting chemicals for the class-
room cleaning, and to particulate 
matter (PM) from chalk and dust 
may deteriorate airway disease. 
Additionally, poor indoor ventila-
tion with exposure to high levels 
of CO2 can reduce concentration 
ability of children.
THE ROLE OF SCHOOLS IN THE 
MANAGEMENT OF CHRONIC 
UPPER AIRWAY DISEASE
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The EAACI/GA2LEN Task Force 
has recently developed recom-
mendations for the management 
of the allergic child at school (Ta-
ble 1). A comprehensive approach 
focused on the child with AR and 
its comorbidities can provide a 
comfortable school life (Figure 1). 
Zeynep Tamay  
Istanbul University Medical Faculty 
Turkey
TABLE 1
Action points (EAACI/GA2LEN Task Force)
Students should be able to take reliever medication for allergic rhinitis (AR) and 
chronic rhinosinusitis (CRS) at school, as required
Students should not be criticized for frequently displaying symptoms of AR or 
CRS
Teachers should be aware of increased symptoms of AR or CRS during outdoor 
exercise activities in peak seasons
Schools should aim to reduce indoor air pollutant sources including allergens, 
and improve indoor ventilation
Teachers should be aware of and take into consideration the negative effect of 
AR or of CRS on examination performance.
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The head teacher, responsible for 
school policy, should aim to create 
an allergy friendly school. Regu-
lar education programs about AR 
and its comorbidities should be 
arranged to improve knowledge 
level and attitude of the school 
staff. Newly admitted students 
with chronic upper airway disease 
and comorbid diseases should be 
identified and recorded during 
the school registration process. 
The status of the illness should be 
checked at the annual re-registra-
tions. Students with chronic upper 
airway disease are encouraged to 
have their medications readily 
available and safely stored at all 
times. Additionally, relieving med-
ication must be always available in 
the school. Schools should aim to 
reduce indoor air pollutant sourc-
es including allergens, improve 
indoor ventilation, and maintain 
healthy indoor and outdoor air 
quality.
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Improved indoor ventilation 
(CO2↓)
No tobacco smoking Child’s medical record (allergens, medicine)
Knowledgeable school staff 
that can handle worsening Easy access to medicine
Reduced indoor allergens 
(dust mite, cockroach, 
domestic animals, spore 
molds)
Reduced indoor pollutants 
(VOC ↓, PM↓, etc)
Regular training programs 
for school staff
Child with AR/CRS
The role of schools in the management of chronic upper airway disease
Figure 1 Management of the child with chronic upper airway disease at school.
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Managing allergic rhinitis and chronic rhino-sinusitis in developing countries - focus on Latin America
• Allergic rhinitis (AR) is highly prevalent among Latin American 
countries
• Many factors can contribute to this high prevalence, some of 
them local and some comparable to other regions worldwide
• Correct management of AR depends on access to trained 
doctors and treatment available
• There is no data available on sinusitis epidemiology for Latin 
American countries
Allergic rhinitis (AR) represents 
probably the most prevalent 
chronic non-communicable dis-
ease globally, as well as in Latin 
America. The ISAAC study evi-
denced that over 30% of paedi-
atric population present current 
symptoms of AR, while almost 
20% suffer from current rhi-
no-conjunctivitis, the most indic-
ative epidemiological tool for up-
per airway atopic condition. The 
remarkable prevalence of AR in 
certain Latin American countries 
positions them among the highest 
incidence worldwide (Table 1).
There was no significant correla-
tion between markers of country 
development such as gross na-
tional product (GNP), infant mor-
tality rate or environmental pol-
lution, and the prevalence of AR 
symptoms. However, conditions 
like environmental tobacco smoke 
or active smoking could have a 
detrimental impact in this popula-
tion (Figure 1).
There is an intriguing report of 
nasal allergies prevalence below 
10% corresponding to 8 Latin 
American countries, based on 
telephone interviews asking for 
AR diagnosis. This wide difference 
could be attributed to methodol-
ogy or to under-diagnosis. One of 
MANAGING ALLERGIC RHINITIS 
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the most common co-morbidity of 
AR is sinusitis, but no data is avail-
able for prevalence of chronic rhi-
no-sinusitis in Latin America.
A survey of 20 physicians and 200 
patients from Argentina on the 
management of AR, showed that 
more than half of patients had 
moderate to severe AR, and two 
out of three had sinusitis, with a 
similar proportion having a sig-
nificant impact on the quality of 
life. Preferred treatment both for 
patients and physicians (60% of 
respondents) were oral anti-his-
tamines and nasal steroids, in 
accordance with first treatment 
options suggested by guidelines. 
Nonetheless, 40% of patients re-
ceived an inappropriate AR man-
agement. Scarce availability and 
poor affordability of essential 
drugs like nasal corticosteroids in 
Latin American countries could 
also explain the elevated preva-
lence and severity of AR. Accord-
ing to current reports 81 million 
of children live in poverty in Latin 
America and appropriate access 
to a correct evaluation and treat-
ment is not guaranteed at all.
Allergic Rhinitis and its Impact on 
Asthma (ARIA) initiative is one of 
the engines promoting the knowl-
edge and management of AR in 
Latin America, in order to achieve 
the necessary changes in health 
policies that finally benefit this 
huge population affected.
KEY REFERENCES
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TABLE 1
Prevalence of rhinitis and related symptoms among Latin-American children according to language they spoke – 
ISAAC phase three 
N Rhinitis 
ever
Rhinitis last 
12m
Rhinitis & 
ocular symp-
toms 12m
Daily inter-
ference 
12m
Hay fever 
ever
Current 
symptoms 
RC
Current 
symptoms of 
severe RC
6 to 7 yr old
Portuguese 21,799 32.8 25.6 25.6 2.1 19.3 11.7 1.3
Spanish 72,052 35.1 29.7 13.8 1.7 12.6 13.1 1.1
OR 95%CI 0.96* 0.86* 0.87* 1.33* 1.74* 0.92* 1.27*
0.93–0.99 0.83–0.89 0.85–0.93 1.19–1.48 1.67–1.81 0.88–0.97 1.10–1.45
Total  
13 to 14 yr old 93,851 34.6 28.7 13.5 1.8 14.6 12.7 1.2
Portuguese 58,418 40.2 28.7 15.2 1.2 22.6 13.3 0.8
Spanish 107,499 46.7 37.3 20.9 1.6 13.8 19.5 1.2
OR 95%CI 0.76* 0.68* 0.68* 0.75* 1.81* 0.64* 0.69*
0.75–0.78 0.66–0.69 0.66–0.69 0.69–0.82 1.77–1.86 0.62–0.65 0.61–0.76
Total 165,917 44.4 34.3 18.9 1.5 17.5 17.3 1.1
RC, rhinoconjunctivitis.
Chi-square *p<0.05, **p<0.001
Figure 1 Association of rhinitis with both personal and parental smoking. 
(From Gómez M, Vollmer WM, Caceres ME, et al. Adolescent smokers 
are at greater risk for current asthma and rhinitis. Int J Tuberc Lung Dis 
2009;13:1023-1028).
Managing allergic rhinitis and chronic rhino-sinusitis in developing countries - focus on Latin America
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Managing allergic rhinitis and chronic rhinosinusitis in developing countries – focus on Eastern Europe
• Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are wide-
spread in Eastern European Countries (EECs) and follow the 
increasing trend  in developed countries
• More epidemiological studies on AR and CRS in EECs are needed
• In EECs networks of specialized allergy centers are set for 
diagnostics and treatment of AR and CRS
Allergic rhinitis (AR) is the most 
widespread allergic disease, 
reaching a prevalence of up to 
40% in some developed coun-
tries. In the East-European coun-
tries (EECs) data on prevalence of 
AR is rather sparse in comparison 
to Western Europe, reflecting the 
lower level of funding for epide-
miological projects. In addition, a 
huge number of subjects, mainly 
with intermittent and/or mild AR 
don`t reach the doctor’s offices.
Data from classical epidemiolog-
ical studies on AR prevalence in 
EECs derive from studies in the 
1950-1990s period. In the Rus-
sian Federation and the CIS coun-
tries prevalence studies were per-
formed using ISAAC approach and 
revealed a prevalence for AR rang-
ing from 1.4 to 39.7% in different 
countries (Table 1). Higher preva-
lence of AR was associated with 
intense urbanization and industri-
alization. The survey showed that 
1.3-52 % of young children suffer 
from AR, while the prevalence in 
older children was 20-26%. For 
the Russian Federation the preva-
lence of AR of 13-39% was found 
in children and adults depending 
on climate, geographic and eco-
logic features of the region. In the 
last 20 years, the prevalence of 
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AR in the Russian Federation in-
creased 4-6 times, peaking at the 
age of 18-24. The incidence of AR 
in Ukraine was 22% and of CRS 
of 20-40%. The urban population 
was more frequently affected with 
20% of nearly 8 million people 
compared to the rural population 
where 14% presented with AR. In 
Belarus, the AR prevalence was 
nearly 4%, with children more fre-
quently affected (5.6%). In Poland, 
almost 25% of adult population 
was affected by AR and 16% by 
CRS. A study on 933 patients in 
Hungary found that 52.5% of pa-
tients suffered from seasonal AR 
and 35.1% from perennial AR. In 
Bulgaria the prevalence of AR was 
found to be 16%, more than half 
associated with pollen sensitiza-
tion.
The main risk factors for the de-
velopment of AR in EECs depicted 
by the surveys were family histo-
ry of atopy, sensitization to aller-
gens, smoking, air pollution and 
climate factors. In Russia, Belarus, 
Poland, Bulgaria and most other 
EECs networks of specialized al-
lergy centers for diagnostics and 
treatment of AR are set in place or 
under development. A deficiency 
in the EECs is the insufficient use 
of educational programs for AR 
and CRS. The main disease-mod-
ifying treatment of AR is allergen 
immunotherapy.
KEY REFERENCES
1. Khaitov RM, Luss LV, Aripova IV, 
Lysikova IV, Ilyna NI. Prevalence of 
children bronchial asthma, allergic 
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and clinical immunology. – 1998. 
#9. – P. 58-69.
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pathogenesis. The current view of 
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urban and rural children in Grodno 
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Immunol 2012;23:339-346.
5. Szilasi M, Gálffy G, Fónay K, Márk 
Z, Rónai Z, Szalai Z, et al. A sur-
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nitis in Hungary from a specialist's 
perspective. Multidiscip Respir 
Med 2012;7:49.
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acteristics of a patient population 
seeking medical advice for nasal 
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236.
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Managing allergic rhinitis and chronic rhinosinusitis in developing countries – focus on Eastern Europe
TABLE 1
AR and CRS prevalence in EECs
Country АR CRS Survey
Russia 13-39% 15%
Khaitov RM, 1998
Ivanchenko OA, 2012
Ukraine 22% 20 – 40% Pukhlik BM, 2008
Belarus 3.84% 9.71
Shpakou A, 2012
Хоха РН, 2014
Moldova 4.8 – 9.8% - Andriesh LP, 1994
Bulgaria 16% - Mileva J, 2000
Hungary 35.1-52.5% - Szilasi M, 2012
Poland 25% 16% Wardas P, 2014
Romania 14% 13 % Grigoriu IC, 2013
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Managing allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Asia Pacific
• Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) have a 
significant impact on quality of life of the affected patients 
in the Asia Pacific region and their prevalence is expected to 
continue its increase
• For both AR and CRS there are significant treatment gaps, 
challenges and unmet needs in Asia Pacific region
• Patients needs and expectation differ from present treatment 
options
• There is an urgent need to improve patient knowledge of 
treatment and management options
• Guidelines on treatment may need to be tailored according to 
regional situation in allergy
INCIDENCE & MANAGEMENT
Allergic rhinitis (AR) and chronic 
rhinosinusitis (CRS) still remain 
largely undertreated in Asia Pacif-
ic, which currently reigns amongst 
the most populated regions of 
the world. The dense population 
is further compounded by rapid 
economic development, urbani-
zation and the subsequent envi-
ronmental pollution. The true in-
cidence and prevalence of AR and 
CRS in the Asia Pacific is difficult 
to determine given the vast region 
with different socio economic and 
health care systems.
The Allergies in Asia-Pacific Sur-
vey, which was published in 2011 
reported an overall prevalence of 
8.7% for the physician-diagnosed 
nasal allergy in eight countries 
in the region after screening of 
33378 households, with 1043 
adults and 192 children includ-
ed in the survey. The prevalence 
varied from that reported for the 
developed countries to the devel-
oping countries, underlying the 
diversity in Asia Pacific. The prev-
alence ranged from 13.2 % in Aus-
tralia, to 9.1% in China, 9.6% in 
Taiwan, 7.1% in Malaysia to 12.3 
% in Vietnam and 2.5% in Philip-
pines. AR affected both adults and 
children, and the average age at 
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diagnosis was 26 years for adults 
and 9 years for children.
The geography of Asia Pacific, 
with the majority of the countries 
having a tropical and subtropi-
cal climate, influence the type of 
predominant AR, with 66% of pa-
tients having intermittent or sea-
sonal AR (SAR), and only 30% re-
porting persistent or perennial AR 
(PAR) (Figure 1).
The majority of the patients were 
treated by general practition-
ers (40%) and by ENT physicians 
(40%), with only 2-3% managed 
by allergists or respiratory physi-
cians. Investigation of allergy was 
not routinely performed, with 42% 
having had no allergy investigation 
at all. When allergy testing was 
done 9% were skin prick tested 
only, 14% blood tested only and 
17% had both tests performed.
BURDEN OF DISEASE AND 
IMPACT ON QUALITY OF LIFE
The burden of AR and CRS is well 
documented and is increasing in 
Asia Pacific with significant impact 
on quality of life (QoL), notably by 
interference with work and school 
performance, productivity, daily 
life, and sleep (Figure 2). Reports 
show that AR significantly trou-
bles 96% of adults and of children. 
The most bothersome symptoms 
included nasal congestion (78%), 
Narayanan Prepageran  
University Malaya 
Kuala Lumpur, Malaysia
401
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SECTIO
N
 I - G
lobal strategy for the m
anagem
ent of allergic rhiniti
s and chronic rhinosinusiti
s
rhinorrhea (74%) and sneezing 
(71%). Only 41% of adults and 
47% of children felt their symp-
toms were controlled, thus it is of 
no surprise that work productivity 
decreased from 88% to 63% when 
the patient had AR (Figure 3).
The impact of AR on the quality 
of sleep is well recognized with 
over 70% of the adults and 60% 
children indicating sleep related 
disturbances (Figure 4).
Up to 41% of children find their 
nasal allergy interfering or pre-
venting them from attending 
school, with reduction of school 
performance from 86% to 66%. 
Nearly 85% of children reported 
a significant impact of allergies on 
their day-to-day life.
Given the huge population poten-
tially affected by AR and CRS in 
Asia Pacific it might be speculated 
that the lost productivity and the 
economic consequences may be 
significantly higher compared to 
other regions.
TREATMENT PARADIGM, 
UNMET NEEDS AND PATIENTS 
PERSPECTIVE
The treatment of AR and CRS is 
well established by guidelines. 
Despite this, reports reveal that 
patients in this region are not 
achieving adequate control of 
their symptoms with up to 58% 
of adult patients claiming that 
their allergies are not optimally 
controlled despite medication. 
Although up to 67% of patients 
were on some form of treatment 
for their symptoms. The usage of 
intranasal corticosteroids (INS) 
was surprisingly very low (19-
20%), despite guidelines clearly 
Figure 1 Intermittent or perennial allergies in Asia Pacific.
Figure 2 Interference with work due to allergic diseases.
Managing allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Asia Pacific
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suggesting their usage as the gold 
standard for moderate to severe 
AR. Thus, the unsatisfactory lev-
el of disease control, may be due 
to the lower usage of INS as the 
primary treatment of choice. Even 
among the patients on INS, only 
27% were very satisfied with their 
steroid nasal spray. Reasons for 
dissatisfaction included low effi-
cacy (72%) and lack of 24-hour re-
lief (15%) (Figure 5). Some patients 
were compliant to the prescribed 
INS due to their concerns about 
side effects, long-term use, or due 
to loss of efficacy over time.
Contrary to popular perception 
that cost would be an issue in Asia 
Pacific, cost was not reported as a 
major factor among uncontrolled 
patients. Low patient education 
and awareness appears to be 
equally important, as only 20% of 
patients claim to have some infor-
Figure 3 Reduction of work productivity due to allergic rhinitis.
Figure 4 Interference with sleep in AR.
Managing allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Asia Pacific
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mation about INS and up to 50% 
of patients reported that they have 
never been shown how to use their 
nasal spray. It is also interesting to 
note that up to 40% of patients 
visit and get advice on allergy from 
their pharmacist, thus education 
on AR management should be 
provided to all health care profes-
sionals (HCP) and not restricted to 
medical doctors alone.
FUTURE DIRECTION AND 
CHALLENGES
The prevalence of AR and CRS in 
Asia Pacific will continue to rise 
drastically in tandem with the ex-
ponential economic growth and ur-
banization in this region. Increased 
risk factors for atopy associated 
with congested modern urban liv-
ing, predominant in major Asian 
cities, in parallel with increased en-
vironmental pollution will increase 
the total burden of allergic diseas-
es on the already precarious health 
care systems in this region. Asia 
Pacific is unique in the fact that it 
contains a highly diverse popula-
tion, with marked variation in the 
genetic background as well in the 
living environments.
There may be a need to tailor the 
existing guidelines according to 
the different needs and challeng-
es in this region. A recent study 
on the acceptance of the ARIA 
guidelines, that is widely used by 
the HCP in Malaysia, revealed 
that although the majority com-
plied with the guideline, up to 
34% of ENTs, 42% of pharmacists 
and 11% of general practitioners 
felt that there was a need to tailor 
the guidelines to suit the regional 
problems and allergens.
CONCLUSION
Both AR and CRS have significant 
impact on the heath care systems 
in Asia Pacific, with a similar dis-
ease burden as for the rest of 
the world and with up to 90% of 
patients reporting an impact on 
quality of life. The rapid economic 
growth with corresponding pollu-
tion and urbanization will increase 
the prevalence of allergic disor-
ders, with increasing socio-eco-
nomic impact in the future.
There is an urgent need to ac-
knowledge the significant the im-
pact of these disorders on societal 
costs and the differences in the 
treatment paradigm, challenges 
and unmet needs for the different 
areas in the region. Poor patient 
and HCP education has a signifi-
cant negative impact. Guidelines 
on treatment of allergic diseases 
need to be adapted according to 
the local needs and challenges.
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Figure 5 The reason patients were dissatisfied with their nasal spray.
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Management of allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Africa
• The prevalence of allergic rhinitis (AR) and of chronic 
rhinosinusitis (CRS) in African countries is increasing due to 
increased urbanization and pollution. The advent of HIV-AIDS 
has further worsened the incidence of CRS in Africa
• The diagnosis of AR in Africa is largely clinical, due to the non-
availability of allergy tests in most countries. Screening for 
AR using total serum IgE can be deceptive in Africans since 
helminthic infections, rather than genetic factors, may be 
responsible for the increase in the total serum IgE levels
• Because of contending socioeconomic challenges, most patients 
are unaware of their AR and CRS. Coupled with out-of-pocket 
payment for healthcare cost, presentation to the hospital is 
often delayed, and it is not uncommon for complications to be 
present at diagnosis
• Treatment is based on the availability of essential drugs and 
their financial affordability, thus allergen immunotherapy for 
AR or endoscopic sinus surgery for CRS are not easily available
BURDEN OF ALLERGIC 
RHINITIS AND CHRONIC 
RHINOSINUSITIS IN AFRICA
Allergic rhinitis (AR) and chronic 
rhinosinusitis (CRS) are prevalent 
non communicable diseases in-
creasing around the world, even 
in Africa. These chronic diseas-
es confer a significant burden 
through direct or indirect symp-
toms, complications and cost.
In contrast to developed coun-
tries, the government health pro-
gram of many African countries 
focus only on transmissible dis-
eases, malnutrition, maternal and 
infant mortality, while data on res-
piratory diseases remain scarce. 
The prevalence of AR is very high 
(>35%) among Nigerian Africans, 
and it is likely that environmental 
factors are responsible for major 
differences with other countries. 
AR prevalence is much higher in 
urban area, especially in capital 
cities from Africa. CRS is not less 
common. The advent of HIV-AIDS 
has further worsened the inci-
dence of CRS in Africa.
Local allergens related to African 
environmental settings are not 
well known. House dust mites and 
cockroaches are reported as ma-
jor allergens in Africa, while pollen 
allergens remain poorly described. 
MANAGEMENT OF ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS IN 
DEVELOPING COUNTRIES - FOCUS ON 
AFRICA
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AR predisposes to development of 
other airway comorbidities such 
as allergic asthma, rhinosinusitis, 
nasal polyposis, adenoid hyper-
trophy and otitis media. Table 1 
shows an overview of AR and re-
lated diseases in Africa.
Both AR and CRS significantly af-
fect the quality of life of Africans 
through direct cost (payments 
to doctors for frequent consul-
tations, prescribed medications, 
over the counter (OTC) drugs, 
alternative and complementary 
drugs), indirect costs (loss of work 
hours and school days) and intan-
gible costs (loss of quality of life, 
pain and suffering, psychologi-
cal maladjustment, social costs). 
These costs become significant in 
countries with high prevalence of 
allergy and low per capital income, 
as seen both in the Anglophone 
and Francophone African coun-
tries.
Abiodun D. Olusesi  
National Hospital Abuja 
Federal Capital Teritory, Nigeria
Dieudonné Nyembue Tshipukane  
University Hospital of Kinshasa 
Democratic Republic of Congo
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TABLE 1
Overview of prevalence of allergic rhinitis and allergic related diseases in African Countries
Country, city Author, year Study population Age AR* AR** Rhinitis** RC** Wheeze** Eczema**
Morocco El KS et al. 2009 Rural Population 37.8
Morocco 
Casablanca Ait-Khaled N et al. 2007 Schoolchildren 13-14 28.1 16.0 23.0
Tunisia, Tunis Khaldi F et al. 2005 Schoolchildren 13-14 27.7
Tunisia, Grand 
Tunis Ait-Khaled N et al. 2007 Schoolchildren 13-14 14.7 15.4 13.0
Egypt, Cairo Georgy V et al. 2006 Schoolchildren nov-15 15.3
Urban Ivory 
Coast Ait-Khaled N et al. 2007 Schoolchildren 13-14 27.6 19.3 18.2
Togo, Loné Ait-Khaled N et al. 2007 Schoolchildren 13-14 14.6
Nigeria Desalu OO et al. 2009 General popu-lation 18-45 29.6
Ethiopia, 
Gondar
Hailu S et al. 
2003 Schoolchildren 14.5
Kenya, Nairobi Ait-Khaled N et al. 2007 Schoolchildren 13-14 19.8
Kenya de SM et al. 1994 Patients 48.6
Kenya Esamai F et al. 2002 Schoolchildren 13-14 38.6
Kenya, Nairobi Ait-Khaled N et al. 2007 Schoolchildren 13-14 19.8 18.0 14.9
Gabon Ait-Khaled N et al. 2007 Schoolchildren 13-14 16.5
Uganda, Ibanda Ait-Khaled N et al. 2007 Schoolchildren 13-14 16.4 13.0 7.7
Cameroon, 
Yaounde
Ait-Khaled N et al. 
2007 Schoolchildren 13-14 8.9 5.7 7.7
Congo, 
Brazzaville
Ait-Khaled N et al. 
2007 Schoolchildren 13-14 33.3 19.9 16.2
Democratic Re-
public of Con-
go, Kinshasa
Ait-Khaled N et al. 
2007 Schoolchildren 13-14 11.8 7.5 10.9
Democratic Re-
public of Con-
go, Kinshasa
Nyembue TD et al. 
2012.
General popu-
lation 5-83 13.9 30.8 24.4 15.4 6.2
Democratic Re-
public of Con-
go, Kinshasa
Nyembue TD et al. 
2012. Patients 4-89 23.9
Zimbabwe Kambarami RA et al. 1999 Children < 2 15.6
Zimbabwe Sibanda EN et al. 2003 Patients 1-62 33.0
South Africa, 
Cape Town
Ait-Khaled N et al. 
2007 Schoolchildren 13-14 20.7 20.3 13.3
South Africa, 
Cape Town
Mercer MJ et al. 
2004 13-14 33.2
Data expressed in percentage, AR: allergic rhinitis. RC: rhinoconjunctivitis. *: diagnosis clinically confirmed via either skin prick 
testing or by specific-IgE in serum. **: 12-month prevalence.
Management of allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Africa
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RISK FACTORS FOR AR AND 
CRS AMONG AFRICANS
Several risk factors are known to 
relate to AR. These include the 
genetic background, cigarette 
smoke, chemicals, cold tempera-
tures, humidity, wind, pollution, 
hairspray, wood smoke and fumes. 
A comparison of risk factors for 
AR from two studies from Africa is 
shown in Table 2. Added to these 
known risk factors are poverty, 
poor education on how to avoid 
risk factors and poor health infra-
structures, which are known to 
be prevalent in Africa, and which 
further increase the burden of the 
disease.
PECULIARITIES OF AR AND CRS 
AMONG AFRICANS
Urban migration of rural workers 
is increasing pollution in urban ar-
eas, and further amplifies the in-
cidence of AR and CRS. The lack 
of information on allergic diseas-
es in Africa can be explained by 
the shortness in physicians and 
other personnel trained in allergy 
diagnosis and management. Due 
to financial constraints, AR and 
CRS patients are primarily seen 
by nurses or by the general prac-
titioners; the education of GPs in 
some African countries is highly 
limited regarding ear, nose and 
throat diseases in general, and AR 
and CRS in particular.
The diagnosis of AR in Afri-
ca is largely clinical, due to the 
non-availability of allergy tests in 
most countries. Allergen-specific 
serum IgE is measured in a very 
limited number of private labora-
tories, and thus is unaffordable to 
most patients. Screening for AR 
using total serum IgE can be de-
ceptive in Africans since helmin-
thic infections, rather than genet-
ic factors, may be responsible for 
the increase in the total serum IgE 
levels.
Because of contending socioeco-
nomic challenges, most patients 
are often unaware of their AR and 
CRS. Coupled with out-of-pocket 
payment for healthcare cost, pres-
entation to the hospital is often 
delayed, and it is not uncommon 
for complications to be present at 
diagnosis (Figure 1). Overall the 
management of AR and CRS in 
many African countries is poorly 
developed and the quality of care 
offered is often at a low standard. 
Only some countries have imple-
mented evidence-based guideline 
recommendations. Treatment of 
AR follows the ARIA guidelines in 
most tertiary care centers.
In most African countries, pharma-
ceutical practices are unregulated, 
resulting in unfettered access to 
OTC drugs and other regulated 
drugs, with management of AR 
and CRS not based on sound ev-
idence. Treatment is based on 
the availability of essential drugs 
and their financial affordability. 
For example, chlorpheniramine 
and beclomethasone are part of 
the WHO essential drugs list and 
diseases are available and subsi-
dized, while, antileukotrienes and 
anti-IgE are not used in many low 
income countries. Antibiotic treat-
ment such as amoxicillin-clavu-
lanate is frequently used for CRS 
compared to others antibiotic 
classes due to its availability in 
deprived countries. Finally endo-
scopic sinus surgery is expensive 
and needs a specific training. Al-
lergen-specific immunotherapy is 
not easily accessible because of 
lack of trained specialists and un-
known regional allergens.
Depending on cultural and social 
barriers patients seek self-treat-
ment and unproven traditional 
therapies. There is widespread use 
of alternative and complementary 
therapy, largely because they are 
cheaper, and also because of local 
beliefs.
TABLE 2
Risk factors for allergic rhinitis identified by two African studies
Desalu et al, (2009) Olusesi, Amodu & Said, (2007) *
Dust (55.8%) Dust (65%)
Kitchen Fumes (20.7%) Smoke (60%)
Cold Weather (10.6%) Perfumes (49%)
Smoke (5.1%) Cold Weather (27%)
Fuel (gasoline) (4.6%) Red Wine (22%)
*Multiple allergy trigger reported by many patients
Management of allergic rhinitis and chronic rhinosinusitis in developing countries - focus on Africa
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Figure 1 Right upper-lateral orbital abscess complicating chronic rhinosinusitis (pre- and postoperatory).
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Managing allergic rhinitis and chronic rhinosinusitis in developing and low income countries - focus on South Asia
• Allergic rhinitis (AR) is overdiagnosed, chronic rhinosinusitis 
(CRS) is less diagnosed
• Specific allergy testing facilities are scanty
• House dust mites are the most common allergen causing AR, 
however specific allergens are noted such as paper mulberry 
tree, cannabis and Parthenium or highly allergenic dusts from 
mechanically operated wheat threshers
• The choice of treatment of AR and CRS is limited by several 
factors, and their management is often not appropriate
“Allergy” and “rhinitis” are very 
commonly used medical terms in 
South Asia. These terms are even 
used when there is no evidence 
of allergy, as the cause of any rhi-
nitis symptoms, hence they are 
over-reported. On the same note, 
the term “rhinosinusitis” is newer 
and thus less diagnosed.
Specific allergy diagnostic facilities 
are scanty in the South Asia region, 
hence the diagnosis of allergic rhi-
nitis (AR) is more often a clinically 
empirical diagnosis. In India, AR is 
rarely given the importance it de-
serves and is considered to be a 
trivial disease, despite the fact that 
symptoms of rhinitis have been 
noted to be present in 75% of chil-
dren and 80% of asthmatic adults 
and despite it's profound impact 
on the quality of life.
According to the skin allergy test-
ing data, house dust mites (Der-
matophagoides farinae) are the 
commonest cause of AR. In addi-
tion many allergens are more fre-
quently encounterd in South Asia, 
such as the allergenic pollens from 
the common paper mulberry tree, 
cannabis and Parthenium in some 
areas of Pakistan and India, where 
they reach significantly high quan-
tities in the air (Figures 1 a, b & c). 
Similarly, the production of highly 
MANAGING ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS IN 
DEVELOPING AND LOW INCOME 
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Osman Mohammad Yusuf  
The Allergy & Asthma Institute 
Islamabad, Pakistan
Figure 1 A - Paper mulberry; B - Parthenium; C - Cannabis.
A
B
C
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allergenic dusts from mechanically 
operated wheat threshers (Figure 
2) or rice huskers in South Asia 
can affect patients several miles 
downwind in wheat & rice grow-
ing countries.
Studies in India have shown that 
63–89% of adults with AR and 
65% of children have underlying 
chronic rhinosinusitis (CRS) and 
nasal polyps (NP). Even when the 
presence of NP and CRS in AR 
is sought for, inadequate treat-
ments, both medical and surgical, 
along with troublesome adverse 
effects of the medications add to 
the problem.
Although topical corticosteroids 
are now increasingly being rec-
ognized as the cornerstone of the 
treatment for AR, in most of the 
South Asian countries, anti-his-
tamines still form the first line of 
treatment. Both first and second 
generation anti-histamines are 
commonly used.
The choice of treatment is limited 
by several factors. Cost is a major 
factor, and includes the cost of 
the drug itself and the doctor’s fee 
plus the logistical costs of access-
ing healthcare (for example travel 
expense), as well as the possible 
adverse effects. Hence, many 
patients prefer to visit alternate 
medicine practitioners, for relief 
of their ailments.
KEY REFERENCES
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Managing allergic rhinitis and chronic rhinosinusitis in developing and low income countries - focus on South Asia
Figure 2 Wheat threshing.
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Managing allergic rhinitis and chronic rhinosinusitis in developing countries – focus on East Asia
• With the rapid economic development of the East-Asia 
countries, the prevalence of allergic rhinitis (AR) and chronic 
rhinosinusitis (CRS) have increased rapidly and demonstrated 
wide inter- and intra-regional differences
• The predominant CRS endotype in Asian subjects is 
characterized by a Th17 cell-mediated predominance of 
neutrophils
• Besides the use of therapies recommended by guidelines, the 
treatment of AR and CRS in East Asia also includes acupuncture 
and traditional Chinese medicine
• Optimal treatment for AR and CRS in East Asian’s should be 
tailored based on evaluation of the patients’ clinical phenotypes 
and endotypes
Despite the presence of a mark-
edly denser population compared 
to western countries, there is little 
epidemiological data on allergic 
rhinitis (AR) and chronic rhinosi-
nusitis (CRS) prevalence in the 
East-Asia region, especially in Chi-
na. The majority of the studies on 
AR in this region have primarily in-
vestigated the prevalence of dis-
ease in children and demonstrat-
ed wide inter- and intra-regional 
differences (Figure 1). Along with 
the rapid economic development 
of the East-Asia countries the 
lifestyles of the citizens have be-
come more westernized in terms 
of urbanization and dietary hab-
its, and the prevalence of upper 
airway diseases such as AR and 
CRS have increased rapidly. The 
potentiating effect of the consid-
erable increases in air pollutant 
levels on the rising prevalence of 
the respiratory disorders cannot 
be ignored (Figure 2).
As wide varieties of grass/tree 
pollen and/or mites are present 
in the different regions, these 
play an important role as tradi-
tional sensitizing allergens in the 
development of AR in East Asia. 
A number of studies from Japan 
suggest Japanese cedar pollen 
to be the most prevalent and im-
MANAGING ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS IN 
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EAST ASIA
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portant sensitizing agent across 
Japan, with seasonal AR caused 
by Japanese cedar pollen (i.e. su-
gi-pollinosis) being considered a 
national affliction. In China, dust 
mites and Artemisia pollen (Figure 
3) have been reported as the most 
common perennial and seasonal 
cause of AR.
While the mucosal inflammatory 
processes in Caucasian subjects 
with CRS are mainly orchestrated 
by Th2 cytokines and are char-
acterized by an increased tissue 
eosinophilia and local IgE produc-
tion, the predominant endotype 
in Asian subjects with CRS with 
nasal polyps (CRSwNP) is char-
acterized as a Th17 cell-mediat-
ed predominance of neutrophils. 
However, it has been demonstrat-
ed that there is a shift over time 
from the predominantly neutro-
philic to an eosinophilic response 
in Asian CRSwNPs patients.
Besides the use of therapies rec-
ommended by the evidence-based 
Allergic Rhinitis and its Impact on 
Asthma (ARIA) and the European 
Position Paper on Rhinosinusitis 
and Nasal Polyps (EPOS) 2012 
guidelines, the treatment of AR 
and CRS in East Asia also includes 
acupuncture and use of traditional 
Chinese medicine involving some 
herbal medicines or formulae, 
Luo Zhang  
Capital Medical University, Beijing  TongRen Hospital, 
Beijing, China
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which have been reported to be 
effective for AR.
However, more emphasis on the 
importance of allergen immuno-
therapy for AR and pharmacother-
apy for CRS is required for treat-
ment of AR and CRS in East Asian 
countries. Furthermore, optimal 
treatment for AR and CRS in East 
Asian should be tailored according 
to the patients’ needs, based on 
careful evaluation of their clinical 
phenotypes and endotypes, which 
may contribute to the choice of 
therapeutic strategy and thus in-
fluence the treatment efficiency.
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Figure 1 Prevalence of allergic rhinitis in adults and children in different cities 
in China.
Figure 2 China central television (CCTV) headquarters in non-haze day (A) 
and in haze day (B).
Figure 3 Artemisia pollen. A: The 
blooming Artemisia. B: Artemisia 
pollen (magnification ×400). C: 
Artemisia pollen by scanning electron 
microscope.
Managing allergic rhinitis and chronic rhinosinusitis in developing countries – focus on East Asia
A B
412
GLOBAL ATLAS OF ALLERGIC RHINITIS AND CHRONIC RHINOSINUSITIS
SE
CT
IO
N
 I 
- 
G
lo
ba
l s
tr
at
eg
y 
fo
r t
he
 m
an
ag
em
en
t 
of
 a
lle
rg
ic
 r
hi
ni
ti
s 
an
d 
ch
ro
ni
c 
rh
in
os
in
us
iti
s
Best buys for allergic rhinitis and chronic rhinosinusitis prevention and control
• Allergen avoidance measures and allergen immunotherapy 
are probably the best two "buys" for prevention and control 
of allergic rhinitis/rhinosinusitis as they target the underlying 
cause of the allergic inflammation
• Studies in which allergic patients were moved to an allergen-
free environment were successful
• Allergen avoidance and associated costs should be balanced 
with the individual burden of the disease
• Both allergen avoidance and immunotherapy require the 
identification of the allergen causing the symptoms; therefore 
seeing an Allergy specialist is crucial to obtaining an appropriate 
and cost-effective treatment
Allergic rhinitis (AR) and chronic 
rhinosinusitis (CRS) cause major 
illness and disability worldwide. 
These conditions impair patients' 
quality of life (QoL), cause sleep 
disturbance and, through loss of 
work and school attendance, are 
responsible for an enormous lost 
in productivity annually. Thus, the 
indirect costs of both these dis-
eases are substantial. Direct costs 
are also high, mostly from medica-
tion use, but are often underesti-
mated because many products to 
allegedly treat these diseases are 
sold over-the-counter. The gener-
al belief that nasal symptoms are 
“normal” leads patients to avoid 
seeing a doctor and to buy over-
the-counter products; however, 
there may be more cost-effective 
ways of treating these conditions 
in the long-term.
There are two main strategies for 
etiological treatment of AR and 
CRS: allergen avoidance and al-
lergen immunotherapy (AIT). Both 
approaches are disease-modifying 
and require the identification of 
the allergen causing the symp-
toms, either by skin prick test or 
serum specific IgE detection.
Some studies have suggested that 
allergen avoidance is not effec-
tive for the treatment of allergic 
BEST BUYS FOR ALLERGIC RHINITIS 
AND CHRONIC RHINOSINUSITIS 
PREVENTION AND CONTROL
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respiratory disease, but this was 
probably due to the fact that aller-
gen avoidance was not complete. 
Studies in which allergic patients 
were moved to an allergen-free 
environment, such as a high-al-
titude village or a hospital room, 
were indeed successful. Allergen 
avoidance involves different meas-
ures depending on the allergen in 
question, but general measures 
can be beneficial to control expo-
sure to a range of indoor allergens 
(Figure 1). Examples include min-
imizing allergen reservoirs, such 
as carpets and sofas, keeping the 
home dry, maintaining good ven-
tilation, regular cleaning of surfac-
es, room air filters and masks. Use 
of acaricides and extensive bed-
room-based environmental con-
trol measures may provide some 
benefit in reducing symptoms in 
house dust mite perennial AR. Na-
sal irrigation may be useful as an 
adjunctive treatment of AR during 
unavoidable exposure to airborne 
allergens and pollutants.
To achieve successful allergen 
avoidance patients’ education to 
follow the recommended meas-
ures is essential, which can be 
complemented with written in-
structions, visual aids and home 
visits, where practical advice can 
be provided and demonstrated. 
However, allergen avoidance  and 
its costs should be balanced with 
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Figure 1 Allergen avoidance in allergic rhinitis. A. Indoor allergens (upper row): pets, moulds and house dust mites). 
Patients sensitized to indoor allergens who have identified allergens that correlate with their rhino-conjunctivitis 
symptoms may benefit from environmental control measures (eg, removal of pets, the use of air filtration systems, bed 
covers and acaricides). B. Outdoor allergens (lower row): tree and/or grass pollens: during plant pollination seasons 
exposure to the small airborne pollen particles is practically unavoidable on outdoor activities; nevertheless, identifying 
the clinically relevant sensitizing pollens and following their pollination calendars (https://www.polleninfo.org/en/
laenderauswahl.html) may help rhinitis patients to better plan outdoor activities and their preventive and symptomatic 
medication during peak pollen exposure days.
the burden of the disease.
Allergen immunotherapy can 
modify the immune response 
to allergens (Figure 2) and is es-
pecially indicated in moderate/
severe rhinitis uncontrolled by 
allergen avoidance and adequate 
evidence-based pharmacologic 
treatment.
In summary, allergen avoidance 
measures and allergen immuno-
therapy are probably the best two 
"buys" for prevention and control 
of allergic rhinitis/rhinosinusitis as 
they target the underlying cause 
of the allergic inflammation.
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Figure 2 Immunological mechanisms of allergen immunotherapy to aeroallergens. Low-dose and repeated allergen 
exposure at mucosal surfaces in atopic individuals drives type I IgE-mediated allergic responses. High-allergen dose 
through a subcutaneous or a sublingual route results in the shift of T cell polarization from a T helper 2 (Th2) to a T 
helper 1 (Th1) response. This is accompanied by an increase in the ratio of Th1 cytokines (IFN-γ, IL-12) to Th2 cytokines 
(IL-4, IL-5 and IL-13). The induction of T regulatory cells [inducible Treg cells (iTreg) and natural Treg cells (nTreg)] 
and cytokines such as IL-10 and TGF-β following immunotherapy play an important role in suppressing Th1 and Th2 
responses and contributes towards the induction of allergen-specific IgA1, IgA2 and in particular IgG4 antibodies with 
inhibitory activity. IgG4 antibodies are able to suppress FcɛRI- and CD23-mediated IgE-facilitated allergen presentation 
and basophil histamine release. (Reproduced with permission from Shamji MH, Durham SR. Mechanisms of immunotherapy to 
aeroallergens. Clin Exp Allergy 2011;41:1235-1246 with permission from Willey Blackwell.)
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The role of the allergist in allergic rhinitis and chronic rhinosinusitis
• Correct and complete diagnosis of allergic diseases requires 
standardised equipment, well trained personnel and 
experienced allergists
• The allergist has an unique arsenal of therapeutic measures, be 
it preventive advice, drug treatment, allergen immunotherapy 
(AIT) or application of biologicals
• For patients with severe or complex forms of rhinitis or 
rhinosinusitis the Allergy Centre offers the best diagnostic and 
therapeutic possibilities
• Continuing medical education of all health care professionals
When allergic rhinitis (AR) symp-
toms occur in relation to specific 
exposures, are reproducible, and 
are absent without exposure, the 
diagnosis is easily made. When, 
however the relation between 
exposure and symptoms is not so 
clear, allergy may, or may not be 
relevant since exposure to irritants, 
infection, anatomic factors, drug 
and medication abuse etc. may 
mimic allergy. Thus, to diagnose 
and treat upper respiratory and 
ocular allergy, not only allergy tests 
but also knowledge and experi-
ence of a specialist are required.
The diagnosis of allergic diseases 
is based on a very careful medi-
cal history, physical examination 
and skin and laboratory tests, us-
ing standardized commercial or 
sometimes native allergen prepa-
rations, both for skin testing and 
provocation. Proof of sensitisa-
tion (positive skin test or specific 
IgE) is in principle a prerequisite 
for the diagnosis of AR, but these 
tests may also fail to identify aller-
gy or to implicate the allergen as 
the main cause of patients’ symp-
toms. When proof of sensitisation 
is absent while the medical histo-
ry is characteristic of allergy or is 
discordant with the clinical history 
provocation tests may be helpful.
THE ROLE OF THE ALLERGIST 
IN ALLERGIC RHINITIS AND 
CHRONIC RHINOSINUSITIS
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The allergist has access to a spe-
cialist laboratory, where sensiti-
sation, cross reactivity between 
allergens and allergen exposure 
can be investigated. The recent in-
troduction of component resolved 
diagnosis offers new opportu-
nities for improved accuracy in 
laboratory testing. The modern al-
lergist is qualified to recommend, 
perform and interpret the results 
of such diagnostic tests.
The allergist has an unique arsenal 
of therapeutic measures, be it pre-
ventive advice, drug treatment, 
allergen immunotherapy (AIT) or 
application of biologicals. Patients 
should be informed accurately 
about how medication should be 
used (as needed or prophylactic) 
and the benefits and side effects 
that can be expected from each 
type of medication. AIT has been 
shown to be remarkably effective 
in patients with rhino-conjunctivi-
tis to pollens, mites, dander and/
or moulds. AIT, although very safe 
when administered properly can 
also provoke severe allergic re-
actions. For all of these reasons, 
it requires a specialised setting 
and good knowledge about in-
dication and contraindications. 
With respect to injection AIT, the 
treatment should be performed by 
qualified medical personnel under 
direct supervision of the special-
ist. Sublingual AIT starts in the 
allergy practice and continues at 
home.
There are significant differences in 
the way AR is managed in primary 
Jan G. de Monchy  
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care compared to an allergist set-
ting (Figure 1). On the other hand 
AR is so prevalent that allergists 
neither could nor should see all 
patients. Only specific patients 
should be referred to the allergist. 
These patients may require lung 
function and or allergen provoca-
tion testing and further tests aimed 
at food, drug or occupational aller-
gy. Very often these patients can 
be referred back with therapeutic 
advice after consultation.
Allergists have the responsibility 
to ensure the best management 
for the allergic patients catered 
for in their region. This implies 
that allergists should help to cre-
ate a local network, where general 
practitioners, paediatricians, ENT 
specialists and Allergists collabo-
rate in providing optimal and cost 
effective patient care. The optimal 
setting for such a network is the 
Allergy Centre. Notably when the 
atopic patient is suffering from 
several allergic diseases such as 
eczema, asthma, food allergy next 
to AR referral to an allergy centre 
is rational and cost effective.
Next to other specialists, Aller-
gists play their role within this 
framework, notably by testing 
counselling and treating patients 
with complex multi-organ aller-
gies. The Allergy Centre offers to 
private allergists, GPs and other 
medical specialists more exten-
sive diagnostic and therapeutic 
possibilities. The Allergy Centre 
can also offer care and education 
through nurses, dieticians and 
other health care workers. The op-
timal location for an Allergy Cen-
tre is in a university hospital or a 
large regional hospital, where all 
relevant specialties are adequate-
ly represented.
In addition, most health care sys-
tems consider continuing medical 
education a potential tool to im-
prove quality of care and reduce 
disease management costs. The 
effectiveness of a one-year con-
tinuing medical education/con-
tinuing professional development 
course for general practitioners, 
regarding the improvement in 
knowledge of ARIA and GINA 
guidelines and compliance with 
them in asthma management was 
proven recently.
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TABLE 1
Short survey showing the differences in managing allergic rhinitis between 
the primacry care physician and the allergy specialist
GPs 20% 80% 40% 60%
 
  
0%
20%
40%
60%
80%
 
  
0%
20%
40%
60%
Allergists 80% 20% 70% 30%
 
  
0%
20%
40%
60%
80%
 
0%
50%
100%
YES NO YES NO
Question 1: Do you perform 
anterior rhinoscopy in patients 
with allergic rhinitis?
Question 2: Do you perform 
Peak Expiratory Flow (PEF) or 
Flow Expiratory Volume 1sec. 
(FEV1) in your patients with 
allergy rhinitis?
The role of the allergist in allergic rhinitis and chronic rhinosinusitis
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Web-based surveys and monitoring in the management of allergic rhinitis and chronic rhinosinusitis
• Over the last two decades Internet has become an important 
source of information
• Online tools can provide feedback about real life and on real 
time and have potential predictive use
• Recently, online tools have been employed to diagnose and 
treat minor symptoms
• Online surveys are easy, inexpensive and convenient tools to 
reach large number of responders
• In cases of patients with limited access to Internet potential 
bias in collected information can rise
The use of Internet in Medicine 
has a great potential for interven-
tions that are just beginning to 
appear. The knowledge of Google 
trends offers data regarding the 
epidemiology of rhinitis. Google 
searches of the term allergic rhi-
nitis (AR) have a clear seasonal-
ity, with peaks during spring and 
late summer, and with patterns 
that differ between the North and 
South hemisphere (Figure 1). They 
closely correlate with searches 
on pollen counts, and informa-
tion about antihistamines, as well 
as with records of antihistamine 
sales, and thus reflect the suffer-
ing caused by the disease in real 
time. They have a potential use to 
predict and monitor outbreaks of 
AR, similar to other diseases such 
as influenza.
As part of the epidemiologic re-
search, online surveys are current-
ly easy to prepare and require a 
limited time to upload the survey, 
while responses are collected di-
rectly in a database-format ready 
to be analysed without further 
management. Another great ad-
vantage of online surveys is that 
they can reach a huge number 
of potential participants. Survey 
Monkey and Google drive are two 
extensively used examples of such 
WEB-BASED SURVEYS AND 
MONITORING IN THE MANAGEMENT 
OF ALLERGIC RHINITIS AND CHRONIC 
RHINOSINUSITIS
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online survey tools. Surveys can 
be dedicated to specific diseases, 
or can render information as part 
of more general approaches to 
health conditions. Online surveys 
addressing topics on rhinitis or 
chronic rhinosinusitis (CRS) have 
been able to identify associations 
of AR with sleep time and duration 
as well as with depression and su-
icidal ideation. They furthermore 
provide data to compare the qual-
ity of life between patients with 
AR and those with CRS, to check 
the impact of rhinitis symptoms 
according to their type or time of 
onset and to identify unmet treat-
ment needs. There are, however, 
limitations in the usefulness of 
online-collected information, as 
younger patients (Figure 2) and 
those with more severe symp-
toms might be more likely to use 
the web to receive information or 
advice and to participate in online 
surveys. Nonetheless, concerns 
about the reliability and compara-
bility of answers are usually pres-
ent in relation to more traditional 
sources of information too.
The Internet also offers interac-
tive questionnaires in several lan-
guages for the patients to assess 
their rhinitis severity and control 
according to e.g. the ARIA classi-
fication (Figure 3). Depending on 
the answers provided the patients 
can reach a recommendation at 
the end of some of these ques-
tionnaires. Tailored, rather than 
static, information seems to work 
better by enabling patients to 
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manage minor symptoms in cer-
tain diseases, and could also prove 
useful in cases of mild rhinitis.
In conclusion, even though current 
data on the usefulness of web-
based tools regarding the man-
agement of AR and CRS are still 
preliminary, they can be consid-
ered promising. With the constant 
progress of online technologies 
further improvement is expected 
which will assist physicians and 
patients in the decision-making 
process.
Figure 1 Seasonality of Google searches on allergic rhinitis, with distinct 
patterns for the North and the South hemisphere. The searches in the US on 
related topics as pollen count or antihistamines follow the same pattern and 
reflect symptoms ( (Reproduced with permission from Kang MG, Song WJ, Choi S, et 
al. Google unveils a glimpse of allergic rhinitis in the real world. Allergy 2015;70:124-
128, with permission from Willey Blackwell.)
Figure 2 The digital breach can 
cause an overrepresentation 
of younger generations in the 
information collected online.
Web-based surveys and monitoring in the management of allergic rhinitis and chronic rhinosinusitis
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Figure 3 Online questionnaire of the ARIA initiative for the evaluation of respiratory health. http://www.whiar.org/
Questionnaire.php
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Vision, roadmap and land-marking event
• Allergy epidemic affects more than one billion patients with a 
Global rise in prevalence, which may reach up to 4 billion affect-
ed individuals in 2050. Allergic rhinitis (AR) and chronic rhinosi-
nusitis (CRS) affect more than 30% of the population worldwide
• Both AR and CRS are inflammatory conditions with a significant 
degree of uncontrolled disease, even despite surgery in CRS
• The already existing many unmet needs and the huge 
socioeconomic burden for the health care systems are expected 
to substantially increase
• The socio-economic impact of chronic upper airway diseases is 
estimated for Europe at above 150 billion Euros per year.
• Effective policies and strategy development are needed at the 
global, regional and national level
• Efforts to overcome unmet needs should focus on 4 main 
directions:
  Intensive research and development
  Improved patient care at the global level
  Increased public awareness
  Upgrade of the Allergy domain in the political agenda
• A “Global Allergy Fight Strategy” should be developed:
  All stakeholders should be involved
  A multidisciplinary and scientific approach should be used
  Next generation guidelines should be developed
  World Respiratory Centers and Integrated Surveillance 
Networks should be established
The World Health Organization 
declares chronic respiratory dis-
eases as one of the four major 
health problems of mankind. The 
prevalence of allergic rhinitis (AR) 
has steadily increased over the 
past decades, affecting up to 30% 
of children and adults in Europe. 
A large-scale European survey has 
demonstrated chronic rhinosinus-
itis (CRS) is affecting 11% of the 
total European population. The 
socio-economic impact of chronic 
upper airway inflammation cannot 
be underestimated. Direct and in-
direct costs of chronic rhinitis and 
rhinosinusitis sum up to more than 
150 billion Euros per year in Europe. 
In addition, up to 20% of patients 
treated for AR and CRS remain un-
controlled, even despite surgery for 
CRS. Given the fact that AR is a ma-
jor risk factor for the development 
of asthma, action should be under-
taken to prevent asthma.
UNMET NEEDS
Unmet needs in the field of AR 
and CRS can arbitrarily be split 
into four different domains: edu-
cation, research, development and 
clinical care.
In view of the major problem of un-
derdiagnosis of AR and CRS, a high-
er level of education of physicians, 
pharmacists and patients is war-
VISION, ROADMAP AND 
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ranted, focusing on the benefits 
of proper diagnosis and adequate 
personalized treatment. Benefits 
of this approach can be evaluated 
from the patient perspective, with 
improved quality of life (QoL) by 
reduced symptoms or cure from 
disease, as well as from a society 
perspective by a significant reduc-
tion of socio-economic impact of 
chronic upper airway disease and 
even prevention of asthma.
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Given the lack of insight into fac-
tors driving uncontrolled upper air-
way disease, research should focus 
on determinants of uncontrolled 
AR and CRS, including severe 
chronic airway disease (SCUAD). 
Better insight into the exogenous 
and endogenous factors being re-
sponsible for uncontrolled disease 
will allow the design of optimal 
treatment strategies. 
The development of novel tools 
for evaluation of subjective bur-
den of the disease by the patients 
are needed, like user-friendly and 
cheap devices for the measure-
ment of nasal patency, hyperre-
activity and inflammation, smell 
dysfunction and control of disease. 
The daily follow-up of symptom 
control and other parameters of 
the disease need to be implement-
ed in routine care, as this will help 
both the patients and physicians to 
design optimal personalized care.
Current clinical care pathways 
should be optimized and personal-
ized for obtaining a higher degree 
of control for both AR as well as 
CRS. In AR, an action plan is need-
ed to improve endotyping, predict 
the success of different medical 
treatment options, and prevent 
the development of asthma. In 
CRS, the choice of prolonged med-
ical treatment or surgery needs 
to be based on the prediction of 
success of both approaches and 
the patients’ preference in this 
regard. In CRS without nasal pol-
yps (CRSsNP), personalized care 
is warranted with improvement of 
insight into the different factors 
of the pathophysiology and better 
drug delivery at the site of inflam-
mation. In CRS with nasal polyps 
(CRSwNP), novel biologicals are 
emerging as effective treatment 
options for those patients not re-
sponding well to current medical 
or surgical treatment. The precise 
positioning of biologicals into ex-
isting care pathways for CRS re-
mains the challenge, as they may 
represent an alternative for sur-
gery. Given the persistence of in-
flammation after surgery (FESS) in 
the majority of patients, post-op-
erative prolonged care and fol-
low-up is mandatory. 
A WORLDWIDE STRATEGY 
TO REDUCE THE BURDEN 
OF CHRONIC UPPER AIRWAY 
DISEASE
In view of the high need to opti-
mize patient care in the epidemic 
of chronic upper airway diseases, a 
worldwide strategy to reduce the 
burden of chronic upper airway dis-
ease is warranted. This action plan 
can only be successful by the com-
bined actions of all the stakehold-
ers: physicians and other health-
care professionals such as allied 
health and pharmacists, research-
ers, patient organizations, industry 
and policy makers. Therefore, join-
ing forces by all stakeholders in a 
unique platform will be necessary 
to reach the goal (Figure 1).
Research and development should 
be synergized and prioritized in or-
der to achieve sustainable results 
on prevention, biomarkers, cura-
tive treatment, anti-viral vaccines, 
and novel drug development. 
There are a number of barriers and 
obstacles in grant giving bodies to 
be solved, particularly to support 
human immunology and allergy re-
search (Table 1).
A WORLDWIDE STRATEGY 
TO FIGHT AND MANAGE 
ALLERGIC DISEASES SHOULD 
BE DEVELOPED (TABLE 2).
All stakeholders including health-
care professionals, psychologists, 
patient organizations, educators, 
industry, and policy makers should 
be involved. A multidisciplinary 
and scientific approach is essen-
tial. Modern global guidelines 
should be developed and imple-
mented for the management of AR, 
CRS and co-morbidities. The new 
generation guidelines should pro-
vide structured, multidisciplinary, 
region and environment-oriented 
and individual patient-focused 
solutions, with full considerations 
on differences across cultures. A 
good move forward is the current 
concept of integrated care path-
ways for reaching an optimal ther-
apeutic approach in patients with 
AR (Figure 2). It is now time to act 
on an integrated care platform for 
chronic airway disease.
Figure 1 Joining forces by all stakeholders in a unique platform is necessary 
to reach the goal of tacking the burden of chronic inflammatory upper airways 
diseases.
Vision, roadmap and land-marking event
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TABLE 1
Obstacles in allergy, rhinitis and rhinisinusitis 
research
• Lack of political awareness and low understanding 
and priority setting for the allergy epidemics
• Curative approaches and research for prevention 
has not been so far efficiently supported
• Small quantities of grants have been given to 
hypothesis-based research, although the real need 
is for large scale, non hypothesis based, in dept 
research, which is now possible with the novel 
developments in next generation DNA and RNA 
sequencing, exposome and epigenetic analysis and 
biomarkers
• Human research is receiving relatively less funding 
in many grant giving bodies compared to animal 
models
• Many major grant giving bodies had to decrease 
their budgets because of economical conditions in 
many countries
TABLE 2
Global allergy fight strategy
• Accept allergies as a Global Public Health Problem
• Upgrade “Allergy” on the political agenda
• Perform research and develop strategies to reduce 
risk factors
• Acknowledge  the role of primary care, allied health 
personnel and pharmacists as the central link 
between patients and physicians and initiate global 
education programmes
• Develop intensive public education and awareness 
programmes
• Increase research funds in general
• Prioritize prevention and curative treatments 
• Generate resources for prevention and control
• Strengthen the specialty of “Allergology”
• Harmonize and economize the educational and 
awareness activities of all stakeholders 
Figure 2 The concept of integrated care pathways for reaching an optimal therapeutic approach in patients with 
allergic rhinitis. (From Bousquet J, Addis A, Adcock I, Agache I, Agusti A, Alonso A, et al.  Integrated care pathways for airway 
diseases (AIRWAYS-ICPs)., Eur Respir J 2014 Aug;44:304-23.)
Vision, roadmap and land-marking event
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organization active in the 
field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug 
allergy and anaphylaxis. Its scope covers both basic science and clinical medicine.
Since its establishment in 1956, EAACI has grown to become the largest medical association in Europe in the field 
of allergy and clinical immunology. Its membership currently includes nearly 7800 members from 121 countries, 
representing academicians, clinicians, and allied health professionals. In addition, EAACI includes 47 National 
Allergy Societies as members.
EAACI’s mission is to provide the most efficient platform for scientific communication and education in the field 
of allergy and immunology, ultimately striving to ease the lives of patients suffering from these diseases. EAACI 
is regarded as the primary source of expertise in Europe for all aspects of allergy. 
EAACI’s activities
• Fostering science through dedicated platforms Annual Congress, Focused Meetings, Guidelines and Position 
Papers
• Educating professionals (Allergy Schools; CME system; knowledge examination in allergy and clinical 
Immunology; Research and Clinical Fellowships)
• Disseminating knowledge through EAACI Journals (Allergy, Pediatric Allergy Immunology, Clinical and 
Translational Allergy, EAACI Newletter) and online communication platforms
• Advocating change and raising awareness among the European Union’s decision makers about the importance 
of allergy and clinical immunology and the opportunities to prevent and treat allergies through Public 
Campaigns and Public Declarations
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) affect more than 30% 
of the population worldwide and pose a huge burden on healthcare systems 
through direct and indirect costs. The European Academy of Allergy and 
Clinical Immunology called on all worldwide leaders to develop the “Global 
Atlas of Allergic Rhinitis and Chronic Rhinosinusitis” 
The EAACI Global Atlas of Allergic Rhinitis and Chronic Rhinosinusitis was 
written by 218 authors from 38 countries and aims to increase awareness on 
the global epidemic and the burden of chronic inflammatory upper airways 
diseases and to warrant their recognition as a main concern in national 
health strategies.
Several priorities can be identified such as the development of novel 
tools for evaluation of subjective burden of the disease by the patients, 
improvement of the current clinical care pathways to obtaining a higher 
degree of control, research focused on determinants of uncontrolled and 
severe AR and CRS, altogether with a higher level of education of physicians, 
pharmacists and patients focusing on the benefits of proper diagnosis and 
adequate personalized treatment.
In view of the high need to optimize patient care in the epidemic of chronic 
upper airway diseases, a worldwide strategy to reduce the burden of chronic 
upper airway disease is warranted.
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